PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	ISTRE, O; BJOENNES, J; NAESS, R; HORNBAEK, K; FORMAN, A				ISTRE, O; BJOENNES, J; NAESS, R; HORNBAEK, K; FORMAN, A			POSTOPERATIVE CEREBRAL EDEMA AFTER TRANSCERVICAL ENDOMETRIAL RESECTION AND UTERINE IRRIGATION WITH 1-CENTER-DOT-5-PERCENT GLYCINE	LANCET			English	Article							SYMPTOMATIC HYPONATREMIA; HYPERAMMONEMIA; SERUM	Absorption of irrigating solution during transcervical resection of endometrium can cause dilutional hyponatraemia, nausea, and cerebral oedema. We studied 6 patients who absorbed more than 1500 mL of 1.5% glycine, and 14 patients who absorbed less. Cerebral oedema was diagnosed by blinded, paired comparison of computed tomography (CT) scans 3-6 hours and 3-6 days after operation. The absorbed volume of irrigating glycine solution was correlated with peroperative decrease in serum sodium. 10 patients who absorbed 500 mL of glycine or more had postoperative nausea, with cerebral oedema suspected in 9. None of the 10 patients who absorbed less than 500 mL had nausea; changes on CT scan suggestive of cerebral edema were found in 1. 8 patients who absorbed 1000 mL or more had a decrease in serum sodium of 10 mmol/L or more, nausea, and cerebral oedema on CT scan. Cerebral oedema may contribute to the development of postoperative nausea in patients undergoing transcervical surgery who absorb more than 500 mL of 1.5% glycine irrigating solution.	HEDMARK CENT HOSP,DEPT RADIOL,N-2300 HAMAR,NORWAY; AARHUS UNIV HOSP,DEPT OBSTET & GYNECOL,AARHUS,DENMARK	Aarhus University	ISTRE, O (corresponding author), HEDMARK CENT HOSP,DEPT OBSTET & GYNAECOL,N-2300 HAMAR,NORWAY.			Forman, Axel/0000-0003-1369-1296				ARIEFF AI, 1991, CRIT CARE MED, V19, P748, DOI 10.1097/00003246-199106000-00002; AYUS JC, 1987, NEW ENGL J MED, V317, P1190, DOI 10.1056/NEJM198711053171905; BERL T, 1990, ANN INTERN MED, V113, P417, DOI 10.7326/0003-4819-113-6-417; BERNSTEIN GT, 1989, J SURG RES, V46, P135, DOI 10.1016/0022-4804(89)90216-3; HARRISON RH, 1956, J UROLOGY, V75, P91; HENDERSON DJ, 1980, UROLOGY, V15, P267, DOI 10.1016/0090-4295(80)90441-0; HOEKSTRA PT, 1983, J UROLOGY, V130, P704, DOI 10.1016/S0022-5347(17)51414-7; IGLESIAS JJ, 1975, J UROLOGY, V114, P929, DOI 10.1016/S0022-5347(17)67177-5; ISTRE O, 1992, OBSTET GYNECOL, V80, P218; KIRWAN PH, 1993, BRIT J OBSTET GYNAEC, V100, P603, DOI 10.1111/j.1471-0528.1993.tb15321.x; MADSEN PAUL O., 1965, INVEST UROL, V3, P122; MAGOS AL, 1991, LANCET, V337, P1074, DOI 10.1016/0140-6736(91)91718-A; NESBIT RM, 1948, J UROLOGY, V59, P1212, DOI 10.1016/S0022-5347(17)69504-1; PERIER C, 1988, CLIN CHEM, V34, P1471; SHEPARD RL, 1987, BRIT J UROL, V60, P349, DOI 10.1111/j.1464-410X.1987.tb04983.x; WITZ CA, 1993, FERTIL STERIL, V60, P745	16	96	98	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 29	1994	344	8931					1187	1189		10.1016/S0140-6736(94)90507-X	http://dx.doi.org/10.1016/S0140-6736(94)90507-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN803	7934539				2022-12-24	WOS:A1994PN80300008
J	THOMAS, KB				THOMAS, KB			THE PLACEBO IN GENERAL-PRACTICE	LANCET			English	Article											THOMAS, KB (corresponding author), UNIV SOUTHAMPTON,ALDERMOOR HLTH CTR,DEPT PRIMARY MED CARE,SOUTHAMPTON SO1 6ST,HANTS,ENGLAND.							BALINT M, 1957, DOCTOR PATIENT ILLNE; Cartwright Ann, 1967, PATIENTS THEIR DOCTO; CROMBIE DL, 1963, J COLL GEN PRACTIT, V6, P582; EIMERL TS, 1962, THESIS U LIVERPOOL; Lin T, 1962, SCOPE EPIDEMIOLOGY P; Marinker M, 1970, J R Coll Gen Pract, V19, P79; Marinker M, 1967, J R Coll Gen Pract, V14, P59; SHEPHERD M, 1966, PSYCHIATRIC ILLNESS; THOMAS KB, 1987, BRIT MED J, V294, P1200, DOI 10.1136/bmj.294.6581.1200; THOMAS KB, 1974, BRIT MED J, V1, P625, DOI 10.1136/bmj.1.5908.625; THOMAS KB, 1978, BRIT MED J, P1327; THOMAS KB, 1972, THESIS U LIVERPOOL; WILSON RM, 1926, BELOVED PHYSICIAN; 1958, 14 GEN REG OFF SUBJ; 1958, J COLL GEN PRACTIT, V1, P107; 1970, BRIT MED J, V11, P437; 1974, OFFICE POPULATION CE	17	56	57	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 15	1994	344	8929					1066	1067		10.1016/S0140-6736(94)91716-7	http://dx.doi.org/10.1016/S0140-6736(94)91716-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL852	7934451				2022-12-24	WOS:A1994PL85200016
J	PAVLIDIS, P; RAMASWAMI, M; TANOUYE, MA				PAVLIDIS, P; RAMASWAMI, M; TANOUYE, MA			THE DROSOPHILA EASILY SHOCKED GENE - A MUTATION IN A PHOSPHOLIPID SYNTHETIC PATHWAY CAUSES SEIZURE, NEURONAL FAILURE, AND PARALYSIS	CELL			English	Article							CHOLINE KINASE; ETHANOLAMINE KINASE; ESCHERICHIA-COLI; SODIUM-CHANNELS; RAT-LIVER; MELANOGASTER; EXPRESSION; PROTEIN; SEQUENCE; CLONING	We have characterized easily shocked (eas), a Drosophila ''bang-sensitive'' paralytic mutant. Electrophysiological recordings from flight muscles in the giant fiber pathway of adult eas flies reveal that induction of paralysis with electrical stimulation results in a brief seizure, followed by a failure of the muscles to respond to giant fiber stimulation. Molecular cloning, germline transformation, and biochemical experiments show that eas mutants are defective in the gene for ethanolamine kinase, which is required for a pathway of phosphatidylethanolamine synthesis. Assays of phospholipid composition reveal that total phosphatidylethanolamine is decreased in eas mutants. The data suggest that eas bang sensitivity is due to an excitability defect caused by altered membrane phospholipid composition.	UNIV CALIF BERKELEY,DEPT ENVIRONM SCI POLICY & MANAGEMENT,BERKELEY,CA 94720; TATA INST FUNDAMENTAL RES,MOLEC BIOL UNIT,BOMBAY 400005,MAHARASHTRA,INDIA	University of California System; University of California Berkeley; Tata Institute of Fundamental Research (TIFR)	PAVLIDIS, P (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,DIV NEUROBIOL,BERKELEY,CA 94720, USA.		Pavlidis, Paul/H-8406-2013	Pavlidis, Paul/0000-0002-0426-5028; Ramaswami, Mani/0000-0001-7631-0468				ALNAES E, 1975, J PHYSL, V248, P306; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BENZER S, 1971, J AMER MED ASSOC, V218, P1015, DOI 10.1001/jama.218.7.1015; BRENNER S, 1987, NATURE, V329, P21, DOI 10.1038/329021a0; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; BURT AM, 1975, ANAL BIOCHEM, V65, P215, DOI 10.1016/0003-2697(75)90506-0; CLEVES AE, 1991, CELL, V64, P789, DOI 10.1016/0092-8674(91)90508-V; DOWNER RGH, 1985, COMPREHENSIVE INSECT, P78; EXTON JH, 1994, CURR OPIN CELL BIOL, V6, P226, DOI 10.1016/0955-0674(94)90140-6; FALK DR, 1984, MUTAT RES, V126, P25, DOI 10.1016/0027-5107(84)90166-0; FAST PG, 1966, LIPIDS, V1, P209, DOI 10.1007/BF02531874; FOLCH J, 1957, J BIOL CHEM, V226, P497; FORTE M, 1981, P NATL ACAD SCI-BIOL, V78, P7195, DOI 10.1073/pnas.78.11.7195; GANETZKY B, 1982, GENETICS, V100, P597; Gorczyca M., 1984, Journal of Neurogenetics, V1, P289, DOI 10.3109/01677068409107093; HALL JC, 1985, COMPREHENSIVE INSECT, V9, P287; HEILIG JS, 1991, EMBO J, V10, P809, DOI 10.1002/j.1460-2075.1991.tb08013.x; Herman Paul K., 1992, Trends in Cell Biology, V2, P363, DOI 10.1016/0962-8924(92)90048-R; HOSAKA K, 1989, J BIOL CHEM, V264, P2053; HOSAKA K, 1992, FEBS LETT, V304, P229, DOI 10.1016/0014-5793(92)80625-Q; IKEDA K, 1980, J NEUROCYTOL, V9, P799, DOI 10.1007/BF01205020; JACKSON FR, 1985, J NEUROSCI, V5, P1144; JAN YN, 1978, P NATL ACAD SCI USA, V75, P515, DOI 10.1073/pnas.75.1.515; JONES KR, 1990, NEURON, V4, P711, DOI 10.1016/0896-6273(90)90197-N; KAHN RA, 1993, CELL, V75, P1045, DOI 10.1016/0092-8674(93)90314-G; KARESS RE, 1984, CELL, V38, P135, DOI 10.1016/0092-8674(84)90534-8; KENNEDY EP, 1957, ANNU REV BIOCHEM, V26, P119, DOI 10.1146/annurev.bi.26.070157.001003; KING DG, 1980, J NEUROCYTOL, V9, P753, DOI 10.1007/BF01205017; LI M, 1993, SCIENCE, V261, P1439, DOI 10.1126/science.8396273; MARTIN JH, 1993, PRINCIPLES NEURAL SC, P777; MCGEE TP, 1994, J CELL BIOL, V124, P273, DOI 10.1083/jcb.124.3.273; MCGEE TP, 1993, PROTEIN LIPID INTERA, P163; MIDOZIC M, 1992, GENE EXPRESSION NEUR, P397; OCONNELL P, 1984, NUCLEIC ACIDS RES, V12, P5495, DOI 10.1093/nar/12.13.5495; OLSEN RW, 1976, BRAIN RES, V102, P283, DOI 10.1016/0006-8993(76)90883-0; Pirrotta V, 1988, VECTORS SURVEY MOL C, P437; PORTER TJ, 1990, J BIOL CHEM, V265, P414; RAMABRAHMAM P, 1981, ARCH BIOCHEM BIOPHYS, V207, P55, DOI 10.1016/0003-9861(81)90007-2; ROBERTSON HM, 1988, GENETICS, V118, P461; ROYDEN CS, 1987, CELL, V51, P165, DOI 10.1016/0092-8674(87)90144-9; Sambrook J., 1989, MOL CLONING LAB MANU; SCHUBIGER M, 1994, NEURON, V12, P373, DOI 10.1016/0896-6273(94)90278-X; SHEETZ MP, 1974, P NATL ACAD SCI USA, V71, P4457, DOI 10.1073/pnas.71.11.4457; SHELLEY RM, 1971, J INSECT PHYSIOL, V17, P545, DOI 10.1016/0022-1910(71)90032-1; Skipski V.P., 1969, METHOD ENZYMOL, V14, P530; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; STRATHMANN M, 1991, P NATL ACAD SCI USA, V88, P1247, DOI 10.1073/pnas.88.4.1247; Sundler R., 1984, Biomembranes, V12, P563; SURDEJ P, 1990, BIOL CELL, V68, P105, DOI 10.1016/0248-4900(90)90295-E; SWOPE SL, 1992, FASEB J, V6, P2514, DOI 10.1096/fasebj.6.8.1375568; TANOUYE MA, 1980, J NEUROPHYSIOL, V44, P405, DOI 10.1152/jn.1980.44.2.405; UCHIDA T, 1992, J BIOL CHEM, V267, P10156; ULANE RE, 1982, LUNG DEV BIOL CLIN P, V1, P295; WEINHOLD PA, 1974, BIOCHEMISTRY-US, V13, P5135, DOI 10.1021/bi00722a013; WILSON C, 1989, GENE DEV, V3, P1301, DOI 10.1101/gad.3.9.1301; Wu C F, 1992, Ion Channels, V3, P261; WU CF, 1980, NATURE, V286, P814, DOI 10.1038/286814a0; YEAGLE PL, 1989, FASEB J, V3, P1833, DOI 10.1096/fasebj.3.7.2469614; ZINN K, 1988, CELL, V53, P577, DOI 10.1016/0092-8674(88)90574-0; [No title captured]	61	147	152	0	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 7	1994	79	1					23	33		10.1016/0092-8674(94)90397-2	http://dx.doi.org/10.1016/0092-8674(94)90397-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PK585	7923374				2022-12-24	WOS:A1994PK58500005
J	RANDALL, MD				RANDALL, MD			ENDOTHELINS - FROM LABORATORY TO CLINIC	LANCET			English	Editorial Material											RANDALL, MD (corresponding author), UNIV NOTTINGHAM,QUEENS MED CTR,SCH MED,DEPT PHYSIOL & PHARMACOL,NOTTINGHAM NG7 2UH,ENGLAND.							CLOZEL M, 1993, NATURE, V365, P759, DOI 10.1038/365759a0; DASHWOOD MR, 1993, CARDIOVASC PHARM S8, V22, pS343; DOUGLAS SA, 1993, J CARDIOVASC PHARM, V22, pS371, DOI 10.1097/00005344-199322008-00097; DOUGLAS SA, 1994, CIRC RES, V75, P190, DOI 10.1161/01.RES.75.1.190; GARDINER SM, 1994, BRIT J PHARMACOL, V112, P823, DOI 10.1111/j.1476-5381.1994.tb13153.x; HUGGINS JP, 1993, PHARMACOL THERAPEUT, V59, P55, DOI 10.1016/0163-7258(93)90041-B; MCMAHON EG, 1991, J CARDIOVASC PHARM, V17, pS29, DOI 10.1097/00005344-199100177-00009; OHLSTEIN EH, 1993, J CARDIOVASC PHARM, V22, pS321, DOI 10.1097/00005344-199322008-00084; RANDALL MD, 1991, PHARMACOL THERAPEUT, V50, P73, DOI 10.1016/0163-7258(91)90073-U; VALLANCE P, 1989, LANCET, V2, P997; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; ZAMORA MR, 1990, LANCET, V336, P1144, DOI 10.1016/0140-6736(90)92766-B; [No title captured]; 1991, LANCET, V337, P79	14	5	5	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 24	1994	344	8926					832	833		10.1016/S0140-6736(94)92819-3	http://dx.doi.org/10.1016/S0140-6736(94)92819-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PH253	7916393				2022-12-24	WOS:A1994PH25300003
J	ARONHEIM, A; ENGELBERG, D; LI, NX; ALALAWI, N; SCHLESSINGER, J; KARIN, M				ARONHEIM, A; ENGELBERG, D; LI, NX; ALALAWI, N; SCHLESSINGER, J; KARIN, M			MEMBRANE TARGETING OF THE NUCLEOTIDE EXCHANGE FACTOR SOS IS SUFFICIENT FOR ACTIVATING THE RAS SIGNALING PATHWAY	CELL			English	Article							RECEPTOR TYROSINE KINASES; SACCHAROMYCES-CEREVISIAE CDC25; EPIDERMAL GROWTH-FACTOR; GENE-PRODUCT; PHOSPHATIDYLINOSITOL 3-KINASE; PROTEIN-KINASE; MAMMALIAN RAS; TRANSDUCTION; GRB2; PHOSPHORYLATION	Activation of growth factor receptors results in tyrosine autophosphorylation and recruitment of SH2 domain-containing effecters, including Grb2. Grb2 recruitment mediates activation of the Ras nucleotide exchanger Sos by an unknown mechanism. To examine the role of membrane recruitment, we prepared Sos derivatives containing either myristoylation or farnesylation signals. This resulted in plasma membrane targeting of Sos and stimulation of the Ras signaling pathway, including ERK and AP-1 activities leading to oncogenic transformation. Sos derivatives with nonfunctional myristoylation or farnesylation sequences were inactive. Farnesylation of Sos also activated pas signaling in yeast. In both mammalian cells and yeast, membrane-targeted Sos derivatives lacking the C-terminal region were considerably more active. Therefore, targeting of Sos to the plasma membrane in the vicinity of Ras appears to be the primary mechanism leading to activation of the Ras pathway. A secondary mechanism could involve relief of the inhibitory effect of the Sos C-terminal region.	UNIV CALIF SAN DIEGO,CTR MOLEC GENET,DEPT MED,PROGRAM BIOMED SCI,LA JOLLA,CA 92093; NYU,MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016	University of California System; University of California San Diego; New York University	ARONHEIM, A (corresponding author), UNIV CALIF SAN DIEGO,DEPT PHARMACOL,LA JOLLA,CA 92093, USA.			Aronheim, Ami/0000-0002-8575-4092				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ARONHEIM A, 1993, P NATL ACAD SCI USA, V90, P8063, DOI 10.1073/pnas.90.17.8063; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BUSS JE, 1988, MOL CELL BIOL, V8, P3960, DOI 10.1128/MCB.8.9.3960; CAMONIS JH, 1986, EMBO J, V5, P375, DOI 10.1002/j.1460-2075.1986.tb04222.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHERNIACK AD, 1994, J BIOL CHEM, V269, P4717; COLICELLI J, 1989, P NATL ACAD SCI USA, V86, P3599, DOI 10.1073/pnas.86.10.3599; DEBELL KE, 1992, J IMMUNOL, V149, P2271; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; DOWNWARD J, 1994, FEBS LETT, V338, P113, DOI 10.1016/0014-5793(94)80346-3; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; ENGELBERG D, 1990, EMBO J, V9, P641, DOI 10.1002/j.1460-2075.1990.tb08156.x; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FEIG LA, 1988, MOL CELL BIOL, V8, P2472, DOI 10.1128/MCB.8.6.2472; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GARREAU H, 1990, FEBS LETT, V269, P53, DOI 10.1016/0014-5793(90)81117-7; GIBBS JB, 1987, J BIOL CHEM, V262, P10426; GONZALEZ FA, 1993, J CELL BIOL, V122, P1089, DOI 10.1083/jcb.122.5.1089; GOODMAN LE, 1990, P NATL ACAD SCI USA, V87, P9665, DOI 10.1073/pnas.87.24.9665; GROSS E, 1992, NATURE, V360, P762, DOI 10.1038/360762a0; GROSS M, 1985, MOL CELL BIOL, V5, P1015, DOI 10.1128/MCB.5.5.1015; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; HAUBRUCK H, 1991, BIOCHIM BIOPHYS ACTA, V1072, P215, DOI 10.1016/0304-419X(91)90015-D; HAYASHI H, 1992, J BIOL CHEM, V267, P22575; HORAK ID, 1989, J VIROL, V63, P2343, DOI 10.1128/JVI.63.5.2343-2347.1989; HUANG WD, 1993, P NATL ACAD SCI USA, V90, P10947, DOI 10.1073/pnas.90.23.10947; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MINDEN A, 1994, IN PRESS MOL CELL BI; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NIMAN HL, 1983, P NATL ACAD SCI-BIOL, V80, P4949, DOI 10.1073/pnas.80.16.4949; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; PAWSON T, 1993, CURR BIOL, V3, P4345; PETITJEAN A, 1990, GENETICS, V124, P797; RANA RS, 1990, PHYSIOL REV, V70, P115, DOI 10.1152/physrev.1990.70.1.115; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SCHWEIGHOFFER F, 1992, SCIENCE, V256, P825, DOI 10.1126/science.1317056; SEGAL M, 1992, J BIOL CHEM, V267, P22747; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; SUSA M, 1992, J BIOL CHEM, V267, P22951; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; TODDERUD G, 1990, SCIENCE, V249, P296, DOI 10.1126/science.2374928; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	65	425	445	1	19	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 23	1994	78	6					949	961		10.1016/0092-8674(94)90271-2	http://dx.doi.org/10.1016/0092-8674(94)90271-2			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PJ294	7923364				2022-12-24	WOS:A1994PJ29400007
J	BERNHARD, JD				BERNHARD, JD			THE SWEAT SUITE	LANCET			English	Editorial Material							GLAND-FUNCTION; DISORDERS; BIOLOGY				BERNHARD, JD (corresponding author), UNIV MASSACHUSETTS,MED CTR,DIV DERMATOL,WORCESTER,MA, USA.							CHAMPION RH, 1992, TXB DERMATOLOGY, P1745; Inaba M., 1992, HUMAN BODY ODOR ETIO; KLIGMAN AM, 1963, BRIT J DERMATOL, V75, P307, DOI 10.1111/j.1365-2133.1963.tb13567.x; PORTER AMW, 1993, J HUM EVOL, V25, P417, DOI 10.1006/jhev.1993.1059; SATO K, 1989, J AM ACAD DERMATOL, V20, P713, DOI 10.1016/S0190-9622(89)70081-5; SATO K, 1989, J AM ACAD DERMATOL, V20, P537, DOI 10.1016/S0190-9622(89)70063-3	6	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 17	1994	344	8925					767	768		10.1016/S0140-6736(94)92336-1	http://dx.doi.org/10.1016/S0140-6736(94)92336-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PG178	7916068				2022-12-24	WOS:A1994PG17800005
J	MACSWEENEY, STR; ELLIS, M; WORRELL, PC; GREENHALGH, RM; POWELL, JT				MACSWEENEY, STR; ELLIS, M; WORRELL, PC; GREENHALGH, RM; POWELL, JT			SMOKING AND GROWTH-RATE OF SMALL ABDOMINAL AORTIC-ANEURYSMS	LANCET			English	Note							MORTALITY	Smoking is an important risk factor for abdominal aortic aneurysm. Limiting the growth rate of small aneurysms has the potential to prevent them reaching a size at which surgical repair is considered. In 43 patients, with small aneurysms, growth rates were studied by serial ultrasound over 3 years. The median expansion rate of these small aneurysms was 0.13 cm per year. Growth rates were higher in those who continued to smoke (0.16 vs 0.09 cm per year in those who no longer smoked, p = 0.038). Higher growth rates were significantly correlated with the concentration of serum cotinine. Stopping smoking could reduce the growth rate of small abdominal aortic aneurysms.			MACSWEENEY, STR (corresponding author), CHARING CROSS & WESTMINSTER MED SCH,DEPT SURG,LONDON W6 8RF,ENGLAND.		Powell, Janet/AAW-8669-2021	Powell, Janet/0000-0002-3905-1468				ADISESHIAH M, 1993, LANCET, V341, P215; ELLIS M, 1991, BRIT J SURG, V78, P614, DOI 10.1002/bjs.1800780529; FEYERABEND C, 1980, ANALYST, V105, P998, DOI 10.1039/an9800500998; HAMMOND EC, 1969, ARCH ENVIRON HEALTH, V19, P167, DOI 10.1080/00039896.1969.10666825; HARRIS PL, 1992, BMJ-BRIT MED J, V305, P697, DOI 10.1136/bmj.305.6855.697; JENKINS AM, 1986, BRIT J SURG, V73, P395, DOI 10.1002/bjs.1800730528; JOHANSSON G, 1986, BRIT J SURG, V73, P101, DOI 10.1002/bjs.1800730205; MACSWEENEY STR, 1993, BRIT J SURG, V80, P582, DOI 10.1002/bjs.1800800510; STRACHAN DP, 1991, BRIT J SURG, V78, P401, DOI 10.1002/bjs.1800780407	9	145	145	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 3	1994	344	8923					651	652		10.1016/S0140-6736(94)92087-7	http://dx.doi.org/10.1016/S0140-6736(94)92087-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PE386	7915350				2022-12-24	WOS:A1994PE38600012
J	STRANDGAARD, S; PAULSON, OB				STRANDGAARD, S; PAULSON, OB			CEREBROVASCULAR CONSEQUENCES OF HYPERTENSION	LANCET			English	Article							ANTIHYPERTENSIVE TREATMENT; BLOOD-PRESSURE; STROKE; INFARCTION		RIGSHOSP, DEPT NEUROL, DK-2100 COPENHAGEN, DENMARK	Rigshospitalet; University of Copenhagen	STRANDGAARD, S (corresponding author), HERLEV HOSP, DEPT MED & NEPHROL B, DK-2730 HERLEV, DENMARK.		Paulson, Olaf B./N-6924-2016	Paulson, Olaf B./0000-0001-7712-8596				[Anonymous], 1991, JAMA, V265, P3255; BRITTON M, 1986, STROKE, V17, P861, DOI 10.1161/01.STR.17.5.861; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; DAHLOF B, 1991, LANCET, V338, P1281, DOI 10.1016/0140-6736(91)92589-T; DONNAN GA, 1992, LANCET, V339, P473, DOI 10.1016/0140-6736(92)91070-O; FUJII K, 1992, HYPERTENSION, V19, P713, DOI 10.1161/01.HYP.19.6.713; HACHINSKI VC, 1987, ARCH NEUROL-CHICAGO, V44, P21, DOI 10.1001/archneur.1987.00520130013009; HANKEY GJ, 1987, MED J AUSTRALIA, V146, P412, DOI 10.5694/j.1326-5377.1987.tb120332.x; IRIE K, 1993, STROKE, V24, P1844, DOI 10.1161/01.STR.24.12.1844; LEDINGHAM JGG, 1979, Q J MED, V48, P25; MOYER JH, 1952, AM J MED SCI, V224, P377, DOI 10.1097/00000441-195210000-00002; PAULSON OB, 1990, CEREBROVAS BRAIN MET, V2, P161; PAULSON OB, 1994, HYPERTENSION PATHOPH; SANDERCOCK P, 1992, LANCET, V339, P537, DOI 10.1016/0140-6736(92)90348-7; SPENCE JD, 1986, STROKE, V17, P808, DOI 10.1161/01.STR.17.5.808; STRANDGAARD S, 1987, LANCET, V2, P658; Strandgaard Svend, 1993, P675; YAO H, 1992, STROKE, V23, P1673, DOI 10.1161/01.STR.23.11.1673	18	58	59	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 20	1994	344	8921					519	521		10.1016/S0140-6736(94)91903-8	http://dx.doi.org/10.1016/S0140-6736(94)91903-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PC535	7914618				2022-12-24	WOS:A1994PC53500014
J	MELNICK, J; DUL, JL; ARGON, Y				MELNICK, J; DUL, JL; ARGON, Y			SEQUENTIAL INTERACTION OF THE CHAPERONES BIP AND GRP94 WITH IMMUNOGLOBULIN-CHAINS IN THE ENDOPLASMIC-RETICULUM	NATURE			English	Article							GLUCOSE-REGULATED PROTEIN; BINDING-SPECIFICITY; BIP; HSP90; GLYCOPROTEIN; CELLS; ASSOCIATION; ABUNDANT; ATPASE; GENES	During their transit through the endoplasmic reticulum, newly synthesized light and heavy chains of immunoglobulins associate with two endoplasmic reticulum stress proteins. BiP/GRP78, a member of the HSP70 family, binds these polypeptides, presumably through promiscuously exposed hydrophobic sequences(1,2), soon after their translocation into the endoplasmic reticulum(3,4). GRP94, another endoplasmic reticulum stress protein(5,6) homologous to HSP90(7-11), also associates,vith unassembled immunoglobulin chains(12), but its interaction is biochemically, kinetically and structurally distinct from BiP's. We report here that whereas BiP preferentially binds an early disulphide intermediate of light chain and dissociates within a few minutes, GRP94 exclusively binds fully oxidized molecules and dissociates with a half-time of 50 min. These results indicate that GRP94 is itself a chaperone which acts after BiP.	DUKE UNIV,MED CTR,DEPT IMMUNOL,DURHAM,NC 27710	Duke University								BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; BOGEN B, 1989, SCAND J IMMUNOL, V29, P273, DOI 10.1111/j.1365-3083.1989.tb01125.x; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; CLAIRMONT CA, 1992, J BIOL CHEM, V267, P3983; COWAN NJ, 1974, J MOL BIOL, V90, P691, DOI 10.1016/0022-2836(74)90533-6; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HUTCHISON KA, 1992, J BIOL CHEM, V267, P14047; KNITTLER MR, 1992, EMBO J, V11, P1573, DOI 10.1002/j.1460-2075.1992.tb05202.x; KOCH G, 1986, J CELL SCI, V86, P217; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LEE AS, 1983, J BIOL CHEM, V258, P597; LEE AS, 1987, TRENDS BIOCHEM SCI, V12, P20, DOI 10.1016/0968-0004(87)90011-9; LI ZH, 1993, EMBO J, V12, P3143, DOI 10.1002/j.1460-2075.1993.tb05983.x; LIN HY, 1993, MOL BIOL CELL, V4, P1109, DOI 10.1091/mbc.4.11.1109; MAZZARELLA RA, 1987, J BIOL CHEM, V262, P8875; MELNICK J, 1992, J BIOL CHEM, V267, P21303; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NADEAU K, 1993, J BIOL CHEM, V268, P1479; NAVARRO D, 1991, VIROLOGY, V184, P253, DOI 10.1016/0042-6822(91)90842-Y; SCHAIFF WT, 1992, J EXP MED, V176, P657, DOI 10.1084/jem.176.3.657; SCHERRER LC, 1990, J BIOL CHEM, V265, P21397; SORGER PK, 1987, J MOL BIOL, V194, P341, DOI 10.1016/0022-2836(87)90380-9; WHELAN SA, 1985, J CELL PHYSIOL, V125, P251, DOI 10.1002/jcp.1041250212; WIECH H, 1992, NATURE, V358, P169, DOI 10.1038/358169a0; WU GE, 1983, CELL, V33, P77, DOI 10.1016/0092-8674(83)90336-7	27	361	370	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 4	1994	370	6488					373	375		10.1038/370373a0	http://dx.doi.org/10.1038/370373a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PA304	7913987				2022-12-24	WOS:A1994PA30400056
J	AZEM, A; KESSEL, M; GOLOUBINOFF, P				AZEM, A; KESSEL, M; GOLOUBINOFF, P			CHARACTERIZATION OF A FUNCTIONAL GROEL(14)(GROES(7))(2) CHAPERONIN HETERO-OLIGOMER	SCIENCE			English	Article							RIBULOSE BISPHOSPHATE CARBOXYLASE; HEAT-SHOCK PROTEINS; ESCHERICHIA-COLI; CENTRAL CAVITY; GROEL; RECONSTITUTION; PURIFICATION; HYDROLYSIS; BINDING; HSP60	Chaperonins GroEL and GroES form two types of hetero-oligomers in vitro that can mediate the folding of proteins. Chemical cross-linking and electron microscopy showed that in the presence of adenosine triphosphate (ATP), two GroES(7) rings can successively bind a single GroEL(14) core oligomer. The symmetric GroEL(14)(GroES(7))(2) chaperonin, whose central cavity appears obstructed by two GroES(7) rings, can nonetheless stably bind and assist the ATP-dependent refolding of RuBisCO enzyme. Thus, unfolded proteins first bind and possibly fold on the external envelope of the chaperonin hetero-oligomer.	HEBREW UNIV JERUSALEM,ALEXANDER SILBERMAN INST LIFE SCI,DEPT BOT,IL-91904 JERUSALEM,ISRAEL; HEBREW UNIV JERUSALEM,HADASSAH MED SCH,DEPT MEMBRANE & ULTRASTRUCT RES,IL-91120 JERUSALEM,ISRAEL	Hebrew University of Jerusalem; Hebrew University of Jerusalem				Goloubinoff, Pierre/0000-0002-4802-0807				AZEM A, 1994, BIOCHEMISTRY-US, V33, P6671, DOI 10.1021/bi00187a037; BRAIG K, 1993, P NATL ACAD SCI USA, V90, P3978, DOI 10.1073/pnas.90.9.3978; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; CHRISTENSEN H, 1991, EUR BIOPHYS J, V19, P221, DOI 10.1007/BF00183530; DARAWSHE S, 1991, EUR J BIOCHEM, V201, P169, DOI 10.1111/j.1432-1033.1991.tb16270.x; ELLIS RJ, 1993, NATURE, V366, P213, DOI 10.1038/366213a0; Georgopoulos C, 1990, Semin Cell Biol, V1, P19; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; GRIMM R, 1993, J BIOL CHEM, V268, P5220; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HOHN T, 1979, J MOL BIOL, V129, P359, DOI 10.1016/0022-2836(79)90501-1; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; ISHII N, 1994, J MOL BIOL, V236, P691, DOI 10.1006/jmbi.1994.1181; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MARTIN J, 1992, SCIENCE, V258, P995, DOI 10.1126/science.1359644; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; SAIBIL H, 1991, NATURE, V353, P25, DOI 10.1038/353025b0; SAIBIL HR, 1993, CURR BIOL, V3, P265, DOI 10.1016/0960-9822(93)90176-O; SCHMIDT M, 1994, SCIENCE, V265, P656, DOI 10.1126/science.7913554; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; TODD MJ, 1993, BIOCHEMISTRY-US, V32, P8560, DOI 10.1021/bi00084a024; VIITANEN PV, 1992, PROTEIN SCI, V1, P363; ZIEMIENOWICZ A, 1993, J BIOL CHEM, V268, P25425	30	145	147	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 29	1994	265	5172					653	656		10.1126/science.7913553	http://dx.doi.org/10.1126/science.7913553			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NZ538	7913553				2022-12-24	WOS:A1994NZ53800031
J	SUPPARATPINYO, K; KHAMWAN, C; BAOSOUNG, V; NELSON, KE; SIRISANTHANA, T				SUPPARATPINYO, K; KHAMWAN, C; BAOSOUNG, V; NELSON, KE; SIRISANTHANA, T			DISSEMINATED PENICILLIUM-MARNEFFEI INFECTION IN SOUTHEAST-ASIA	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PATIENT; THAILAND; MYCOSIS; CHINA	Disseminated infection with the fungal pathogen Penicillium marneffei is, after extrapulmonary tuberculosis and cryptococcal meningitis, the third most common opportunistic infection in HIV disease in northern Thailand. We report the clinical, microbiological, and therapeutic features of a large series of HIV-infected adults with disseminated P marneffei infection. From August, 1987, to June, 1992, 92 patients with Pmarneffei infection confirmed by culture were seen at Chiang Mai University Hospital, of whom 86 were also infected with HIV. Clinical information was available for 80 of these patients. The most common presenting symptoms and signs were fever (92%), anaemia (77%), weight loss (76%), and skin lesions (71%). 87% of patients presenting with skin lesions had generalised papules with central umbilication. Presumptive diagnosis was made in 50 patients by microscopic examination of Wright's-stained bone-marrow aspirate and/or touch smears of skin biopsy or lymph-node biopsy specimens. Most patients who were diagnosed responded initially to amphotericin or itraconazole, whereas most who were not diagnosed and treated died. 12 patients relapsed within 6 months of cessation of treatment. P marneffei has become an important pathogen of HIV-associated opportunistic infection in Thailand.	CHIANG MAI UNIV,FAC MED,DEPT MED,INFECT DIS SECT,CHIANG MAI 50002,THAILAND; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT EPIDEMIOL,BALTIMORE,MD	Chiang Mai University; Johns Hopkins University								ANCELLE T, 1988, Bulletin de la Societe Francaise de Mycologie Medicale, V17, P73; [Anonymous], 1959, BULL SOC MYCOL FR; CHAN JKC, 1989, ACTA CYTOL, V33, P523; CHAN YF, 1990, J BONE JOINT SURG BR, V72, P500, DOI 10.1302/0301-620X.72B3.2341456; CHIEWCHANVIT S, 1991, MYCOSES, V34, P245, DOI 10.1111/j.1439-0507.1991.tb00652.x; DENG ZL, 1985, AM J CLIN PATHOL, V84, P323, DOI 10.1093/ajcp/84.3.323; DENG ZL, 1988, REV INFECT DIS, V10, P640; DISALVO AF, 1973, AM J CLIN PATHOL, V60, P259; HILMARSDOTTIR I, 1993, J ACQ IMMUN DEF SYND, V6, P466; HOCKEY LJ, 1982, J CLIN MICROBIOL, V16, P1080, DOI 10.1128/JCM.16.6.1080-1085.1982; HULSHOF CMJ, 1990, EUR J CLIN MICROBIOL, V9, P370, DOI 10.1007/BF01973751; JAYANETRA P, 1984, AM J TROP MED HYG, V33, P637, DOI 10.4269/ajtmh.1984.33.637; JONES PD, 1992, CLIN INFECT DIS, V15, P744, DOI 10.1093/clind/15.4.744; LI JS, 1991, CHINESE MED J-PEKING, V104, P247; MA KF, 1991, ACTA CYTOL, V35, P557; PAUTLER KB, 1984, SABOURAUDIA, V22, P433; PETO TEA, 1988, J INFECTION, V16, P285, DOI 10.1016/S0163-4453(88)97700-6; PIEHL MR, 1988, ARCH PATHOL LAB MED, V112, P1262; SATHAPATAYAVONGS B, 1989, J INFECTION, V19, P84, DOI 10.1016/S0163-4453(89)95136-0; SIRISANTHANA V, 1993, PEDIATR INFECT DIS J, V12, P1021, DOI 10.1097/00006454-199312000-00013; SO SY, 1985, AM REV RESPIR DIS, V131, P662, DOI 10.1164/arrd.1985.131.4.662; SUPPARATPINYO K, 1992, CLIN INFECT DIS, V14, P871, DOI 10.1093/clinids/14.4.871; SUPPARATPINYO K, 1993, ANTIMICROB AGENTS CH, V37, P2407, DOI 10.1128/AAC.37.11.2407; TSANG DNC, 1991, REV INFECT DIS, V13, P766; TSANG DNC, 1988, HISTOPATHOLOGY, V13, P311, DOI 10.1111/j.1365-2559.1988.tb02041.x; TSUI WMS, 1992, HISTOPATHOLOGY, V20, P287, DOI 10.1111/j.1365-2559.1992.tb00985.x; VIVIANI MA, 1993, EUR J EPIDEMIOL, V9, P79, DOI 10.1007/BF00463094; Weniger B G, 1991, AIDS, V5 Suppl 2, pS71, DOI 10.1097/00002030-199101001-00011; YUEN WC, 1986, BRIT J SURG, V73, P1007, DOI 10.1002/bjs.1800731224; 1987, MMWR S1S, V36, pS1	30	403	458	2	24	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 9	1994	344	8915					110	113		10.1016/S0140-6736(94)91287-4	http://dx.doi.org/10.1016/S0140-6736(94)91287-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NV732	7912350	hybrid			2022-12-24	WOS:A1994NV73200015
J	BERREBI, A; KOBUCH, WE; BESSIERES, MH; BLOOM, MC; ROLLAND, M; SARRAMON, MF; ROQUES, C; FOURNIE, A				BERREBI, A; KOBUCH, WE; BESSIERES, MH; BLOOM, MC; ROLLAND, M; SARRAMON, MF; ROQUES, C; FOURNIE, A			TERMINATION OF PREGNANCY FOR MATERNAL TOXOPLASMOSIS	LANCET			English	Article							CONGENITAL TOXOPLASMOSIS	Termination of pregnancy is usually recommended to pregnant women who have infection with Toxoplasma gondii before 26 weeks of pregnancy if the fetus is infected. No prospective studies are available on the outcome if such pregnancies are allowed to continue with anti-parasitic treatment. We prospectively studied 163 mothers with acute toxoplasma infection before 28 weeks of amenorrhoea. All received anti-parasitic treatment with 9 million IU spiramycin orally. 23 also received pyrimethamine and sulphadiazine. All had cordocentesis and regular obstetric ultrasound examinations. The 162 liveborn infants were followed up for 15 to 71 months. 3 fetuses died in utero. 27 of 162 liveborn infants had proven congenital toxoplasmosis: 10 had one or more clinical signs of congenital toxoplasmosis; 5 had isolated or multiple intracranial calcifications; 7 had peripheral chorioretinitis; and 2 had moderate ventricular dilations. All 27 are free from symptoms and have normal neurological development at 15 to 71 months of age. We conclude that in first and second trimester pregnancies with acute fetal toxoplasma infection, the pregnancy need not be interrupted if repeated fetal ultrasound is normal, and antiparasitic treatment is given.	CHU RANGUEIL,DEPT MICROBIOL PARASITOL,TOULOUSE,FRANCE; UNIV TOULOUSE,DEPT PEDIAT,TOULOUSE,FRANCE	CHU de Toulouse; Universite de Toulouse	BERREBI, A (corresponding author), UNIV TOULOUSE,CHU LA GRAVE,DEPT OBSTET & GYNECOL,PL LANGE,F-31052 TOULOUSE,FRANCE.							Berrebi A., 1993, Journal de Gynecologie Obstetrique et Biologie de la Reproduction, V22, P261; CARDOZA JD, 1988, RADIOLOGY, V169, P711, DOI 10.1148/radiology.169.3.3055034; COUVREUR J, 1991, ARCH FR PEDIATR, V48, P397; DAFFOS F, 1988, NEW ENGL J MED, V318, P271, DOI 10.1056/NEJM198802043180502; DAFFOS F, 1992, 11E SEM DIAGN ANT MA, P9; DESMONTS G, 1974, NEW ENGL J MED, V290, P1110, DOI 10.1056/NEJM197405162902003; DESMONTS G, 1985, LANCET, V1, P500; Dorangeon P. H., 1992, Journal de Gynecologie Obstetrique et Biologie de la Reproduction, V21, P549; HOHFELD P, 1989, J PEDIATR, V115, P765; KOPPE JG, 1974, EUR J OBSTET GYN R B, V4, P101, DOI 10.1016/0028-2243(74)90029-X; Kraubig H., 1966, P104; Remington JS., 1990, INFECT DIS FETUS NEW, V3, P89; THALHAMMER O, 1957, TOXOPLASMOSE BEI MEN, P1; WILSON CB, 1980, AM J OBSTET GYNECOL, V138, P357, DOI 10.1016/0002-9378(80)90129-5; 1988, NEW ENGL J MED, V318, P313	15	62	68	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 2	1994	344	8914					36	39		10.1016/S0140-6736(94)91054-5	http://dx.doi.org/10.1016/S0140-6736(94)91054-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU917	7912304				2022-12-24	WOS:A1994NU91700017
J	FRANCIS, CY; WHORWELL, PJ				FRANCIS, CY; WHORWELL, PJ			BRAN AND IRRITABLE-BOWEL-SYNDROME - TIME FOR REAPPRAISAL	LANCET			English	Article								Whilst following up large numbers of patients with irritable bowel syndrome we got the impression that wholemeal wheat and bran products made people with the condition worse rather than better. One hundred consecutive new referrals, all of whom had tried bran, were questioned to resolve this issue. 55% of patients were made worse by bran whereas only 10% had found it helpful. With the exception of fruit, other forms of dietary fibre were not as detrimental and proprietary supplements were found to be beneficial. All symptoms of irritable bowel syndrome were exacerbated by bran, with bowel disturbance most often adversely affected, followed by abdominal distension and pain. The results of this study suggest that the use of bran in irritable bowel syndrome should be reconsidered. The study also raises the possibility that excessive consumption of bran in the community may actually be creating patients with irritable bowel syndrome by exacerbating mild, noncomplaining cases.	UNIV S MANCHESTER HOSP, DEPT MED, MANCHESTER M20 8LR, LANCS, ENGLAND	Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital				Whorwell, Peter/0000-0002-5220-8474				DICKINSON RJ, 1982, LANCET, V2, P393; HARVEY RF, 1987, LANCET, V1, P963; HEATON KW, 1993, EUR J GASTROEN HEPAT, V5, P567, DOI 10.1097/00042737-199308000-00001; LYNN RB, 1993, NEW ENGL J MED, V329, P1940, DOI 10.1056/NEJM199312233292608; PAINTER NS, 1972, BRIT MED J, V2, P46, DOI 10.1136/bmj.2.5804.46-b; PAINTER NS, 1976, LANCET, V1, P540; RITCHIE J, 1982, PRACTITIONER, V226, P633; Thompson WG., 1989, GASTROENTEROL INT, V2, P92; 1980, MED ASPECTS DIETARY	9	208	215	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 2	1994	344	8914					39	40		10.1016/S0140-6736(94)91055-3	http://dx.doi.org/10.1016/S0140-6736(94)91055-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU917	7912305				2022-12-24	WOS:A1994NU91700018
J	KOVACS, JA; KOVACS, AAS				KOVACS, JA; KOVACS, AAS			PCP PROPHYLAXIS IN PEDIATRIC HIV-INFECTION - TIME FOR A CHANGE	LANCET			English	Editorial Material							PNEUMOCYSTIS-CARINII PNEUMONIA; CHILDREN		UNIV SO CALIF,LOS ANGELES CTY MED CTR,COMPREHENS MATERNAL CHILD HIV MANAGEMENT & RES CT,LOS ANGELES,CA 90033	University of Southern California	KOVACS, JA (corresponding author), NIH,DEPT CRIT CARE MED,BETHESDA,MD 20892, USA.		Kovacs, Joseph/AAU-6105-2021	Kovacs, Joseph/0000-0002-5191-9880				CHANOCK SJ, 1994, PEDIATRICS, V93, P519; CONNOR E, 1991, JAMA-J AM MED ASSOC, V265, P1693, DOI 10.1001/jama.265.13.1693; FREDERICK T, 1994, 1ST NAT C HUM RETR R, P693; KOVACS A, 1991, JAMA-J AM MED ASSOC, V265, P1698, DOI 10.1001/jama.265.13.1698; KOVACS A, 1993, 33RD ICAAC, P828; SIMONDS RJ, 1993, JAMA-J AM MED ASSOC, V270, P470, DOI 10.1001/jama.270.4.470; 1991, JAMA-J AM MED ASSOC, V265, P1637; 1994, BRIT MED J, V308, P437; 1989, MMWR-MORBID MORTAL W, V38, P1; 1993 CTR DIS CONTR P	10	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 2	1994	344	8914					5	6		10.1016/S0140-6736(94)91042-1	http://dx.doi.org/10.1016/S0140-6736(94)91042-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU917	7912309				2022-12-24	WOS:A1994NU91700005
J	GEPPERT, M; BOLSHAKOV, VY; SIEGELBAUM, SA; TAKEI, K; DECAMILLI, P; HAMMER, RE; SUDHOF, TC				GEPPERT, M; BOLSHAKOV, VY; SIEGELBAUM, SA; TAKEI, K; DECAMILLI, P; HAMMER, RE; SUDHOF, TC			THE ROLE OF RAB3A IN NEUROTRANSMITTER RELEASE	NATURE			English	Article							GTP-BINDING PROTEIN; SYNAPTIC VESICLES; TRANSMITTER RELEASE; SYNAPSIN-I; PROBABILITY; EXOCYTOSIS; PLASTICITY; RECEPTOR; NEURONS; MICE	THE small GTP-binding protein Rab3A is a Rab family member(1-3) that is abundant in brain synaptic vesicles(4,5). Here we show that mice in which the rab3A gene has been mutated by homologous recombination do not express Rab3A but are viable and fertile. Electrophysiological recordings in hippocampal CA1 pyramidal cells indicate that most of their synaptic parameters are also normal, although synaptic depression after short trains of repetitive stimuli (15-30 stimuli at 14 Hz) is significantly increased. Levels of the Rab3A-binding protein rabphilin are decreased by 70%, but expression of more than 20 other synaptic proteins is unchanged. No compensatory changes were detected in other GTP-binding proteins or in proteins that interact with Rab3. Rab3A thus appears not to be essential for synaptic vesicle exocytosis but to play a role in the recruitment of synaptic vesicles for exocytosis during repetitive stimulation.	UNIV TEXAS, SW MED CTR, DEPT MOLEC GENET, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, HOWARD HUGHES MED INST, DALLAS, TX 75235 USA; COLUMBIA UNIV, HOWARD HUGHES MED INST, CTR NEUROBIOL & BEHAV, DEPT PHARMACOL, NEW YORK, NY 10032 USA; YALE UNIV, SCH MED, DEPT CELL BIOL, NEW HAVEN, CT 06510 USA; YALE UNIV, SCH MED, HOWARD HUGHES MED INST, NEW HAVEN, CT 06510 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Columbia University; Howard Hughes Medical Institute; Yale University; Howard Hughes Medical Institute; Yale University				Hammer, Robert E./0000-0001-5487-7551; Takei, Kohji/0000-0002-6555-9425				BALDINI G, 1992, P NATL ACAD SCI USA, V89, P5049, DOI 10.1073/pnas.89.11.5049; BAUMERT M, 1993, BIOCHEM J, V293, P157, DOI 10.1042/bj2930157; BLANTON MG, 1989, J NEUROSCI METH, V30, P203, DOI 10.1016/0165-0270(89)90131-3; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOLSHAKOV VY, 1994, SCIENCE, V264, P1148, DOI 10.1126/science.7909958; BURTON J, 1993, NATURE, V361, P464, DOI 10.1038/361464a0; DECAMILLI P, 1983, J CELL BIOL, V96, P1337, DOI 10.1083/jcb.96.5.1337; FYKSE EM, 1993, J NEUROSCI, V13, P4997; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HAWKINS RD, 1993, ANNU REV NEUROSCI, V16, P625, DOI 10.1146/annurev.ne.16.030193.003205; HESSLER NA, 1993, NATURE, V366, P569, DOI 10.1038/366569a0; JOHNSTON PA, 1989, J BIOL CHEM, V264, P1268; MATTEOLI M, 1991, J CELL BIOL, V115, P625, DOI 10.1083/jcb.115.3.625; MIGNERY GA, 1989, NATURE, V342, P192, DOI 10.1038/342192a0; OCONNOR V, 1994, CELL, V76, P785, DOI 10.1016/0092-8674(94)90352-2; Peters A, 1991, FINE STRUCTURE NERVO; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; ROSAHL TW, 1993, CELL, V75, P661, DOI 10.1016/0092-8674(93)90487-B; ROSENMUND C, 1993, SCIENCE, V262, P754, DOI 10.1126/science.7901909; Sambrook J., 1989, MOL CLONING LAB MANU; SHIRATAKI H, 1992, J BIOL CHEM, V267, P10946; SIMONS K, 1993, NEURON, V11, P789, DOI 10.1016/0896-6273(93)90109-5; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; TAKEI K, 1992, J NEUROSCI, V12, P489; VONMOLLARD GF, 1994, J BIOL CHEM, V269, P10971; VONMOLLARD GF, 1990, P NATL ACAD SCI USA, V87, P1988, DOI 10.1073/pnas.87.5.1988; VONMOLLARD GF, 1991, NATURE, V349, P79, DOI 10.1038/349079a0	30	412	420	0	16	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUN 9	1994	369	6480					493	497		10.1038/369493a0	http://dx.doi.org/10.1038/369493a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NQ286	7911226				2022-12-24	WOS:A1994NQ28600060
J	FORMAN, D; PIKE, MC; DAVEY, G; DAWSON, S; BAKER, K; CHILVERS, CED; OLIVER, RTD; COUPLAND, C; CARTWRIGHT, RA; ELWOOD, PC; BIRCH, J; TYRELL, C; BRETT, R; BUSH, T; ISBELL, V; CORNWELL, A; STEER, R; THISTLETHWAITE, S; GELLMAN, H; HUGHES, J; LLEWELLYN, M; ARDERNJONES, A; ALLEN, A; HILTON, E; LLOYD, B; MCVEIGH, S; THORNE, M; TROWBRIDGE, P; REID, S				FORMAN, D; PIKE, MC; DAVEY, G; DAWSON, S; BAKER, K; CHILVERS, CED; OLIVER, RTD; COUPLAND, C; CARTWRIGHT, RA; ELWOOD, PC; BIRCH, J; TYRELL, C; BRETT, R; BUSH, T; ISBELL, V; CORNWELL, A; STEER, R; THISTLETHWAITE, S; GELLMAN, H; HUGHES, J; LLEWELLYN, M; ARDERNJONES, A; ALLEN, A; HILTON, E; LLOYD, B; MCVEIGH, S; THORNE, M; TROWBRIDGE, P; REID, S			ETIOLOGY OF TESTICULAR CANCER - ASSOCIATION WITH CONGENITAL-ABNORMALITIES, AGE AT PUBERTY, INFERTILITY, AND EXERCISE	BRITISH MEDICAL JOURNAL			English	Article							GERM-CELL TUMORS; RISK-FACTORS; CARCINOMA INSITU; DOWNS-SYNDROME; UNITED-STATES; YOUNG MEN; TESTIS; EPIDEMIOLOGY; CRYPTORCHIDISM; VASECTOMY	Objective-To determine the risk of testicular cancer associated with undescended testis, inguinal hernia, age at puberty, marital status, infertility, vasectomy, and amount of exercise. Design-A population based case-control study with a questionnaire administered by an interviewer and with relevant supplementary data extracted from general practitioners' notes. Setting-Nine health regions within England and Wales. Subjects-794 men, aged 15-49 years, with a testicular germ cell tumour diagnosed between 1 January 1984 and 1 January 1987; each had an age matched (within one year) control selected from the list of their general practitioner. Results-There was a significant association of testicular cancer with undescended testis (odds ratio 3.82; 95% confidence interval 2.24 to 6.52) and inguinal hernia (1.91; 1.12 to 3.23). The excess risk associated with undescended testis was eliminated in men who had had an orchidopexy before the age of 10 years. There were positive associations with early age at voice breaking, early age at starting to shave, and infertility. There was a significant association with a sedentary lifestyle and a moderate protective effect of exercise. There was no association with vasectomy. Conclusion-This study confirms previous reports that developmental urogenital abnormalities result in an increased risk of testicular cancer. The trend to perform orchidopexy at younger ages may reduce the risk associated with undescended testis. The increased risks associated with early age at puberty and low amounts of exercise may be related to effects of exposure to endogenous hormones. Changes in both of these factors may partly contribute to the increasing rates of testicular cancer observed in the past few decades.	MRC,EPIDEMIOL UNIT,CARDIFF,WALES; UNIV MANCHESTER,DEPT EPIDEMIOL & SOCIAL ONCOL,MANCHESTER,LANCS,ENGLAND; FREEDOM FIELDS HOSP,PLYMOUTH ONCOL UNIT,PLYMOUTH,DEVON,ENGLAND; UNIV LEEDS,LEUKAEMIA RES FUND CTR,LEEDS,ENGLAND; INST CANC RES,EPIDEMIOL SECT,SUTTON,SURREY,ENGLAND; UNIV NOTTINGHAM,SCH MED,DEPT EPIDEMIOL & PUBL HLTH MED,NOTTINGHAM NG7 2RD,ENGLAND; ROYAL LONDON HOSP,DEPT MED ONCOL,LONDON E1 1BB,ENGLAND	University of Manchester; University of Leeds; University of London; Institute of Cancer Research - UK; University of Nottingham; Barts Health NHS Trust; Royal London Hospital	FORMAN, D (corresponding author), RADCLIFFE INFIRM,IMPERIAL CANC RES FUND,CANC EPIDEMIOL UNIT,GIBSON BLDG,OXFORD OX2 6HE,ENGLAND.			Coupland, Carol/0000-0002-2327-3306				BEITINS IZ, 1991, J CLIN ENDOCR METAB, V72, P1350, DOI 10.1210/jcem-72-6-1350; BENSON RC, 1991, MAYO CLIN PROC, V66, P372, DOI 10.1016/S0025-6196(12)60660-0; BOYLE P, 1987, EUR J CANCER CLIN ON, V23, P827, DOI 10.1016/0277-5379(87)90286-0; BRAUN DL, 1985, AM J PEDIAT HEMATOL, V7, P208; Breslow N. E., 1980, SCI PUBLICATION, V32; BROWN LM, 1986, INT J EPIDEMIOL, V15, P164, DOI 10.1093/ije/15.2.164; BROWN LM, 1986, CANCER RES, V46, P4812; CALE ARJ, 1990, BRIT MED J, V300, P370, DOI 10.1136/bmj.300.6721.370; CHILVERS C, 1986, J PEDIATR SURG, V21, P691, DOI 10.1016/S0022-3468(86)80389-X; CHILVERS C, 1989, UROLOGICAL GENITAL C, P396; CHILVERS C, 1992, EUROPEAN UROLOGY UPD, V1, P74; COGGON D, 1986, BRIT J IND MED, V43, P381; COLDMAN AJ, 1982, BRIT J CANCER, V46, P749, DOI 10.1038/bjc.1982.267; DAVIS E, 1981, J ACM, V28, P721, DOI 10.1145/322276.322284; DEPUE RH, 1983, J NATL CANCER I, V71, P1151; DEPUE RH, 1986, J NATL CANCER I, V77, P830, DOI 10.1093/jnci/77.3.830; Doll R, 1992, Clin Oncol (R Coll Radiol), V4, P257, DOI 10.1016/S0936-6555(05)81065-9; FORMAN D, IN PRESS CANCER SURV; FORMAN D, 1970, PROGR CLIN BIOL RES, V357, P245; FORMAN D, 1989, UROLOGICAL GENITAL C, P289; FRISCH RE, 1981, JAMA-J AM MED ASSOC, V246, P1559, DOI 10.1001/jama.246.14.1559; GERSHMAN ST, 1988, INT J EPIDEMIOL, V17, P738, DOI 10.1093/ije/17.4.738; GRAHAM S, 1972, CANCER, V29, P1242, DOI 10.1002/1097-0142(197205)29:5<1242::AID-CNCR2820290517>3.0.CO;2-R; GRAHAM S, 1977, J NATL CANCER I, V58, P1225; HANSEN PV, 1989, CANCER, V64, P956, DOI 10.1002/1097-0142(19890815)64:4<956::AID-CNCR2820640431>3.0.CO;2-3; HASEN J, 1980, HORM RES, V12, P345, DOI 10.1159/000179141; HAUGHEY BP, 1989, AM J EPIDEMIOL, V130, P25, DOI 10.1093/oxfordjournals.aje.a115319; HENDERSON BE, 1979, INT J CANCER, V23, P598, DOI 10.1002/ijc.2910230503; JOHNSON DE, 1987, UROLOGY, V30, P199, DOI 10.1016/0090-4295(87)90231-7; LYNGE E, 1993, EUR J CANCER, V29A, P1064, DOI 10.1016/S0959-8049(05)80226-6; MCDOWALL ME, 1986, J EPIDEMIOL COMMUN H, V40, P26, DOI 10.1136/jech.40.1.26; MILLS PK, 1984, LANCET, V1, P207; MORRISON AS, 1976, J NATL CANCER I, V56, P731, DOI 10.1093/jnci/56.4.731; MOSS AR, 1986, AM J EPIDEMIOL, V124, P39, DOI 10.1093/oxfordjournals.aje.a114369; MUSTACCHI P, 1976, J NATL CANCER I, V56, P717, DOI 10.1093/jnci/56.4.717; NEWELL GR, 1987, J NATL CANCER I, V78, P881; OLIVER RTD, 1990, CANCER SURV, V9, P263; OPSTAD PK, 1992, J CLIN ENDOCR METAB, V74, P1176, DOI 10.1210/jc.74.5.1176; PEARCE N, 1987, CANCER, V59, P1677, DOI 10.1002/1097-0142(19870501)59:9<1677::AID-CNCR2820590926>3.0.CO;2-Q; PIKE MC, 1986, LANCET, V1, P1246; POTTERN LM, 1985, J NATL CANCER I, V74, P377; PRYOR JP, 1983, BRIT J UROL, V55, P780, DOI 10.1111/j.1464-410X.1983.tb03425.x; RAJPERTDEMEYTS E, 1993, EUR UROL, V23, P54; ROSS RK, 1979, BRIT J CANCER, V39, P284, DOI 10.1038/bjc.1979.53; SASAGAWA I, 1993, ARCH ANDROLOGY, V30, P93, DOI 10.3109/01485019308987740; SCHOTTENFELD D, 1980, AM J EPIDEMIOL, V112, P232, DOI 10.1093/oxfordjournals.aje.a112989; SHARPE RM, 1993, LANCET, V341, P1392, DOI 10.1016/0140-6736(93)90953-E; SKAKKEBAEK NE, 1978, HISTOPATHOLOGY, V2, P157, DOI 10.1111/j.1365-2559.1978.tb01706.x; STONE JM, 1991, CANCER, V68, P211, DOI 10.1002/1097-0142(19910701)68:1<211::AID-CNCR2820680139>3.0.CO;2-Q; STRADER CH, 1988, AM J EPIDEMIOL, V127, P1013, DOI 10.1093/oxfordjournals.aje.a114877; STRADER CH, 1988, AM J EPIDEMIOL, V128, P56, DOI 10.1093/oxfordjournals.aje.a114958; SWERDLOW AJ, 1989, INT J CANCER, V43, P549, DOI 10.1002/ijc.2910430403; SWERDLOW AJ, 1988, BRIT J IND MED, V45, P225; SWERDLOW AJ, 1987, BRIT J CANCER, V55, P97, DOI 10.1038/bjc.1987.20; TANNER JM, 1978, FETUS MAN PHYSICAL G; TARONE RE, 1991, J NATL CANCER I, V83, P1497, DOI 10.1093/jnci/83.20.1497; THORNHILL JA, 1987, BRIT J UROL, V59, P367, DOI 10.1111/j.1464-410X.1987.tb04660.x; WANDERAS EH, 1990, BRIT J UROL, V66, P315, DOI 10.1111/j.1464-410X.1990.tb14935.x; 1986, BRIT MED J, V293, P1401; 1993, SERIES MBI, V20	60	220	225	2	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 28	1994	308	6941					1393	1399		10.1136/bmj.308.6941.1393	http://dx.doi.org/10.1136/bmj.308.6941.1393			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NP420	7912596				2022-12-24	WOS:A1994NP42000012
J	LOPEZMIRANDA, J; ORDOVAS, JM; ESPINO, A; MARIN, C; SALAS, J; LOPEZSEGURA, F; JIMENEZPEREPEREZ, J; PEREZJIMENEZ, F				LOPEZMIRANDA, J; ORDOVAS, JM; ESPINO, A; MARIN, C; SALAS, J; LOPEZSEGURA, F; JIMENEZPEREPEREZ, J; PEREZJIMENEZ, F			INFLUENCE OF MUTATION IN HUMAN APOLIPOPROTEIN A-1 GENE PROMOTER ON PLASMA LDL CHOLESTEROL RESPONSE TO DIETARY-FAT	LANCET			English	Article							A-I GENE; POLYMORPHISM; REGION; CIII; TRANSCRIPTION; INTERVENTION; ASSOCIATION; CLUSTER; SITES	The plasma lipid response to changes in dietary fat and cholesterol can vary between individuals. At present, responders cannot be identified in advance. An adenine to guanine (A-->G) mutation in the promoter of the apolipoprotein A1 gene (apoA-1) has been suggested as affecting plasma high-density lipoprotein cholesterol. In 50 young men we examined the effect of the same mutation on the responses of both high and low density lipoprotein cholesterol to low-fat diet. The frequency for the A allele was 0.14. Subjects were fed a low-fat diet for 25 days, followed by a diet rich in monounsaturated fatty acid (MUFA, 22% out of 40% fat) for 28 days and lipoproteins were measured at the end of each diet. There were no differences in initial total cholesterol between subjects with the G/G mutation (170 mg/dL: 100 mg/dL= 2.59 mmol/L)) and the G/A mutation (169 mg/dL) genotypes. After consumption of the high monounsaturated fat diet, significant increases were noted in plasma LDL cholesterol (10 mg/dL, p=0.035) in the G/A subjects but not in the G/G subjects (1 mg/dL, p=0.996). These differences showed that a significant diet-gene interaction (p=0.015) existed. No differences were observed on HDL cholesterol between groups. Plasma low-density lipoprotein cholesterol responsiveness to diet may be explained by variation at the apoA-1 gene locus.	TUFTS UNIV,USDA,HUMAN NUTR RES CTR AGING,LIPID METAB LAB,BOSTON,MA 02111; HOSP UNIV REINA SOFIA,CORDOBA,SPAIN	Tufts University; United States Department of Agriculture (USDA); Hospital Universitario Reina Sofia - Cordoba			Jimenez, Francisco Perez/AAJ-9559-2021; Marin Hinojosa, Carmen/AFO-1294-2022; Lopez-Miranda, Jose/Y-8306-2019; Ordovas, Jose/B-8727-2013	Marin Hinojosa, Carmen/0000-0003-2884-4806; Lopez-Miranda, Jose/0000-0002-8844-0718; Perez Jimenez, Francisco/0000-0001-9808-1280; Salas-Coronas, Joaquin/0000-0002-4302-7022; Perez-Jimenez, Francisco/0000-0001-7499-7681; Ordovas, Jose/0000-0002-7581-5680				BLANGERO J, 1990, AM J HUM GENET, V47, P414; CLARKSON TB, 1980, CHILDHOOD PREVENTION, P127; FIELDING CJ, 1972, BIOCHEM BIOPH RES CO, V46, P1493, DOI 10.1016/0006-291X(72)90776-0; HEGSTED DM, 1965, AM J CLIN NUTR, V17, P281; JACOBS DR, 1983, ARTERIOSCLEROSIS, V3, P349, DOI 10.1161/01.ATV.3.4.349; JEENAH M, 1990, MOL BIOL MED, V7, P233; KARATHANASIS SK, 1985, P NATL ACAD SCI USA, V82, P6374, DOI 10.1073/pnas.82.19.6374; KEYS A, 1957, LANCET, V2, P959; MANTTARI M, 1991, METABOLISM, V40, P217, DOI 10.1016/0026-0495(91)90179-Z; MCCALL MR, 1994, ARTERIOSCLER THROMB, V14, P248, DOI 10.1161/01.ATV.14.2.248; PAGANI F, 1990, J LIPID RES, V31, P1371; PAGANI F, 1992, EUR J EPIDEMIOL, V8, P54, DOI 10.1007/BF00145350; PAN XM, 1993, J VASC SURG, V18, P161, DOI 10.1016/0741-5214(93)90595-D; PAPAZAFIRI P, 1991, J BIOL CHEM, V266, P5790; PAULHAYASE H, 1992, HUM GENET, V88, P439, DOI 10.1007/BF00215679; REICHL D, 1989, ARTERIOSCLEROSIS, V9, P785, DOI 10.1161/01.ATV.9.6.785; SIGURDSSON G, 1992, ARTERIOSCLER THROMB, V12, P1017, DOI 10.1161/01.ATV.12.9.1017; SMITH JD, 1992, J CLIN INVEST, V89, P1796, DOI 10.1172/JCI115783; TIKKANEN MJ, 1990, CLIN GENET, V37, P327, DOI 10.1111/j.1399-0004.1990.tb03514.x; TUTEJA R, 1992, FEBS LETT, V304, P98, DOI 10.1016/0014-5793(92)80597-A; TYBJAERGHANSEN A, 1993, ATHEROSCLEROSIS, V100, P157, DOI 10.1016/0021-9150(93)90202-6; VONECKARDSTEIN A, 1992, AM J HUM GENET, V50, P1115; WOJCIECHOWSKI AP, 1991, NATURE, V349, P161, DOI 10.1038/349161a0; XU CF, 1990, GENET EPIDEMIOL, V7, P261, DOI 10.1002/gepi.1370070405; 1993, JAMA-J AM MED ASSOC, V269, P3015	25	76	77	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 21	1994	343	8908					1246	1249		10.1016/S0140-6736(94)92149-0	http://dx.doi.org/10.1016/S0140-6736(94)92149-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NM144	7910273				2022-12-24	WOS:A1994NM14400007
J	MICHIE, C; HARVEY, D				MICHIE, C; HARVEY, D			CAN EXPRESSION OF CD45RO, A T-CELL SURFACE-MOLECULE, BE USED TO DETECT CONGENITAL INFECTION	LANCET			English	Note							LYMPHOCYTES; ANTIGEN	Exclusion or confirmation of congenital infection can be difficult in newborn infants. The presence of an infective organism in a fetus leads to activation of fetal T lymphocytes. We have examined expression of isoforms of a T-cell surface molecule, CD45RO, in 119 infants, 8 of whom had an intrauterine infection diagnosed antenatally. CD45RO was expressed on fewer than 10% of T cells in control infants and on more than 17% of T cells from infants with known infection (p<0.006). This method allows screening of infants for infection by a range of organisms as a cause of their infection.			MICHIE, C (corresponding author), ROYAL POSTGRAD MED SCH,DEPT PAEDIAT & NEONATAL MED,LONDON W12 0NN,ENGLAND.							AKBAR AN, 1988, J IMMUNOL, V140, P2171; ERBER WN, 1984, LANCET, V1, P1042; ERKELLERYUKSEL FM, 1992, J PEDIATR-US, V120, P216, DOI 10.1016/S0022-3476(05)80430-5; FROEBEL KS, 1991, AIDS, V5, P97, DOI 10.1097/00002030-199101000-00015; MICHIE CA, 1992, PEDIATR INFECT DIS J, V11, P1050, DOI 10.1097/00006454-199211120-00012; MICHIE CA, 1992, NATURE, V360, P264, DOI 10.1038/360264a0; PARKER DJ, 1988, J IMMUNOL METHODS, V110, P37, DOI 10.1016/0022-1759(88)90080-4; RUDD P, 1988, CLIN OBSTET GYNAECOL, V2, P55; THOMAS ML, 1989, ANNU REV IMMUNOL, V7, P339, DOI 10.1146/annurev.immunol.7.1.339; UEHARA T, 1992, BLOOD, V80, P452	10	31	32	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 21	1994	343	8908					1259	1260		10.1016/S0140-6736(94)92153-9	http://dx.doi.org/10.1016/S0140-6736(94)92153-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NM144	7910277				2022-12-24	WOS:A1994NM14400011
J	FRERICHS, RR				FRERICHS, RR			PERSONAL SCREENING FOR HIV IN DEVELOPING-COUNTRIES	LANCET			English	Editorial Material											FRERICHS, RR (corresponding author), UNIV CALIF LOS ANGELES,DEPT EPIDEMIOL,LOS ANGELES,CA 90024, USA.							BAMBER SD, 1993, GENITOURIN MED, V69, P148; COHEN J, 1993, SCIENCE, V260, P1254, DOI 10.1126/science.8493564; FRERICHS RR, 1992, LANCET, V340, P1496, DOI 10.1016/0140-6736(92)92755-5; FRERICHS RR, 1993, NEW ENGL J MED, V328, P1717, DOI 10.1056/NEJM199306103282318; FRERICHS RR, 1994, J ACQ IMMUN DEF SYND, V7, P552; KALLINGS LO, 1993, VACCINE, V11, P525, DOI 10.1016/0264-410X(93)90223-K; MASTRO TD, 1994, LANCET, V343, P204, DOI 10.1016/S0140-6736(94)90990-3; NELSON KE, 1993, JAMA-J AM MED ASSOC, V270, P955, DOI 10.1001/jama.270.8.955; NOPKESORN T, 1993, AIDS, V7, P1233, DOI 10.1097/00002030-199309000-00013; TAMASHIRO H, 1993, LANCET, V342, P87, DOI 10.1016/0140-6736(93)91289-X; TAMASHIRO H, IN PRESS B WHO; TRUSSELL J, 1992, FAM PLANN PERSPECT, V24, P20, DOI 10.2307/2135721; WELLER SC, 1993, SOC SCI MED, V36, P1635, DOI 10.1016/0277-9536(93)90352-5; Weniger B G, 1991, AIDS, V5 Suppl 2, pS71, DOI 10.1097/00002030-199101001-00011	14	21	21	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 16	1994	343	8903					960	962		10.1016/S0140-6736(94)90072-8	http://dx.doi.org/10.1016/S0140-6736(94)90072-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF700	7909015				2022-12-24	WOS:A1994NF70000016
J	ROSENSTEIN, BJ				ROSENSTEIN, BJ			GENOTYPE-PHENOTYPE CORRELATIONS IN CYSTIC-FIBROSIS	LANCET			English	Editorial Material							DELTA-F508; ASSOCIATION; MUTATIONS; DELETION; DISEASE				ROSENSTEIN, BJ (corresponding author), JOHNS HOPKINS UNIV HOSP,CTR SYST FIBROSIS,BALTIMORE,MD 21205, USA.							CAMPBELL PW, 1991, J PEDIATR-US, V118, P239, DOI 10.1016/S0022-3476(05)80490-1; CURTIS A, 1991, J MED GENET, V28, P34, DOI 10.1136/jmg.28.1.34; DEARCE M, 1992, CLIN GENET, V42, P271; KEREM E, 1990, NEW ENGL J MED, V323, P1517, DOI 10.1056/NEJM199011293232203; KEREM E, 1989, J PEDIATR-US, V114, P767, DOI 10.1016/S0022-3476(89)80134-9; KRISTIDIS P, 1992, AM J HUM GENET, V50, P1178; KUBESCH P, 1993, LANCET, V341, P189, DOI 10.1016/0140-6736(93)90062-L; LESTER LA, 1994, PEDIATRICS, V93, P114; LIECHTIGALLATI S, 1992, PEDIATR RES, V32, P175, DOI 10.1203/00006450-199208000-00010; SANTIS G, 1990, LANCET, V335, P1426, DOI 10.1016/0140-6736(90)91448-J; SANTIS G, 1990, LANCET, V336, P1081, DOI 10.1016/0140-6736(90)92566-Z; TSIU LC, 1992, TRENDS GENET, V8, P392; 1993, NEW ENGL J MED, V329, P1308	13	19	19	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 26	1994	343	8900					746	747		10.1016/S0140-6736(94)91832-5	http://dx.doi.org/10.1016/S0140-6736(94)91832-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NC351	7907726				2022-12-24	WOS:A1994NC35100004
J	GHOSH, A; CARNAHAN, J; GREENBERG, ME				GHOSH, A; CARNAHAN, J; GREENBERG, ME			REQUIREMENT FOR BDNF IN ACTIVITY-DEPENDENT SURVIVAL OF CORTICAL-NEURONS	SCIENCE			English	Article							NERVE GROWTH-FACTOR; FACTOR MESSENGER-RNA; NEUROTROPHIC FACTOR; SENSORY NEURONS; GANGLION-CELLS; SYMPATHETIC-GANGLION; CILIARY GANGLION; CALCIUM; CULTURE; DEATH	Cultured embryonic cortical neurons from rats were used to explore mechanisms of activity-dependent neuronal survival. Cell survival was increased by the activation of voltage-sensitive calcium channels (VSCCs) but not by activation of N-methyl-D-aspartate receptors. These effects correlated with the expression of brain-derived neurotrophic factor (BDNF) induced by these two classes of calcium channels. Antibodies to BDNF (which block intracellular signaling by BDNF, but not by nerve growth factor, NT3, or NT4/5) reduced the survival of cortical neurons and reversed the VSCC-mediated increase in survival. Thus, endogenous BDNF is a trophic factor for cortical neurons whose expression is VSCC-regulated and that functions in the VSCC-dependent survival of these neurons.	HARVARD UNIV, SCH MED, DEPT MICROBIOL & MOLEC GENET, BOSTON, MA 02115 USA; AMGEN INC, THOUSAND OAKS, CA 91320 USA	Harvard University; Harvard Medical School; Amgen					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028829, R37NS028829] Funding Source: NIH RePORTER; NINDS NIH HHS [NS28829] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BADING H, 1991, SCIENCE, V253, P912, DOI 10.1126/science.1715095; BARDE YA, 1980, P NATL ACAD SCI-BIOL, V77, P1199, DOI 10.1073/pnas.77.2.1199; Bayer S.A., 1991, NEOCORTICAL DEV; BAYER SA, 1990, EXP NEUROL, V107, P48, DOI 10.1016/0014-4886(90)90062-W; BLACK IB, 1972, J NEUROCHEM, V19, P1367, DOI 10.1111/j.1471-4159.1972.tb01461.x; BONNI A, UNPUB; CASTREN E, 1992, P NATL ACAD SCI USA, V89, P9444, DOI 10.1073/pnas.89.20.9444; CHALAZONITIS A, 1980, DEV BIOL, V78, P173, DOI 10.1016/0012-1606(80)90327-9; CHOI DW, 1988, TRENDS NEUROSCI, V11, P465, DOI 10.1016/0166-2236(88)90200-7; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLINS F, 1989, BRAIN RES, V502, P99, DOI 10.1016/0006-8993(89)90465-4; COLLINS F, 1991, J NEUROSCI, V11, P2582; FRANKLIN JL, 1992, TRENDS NEUROSCI, V15, P501, DOI 10.1016/0166-2236(92)90103-F; FURBER S, 1987, J NEUROSCI, V7, P1816; GALLI L, 1988, SCIENCE, V242, P90, DOI 10.1126/science.3175637; GALLO V, 1987, J NEUROSCI, V7, P2203; Ghosh A., UNPUB; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; GUILLERY RW, 1973, J COMP NEUROL, V149, P423, DOI 10.1002/cne.901490403; HASHISAKI GT, 1989, J COMP NEUROL, V283, P465, DOI 10.1002/cne.902830402; HOFER M, 1990, EMBO J, V9, P2459, DOI 10.1002/j.1460-2075.1990.tb07423.x; ISACKSON PJ, 1991, NEURON, V6, P937, DOI 10.1016/0896-6273(91)90234-Q; KOIKE T, 1989, P NATL ACAD SCI USA, V86, P6421, DOI 10.1073/pnas.86.16.6421; KOIKE T, 1991, P NATL ACAD SCI USA, V88, P3892, DOI 10.1073/pnas.88.9.3892; KOKAIA Z, 1993, P NATL ACAD SCI USA, V90, P6711, DOI 10.1073/pnas.90.14.6711; LARMET Y, 1992, NEURON, V9, P563, DOI 10.1016/0896-6273(92)90193-H; LINDSAY RM, 1985, DEV BIOL, V112, P319, DOI 10.1016/0012-1606(85)90402-6; MADERDRUT JL, 1988, BRAIN RES, V444, P189, DOI 10.1016/0006-8993(88)90928-6; MAISONPIERRE PC, 1990, NEURON, V5, P501, DOI 10.1016/0896-6273(90)90089-X; MEISTER M, 1991, SCIENCE, V252, P939, DOI 10.1126/science.2035024; MIRANDA RC, 1993, P NATL ACAD SCI USA, V90, P6439, DOI 10.1073/pnas.90.14.6439; NISHI R, 1981, DEV BIOL, V87, P301, DOI 10.1016/0012-1606(81)90153-6; PASIC TR, 1989, J COMP NEUROL, V283, P474, DOI 10.1002/cne.902830403; SCOTT BS, 1970, EXP NEUROL, V27, P16, DOI 10.1016/0014-4886(70)90197-4; TYMIANSKI M, 1993, J NEUROSCI, V13, P2085; YUSTE R, 1992, SCIENCE, V257, P666, DOI 10.1126/science.1496379; ZAFRA F, 1990, EMBO J, V9, P3545, DOI 10.1002/j.1460-2075.1990.tb07564.x; ZAFRA F, 1992, J NEUROSCI, V12, P4793	38	815	835	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 18	1994	263	5153					1618	1623		10.1126/science.7907431	http://dx.doi.org/10.1126/science.7907431			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NB673	7907431				2022-12-24	WOS:A1994NB67300034
J	CRYNS, VL; THOR, A; XU, HJ; HU, SX; WIERMAN, ME; VICKERY, AL; BENEDICT, WF; ARNOLD, A				CRYNS, VL; THOR, A; XU, HJ; HU, SX; WIERMAN, ME; VICKERY, AL; BENEDICT, WF; ARNOLD, A			LOSS OF THE RETINOBLASTOMA TUMOR-SUPPRESSOR GENE IN PARATHYROID CARCINOMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SUSCEPTIBILITY GENE; CELL-CYCLE; EXPRESSION; PROTEIN; CANCER; POLYMORPHISMS; PROGRESSION; DIAGNOSIS; FEATURES; SEQUENCE	Background. The origin and molecular pathogenesis of parathyroid carcinoma are unknown. This life-threatening cause of primary hyperparathyroidism cannot be reliably distinguished from its benign counterpart on the basis of histopathological features alone. Because the PRAD1, or cyclin D1, gene, a cell-cycle regulator, has been implicated in a subgroup of benign parathyroid tumors, we examined the possibility that another cell-cycle regulator with possible functional links to PRAD1, the retinoblastoma tumor-suppressor gene (RB), might be involved in the molecular pathogenesis of parathyroid carcinoma. Methods. Parathyroid carcinomas from 9 patients and adenomas from 21 were studied for evidence of tumor-specific loss of RB gene DNA (allelic loss) by analysis of four DNA polymorphisms and for evidence of altered expression of RB protein by immunohistochemical staining. Results. All of 11 specimens from 5 patients with parathyroid carcinoma and informative DNA patterns and 1 of 19 specimens from 19 patients with parathyroid adenoma and informative DNA patterns lacked an RB allele. Fourteen of 16 specimens (88 percent) from the nine patients with carcinoma had abnormal expression of RB protein (a complete or predominant absence of nuclear staining for the protein). None of the 19 adenomas, including the tumor with loss of an RB allele, had unequivocally abnormal staining for RB protein. Conclusions. Inactivation of the RB gene is common in parathyroid carcinoma and is likely to be an important contributor to its molecular pathogenesis. The presence of such inactivation may help to distinguish benign from malignant parathyroid disease and may have useful diagnostic, prognostic, and therapeutic implications.	MASSACHUSETTS GEN HOSP, DEPT MED, ENDOCRINE ONCOL LAB, BOSTON, MA 02114 USA; MASSACHUSETTS GEN HOSP, CTR CANC, BOSTON, MA 02114 USA; MASSACHUSETTS GEN HOSP, DEPT PATHOL, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, BOSTON, MA USA; BAYLOR COLL MED, CTR BIOTECHNOL, THE WOODLANDS, TX 77381 USA; VET AFFAIRS MED CTR, ENDOCRINOL SECT, DENVER, CO USA; UNIV COLORADO, HLTH SCI CTR, DENVER, CO USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NCI NIH HHS [1K08 CA-01752-01A1, 1F32 CA-0938101] Funding Source: Medline; NIDDK NIH HHS [5T32 DK-0702817] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA001752, F32CA009381] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007028] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON BJ, 1983, SURGERY, V94, P906; ARNOLD A, 1988, NEW ENGL J MED, V318, P658, DOI 10.1056/NEJM198803173181102; ARNOLD A, 1989, J CLIN INVEST, V83, P2034, DOI 10.1172/JCI114114; BENEDICT WF, 1990, J CLIN INVEST, V85, P988, DOI 10.1172/JCI114575; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CRYNS VL, 1993, J CLIN ENDOCR METAB, V77, P644, DOI 10.1210/jc.77.3.644; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; IWAMURA Y, 1992, JPN J CLIN ONCOL, V22, P6; KAY S, 1973, ARCH PATHOL, V96, P316; LEVIN KE, 1987, SURGERY, V101, P649; LOGOTHETIS CJ, 1992, J NATL CANCER I, V84, P1256, DOI 10.1093/jnci/84.16.1256; MALLETTE LE, 1992, AM J CLIN PATHOL, V98, P305, DOI 10.1093/ajcp/98.3.305; MATSUO K, 1991, MOL ENDOCRINOL, V5, P1873, DOI 10.1210/mend-5-12-1873; MCGEE TL, 1989, GENE, V80, P119, DOI 10.1016/0378-1119(89)90256-4; MCGEE TL, 1990, NUCLEIC ACIDS RES, V18, P207, DOI 10.1093/nar/18.1.207-a; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; ROTH SI, 1962, ARCH PATHOL, V73, P495; SAMBROOK J, 1989, MOL CLONING LABORATO, V2; SANDELIN K, 1992, WORLD J SURG, V16, P724, DOI 10.1007/BF02067369; SCHANTZ A, 1973, CANCER-AM CANCER SOC, V31, P600, DOI 10.1002/1097-0142(197303)31:3<600::AID-CNCR2820310316>3.0.CO;2-0; SHANE E, 1982, ENDOCR REV, V3, P218, DOI 10.1210/edrv-3-2-218; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SMITH JF, 1984, J CLIN PATHOL, V37, P1370, DOI 10.1136/jcp.37.12.1370; SNOVER DC, 1981, AM J CLIN PATHOL, V75, P345; WANG CA, 1985, AM J SURG, V149, P522, DOI 10.1016/S0002-9610(85)80050-7; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WIGGS J, 1988, NEW ENGL J MED, V318, P151, DOI 10.1056/NEJM198801213180305; WRIGHT DK, 1990, PCR PROTOCOLS GUIDE, P153; WYNNE AG, 1992, MEDICINE, V71, P197, DOI 10.1097/00005792-199207000-00002; XU HJ, 1991, CANCER RES, V51, P2735; XU HJ, 1991, ONCOGENE, V6, P1139; YANDELL DW, 1989, AM J HUM GENET, V45, P547	35	233	238	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 17	1994	330	11					757	761		10.1056/NEJM199403173301105	http://dx.doi.org/10.1056/NEJM199403173301105			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NA742	7906387	Bronze			2022-12-24	WOS:A1994NA74200005
J	HIRAOKA, M; KASUGA, K; HORI, C; SUDO, M				HIRAOKA, M; KASUGA, K; HORI, C; SUDO, M			ULTRASONIC INDICATORS OF URETERAL REFLUX IN THE NEWBORN	LANCET			English	Note							URINARY-TRACT; CHILDREN	There is controversy over the value of ultrasonic screening for detection of vesicoureteric reflux (VUR) in babies. We scanned 300 newborn babies and identified 53 with a dilated renal pelvis or other minor abnormalities. Eventually, 9 of these were investigated by voiding cystourethrography and 3 (5 kidneys) proved to have VUR exceeding grade II, In 3 babies the reason for cystourethrography was persistent renal pelvis dilation; in 3 it was urinary tract infection; and in 3 it was a new ultrasonic sign observed early in the series-ballooning of the renal pelvis during voiding. Whereas persistent dilation of the renal pelvis was a non-specific indicator (absent in 2 of the 5 affected kidneys and present in 5 of those unaffected), ballooning was consistently seen in all 5 affected renal pelvises. This sign, easily obtained in a baby who has been sleeping, deserves prospective assessment for its value in screening.	KASUGA LADLES CLIN,HARUE,FUKUI 91904,JAPAN		HIRAOKA, M (corresponding author), FUKUI MED SCH,DEPT PEDIAT,MATSUOKA,FUKUI 91011,JAPAN.							GORDON AC, 1990, BRIT J UROL, V65, P407, DOI 10.1111/j.1464-410X.1990.tb14766.x; HINCHLIFFE SA, 1992, PEDIATR NEPHROL, V6, P439, DOI 10.1007/BF00874007; SCOTT JES, 1991, LANCET, V338, P1571, DOI 10.1016/0140-6736(91)92385-F; STEELE BT, 1989, J PEDIATR-US, V115, P95, DOI 10.1016/S0022-3476(89)80337-3; STEINHART JM, 1988, PEDIATRICS, V82, P609; TSAI TC, 1989, J CLIN ULTRASOUND, V17, P647, DOI 10.1002/jcu.1870170906; VERBER IG, 1989, ARCH DIS CHILD, V64, P1533, DOI 10.1136/adc.64.11.1533; 1991, LANCET, V338, P1050	8	26	26	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 26	1994	343	8896					519	520		10.1016/S0140-6736(94)91466-4	http://dx.doi.org/10.1016/S0140-6736(94)91466-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MX888	7906765				2022-12-24	WOS:A1994MX88800014
J	JOSEPH, AM				JOSEPH, AM			IS CONGRESS BLOWING SMOKE AT THE VA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											JOSEPH, AM (corresponding author), VET AFFAIRS MED CTR,GEN INTERNAL MED SECT,1 VET DR,MINNEAPOLIS,MN 55417, USA.			Joseph, Anne/0000-0002-3440-2679				ALLEN A, 1989, VA PRACT         FEB, P15; DAWLEY HH, 1989, VA PRACT         APR, P47; JOSEPH A, 1988, JAMA-J AM MED ASSOC, V260, P1551, DOI 10.1001/jama.1988.03410110059012; JOSEPH AM, 1992, JAMA-J AM MED ASSOC, V267, P87; LUCK TC, 1990, VA PRACT         JAN, P71; MCALLISTER B, 1992, WASHINGTON POST 0604, pA27; SIROTA AD, 1987, VA PRACT         FEB, P11; 1990, 1090142 US DEP VET A; 1992, SMOKE FREE ENV SMO S, V1; 1993, MA1314 JOINT COMM AC; 1990, 1090141 US DEP VET A; 1992, EPA600690006F PUBL; 1986, HLTH CONSEQUENCES IN; 1993, FY1992 US DEP VET AF; 1993, ESTABLISHING PATIENT	15	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 19	1994	272	15					1215	1216		10.1001/jama.272.15.1215	http://dx.doi.org/10.1001/jama.272.15.1215			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL212	7933352				2022-12-24	WOS:A1994PL21200038
J	CHANG, EC; BARR, M; WANG, Y; JUNG, V; XU, HP; WIGLER, MH				CHANG, EC; BARR, M; WANG, Y; JUNG, V; XU, HP; WIGLER, MH			COOPERATIVE INTERACTION OF S-POMBE PROTEINS REQUIRED FOR MATING AND MORPHOGENESIS	CELL			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; SCHIZOSACCHAROMYCES-POMBE; GENE-PRODUCT; SEXUAL-DIFFERENTIATION; SIGNAL TRANSDUCTION; MOLECULAR-CLONING; SEQUENCE-ANALYSIS; EXCHANGE FACTOR; HUMAN ONCOGENE; CELL POLARITY	We isolated two S. pombe genes, scd1 and scd2, that are required for normal morphology and mating. scd1 and scd1 are homologous to CDC24 and BEM1, respectively, of S. cerevisiae. Epistasis analyses indicate that scd2 and rest converge upon scd1, which, in turn, interacts with cdc42sp, a RHO-like GTPase. Studies with the yeast two-hybrid system indicate that scd2 forms complexes with both scd1 and cdc42sp. Furthermore, biochemical studies indicate that the interaction between scd1 and scd2 is direct. The yeast two-hybrid data further suggest that scd1, scd2, cdc42sp, and ras1, in its GTP-bound state, act cooperatively to form a protein complex.			CHANG, EC (corresponding author), COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724, USA.			Wigler, Michael/0000-0003-4396-1971				ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; ADAMS JM, 1992, ONCOGENE, V7, P611; BALLESTER R, 1989, CELL, V59, P681, DOI 10.1016/0092-8674(89)90014-7; BENDER A, 1991, MOL CELL BIOL, V11, P1295, DOI 10.1128/MCB.11.3.1295; BENDER A, 1989, P NATL ACAD SCI USA, V86, P9976, DOI 10.1073/pnas.86.24.9976; CEN H, 1992, EMBO J, V11, P4007, DOI 10.1002/j.1460-2075.1992.tb05494.x; CHANT J, 1991, CELL, V65, P1203, DOI 10.1016/0092-8674(91)90015-Q; CHENEVERT J, 1992, NATURE, V356, P77, DOI 10.1038/356077a0; COTTAREL G, 1993, CURR GENET, V23, P547, DOI 10.1007/BF00312650; DOWNWARD J, 1992, NATURE, V358, P282, DOI 10.1038/358282a0; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FAWELL E, 1992, GENE, V114, P153, DOI 10.1016/0378-1119(92)90724-4; FEIG LA, 1986, P NATL ACAD SCI USA, V83, P4607, DOI 10.1073/pnas.83.13.4607; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FUKUI Y, 1988, MOL GEN GENET, V215, P26, DOI 10.1007/BF00331298; FUKUI Y, 1986, CELL, V44, P329, DOI 10.1016/0092-8674(86)90767-1; FUKUI Y, 1985, EMBO J, V4, P687, DOI 10.1002/j.1460-2075.1985.tb03684.x; FUKUI Y, 1989, MOL CELL BIOL, V9, P5617, DOI 10.1128/MCB.9.12.5617; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HARLOW E, 1988, ANTIBODIES LABORATOR; HARTWELL LH, 1973, GENETICS, V74, P267; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOFFMAN CS, 1990, GENETICS, V124, P807; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KAWAMUKAI M, 1992, MOL BIOL CELL, V3, P167, DOI 10.1091/mbc.3.2.167; MARCUS S, 1994, P NATL ACAD SCI USA, V91, P7762, DOI 10.1073/pnas.91.16.7762; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; MCLEOD M, 1987, EMBO J, V6, P729, DOI 10.1002/j.1460-2075.1987.tb04814.x; MILLER PJ, 1994, MOL CELL BIOL, V14, P1075, DOI 10.1128/MCB.14.2.1075; MIYAMOTO S, 1987, GENE, V54, P125, DOI 10.1016/0378-1119(87)90354-4; MIYAMOTO S, 1991, BIOCHEM BIOPH RES CO, V181, P604, DOI 10.1016/0006-291X(91)91233-3; MOLZ L, 1989, GENETICS, V122, P773; MUNDER T, 1992, MOL CELL BIOL, V12, P2091, DOI 10.1128/MCB.12.5.2091; NADINDAVIS SA, 1986, EMBO J, V5, P2963, DOI 10.1002/j.1460-2075.1986.tb04593.x; NEIMAN AM, 1993, MOL BIOL CELL, V4, P107, DOI 10.1091/mbc.4.1.107; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; POWERS S, 1991, CELL, V65, P1225, DOI 10.1016/0092-8674(91)90017-S; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RIDLEY AL, 1993, CELL, V70, P389; RIDLEY AL, 1993, CELL, V70, P401; RODAWAY ARF, 1989, NATURE, V342, P624, DOI 10.1038/342624a0; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SLOAT BF, 1981, J CELL BIOL, V89, P395, DOI 10.1083/jcb.89.3.395; SZANKASI P, 1988, J MOL BIOL, V204, P917, DOI 10.1016/0022-2836(88)90051-4; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WANG Y, 1991, MOL CELL BIOL, V11, P3554, DOI 10.1128/MCB.11.7.3554; WIGLER M, 1988, COLD SPRING HARB SYM, V53, P649, DOI 10.1101/SQB.1988.053.01.074; WILLUMSEN BM, 1984, EMBO J, V3, P2581, DOI 10.1002/j.1460-2075.1984.tb02177.x; XU HP, 1990, CELL REGUL, V1, P763, DOI 10.1091/mbc.1.10.763; XU HP, 1994, MOL CELL BIOL, V14, P50, DOI 10.1128/MCB.14.1.50; ZHENG Y, 1994, J BIOL CHEM, V269, P2369	59	255	259	1	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 7	1994	79	1					131	141		10.1016/0092-8674(94)90406-5	http://dx.doi.org/10.1016/0092-8674(94)90406-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PK585	7923372				2022-12-24	WOS:A1994PK58500014
J	STEWART, THM				STEWART, THM			POSTMASTECTOMY RADIOTHERAPY - MORE THAN A LOCAL MATTER	LANCET			English	Editorial Material							BREAST-CANCER				STEWART, THM (corresponding author), OTTAWA GEN HOSP,DEPT MED,OTTAWA K1H 8L6,ON,CANADA.							CUZICK J, 1987, CANCER TREAT REP, V71, P15; CUZICK J, 1994, J CLIN ONCOL, V12, P447, DOI 10.1200/JCO.1994.12.3.447; OVERGAARD M, 1990, INT J RADIAT ONCOL, V19, P1121, DOI 10.1016/0360-3016(90)90214-5; PREHN TR, 1994, CANCER RES, V54, P908; RAGAZ J, 1993, P AN M AM SOC CLIN, V12, P60; ROTSTEIN S, 1985, INT J RADIAT ONCOL, V11, P921, DOI 10.1016/0360-3016(85)90114-2; STEWART THM, 1993, CLIN EXP METASTAS, V11, P295, DOI 10.1007/BF00058049; STEWART THM, 1992, CELLULAR IMMUNE MECHANISMS AND TUMOR DORMANCY, P213; STEWART THM, 1994, LANCET, V343, P402; STJERNSW.J, 1974, LANCET, V2, P1285, DOI 10.1016/S0140-6736(74)90142-1	10	10	10	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 6	1994	344	8919					351	352		10.1016/S0140-6736(94)91396-X	http://dx.doi.org/10.1016/S0140-6736(94)91396-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PA303	7914302				2022-12-24	WOS:A1994PA30300005
J	MILLER, FH				MILLER, FH			INFANT RESUSCITATION, A US UK DIVIDE	LANCET			English	Editorial Material											MILLER, FH (corresponding author), BOSTON UNIV,SCH LAW,BOSTON,MA 02215, USA.							BRAHAMS D, 1992, LANCET, V339, P1472, DOI 10.1016/0140-6736(92)92052-H	1	2	2	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 25	1994	343	8913					1584	1585		10.1016/S0140-6736(94)93051-1	http://dx.doi.org/10.1016/S0140-6736(94)93051-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU354	7911914				2022-12-24	WOS:A1994NU35400004
J	SEMBA, RD; MIOTTI, PG; CHIPHANGWI, JD; SAAH, AJ; CANNER, JK; DALLABETTA, GA; HOOVER, DR				SEMBA, RD; MIOTTI, PG; CHIPHANGWI, JD; SAAH, AJ; CANNER, JK; DALLABETTA, GA; HOOVER, DR			MATERNAL VITAMIN-A-DEFICIENCY AND MOTHER-TO-CHILD TRANSMISSION OF HIV-1	LANCET			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; A-DEFICIENCY; INFECTION; RISK; ASSOCIATION; INFANTS; WOMEN	Studies show that around 10-40% HIV-positive women will give birth to children who are also infected. However, the risk factors for transmission from mother to child are not well understood and the effects of maternal nutritional status are unknown. We conducted a study of vitamin A status in pregnant women as a risk factor for mother-to-child transmission of HIV in Malawi. Serum vitamin A, height, weight, CD4 T-cell counts, and duration of breastfeeding were measured in 338 HIV-positive mothers whose infant's HIV serostatus was known. Mother-to-child transmission of HIV was 21.9% among mothers whose infants survived to 12 months of age. Mean vitamin A concentration in 74 mothers who transmitted HIV to their infants was lower than that in 264 mothers who did not transmit HIV to their infants (0.86 [0.03] vs 1.07 [0.02], p<0.0001). We divided HIV positive mothers to 4 groups, those with vitamin A concentrations of less than 0.70, between 0.70 and 1.05, between 1.05 and 1.40, and greater than or equal to 1.40 mu mol/L. The mother-to-child transmission rates for each group were 32.4%, 26.2%, 16.0%, and 7.2%, respectively (p<0.0001). Maternal CD4 cell counts, CD4%, and CD4/CD8 ratio were also associated with increased mother-to-child transmission of HIV. Maternal age, body-mass index, and breastfeeding practices were not significantly associated with higher mother-to-child transmission. Our study suggests that maternal vitamin A deficiency contributes to mother-to-child transmission of HIV.	DEPT INT HLTH,DIV HUMAN NUTR,BALTIMORE,MD 21287; MALAWI MED COLL,BLANTYRE,MALAWI; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT EPIDEMIOL,PROGRAM INFECT DIS,BALTIMORE,MD	University of Malawi; Johns Hopkins University	SEMBA, RD (corresponding author), DANA CTR,DEPT IMMUNOL & INFECT DIS,600 N WOLFE ST,BALTIMORE,MD 21287, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD030042, R55HD030042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI026499, R21AI033874] Funding Source: NIH RePORTER; NIAID NIH HHS [AI26499, AI33874] Funding Source: Medline; NICHD NIH HHS [HD30042] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BAUM MK, 1991, J ACQ IMMUN DEF SYND, V4, P1122; BEACH RS, 1992, AIDS, V6, P701, DOI 10.1097/00002030-199207000-00013; BLANCHE S, 1989, NEW ENGL J MED, V320, P1643, DOI 10.1056/NEJM198906223202502; BOYLAN L, 1991, EPIDEMIOL REV, V13, P143, DOI 10.1093/oxfordjournals.epirev.a036067; BRAY GA, 1978, INT J OBESITY, V2, P99; BUCK J, 1990, J EXP MED, V171, P1613, DOI 10.1084/jem.171.5.1613; CAMPOS FACS, 1987, AM J CLIN NUTR, V46, P91, DOI 10.1093/ajcn/46.1.91; DABIS F, 1993, AIDS, V7, P1139, DOI 10.1097/00002030-199308000-00027; DUNN DT, 1992, LANCET, V340, P585, DOI 10.1016/0140-6736(92)92115-V; Dushimimana A., 1992, 8 INT C AIDS AMST; GAL I, 1974, AM J CLIN NUTR, V27, P688, DOI 10.1093/ajcn/27.7.688; GARBE A, 1992, J EXP MED, V176, P109, DOI 10.1084/jem.176.1.109; GOEDERT JJ, 1991, LANCET, V338, P1471, DOI 10.1016/0140-6736(91)92297-F; GOEDERT JJ, 1989, LANCET, V2, P1351; GRAHAM NMH, 1991, J ACQ IMMUN DEF SYND, V4, P976; LEPAGE P, 1993, AM J EPIDEMIOL, V137, P589, DOI 10.1093/oxfordjournals.aje.a116716; MIOTTI PG, 1992, J INFECT DIS, V165, P1116, DOI 10.1093/infdis/165.6.1116; MIOTTI PG, 1993, 9TH INT C AIDS BERL; RYDER RW, 1989, NEW ENGL J MED, V320, P1637, DOI 10.1056/NEJM198906223202501; SEMBA RD, 1993, LANCET, V341, P5, DOI 10.1016/0140-6736(93)92478-C; SEMBA RD, 1992, J NUTR, V122, P101, DOI 10.1093/jn/122.1.101; SEMBA RD, 1993, ARCH INTERN MED, V153, P2149, DOI 10.1001/archinte.153.18.2149; SEMBA RD, 1994, IN PRESS CLIN INFECT; SOMMER A, 1987, AM J CLIN NUTR, V45, P977, DOI 10.1093/ajcn/45.5.977; TANG AM, 1993, AM J EPIDEMIOL, V138, P937, DOI 10.1093/oxfordjournals.aje.a116814; Wallingford JC, 1986, VITAMIN A DEFICIENCY, P101; 1988, LANCET, V2, P1043; 1992, LANCET, V339, P1007	29	309	316	0	10	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 25	1994	343	8913					1593	1597		10.1016/S0140-6736(94)93056-2	http://dx.doi.org/10.1016/S0140-6736(94)93056-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU354	7911919	hybrid			2022-12-24	WOS:A1994NU35400009
J	LEUNG, J; BOUVIERDURAND, M; MORRIS, PC; GUERRIER, D; CHEFDOR, F; GIRAUDAT, J				LEUNG, J; BOUVIERDURAND, M; MORRIS, PC; GUERRIER, D; CHEFDOR, F; GIRAUDAT, J			ARABIDOPSIS ABA RESPONSE GENE ABI1 - FEATURES OF A CALCIUM-MODULATED PROTEIN PHOSPHATASE	SCIENCE			English	Article							ARTIFICIAL CHROMOSOME LIBRARY; THALIANA L HEYNH; ABSCISIC-ACID; COLD-ACCLIMATION; GUARD-CELLS; EXPRESSION; ACTIVATOR; MUTATIONS; STOMATA; CLONING	The Arabidopsis ABI1 locus is essential for a wide spectrum of abscisic acid (ABA) responses throughout plant development. Here, ABI1 was shown to regulate stomatal aperture in leaves and mitotic activity in root meristems. The ABI1 gene was cloned and predicted to encode a signaling protein. Although its carboxyl-terminal domain is related to serine-threonine phosphatase 2C, the ABI1 protein has a unique amino-terminal extension containing an EF hand calcium-binding site. These results suggest that the ABI1 protein is a Ca2+-modulated phosphatase and functions to integrate ABA and Ca2+ signals with phosphorylation-dependent response pathways.	INST SCI VEGETALES, CNRS, UPR 40, F-91198 GIF SUR YVETTE, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay				Morris, Peter/0000-0003-0919-6305				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BAIROCH A, 1992, NUCLEIC ACIDS RES, V20, P2013, DOI 10.1093/nar/20.suppl.2013; BLATT MR, 1993, ANNU REV PLANT PHYS, V44, P543, DOI 10.1146/annurev.pp.44.060193.002551; BOUVIERDURAND M, 1989, PLANT PHYSIOL BIOCH, V27, P511; BOUVIERDURAND M, UNPUB; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; DEBLAERE R, 1985, NUCLEIC ACIDS RES, V13, P4777, DOI 10.1093/nar/13.13.4777; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FINKELSTEIN RR, 1990, PLANT PHYSIOL, V94, P1172, DOI 10.1104/pp.94.3.1172; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GILMOUR SJ, 1991, PLANT MOL BIOL, V17, P1233, DOI 10.1007/BF00028738; GILROY S, 1992, CURR PLANT SCI BIOT, V13, P105; GIRAUDAT J, 1992, PLANT CELL, V4, P1251, DOI 10.1105/tpc.4.10.1251; GRILL E, 1991, MOL GEN GENET, V226, P484, DOI 10.1007/BF00260662; GUILTINAN MJ, 1990, SCIENCE, V250, P267, DOI 10.1126/science.2145628; HAUGE BM, 1993, PLANT J, V3, P745, DOI 10.1111/j.1365-313X.1993.00745.x; HETHERINGTON AM, 1991, NEW PHYTOL, V119, P9, DOI 10.1111/j.1469-8137.1991.tb01004.x; HORNBERG C, 1984, NATURE, V310, P321, DOI 10.1038/310321a0; JACOBS T, 1992, DEV BIOL, V153, P1, DOI 10.1016/0012-1606(92)90087-W; KOORNNEEF M, 1984, PHYSIOL PLANTARUM, V61, P377, DOI 10.1111/j.1399-3054.1984.tb06343.x; LANG V, 1992, PLANT MOL BIOL, V20, P951, DOI 10.1007/BF00027165; LEE Y, 1991, P NATL ACAD SCI USA, V88, P2127, DOI 10.1073/pnas.88.6.2127; LEUNG J, 1991, J MOL BIOL, V219, P175, DOI 10.1016/0022-2836(91)90560-S; LEUNG J, UNPUB; LEVI M, 1990, PHYSIOL PLANTARUM, V79, P231; LEVI M, 1993, IN VITRO CELL DEV-PL, V29P, P47, DOI 10.1007/BF02632250; LUAN S, 1993, P NATL ACAD SCI USA, V90, P2202, DOI 10.1073/pnas.90.6.2202; MAEDA T, 1993, MOL CELL BIOL, V13, P5408, DOI 10.1128/MCB.13.9.5408; MCAINSH MR, 1991, ABSCISIC ACID PHYSL, P137; MCCARTY DR, 1991, CELL, V66, P895, DOI 10.1016/0092-8674(91)90436-3; MONCRIEF ND, 1990, J MOL EVOL, V30, P522, DOI 10.1007/BF02101108; NORDIN K, 1993, PLANT MOL BIOL, V21, P641, DOI 10.1007/BF00014547; OEDA K, 1991, EMBO J, V10, P1793, DOI 10.1002/j.1460-2075.1991.tb07704.x; PUTNOKY P, 1990, J BACTERIOL, V172, P5450, DOI 10.1128/jb.172.9.5450-5458.1990; SCHNALL JA, 1992, PLANT PHYSIOL, V100, P216, DOI 10.1104/pp.100.1.216; SCHROEDER JI, 1992, PHILOS T R SOC B, V338, P83, DOI 10.1098/rstb.1992.0131; SKRIVER K, 1990, PLANT CELL, V2, P503, DOI 10.1105/tpc.2.6.503; Staiger C, 1993, CURR OPIN CELL BIOL, V5, P226, DOI 10.1016/0955-0674(93)90107-2; TAMURA S, 1989, P NATL ACAD SCI USA, V86, P1796, DOI 10.1073/pnas.86.6.1796; VALVEKENS D, 1988, P NATL ACAD SCI USA, V85, P5536, DOI 10.1073/pnas.85.15.5536; VARTANIAN N, 1994, PLANT PHYSIOL, V104, P761, DOI 10.1104/pp.104.2.761; WARD ER, 1990, PLANT MOL BIOL, V14, P561, DOI 10.1007/BF00027501; YAMAGUCHISHINOZAKI K, 1993, MOL GEN GENET, V236, P331, DOI 10.1007/BF00277130; ZEEVAART JAD, 1988, ANNU REV PLANT PHYS, V39, P439, DOI 10.1146/annurev.pp.39.060188.002255	44	652	683	4	110	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 3	1994	264	5164					1448	1452		10.1126/science.7910981	http://dx.doi.org/10.1126/science.7910981			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NP221	7910981				2022-12-24	WOS:A1994NP22100039
J	MERINEY, SD; GRAY, DB; PILAR, GR				MERINEY, SD; GRAY, DB; PILAR, GR			SOMATOSTATIN-INDUCED INHIBITION OF NEURONAL CA2+ CURRENT MODULATED BY CGMP-DEPENDENT PROTEIN-KINASE	NATURE			English	Article							RAT SYMPATHETIC NEURONS; CHICK SENSORY NEURONS; CALCIUM CURRENT; GANGLION NEURONS; CILIARY GANGLION; BINDING PROTEIN; CHANNELS; ACTIVATION; PATHWAYS	NEUROTRANSMITTER release is frequently regulated by peptides that modulate neuronal calcium channels. Whole-cell recordings show that the ion permeability(1) and voltage dependence(2) of these channels are controlled by a membrane-associated pathway involving GTP-binding proteins. Here we use perforated-patch recordings to show that, in addition to this pathway, the peptide somatostatin inhibits the calcium current in chick ciliary ganglion neurons by a second soluble pathway involving a cyclic GMP-dependent protein kinase (cGMP-PK). This somatostatin inhibition of Ca2+ current did not desensitize and was not characterized by the slowing of Ca2+-current activation (kinetic slowing) observed in whole-cell recordings. When cGMP-PK was inhibited, somatostatin inhibition of Ca2+ current resembled that observed with whole-cell recordings. cGMP agonists mimic the effect of somatostatin only in perforated patch recordings. An endogenous cGMP-PK therefore forms part of the mechanism by which somatostatin induces a sustained inhibition of neuronal calcium channels.	UNIV CONNECTICUT,DEPT PHYSIOL & NEUROBIOL,STORRS,CT 06269	University of Connecticut								ASHKENAZIE A, 1987, SCIENCE, V238, P272; BEAN BP, 1989, NATURE, V340, P153, DOI 10.1038/340153a0; BLEY KR, 1990, NEURON, V2, P379; BUTT E, 1990, FEBS LETT, V263, P47, DOI 10.1016/0014-5793(90)80702-K; DIVERSEPIERLUISSI M, 1993, NEURON, V10, P753, DOI 10.1016/0896-6273(93)90175-Q; DRYER SE, 1991, NEUROSCIENCE, V44, P663, DOI 10.1016/0306-4522(91)90086-4; ELMSLIE KS, 1990, NEURON, V5, P75, DOI 10.1016/0896-6273(90)90035-E; GOLARD A, 1993, J NEUROSCI, V13, P3884; GRASSI F, 1989, NEUROSCI LETT, V105, P113, DOI 10.1016/0304-3940(89)90021-9; GRAY DB, 1990, J NEUROSCI, V10, P2687; HILLE B, 1992, NEURON, V9, P187, DOI 10.1016/0896-6273(92)90158-A; IKEDA SR, 1989, J PHYSIOL-LONDON, V409, P221, DOI 10.1113/jphysiol.1989.sp017494; KASAI H, 1989, PFLUG ARCH EUR J PHY, V414, P145, DOI 10.1007/BF00580956; KUO CC, 1993, NATURE, V365, P258, DOI 10.1038/365258a0; LEWIS DL, 1986, P NATL ACAD SCI USA, V83, P9035, DOI 10.1073/pnas.83.23.9035; MARCHETTI C, 1986, PFLUG ARCH EUR J PHY, V406, P104, DOI 10.1007/BF00586670; MATTERA R, 1989, SCIENCE, V243, P804, DOI 10.1126/science.2536957; PENINGTON NJ, 1991, J NEUROSCI, V11, P3594, DOI 10.1523/jneurosci.11-11-03594.1991; RAE J, 1991, J NEUROSCI METH, V37, P15, DOI 10.1016/0165-0270(91)90017-T; SAH DWY, 1990, J NEUROSCI, V10, P136; SHAPIRO MS, 1993, NEURON, V10, P11, DOI 10.1016/0896-6273(93)90237-L; WANG HL, 1990, NEUROSCIENCE, V38, P335, DOI 10.1016/0306-4522(90)90032-Y; WANKE E, 1987, P NATL ACAD SCI USA, V84, P4313, DOI 10.1073/pnas.84.12.4313; WENTZEK LAF, 1993, J NEUROSCI, V13, P3143; YATANI A, 1987, SCIENCE, V238, P1288, DOI 10.1126/science.2446390	25	126	127	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 26	1994	369	6478					336	339		10.1038/369336a0	http://dx.doi.org/10.1038/369336a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NN109	7910377				2022-12-24	WOS:A1994NN10900055
J	LAI, ME; MAZZOLENI, AP; ARGIOLU, F; DEVIRGILIS, S; BALESTRIERI, A; PURCELL, RH; CAO, A; FARCI, P				LAI, ME; MAZZOLENI, AP; ARGIOLU, F; DEVIRGILIS, S; BALESTRIERI, A; PURCELL, RH; CAO, A; FARCI, P			HEPATITIS-C VIRUS IN MULTIPLE EPISODES OF ACUTE HEPATITIS IN POLYTRANSFUSED THALASSEMIC CHILDREN	LANCET			English	Note							NON-B-HEPATITIS; NON-A	We investigated the course of distinct episodes of acute non-A, non-B (NANB) hepatitis in three polytransfused thalassaemic children. In each case, the first episode was associated with the appearance of serum hepatitis C virus (HCV) RNA and anti-HCV seroconversion. The second episode was accompanied by the reappearance of HCV viraemia, which in two patients was due to reinfection with a different HCV strain and in the third could be the result of either reactivation of primary infection or reinfection with a new but closely related strain. Thus HCV infection may not induce protective immunity, which has implications for vaccine development.	UNIV CAGLIARI,INST CLIN & BIOL DEV AGE,CAGLIARI,ITALY; UNIV CAGLIARI,CTR THALASSAEMIA,CAGLIARI,ITALY; NIAID,INFECT DIS LAB,HEPATITIS VIRUSES SECT,BETHESDA,MD 20892	University of Cagliari; University of Cagliari; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	LAI, ME (corresponding author), UNIV CAGLIARI,INST INTERNAL MED,VIA SAN GIORGIO 12,I-09124 CAGLIARI,ITALY.							CHOO QL, 1991, P NATL ACAD SCI USA, V88, P2451, DOI 10.1073/pnas.88.6.2451; FARCIP, 1992, SCIENCE, V258, P135; GALBRAITH RM, 1979, LANCET, V1, P951; HRUBY MA, 1978, JAMA-J AM MED ASSOC, V240, P1355; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; LAI ME, 1993, J PEDIATR GASTR NUTR, V16, P458, DOI 10.1097/00005176-199305000-00020; MOSLEY JW, 1977, NEW ENGL J MED, V296, P75, DOI 10.1056/NEJM197701132960204; SIMMONDS P, 1993, J GEN VIROL, V74, P661, DOI 10.1099/0022-1317-74-4-661; WEINER AJ, 1991, VIROLOGY, V180, P842, DOI 10.1016/0042-6822(91)90104-J	9	255	260	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 12	1994	343	8894					388	390		10.1016/S0140-6736(94)91224-6	http://dx.doi.org/10.1016/S0140-6736(94)91224-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW283	7905553				2022-12-24	WOS:A1994MW28300010
J	ANNAS, GJ				ANNAS, GJ			DEATH BY PRESCRIPTION - THE OREGON INITIATIVE	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material														Annas, George/0000-0001-5836-7831				ANNAS GJ, 1985, AM J PUBLIC HEALTH, V75, P1096, DOI 10.2105/AJPH.75.9.1096; ANNAS GJ, 1993, NEW ENGL J MED, V328, P1573, DOI 10.1056/NEJM199305273282121; Callahan Daniel, 1993, TROUBLED DREAM LIFE; CAPRON AM, 1992, HASTINGS CENT REP, V22, P30, DOI 10.2307/3562562; COHEN JS, 1994, NEW ENGL J MED, V331, P89, DOI 10.1056/NEJM199407143310206; GIANELLI DM, 1994, AM MED NEWS     0725, P1; GIANELLI DM, 1994, AM MED NEWS     0912, P34; Humphry D., 1992, DYING DIGNITY UNDERS; NULAND SB, 1994, WE DIE, P288; ORENTLICHER D, 1994, MED UNBOUND HUMAN BO, P256; QUILL TE, 1991, NEW ENGL J MED, V324, P691, DOI 10.1056/NEJM199103073241010; SKELLY FJ, 1994, AM MED NEWS     0815, P19; WEILER PC, 1993, MEASURE MALPRACTICE, P55; YANKELOVICH D, 1994, NY TIMES        0917, P23; 1994, DEATH IS SOUGHT ASSI; 1994, AHCPR940592 DEP HLTH, P16; 1992, JAMA-J AM MED ASSOC, V267, P2229; 1994, FINAL REPORT MICHIGA; 1992, HASTINGS CTR REP, V22, P7	19	50	50	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 3	1994	331	18					1240	1243		10.1056/NEJM199411033311822	http://dx.doi.org/10.1056/NEJM199411033311822			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN806	7935680				2022-12-24	WOS:A1994PN80600038
J	GLANTZ, SA; BEGAY, ME				GLANTZ, SA; BEGAY, ME			TOBACCO INDUSTRY CAMPAIGN CONTRIBUTIONS ARE AFFECTING TOBACCO CONTROL POLICY-MAKING IN CALIFORNIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PACS	Objective.-To test the hypothesis that tobacco industry campaign contributions are influencing the behavior of members of the California legislature. Design.-Multivariate simultaneous-equations regression was used to analyze data on campaign contributions from the tobacco industry to members of the California legislature in 1991 and 1992, members' tobacco control policy positions, and members' personal characteristics. Data Sources.-The following sources were analyzed: campaign contributions from disclosure statements filed with the California Fair Political Practices Commission; constituent attitudes on tobacco control from the California Tobacco Survey; legislators' personal characteristics, from a survey of key informants conducted by the California Journal; and the tobacco policy score, a survey of key informants working on tobacco issues in the state legislature. Specific voting on tobacco-related bills was also analyzed. Setting.-California legislature in 1991 and 1992. Patients or Other Participants.-All members of the California legislature in 1991 and 1992. Main Outcome Measures.-Tobacco policy score, campaign contributions, and votes on individual tobacco-related bills. Results.-The tobacco industry is having a statistically detectable effect on behavior of members of the California legislature on tobacco policymaking. On a scale of 0 to 10, a legislator's tobacco policy score dropped tie, became more protobacco industry) by -0.11 for every $1000 in tobacco campaign contributions, after accounting for the fact that a more protobacco position was associated with greater contributions ($1855 for each -1.0 reduction in score). Members who were rated as effective received larger contributions from the industry. Members rated higher in integrity and intelligence were more antitobacco (higher scores) and Republicans more protobacco (lower scores) after taking into account the effects of contributions from the industry. Constituent attitudes were not reflected in legislators' perceived behavior. Conclusion.-Tobacco industry campaign contributions influence California legislators in matters related to tobacco policymaking, independent of constituents' support for tobacco control.			GLANTZ, SA (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,INST HLTH POLICY STUDIES,BOX 0124,SAN FRANCISCO,CA 94143, USA.				NCI NIH HHS [CA-61021] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061021] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEGAY M, 1994, TWILIGHT PROPOSITION; BEGAY ME, 1993, AM J PUBLIC HEALTH, V83, P1214, DOI 10.2105/AJPH.83.9.1214; BEGAY ME, 1992, TOBACCO IND POLITICA; BURNS D, 1992, TOBACCO USE CALIFORN; DREW E, 1983, POLITICS MONEY; Fenno RichardF., 1978, HOMESTYLE HOUSE MEMB; GERBER E, 1991, THESIDS U MICHIGAN A; GLANTZ S, 1993, TOBACCO BIOL POLITIC; GLANTZ S, 1990, PRIMER APPLIED REGRE, pCH5; GLANTZ SA, 1994, AM J PUBLIC HEALTH, V84, P1081, DOI 10.2105/AJPH.84.7.1081; GRENZKE JM, 1989, AM J POLIT SCI, V33, P1, DOI 10.2307/2111251; JACKSON B, 1988, HONEST GRAFT; Jewell MalcolmE., 1982, REPRESENTATION STATE; Kingdon, 1989, CONGRESSMENS VOTING; Pierce JP, 1994, TOBACCO USE CALIFORN; PRICE C, 1991, CALIF J, V22, P343; SKOLNICK AA, 1994, JAMA-J AM MED ASSOC, V271, P1387, DOI 10.1001/jama.271.18.1387; SKOLNICK AA, 1992, JAMA-J AM MED ASSOC, V267, P2723; SKOLNICK AA, 1992, JAMA-J AM MED ASSOC, V267, P2721, DOI 10.1001/jama.267.20.2721; TAYLOR P, 1984, SMOKE RING; WRIGHT JR, 1985, AM POLIT SCI REV, V79, P400, DOI 10.2307/1956656; ZEIGER R, 1992, CALIF J, V23, P173; 1991, 1991 1992 DIRECTORY; 1993, HLTH LETT, V9, P1; 1993, LOBBYING EXPENDITURE; 1988, SAS ETS USERS GUIDE; 1993, PRICE ADM	27	71	71	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 19	1994	272	15					1176	1182		10.1001/jama.272.15.1176	http://dx.doi.org/10.1001/jama.272.15.1176			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PL212	7933347				2022-12-24	WOS:A1994PL21200031
J	ROBILLARD, PY; HULSEY, TC; PERIANIN, J; JANKY, E; MIRI, EH; PAPIERNIK, E				ROBILLARD, PY; HULSEY, TC; PERIANIN, J; JANKY, E; MIRI, EH; PAPIERNIK, E			ASSOCIATION OF PREGNANCY-INDUCED HYPERTENSION WITH DURATION OF SEXUAL COHABITATION BEFORE CONCEPTION	LANCET			English	Article							PRE-ECLAMPSIA; PREECLAMPSIA; CONTRACEPTION; IMMUNOLOGY; ANTIBODIES; PATERNITY	Pregnancy-induced hypertension affects at least 10% of all pregnancies. An association with first pregnancy or a change in paternity for subsequent pregnancies has been suggested. We studied the duration of sexual cohabitation with the father prior to conception and the incidence of pregnancy-induced hypertension. During a five-month period, 1011 consecutive women who delivered in an obstetric unit were interviewed about paternity and duration of sexual cohabitation before conception. Obstetric charts were abstracted to identify three groups: those with pregnancy-induced hypertension, chronic hypertension, and normal blood pressure. The incidence of pregnancy-induced hypertension was 11.9% among primigravidae, 4.7% among same-paternity multigravidae, and 24.0% among new-paternity multigravidae. For both primigravidae and multigravidae, length of sexual cohabitation before conception was inversely related to the incidence of pregnancy-induced hypertension (p<0.0001). Similar results were observed after control for race, education, maternal age, marital status, and number of pregnancies. Pregnancy-induced hypertension may be a problem of primipaternity rather than primigravidity. Furthermore, an extended duration of sexual cohabitation before conception may protect against pregnancy-induced hypertension.	UNIV HOSP POINTE PITRE, CHRU, GYNAECOL OBSTET UNIT, F-97159 POINTE A PITRE, Guadeloupe, FRANCE; MED UNIV S CAROLINA, CHILDRENS HOSP, DIV NEONATOL, CHARLESTON, SC 29425 USA; MATERN PORT ROYAL, F-75674 PARIS 14, FRANCE	CHU Guadeloupe; Medical University of South Carolina; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite	ROBILLARD, PY (corresponding author), UNIV HOSP POINTE A PITRE, CHRU, PAEDIAT UNIT, BP 465, F-97159 POINTE A PITRE, Guadeloupe, FRANCE.		Robillard, Pierre-Yves/AAD-9774-2021					[Anonymous], PREECLAMPSIA; Beer A E, 1985, Birth Defects Orig Artic Ser, V21, P131; BEER AE, 1989, JAMA-J AM MED ASSOC, V262, P3184, DOI 10.1001/jama.262.22.3184; BEER AE, 1990, IMMUNOLOGICAL DIS, P329; BRONSON R, 1984, FERTIL STERIL, V42, P171; CHARBIT Y, 1984, CARIBBEAN FAMILY STR; CHNG PK, 1982, BRIT J OBSTET GYNAEC, V89, P862, DOI 10.1111/j.1471-0528.1982.tb05042.x; DAVEY DA, 1986, CLIN EXP HYPERTENS B, V5, P97, DOI 10.3109/10641958609023478; FEENEY JG, 1980, EUR J OBSTET GYN R B, V11, P35, DOI 10.1016/0028-2243(80)90051-9; GOLDBERG JM, 1990, AM J OBSTET GYNECOL, V163, P65, DOI 10.1016/S0002-9378(11)90669-3; IKEDIFE D, 1980, BRIT MED J, V280, P985, DOI 10.1136/bmj.280.6219.985-a; KANBOURSHAKIR A, 1990, P NATL ACAD SCI USA, V87, P444, DOI 10.1073/pnas.87.1.444; KLONOFFCOHEN HS, 1989, JAMA-J AM MED ASSOC, V262, P3143, DOI 10.1001/jama.262.22.3143; MARTI JJ, 1977, AM J OBSTET GYNECOL, V128, P489, DOI 10.1016/0002-9378(77)90030-8; MASSIAH H, 1983, WOMEN HEADS HOUSEHOL; NEED JA, 1975, BRIT MED J, V1, P548, DOI 10.1136/bmj.1.5957.548; REDMAN CWG, 1991, SEMIN PERINATOL, V15, P257; ROBILLARD PY, 1993, J REPROD IMMUNOL, V24, P1, DOI 10.1016/0165-0378(93)90032-D; ROBILLARD PY, IN PRESS INT J FETOM; SAFTLAS AF, 1990, AM J OBSTET GYNECOL, V163, P460, DOI 10.1016/0002-9378(90)91176-D; SERHAL PF, 1987, LANCET, V2, P744; SPECK EH, 1980, PREGNANCY HYPERTENS, P45; 1990, RESULTATS RECENSEMEN; 1994, LANCET, V344, P969	24	246	254	0	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 8	1994	344	8928					973	975		10.1016/S0140-6736(94)91638-1	http://dx.doi.org/10.1016/S0140-6736(94)91638-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PK978	7934427				2022-12-24	WOS:A1994PK97800006
J	KASTNER, P; GRONDONA, JM; MARK, M; GANSMULLER, A; LEMEUR, M; DECIMO, D; VONESCH, JL; DOLLE, P; CHAMBON, P				KASTNER, P; GRONDONA, JM; MARK, M; GANSMULLER, A; LEMEUR, M; DECIMO, D; VONESCH, JL; DOLLE, P; CHAMBON, P			GENETIC-ANALYSIS OF RXR-ALPHA, DEVELOPMENTAL FUNCTION - CONVERGENCE OF RXR AND RAR SIGNALING PATHWAYS IN HEART AND EYE MORPHOGENESIS	CELL			English	Article							REPLICATION-DEFECTIVE RETROVIRUS; 9-CIS RETINOIC ACID; CARDIAC MORPHOGENESIS; CLONAL ANALYSIS; RECEPTOR-GAMMA; MUTANT MICE; MOUSE; EXPRESSION; TRANSACTIVATION; TRANSCRIPTION	A null mutation was generated in the mouse RXR alpha gene by targeted disruption. Growth deficiency occurred in heterozygote mice. Null mutants died in utero and displayed myocardial and ocular malformations. These malformations belong to the fetal vitamin A deficiency syndrome, supporting the idea that RXR alpha is involved in retinoid signaling in vivo. A phenotypic synergy was observed when the RXR alpha mutation was introduced into RAR alpha or RAR gamma mutant backgrounds: RXR alpha null mutants and RXR alpha(+/-)/RAR gamma(-/-) double mutants displayed similar ocular defects, which became more severe in RXR alpha(-/-)/RAR gamma(+/-) and RXR alpha(-/-)/RAR gamma(-/-) mutants. Furthermore, RXR alpha/RAR double mutants exhibited several malformations not seen in single mutants. This functional convergence strongly suggests that RXR alpha/RAR heterodimers mediate retinoid signaling in vivo.			KASTNER, P (corresponding author), FAC MED STRASBOURG, INST CHIM BIOL,CNRS,GENET MOLEC EUCARYOTES LAB, INSERM, U184, F-67085 STRASBOURG, FRANCE.		Grondona, Jesus M./F-1650-2011; Dolle, Pascal/A-8037-2010	Grondona, Jesus M./0000-0003-1781-1486; Dolle, Pascal/0000-0002-9294-9090; Decimo, Didier/0000-0002-0390-1205				ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BEDO G, 1989, NATURE, V339, P231, DOI 10.1038/339231a0; BLOMHOFF RB, 1994, VITAMIN A HLTH DISEA; CHALLICE CE, 1974, TISSUE CELL, V6, P447, DOI 10.1016/0040-8166(74)90037-8; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; COULOMBRE AJ, 1977, HDB TERATOLOGY, P329; COULOMBRE JL, 1969, INVEST OPHTH VISUAL, V8, P251; DELUCA HF, 1988, FASEB J, V2, P224, DOI 10.1096/fasebj.2.3.3280376; DOLLE P, 1994, MECH DEVELOP, V45, P91, DOI 10.1016/0925-4773(94)90023-X; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GIGUERE V, 1994, ENDOCR REV, V15, P61, DOI 10.1210/er.15.1.61; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; Hay E.D., 1980, International Review of Cytology, V63, P263, DOI 10.1016/S0074-7696(08)61760-X; HEERY DM, 1993, P NATL ACAD SCI USA, V90, P4281, DOI 10.1073/pnas.90.9.4281; HERO I, 1990, INVEST OPHTH VIS SCI, V31, P197; JOHNSTON MC, 1979, EXP EYE RES, V29, P27, DOI 10.1016/0014-4835(79)90164-7; Kastner P., 1994, Vitamin A in health and disease., P189; Kaufman M.H., 1992, ATLAS MOUSE DEV; KIRBY ML, 1983, SCIENCE, V220, P1059, DOI 10.1126/science.6844926; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LAND MF, 1992, ANNU REV NEUROSCI, V15, P1, DOI 10.1146/annurev.ne.15.030192.000245; LEGRAND J, 1986, THYROID HORMONE META, V8, P503; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LI E, 1993, P NATL ACAD SCI USA, V90, P1590, DOI 10.1073/pnas.90.4.1590; LIU Q, 1993, MOL ENDOCRINOL, V7, P651, DOI 10.1210/me.7.5.651; LOHNES D, 1993, CELL, V73, P643, DOI 10.1016/0092-8674(93)90246-M; LOHNES D, 1994, IN PRESS DEVELOPMENT; LUFKIN T, 1993, P NATL ACAD SCI USA, V90, P7225, DOI 10.1073/pnas.90.15.7225; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; LYONS GE, 1990, J CELL BIOL, V111, P2427, DOI 10.1083/jcb.111.6.2427; Mangelsdorf David J., 1994, P319; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; Mann I, 1937, DEV ABNORMALITIES EY; MARK M, 1993, DEVELOPMENT, V119, P319; MARSHARMSTRONG N, 1994, P NATL ACAD SCI USA, V91, P7286, DOI 10.1073/pnas.91.15.7286; MCCAFFERY P, 1993, DEV BIOL, V158, P390, DOI 10.1006/dbio.1993.1197; MENDELSOHN C, 1994, IN PRESS DEV BIOL; MENDELSOHN C, 1994, IN PRESS DEVELOPMENT; MIKAWA T, 1992, DEV DYNAM, V195, P133, DOI 10.1002/aja.1001950208; MIKAWA T, 1992, DEV DYNAM, V193, P11, DOI 10.1002/aja.1001930104; MOENS CB, 1993, DEVELOPMENT, V119, P485; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; NODEN DM, 1991, DEVELOPMENT, V111, P867; ORO AE, 1992, DEVELOPMENT, V115, P449; RUBERTE E, 1990, DEVELOPMENT, V108, P213; RUMYANTSEV PP, 1977, INT REV CYTOL, V51, P187; SASSOON DA, 1988, DEVELOPMENT, V104, P155; SPORN MB, 1994, RETINOIDS, P319; STEPHAN F, 1954, TRAITE ZOOL, V12, P854; SUCOV HM, 1994, GENE DEV, V8, P1007, DOI 10.1101/gad.8.9.1007; WARKANY J, 1946, ARCH OPHTHALMOL-CHIC, V35, P150, DOI 10.1001/archopht.1946.00890200155008; WILSON JG, 1949, AM J ANAT, V85, P113, DOI 10.1002/aja.1000850106; WILSON JG, 1953, AM J ANAT, V92, P189, DOI 10.1002/aja.1000920202	56	592	606	2	21	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 23	1994	78	6					987	1003		10.1016/0092-8674(94)90274-7	http://dx.doi.org/10.1016/0092-8674(94)90274-7			17	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PJ294	7923367				2022-12-24	WOS:A1994PJ29400010
J	CHEN, S; ROSEMAN, AM; HUNTER, AS; WOOD, SP; BURSTON, SG; RANSON, NA; CLARKE, AR; SAIBIL, HR				CHEN, S; ROSEMAN, AM; HUNTER, AS; WOOD, SP; BURSTON, SG; RANSON, NA; CLARKE, AR; SAIBIL, HR			LOCATION OF A FOLDING PROTEIN AND SHAPE CHANGES IN GROEL-GROES COMPLEXES IMAGED BY CRYOELECTRON MICROSCOPY	NATURE			English	Article							CHAPERONIN GROEL; CENTRAL CAVITY; BINDING; SURFACE; CYCLE; ATP	PROTEIN folding mediated by the molecular chaperone GroEL occurs by its binding to non-native polypeptide substrates and is driven by ATP hydrolysis(1). Both of these processes are influenced by the reversible association of the co-protein, GroES (refs 2-4). GroEL and other chaperonin 60 molecules(5) are large, cylindrical oligomers consisting of two stacked heptameric rings of subunits(6,7); each ring forms a cage-like structure(8) thought to bind polypeptides in a central cavity(8-10). Chaperonins play a passive role in folding by binding or sequestering folding proteins to prevent their aggregation(11-13), but they may also actively unfold substrate proteins trapped in misfolded forms, enabling them to assume productive folding conformations(14-16). Biochemical studies show that GroES improves the efficiency of GroEL function(2,3,17), but the structural basis for this is unknown. Here we report the first direct visualization, by cryo-electron microscopy, of a non-native protein substrate (malate dehydrogenase) bound to the mobile, outer domains at one end of GroEL. Addition of GroES to GroEL in the presence of ATP causes a dramatic hinge opening of about 60 degrees. GroES binds to the equivalent surface of the GroEL outer domains, but on the opposite end of the GroEL oligomer to the protein substrate.	UNIV BRISTOL,DEPT BIOCHEM,BRISTOL BS8 1TD,ENGLAND; UNIV BRISTOL,CTR MOLEC RECOGNIT,BRISTOL BS8 1TD,ENGLAND	University of Bristol; University of Bristol	CHEN, S (corresponding author), UNIV LONDON BIRKBECK COLL,DEPT CRYSTALLOG,MALET ST,LONDON WC1E 7HX,ENGLAND.		Wood, Stephen P/B-1438-2009; Roseman, Alan/AAE-6689-2019	Ranson, Neil/0000-0002-3640-5275; Roseman, Alan/0000-0002-4783-2619	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AZEM A, 1994, SCIENCE, V265, P653, DOI 10.1126/science.7913553; BADCOE IG, 1991, BIOCHEMISTRY-US, V30, P9195, DOI 10.1021/bi00102a010; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P25672; BRAIG K, 1993, P NATL ACAD SCI USA, V90, P3978, DOI 10.1073/pnas.90.9.3978; ELLIS RJ, 1989, TRENDS BIOCHEM SCI, V14, P339, DOI 10.1016/0968-0004(89)90168-0; FISHER MT, 1994, J BIOL CHEM, V269, P13629; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; HARRIS JR, IN PRESS J STRUCT BI; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HUTCHINSON EG, 1989, EMBO J, V8, P1485, DOI 10.1002/j.1460-2075.1989.tb03532.x; ISHII N, 1994, J MOL BIOL, V236, P691, DOI 10.1006/jmbi.1994.1181; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; KUBOTA H, 1994, CURR BIOL, V4, P89, DOI 10.1016/S0960-9822(94)00024-2; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LLORCA O, 1994, FEBS LETT, V345, P181, DOI 10.1016/0014-5793(94)00432-3; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; MENDOZA JA, 1991, J BIOL CHEM, V266, P16973; NILSSON B, 1991, ANNU REV MICROBIOL, V45, P607; PERALTA D, 1994, FEBS LETT, V339, P40; SAIBIL HR, 1993, CURR BIOL, V3, P265, DOI 10.1016/0960-9822(93)90176-O; SCHMIDT M, 1994, J BIOL CHEM, V269, P10304; SCHMIDT R, 1994, SCIENCE, V265, P656; STANIFORTH RA, 1994, FEBS LETT, V344, P129, DOI 10.1016/0014-5793(94)00348-3; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; ZAHN R, 1994, NATURE, V368, P261, DOI 10.1038/368261a0	27	330	332	1	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 15	1994	371	6494					261	264		10.1038/371261a0	http://dx.doi.org/10.1038/371261a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PG290	7915827				2022-12-24	WOS:A1994PG29000057
J	CHOWIENCZYK, PJ; WATTS, GF; COCKCROFT, JR; BRETT, SE; RITTER, JM				CHOWIENCZYK, PJ; WATTS, GF; COCKCROFT, JR; BRETT, SE; RITTER, JM			SEX-DIFFERENCES IN ENDOTHELIAL FUNCTION IN NORMAL AND HYPERCHOLESTEROLEMIC SUBJECTS	LANCET			English	Note							DEPENDENT VASODILATION; L-ARGININE; VESSELS	Acetylcholine stimulates endothelial synthesis of nitric oxide from L-arginine. To investigate the influence of sex on endothelial function, we measured vasodilator responses to brachial artery administration of acetylcholine in hypercholesterolaemic and control men and women. Mean response to acetylcholine was impaired (55% of that in controls at 15 mu g/min) in hypercholesterolaemic men but not in hypercholesterolaemic women. L-arginine normalised responses to acetylcholine in hypercholesterolaemic men, but had similar effects in hypercholesterolaemic and control women. These results suggest that women are protected against adverse effects of hypercholesterolaemia on the L-arginine/nitric-oxide pathway.	UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,DEPT CLIN PHARMACOL,LONDON SE1 9RT,ENGLAND; UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,DEPT ENDOCRINOL & CHEM PATHOL,LONDON SE1 9RT,ENGLAND	University of London; King's College London; University of London; King's College London				Chowienczyk, Phil/0000-0003-4507-038X; Watts, Gerald/0000-0003-2276-1524				CALVER A, 1991, CLIN SCI, V81, P695, DOI 10.1042/cs0810695; CASINO PR, 1993, CIRCULATION, V88, P2541, DOI 10.1161/01.CIR.88.6.2541; CHOWIENCZYK PJ, 1994, CLIN SCI, V87, P45, DOI 10.1042/cs0870045; CHOWIENCZYK PJ, 1992, LANCET, V340, P1430, DOI 10.1016/0140-6736(92)92621-L; CREAGER MA, 1992, J CLIN INVEST, V90, P1248, DOI 10.1172/JCI115987; HAYASHI T, 1992, P NATL ACAD SCI USA, V89, P11259, DOI 10.1073/pnas.89.23.11259; IMAIZUMI T, 1992, HYPERTENSION, V20, P511, DOI 10.1161/01.HYP.20.4.511; JACOBS M, 1990, BRIT J PHARMACOL, V100, P21, DOI 10.1111/j.1476-5381.1990.tb12045.x; SACK MN, 1994, LANCET, V343, P269, DOI 10.1016/S0140-6736(94)91117-7; WEINER C, 1993, ENDOTHELIUM, V1, pS1	10	73	73	1	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 30	1994	344	8918					305	306		10.1016/S0140-6736(94)91342-0	http://dx.doi.org/10.1016/S0140-6736(94)91342-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NZ233	7914265				2022-12-24	WOS:A1994NZ23300011
J	CARROLL, SB; GATES, J; KEYS, DN; PADDOCK, SW; PANGANIBAN, GEF; SELEGUE, JE; WILLIAMS, JA				CARROLL, SB; GATES, J; KEYS, DN; PADDOCK, SW; PANGANIBAN, GEF; SELEGUE, JE; WILLIAMS, JA			PATTERN-FORMATION AND EYESPOT DETERMINATION IN BUTTERFLY WINGS	SCIENCE			English	Article							PRECIS-COENIA LEPIDOPTERA; LIMB DEVELOPMENT; IMAGINAL DISKS; DROSOPHILA-MELANOGASTER; ENGRAILED GENE; HOMEOBOX GENE; EXPRESSION; WINGLESS; PROTEIN; ENCODES	Butterfly wings display pattern elements of many types and colors. To identify the molecular processes underlying the generation of these patterns, several butterfly cognates of Drosophila appendage patterning genes have been cloned and their expression patterns have been analyzed. Butterfly wing patterns are organized by two spatial coordinate systems. One system specifies positional information with respect to the entire wing field and is conserved between fruit flies and butterflies. A second system, superimposed on the general system and involving several of the same genes, operates within each wing subdivision to elaborate discrete pattern elements. Eyespots, which form from discrete developmental organizers, are marked by Distal-less gene expression. These circular pattern elements appear to be generated by a process similar to, and perhaps evolved from, proximodistal pattern formation in insect appendages.	UNIV WISCONSIN,MOLEC BIOL LAB,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison	CARROLL, SB (corresponding author), UNIV WISCONSIN,HOWARD HUGHES MED INST,MADISON,WI 53706, USA.		Boekhoff-Falk, Grace E/B-2240-2008	Boekhoff-Falk, Grace E/0000-0002-9877-8309				CAMPBELL G, 1993, CELL, V74, P1113, DOI 10.1016/0092-8674(93)90732-6; CAMPBELL S, 1992, GENE DEV, V6, P367, DOI 10.1101/gad.6.3.367; COHEN B, 1993, DEVELOPMENT, V117, P597; COHEN B, 1992, GENE DEV, V6, P715, DOI 10.1101/gad.6.5.715; COHEN SM, 1989, EMBO J, V8, P2045, DOI 10.1002/j.1460-2075.1989.tb03613.x; COHEN SM, 1989, NATURE, V338, P432, DOI 10.1038/338432a0; Cohen Stephen M., 1993, P747; COLEMAN KG, 1987, GENE DEV, V1, P19, DOI 10.1101/gad.1.1.19; COUSO JP, 1993, SCIENCE, V259, P484, DOI 10.1126/science.8424170; COUSO JP, 1994, DEVELOPMENT, V120, P621; DIASBENJUMEA F, 1993, CELL, V75, P741; DOCTOR JS, 1992, DEV BIOL, V151, P491, DOI 10.1016/0012-1606(92)90188-M; DOLLE P, 1992, DIFFERENTIATION, V49, P93, DOI 10.1111/j.1432-0436.1992.tb00773.x; FRENCH V, 1992, DEVELOPMENT, V116, P103; GARCIABELLIDO A, 1975, CIBA F S, V29, P16; HUI CC, 1992, P NATL ACAD SCI USA, V89, P167, DOI 10.1073/pnas.89.1.167; JIANG J, 1991, GENE DEV, V5, P1881, DOI 10.1101/gad.5.10.1881; KLESSIG DF, 1983, PLANT MOL BIOL REP, V1, P12; KORNBERG T, 1985, CELL, V40, P45, DOI 10.1016/0092-8674(85)90307-1; LAWRENCE PA, 1976, DEV BIOL, V50, P321, DOI 10.1016/0012-1606(76)90155-X; MASUCCI JD, 1990, GENE DEV, V4, P2011, DOI 10.1101/gad.4.11.2011; Nijhout H.F., 1991, DEV EVOLUTION BUTTER; NIJHOUT HF, 1985, J EMBRYOL EXP MORPH, V86, P191; NIJHOUT HF, 1980, DEV BIOL, V80, P275, DOI 10.1016/0012-1606(80)90404-2; NIJHOUT HF, 1988, DEVELOPMENT, V102, P377; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; PATEL NH, 1989, DEVELOPMENT, V107, P201; PATEL NH, 1989, CELL, V58, P955, DOI 10.1016/0092-8674(89)90947-1; PHILLIPS RG, 1993, DEVELOPMENT, V118, P427; PRICE M, 1991, NATURE, V351, P748, DOI 10.1038/351748a0; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIDOW A, 1992, P NATL ACAD SCI USA, V89, P5098, DOI 10.1073/pnas.89.11.5098; SPENCER FA, 1982, CELL, V28, P45; STEVENS ME, 1986, DEV BIOL, V117, P326, DOI 10.1016/0012-1606(86)90375-1; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; WILLIAMS JA, 1993, DEVELOPMENT, V117, P571; WILLIAMS JA, 1988, EMBO J, V7, P1355, DOI 10.1002/j.1460-2075.1988.tb02951.x; WILLIAMS JA, 1993, BIOESSAYS, V15, P167; WILLIAMS JA, 1991, GENE DEV, V5, P248; WILLIAMS JA, 1994, NATURE, V368, P298; WILLIAMS JJ, UNPUB; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G; XU Y, 1993, P NATL ACAD SCI USA, V90, P227, DOI 10.1073/pnas.90.1.227; YAMAMOTO RT, 1993, J ECON ENTOMOL, V621, P1427	45	287	294	0	73	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 1	1994	265	5168					109	114		10.1126/science.7912449	http://dx.doi.org/10.1126/science.7912449			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NV301	7912449				2022-12-24	WOS:A1994NV30100038
J	TURKOF, E; TAMBWEKAR, S; MANSUKHANI, K; MILLESI, H; MAYR, N				TURKOF, E; TAMBWEKAR, S; MANSUKHANI, K; MILLESI, H; MAYR, N			INTRAOPERATIVE SPINAL ROOT STIMULATION TO DETECT MOST PROXIMAL SITE OF LEPROUS ULNAR NEURITIS	LANCET			English	Note							MUSCLE	In 10 patients with leprous ulnar neuritis, we investigated the most proximal site of lesion in the affected nerves. Spinal roots C8 and T1 were stimulated intraoperatively to evoke efferent mixed compound nerve action potentials which were recorded from the exposed ulnar nerves. The site at which amplitudes reached a maximum was considered the most proximal site of lesion. Nerve damage was found far proximally from the thickened segments in otherwise inconspicuous sections. Epineuriotomy within these apparently unaffected segments revealed fibrosis of the interfascicular epineurium in 9 patients, which is an indication for microsurgical interfascicular neurolysis.	UNIV VIENNA,ALLGEMEINES KRANKENHAUS WIEN,NEUROL KLIN,A-1090 VIENNA,AUSTRIA; UNIV VIENNA,SURG CLIN,DEPT PLAST & RECONSTRUCT SURG,VIENNA,AUSTRIA; LUDWIG BOLTZMANN INST EXPTL PLAST SURG,VIENNA,AUSTRIA; KEM HOSP BOMBAY,DEPT PLAST & RECONSTRUCT SURG,BOMBAY,MAHARASHTRA,INDIA; KEM HOSP BOMBAY,DEPT NEUROL,BOMBAY,MAHARASHTRA,INDIA; UNIV VIENNA,NEUROL CLIN,VIENNA,AUSTRIA	University of Vienna; University of Vienna; Ludwig Boltzmann Institute; Seth Gordhandas Sunderdas Medical College & King Edward Memorial Hospital; Seth Gordhandas Sunderdas Medical College & King Edward Memorial Hospital; University of Vienna								[Anonymous], 1993, Wkly Epidemiol Rec, V68, P181; ENNA CD, 1974, J NEUROSURG, V40, P734, DOI 10.3171/jns.1974.40.6.0734; GIRAUDEAU P, 1982, ACTA LEPROL GENEVE, V86, P227; MCLEOD JG, 1975, BRAIN, V98, P203, DOI 10.1093/brain/98.2.203; MERTON PA, 1982, LANCET, V2, P597; PANDYA JN, 1976, INT J LEPROSY, V46, P47; PEREIRA JH, 1991, LANCET, V338, P1239, DOI 10.1016/0140-6736(91)92105-B; SUNDERLAND S, 1973, BRAIN, V96, P865, DOI 10.1093/brain/96.4.865	8	15	15	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 25	1994	343	8913					1604	1605		10.1016/S0140-6736(94)93059-7	http://dx.doi.org/10.1016/S0140-6736(94)93059-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU354	7911922				2022-12-24	WOS:A1994NU35400012
J	SUBERBIELLE, C; CAILLATZUCMAN, S; LEGENDRE, C; BODEMER, C; NOEL, LH; KREIS, H; BACH, JF				SUBERBIELLE, C; CAILLATZUCMAN, S; LEGENDRE, C; BODEMER, C; NOEL, LH; KREIS, H; BACH, JF			PERIPHERAL MICROCHIMERISM IN LONG-TERM CADAVERIC-KIDNEY ALLOGRAFT RECIPIENTS	LANCET			English	Note							TRANSPLANTATION; CHIMERISM; TOLERANCE	Microchimerism after allogeneic organ transplantation may be a mechanism for induction of donor-specific graft acceptance. However, the frequency of chimerism and its relevance in long-term tolerance are uncertain. We studied 15 long-surviving (more than 20 years) cadaveric-kidney transplant recipients for the systemic presence of donor alleles with allele-specific genomic amplification of DRB1 and H-Y loci. Microchimerism was observed in 1 case in peripheral blood and in 4 cases in shin. Chimerism and number of HLA alleles shared by donor and recipient were not correlated. This low frequency of microchimerism in long-term kidney allograft recipients raises doubts about a major participation of chimerism in donor-specific tolerance.	HOP NECKER ENFANTS MALAD,INSERM,U25,F-75015 PARIS,FRANCE; HOP NECKER ENFANTS MALAD,SERV TRANSPLANTAT RENALE,PARIS,FRANCE; HOP NECKER ENFANTS MALAD,SERV DERMATOL,F-75730 PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite				Caillat-Zucman, Sophie/0000-0002-4535-3550				COLLINS RH, 1993, NEW ENGL J MED, V328, P762, DOI 10.1056/NEJM199303183281104; DALLMAN MJ, 1993, IMMUNOL REV, V133, P5, DOI 10.1111/j.1600-065X.1993.tb01507.x; NAKAGOME Y, 1991, AM J MED GENET, V41, P112, DOI 10.1002/ajmg.1320410127; OLERUP O, 1992, TISSUE ANTIGENS, V39, P225, DOI 10.1111/j.1399-0039.1992.tb01940.x; POSSELT AM, 1990, SCIENCE, V249, P1293, DOI 10.1126/science.2119056; SHARABI Y, 1989, J EXP MED, V169, P493, DOI 10.1084/jem.169.2.493; STARZL TE, 1993, NEW ENGL J MED, V328, P745, DOI 10.1056/NEJM199303183281101; STARZL TE, 1993, TRANSPLANTATION, V55, P1272, DOI 10.1097/00007890-199306000-00012; STARZL TE, 1992, LANCET, V340, P876, DOI 10.1016/0140-6736(92)93286-V; TIERCY JM, 1991, P NATL ACAD SCI USA, V88, P7121, DOI 10.1073/pnas.88.16.7121	10	115	116	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 11	1994	343	8911					1468	1469		10.1016/S0140-6736(94)92583-6	http://dx.doi.org/10.1016/S0140-6736(94)92583-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NQ415	7911179				2022-12-24	WOS:A1994NQ41500010
J	CAUL, EO				CAUL, EO			SMALL ROUND STRUCTURED VIRUSES - AIRBORNE TRANSMISSION AND HOSPITAL CONTROL	LANCET			English	Editorial Material											CAUL, EO (corresponding author), PUBL HLTH LAB,REG VIRUS LAB,BRISTOL,AVON,ENGLAND.							Caul E. O., 1993, PHLS Microbiology Digest, V10, P2; CAUL E O, 1988, P139; CHADWICK PR, 1994, LANCET, V343, P171, DOI 10.1016/S0140-6736(94)90959-8; GELLERT GA, 1994, LANCET, V343, P609; GREEN SM, IN PRESS J GEN VIROL; GREENBERG HB, 1979, LANCET, V1, P55; JIANG X, 1993, VIROLOGY, V195, P51, DOI 10.1006/viro.1993.1345; KAPIKIAN AZ, 1994, VIRAL INFECT GASTROI, P471; LAMBDEN PR, 1993, SCIENCE, V259, P516, DOI 10.1126/science.8380940; SAWYER LA, 1988, AM J EPIDEMIOL, V127, P1261, DOI 10.1093/oxfordjournals.aje.a114918; Zahorsky J., 1929, ARCH PEDIAT, V46, P391	11	140	144	0	15	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 21	1994	343	8908					1240	1242		10.1016/S0140-6736(94)92146-6	http://dx.doi.org/10.1016/S0140-6736(94)92146-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NM144	7910270				2022-12-24	WOS:A1994NM14400004
J	LOEVINSOHN, ME				LOEVINSOHN, ME			CLIMATIC WARMING AND INCREASED MALARIA INCIDENCE IN RWANDA	LANCET			English	Article								Global climatic change is expected to increase the incidence of vector-borne diseases, especially malaria. This study assessed the contribution of climate to a malaria epidemic in Rwanda, focusing on the catchment area of one health centre where diagnosis was consistent and non-climatic variables well monitored. In late 1987 malaria incidence in the area increased by 337% over the 3 previous years. The increase was greatest in groups with little acquired immunity-children under 2 years (564%) and people in high-altitude areas (501%). Case-fatality rose significantly (relative risk = 485, p<0.001). 1987 also saw record high temperatures and rainfall. An autoregressive equation including lagged effects of these two variables explained 80% of the variance in monthly malaria incidence. Temperature (especially mean minimum) predicted incidence best at higher altitudes where malaria had increased most. Empirically derived relations were consistent with the estimated generation time of the disease and with the known sensitivity of the plasmodium parasite to temperature. The patterns of climatic warming between day and night and among seasons will be critical to the effect on malaria. These findings are most relevant to regions near the altitude or latitude limits of the disease, where several epidemics have lately been reported.	INST SCI AGRON RWANDA,BUTARE,RWANDA; APPL ECOL CONSULTANTS,BUTARE,RWANDA									[Anonymous], 1976, TIME SERIES ANAL; AULT SK, 1989, DEMOGRAPHY VECTOR BO, P283; Bennett R., 1979, SPATIAL TIME SERIES; BUGILIMFURA L, 1988, REV MED RWANDAISE, V20, P93; DETINOVA TS, 1962, WHO MONOGR SER, V47; DIETZ K, 1974, B WORLD HEALTH ORGAN, V50, P347; Folland CK, 1990, CLIMATE CHANGE: THE IPCC SCIENTIFIC ASSESSMENT, P195; GASCON J, 1988, T ROY SOC TROP MED H, V82, P222, DOI 10.1016/0035-9203(88)90418-X; LEPERS JP, 1990, B SOC PATHOL EXOT, V83, P330; MALATRE X, 1990, REV MED RWANDAISE, V22, P31; Mitchell JFB, 1990, CLIMATE CHANGE: THE IPCC SCIENTIFIC ASSESSMENT, P131; MOLINEAUX L, 1988, MALARIA PRINCIPLES P, P914; Munyantore S, 1989, REV MED RWANDAISE, V21, P14; MUNYANTORE S, 1993, INFLUENCE RIZICULTUR; ROPELEWSKI CF, 1987, MON WEATHER REV, V115, P1606, DOI 10.1175/1520-0493(1987)115<1606:GARSPP>2.0.CO;2; Wigley TML, 1990, CLIMATE CHANGE: THE IPCC SCIENTIFIC ASSESSMENT, P239; 1991, ELEMENTS ELABORATION; 1983, RECENSEMENT GENERAL; 1990, WORLD HLTH STAT Q, V43, P68; 1990, WHO PEP9010; 1991, RECONSEMENT GENERAL	21	201	209	0	50	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 19	1994	343	8899					714	718		10.1016/S0140-6736(94)91586-5	http://dx.doi.org/10.1016/S0140-6736(94)91586-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NB809	7907685				2022-12-24	WOS:A1994NB80900015
J	KNOX, KK; CARRIGAN, DR				KNOX, KK; CARRIGAN, DR			DISSEMINATED ACTIVE HHV-6 INFECTIONS IN PATIENTS WITH AIDS	LANCET			English	Note							HUMAN HERPESVIRUS-6	Human herpesvirus 6 (HHV-6) infected cells were detected in all lung, lymph-node, spleen, liver, and kidney tissues obtained at necropsy from an unselected series of nine patients with AIDS. This infection rate was significantly higher than that for cytomegalovirus. Lung infection with HHV-6 was extensive enough in one patient to account for fatal pneumonitis. In other tissues increased numbers of HHV-6 infected cells were related to the presence of lymphocytic infiltrates or residual lymphoid tissue, with lymphocytes being predominantly infected. Thus HHV-6 is an important pathogen in patients with AIDS.			KNOX, KK (corresponding author), MED COLL WISCONSIN,DEPT PATHOL,8700 W WISCONSIN AVE,MILWAUKEE,WI 53226, USA.							CARRIGAN DR, 1990, J INFECT DIS, V162, P844, DOI 10.1093/infdis/162.4.844; CARRIGAN DR, 1991, LANCET, V338, P147, DOI 10.1016/0140-6736(91)90137-E; DROBYSKI WR, 1993, J INFECT DIS, V167, P735, DOI 10.1093/infdis/167.3.735; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; FAUCI AS, 1993, J ACQ IMMUN DEF SYND, V6, P665; GALLO RC, 1988, J ACQ IMMUN DEF SYND, V1, P521; LUSSO P, 1989, NATURE, V337, P370, DOI 10.1038/337370a0; MCKENZIE R, 1991, MEDICINE, V70, P326, DOI 10.1097/00005792-199109000-00004; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; PELLETT PE, 1992, ADV VIRUS RES, V41, P1, DOI 10.1016/S0065-3527(08)60034-2	10	115	120	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 5	1994	343	8897					577	578		10.1016/S0140-6736(94)91524-5	http://dx.doi.org/10.1016/S0140-6736(94)91524-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY843	7906332				2022-12-24	WOS:A1994MY84300012
J	ALMARRI, A; BATCHELOR, JR				ALMARRI, A; BATCHELOR, JR			HLA AND HEPATITIS-B INFECTION	LANCET			English	Note							VACCINE	The mechanism underlying the development of chronic infection with hepatitis B virus is not known. We have done two independent studies in Qatar, where such infection is common, to determine whether immunity to this virus is influenced by the HLA phenotype of an individual. The first study generated a hypothesis to test in the second. In both studies, there was a significant deficiency of HLA-DR2 and an excess of HLA-DR7 in patients with chronic persistent infection with hepatitis B virus. We conclude that HLA phenotype is one of the factors influencing the response to infection with this virus.	HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT IMMUNOL,LONDON W12 0NN,ENGLAND; HAMAD HOSP,DEPT CLIN LAB & PATHOL,DOHA,QATAR	Imperial College London; Hamad Medical Corporation; Hamad General Hospital			谷, 雷雷/A-2889-2009					BIDWELL JL, 1988, TRANSPLANTATION, V45, P640, DOI 10.1097/00007890-198803000-00027; CRAVEN DE, 1986, ANN INTERN MED, V105, P356, DOI 10.7326/0003-4819-105-3-356; HATTUM JV, 1987, HEPATOLOGY, V7, P11; HILL AVS, 1992, NATURE, V360, P434, DOI 10.1038/360434a0; POZZILLI P, 1987, DIABETOLOGIA, V30, P817; WEISSMAN JY, 1988, JAMA-J AM MED ASSOC, V260, P1734, DOI 10.1001/jama.260.12.1734; YANG PM, 1989, HEPATO-GASTROENTEROL, V36, P363; 1994, LANCET, V343, P927	8	97	106	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 29	1994	344	8931					1194	1195		10.1016/S0140-6736(94)90510-X	http://dx.doi.org/10.1016/S0140-6736(94)90510-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN803	7934542				2022-12-24	WOS:A1994PN80300011
J	GINSBERG, JS; BARRON, WM				GINSBERG, JS; BARRON, WM			PREGNANCY AND PROSTHETIC HEART-VALVES	LANCET			English	Editorial Material							HEPARIN-THERAPY; ANTICOAGULANTS; WARFARIN; FETAL; RISKS; WOMEN		LOYOLA UNIV,MED CTR,DEPT MED,CHICAGO,IL 60611; LOYOLA UNIV,MED CTR,DEPT OBSTET & GYNECOL,CHICAGO,IL	Loyola University Chicago; Loyola University Chicago	GINSBERG, JS (corresponding author), MCMASTER UNIV,MED CTR,DEPT MED,HAMILTON L8N 3Z5,ON,CANADA.		ginsberg, jeffrey s/ABC-1065-2020					BARBOUR LA, 1994, AM J OBSTET GYNECOL, V170, P862, DOI 10.1016/S0002-9378(94)70299-3; BRILLEDWARDS P, 1993, ANN INTERN MED, V119, P104, DOI 10.7326/0003-4819-119-2-199307150-00002; CARUSO A, 1994, EUR J OBSTET GYN R B, V54, P7, DOI 10.1016/0028-2243(94)90074-4; DAHLMAN TC, 1993, AM J OBSTET GYNECOL, V168, P1265, DOI 10.1016/0002-9378(93)90378-V; GINSBERG JS, 1989, CHEST, V95, pS156, DOI 10.1378/chest.95.2.156S; GINSBERG JS, 1990, THROMB HAEMOSTASIS, V64, P286; GINSBERG JS, 1989, ARCH INTERN MED, V149, P2233, DOI 10.1001/archinte.149.10.2233; HALL JG, 1980, AM J MED, V68, P122, DOI 10.1016/0002-9343(80)90181-3; HIRSH J, 1991, NEW ENGL J MED, V324, P1565; HULL R, 1982, NEW ENGL J MED, V306, P189, DOI 10.1056/NEJM198201283060401; ITURBEALESSIO I, 1986, NEW ENGL J MED, V315, P1390, DOI 10.1056/NEJM198611273152205; SBAROUNI E, 1994, BRIT HEART J, V71, P196; TURPIE AGG, 1993, NEW ENGL J MED, V329, P524, DOI 10.1056/NEJM199308193290802; WONG V, 1993, AM J MED GENET, V45, P17, DOI 10.1002/ajmg.1320450107	14	35	35	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 29	1994	344	8931					1170	1172		10.1016/S0140-6736(94)90501-0	http://dx.doi.org/10.1016/S0140-6736(94)90501-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN803	7934533				2022-12-24	WOS:A1994PN80300002
J	GOODALE, MA				GOODALE, MA			ACTIVE MINDS, SLEEPING BODIES	LANCET			English	Editorial Material							REM		UNIV WESTERN ONTARIO,GRAD PROGRAM NEUROSCI,LONDON,ON,CANADA	Western University (University of Western Ontario)	GOODALE, MA (corresponding author), UNIV WESTERN ONTARIO,DEPT PSYCHOL,LONDON,ON,CANADA.		Goodale, Melvyn A/M-5907-2013	Goodale, Melvyn A/0000-0001-6748-0561				ASERINSKY E, 1953, SCIENCE, V118, P273, DOI 10.1126/science.118.3062.273; BLOCH V, 1977, NEUROBIOLOGY SLEEP M; DEMENT W, 1960, SCIENCE, V131, P1705, DOI 10.1126/science.131.3415.1705; DEMENT W, 1957, J EXP PSYCHOL, V53, P339, DOI 10.1037/h0048189; DUJARDIN K, 1990, PHYSIOL BEHAV, V47, P1271, DOI 10.1016/0031-9384(90)90382-E; KARNI A, 1994, SCIENCE, V265, P679, DOI 10.1126/science.8036518; Kleitman N., 1961, NATURE SLEEP; LAVIE P, 1984, NEUROLOGY, V34, P1118; MCGRATH MJ, 1978, PSYCHOL BULL, V85, P24, DOI 10.1037/0033-2909.85.1.24; SMITH C, 1985, NEUROSCI BIOBEHAV R, V9, P157, DOI 10.1016/0149-7634(85)90042-9; SMITH C, 1991, SLEEP, V14, P325, DOI 10.1093/sleep/14.4.325; VANDERWOLF CH, 1983, HDB BEHAVIORAL NEURO, V6, P67; WYATT RJ, 1971, NEW ENGL J MED, V285, P987, DOI 10.1056/NEJM197110282851802	13	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 15	1994	344	8929					1036	1037		10.1016/S0140-6736(94)91703-5	http://dx.doi.org/10.1016/S0140-6736(94)91703-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL852	7934440				2022-12-24	WOS:A1994PL85200003
J	WEIR, CJ; MURRAY, GD; ADAMS, FG; MUIR, KW; GROSSET, DG; LEES, KR				WEIR, CJ; MURRAY, GD; ADAMS, FG; MUIR, KW; GROSSET, DG; LEES, KR			POOR ACCURACY OF STROKE SCORING SYSTEMS FOR DIFFERENTIAL CLINICAL-DIAGNOSIS OF INTRACRANIAL HEMORRHAGE AND INFARCTION	LANCET			English	Article							HEMORRHAGE; COMMUNITY; PROJECT	The differentiation of cerebral infarction and cerebral haemorrhage is the most important first step in the management of acute stroke, because clinical management of the two disorders differs substantially. The Guy's Hospital and Siriraj stroke diagnostic scores were developed to aid clinicians in this decision. We have tested the performance of the two scores on a group of 1059 patients admitted to the acute stroke unit (ASU) at the Western Infirmary, Glasgow, with suspected stroke between May, 1990, and December, 1993. The diagnosis was confirmed as stroke by computed tomography (CT) scanning or necropsy (n=10) in 991 patients. For each clinical score we subjectively identified the cut-off point that maximised sensitivity to cerebral haemorrhage with the smallest loss of specificity. At its optimum cut-off point the Guy's Hospital score had a sensitivity for the diagnosis of haemorrhage of 70% and specificity of 64%. The corresponding figures for the Siriraj score at its optimum cut-off point were 68% sensitivity and 64% specificity. The overall predictive accuracy of both scores was 64%. The greater complexity of the Guy's Hospital score (thirteen variables included) did not result in substantially superior performance to the Siriraj score (five variables). This validation study suggests that neither score is useful for exclusion of haemorrhage before anticoagulant treatment is initiated or as a diagnostic screening procedure for trials of low-risk treatments such as aspirin. Our findings emphasise the need for routine CT scanning in this setting, since this method remains the most accurate for differentiating between haemorrhage and infarction.	UNIV GLASGOW,WESTERN INFIRM,DEPT MED & THERAPEUT,GLASGOW G11 6NT,LANARK,SCOTLAND; UNIV GLASGOW,ROBERTSON CTR BIOSTAT,GLASGOW G61 1BD,LANARK,SCOTLAND; WESTERN INFIRM & ASSOCIATED HOSP,DEPT RADIOL,GLASGOW,LANARK,SCOTLAND	University of Glasgow; University of Glasgow			Muir, Keith W/A-7670-2011	Muir, Keith W/0000-0001-9535-022X; Murray, Gordon/0000-0001-9866-4734; Grosset, Donald/0000-0002-2757-8203; Weir, Christopher/0000-0002-6494-4903	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Allen CMC, 1983, Q J MED, V208, P515; ALTMAN DG, 1991, PRACTICAL STAT MED R, P417; BAMFORD J, 1988, J NEUROL NEUROSUR PS, V51, P1373, DOI 10.1136/jnnp.51.11.1373; CELANI MG, 1994, BRIT MED J, V308, P1674, DOI 10.1136/bmj.308.6945.1674; HARRISON MJG, 1980, POSTGRAD MED J, V56, P629, DOI 10.1136/pgmj.56.659.629; MORRIS AD, 1993, J NEUROL NEUROSUR PS, V56, P352, DOI 10.1136/jnnp.56.4.352; POUNGVARIN N, 1991, BRIT MED J, V302, P1565, DOI 10.1136/bmj.302.6792.1565; SANDERCOCK P, 1985, BRIT MED J, V290, P193, DOI 10.1136/bmj.290.6463.193; SANDERCOCK PAG, 1985, BRIT MED J, V291, P1675, DOI 10.1136/bmj.291.6510.1675; SANDERCOCK PAG, 1986, BRIT MED J, V292, P173; VONARBIN M, 1981, STROKE, V12, P288, DOI 10.1161/01.STR.12.3.288	11	88	88	1	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 8	1994	344	8928					999	1002		10.1016/S0140-6736(94)91648-9	http://dx.doi.org/10.1016/S0140-6736(94)91648-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PK978	7934437				2022-12-24	WOS:A1994PK97800016
J	DUNAIEF, JL; STROBER, BE; GUHA, S; KHAVARI, PA; ALIN, K; LUBAN, J; BEGEMANN, M; CRABTREE, GR; GOFF, SP				DUNAIEF, JL; STROBER, BE; GUHA, S; KHAVARI, PA; ALIN, K; LUBAN, J; BEGEMANN, M; CRABTREE, GR; GOFF, SP			THE RETINOBLASTOMA PROTEIN AND BRG1 FORM A COMPLEX AND COOPERATE TO INDUCE CELL-CYCLE ARREST	CELL			English	Article							LARGE T-ANTIGEN; TRANSCRIPTION FACTOR E2F; SV40 LARGE-T; GENE-PRODUCT; SUSCEPTIBILITY GENE; BINDING PROTEIN; SNF6 PROTEINS; E1A PRODUCTS; EXPRESSION; DOMAIN	The retinoblastoma tumor suppressor protein (RB) binds several cellular proteins involved in cell cycle progression. Using the yeast two-hybrid system, we found that RB bound specifically to the protein BRG1. BRG1 shares extensive sequence similarity to Drosophila brahma, an activator of homeotic gene expression, and the yeast transcriptional activator SNF2/SWI2. BRG1 contains an RB-binding motif found in viral oncoproteins and bound to the A/B pocket and the hypophosphorylated form of RB. BRG1 did not bind RB in viral oncoprotein-transformed cells. Coimmunoprecipitation experiments suggested BRG1 associates with the RB family in vivo. In the human carcinoma cell line SW13, BRG1 exhibited tumor suppressor activity by inducing formation of flat, growth-arrested cells. This activity depended on the ability of BRG1 to cooperate and complex with RB, as both an RB-nonbinding mutant of BRG1 and the sequestration of RB by adenovirus E1A protein abolished flat cell formation.	COLUMBIA UNIV,COLL PHYS & SURG,HOWARD HUGHES MED INST,NEW YORK,NY 10032; COLUMBIA UNIV,COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032; COLUMBIA UNIV,COLL PHYS & SURG,CTR CANC,NEW YORK,NY 10032; STANFORD UNIV,DEPT DEV BIOL,STANFORD,CA 94305	Columbia University; Howard Hughes Medical Institute; Columbia University; Columbia University; Stanford University	DUNAIEF, JL (corresponding author), COLUMBIA UNIV,COLL PHYS & SURG,DEPT MICROBIOL,NEW YORK,NY 10032, USA.		Strober, Bruce/AAQ-6953-2020	Strober, Bruce/0000-0002-8394-2057; Luban, Jeremy/0000-0001-5650-4054	NHLBI NIH HHS [MSTP 5T35HL07616] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T35HL007616] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CAIRNS BR, 1994, P NATL ACAD SCI USA, V91, P1950, DOI 10.1073/pnas.91.5.1950; CARLSON M, 1994, CURR OPIN CELL BIOL, V6, P396, DOI 10.1016/0955-0674(94)90032-9; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; COBRINIK D, 1992, TRENDS BIOCHEM SCI, V17, P312, DOI 10.1016/0968-0004(92)90443-D; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; EGAN C, 1989, ONCOGENE, V4, P383; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FRANKE A, 1992, EMBO J, V11, P2941, DOI 10.1002/j.1460-2075.1992.tb05364.x; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HANES SD, 1989, CELL, V57, P1275, DOI 10.1016/0092-8674(89)90063-9; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HARLOW E, 1992, NATURE, V359, P270, DOI 10.1038/359270a0; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; IMAI Y, 1991, J VIROL, V65, P4966, DOI 10.1128/JVI.65.9.4966-4972.1991; JIANG W, 1993, P NATL ACAD SCI USA, V90, P9026, DOI 10.1073/pnas.90.19.9026; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; LAURENT BC, 1992, GENE DEV, V6, P1707, DOI 10.1101/gad.6.9.1707; LAURENT BC, 1991, P NATL ACAD SCI USA, V88, P2687, DOI 10.1073/pnas.88.7.2687; LAURENT BC, 1992, MOL CELL BIOL, V12, P1893, DOI 10.1128/MCB.12.4.1893; LAURENT BC, 1993, GENE DEV, V7, P583, DOI 10.1101/gad.7.4.583; LEE EYHP, 1988, P NATL ACAD SCI USA, V85, P6017, DOI 10.1073/pnas.85.16.6017; LUBAN J, 1993, CELL, V73, P1067, DOI 10.1016/0092-8674(93)90637-6; LUBAN J, 1992, J VIROL, V66, P5157, DOI 10.1128/JVI.66.8.5157-5160.1992; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; MORAN E, 1988, NATURE, V334, P168, DOI 10.1038/334168a0; MORAN E, 1986, MOL CELL BIOL, V6, P3470, DOI 10.1128/MCB.6.10.3470; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; PETERSON CL, 1994, P NATL ACAD SCI USA, V91, P2905, DOI 10.1073/pnas.91.8.2905; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; RANDAZZO FM, 1994, DEV BIOL, V161, P229, DOI 10.1006/dbio.1994.1023; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; TSUCHIYA E, 1992, EMBO J, V11, P4017, DOI 10.1002/j.1460-2075.1992.tb05495.x; WARNEFORD S, 1991, CELL GROWTH DIFFER, V2, P439; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3; YEE SP, 1985, VIROLOGY, V147, P142, DOI 10.1016/0042-6822(85)90234-X; YOSHINAGA SK, 1992, SCIENCE, V258, P1598, DOI 10.1126/science.1360703	66	539	551	1	23	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 7	1994	79	1					119	130		10.1016/0092-8674(94)90405-7	http://dx.doi.org/10.1016/0092-8674(94)90405-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PK585	7923370				2022-12-24	WOS:A1994PK58500013
J	GOTZSCHE, PC				GOTZSCHE, PC			IS THERE LOGIC IN THE PLACEBO	LANCET			English	Article							PAIN				GOTZSCHE, PC (corresponding author), RIGSHOSP, NORDIC COCHRANE CTR, RES & DEV SECRETARIAT, 9 BLEGDAMSVEJ, DK-2100 COPENHAGEN 0, DENMARK.							Cochrane A. L, 1972, PUBLIC HEALTH, DOI DOI 10.1016/S0033-3506(73)80082-4; GAM AN, 1993, PAIN, V52, P63, DOI 10.1016/0304-3959(93)90114-5; KENNEDY W P, 1961, Med World, V95, P203; PECK C, 1991, THEOR MED, V12, P247, DOI 10.1007/BF00489609; SHAPIRO AK, 1968, PSYCHIAT QUART, V42, P653, DOI 10.1007/BF01564309; SHEPHERD M, 1993, PSYCHOL MED, V23, P569, DOI 10.1017/S0033291700025356; WARE JE, 1993, BRIT MED J, V306, P1429, DOI 10.1136/bmj.306.6890.1429; Wulff H. R., 1986, PHILOS MED	8	117	117	0	12	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 1	1994	344	8927					925	926						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PJ287	7934350				2022-12-24	WOS:A1994PJ28700014
J	REHMAN, I; QUINN, AG; HEALY, E; REES, JL				REHMAN, I; QUINN, AG; HEALY, E; REES, JL			HIGH-FREQUENCY OF LOSS OF HETEROZYGOSITY IN ACTINIC KERATOSES, A USUALLY BENIGN DISEASE	LANCET			English	Note							SQUAMOUS-CELL CARCINOMA; SKIN	Actinic keratoses (AKs) are focal areas of dysplasia with low risk of progression to squamous cell cancer; many regress spontaneously. Using polymerase-chain-reaction microsatellite analysis, we found that loss of heterozygosity on several chromosome arms, including 17p, 17q, 9p, 9q, and 13q, was common in AKs. More than half the AKs examined showed loss of heterozygosity at four or more loci. The apparent genetic instability of these lesions contrasts with their benign clinical course.	UNIV NEWCASTLE UPON TYNE,ROYAL VICTORIA INFIRM,DEPT DERMATOL,NEWCASTLE TYNE NE1 4LP,ENGLAND	Newcastle University - UK				Healy, Eugene/0000-0001-5591-6970				CAMPBELL C, 1993, J INVEST DERMATOL, V100, P746, DOI 10.1111/1523-1747.ep12475717; CAMPBELL C, 1993, BRIT J DERMATOL, V129, P235, DOI 10.1111/j.1365-2133.1993.tb11840.x; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; KNUDSON A, 1991, ORIGINS OF HUMAN CANCER, P17; KWA RE, 1992, J AM ACAD DERMATOL, V26, P1, DOI 10.1016/0190-9622(92)70001-V; LANE DP, 1994, INT J CANCER, V57, P623, DOI 10.1002/ijc.2910570502; MARKS R, 1988, LANCET, V1, P795, DOI 10.1016/s0140-6736(88)91658-3; QUINN AG, 1994, CANCER RES, V54, P4756; WEINBERG RA, 1991, ORIGINS OF HUMAN CANCER, P1; YOKOTA J, 1993, FASEB J, V7, P920, DOI 10.1096/fasebj.7.10.8344488	10	60	61	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 17	1994	344	8925					788	789		10.1016/S0140-6736(94)92343-4	http://dx.doi.org/10.1016/S0140-6736(94)92343-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PG178	7916075				2022-12-24	WOS:A1994PG17800012
J	CHAN, SK; JAFFE, L; CAPOVILLA, M; BOTAS, J; MANN, RS				CHAN, SK; JAFFE, L; CAPOVILLA, M; BOTAS, J; MANN, RS			THE DNA-BINDING SPECIFICITY OF ULTRABITHORAX IS MODULATED BY COOPERATIVE INTERACTIONS WITH EXTRADENTICLE, ANOTHER HOMEOPROTEIN	CELL			English	Article							HUMAN PROTOONCOGENE PBX1; MAGNETIC-RESONANCE SPECTROSCOPY; DROSOPHILA HOMEODOMAIN PROTEINS; HOMEOTIC GENE-EXPRESSION; FUNCTIONAL SPECIFICITY; ANTENNAPEDIA HOMEODOMAIN; ECTOPIC EXPRESSION; VISCERAL MESODERM; CRYSTAL-STRUCTURE; HOMEOBOX GENES	The Ultrabithorax (Ubx) and Antennapedia (Antp) genes of Drosophila encode homeodomain proteins that have very similar DNA binding specificities in vitro but specify the development of different segmental patterns in vivo. We describe cooperative interactions between Ubx protein and a divergent homeodomain protein, extradenticle (exd), that selectively increases the affinity of Ubx, but not Antp, for a particular DNA target. We also provide evidence that Ubx and exd bind to neighboring sites on this DNA and interact directly to stabilize the DNA-bound form of Ubx. Thus, the ability of different homeotic genes to specify distinct segmental patterns may depend on cooperative interactions with proteins such as exd that selectively modulate their otherwise similar DNA binding specificities.	COLUMBIA UNIV,CTR NEUROBIOL & BEHAV,NEW YORK,NY 10032; BAYLOR COLL MED,INST MOLEC GENET,HOUSTON,TX 77030	Columbia University; Baylor College of Medicine	CHAN, SK (corresponding author), COLUMBIA UNIV,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032, USA.		Capovilla, Maria/O-8483-2016	Capovilla, Maria/0000-0002-1308-7964	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054510] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM054510] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREW DJ, 1992, NEW BIOL, V4, P5; BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; BILLETER M, 1990, J MOL BIOL, V214, P183, DOI 10.1016/0022-2836(90)90155-F; CAPOVILLA M, 1994, CELL, V76, P461, DOI 10.1016/0092-8674(94)90111-2; CHAN SK, 1993, GENE DEV, V7, P796, DOI 10.1101/gad.7.5.796; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; DESPLAN C, 1988, CELL, V54, P1081, DOI 10.1016/0092-8674(88)90123-7; DESSAIN S, 1992, EMBO J, V11, P991, DOI 10.1002/j.1460-2075.1992.tb05138.x; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EKKER SC, 1992, EMBO J, V11, P4059, DOI 10.1002/j.1460-2075.1992.tb05499.x; FLEGEL WA, 1993, MECH DEVELOP, V41, P155, DOI 10.1016/0925-4773(93)90045-Y; FURUKUBOTOKUNAGA K, 1993, P NATL ACAD SCI USA, V90, P6360, DOI 10.1073/pnas.90.13.6360; GIBSON G, 1988, DEVELOPMENT, V102, P657; GONZALEZREYES A, 1990, NATURE, V344, P78, DOI 10.1038/344078a0; GONZALEZREYES A, 1990, CELL, V61, P515, DOI 10.1016/0092-8674(90)90533-K; GRUENEBERG DA, 1992, SCIENCE, V257, P1089, DOI 10.1126/science.257.5073.1089; HAYASHI S, 1990, CELL, V63, P883, DOI 10.1016/0092-8674(90)90492-W; HOEY T, 1988, NATURE, V332, P858, DOI 10.1038/332858a0; IMMERGLUCK K, 1990, CELL, V62, P261, DOI 10.1016/0092-8674(90)90364-K; JOHNSON A, 1993, TRANSCRIPTIONAL REGU; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KELEHER CA, 1988, CELL, V53, P927, DOI 10.1016/S0092-8674(88)90449-7; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; LIN L, 1992, GENE DEV, V6, P1071, DOI 10.1101/gad.6.6.1071; LOPEZ AJ, 1991, P NATL ACAD SCI USA, V88, P9924, DOI 10.1073/pnas.88.22.9924; LUBAN J, 1993, CELL, V73, P1067, DOI 10.1016/0092-8674(93)90637-6; MANN RS, 1990, CELL, V60, P597, DOI 10.1016/0092-8674(90)90663-Y; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MONICA K, 1991, MOL CELL BIOL, V11, P6149, DOI 10.1128/MCB.11.12.6149; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; OTTING G, 1990, EMBO J, V9, P3085, DOI 10.1002/j.1460-2075.1990.tb07505.x; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; PANGANIBAN GEF, 1990, DEVELOPMENT, V110, P1041; PEIFER M, 1990, GENE DEV, V4, P1209, DOI 10.1101/gad.4.7.1209; RAUSKOLB C, 1993, CELL, V74, P1101, DOI 10.1016/0092-8674(93)90731-5; RAUSKOLB C, 1994, IN PRESS EMBO; REUTER R, 1990, DEVELOPMENT, V110, P1031; SMITH MC, 1988, J BIOL CHEM, V263, P7211; TREISMAN J, 1992, BIOESSAYS, V14, P145, DOI 10.1002/bies.950140302; TREMML G, 1989, EMBO J, V8, P2677, DOI 10.1002/j.1460-2075.1989.tb08408.x; VANDIJK MA, 1993, P NATL ACAD SCI USA, V90, P6061, DOI 10.1073/pnas.90.13.6061; VERSHON AK, 1993, CELL, V72, P105, DOI 10.1016/0092-8674(93)90054-T; WAKIMOTO BT, 1981, DEV BIOL, V81, P51, DOI 10.1016/0012-1606(81)90347-X; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5; XU T, 1993, DEVELOPMENT, V117, P1223; XUE D, 1993, SCIENCE, V261, P1324, DOI 10.1126/science.8103239; ZENG WL, 1993, DEVELOPMENT, V118, P339	49	341	342	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 26	1994	78	4					603	615		10.1016/0092-8674(94)90525-8	http://dx.doi.org/10.1016/0092-8674(94)90525-8			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PD693	7915199				2022-12-24	WOS:A1994PD69300009
J	MILLER, JD				MILLER, JD			SWELLING AND BLOOD-FLOW IN THE INJURED CHILDS BRAIN	LANCET			English	Editorial Material							HEAD-INJURY; METABOLISM				MILLER, JD (corresponding author), WESTERN GEN HOSP, DEPT CLIN NEUROSCI, EDINBURGH, MIDLOTHIAN, SCOTLAND.							ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; CHAN KH, 1993, NEUROSURGERY, V32, P547, DOI 10.1227/00006123-199304000-00009; CHAN KH, 1992, J NEUROL NEUROSUR PS, V55, P787, DOI 10.1136/jnnp.55.9.787; DEARDEN NM, 1991, CURR OPIN ANESTHESIO, V4, P279; LANG DA, 1994, J NEUROSURG, V80, P675, DOI 10.3171/jns.1994.80.4.0675; MUIZELAAR JP, 1989, J NEUROSURG, V71, P63, DOI 10.3171/jns.1989.71.1.0063; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; RAIMONDI AJ, 1984, CHILD BRAIN, V11, P12; SCHRODER ML, 1993, J NEUROTRAUMA S, V10, pS57; SHARPLES PM, 1991, ARCH DIS CHILD, V66, P1326, DOI 10.1136/adc.66.11.1326; SHARPLES PM, IN PRESS J NEUROL NE; TEASDALE GM, 1990, BRIT MED J, V300, P363, DOI 10.1136/bmj.300.6721.363	13	9	10	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 13	1994	344	8920					421	422						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB761	7914562				2022-12-24	WOS:A1994PB76100005
J	VARTIAINEN, E; PUSKA, P; PEKKANEN, J; TUOMILEHTO, J; LONNQVIST, J; EHNHOLM, C				VARTIAINEN, E; PUSKA, P; PEKKANEN, J; TUOMILEHTO, J; LONNQVIST, J; EHNHOLM, C			SERUM-CHOLESTEROL CONCENTRATION AND MORTALITY FROM ACCIDENTS, SUICIDE, AND OTHER VIOLENT CAUSES	BRITISH MEDICAL JOURNAL			English	Article							DEATH; RISK	Objective-To study the association of mortality from accidents, suicides, and other violent deaths with serum cholesterol concentration. Design-Baseline measurements in two randomly chosen independent cohorts were carried out in 1972 and 1977. Mortality was monitored over 10-15 years through the national death registry. Setting-Eastern Finland. Subjects-The two cohorts comprised men (n=10898) and women (n=11534) born between 1913 and 1947. There were 193 deaths due to accidents, suicides, and violence among men and 43 among women. Main outcome measure-Mortality from accidents, suicides, and other violent deaths was used as the end point. Deaths from these causes were pooled together in the analyses. Results-Serum cholesterol concentration was not associated with mortality from accidents, suicides, and other violent deaths in the univariate analyses or in the proportional hazards regression analyses including smoking, systolic blood pressure, alcohol drinking, and education. In both genders smoking was more prevalent among those who died from accidents, suicides, and other violent causes than from other causes. Frequent use of alcohol increased mortality from these causes. Conclusion-The risk of accidents, suicides, and other violent deaths was not related to serum cholesterol concentration, whereas such deaths were more prevalent in smokers and alcohol drinkers.			VARTIAINEN, E (corresponding author), NATL PUBL HLTH INST,MANNERHEIMINTIE 166,SF-00300 HELSINKI,FINLAND.							[Anonymous], COMMUNITY CONTROL CA; COX DR, 1972, J R STAT SOC B, V34, P187; KROMHOUT D, 1992, LANCET, V340, P317, DOI 10.1016/0140-6736(92)92415-C; LAW MR, 1994, BRIT MED J, V308, P373, DOI 10.1136/bmj.308.6925.373; LINDBERG G, 1992, BRIT MED J, V305, P277, DOI 10.1136/bmj.305.6848.277; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; PEKKANEN J, 1989, ARCH INTERN MED, V149, P1589, DOI 10.1001/archinte.149.7.1589; SCHUIT AJ, 1993, LANCET, V341, P827, DOI 10.1016/0140-6736(93)90600-L; SMITH GD, 1992, LANCET, V340, P709; SMITH GD, 1992, BMJ-BRIT MED J, V304, P431, DOI 10.1136/bmj.304.6824.431; SMITH GD, 1990, BRIT MED J, V301, P552; 1990, SAS USERS GUIDE STAT	12	53	53	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 13	1994	309	6952					445	447						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PC404	7920128	Green Published			2022-12-24	WOS:A1994PC40400018
J	QUIRING, R; WALLDORF, U; KLOTER, U; GEHRING, WJ				QUIRING, R; WALLDORF, U; KLOTER, U; GEHRING, WJ			HOMOLOGY OF THE EYELESS GENE OF DROSOPHILA TO THE SMALL EYE GENE IN MICE AND ANIRIDIA IN HUMANS	SCIENCE			English	Article							HOMEOBOX-CONTAINING GENE; PAIRED BOX GENE; HUMAN PAX6 GENE; STRUCTURAL-ANALYSIS; EXPRESSION PATTERN; MOLECULAR-GENETICS; NEURAL-TUBE; SEQUENCE; DNA; MELANOGASTER	A Drosophila gene that contains both a paired box and a homeobox and has extensive sequence homology to the mouse Pax-6 (Small eye) gene was isolated and mapped to chromosome IV in a region close to the eyeless locus. Two spontaneous mutations, ey(2) and ey(R), contain transposable element insertions into the cloned gene and affect gene expression, particularly in the eye primordia. This indicates that the cloned gene encodes ey. The finding that ey of Drosophila, Small eye of the mouse, and human Aniridia are encoded by homologous genes suggests that eye morphogenesis is under similar genetic control in both vertebrates and insects, in spite of the large differences in eye morphology and mode of development.	UNIV BASEL,BIOCTR,DEPT CELL BIOL,CH-4056 BASEL,SWITZERLAND	University of Basel								ASHBURNER M, 1989, DROSOPHILA LABORATOR; BALLING R, 1988, CELL, V55, P531, DOI 10.1016/0092-8674(88)90039-6; BAUMGARTNER S, 1987, GENE DEV, V1, P1247, DOI 10.1101/gad.1.10.1247; BENDER W, 1983, SCIENCE, V221, P23, DOI 10.1126/science.221.4605.23; BONINI NM, 1993, CELL, V72, P379, DOI 10.1016/0092-8674(93)90115-7; BOPP D, 1986, CELL, V47, P1033, DOI 10.1016/0092-8674(86)90818-4; BURGLIN TR, GUIDEBOOK HOMEOBOX G, P25; CALLAERTS P, UNPUB; CARRIERE C, 1993, MOL CELL BIOL, V13, P7257, DOI 10.1128/MCB.13.12.7257; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; CHALEPAKIS G, 1991, CELL, V66, P873, DOI 10.1016/0092-8674(91)90434-Z; CHALEPAKIS G, 1993, J NEUROBIOL, V24, P1367, DOI 10.1002/neu.480241009; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOZIER C, 1993, CELL GROWTH DIFFER, V4, P281; DRIVER A, 1989, MOL GEN GENET, V220, P49, DOI 10.1007/BF00260854; EPSTEIN DJ, 1991, CELL, V67, P767, DOI 10.1016/0092-8674(91)90071-6; FRIGERIO G, 1986, CELL, V47, P735, DOI 10.1016/0092-8674(86)90516-7; FROMMER G, 1994, CHROMOSOMA, V103, P82, DOI 10.1007/BF00352316; GLASER T, 1992, NAT GENET, V2, P232, DOI 10.1038/ng1192-232; GRUSS P, 1992, CELL, V69, P719, DOI 10.1016/0092-8674(92)90281-G; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; HIROMI Y, 1987, CELL, V50, P963, DOI 10.1016/0092-8674(87)90523-X; HOGAN BLM, 1988, DEVELOPMENT, V103, P115; JACOB F, 1977, SCIENCE, V196, P1161, DOI 10.1126/science.860134; JORDAN T, 1992, NAT GENET, V1, P328, DOI 10.1038/ng0892-328; JURGENS G, 1993, DEV DROSOPHILA MELAN, V1, P702; KRAUSS S, 1991, EMBO J, V10, P3609, DOI 10.1002/j.1460-2075.1991.tb04927.x; KRAUSS S, 1991, NATURE, V353, P267, DOI 10.1038/353267a0; LEEMANS R, UNPUB; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; LOOSLI F, UNPUB; MARTIN P, 1992, ONCOGENE, V7, P1721; MATSUO T, 1993, NAT GENET, V3, P299, DOI 10.1038/ng0493-299; MLODZIK M, 1990, GENE DEV, V4, P1848, DOI 10.1101/gad.4.11.1848; NOLL M, 1993, CURR OPIN GENET DEV, V3, P595, DOI 10.1016/0959-437X(93)90095-7; OHARE K, 1983, P NATL ACAD SCI-BIOL, V80, P6917, DOI 10.1073/pnas.80.22.6917; OHARE K, 1991, MOL GEN GENET, V225, P17, DOI 10.1007/BF00282637; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PICK L, 1990, GENE DEV, V4, P1224, DOI 10.1101/gad.4.7.1224; PLATE L, 1924, ALLGEMEINE ZOOLOGIE; POOLE SJ, 1985, CELL, V40, P37, DOI 10.1016/0092-8674(85)90306-X; PUSCHEL AW, 1992, DEVELOPMENT, V114, P643; READY DF, 1976, DEV BIOL, V53, P217, DOI 10.1016/0012-1606(76)90225-6; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEITZ K, 1993, GENE DEV, V7, P114, DOI 10.1101/gad.7.1.114; SHEA MJ, 1990, GENE DEV, V4, P1128, DOI 10.1101/gad.4.7.1128; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; TASSABEHJI M, 1992, NATURE, V355, P635, DOI 10.1038/355635a0; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TON CCT, 1991, CELL, V67, P1059, DOI 10.1016/0092-8674(91)90284-6; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; WALLDORF U, UNPUB; WALTHER C, 1991, GENOMICS, V11, P424, DOI 10.1016/0888-7543(91)90151-4; WALTHER C, 1991, DEVELOPMENT, V113, P1435	54	864	889	1	105	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 5	1994	265	5173					785	789		10.1126/science.7914031	http://dx.doi.org/10.1126/science.7914031			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PA372	7914031				2022-12-24	WOS:A1994PA37200034
J	DERKX, FHM; SCHALEKAMP, MADH				DERKX, FHM; SCHALEKAMP, MADH			RENAL-ARTERY STENOSIS AND HYPERTENSION	LANCET			English	Article							RENOVASCULAR HYPERTENSION; ANGIOPLASTY; DIAGNOSIS; CAPTOPRIL; TESTS				DERKX, FHM (corresponding author), ERASMUS UNIV ROTTERDAM,HOSP DIJKZIGT,DEPT INTERNAL MED 1,ROOM L242,DR MOLEWATERPLEIN 40,3015 GD ROTTERDAM,NETHERLANDS.							[Anonymous], 1987, Arch Intern Med, V147, P820; BLAUFOX MD, 1990, HYPERTENSION PATHOPH, P1509; DAVIDSON RA, 1992, JAMA-J AM MED ASSOC, V268, P3353, DOI 10.1001/jama.268.23.3353; DEAN RH, 1981, ARCH SURG-CHICAGO, V116, P1408; DERKX FHM, 1993, NETH J MED, V43, pS12; DERKX FHM, 1993, J HYPERTENS, V11, pS200; DERKX FHM, 1987, RENOVASCULAR HYPERTE, P295; DORROS G, 1993, CATHET CARDIOVASC DI, V3, P191; ELLIOTT WJ, 1993, ARCH INTERN MED, V153, P755, DOI 10.1001/archinte.153.6.755; FOMMEI E, 1993, EUR J NUCL MED, V20, P617; HUDSPETH DA, 1993, J VASC SURG, V18, P389; HUNT JC, 1974, ARCH INTERN MED, V133, P988, DOI 10.1001/archinte.133.6.988; Marks L S, 1975, Urol Clin North Am, V2, P311; MAY AG, 1963, SURGERY, V53, P5213; NEIMAN HL, 1985, ANGIOGRAPHY VASCULAR, P1; Pickering T, 1990, HYPERTENSION PATHOPH, P1539; PICKERING TG, 1985, J HYPERTENS, V3, pS291; PLOUIN PF, 1993, HYPERTENSION, V21, P89, DOI 10.1161/01.HYP.21.1.89; RAMSAY LE, 1990, BRIT MED J, V300, P569, DOI 10.1136/bmj.300.6724.569; SIMON G, 1994, AM J HYPERTENS, V7, P1; VANJAARSVELD BC, 1994, NETH J MED, V44, pA65; WEIBULL H, 1993, J VASC SURG, V18, P841, DOI 10.1016/0741-5214(93)90340-R; WENTING GJ, 1984, BMJ-BRIT MED J, V288, P886, DOI 10.1136/bmj.288.6421.886	23	183	192	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 23	1994	344	8917					237	239		10.1016/S0140-6736(94)93002-3	http://dx.doi.org/10.1016/S0140-6736(94)93002-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY060	7913161	Green Submitted			2022-12-24	WOS:A1994NY06000014
J	MELKI, J; LEFEBVRE, S; BURGLEN, L; BURLET, P; CLERMONT, O; MILLASSEAU, P; REBOULLET, S; BENICHOU, B; ZEVIANI, M; LEPASLIER, D; COHEN, D; WEISSENBACH, J; MUNNICH, A				MELKI, J; LEFEBVRE, S; BURGLEN, L; BURLET, P; CLERMONT, O; MILLASSEAU, P; REBOULLET, S; BENICHOU, B; ZEVIANI, M; LEPASLIER, D; COHEN, D; WEISSENBACH, J; MUNNICH, A			DE-NOVO AND INHERITED DELETIONS OF THE 5Q13 REGION IN SPINAL MUSCULAR ATROPHIES	SCIENCE			English	Article							WERDNIG-HOFFMANN DISEASE; GENE; CHILDHOOD; CONTIG	Spinal muscular atrophies (SMAs) represent the second most common fatal autosomal recessive disorder after cystic fibrosis. Childhood spinal muscular atrophies are divided into severe (type I) and mild forms (types II and III). By a combination of genetic and physical mapping, a yeast artificial chromosome contig of the 5q13 region spanning the disease locus was constructed that showed the presence of low copy repeats in this region. Allele segregation was analyzed at the closest genetic loci detected by markers C212 and C272 in 201 SMA families. Inherited and de novo deletions were observed in nine unrelated SMA patients. Moreover, deletions were strongly suggested in at least 18 percent of SMA type I patients by the observation of marked heterozygosity deficiency for the loci studied. These results indicate that deletion events are statistically associated with the severe form of spinal muscular atrophy.	HOP NECKER ENFANTS MALAD,INSERM,U393,UNITE RECH HANDICAPS GENET ENFANT,F-75743 PARIS,FRANCE; GENETHON,EVRY,FRANCE; CTR ETUD POLYMORPHISME HUMAIN,PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			Lefebvre, Suzie/D-5092-2017; Zeviani, Massimo/K-2891-2014; Zeviani, Massimo/AAU-2632-2021	Zeviani, Massimo/0000-0002-9067-5508; BERNARD, BENICHOU/0000-0002-9331-0926; Le Paslier, Denis/0000-0003-4335-9956				BRZUSTOWICZ LM, 1990, NATURE, V344, P540, DOI 10.1038/344540a0; CHUMAKOV IM, 1992, NAT GENET, V1, P222, DOI 10.1038/ng0692-222; CLERMONT O, 1994, AM J HUM GENET, V54, P687; CZEIZEL A, 1989, J MED GENET, V26, P761, DOI 10.1136/jmg.26.12.761; DANIELS RJ, 1992, GENOMICS, V12, P335, DOI 10.1016/0888-7543(92)90382-3; FRANCIS MJ, 1993, HUM MOL GENET, V2, P1161, DOI 10.1093/hmg/2.8.1161; GILLIAM TC, 1990, NATURE, V345, P823, DOI 10.1038/345823a0; GREEN ED, 1990, P NATL ACAD SCI USA, V87, P1213, DOI 10.1073/pnas.87.3.1213; HAUSMANOWAPETRUSEWICZ I, 1985, J MED GENET, V22, P350, DOI 10.1136/jmg.22.5.350; HAZAN J, 1992, GENOMICS, V12, P183, DOI 10.1016/0888-7543(92)90364-X; KLEYN PW, 1993, P NATL ACAD SCI USA, V90, P6801, DOI 10.1073/pnas.90.14.6801; MELKI J, 1990, LANCET, V336, P271, DOI 10.1016/0140-6736(90)91803-I; MELKI J, 1990, NATURE, V344, P764; Monaco AP, 1988, GENOMICS, V2, P90, DOI 10.1016/0888-7543(88)90113-9; Munsat TL., 1991, NEUROMUSCUL DISORD, V1, P81, DOI [10.1016/0960-8966(91)90052-t, DOI 10.1016/0960-8966(91)90052-T]; PEARN J, 1978, J MED GENET, V15, P403; PEARN JH, 1973, J MED GENET, V10, P260, DOI 10.1136/jmg.10.3.260; ROBERTS DF, 1970, ARCH DIS CHILD, V45, P33, DOI 10.1136/adc.45.239.33; SMITH LM, 1986, NATURE, V321, P674, DOI 10.1038/321674a0; ZERRES K, 1988, THESIS U BONN	20	290	299	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 3	1994	264	5164					1474	1477		10.1126/science.7910982	http://dx.doi.org/10.1126/science.7910982			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NP221	7910982				2022-12-24	WOS:A1994NP22100047
J	KERR, GS; HALLAHAN, CW; GIORDANO, J; LEAVITT, RY; FAUCI, AS; ROTTEM, M; HOFFMAN, GS				KERR, GS; HALLAHAN, CW; GIORDANO, J; LEAVITT, RY; FAUCI, AS; ROTTEM, M; HOFFMAN, GS			TAKAYASU ARTERITIS	ANNALS OF INTERNAL MEDICINE			English	Article							NORTH-AMERICAN PATIENTS; SURGICAL-TREATMENT; ANGIOGRAPHIC FINDINGS; DISEASE; AORTOARTERITIS; GRANULOMATOSIS; INVOLVEMENT; AORTITIS; METHOTREXATE; SARCOIDOSIS	Objective: To evaluate prospectively the clinical features, angiographic findings, and response to treatment of patients with Takayasu arteritis. Design: 60 patients with Takayasu arteritis were studied at the National Institute of Allergy and Infectious Diseases between 1970 and 1990 and were followed for 6 months to 20 years (median follow-up, 5.3 years). Measurements: Data on clinical features, angiographic and laboratory findings, disease course, and response to therapy were all recorded and stored in a computer-based retrieval system. Setting: The Warren Magnuson Clinical Center of the National Institutes of Health. Results: In our series of patients, Takayasu arteritis was more common in Asian persons compared with persons from other racial groups. Females (97%) were most frequently affected. The median age at disease onset was 25 years. Juveniles had a delay in diagnosis that was about four times that of adults. The clinical presentation ranged from asymptomatic to catastrophic with stroke. The most common clinical finding was a bruit. Hypertension was most often associated with renal artery stenosis. Only 33% of all patients had systemic symptoms on presentation. Sixty-eight percent of patients had extensive vascular disease; stenotic lesions were 3.6-fold more common than were aneurysms (98% compared with 27%). The erythrocyte sedimentation rate was not a consistently reliable surrogate marker of disease activity. Surgical bypass biopsy specimens from clinically inactive patients showed histologically active disease in 44% of patients. Although clinically significant palliation usually occurred after angioplasty or bypass of severely stenotic vessels, restenosis was common. Medical therapy was required for 80% of patients, whereas 20% had monophasic self-limiting disease. Immunosuppressive treatment with glucocorticoids alone or in combination with a cytotoxic agent failed to induce remission in one fourth of patients; about half of those who achieved remission later relapsed. Conclusions: In North America, Takayasu arteritis is a rare disease. It is heterogeneous in presentation, progression, and response to therapy. Current laboratory markers of disease activity are insufficiently reliable to guide management. Most patients require repeated and, at times, prolonged courses of therapy. Although mortality was low, substantial morbidity occurred in most patients.	NIAID, IMMUNOREGULAT LAB, BETHESDA, MD 20892 USA; GEORGE WASHINGTON UNIV HOSP, WASHINGTON, DC 20037 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); George Washington University			Ulatan, Jeffrey/AAM-5560-2020	Ulatan, Jeffrey/0000-0002-3756-0568				ABE K, 1976, JPN HEART J, V17, P1; ACHAR KN, 1986, AM J GASTROENTEROL, V81, P1215; ASKUPMARK E, 1961, ACTA MED SCAND, V169, P467; ASO T, 1992, HEART VESSELS S, V7, P15; CHUGH KS, 1992, AM J NEPHROL, V12, P1, DOI 10.1159/000168409; CIPRIANO PR, 1977, AM J CARDIOL, V39, P744, DOI 10.1016/S0002-9149(77)80139-2; DANARAJ TJ, 1959, CIRCULATION, V20, P856, DOI 10.1161/01.CIR.20.5.856; DEUTSCH V, 1974, AM J ROENTGENOL, V122, P13, DOI 10.2214/ajr.122.1.13; DIGIACOMO V, 1985, ANGIOLOGY, V36, P70, DOI 10.1177/000331978503600202; FRAGA A, 1972, ARTHRITIS RHEUM, V15, P617, DOI 10.1002/art.1780150608; GIORDANO JM, 1991, SURGERY, V109, P252; HALL S, 1985, MEDICINE, V64, P89, DOI 10.1097/00005792-198503000-00002; HE NS, 1990, CHINESE MED J-PEKING, V103, P666; HOFFMAN GS, 1992, ARTHRITIS RHEUM, V35, P1322, DOI 10.1002/art.1780351113; HOFFMAN GS, 1992, ANN INTERN MED, V116, P488, DOI 10.7326/0003-4819-116-6-488; HOFFMAN GS, 1994, ARTHRITIS RHEUM, V37, P578, DOI 10.1002/art.1780370420; ISAACSON C, 1961, J PATHOL BACTERIOL, V81, P69, DOI 10.1002/path.1700810109; ISHIKAWA K, 1988, J AM COLL CARDIOL, V12, P964, DOI 10.1016/0735-1097(88)90462-7; ISHIKAWA K, 1982, AM J CARDIOL, V50, P1293, DOI 10.1016/0002-9149(82)90466-0; JUDGE RD, 1962, AM J MED, V32, P379, DOI 10.1016/0002-9343(62)90128-6; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KHRAISHI MM, 1992, ARTHRITIS RHEUM, V35, P573, DOI 10.1002/art.1780350514; KUMAR S, 1989, CARDIOVASC INTER RAD, V12, P321, DOI 10.1007/BF02575430; LAGNEAU P, 1987, ANN SURG, V205, P157, DOI 10.1097/00000658-198702000-00010; LANDE A, 1976, NEW YORK STATE J MED, V76, P1477; LEE J, 1990, HLA SYSTEM; LEE KS, 1967, ACTA PAEDIATR SCAND, V56, P526, DOI 10.1111/j.1651-2227.1967.tb15418.x; LENHOFF SJ, 1982, POSTGRAD MED J, V58, P386, DOI 10.1136/pgmj.58.680.386; LUPIH E, 1975, CHEST, V67, P69, DOI 10.1378/chest.67.1.69; LUPIHERRERA E, 1977, AM HEART J, V93, P94, DOI 10.1016/S0002-8703(77)80178-6; MAEDA S, 1983, ACTA PATHOL JAPON, V33, P183; Matsumura A, 1992, Heart Vessels Suppl, V7, P120, DOI 10.1007/BF01744557; MENDELOFF AI, 1980, INFLAMM BOWEL DIS, P5; MEVORACH D, 1992, ANN RHEUM DIS, V51, P904, DOI 10.1136/ard.51.7.904; MORIUCHI J, 1982, HUM IMMUNOL, V4, P87, DOI 10.1016/0198-8859(82)90054-4; NAKAO K, 1967, CIRCULATION, V35, P1141, DOI 10.1161/01.CIR.35.6.1141; NUMANO F, 1982, JPN CIRC J, V46, P184, DOI 10.1253/jcj.46.184; NUSINOW SR, 1984, ARTHRITIS RHEUM, V27, P1405, DOI 10.1002/art.1780271211; PAJARI R, 1986, THORAC CARDIOV SURG, V34, P176, DOI 10.1055/s-2007-1020404; ROSE AG, 1980, ARCH PATHOL LAB MED, V104, P231; ROSE CD, 1990, J RHEUMATOL, V17, P102; Sabba C, 1990, Am J Cardiovasc Pathol, V3, P95; SEN PK, 1973, MONOGRAPH BASED STUD; SHARMA S, 1991, BRIT J RADIOL, V64, P690, DOI 10.1259/0007-1285-64-764-690; SHARMA S, 1990, CLIN RADIOL, V42, P177, DOI 10.1016/S0009-9260(05)81929-4; SHARMA S, 1992, AM J ROENTGENOL, V158, P417, DOI 10.2214/ajr.158.2.1346073; SIMES RJ, 1986, BIOMETRIKA, V73, P751, DOI 10.2307/2336545; SUBRAMANYAN R, 1989, CIRCULATION, V80, P429, DOI 10.1161/01.CIR.80.3.429; TAKAGI A, 1989, J CARDIOVASC SURG, V30, P553; VINIJCHAIKUL K, 1967, AM J MED, V43, P15, DOI 10.1016/0002-9343(67)90145-3; VOLKMAN DJ, 1982, NEW ENGL J MED, V306, P464, DOI 10.1056/NEJM198202253060806; WAERN AU, 1983, ANGIOLOGY, V34, P311; Weaver F A, 1992, Heart Vessels Suppl, V7, P154, DOI 10.1007/BF01744562; WEAVER RL, 1990, WAVE MOTION, V12, P129, DOI 10.1016/0165-2125(90)90034-2; WONG VCW, 1983, AM J MED, V75, P597, DOI 10.1016/0002-9343(83)90439-4; WOOLF AD, 1987, ANN RHEUM DIS, V46, P441, DOI 10.1136/ard.46.6.441; YAMADA I, 1992, AM J ROENTGENOL, V159, P263, DOI 10.2214/ajr.159.2.1352939; YAMATO M, 1986, RADIOLOGY, V161, P329, DOI 10.1148/radiology.161.2.2876459; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; ZHENG DY, 1990, CHINESE MED J-PEKING, V103, P536; 1990, AM SOC HISTOCOMPATIB; 1992, HEART VESSELS S, V7, P1; 1990, NATIONAL DATA BOOK, P77	63	1304	1429	2	37	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1994	120	11					919	929		10.7326/0003-4819-120-11-199406010-00004	http://dx.doi.org/10.7326/0003-4819-120-11-199406010-00004			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NN110	7909656				2022-12-24	WOS:A1994NN11000004
J	GODDARD, CJR; WARNES, TW				GODDARD, CJR; WARNES, TW			PRIMARY BILIARY-CIRRHOSIS - HOW SHOULD WE EVALUATE NEW TREATMENTS	LANCET			English	Editorial Material							CONTROLLED TRIAL; PROGNOSIS; COLCHICINE; MODEL				GODDARD, CJR (corresponding author), MANCHESTER ROYAL INFIRM,LIVER UNIT,MANCHESTER,LANCS,ENGLAND.							BABBS C, 1988, LANCET, V1, P1021; BIRCHER J, 1983, SEMIN LIVER DIS, V3, P275, DOI 10.1055/s-2008-1040780; CHRISTENSEN E, 1993, GASTROENTEROLOGY, V105, P1865, DOI 10.1016/0016-5085(93)91086-W; DICKSON ER, 1989, HEPATOLOGY, V10, P1, DOI 10.1002/hep.1840100102; HEATHCOTE EJ, 1994, HEPATOLOGY, V10, P1149; KAPLAN MM, 1986, NEW ENGL J MED, V315, P1448, DOI 10.1056/NEJM198612043152304; KAPLAN MM, 1991, GASTROENTEROLOGY, V101, P1332, DOI 10.1016/0016-5085(91)90085-Y; LINDOR KD, 1994, GASTROENTEROLOGY, V106, P1284, DOI 10.1016/0016-5085(94)90021-3; LOMBARD M, 1993, GASTROENTEROLOGY, V104, P519, DOI 10.1016/0016-5085(93)90422-9; POUPON RE, 1994, NEW ENGL J MED, V330, P1342, DOI 10.1056/NEJM199405123301903; POUPON RE, 1994, HEPATOLOGY, V19, P635, DOI 10.1002/hep.1840190314; ROLL J, 1983, NEW ENGL J MED, V308, P1, DOI 10.1056/NEJM198301063080101; WARNES TW, 1987, J HEPATOL, V5, P1, DOI 10.1016/S0168-8278(87)80053-3; WIESNER RH, 1988, HEPATOLOGY, V8, P668, DOI 10.1002/hep.1840080339	14	12	12	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 28	1994	343	8909					1305	1306		10.1016/S0140-6736(94)92461-9	http://dx.doi.org/10.1016/S0140-6736(94)92461-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NN217	7910318				2022-12-24	WOS:A1994NN21700004
J	WOO, DDL; MIAO, SYP; PELAYO, JC; WOOLF, AS				WOO, DDL; MIAO, SYP; PELAYO, JC; WOOLF, AS			TAXOL INHIBITS PROGRESSION OF CONGENITAL POLYCYSTIC KIDNEY-DISEASE	NATURE			English	Article							PROTOONCOGENE EXPRESSION; CYST FORMATION; CYCLIC-AMP; MICROTUBULES; CELLS; SECRETION; MEMBRANE; GROWTH; MOUSE; EPITHELIA	POLYCYSTIC kidney diseases (PKD) are the most common hereditary diseases of the human kidney and account for ten per cent of patients requiring renal transplantation or dialysis. Renal cyst formation has been attributed to enhanced cell proliferation, unbalanced cell death, abnormal targeting of membrane proteins; aberrant kidney development and tubular obstruction, but there is no treatment that blocks the formation and enlargement of renal cysts. We have now developed an in vitro model of spontaneous cyst formation that distinguishes polycystic kidney epithelium from its normal counterpart. Inhibitors of DNA, RNA and protein synthesis did not prevent in vitro cyst formation, but this was reversibly inhibited by ouabain, amiloride and the microtubule-specific agents colchicine, vinblastine and taxol. The cpk mouse is a well-characterized recessive PKD model(1-3) and we find that cpk/cpk mice develop PKD and die from uraemia by 4-5 weeks of age, but when treated weekly with taxol they survive for more than 200 days with minimal loss of renal function, show limited collecting-dust cyst enlargement, and attain adult size. Our results indicate that the microtubule cytoskeleton has a central role in the pathogenesis of PKD in cpk mice and that taxol may also be useful in treating human PKD.	UNIV CALIF LOS ANGELES,SCH MED,DEPT PAEDIAT,LOS ANGELES,CA 90024; INST CHILD HLTH,DEV BIOL UNIT,LONDON WC1N 1EH,ENGLAND	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of London; University College London	WOO, DDL (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,DEPT MED,7-155 FACTOR BLDG,LOS ANGELES,CA 90024, USA.		Woolf, Adrian S./AAZ-1075-2020	Woolf, Adrian S./0000-0001-5541-1358				AVNER ED, 1988, PEDIATR NEPHROL, V2, P210, DOI 10.1007/BF00862593; AVNER ED, 1987, PEDIATR NEPHROL, V1, P587, DOI 10.1007/BF00853593; AVNER ED, 1992, P NATL ACAD SCI USA, V89, P7447, DOI 10.1073/pnas.89.16.7447; BLOOM TL, 1989, DEVELOPMENT, V106, P159; BRENNER BM, 1983, KIDNEY INT, V23, P647, DOI 10.1038/ki.1983.72; CARONE FA, 1989, KIDNEY INT, V35, P1351, DOI 10.1038/ki.1989.134; COWLEY BD, 1987, P NATL ACAD SCI USA, V84, P8394, DOI 10.1073/pnas.84.23.8394; COWLEY BD, 1991, J AM SOC NEPHROL, V1, P1048; DEALMEIDA JB, 1991, AM J PHYSIOL, V260, pC691, DOI 10.1152/ajpcell.1991.260.4.C691; FLEMING TP, 1988, ANNU REV CELL BIOL, V4, P459, DOI 10.1146/annurev.cellbio.4.1.459; GATTONE VH, 1988, LAB INVEST, V59, P231; KELLY R, 1990, CELL, V60, P5; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; MANGOOKARIM R, 1989, FASEB J, V3, P2629, DOI 10.1096/fasebj.3.14.2480260; MARO R, 1991, DEVELOPMENT S1, V1, P17; PARCZYK K, 1989, J BIOL CHEM, V264, P16837; PREMINGER GM, 1982, J UROLOGY, V127, P556, DOI 10.1016/S0022-5347(17)53911-7; ROGALSKI AA, 1984, J CELL BIOL, V99, P1101, DOI 10.1083/jcb.99.3.1101; Russell E, 1977, MOUSE NEWSLETTER, V56, P40; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; SLOT C, 1965, SCAND J CLIN LAB INV, V17, P381, DOI 10.3109/00365516509077065; THYBERG J, 1985, EXP CELL RES, V159, P1, DOI 10.1016/S0014-4827(85)80032-X; VALENTICH JD, 1979, J CELL PHYSIOL, V100, P291, DOI 10.1002/jcp.1041000210; WILSON PD, 1991, AM J PHYSIOL, V260, pF420, DOI 10.1152/ajprenal.1991.260.3.F420; WILSON PD, 1986, KIDNEY INT, V30, P371, DOI 10.1038/ki.1986.194; YANG AH, 1987, IN VITRO CELL DEV B, V23, P34	26	129	147	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 21	1994	368	6473					750	753		10.1038/368750a0	http://dx.doi.org/10.1038/368750a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NG553	7908721				2022-12-24	WOS:A1994NG55300061
J	OZEL, M; DIRINGER, H				OZEL, M; DIRINGER, H			SMALL VIRUS-LIKE STRUCTURE IN FRACTIONS FROM SCRAPIE HAMSTER BRAIN	LANCET			English	Note							PROTEIN	The scrapie model in hamsters has been used to search for the agents that cause Creutzfeldt-Jakob disease in man and similar transmissible encephalopathies in animals. We found structures that are extraordinarily small for a virus, but exhibit viral structural properties in negatively stained samples, by electron microscopy in fractions containing scrapie-associated fibrils.	BUNDESGESUNDHEITSAMT,ROBERT KOCH INST,D-13353 BERLIN,GERMANY	Robert Koch Institute								DIRINGER H, 1992, EXP CLIN IMMUNOGENET, V9, P212; DIRINGER H, 1983, EUR J BIOCHEM, V134, P550; HILMERT H, 1984, BIOSCIENCE REP, V4, P165, DOI 10.1007/BF01120313; MERZ PA, 1983, NATURE, V306, P474, DOI 10.1038/306474a0; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; Rohwer R G, 1991, Curr Top Microbiol Immunol, V172, P195; STAHL N, 1987, CELL, V51, P229, DOI 10.1016/0092-8674(87)90150-4; TISCHER I, 1982, NATURE, V295, P64, DOI 10.1038/295064a0	8	34	34	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 9	1994	343	8902					894	895		10.1016/S0140-6736(94)90010-8	http://dx.doi.org/10.1016/S0140-6736(94)90010-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF213	7908360				2022-12-24	WOS:A1994NF21300010
J	WILSON, APR				WILSON, APR			DONOR SERUM FOR PERITONITIS	LANCET			English	Editorial Material											WILSON, APR (corresponding author), UNIV COLL HOSP LONDON,DEPT CLIN MICROBIOL,WC1 LONDON,ENGLAND.							BILLING AG, 1994, EUR J CLIN INVEST, V24, P28, DOI 10.1111/j.1365-2362.1994.tb02056.x; BOHNEN J, 1983, ARCH SURG-CHICAGO, V118, P285; BOHNEN JMA, 1988, ARCH SURG-CHICAGO, V123, P225; DUNN DL, 1987, ARCH SURG-CHICAGO, V122, P105; EDMONISTON CE, 1990, WORLD J SURG, V14, P176; ROTSTEIN OD, 1990, WORLD J SURG, V14, P159, DOI 10.1007/BF01664868; SCHEIN M, 1988, SURG GYNECOL OBSTET, V166, P187; SKAU T, 1986, J SURG RES, V40, P13, DOI 10.1016/0022-4804(86)90139-3	8	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 2	1994	343	8901					807	807		10.1016/S0140-6736(94)92019-2	http://dx.doi.org/10.1016/S0140-6736(94)92019-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ND792	7908072				2022-12-24	WOS:A1994ND79200002
J	DZUBOW, LM				DZUBOW, LM			MOHS SURGERY	LANCET			English	Editorial Material							BASAL-CELL CARCINOMA; RECURRENCE; RATES; SKIN				DZUBOW, LM (corresponding author), UNIV PENN, DEPT DERMATOL, PHILADELPHIA, PA 19104 USA.							CLOUSTON PD, 1990, ARCH NEUROL-CHICAGO, V47, P73, DOI 10.1001/archneur.1990.00530010091025; Mohs FE, 1991, MOHS MICROGRAPHIC SU, P1; ROBINSON JK, 1993, CLIN PLAST SURG, V20, P149; ROWE DE, 1989, J DERMATOL SURG ONC, V15, P315, DOI 10.1111/j.1524-4725.1989.tb03166.x; ROWE DE, 1992, J AM ACAD DERMATOL, V26, P976, DOI 10.1016/0190-9622(92)70144-5; ROWE DE, 1989, J DERMATOL SURG ONC, V15, P424, DOI 10.1111/j.1524-4725.1989.tb03249.x; TROMOVITCH TA, 1974, ARCH DERMATOL, V110, P231, DOI 10.1001/archderm.110.2.231	7	8	8	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 19	1994	343	8895					433	434		10.1016/S0140-6736(94)92687-5	http://dx.doi.org/10.1016/S0140-6736(94)92687-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW690	7905951	hybrid			2022-12-24	WOS:A1994MW69000005
J	CARMEL, R				CARMEL, R			APPROACH TO A LOW VITAMIN-B-12 LEVEL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							COBALAMIN DEFICIENCY; PERNICIOUS-ANEMIA				CARMEL, R (corresponding author), UNIV SO CALIF, LOS ANGELES, CA USA.							CARMEL R, 1979, ARCH INTERN MED, V139, P47, DOI 10.1001/archinte.139.1.47; CARMEL R, 1990, AM J HEMATOL, V34, P108, DOI 10.1002/ajh.2830340206; CARMEL R, 1988, ARCH INTERN MED, V148, P1715, DOI 10.1001/archinte.148.8.1715; FAIRBANKS VF, 1983, MAYO CLIN PROC, V58, P541; GAFFNEY GW, 1957, J GERONTOL, V12, P32, DOI 10.1093/geronj/12.1.32; MARCUS DL, 1987, J AM GERIATR SOC, V35, P635, DOI 10.1111/j.1532-5415.1987.tb04339.x; PENNYPACKER LC, 1992, J AM GERIATR SOC, V40, P1197, DOI 10.1111/j.1532-5415.1992.tb03641.x	7	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 26	1994	272	16					1233	1233						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN068	7933355				2022-12-24	WOS:A1994PN06800002
J	AMBACH, W				AMBACH, W			OCCUPATIONAL LOW-DOSE EXPOSURE TO IONIZING-RADIATION	LANCET			English	Editorial Material											AMBACH, W (corresponding author), UNIV INNSBRUCK, INST MED PHYS, A-6020 INNSBRUCK, AUSTRIA.							Ennemoser O., 1993, Lancet (North American Edition), V341, P828, DOI 10.1016/0140-6736(93)90603-E; PERSHAGEN G, 1994, NEW ENGL J MED, V330, P159, DOI 10.1056/NEJM199401203300302; 1991, IRCP60 INT COMM RAD; 1990, BEIR5 COMM BIOL EFF	4	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	OCT 15	1994	344	8929					1037	1037		10.1016/S0140-6736(94)91704-3	http://dx.doi.org/10.1016/S0140-6736(94)91704-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL852	7934441				2022-12-24	WOS:A1994PL85200004
J	CLAGUE, JE; HORAN, MA				CLAGUE, JE; HORAN, MA			URINE CULTURE IN THE ELDERLY - SCIENTIFICALLY DOUBTFUL AND PRACTICALLY USELESS	LANCET			English	Editorial Material							BACTERIURIA; POPULATION				CLAGUE, JE (corresponding author), UNIV MANCHESTER,WITHINGTON HOSP,DEPT GERIATR MED,MANCHESTER M20 8LR,LANCS,ENGLAND.							ABRUTYN E, 1994, ANN INTERN MED, V120, P827, DOI 10.7326/0003-4819-120-10-199405150-00003; BOSCIA JA, 1986, AM J MED, V81, P979, DOI 10.1016/0002-9343(86)90391-8; BOSCIA JA, 1986, AM J MED, V80, P208, DOI 10.1016/0002-9343(86)90011-2; BROCKLEHURST J C, 1977, Age and Ageing, V6, P240; BROCKLEHURST JC, 1968, GERONTOL CLIN, V10, P242, DOI 10.1159/000245189; DONTAS AS, 1977, AGE AGEING, V16, P215; ELLIOTT TSJ, 1985, J INFECTION, V11, P191, DOI 10.1016/S0163-4453(85)92997-4; GUTMAN SI, 1987, AM J CLIN PATHOL, V88, P204, DOI 10.1093/ajcp/88.2.204; KASS EH, 1956, T ASSOC AM PHYSICIAN, V69, P56; NICOLLE LE, 1987, AM J MED, V83, P27, DOI 10.1016/0002-9343(87)90493-1; NORDENSTAM GR, 1986, NEW ENGL J MED, V314, P1152, DOI 10.1056/NEJM198605013141804	11	19	19	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 15	1994	344	8929					1035	1036		10.1016/S0140-6736(94)91702-7	http://dx.doi.org/10.1016/S0140-6736(94)91702-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL852	7934439				2022-12-24	WOS:A1994PL85200002
J	FEDSON, DS				FEDSON, DS			ADULT IMMUNIZATION - SUMMARY OF THE NATIONAL VACCINE ADVISORY-COMMITTEE REPORT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES; CHANGING EPIDEMIOLOGY; MISSED OPPORTUNITIES; RUBELLA; TRANSMISSION; RESURGENCE; INFLUENZA; POLICIES; MEASLES; IMPACT	In January 1994 the National Vaccine Advisory Committee adopted a report that reviewed the status of adult immunization in the United States. Vaccine-preventable infections of adults represent a continuing cause of morbidity and mortality. Their major impact is among older persons. Effective and safe vaccines against these diseases are available, but they are poorly used. Several reasons account for low immunization levels among adults, including inadequate awareness by health care providers and the public of the importance and benefits of vaccination. Health care providers often fail to take advantage of opportunities to immunize adults during office, clinic, and hospital contacts and fail to organize programs in medical settings that ensure adults are offered the vaccines they need. Inadequate reimbursement for adult immunization by public and private health insurers and a lack of federal programs to support vaccine delivery are also major problems. The National Vaccine Advisory Committee's report includes five goals and 18 recommendations for improving adult immunization. To reach the Public Health Service adult immunization goals for the year 2000, the Committee recommends (1) improvements in public and provider education; (2) major changes in clinical practice; (3) increased financial support by public and private health insurers; (4) improved surveillance of vaccine-preventable diseases and vaccine production and delivery; and (5) support for research on vaccine-preventable diseases, new and improved vaccines, immunization practices, and international programs for adult immunization.			FEDSON, DS (corresponding author), NATL VACCINE PROGRAM OFF,ROCKWALL 2 BLDG,SUITE 1075,5600 FISHERS LN,ROCKVILLE,MD 20852, USA.							ALTER MJ, 1990, JAMA-J AM MED ASSOC, V263, P1218, DOI 10.1001/jama.263.9.1218; ANDERSON K, 1993, OPTIONS CONTROL INFL, V2, P109; [Anonymous], 1989, GUIDE CLIN PREVENTIV; ATKINSON WL, 1991, AM J MED, V91, pS320, DOI 10.1016/0002-9343(91)90389-F; ATKINSON WL, 1992, ANNU REV MED, V43, P451, DOI 10.1146/annurev.med.43.1.451; BARTON MB, 1990, AM J PUBLIC HEALTH, V80, P534, DOI 10.2105/AJPH.80.5.534; BREIMAN RF, 1994, JAMA-J AM MED ASSOC, V271, P1831, DOI 10.1001/jama.271.23.1831; BUTLER JC, 1993, JAMA-J AM MED ASSOC, V270, P1826, DOI 10.1001/jama.270.15.1826; DEQUADROS CA, 1991, PEDIATR INFECT DIS J, V10, P222, DOI 10.1097/00006454-199103000-00011; Fedson D S, 1992, Clin Geriatr Med, V8, P183; GARDNER P, 1993, NEW ENGL J MED, V328, P1252, DOI 10.1056/NEJM199304293281708; GOODMAN AK, 1987, AM J PUBLIC HEALTH, V77, P725, DOI 10.2105/AJPH.77.6.725; HINMAN AR, 1986, AM J DIS CHILD, V140, P528, DOI 10.1001/archpedi.1986.02140200038022; HOWSON CP, 1992, JAMA-J AM MED ASSOC, V267, P392, DOI 10.1001/jama.267.3.392; LEE SH, 1992, JAMA-J AM MED ASSOC, V267, P2616, DOI 10.1001/jama.267.19.2616; MARINER WK, 1992, HEALTH AFFAIR, V11, P255, DOI 10.1377/hlthaff.11.1.255; MCBEAN AM, 1993, ARCH INTERN MED, V153, P2105, DOI 10.1001/archinte.153.18.2105; MITCHELL VS, 1993, CHILDRENS VACCINE IN; Neustadt RE, 1978, SWINE FLU AFFAIR DEC, P48; PETER G, 1992, NEW ENGL J MED, V327, P1794, DOI 10.1056/NEJM199212173272507; SOSIN DM, 1989, PEDIATRICS, V84, P779; WHARTON M, 1990, ARCH INTERN MED, V150, P47, DOI 10.1001/archinte.150.1.47; WILLIAMS WW, 1988, ANN INTERN MED, V108, P616, DOI 10.7326/0003-4819-108-4-616; 1990, MMWR MORBID MORTAL W, V39, P725; 1994, MMWR MORBID MORTAL W, V43, P144; 1993, JORDAN REPORT ACCELE; 1993, MMWR MORBID MORTAL W, V42, P601; 1991, MMWR MORBID MORTAL W, V40, P1; 1993, MMWR MORBID MORTAL W, V42, P847; 1994, GUIDE ADULT IMMUNIZA; 1994, ADULT IMMUNIZATION; 1994, MMWR MORBID MORTAL W, V43, P1; 1991, DHHS PHS9150212 PUBL; 1993, MMWR MORBID MORTAL W, V42, P501; 1993, MMWR MORBID MORTAL W, V42, P840; 1993, MMWR MORBID MORTAL W, V42, P768; 1994, MMWR MORBID MORTAL W, V43, P57	37	119	122	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 12	1994	272	14					1133	1137		10.1001/jama.272.14.1133	http://dx.doi.org/10.1001/jama.272.14.1133			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PK124	7933327				2022-12-24	WOS:A1994PK12400034
J	KADHIM, MA; LORIMORE, SA; HEPBURN, MD; GOODHEAD, DT; BUCKLE, VJ; WRIGHT, EG				KADHIM, MA; LORIMORE, SA; HEPBURN, MD; GOODHEAD, DT; BUCKLE, VJ; WRIGHT, EG			ALPHA-PARTICLE-INDUCED CHROMOSOMAL INSTABILITY IN HUMAN BONE-MARROW CELLS	LANCET			English	Note							LEUKEMIA; RADON; EXPOSURE	alpha-particles, which are ionising radiation of high linear-energy-transfer emitted, for example, from radon or plutonium, pass through tissue as highly structured tracks. Single target cells in the path of the tracks might be damaged by even Tow-dose alpha-irradiation. We found non-clonal cytogenetic aberrations, characterised by a high frequency of chromatid aberrations with chromosome aberrations, in clonal descendants of haemopoietic stem cells after exposure to alpha-particles of bone marrow cells from two of four haematologically normal individuals (up to 25% abnormal metaphases). The data are consistent with a transmissible genetic instability induced in a stem cell resulting in a diversity of aberrations in its clonal progeny many cell divisions later.	MRC,RADIOBIOL UNIT,DIDCOT OX11 0RD,OXON,ENGLAND; NINEWELLS HOSP & MED SCH,DEPT HAEMATOL,DUNDEE,SCOTLAND; JOHN RADCLIFFE HOSP,INST MOLEC MED,OXFORD OX3 9DU,ENGLAND	MRC Harwell; University of Dundee; University of Oxford								ALEXANDER FE, 1990, LANCET, V335, P1336; ALEXANDER FE, 1990, LANCET, V336, P1461, DOI 10.1016/0140-6736(90)93176-P; DIONIAN J, 1986, NRPBR196 NAT RAD PRO; GOODHEAD DT, 1988, HEALTH PHYS, V55, P231, DOI 10.1097/00004032-198808000-00015; HENSHAW DL, 1990, LANCET, V335, P1008, DOI 10.1016/0140-6736(90)91071-H; HOLYOAKE TL, 1993, LEUKEMIA, V7, P207; KADHIM MA, 1992, NATURE, V355, P738, DOI 10.1038/355738a0; LORIMORE SA, 1993, INT J RADIAT BIOL, V63, P655, DOI 10.1080/09553009314450851; LUCIE NP, 1989, LANCET, V2, P99; RICHARDSON RB, 1991, BRIT J RADIOL, V64, P608, DOI 10.1259/0007-1285-64-763-608	10	184	191	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 8	1994	344	8928					987	988		10.1016/S0140-6736(94)91643-8	http://dx.doi.org/10.1016/S0140-6736(94)91643-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PK978	7934432				2022-12-24	WOS:A1994PK97800011
J	SCHEINBERG, IH; STERNLIEB, I				SCHEINBERG, IH; STERNLIEB, I			IS NON-INDIAN CHILDHOOD CIRRHOSIS CAUSED BY EXCESS DIETARY COPPER	LANCET			English	Article							STORAGE DISEASE; LIVER	Indian childhood cirrhosis is generally believed to be caused by toxic excesses of hepatic copper derived from milk boiled in copper vessels. Sporadic cases of a disorder indistinguishable from Indian childhood cirrhosis have appeared in other countries where the toxic hepatic copper has been thought to be derived from drinking water. In published reports of seven 2-year-old or younger infants with non-Indian childhood cirrhosis (five of whom died), the copper content of their drinking water-which the authors considered the essential, if not the sole,aetiological factor-ranged from 0.05 to 6.8 mg Cu/L. We identified three Massachusetts towns in which between 1969 and 1991 there were 64 124 child-years of exposure of children under the age of 6 years to drinking water that contained between 8.5 and 8.8 mg Cu/L. Data from the Massachusetts Department of Public Health showed that there were 135 deaths among these children, but no deaths from cirrhosis or any form of liver disease. These data, and evidence of a genetic aetiology in three of the seven infants reported previously, suggest that non-Indian childhood cirrhosis is an inherited disorder.	ST LUKES ROOSEVELT HOSP,NEW YORK,NY 10019	Mount Sinai St. Luke's; Mount Sinai West	SCHEINBERG, IH (corresponding author), COLUMBIA UNIV,NATL CTR STUDY WILSONS DIS,432 W 58TH ST,SUITE 614,NEW YORK,NY 10019, USA.							ADAMSON M, 1992, GASTROENTEROLOGY, V102, P1771, DOI 10.1016/0016-5085(92)91742-M; ALJAJEH IA, 1994, VIRCHOWS ARCH, V424, P225; GOLDFISCHER S, 1980, AM J PATHOL, V99, P715; LEFKOWITCH JH, 1982, NEW ENGL J MED, V307, P271, DOI 10.1056/NEJM198207293070502; Lim C T, 1979, J Singapore Paediatr Soc, V21, P99; MULLERHOCKER J, 1987, VIRCHOWS ARCH A, V411, P379, DOI 10.1007/BF00713384; MULLERHOCKER J, 1988, PATHOL RES PRACT, V183, P39, DOI 10.1016/S0344-0338(88)80157-2; TANNER MS, 1983, LANCET, V2, P992; TANNER MS, 1986, RECENT ADV PAEDIATRI, V8, P103; WALKERSMITH J, 1973, ARCH DIS CHILD, V48, P476, DOI 10.1136/adc.48.6.476; WEISS M, 1989, ACTA PAEDIATR SCAND, V79, P152; 1993, LEAD COPPER REPORT E; 1991, US FED REG, V56, P26460; [No title captured]	14	55	55	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 8	1994	344	8928					1002	1004		10.1016/S0140-6736(94)91649-7	http://dx.doi.org/10.1016/S0140-6736(94)91649-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PK978	7934386				2022-12-24	WOS:A1994PK97800017
J	GURDON, JB; HARGER, P; MITCHELL, A; LEMAIRE, P				GURDON, JB; HARGER, P; MITCHELL, A; LEMAIRE, P			ACTIVIN SIGNALING AND RESPONSE TO A MORPHOGEN GRADIENT	NATURE			English	Article							DROSOPHILA EMBRYO; XENOPUS-LAEVIS; MESODERM INDUCTION; AXIAL MESODERM; RETINOIC ACID; PROTEIN; HOMOLOG; PATTERN; CELLS; THRESHOLDS	Using combinations of amphibian embryo tissues, it is shown that the selection of genes expressed by a cell is determined by its distance from a source of activin, a peptide growth factor contained in vegetal cells and able to induce other cells to form mesoderm. This long-range signal spreads over at least 10 cell diameters In a few hours. It does so by passive diffusion, because It can by-pass cells that do not themselves respond to the signal nor synthesize protein. These results provide direct support for the operation of a morphogen concentration gradient In vertebrate development.	UNIV CAMBRIDGE,DEPT ZOOL,CAMBRIDGE CB2 3EJ,ENGLAND	University of Cambridge	GURDON, JB (corresponding author), WELLCOME CRC INST,TENNIS COURT RD,CAMBRIDGE CB2 1QR,ENGLAND.		Lemaire, Patrick/D-4237-2009; Lemaire, Patrick/P-8228-2019; Lemaire, Patrick/B-5560-2012	Lemaire, Patrick/0000-0003-4925-2009; Lemaire, Patrick/0000-0003-4925-2009; GURDON, JOHN/0000-0002-5621-3799	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ASASHIMA M, 1991, P NATL ACAD SCI USA, V88, P6511, DOI 10.1073/pnas.88.15.6511; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BROCKES JP, 1989, NEURON, V2, P1285, DOI 10.1016/0896-6273(89)90066-4; BURRUS LW, 1994, BIOESSAYS, V16, P155, DOI 10.1002/bies.950160303; CASCIO S, 1987, DEVELOPMENT, V100, P297; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; CORNELL RA, 1994, DEVELOPMENT, V120, P453; COUSO JP, 1994, DEVELOPMENT, V120, P621; DALE L, 1993, EMBO J, V12, P4471, DOI 10.1002/j.1460-2075.1993.tb06136.x; DALE L, 1987, DEVELOPMENT, V99, P527; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; GONZALEZ F, 1991, MECH DEVELOP, V35, P43, DOI 10.1016/0925-4773(91)90040-D; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; GREEN JBA, 1994, DEVELOPMENT, V120, P2271; GREEN JBA, 1992, CELL, V71, P731, DOI 10.1016/0092-8674(92)90550-V; GREEN JBA, 1991, TRENDS GENET, V7, P245, DOI 10.1016/0168-9525(91)90323-I; GURDON JB, 1985, P NATL ACAD SCI USA, V82, P139, DOI 10.1073/pnas.82.1.139; GURDON JB, 1989, DEVELOPMENT, V105, P27; GURDON JB, 1992, DEVELOPMENT, P137; HEEMSKERK J, 1994, CELL, V76, P449, DOI 10.1016/0092-8674(94)90110-4; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; HOPWOOD ND, 1992, DEVELOPMENT, V114, P31; JONES EA, 1987, DEVELOPMENT, V101, P557; LAWRENCE PA, 1988, CELL, V54, P1, DOI 10.1016/0092-8674(88)90172-9; LEMAIRE P, 1994, DEVELOPMENT, V120, P1191; MCMAHON AP, 1992, TRENDS GENET, V8, P236, DOI 10.1016/0168-9525(92)90122-K; MOODY SA, 1987, DEV BIOL, V122, P300, DOI 10.1016/0012-1606(87)90296-X; NAKAMURA O, 1971, P JPN ACAD, V47, P313, DOI 10.2183/pjab1945.47.313; NIEHRS C, 1994, SCIENCE, V263, P817, DOI 10.1126/science.7905664; NIEUWKOOP P D, 1969, Wilhelm Roux' Archiv fuer Entwicklungsmechanik der Organismen, V162, P341, DOI 10.1007/BF00578701; PLACZEK M, 1990, DEVELOPMENT, V110, P19; ROSA FM, 1989, CELL, V57, P965, DOI 10.1016/0092-8674(89)90335-8; SLACK JMW, 1993, MECH DEVELOP, V41, P91, DOI 10.1016/0925-4773(93)90040-5; SMITH JC, 1993, EMBO J, V12, P4463, DOI 10.1002/j.1460-2075.1993.tb06135.x; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; Spemann H, 1924, ARCH MIKROSK ANAT EN, V100, P599, DOI 10.1007/BF02108133; STJOHNSTON D, 1992, CELL, V68, P201; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; THOMSEN GH, 1993, CELL, V74, P433, DOI 10.1016/0092-8674(93)80045-G; TICKLE C, 1985, DEV BIOL, V109, P82, DOI 10.1016/0012-1606(85)90348-3; TICKLE C, 1982, NATURE, V296, P564, DOI 10.1038/296564a0; VINCENT JP, 1994, CELL, V77, P909, DOI 10.1016/0092-8674(94)90139-2; WILSON PA, 1994, CURR BIOL, V4, P676, DOI 10.1016/S0960-9822(00)00152-4; WOLPERT L, 1989, DEVELOPMENT S, P3	47	306	309	1	23	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 6	1994	371	6497					487	492		10.1038/371487a0	http://dx.doi.org/10.1038/371487a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PK589	7935761				2022-12-24	WOS:A1994PK58900046
J	FITZSIMONS, RB				FITZSIMONS, RB			FACIOSCAPULOHUMERAL DYSTROPHY - THE ROLE OF INFLAMMATION	LANCET			English	Editorial Material							MUSCULAR-DYSTROPHY; REGION; CELLS; FSHD; ARM				FITZSIMONS, RB (corresponding author), MOORFIELDS EYE HOSP,LONDON,ENGLAND.							ASHTON N, 1969, CORNEOPLASTIC SURGER, P586; BROUWER OF, 1992, BRAIN, V115, P1587, DOI 10.1093/brain/115.5.1587; COPEMAN PWM, 1971, BRIT J DERMATOL, V85, P205, DOI 10.1111/j.1365-2133.1971.tb07218.x; FITZSIMONS RB, 1987, BRAIN, V110, P631, DOI 10.1093/brain/110.3.631; GRIGGS RC, 1993, NEUROLOGY, V43, P2369, DOI 10.1212/WNL.43.11.2369; KORF BR, 1985, ANN NEUROL, V17, P513, DOI 10.1002/ana.410170516; MARKS RM, 1986, J INVEST DERMATOL, V87, P519, DOI 10.1111/1523-1747.ep12455604; MUNSAT TL, 1972, NEUROLOGY, V22, P335, DOI 10.1212/WNL.22.4.335; POWERS JM, 1992, J NEUROPATH EXP NEUR, V51, P630, DOI 10.1097/00005072-199211000-00007; PRINEAS JW, 1993, BRAIN, V116, P681, DOI 10.1093/brain/116.3.681; WIJMENGA C, 1993, HUM MOL GENET, V2, P1667, DOI 10.1093/hmg/2.10.1667; WINOKUR ST, 1993, AM J HUM GENET, V53, P874	12	18	18	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 1	1994	344	8927					902	903		10.1016/S0140-6736(94)92263-2	http://dx.doi.org/10.1016/S0140-6736(94)92263-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PJ287	7934342				2022-12-24	WOS:A1994PJ28700004
J	OZEL, M; XI, YG; BALDAUF, E; DIRINGER, H; POCCHIARI, M				OZEL, M; XI, YG; BALDAUF, E; DIRINGER, H; POCCHIARI, M			SMALL VIRUS-LIKE STRUCTURE IN BRAINS FROM CASES OF SPORADIC AND FAMILIAL CREUTZFELDT-JAKOB-DISEASE	LANCET			English	Note							PROTEIN	We have previously observed small virus-like particles in the brain of hamsters with experimental scrapie. Here we report that small virus-like structures can be isolated from brains of patients with Creutzfeldt-Jakob disease and identified by electronmicroscopy.	BUNDESGESUNDHEITSAMT,ROBERT KOCH INST,D-13353 BERLIN,GERMANY; IST SUPER SANITA,VIROL LAB,I-00161 ROME,ITALY	Robert Koch Institute; Istituto Superiore di Sanita (ISS)			Pocchiari, Maurizio/J-8443-2018	Pocchiari, Maurizio/0000-0002-7269-2486				DIRINGER H, 1983, EUR J BIOCHEM, V134, P555, DOI 10.1111/j.1432-1033.1983.tb07602.x; DIRINGER H, 1992, EXP CLIN IMMUNOGENET, V9, P212; HILMERT H, 1984, BIOSCIENCE REP, V4, P165, DOI 10.1007/BF01120313; OZEL M, 1994, LANCET, V343, P894, DOI 10.1016/S0140-6736(94)90010-8; POCCHIARI M, 1993, ANN NEUROL, V34, P802, DOI 10.1002/ana.410340608; POCCHIARI M, 1994, MOL ASPECTS MED, V15, P195, DOI 10.1016/0098-2997(94)90042-6	6	17	17	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 1	1994	344	8927					923	924		10.1016/S0140-6736(94)92272-1	http://dx.doi.org/10.1016/S0140-6736(94)92272-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PJ287	7934349				2022-12-24	WOS:A1994PJ28700013
J	BALFOUR, TW				BALFOUR, TW			WHERE HAS ALL THE APPENDICITIS GONE	LANCET			English	Editorial Material											BALFOUR, TW (corresponding author), CITY HOSP NOTTINGHAM,DEPT SURG,NOTTINGHAM,ENGLAND.							DONNAN SPB, 1986, AETIOLOGY ACUTE APPE, P16; LOGAN RFA, 1991, OXFORD TXB PUBLIC HL, V3, P333; MCCAHY P, 1994, ANN ROY COLL SURG, V76, P282	3	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 10	1994	344	8924					700	700		10.1016/S0140-6736(94)92201-2	http://dx.doi.org/10.1016/S0140-6736(94)92201-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PF187	7915770				2022-12-24	WOS:A1994PF18700003
J	ORAHILLY, S; HATTERSLEY, A; VAAG, A; GRAY, H				ORAHILLY, S; HATTERSLEY, A; VAAG, A; GRAY, H			INSULIN-RESISTANCE AS THE MAJOR CAUSE OF IMPAIRED GLUCOSE-TOLERANCE - A SELF-FULFILLING PROPHESY	LANCET			English	Article							DEPENDENT DIABETES-MELLITUS; TYROSINE KINASE DOMAIN; GLUCOKINASE GENE; RECEPTOR GENE; NONSENSE MUTATION; SKELETAL-MUSCLE; PATIENT; YOUNG; LOAD	Non-insulin-dependent diabetes (NIDDM) is a heterogeneous state involving various degrees of beta-cell dysfunction and insulin resistance, although the relative importance of these two factors is controversial. Several single gene disorders of carbohydrate metabolism have their main pathophysiological defect largely restricted to the beta-cell or to insulin-sensitive tissues. We have noted that with insulin resistance the fasting plasma glucose is often normal and severe hyperglycaemia occurs after a glucose load. By contrast, in glucokinase-deficient diabetes, which is characterised by reduced insulin secretion, the reverse is the case. Supportive evidence showing that beta-cell dysfunction and insulin resistance may have different effects on fasting and post-prandial glucose concentrations comes from studies of identical twins of NIDDM patients, hemi-pancreatectomised normal subjects, and insulin-resistant Asian subjects. NIDDM is usually preceded by a period of less severe hyperglycemia, referred to as impaired glucose tolerance (IGT). Studies of the IGT phase usually conclude that insulin resistance is the major abnormality and is thus the primary defect in NIDDM. However, the definition of IGT is based on the 2 h plasma glucose after an oral glucose-tolerance test without consideration of the fasting glucose concentrations (provided these concentrations are non-diabetic). Our observations suggest that this definition of IGT may result in the over-representation of insulin-resistant individuals and the under-representation of subjects with beta-cell dysfunction in any cross sectional study of IGT. The belief that the prediabetic state of IGT is dominated by insulin resistance may be a self-fulfilling prophesy because of the excessive emphasis put on the post-prandial rather than the fasting state.	UNIV CAMBRIDGE, ADDENBROOKES HOSP, DEPT CLIN BIOCHEM, CAMBRIDGE CB2 2QQ, CAMBS, ENGLAND; UNIV BIRMINGHAM, DEPT MED, BIRMINGHAM, ENGLAND; ODENSE UNIV HOSP, DEPT INTERNAL MED, ODENSE, DENMARK	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Birmingham; University of Southern Denmark; Odense University Hospital	ORAHILLY, S (corresponding author), UNIV CAMBRIDGE, ADDENBROOKES HOSP, DEPT MED, CAMBRIDGE CB2 2QQ, CAMBS, ENGLAND.		O'Rahilly, Stephen/ABF-6509-2020	O'Rahilly, Stephen/0000-0003-2199-4449; Hattersley, Andrew/0000-0001-5620-473X; Vaag, Allan Arthur/0000-0002-3690-2191	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		CAMA A, 1991, J CLIN ENDOCR METAB, V73, P894, DOI 10.1210/jcem-73-4-894; CARO JF, 1988, J CLIN INVEST, V81, P976, DOI 10.1172/JCI113451; DEFRONZO RA, 1983, DIABETES, V32, P35, DOI 10.2337/diab.32.1.35; FELIG P, 1970, NEW ENGL J MED, V282, P166; FERRANNINI E, 1985, DIABETES, V34, P580, DOI 10.2337/diabetes.34.6.580; FINK RI, 1992, METABOLISM, V41, P897, DOI 10.1016/0026-0495(92)90174-9; FROGUEL P, 1992, NATURE, V356, P162, DOI 10.1038/356162a0; FUKUMOTO H, 1989, J BIOL CHEM, V264, P7776; HAGER J, IN PRESS DIABETES; HATTERSLEY AT, 1992, LANCET, V339, P1307, DOI 10.1016/0140-6736(92)91958-B; HOLROYDE MJ, 1976, BIOCHEM J, V153, P363, DOI 10.1042/bj1530363; KADOWAKI T, 1988, SCIENCE, V240, P787, DOI 10.1126/science.2834824; KAHN CR, 1976, NEW ENGL J MED, V294, P739, DOI 10.1056/NEJM197604012941401; KATAGIRI H, 1992, LANCET, V340, P1316, DOI 10.1016/0140-6736(92)92494-Z; KELLEY D, 1988, J CLIN INVEST, V81, P1563, DOI 10.1172/JCI113489; KROOK A, 1993, LANCET, V342, P277, DOI 10.1016/0140-6736(93)91820-C; KROOK A, 1994, DIABETES, V43, P357, DOI 10.2337/diabetes.43.3.357; LUNDGREN H, 1990, DIABETIC MED, V7, P407, DOI 10.1111/j.1464-5491.1990.tb01415.x; MATSCHINSKY FM, 1990, DIABETES, V39, P647, DOI 10.2337/diabetes.39.6.647; MCKEIGUE PM, 1989, J CLIN EPIDEMIOL, V42, P597, DOI 10.1016/0895-4356(89)90002-4; MODAN M, 1989, DIABETES, V38, P1630, DOI 10.2337/diabetes.38.12.1630; MOLL, 1993, MOLLER DE, P49; MOLLER DE, 1990, J BIOL CHEM, V265, P14979; MOLLER DE, 1994, DIABETES, V43, P247, DOI 10.2337/diabetes.43.2.247; MOLLER DE, 1990, MOL ENDOCRINOL, V4, P1183, DOI 10.1210/mend-4-8-1183; ODAWARA M, 1989, SCIENCE, V245, P66, DOI 10.1126/science.2544998; SAKURA H, 1992, J CLIN ENDOCR METAB, V75, P1571, DOI 10.1210/jc.75.6.1571; STOFFEL M, 1992, NAT GENET, V2, P153, DOI 10.1038/ng1092-153; TAYLOR SI, 1990, DIABETES CARE, V13, P257, DOI 10.2337/diacare.13.3.257; TURNER RC, 1976, LANCET, V1, P1272; VANDENOUWELAND JMW, 1992, NAT GENET, V1, P368, DOI 10.1038/ng0892-368; VELHO G, 1992, LANCET, V340, P444, DOI 10.1016/0140-6736(92)91768-4; WATTRE S, 1993, SCAND J CLIN LAB INV, V53, P2	33	65	65	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 27	1994	344	8922					585	589		10.1016/S0140-6736(94)91969-0	http://dx.doi.org/10.1016/S0140-6736(94)91969-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD424	7914964				2022-12-24	WOS:A1994PD42400013
J	POPE, M; BETJES, MGH; ROMANI, N; HIRMAND, H; CAMERON, PU; HOFFMAN, L; GEZELTER, S; SCHULER, G; STEINMAN, RM				POPE, M; BETJES, MGH; ROMANI, N; HIRMAND, H; CAMERON, PU; HOFFMAN, L; GEZELTER, S; SCHULER, G; STEINMAN, RM			CONJUGATES OF DENDRITIC CELLS AND MEMORY T-LYMPHOCYTES FROM SKIN FACILITATE PRODUCTIVE INFECTION WITH HIV-1	CELL			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; EPIDERMAL LANGERHANS CELLS; FEMALE RHESUS MACAQUES; IMMUNE-RESPONSES; ADHESION MOLECULE; LYMPHOID-TISSUE; GENITAL-TRACT; HUMAN BLOOD; AIDS; LYMPHADENOPATHY	Experimentally, a productive infection with HIV-1 requires that virus be administered to T cells that are activated by mitogens. We describe a productive milieu for HIV-1 within the confines of normal skin that does not require standard stimuli. The milieu consists of dendritic cells and T cells that emigrate from skin and produce distinctive stable, nonproliferating conjugates. These conjugates, upon exposure to each of seven different HIV-1 isolates, begin to release high levels of virus progeny within 4 days. Numerous infected syncytia, comprised of both dendritic and T cells, rapidly develop. We propose that conjugates of dendritic cells and T cells, as found in the external linings of organs involved in sexual transmission of HIV-1, represent an important site for the productive phase of HIV-1 infection. Because the affected T cells carry the memory phenotype, this site additionally provides a mechanism for the chronic depletion of CD4(+) memory cells in HIV-1 disease.	VRIJE UNIV AMSTERDAM, DEPT CELL BIOL, 1081 BT AMSTERDAM, NETHERLANDS; CORNELL UNIV, COLL MED, DIV PLAST SURG, NEW YORK, NY 10021 USA; UNIV INNSBRUCK, DEPT DERMATOL, A-6020 INNSBRUCK, AUSTRIA	Vrije Universiteit Amsterdam; Cornell University; University of Innsbruck	POPE, M (corresponding author), ROCKEFELLER UNIV, CELLULAR PHYSIOL & IMMUNOL LAB, NEW YORK, NY 10021 USA.		Steinman, Ralph/F-7729-2012; Cameron, Paul/H-3474-2011	Romani, Nikolaus/0000-0003-1614-9128; Cameron, Paul Urquhart/0000-0002-1906-6945; Betjes, Michiel/0000-0001-9435-6208	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI007012, R37AI007012, P01AI024775] Funding Source: NIH RePORTER; NIAID NIH HHS [AI07012, AI24775] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKBAR AN, 1988, J IMMUNOL, V140, P2171; ARMSTRONG JA, 1984, LANCET, V2, P370; ASJO B, 1993, J VIROL, V67, P4395; BERGER R, 1992, J INVEST DERMATOL, V99, P271, DOI 10.1111/1523-1747.ep12616619; BHARDWAJ N, 1994, INFECT IMMUN, V62, P135, DOI 10.1128/IAI.62.1.135-144.1994; BIBERFELD P, 1986, AM J PATHOL, V125, P436; CAMERON PU, 1994, AIDS RES HUM RETROV, V10, P61, DOI 10.1089/aid.1994.10.61; CAMERON PU, 1992, SCIENCE, V257, P383, DOI 10.1126/science.1352913; CHEN LL, 1978, J CELL BIOL, V79, P184, DOI 10.1083/jcb.79.1.184; CHESEBRO B, 1992, J VIROL, V66, P6547, DOI 10.1128/JVI.66.11.6547-6554.1992; CIMARELLI A, 1994, J ACQ IMMUN DEF SYND, V7, P230; CONNOR RI, 1993, J VIROL, V67, P1772, DOI 10.1128/JVI.67.4.1772-1777.1993; COOMBS RW, 1989, NEW ENGL J MED, V321, P1626, DOI 10.1056/NEJM198912143212402; DANIELS TE, 1984, J INVEST DERMATOL, V82, P21, DOI 10.1111/1523-1747.ep12259038; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; ENK AH, 1993, J IMMUNOL, V150, P3698; FOLKS T, 1986, SCIENCE, V231, P600, DOI 10.1126/science.3003906; FOSTER CA, 1990, J EXP MED, V171, P997, DOI 10.1084/jem.171.4.997; GRAY D, 1993, ANNU REV IMMUNOL, V11, P49, DOI 10.1146/annurev.immunol.11.1.49; HANNA MG, 1968, J IMMUNOL, V101, P949; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; HUMPHREY JH, 1984, EUR J IMMUNOL, V14, P859, DOI 10.1002/eji.1830140916; INABA K, 1984, J EXP MED, V160, P1717, DOI 10.1084/jem.160.6.1717; INABA K, 1986, J EXP MED, V163, P247, DOI 10.1084/jem.163.2.247; KALTER DC, 1991, J IMMUNOL, V146, P3396; KAPLAN G, 1987, J EXP MED, V165, P763, DOI 10.1084/jem.165.3.763; KLATZMANN D, 1984, SCIENCE, V225, P59, DOI 10.1126/science.6328660; KOOT M, 1992, AIDS, V6, P49, DOI 10.1097/00002030-199201000-00006; LANE HC, 1985, NEW ENGL J MED, V313, P79, DOI 10.1056/NEJM198507113130204; LARSEN CP, 1990, J EXP MED, V172, P1483, DOI 10.1084/jem.172.5.1483; MACKAY CR, 1988, EUR J IMMUNOL, V18, P1681, DOI 10.1002/eji.1830181105; MACKAY CR, 1990, J EXP MED, V171, P801, DOI 10.1084/jem.171.3.801; MILLER CJ, 1992, LAB INVEST, V67, P628; MILLER CJ, 1992, AM J PATHOL, V141, P655; MILLER CJ, 1992, J MED PRIMATOL, V21, P64; MILLER CJ, 1993, LAB INVEST, V68, P129; MURRAY HW, 1985, NEW ENGL J MED, V313, P1504, DOI 10.1056/NEJM198512123132403; NESTLE FO, 1994, CELL IMMUNOL, V156, P220, DOI 10.1006/cimm.1994.1166; NOSSAL GJV, 1968, J EXP MED, V127, P277, DOI 10.1084/jem.127.2.277; NUOVO GJ, 1993, AM J PATHOL, V143, P40; ODOHERTY U, 1993, J EXP MED, V178, P1067, DOI 10.1084/jem.178.3.1067; OU CY, 1988, SCIENCE, V239, P295, DOI 10.1126/science.3336784; PANCHOLI P, 1992, IMMUNOLOGY, V76, P217; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; PICKER LJ, 1991, NATURE, V349, P796, DOI 10.1038/349796a0; RACZ P, 1986, PROG ALLERGY, V37, P81; REKA S, 1993, CYTOKINE, V5, P305, DOI 10.1016/1043-4666(93)90061-9; SAKSELA K, 1994, P NATL ACAD SCI USA, V91, P1104, DOI 10.1073/pnas.91.3.1104; SANDERS ME, 1988, J IMMUNOL, V140, P1401; SCHNITTMAN SM, 1990, P NATL ACAD SCI USA, V87, P6058, DOI 10.1073/pnas.87.16.6058; SHIMIZU Y, 1991, NATURE, V349, P799, DOI 10.1038/349799a0; SIEKEVITZ M, 1987, SCIENCE, V238, P1575, DOI 10.1126/science.2825351; SPIEGEL H, 1992, AM J PATHOL, V140, P15; STEINMAN RM, 1991, ANNU REV IMMUNOL, V9, P271, DOI 10.1146/annurev.iy.09.040191.001415; STOSSEL H, 1990, J EXP MED, V172, P1471, DOI 10.1084/jem.172.5.1471; SZAKAL AK, 1989, ANNU REV IMMUNOL, V7, P91, DOI 10.1146/annurev.immunol.7.1.91; TONGSTARKSEN SE, 1989, J IMMUNOL, V142, P702; VANNOESEL CJM, 1990, J CLIN INVEST, V86, P293, DOI 10.1172/JCI114698; WOOD GS, 1983, J IMMUNOL, V131, P212; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L	61	463	472	0	4	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	AUG 12	1994	78	3					389	398		10.1016/0092-8674(94)90418-9	http://dx.doi.org/10.1016/0092-8674(94)90418-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PC405	7914836				2022-12-24	WOS:A1994PC40500006
J	LAGA, M; ALARY, M; NZILA, N; MANOKA, AT; TULIZA, M; BEHETS, F; GOEMAN, J; STLOUIS, M; PIOT, P				LAGA, M; ALARY, M; NZILA, N; MANOKA, AT; TULIZA, M; BEHETS, F; GOEMAN, J; STLOUIS, M; PIOT, P			CONDOM PROMOTION, SEXUALLY-TRANSMITTED DISEASES TREATMENT, AND DECLINING INCIDENCE OF HIV-1 INFECTION IN FEMALE ZAIRIAN SEX WORKERS	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; RISK-FACTORS; PROSTITUTES; TRANSMISSION; AFRICA	The control of sexually transmitted diseases, including HIV-1, among sex workers and their clients in urban areas in developing countries, is considered a valuable and cost-effective intervention to contain the spread of HIV-1. The effect of a programme of STD treatment combined with condom promotion on HIV-1 incidence has so far not been measured. During an intervention including condom promotion, as well as monthly sexually transmitted disease screening and treatment among 531 initially HIV-1 negative female sex workers in Kinshasa, Zaire, 70 became infected with HIV-1 (incidence of 8.0 per 100 women-years [wy]). A decline of HIV-1 incidence was observed over time, from 11.7/100 wy during the first 6 months, to 4.4/100 wy over the last 6 months, 3 years later (p = 0.003). Simultaneously, regular use of condoms with clients went up from 11% to 52% and 68%, after 6 and 36 months of intervention, respectively. Risk factors for HIV-1 seroconversion after multivariate analysis included irregular condom use (RR 1.6 [95% Cl 1.1-2.8]), gonorrhoea (RR 2.5 [1.1-6.4]), trichomoniasis (RR 1.7 [1.1-2.8]), and genital ulcer disease (RR 2.5 [1.1-6.4]), during the probable period of acquisition of HIV-1. In women who attended more than 90% of their clinic appointments, the HIV-1 incidence was 2.7/100 wy compared to 7.1, 20.3, and 44.1 per 100 wy among women who attended 76-90%, 50-75%, and less than 50% of the monthly appointments, respectively (p < 0.0001). These trends remained after controlling for reported condom use and number of clients. This study confirms earlier findings that STDs facilitate transmission of HIV-1 and shows that a clinic-based intervention consisting of STD care and condom promotion can result in a major decline of HIV-1 incidence among female sex workers.	MINIST HLTH, PROJET SIDA, KINSHASA, DEM REP CONGO; CTR DIS CONTROL, DIV HIV AIDS, ATLANTA, GA 30333 USA	Centers for Disease Control & Prevention - USA	LAGA, M (corresponding author), INST TROP MED, WHO,COLLABORATING CTR AIDS,DEPT INFECT & IMMUN, DIV MICROBIOL, NATL ST 155, B-2000 ANTWERP, BELGIUM.							ALLEN S, 1992, JAMA-J AM MED ASSOC, V268, P3338, DOI 10.1001/jama.268.23.3338; LAGA M, 1993, AIDS, V7, P95, DOI 10.1097/00002030-199301000-00015; NGUGI EN, 1988, LANCET, V2, P887, DOI 10.1016/S0140-6736(88)92480-4; NZILA N, 1991, AIDS, V5, P715, DOI 10.1097/00002030-199106000-00011; SIRAPRAPASIRI T, 1991, AIDS, V5, P579, DOI 10.1097/00002030-199105000-00017; WILLERFORD DM, 1993, J INFECT DIS, V167, P1414, DOI 10.1093/infdis/167.6.1414	6	352	357	0	17	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 23	1994	344	8917					246	248		10.1016/S0140-6736(94)93005-8	http://dx.doi.org/10.1016/S0140-6736(94)93005-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY060	7913164				2022-12-24	WOS:A1994NY06000017
J	LEVINE, DS				LEVINE, DS			BARRETTS-ESOPHAGUS AND P53	LANCET			English	Editorial Material							SUPPRESSOR GENE; ADENOCARCINOMA; ESOPHAGUS; DYSPLASIA; 17P				LEVINE, DS (corresponding author), UNIV WASHINGTON,DEPT MED,DIV GASTROENTEROL,SEATTLE,WA, USA.							BLOUNT PL, 1991, CANCER RES, V51, P5482; BLOUNT PL, 1993, P NATL ACAD SCI USA, V90, P3221, DOI 10.1073/pnas.90.8.3221; BLOUNT PL, 1994, CANCER RES, V54, P2292; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; JANKOWSKI J, 1992, GUT, V33, P1033, DOI 10.1136/gut.33.8.1033; LEVINE DS, 1993, GASTROENTEROLOGY, V105, P40, DOI 10.1016/0016-5085(93)90008-Z; NESHAT K, 1994, GASTROEN CLIN BIOL, V18, pD71; NESHAT K, 1994, GASTROENTEROLOGY, V106, P1589, DOI 10.1016/0016-5085(94)90415-4; RAMEL S, 1992, GASTROENTEROLOGY, V102, P1220; REID BJ, 1992, GASTROENTEROLOGY, V102, P1212; YOUNES M, 1993, GASTROENTEROLOGY, V105, P1637, DOI 10.1016/0016-5085(93)91058-P	11	14	14	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 23	1994	344	8917					212	213		10.1016/S0140-6736(94)92993-9	http://dx.doi.org/10.1016/S0140-6736(94)92993-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY060	7913153				2022-12-24	WOS:A1994NY06000005
J	MUIRHEAD, CR				MUIRHEAD, CR			RADON RISKS	LANCET			English	Editorial Material							INDOOR RADON; LUNG-CANCER				MUIRHEAD, CR (corresponding author), NATL RADIOL PROTECT BOARD,CHILTON,OXON,ENGLAND.			Muirhead, Colin/0000-0001-5394-1267				[Anonymous], 1988, IARC MONOGRAPHS EVAL, V43; [Anonymous], 1993, ANN ICRP, V65; BLOT WJ, 1990, J NATL CANCER I, V82, P1025, DOI 10.1093/jnci/82.12.1025; LUBIN JH, 1994, NIH943644 PUBL; PERSHAGEN G, 1994, NEW ENGL J MED, V330, P159, DOI 10.1056/NEJM199401203300302; STIDLEY CA, 1993, HEALTH PHYS, V65, P234, DOI 10.1097/00004032-199309000-00001; 1990, NRPB1 NAT RAD PROT B; 1988, HLTH RISKS RADON OTH; 1993, NRPB4 NAT RAD PROT B; 1991, COMP DOSIMETRY RADON	10	15	15	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 16	1994	344	8916					143	144		10.1016/S0140-6736(94)92751-0	http://dx.doi.org/10.1016/S0140-6736(94)92751-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW810	7912759				2022-12-24	WOS:A1994NW81000003
J	VERMEER, BJ; VANDERSPEKKEIJSER, LMT; FIBBE, WE				VERMEER, BJ; VANDERSPEKKEIJSER, LMT; FIBBE, WE			SKIN BIOPSIES IN BONE-MARROW TRANSPLANTATION	LANCET			English	Editorial Material							VERSUS-HOST DISEASE; ACUTE GRAFT; RECIPIENTS		LEIDEN UNIV,MED CTR,DEPT HAEMATOL,LEIDEN,NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	VERMEER, BJ (corresponding author), LEIDEN UNIV,MED CTR,DEPT DERMATOL,LEIDEN,NETHERLANDS.							DARMSTADT GL, 1992, J INVEST DERMATOL, V99, P397, DOI 10.1111/1523-1747.ep12616112; HEPBURN NC, 1993, Q J MED, V86, P715; HOOD AF, 1987, ARCH DERMATOL, V123, P745, DOI 10.1001/archderm.123.6.745; LAMPERT IA, 1982, CLIN EXP IMMUNOL, V50, P123; LEBOIT PE, 1989, J AM ACAD DERMATOL, V20, P236, DOI 10.1016/S0190-9622(89)70028-1; LERNER KG, 1974, TRANSPLANT P, V6, P367; LEVER R, 1986, BRIT J DERMATOL, V114, P161, DOI 10.1111/j.1365-2133.1986.tb02794.x; SALE GE, 1977, AM J PATHOL, V89, P621; VOLCPLATZER B, 1988, J INVEST DERMATOL, V91, P162, DOI 10.1111/1523-1747.ep12464407	9	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 9	1994	344	8915					75	76		10.1016/S0140-6736(94)91277-7	http://dx.doi.org/10.1016/S0140-6736(94)91277-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NV732	7912389				2022-12-24	WOS:A1994NV73200005
J	DALVA, MB; KATZ, LC				DALVA, MB; KATZ, LC			REARRANGEMENTS OF SYNAPTIC CONNECTIONS IN VISUAL-CORTEX REVEALED BY LASER PHOTOSTIMULATION	SCIENCE			English	Article							CAT STRIATE CORTEX; CLUSTERED HORIZONTAL CONNECTIONS; INTRINSIC CONNECTIONS; AREA 17; FUNCTIONAL ARCHITECTURE; CEREBRAL-CORTEX; LOCAL CIRCUITS; AXONAL ARBORS; BRAIN-SLICES; LAYER-III	Assessing patterns of synaptic connections in the developing mammalian neocortex has relied primarily on anatomical studies. In a physiological approach described here, the patterns of synaptic connections in slices of developing ferret visual cortex were determined with scanning laser photostimulation. Functional synaptic inputs to pyramidal cells in cortical layers 2 and 3 originating from sites close to the neuronal cell body appeared at least 2 weeks before eye opening, prior to the formation of long-range horizontal connections. Extensive long-range horizontal connections appeared in the next 10 days of development. The number of local connections peaked at the time of eye opening; the number of these connections subsequently declined to the level found in the adult while the specificity of long-distance connections increased. Thus, the relative influence of local connections on the activity of layer 2 and layer 3 neurons declines as the cortex matures while the influence of longer range connections increases substantially.			DALVA, MB (corresponding author), DUKE UNIV, MED CTR, DEPT NEUROBIOL, DURHAM, NC 27710 USA.			Dalva, Matthew/0000-0002-7737-8787	NATIONAL EYE INSTITUTE [R01EY007960] Funding Source: NIH RePORTER; NEI NIH HHS [EY07960] Funding Source: Medline; PHS HHS [T32-6M08441] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADAMS JC, 1981, J HISTOCHEM CYTOCHEM, V29, P775, DOI 10.1177/29.6.7252134; ANTONINI A, 1993, SCIENCE, V260, P1819, DOI 10.1126/science.8511592; ARMSTRONGJAMES M, 1988, CEREBRAL CORTEX DEV, V7, pCH8; BURKHALTER A, 1993, J NEUROSCI, V13, P1916, DOI 10.1523/jneurosci.13-05-01916.1993; CALLAWAY EM, 1991, P NATL ACAD SCI USA, V88, P745, DOI 10.1073/pnas.88.3.745; CALLAWAY EM, 1993, P NATL ACAD SCI USA, V90, P7661, DOI 10.1073/pnas.90.16.7661; CALLAWAY EM, 1990, J NEUROSCI, V10, P1134; CALLAWAY EM, 1992, J NEUROSCI, V12, P570; CAMPBELL G, 1992, J NEUROSCI, V12, P1847; Dalva M. B., 1992, Society for Neuroscience Abstracts, V18, P1455; DURACK J, UNPUB; EDELMAN GM, 1988, NEURAL DARWINISIM TH; FARBER IC, 1983, SCIENCE, V222, P1025, DOI 10.1126/science.6648515; FRIAUF E, 1990, J NEUROSCI, V10, P2601; GILBERT CD, 1989, J NEUROSCI, V9, P2432; GILBERT CD, 1983, J NEUROSCI, V3, P1116; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; HATA Y, 1993, NEUROPHYSIOLOGY, V69, P40; HESSLER NA, 1993, NATURE, V366, P569, DOI 10.1038/366569a0; HESTRIN S, 1992, NATURE, V357, P686, DOI 10.1038/357686a0; HIRSCH JA, 1993, J PHYSIOL-LONDON, V461, P247, DOI 10.1113/jphysiol.1993.sp019512; JONES EG, 1984, CEREBRAL CORTEX CELL, V1, pCH8; KATZ LC, 1989, J NEUROSCI, V9, P1389; KATZ LC, 1987, J NEUROSCI, V7, P1223; KATZ LC, 1991, EUR J NEUROSCI, V3, P1, DOI 10.1111/j.1460-9568.1991.tb00805.x; KATZ LC, IN PRESS J NEUROSCI; KAUR C, 1989, ACTA ANAT, V136, P204; KISVARDAY ZF, 1986, EXP BRAIN RES, V64, P541, DOI 10.1007/BF00340492; KISVARDAY ZF, 1992, NEUROSCIENCE, V46, P275, DOI 10.1016/0306-4522(92)90050-C; LIVINGSTONE MS, 1984, J NEUROSCI, V4, P2830; LOWEL S, 1992, SCIENCE, V255, P209, DOI 10.1126/science.1372754; LUBKE J, 1992, J COMP NEUROL, V323, P42, DOI 10.1002/cne.903230105; LUND JS, 1977, J COMP NEUROL, V176, P149, DOI 10.1002/cne.901760203; LUND JS, 1975, J COMP NEUROL, V159, P305, DOI 10.1002/cne.901590303; MALACH R, 1993, P NATL ACAD SCI USA, V90, P10469, DOI 10.1073/pnas.90.22.10469; MALSBURG CV, 1973, KYBERNETIK, V14, P85, DOI 10.1007/BF00288907; MARTIN KAC, 1984, J PHYSIOL-LONDON, V353, P463, DOI 10.1113/jphysiol.1984.sp015347; MCGUIRE BA, 1991, J COMP NEUROL, V305, P370, DOI 10.1002/cne.903050303; MILLER KD, 1989, SCIENCE, V245, P605, DOI 10.1126/science.2762813; MILLER KD, 1994, J NEUROSCI, V14, P409; MISSON JP, 1991, GLIA, V4, P138, DOI 10.1002/glia.440040205; OROURKE NA, 1990, NEURON, V5, P159, DOI 10.1016/0896-6273(90)90306-Z; ROCKLAND KS, 1982, SCIENCE, V215, P1532, DOI 10.1126/science.7063863; ROCKLAND KS, 1985, J COMP NEUROL, V241, P225, DOI 10.1002/cne.902410209; ROSENMUND C, 1993, SCIENCE, V262, P754, DOI 10.1126/science.7901909; TSO DY, 1986, J NEUROSCI, V6, P1160; TSUMOTO T, 1987, NATURE, V327, P513, DOI 10.1038/327513a0; WILCOX M, 1990, J ORG CHEM, V55, P1585, DOI 10.1021/jo00292a038	48	114	150	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 8	1994	265	5169					255	258		10.1126/science.7912852	http://dx.doi.org/10.1126/science.7912852			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NV957	7912852				2022-12-24	WOS:A1994NV95700043
J	SMITH, JC; CRANSTON, D; OBRIEN, T; GUILLEBAUD, J; HINDMARSH, J; TURNER, AG				SMITH, JC; CRANSTON, D; OBRIEN, T; GUILLEBAUD, J; HINDMARSH, J; TURNER, AG			FATHERHOOD WITHOUT APPARENT SPERMATOZOA AFTER VASECTOMY	LANCET			English	Note								Fatherhood after vasectomy is rare. We describe 6 cases of DNA-proven fatherhood after vasectomy in association with persistently negative semen examination. All vasectomy patients and their partners should be counselled about the small possibility of late failure, and warning of failure should be recorded.	CHURCHILL HOSP,ELLIOT SMITH CLIN,OXFORD,ENGLAND; MARGARET PYKE CTR STUDY & TRAINING FAMILY PLANNING,LONDON,ENGLAND; S CLEVELAND HOSP,MIDDLESBROUGH,CLEVELAND,ENGLAND; PETERBOROUGH DIST GEN HOSP,PETERBOROUGH,LINCS,ENGLAND; STAMFORD HOSP,PETERBOROUGH,LINCS,ENGLAND	University of Oxford; University of London; University College London	SMITH, JC (corresponding author), CHURCHILL HOSP,DEPT UROL,OXFORD OX3 7LJ,ENGLAND.		Cranston, David/K-7063-2019					BUNGE RG, 1968, J UROLOGY, V100, P762, DOI 10.1016/S0022-5347(17)62620-X; Esho J O, 1974, Urology, V3, P211, DOI 10.1016/S0090-4295(74)80018-X; PHILP T, 1984, BRIT MED J, V289, P77, DOI 10.1136/bmj.289.6437.77; Pugh R C, 1969, Br J Urol, V41, P340, DOI 10.1111/j.1464-410X.1969.tb11894.x; SMITH JC, 1971, LANCET, V1, P38; TEMPLE JG, 1970, LANCET, V2, P1258; THOMSON JA, 1993, BRIT MED J, V307, P299, DOI 10.1136/bmj.307.6899.299	7	46	47	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 2	1994	344	8914					30	30		10.1016/S0140-6736(94)91052-9	http://dx.doi.org/10.1016/S0140-6736(94)91052-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU917	7912302				2022-12-24	WOS:A1994NU91700015
J	THOMAS, DP				THOMAS, DP			VIRAL CONTAMINATION OF BLOOD PRODUCTS	LANCET			English	Editorial Material							HEMOPHILIA-A; PARVOVIRUS-B19; TRANSMISSION; CONCENTRATE				THOMAS, DP (corresponding author), BIO PROD LAB, ELSTREE, HERTS, ENGLAND.							LYON DJ, 1989, LANCET, V1, P1085; MANNUCCI PM, 1994, ANN INTERN MED, V120, P1, DOI 10.7326/0003-4819-120-1-199401010-00001; MANNUCCI PM, 1993, VIROLOGICAL SAFETY A, P253; MCOMISH F, 1993, J CLIN MICROBIOL, V31, P323, DOI 10.1128/JCM.31.2.323-328.1993; MORTIMER PP, 1983, LANCET, V2, P482; NORMANN A, 1992, LANCET, V340, P1232, DOI 10.1016/0140-6736(92)92938-C; PEERLINCK K, 1993, THROMB HAEMOSTASIS, V69, P115; PEERLINCK K, 1993, LANCET, V341, P179, DOI 10.1016/0140-6736(93)90044-H; PROWSE C, 1993, BRIT MED J, V307, P561, DOI 10.1136/bmj.307.6903.561-e; SANTAGOSTINO E, 1994, LANCET, V343, P798, DOI 10.1016/S0140-6736(94)91878-3; TEMPERLEY IJ, 1992, LANCET, V340, P1466; WILLIAMS MD, 1990, VOX SANG, V58, P177, DOI 10.1111/j.1423-0410.1990.tb02086.x	12	12	14	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 25	1994	343	8913					1583	1584		10.1016/S0140-6736(94)93050-3	http://dx.doi.org/10.1016/S0140-6736(94)93050-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU354	7911913				2022-12-24	WOS:A1994NU35400003
J	NIGHTINGALE, SL				NIGHTINGALE, SL			NEW RULE ON LABELING FOODS AS HEALTHY ISSUED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 15	1994	271	23					1818	1818						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NP959	7910857				2022-12-24	WOS:A1994NP95900004
J	NAKAOKA, H; PEREZ, DM; BAEK, KJ; DAS, T; HUSAIN, A; MISONO, K; IM, MJ; GRAHAM, RM				NAKAOKA, H; PEREZ, DM; BAEK, KJ; DAS, T; HUSAIN, A; MISONO, K; IM, MJ; GRAHAM, RM			G(H) - A GTP-BINDING PROTEIN WITH TRANSGLUTAMINASE ACTIVITY AND RECEPTOR SIGNALING FUNCTION	SCIENCE			English	Article							PIG LIVER TRANSGLUTAMINASE; PHOSPHOLIPASE-C; ALPHA-SUBUNITS; ALPHA-1-ADRENERGIC RECEPTOR; CDNA CLONES; IDENTIFICATION; RECONSTITUTION; PURIFICATION; FAMILY; ALPHA(1)-ADRENOCEPTOR	The alpha(1)-adrenergic receptors activate a phospholipase C enzyme by coupling to members of the large molecular size (approximately 74 to 80 kilodaltons) G alpha(h) family of guanosine triphosphate (GTP)-binding proteins. Rat liver G alpha(h) is now shown to be a tissue transglutaminase type II (TGase II). The transglutaminase activity of rat liver TGase II expressed in COS-1 cells was inhibited by the nonhydrolyzable GTP analog guanosine 5'-O-(3-thiotriphosphate) or by alpha(1)-adrenergic receptor activation. Rat liver TGase II also mediated alpha(1)-adrenergic receptor stimulation of phospholipase C activity. Thus, G alpha(h) represents a new class of GTP-binding proteins that participate in receptor signaling and may be a component of a complex regulatory network in which receptor-stimulated GTP binding switches the function of G alpha(h) from transglutamination to receptor signaling.	CLEVELAND CLIN FDN,RES INST,DEPT CARDIOVASC BIOL,CLEVELAND,OH 44195	Cleveland Clinic Foundation			Husain, Ahsan/J-6861-2012	Husain, Ahsan/0000-0003-3426-3469				ACHYUTHAN KE, 1987, J BIOL CHEM, V262, P1901; BAEK KJ, 1993, J BIOL CHEM, V268, P27390; BERNSTEIN G, 1992, CELL, V70, P411; BIRCKBICHLER PJ, 1985, HYBRIDOMA, V4, P179, DOI 10.1089/hyb.1985.4.179; DAS T, 1993, J BIOL CHEM, V268, P27398; FOLK JE, 1980, ANNU REV BIOCHEM, V49, P517, DOI 10.1146/annurev.bi.49.070180.002505; FRANKE RR, 1992, J BIOL CHEM, V267, P14767; GENTILE V, 1991, J BIOL CHEM, V266, P478; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; IKURA K, 1988, BIOCHEMISTRY-US, V27, P2898, DOI 10.1021/bi00408a035; IM MJ, 1990, J BIOL CHEM, V265, P18952; IM MJ, 1990, J BIOL CHEM, V265, P18944; IM MJ, 1992, J BIOL CHEM, V267, P8887; LEE KN, 1989, BIOCHEM BIOPH RES CO, V162, P1370, DOI 10.1016/0006-291X(89)90825-5; LEE KN, 1993, BIOCHIM BIOPHYS ACTA, V1201, P1; NAKANISHI K, 1991, EUR J BIOCHEM, V202, P15, DOI 10.1111/j.1432-1033.1991.tb16338.x; NAKAOKA H, UNPUB; PEREZ DM, 1991, MOL PHARMACOL, V40, P876; PEREZ DM, 1993, MOL PHARMACOL, V44, P784; QIAN NX, 1993, P NATL ACAD SCI USA, V90, P4077, DOI 10.1073/pnas.90.9.4077; TAKEUCHI Y, 1992, FEBS LETT, V307, P177, DOI 10.1016/0014-5793(92)80762-6; WANGE RL, 1991, J BIOL CHEM, V266, P11409; WU DQ, 1992, J BIOL CHEM, V267, P25798	24	527	539	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 10	1994	264	5165					1593	1596		10.1126/science.7911253	http://dx.doi.org/10.1126/science.7911253			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NQ285	7911253				2022-12-24	WOS:A1994NQ28500037
J	LIN, JP; BROWN, JK; WALSH, EG				LIN, JP; BROWN, JK; WALSH, EG			PHYSIOLOGICAL MATURATION OF MUSCLES IN CHILDHOOD	LANCET			English	Article								Little is known about the motor muscle physiology of growing children and it has been assumed that increasing motor dexterity and speed correspond solely to brain maturation, although there is evidence that muscles mature from studies of other mammalian species. Such a finding in children would throw light on the possible mechanics of motor delays in speech, hand function, athletic, and musical skills as well as helping towards a better understanding of pathological motor disorders such as the cerebral palsies. Our non-invasive observations of soleus-muscle relaxation times in healthy children suggest that a child's muscles are initially slow to relax but relaxation doubles in speed up to adult rates by early adolescence. Half-relaxation times halved from about 90 ms at age 3 to about 40 ms at age 10. On the basis of these studies, we suggest that muscle maturation rate-limits motor tasks; which should be borne in mind when considering motor development in muscles and when attempting to determine the effects of early brain or spinal cord damage. Such methods of measuring the dynamics of muscle open up new areas of research and offer the possibility of developing operationally-defined in-vivo measurements for use in motor assessment and for following up the effects on muscle or treatments such as physiotherapy, orthotics, surgery, and drugs.	ROYAL HOSP SICK CHILDREN, EDINBURGH, MIDLOTHIAN, SCOTLAND; UNIV EDINBURGH, DEPT PHYSIOL, EDINBURGH, SCOTLAND	University of Edinburgh			Lin, Jean-Pierre/R-3779-2019	Lin, Jean-Pierre/0000-0001-9314-2259				BARRY JA, 1994, EXP PHYSIOL, V79, P515, DOI 10.1113/expphysiol.1994.sp003784; BROOKE MH, 1969, NEUROLOGY, V19, P591, DOI 10.1212/WNL.19.6.591; BULLER AJ, 1960, J PHYSIOL-LONDON, V150, P417, DOI 10.1113/jphysiol.1960.sp006395; DAVIES CTM, 1983, J APPL PHYSIOL, V55, P191, DOI 10.1152/jappl.1983.55.1.191; EYRE JA, 1991, J PHYSIOL-LONDON, V434, P441, DOI 10.1113/jphysiol.1991.sp018479; GARNETT RAF, 1979, J PHYSIOL-LONDON, V287, P33, DOI 10.1113/jphysiol.1979.sp012643; KALVERBOER AF, 1993, MOTOR DEV EARLY LATE; MALINA RM, 1991, GROWTH MATURATION PH, P115; MARGRETH A, 1980, PLASTICITY MUSCLE, P193; PARKER DF, 1990, ANN HUM BIOL, V17, P199, DOI 10.1080/03014469000000962; PETTE D, 1980, PLASTICITY MUSCLE; SALE D, 1982, J APPL PHYSIOL, V52, P1636, DOI 10.1152/jappl.1982.52.6.1636; SALMONS S, 1976, NATURE, V263, P30, DOI 10.1038/263030a0; WALSH EG, 1993, EXP PHYSIOL, V78, P531, DOI 10.1113/expphysiol.1993.sp003704; WALSH EG, 1992, CLIN DEV MED SERIES, V125, P26; WATTS C, 1992, J PHYSIOL-LONDON, V452, pP273	16	14	14	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 4	1994	343	8910					1386	1389		10.1016/S0140-6736(94)92522-4	http://dx.doi.org/10.1016/S0140-6736(94)92522-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NP955	7910882				2022-12-24	WOS:A1994NP95500008
J	WAGA, S; STILLMAN, B				WAGA, S; STILLMAN, B			ANATOMY OF A DNA-REPLICATION FORK REVEALED BY RECONSTITUTION OF SV40 DNA-REPLICATION IN-VITRO	NATURE			English	Article							SIMIAN VIRUS-40 DNA; POLYMERASE-ALPHA-PRIMASE; LAGGING STRAND SYNTHESIS; CELL NUCLEAR ANTIGEN; T-ANTIGEN; SACCHAROMYCES-CEREVISIAE; FACTOR-C; INVITRO REPLICATION; ACCESSORY PROTEINS; INITIATION	Complete enzymatic replication of DNA from the simian virus 40 origin has been reconstituted with T antigen and highly purified cellular proteins. DNA polymerase-alpha/primase functions primarily to synthesize RNA-DNA primers for initiation of DNA replication at the origin and for priming each Okazaki fragment. A polymerase switching mechanism requiring replication factor C and the proliferating cell nuclear antigen allows two molecules of DNA polymerase-delta to replicate both strands of the double helix conjointly.			WAGA, S (corresponding author), COLD SPRING HARBOR LAB,POB 100,COLD SPRING HARBOR,NY 11724, USA.			Waga, Shou/0000-0003-4986-8735; Stillman, Bruce/0000-0002-9453-4091				ARAKI H, 1992, EMBO J, V11, P733, DOI 10.1002/j.1460-2075.1992.tb05106.x; BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; BULLOCK PA, 1991, MOL CELL BIOL, V11, P2350, DOI 10.1128/MCB.11.5.2350; BURGERS PMJ, 1991, J BIOL CHEM, V266, P22698; CHA TA, 1988, CANCER CELL, V6, P1; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; COLLINS KL, 1991, MOL CELL BIOL, V11, P2108, DOI 10.1128/MCB.11.4.2108; DEAN FB, 1992, J BIOL CHEM, V267, P14129; DENIS D, 1993, MOL CELL BIOL, V13, P2882, DOI 10.1128/MCB.13.5.2882; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; EKI T, 1992, J BIOL CHEM, V267, P7284; ELIASSON R, 1978, J BIOL CHEM, V253, P7469; FIEN K, 1992, MOL CELL BIOL, V12, P155, DOI 10.1128/MCB.12.1.155; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GOULIAN M, 1990, J BIOL CHEM, V265, P18461; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; KONRAD EB, 1974, P NATL ACAD SCI USA, V71, P2048, DOI 10.1073/pnas.71.5.2048; Kornberg A., 1992, DNA REPLICATION; LEE SH, 1991, J BIOL CHEM, V266, P594; LI JJ, 1985, MOL CELL BIOL, V5, P1238, DOI 10.1128/MCB.5.6.1238; LI JJ, 1984, P NATL ACAD SCI-BIOL, V81, P6973, DOI 10.1073/pnas.81.22.6973; MARIANS KJ, 1992, ANNU REV BIOCHEM, V61, P673, DOI 10.1146/annurev.bi.61.070192.003325; MCHENRY CS, 1991, J BIOL CHEM, V266, P19127; MELENDY T, 1993, J BIOL CHEM, V268, P3389; MELENDY T, 1992, NUCLEIC ACIDS MOL BI, V6, P129; MURAKAMI Y, 1993, J BIOL CHEM, V268, P11018; MURAKAMI Y, 1992, P NATL ACAD SCI USA, V89, P952, DOI 10.1073/pnas.89.3.952; NETHANEL T, 1990, J VIROL, V64, P5912, DOI 10.1128/JVI.64.12.5912-5918.1990; NISHIDA C, 1988, J BIOL CHEM, V263, P501; PODUST VN, 1993, NUCLEIC ACIDS RES, V21, P841, DOI 10.1093/nar/21.4.841; PRELICH G, 1988, CELL, V53, P117, DOI 10.1016/0092-8674(88)90493-X; ROBERTS JD, 1991, P NATL ACAD SCI USA, V88, P3465, DOI 10.1073/pnas.88.8.3465; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; STILLMAN BW, 1985, MOL CELL BIOL, V5, P2051, DOI 10.1128/MCB.5.8.2051; TSURIMOTO T, 1989, MOL CELL BIOL, V9, P609, DOI 10.1128/MCB.9.2.609; TSURIMOTO T, 1990, NATURE, V346, P534, DOI 10.1038/346534a0; TSURIMOTO T, 1989, EMBO J, V8, P3883, DOI 10.1002/j.1460-2075.1989.tb08567.x; TSURIMOTO T, 1990, P NATL ACAD SCI USA, V87, P1023, DOI 10.1073/pnas.87.3.1023; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1961; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; TSURIMOTO T, 1989, MOL CELL BIOL, V9, P3839, DOI 10.1128/MCB.9.9.3839; TURCHI JJ, 1993, J BIOL CHEM, V268, P15136; VEAUTE X, 1993, SCIENCE, V261, P598, DOI 10.1126/science.8342022; WAGA S, IN PRESS J BIOL CHEM; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; WANG ZG, 1993, MOL CELL BIOL, V13, P1051, DOI 10.1128/MCB.13.2.1051; WEINBERG DH, 1990, P NATL ACAD SCI USA, V87, P8692, DOI 10.1073/pnas.87.22.8692; WOBBE CR, 1985, P NATL ACAD SCI USA, V82, P5710, DOI 10.1073/pnas.82.17.5710; YOUNG MC, 1992, BIOCHEMISTRY-US, V31, P8675, DOI 10.1021/bi00152a001	50	511	517	1	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 19	1994	369	6477					207	212		10.1038/369207a0	http://dx.doi.org/10.1038/369207a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NM067	7910375				2022-12-24	WOS:A1994NM06700048
J	NORTHRIDGE, DB; HALL, RJC				NORTHRIDGE, DB; HALL, RJC			POST-MYOCARDIAL-INFARCTION EXERCISE TESTING IN THE THROMBOLYTIC ERA	LANCET			English	Editorial Material							PROGNOSTIC VALUE; SOON; RISK				NORTHRIDGE, DB (corresponding author), UNIV WALES HOSP,DEPT CARDIOL,CARDIFF,WALES.							ARNOLD AER, 1993, EUR HEART J, V14, P306, DOI 10.1093/eurheartj/14.3.306; DEBELDER MA, 1988, BRIT HEART J, V60, P377; DEFEYTER PJ, 1982, CIRCULATION, V66, P527, DOI 10.1161/01.CIR.66.3.527; ELLIS SG, 1989, CIRCULATION, V80, P1159, DOI 10.1161/01.CIR.80.5.1159; PATERSON RE, 1983, AM J CARDIOL, V51, P361; PEART I, 1989, BRIT HEART J, V61, P231; PICCALO G, 1992, AM J CARDIOL, V70, P31, DOI 10.1016/0002-9149(92)91385-H; STEVENSON R, 1993, BRIT HEART J, V70, P415; THEROUX P, 1979, NEW ENGL J MED, V301, P341, DOI 10.1056/NEJM197908163010701	9	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 14	1994	343	8907					1175	1176		10.1016/S0140-6736(94)92396-5	http://dx.doi.org/10.1016/S0140-6736(94)92396-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NL175	7909864				2022-12-24	WOS:A1994NL17500005
J	ROBERTS, CWM; SHUTTER, JR; KORSMEYER, SJ				ROBERTS, CWM; SHUTTER, JR; KORSMEYER, SJ			HOX11 CONTROLS THE GENESIS OF THE SPLEEN	NATURE			English	Article							T-CELL LEUKEMIA; HOMEOBOX GENE; DEVELOPMENTAL DEFECTS; TARGETED DISRUPTION; EXPRESSION; MURINE; ORGANIZATION; HOX-1.6; CODES	MANY homeobox genes are clustered in a linear array along a chromosome, reflecting their ordered expression along the anterior-posterior axis of the embryo(1). Expression patterns(2,3) as well as grafting(4), ectopic expression(5,6) and loss-of-function experiments(7-11) suggest that the Hox genes encode a combinatorial system of positional specification along that axis. In contrast, the function of orphan homeobox genes(12) located at sites outside the four mammalian Hox clusters is less well understood. To assess the functional role of the orphan homeobox gene Hox11, we have generated Hox11-deficient mice through gene targeting. Hox11(-/-) mice have no spleen, but otherwise appear normal. Hox11 is normally expressed in the splenic anlage arising from the splanchnic mesoderm. Hox11(-/-) embryos have no cellular organization at the site of splenic development but all other splanchnic derivatives develop normally. Hox11 controls the genesis of a single organ, providing new insight into the genetic regulation of morphogenesis.	WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)	ROBERTS, CWM (corresponding author), WASHINGTON UNIV,SCH MED,HOWARD HUGHES MED INST,ST LOUIS,MO 63110, USA.		Roberts, Charles/N-2541-2018	Roberts, Charles/0000-0003-1135-1896				BALLING R, 1989, CELL, V58, P337, DOI 10.1016/0092-8674(89)90848-9; CARTER TC, 1954, MOUSE NEWS LETT, V11, P16; CHISAKA O, 1992, NATURE, V355, P516, DOI 10.1038/355516a0; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; DUBE ID, 1991, BLOOD, V78, P2996; DUBOULE D, 1989, EMBO J, V8, P1497, DOI 10.1002/j.1460-2075.1989.tb03534.x; GRAHAM A, 1989, CELL, V57, P367, DOI 10.1016/0092-8674(89)90912-4; GREEN MC, 1967, DEV BIOL, V15, P62, DOI 10.1016/0012-1606(67)90006-1; GUTHRIE S, 1992, NATURE, V356, P157, DOI 10.1038/356157a0; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; HATANO M, 1992, BLOOD S, V80, pA355; KENNEDY MA, 1991, P NATL ACAD SCI USA, V88, P8900, DOI 10.1073/pnas.88.20.8900; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; KOYAMA A, 1960, ACTA HAEMATOL JPN, V23, P20; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LEMOUELLIC H, 1992, CELL, V69, P251, DOI 10.1016/0092-8674(92)90406-3; LU M, 1991, EMBO J, V10, P2905, DOI 10.1002/j.1460-2075.1991.tb07840.x; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; MANSEAU LJ, 1989, TRENDS GENET, V5, P400, DOI 10.1016/0168-9525(89)90198-4; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; NIEHRS C, 1990, CURR OPIN GENET DEV, V2, P550; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; RAJU R, 1993, MECH DEVELOP, V44, P51; RAMIREZSOLIS R, 1993, CELL, V73, P279, DOI 10.1016/0092-8674(93)90229-J; RUGH R, 1990, MOUSE ITS REPRODUCTI; SCOTT MP, 1992, CELL, V71, P551, DOI 10.1016/0092-8674(92)90588-4; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; STERN CD, 1990, CURR OPIN GENET DEV, V2, P556; WALDMAN JD, 1977, J PEDIATR-US, V90, P555, DOI 10.1016/S0022-3476(77)80365-X; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75	30	240	248	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 21	1994	368	6473					747	749		10.1038/368747a0	http://dx.doi.org/10.1038/368747a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NG553	7908720				2022-12-24	WOS:A1994NG55300060
J	STEEL, M				STEEL, M			CYCLINS AND CANCER - WHEELS WITHIN WHEELS	LANCET			English	Editorial Material							CELL-CYCLE				STEEL, M (corresponding author), UNIV ST ANDREWS,SCH BIOL & MED SCI,ST ANDREWS KY16 9ST,FIFE,SCOTLAND.							COBRINIK D, 1992, TRENDS BIOCHEM SCI, V17, P312, DOI 10.1016/0968-0004(92)90443-D; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Hagan Iain, 1992, Trends in Cell Biology, V2, P245, DOI 10.1016/0962-8924(92)90313-C; HARPER JW, 1993, CELL, V75, P805; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; KEYOMARSI K, 1994, CANCER RES, V54, P380; MARX J, 1994, SCIENCE, V263, P319, DOI 10.1126/science.8278804; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; STURZBECHER HW, 1990, ONCOGENE, V5, P795	13	9	11	1	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 16	1994	343	8903					931	932		10.1016/S0140-6736(94)90062-0	http://dx.doi.org/10.1016/S0140-6736(94)90062-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF700	7909007				2022-12-24	WOS:A1994NF70000006
J	FORD, D; EASTON, DF; BISHOP, DT; NAROD, SA; GOLDGAR, DE; HAITES, N; MILNER, B; ALLAN, L; PONDER, BAJ; PETO, J; SMITH, S; STRATTON, M; LENOIR, GM; FEUNTEUN, J; LYNCH, H; ARASON, A; BARKARDOTTIR, R; EGILSSON, V; BLACK, DM; KELSELL, D; SPURR, N; DEVILEE, P; CORNELISSE, CJ; VARSEN, H; BIRCH, JM; SKOLNICK, M; SANTIBANEZKOREF, MS; TEARE, D; STEEL, M; PORTER, D; COHEN, BB; CAROTHERS, A; SMYTH, E; WEBER, B; NEWBOLD, B; BOEHNKE, M; COLLINS, FS; CANNONALBRIGHT, LA; GOLDGAR, D				FORD, D; EASTON, DF; BISHOP, DT; NAROD, SA; GOLDGAR, DE; HAITES, N; MILNER, B; ALLAN, L; PONDER, BAJ; PETO, J; SMITH, S; STRATTON, M; LENOIR, GM; FEUNTEUN, J; LYNCH, H; ARASON, A; BARKARDOTTIR, R; EGILSSON, V; BLACK, DM; KELSELL, D; SPURR, N; DEVILEE, P; CORNELISSE, CJ; VARSEN, H; BIRCH, JM; SKOLNICK, M; SANTIBANEZKOREF, MS; TEARE, D; STEEL, M; PORTER, D; COHEN, BB; CAROTHERS, A; SMYTH, E; WEBER, B; NEWBOLD, B; BOEHNKE, M; COLLINS, FS; CANNONALBRIGHT, LA; GOLDGAR, D			RISKS OF CANCER IN BRCA1-MUTATION CARRIERS	LANCET			English	Article							BREAST-CANCER; OVARIAN	Germline mutations in a gene on chromosome 17q known as BRCA1 are responsible for a large proportion of inherited predispositions to breast and ovarian cancer. In 33 families with evidence of linkage to BRCA1, we estimated the risks of breast and ovarian cancer from the occurrence of second cancers in individuals with breast cancer, and examined the risks of other cancers in BRCA1 carriers. 26 contralateral primary breast cancers occurring more than 3 years after a first breast cancer were observed before age 70, giving an estimated cumulative risk of breast cancer in gene carriers of 87% by age 70. 23 primary ovarian cancers occurred in women with a previous breast cancer, resulting in an estimated cumulative risk of ovarian cancer of 44% by age 70. 87 cancers other than breast or ovarian cancer were observed in individuals with breast or ovarian cancer and their first-degree relatives compared with 69.3 expected, based on national incidence rates. Significant excesses were observed for colon cancer (estimated relative risk [RR] to gene carriers 4.11 [95% Cl 2.36-7.15]) and prostate cancer(3.33 [1.78-6.20]). No significant excesses (or deficits) were noted for cancers of other sites. Our study provides estimates of breast and ovarian cancer risks which are useful for counselling BRCA1-mutation carriers. It also shows that carriers are at increased risk of colon and prostate cancer, which may be of clinical significance in certain families if the risks are associated with specific mutations.	ST JAMES HOSP,ICRF,GENET EPIDEMIOL UNIT,LEEDS,ENGLAND; MONTREAL GEN HOSP,MONTREAL,PQ,CANADA; UNIV UTAH,DEPT MED INFORMAT,SALT LAKE CITY,UT 84112; UNIV ABERDEEN,ABERDEEN,SCOTLAND; CANC RES CAMPAIGN,LONDON,ENGLAND; INST CANC RES,LONDON,ENGLAND; INT AGCY RES CANC,LYON,FRANCE; UNIV ICELAND,REYKJAVIK,ICELAND; IMPERIAL CANC RES FUND,LEEDS,W YORKSHIRE,ENGLAND; LEIDEN UNIV,LEIDEN,NETHERLANDS; FDN DETECT HEREDITARY TUMOURS,LEIDEN,NETHERLANDS; CHRISTIE HOSP & HOLT RADIUM INST,MANCHESTER M20 9BX,LANCS,ENGLAND; IMPERIAL CANC RES FUND,LONDON,ENGLAND; MRC,HUMAN GENET UNIT,EDINBURGH,MIDLOTHIAN,SCOTLAND; UNIV MICHIGAN,ANN ARBOR,MI 48109; INST CANC RES,CAMBRIDGE,CAMBS,ENGLAND	Saint James's University Hospital; McGill University; Utah System of Higher Education; University of Utah; University of Aberdeen; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; World Health Organization; International Agency for Research on Cancer (IARC); University of Iceland; Leiden University; Leiden University - Excl LUMC; Christie NHS Foundation Trust; Christie Hospital; Cancer Research UK; University of Edinburgh; University of Michigan System; University of Michigan; University of London; Institute of Cancer Research - UK	FORD, D (corresponding author), INST CANC RES,EPIDEMIOL SECT,BLOCK D,BELMONT SM2 5NG,SURREY,ENGLAND.		Feunteun, Jean/AAZ-1267-2020; Narod, Steven A/AAA-6112-2022; DEVILEE, PETER/ABR-2140-2022; Kelsell, David P/F-8767-2011	Bishop, Tim/0000-0002-8752-8785	NCI NIH HHS [CA57601] Funding Source: Medline; NHGRI NIH HHS [HG00209] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA057601] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARASON A, 1993, AM J HUM GENET, V52, P711; BOWCOCK AM, 1993, AM J HUM GENET, V52, P718; Cannon L., 1982, CANCER SURV, V1, P47; EASTON DF, 1993, AM J HUM GENET, V52, P678; EASTON DF, 1992, THESIS U LONDON; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; HALL JM, 1992, AM J HUM GENET, V53, P678; MUIR C, 1987, CANCER INCIDENCE 5 C, V5; NAROD SA, 1991, LANCET, V338, P82; TOBACMAN JK, 1982, LANCET, V2, P795; TULINIUS H, 1992, BRIT MED J, V305, P855, DOI 10.1136/bmj.305.6858.855; WEBER JL, 1990, NUCLEIC ACIDS RES, V18, P4640, DOI 10.1093/nar/18.15.4640-a	12	1464	1494	4	107	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 19	1994	343	8899					692	695		10.1016/S0140-6736(94)91578-4	http://dx.doi.org/10.1016/S0140-6736(94)91578-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NB809	7907678				2022-12-24	WOS:A1994NB80900007
J	NICOLAOU, KC; YANG, Z; LIU, JJ; UENO, H; NANTERMET, PG; GUY, RK; CLAIBORNE, CF; RENAUD, J; COULADOUROS, EA; PAULVANNAN, K; SORENSEN, EJ				NICOLAOU, KC; YANG, Z; LIU, JJ; UENO, H; NANTERMET, PG; GUY, RK; CLAIBORNE, CF; RENAUD, J; COULADOUROS, EA; PAULVANNAN, K; SORENSEN, EJ			TOTAL SYNTHESIS OF TAXOL	NATURE			English	Article							SYSTEM; AGENT	TAXOL(1-4), a substance originally isolated from the Pacific yew tree (Taxus brevifolia) more than two decades ago, has recently been approved for the clinical treatment of cancer patients. Hailed as having provided one of the most significant advances in cancer therapy(5), this molecule exerts its anticancer activity by inhibiting mitosis through enhancement of the polymerization of tubulin and consequent stabilization of microtubules(6). The scarcity of taxol and the ecological impact of harvesting it have prompted extensive searches for alternative sources including semisynthesis, cellular culture production and chemical synthesis(2,3). The latter has been attempted for almost two decades, but these attempts have been thwarted by the magnitude of the synthetic challenge. Here we report the total synthesis of taxol by a convergent strategy, which opens a chemical pathway for the production of both the natural product itself and a variety of designed taxoids.	UNIV CALIF SAN DIEGO, DEPT CHEM, SAN DIEGO, CA 92093 USA	University of California System; University of California San Diego	NICOLAOU, KC (corresponding author), SCRIPPS RES INST, DEPT CHEM, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.		Yang, Zhen/GWQ-4960-2022; Guy, Rodney/J-7107-2013; Yang, Zhen/J-6306-2015	Guy, Rodney/0000-0002-9638-2060; Yang, Zhen/0000-0001-8036-934X				Chamberlin A.R., 1990, ORG REACT, V39, P1; Griffith W. P., 1990, ALDRICHIM ACTA, V23, P13; GUENARD D, 1993, ACCOUNTS CHEM RES, V26, P160, DOI 10.1021/ar00028a005; MAGEE TV, 1992, J ORG CHEM, V57, P3274, DOI 10.1021/jo00038a008; MCMURRY JE, 1989, CHEM REV, V89, P1513, DOI 10.1021/cr00097a007; NICOLAOU KC, 1992, J CHEM SOC CHEM COMM, P1117, DOI 10.1039/c39920001117; NICOLAOU KC, 1993, J CHEM SOC CHEM COMM, P1024, DOI 10.1039/c39930001024; NICOLAOU KC, 1994, J CHEM SOC CHEM COMM, P295, DOI 10.1039/c39940000295; NICOLAOU KC, 1994, ANGEW CHEM INT EDIT, V33, P15, DOI 10.1002/anie.199400151; NICOLAOU KC, 1992, J CHEM SOC CHEM COMM, P1118, DOI 10.1039/c39920001118; OJIMA I, 1992, TETRAHEDRON, V48, P6985, DOI 10.1016/S0040-4020(01)91210-4; ROWINSKY EK, 1990, JNCI-J NATL CANCER I, V82, P1247, DOI 10.1093/jnci/82.15.1247; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; Sharpless K. B., 1979, ALDRICHIM ACTA, V12, P63; WANI MC, 1971, J AM CHEM SOC, V93, P2325, DOI 10.1021/ja00738a045; 1993, PACLITAXEL TAXOF S3, V20, P1	16	979	1099	19	700	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 17	1994	367	6464					630	634		10.1038/367630a0	http://dx.doi.org/10.1038/367630a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC); Current Chemical Reactions (CCR-EXPANDED)	Science & Technology - Other Topics	MW688	7906395				2022-12-24	WOS:A1994MW68800049
J	ASAI, T; BATES, DB; KOGOMA, T				ASAI, T; BATES, DB; KOGOMA, T			DNA-REPLICATION TRIGGERED BY DOUBLE-STRANDED BREAKS IN ESCHERICHIA-COLI - DEPENDENCE ON HOMOLOGOUS RECOMBINATION FUNCTIONS	CELL			English	Article							ESCHERICHIA-COLI; RECBCD ENZYME; BACTERIOPHAGE-LAMBDA; RECD MUTANTS; GENETIC-RECOMBINATION; PURIFIED SUBUNITS; INITIATION SITE; EXONUCLEASE-V; CHI; REPAIR	Homologous recombination-dependent DMA replication (RDR) of a lambda cos site-carrying plasmid is demonstrated in E. coli cells when the cells express lambda terminase that introduces a double-stranded break into the cos site. RDR occurs in normal wild-type cells if the plasmid also contains the recombination hotspot chi. chi is dispensable when cells are induced for the SOS. response or contain a recD mutation. recBC sbcA mutant cells are also capable of RDR induction. A recN mutation greatly reduces RDR in normal cells, but not in SOS-induced cells. RDR proceeds by the theta mode or rolling circle mode of DNA synthesis, yielding covalently closed circular plasmid monomers or linear plasmid multimers, respectively. Previously described inducible stable DNA replication is considered to be a special type of RDR that starts exclusively from specific sites (oriMs) on the chromosome.	UNIV NEW MEXICO, SCH MED, DEPT CELL BIOL, ALBUQUERQUE, NM 87131 USA; UNIV NEW MEXICO, SCH MED, DEPT MICROBIOL, ALBUQUERQUE, NM 87131 USA; UNIV NEW MEXICO, SCH MED, CTR CANC RES & TREATMENT, ALBUQUERQUE, NM 87131 USA	University of New Mexico; University of New Mexico; University of New Mexico				Bates, David/0000-0002-0870-055X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022092] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM022092-22, GM22092] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMUNDSEN SK, 1986, P NATL ACAD SCI USA, V83, P5558, DOI 10.1073/pnas.83.15.5558; ASAI T, 1994, J MOL BIOL, V235, P1459, DOI 10.1006/jmbi.1994.1101; ASAI T, 1993, EMBO J, V12, P3287, DOI 10.1002/j.1460-2075.1993.tb05998.x; ASAI T, 1994, J BACTERIOL, V176, P1807, DOI 10.1128/jb.176.7.1807-1812.1994; BACHMANN BJ, 1972, BACTERIOL REV, V36, P525, DOI 10.1128/MMBR.36.4.525-557.1972; BAILONE A, 1988, MOL GEN GENET, V214, P389, DOI 10.1007/BF00330471; BECKER A, 1990, J BACTERIOL, V172, P2819, DOI 10.1128/jb.172.6.2819-2824.1990; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; BOEHMER PE, 1991, GENE, V102, P1, DOI 10.1016/0378-1119(91)90529-K; CHAUDHURY AM, 1984, P NATL ACAD SCI-BIOL, V81, P7850, DOI 10.1073/pnas.81.24.7850; CLARK AJ, 1993, J BACTERIOL, V175, P7673, DOI 10.1128/JB.175.23.7673-7682.1993; CLARK AJ, 1991, BIOCHIMIE, V73, P523, DOI 10.1016/0300-9084(91)90124-J; COHEN A, 1986, J BACTERIOL, V167, P327, DOI 10.1128/jb.167.1.327-335.1986; COX MM, 1993, BIOESSAYS, V15, P617, DOI 10.1002/bies.950150908; DABERT P, 1992, P NATL ACAD SCI USA, V89, P12073, DOI 10.1073/pnas.89.24.12073; DIXON DA, 1991, CELL, V66, P361, DOI 10.1016/0092-8674(91)90625-9; DIXON DA, 1993, CELL, V73, P87, DOI 10.1016/0092-8674(93)90162-J; DIXON DA, 1994, P NATL ACAD SCI USA, V91, P2980, DOI 10.1073/pnas.91.8.2980; FAULDS D, 1979, J MOL BIOL, V131, P681, DOI 10.1016/0022-2836(79)90197-9; FEISS M, 1983, LAMBDA, V2, P305; FORMOSA T, 1986, CELL, V47, P793, DOI 10.1016/0092-8674(86)90522-2; GILLEN JR, 1981, J BACTERIOL, V145, P521, DOI 10.1128/JB.145.1.521-532.1981; HALL SD, 1994, P NATL ACAD SCI USA, V91, P3205, DOI 10.1073/pnas.91.8.3205; HUISMAN O, 1983, J BACTERIOL, V153, P169, DOI 10.1128/JB.153.1.169-175.1983; JOSEPH JW, 1983, J BIOL CHEM, V258, P418; KANNAN P, 1990, CURR MICROBIOL, V21, P7, DOI 10.1007/BF02090093; Kobayashi I, 1992, Adv Biophys, V28, P81, DOI 10.1016/0065-227X(92)90023-K; Kornberg A., 1992, DNA REPLICATION; KOWALCZYKOWSKI SC, 1994, IN PRESS MICROBIOL R; KRASIN F, 1977, J MOL BIOL, V116, P81, DOI 10.1016/0022-2836(77)90120-6; KREUZER KN, 1994, IN PRESS MOL BIOL T, V4; KUSANO K, 1989, J MOL BIOL, V209, P623, DOI 10.1016/0022-2836(89)90000-4; KUSANO K, 1994, P NATL ACAD SCI USA, V91, P1173, DOI 10.1073/pnas.91.3.1173; KUZMINOV A, 1994, EMBO J, V13, P2764, DOI 10.1002/j.1460-2075.1994.tb06570.x; LOVETT ST, 1988, GENETICS, V120, P37; LOVETT ST, 1989, P NATL ACAD SCI USA, V86, P2627, DOI 10.1073/pnas.86.8.2627; MAGEE TR, 1992, EMBO J, V11, P4219, DOI 10.1002/j.1460-2075.1992.tb05516.x; MARIANS KJ, 1992, ANNU REV BIOCHEM, V61, P673, DOI 10.1146/annurev.bi.61.070192.003325; MASTERSON C, 1992, J BIOL CHEM, V267, P13564; MEYEROWITZ EM, 1980, GENE, V11, P271, DOI 10.1016/0378-1119(80)90067-0; Miller J.H., 1972, EXPT MOL GENETICS; Mosig G, 1983, BACTERIOPHAGE, V4, P120; MURIALDO H, 1988, MOL GEN GENET, V213, P42, DOI 10.1007/BF00333396; MURIALDO H, 1984, GENE, V30, P183, DOI 10.1016/0378-1119(84)90119-7; PALAS KM, 1990, J BIOL CHEM, V265, P3447; PICKSLEY SM, 1984, MOL GEN GENET, V195, P267, DOI 10.1007/BF00332758; PONTICELLI AS, 1985, CELL, V41, P145, DOI 10.1016/0092-8674(85)90069-8; PRENTKI P, 1984, GENE, V29, P303, DOI 10.1016/0378-1119(84)90059-3; RINKEN R, 1992, J BACTERIOL, V174, P1172, DOI 10.1128/jb.174.4.1172-1178.1992; RINKEN R, 1992, J BACTERIOL, V174, P5424, DOI 10.1128/JB.174.16.5424-5429.1992; SARGENTINI NJ, 1986, RADIAT RES, V107, P58, DOI 10.2307/3576850; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; SILBERSTEIN Z, 1987, J BACTERIOL, V169, P3131, DOI 10.1128/jb.169.7.3131-3137.1987; SINGER M, 1989, MICROBIOL REV, V53, P1; SMITH GR, 1988, MICROBIOL REV, V52, P1; SMITH GR, 1991, CELL, V64, P19, DOI 10.1016/0092-8674(91)90205-D; STAHL FW, 1990, GENETICS, V126, P519; SUN H, 1991, CELL, V64, P1155, DOI 10.1016/0092-8674(91)90270-9; SUN H, 1989, NATURE, V338, P87, DOI 10.1038/338087a0; TAYLOR AF, 1985, CELL, V41, P153, DOI 10.1016/0092-8674(85)90070-4; TAYLOR AF, 1992, P NATL ACAD SCI USA, V89, P5226, DOI 10.1073/pnas.89.12.5226; THALER DS, 1989, GENOME, V31, P53, DOI 10.1139/g89-013; THALER DS, 1988, ANNU REV GENET, V22, P169, DOI 10.1146/annurev.ge.22.120188.001125; UMEZU K, 1993, J MOL BIOL, V230, P1145, DOI 10.1006/jmbi.1993.1231; WILLETTS NS, 1969, J BACTERIOL, V100, P231, DOI 10.1128/JB.100.1.231-239.1969; WU TC, 1994, SCIENCE, V263, P515, DOI 10.1126/science.8290959; YAGIL E, 1985, GENET RES, V45, P1, DOI 10.1017/S0016672300021911	67	101	102	0	4	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 23	1994	78	6					1051	1061		10.1016/0092-8674(94)90279-8	http://dx.doi.org/10.1016/0092-8674(94)90279-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PJ294	7923355	Green Accepted			2022-12-24	WOS:A1994PJ29400015
J	MARAN, A; MAITRA, RK; KUMAR, A; DONG, BH; XIAO, W; LI, GY; WILLIAMS, BRG; TORRENCE, PF; SILVERMAN, RH				MARAN, A; MAITRA, RK; KUMAR, A; DONG, BH; XIAO, W; LI, GY; WILLIAMS, BRG; TORRENCE, PF; SILVERMAN, RH			BLOCKAGE OF NF-KAPPA-B SIGNALING BY SELECTIVE ABLATION OF AN MESSENGER-RNA TARGET BY 2-5A ANTISENSE CHIMERAS	SCIENCE			English	Article							ACTIVATED PROTEIN-KINASE; CONSTITUTIVE EXPRESSION; BETA-INTERFERON; RNA; GENE; 2',5'-OLIGOADENYLATE; CELLS; RESISTANCE; INDUCTION; PROMOTER	Activation of 2-5A-dependent ribonuclease by 5'-phosphorylated, 2',5'-linked oligoadenylates, known as 2-5A, is one pathway of interferon action. Unaided uptake into HeLa cells of 2-5A linked to an antisense oligonucleotide resulted in the selective ablation of messenger RNA for the double-stranded RNA (dsRNA)-dependent protein kinase PKR. Similarly, purified, recombinant human 2-5A-dependent ribonuclease was induced to selectively cleave PKR messenger RNA. Cells depleted of PKR activity were unresponsive to activation of nuclear factor-kappa B (NF-kappa B) by the dsRNA poly(l):poly(C), which provides direct evidence that PKR is a transducer for the dsRNA signaling of NF-kappa B.	CLEVELAND CLIN FDN,DEPT CANC BIOL,CLEVELAND,OH 44195; NIDDKD,BIOMED CHEM SECT,BETHESDA,MD 20892	Cleveland Clinic Foundation; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			Williams, Bryan R. G./A-5021-2009	Williams, Bryan R. G./0000-0002-4969-1151	NATIONAL CANCER INSTITUTE [R01CA044059] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028253, R01AI034039, R21AI034039] Funding Source: NIH RePORTER; NCI NIH HHS [CA 44059] Funding Source: Medline; NIAID NIH HHS [AI 34039-02, AI 28253] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CAYLEY PJ, 1982, BIOCHEM BIOPH RES CO, V108, P1243, DOI 10.1016/0006-291X(82)92133-7; CHEBATH J, 1987, NATURE, V330, P587, DOI 10.1038/330587a0; CLEMENS MJ, 1978, CELL, V13, P565, DOI 10.1016/0092-8674(78)90329-X; COCCIA EM, 1990, VIROLOGY, V179, P228, DOI 10.1016/0042-6822(90)90292-Y; DONG BH, 1994, J BIOL CHEM, V269, P14153; FLOYDSMITH G, 1981, SCIENCE, V212, P1030, DOI 10.1126/science.6165080; HASSEL BA, 1993, EMBO J, V12, P3297, DOI 10.1002/j.1460-2075.1993.tb05999.x; HAUGH MC, 1983, EUR J BIOCHEM, V132, P77, DOI 10.1111/j.1432-1033.1983.tb07327.x; KERR IM, 1978, P NATL ACAD SCI USA, V75, P256, DOI 10.1073/pnas.75.1.256; Kinjo J E, 1992, Drug Des Discov, V8, P241; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; KOVACS T, 1993, BIOORG CHEM, V21, P192, DOI 10.1006/bioo.1993.1017; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; Kumar A., UNPUB; LENARDO MJ, 1989, CELL, V57, P287, DOI 10.1016/0092-8674(89)90966-5; LESIAK K, 1993, BIOCONJUGATE CHEM, V4, P467, DOI 10.1021/bc00024a008; Maitra R., UNPUB; MARAN A, UNPUB; MARCUS PI, 1988, J GEN VIROL, V69, P1637, DOI 10.1099/0022-1317-69-7-1637; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; MEURS EF, 1992, J VIROL, V66, P5805, DOI 10.1128/JVI.66.10.5805-5814.1992; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; NAKAJIMAIIJIMA S, 1985, P NATL ACAD SCI USA, V82, P6133, DOI 10.1073/pnas.82.18.6133; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; RUTHERFORD MN, 1988, EMBO J, V7, P751, DOI 10.1002/j.1460-2075.1988.tb02872.x; RYSIECKI G, 1989, J INTERFERON RES, V9, P649, DOI 10.1089/jir.1989.9.649; SAFER B, 1983, CELL, V33, P7, DOI 10.1016/0092-8674(83)90326-4; SILVERMAN RH, 1987, LYMPHOKINES INTERFER, P149; TORRENCE PF, 1993, P NATL ACAD SCI USA, V90, P1300, DOI 10.1073/pnas.90.4.1300; VISVANATHAN KV, 1989, EMBO J, V8, P1129, DOI 10.1002/j.1460-2075.1989.tb03483.x; WELLS JA, 1984, J BIOL CHEM, V259, P1363; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WRESCHNER DH, 1981, NATURE, V289, P414, DOI 10.1038/289414a0; XANTHOUDAKIS S, 1989, J BIOL CHEM, V264, P1139; Xiao W., UNPUB; ZHOU AM, 1993, CELL, V72, P753, DOI 10.1016/0092-8674(93)90403-D; ZINN K, 1988, SCIENCE, V240, P210, DOI 10.1126/science.3281258	37	217	225	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 5	1994	265	5173					789	792		10.1126/science.7914032	http://dx.doi.org/10.1126/science.7914032			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PA372	7914032				2022-12-24	WOS:A1994PA37200035
J	BRAKS, JAM; MARTENS, GJM				BRAKS, JAM; MARTENS, GJM			7B2 IS A NEUROENDOCRINE CHAPERONE THAT TRANSIENTLY INTERACTS WITH PROHORMONE CONVERTASE PC2 IN THE SECRETORY PATHWAY	CELL			English	Article							PITUITARY POLYPEPTIDE 7B2; SUBTILISIN-LIKE PROTEASE; PROCESSING ENDOPROTEASES; ENDOCRINE PROTEIN; CDNA SEQUENCE; CELLS; RAT; GENE; BIOSYNTHESIS; IDENTIFICATION	The neuroendocrine polypeptide 7B2 is a highly conserved secretory protein selectively present in prohormone-producing cells equipped with a regulated secretory pathway. We find that the amino-terminal half of 7B2 is distantly related to chaperonins, a subclass of molecular chaperones. When incubated in vitro with newly synthesized pituitary proteins, recombinant 7B2 specifically associates with prohormone convertase PC2. Metabolic cell labeling combined with coimmunoprecipitation studies showed that, in vivo, the precursor form of 7B2 interacts with the preform of PC2. Pulse-chase analysis revealed that this association is transient in that it commences early in the secretory pathway, while dissociation in the later stages appears to coincide with the cleavages of 7B2, proPC2, and prohormone. Our results suggest that 7B2 is a novel type of molecular chaperone preventing premature activation of proPC2 in the regulated secretory pathway.			BRAKS, JAM (corresponding author), CATHOLIC UNIV NIJMEGEN,DEPT ANIM PHYSIOL,TOERNOOIVELD,6525 ED NIJMEGEN,NETHERLANDS.		Martens, Gerard JM/D-1925-2010	Martens, Gerard/0000-0003-1761-4570				ALARCON C, 1993, J BIOL CHEM, V268, P4276; AYOUBI TAY, 1990, J BIOL CHEM, V265, P15644; AYOUBI TAY, 1991, CELL TISSUE RES, V264, P329, DOI 10.1007/BF00313970; BARR PJ, 1991, DNA CELL BIOL, V10, P319, DOI 10.1089/dna.1991.10.319; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BENJANNET S, 1993, BIOCHEM J, V294, P735, DOI 10.1042/bj2940735; BRAKS JAM, 1992, FEBS LETT, V305, P45, DOI 10.1016/0014-5793(92)80652-W; BRAYTON KA, 1988, DNA-J MOLEC CELL BIO, V7, P713, DOI 10.1089/dna.1988.7.713; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; CULLINAN WE, 1991, ENZYME, V45, P285, DOI 10.1159/000468902; DAVID V, 1993, J BIOL CHEM, V268, P9585; DAY R, 1992, MOL ENDOCRINOL, V6, P485, DOI 10.1210/me.6.3.485; EIPPER BA, 1988, ANNU REV PHYSIOL, V50, P333, DOI 10.1146/annurev.ph.50.030188.002001; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; FRICKER LD, 1988, ANNU REV PHYSIOL, V50, P309, DOI 10.1146/annurev.ph.50.030188.001521; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GLEMBOTSKI CC, 1982, J BIOL CHEM, V257, P493; GUEST PC, 1992, J BIOL CHEM, V267, P22401; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HSI KL, 1982, FEBS LETT, V147, P261, DOI 10.1016/0014-5793(82)81055-7; IGUCHI H, 1987, PEPTIDES, V8, P593, DOI 10.1016/0196-9781(87)90030-1; JENKS BG, 1993, SCIENCE, V10, P1; JINDAL S, 1989, MOL CELL BIOL, V9, P2279, DOI 10.1128/MCB.9.5.2279; JULIUS D, 1984, CELL, V37, P1075, DOI 10.1016/0092-8674(84)90442-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; MARCINKIEWICZ M, 1987, CELL TISSUE RES, V250, P205, DOI 10.1007/BF00214673; MARTEL R, 1990, GENE, V94, P181, DOI 10.1016/0378-1119(90)90385-5; MARTENS GJM, 1988, FEBS LETT, V234, P160, DOI 10.1016/0014-5793(88)81324-3; MARTENS GJM, 1994, P NATL ACAD SCI USA, V91, P5784, DOI 10.1073/pnas.91.13.5784; MARTENS GJM, 1989, EUR J BIOCHEM, V181, P75, DOI 10.1111/j.1432-1033.1989.tb14695.x; MATTHEWS G, 1994, J BIOL CHEM, V269, P588; MBIKAY M, 1989, INT J PEPT PROT RES, V33, P39; ORCI L, 1987, CELL, V51, P1039, DOI 10.1016/0092-8674(87)90590-3; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SEEMULLER U, 1980, H-S Z PHYSIOL CHEM, V361, P1841; SEIDAH NG, 1992, TRENDS ENDOCRIN MET, V3, P133, DOI 10.1016/1043-2760(92)90102-7; SEIDAH NG, 1983, ARCH BIOCHEM BIOPHYS, V225, P525, DOI 10.1016/0003-9861(83)90063-2; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SENATOROV VV, 1993, J NEUROENDOCRINOL, V5, P533, DOI 10.1111/j.1365-2826.1993.tb00518.x; SHEN FS, 1993, J BIOL CHEM, V268, P24910; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; SMEEKENS SP, 1992, P NATL ACAD SCI USA, V89, P8822, DOI 10.1073/pnas.89.18.8822; STEEL JH, 1988, ENDOCRINOLOGY, V122, P270, DOI 10.1210/endo-122-1-270; STEINER DF, 1992, J BIOL CHEM, V267, P23435; THOMAS L, 1991, P NATL ACAD SCI USA, V88, P5297, DOI 10.1073/pnas.88.12.5297; VANDENOUWELAND AMW, 1990, NUCLEIC ACIDS RES, V18, P664, DOI 10.1093/nar/18.3.664; VANDUIJNHOVEN HLP, 1991, J IMMUNOL METHODS, V142, P187, DOI 10.1016/0022-1759(91)90106-P; VINDROLA O, 1992, MOL ENDOCRINOL, V6, P1088, DOI 10.1210/me.6.7.1088; WALDBIESER GC, 1991, ENDOCRINOLOGY, V128, P3228, DOI 10.1210/endo-128-6-3228; ZHOU A, 1993, J BIOL CHEM, V268, P1763; ZHU XL, 1989, NATURE, V339, P483, DOI 10.1038/339483a0	58	192	195	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 29	1994	78	2					263	273		10.1016/0092-8674(94)90296-8	http://dx.doi.org/10.1016/0092-8674(94)90296-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NZ242	7913882				2022-12-24	WOS:A1994NZ24200010
J	SHIANG, R; THOMPSON, LM; ZHU, YZ; CHURCH, DM; FIELDER, TJ; BOCIAN, M; WINOKUR, ST; WASMUTH, JJ				SHIANG, R; THOMPSON, LM; ZHU, YZ; CHURCH, DM; FIELDER, TJ; BOCIAN, M; WINOKUR, ST; WASMUTH, JJ			MUTATIONS IN THE TRANSMEMBRANE DOMAIN OF FGFR3 CAUSE THE MOST COMMON GENETIC FORM OF DWARFISM, ACHONDROPLASIA	CELL			English	Article							GROWTH-FACTOR RECEPTOR; GRADIENT GEL-ELECTROPHORESIS; SINGLE-BASE CHANGES; HOMOZYGOUS ACHONDROPLASIA; IMMUNOGLOBULIN DOMAIN; HUNTINGTONS-DISEASE; EXPRESSION PATTERN; HUMAN CHROMOSOME-4; DNA; FAMILY	Achondroplasia (ACH) is the most common genetic form of dwarfism. This disorder is inherited as an autosomal dominant trait, although the majority of cases are sporadic. A gene for ACH was recently localized to 4p16.3 by linkage analyses. The ACH candidate region includes the gene encoding fibroblast growth factor receptor 3 (FGFR3), which was originally considered as a candidate for the Huntington's disease gene. DNA studies revealed point mutations in the FGFR3 gene in ACH heterozygotes and homozygotes. The mutation on 15 of the 16 ACH-affected chromosomes was the same, a G-->A transition, at nucleotide 1138 of the cDNA. The mutation on the only ACH-affected chromosome 4 without the G-->A transition at nucleotide 1138 had a G-->C transversion at this same position. Both mutations result in the substitution of an arginine residue for a glycine at position 380 of the mature protein, which is in the transmembrane domain of FGFR3.	UNIV CALIF IRVINE, COLL MED, DEPT PEDIAT, IRVINE, CA 92717 USA; UNIV CALIF IRVINE, HUMAN GENOME RES CTR, IRVINE, CA 92717 USA	University of California System; University of California Irvine	SHIANG, R (corresponding author), UNIV CALIF IRVINE, COLL MED, DEPT BIOL CHEM, IRVINE, CA 92717 USA.				NHGRI NIH HHS [HG00834] Funding Source: Medline; NINDS NIH HHS [NS25631] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [P01HG000834] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS025631] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AVIVI A, 1993, FEBS LETT, V330, P249, DOI 10.1016/0014-5793(93)80882-U; BARKER D, 1984, CELL, V36, P131, DOI 10.1016/0092-8674(84)90081-3; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BAXENDALE S, 1993, NAT GENET, V4, P181, DOI 10.1038/ng0693-181; BIRD AP, 1980, NUCLEIC ACIDS RES, V8, P1499, DOI 10.1093/nar/8.7.1499; CHELLAIAH AT, 1994, J BIOL CHEM, V269, P11620; DUNCAN BK, 1980, NATURE, V287, P560, DOI 10.1038/287560a0; EISEMANN A, 1991, ONCOGENE, V6, P1195; FRANCOMANO CA, 1994, HUM MOL GENET, V3, P787, DOI 10.1093/hmg/3.5.787; GAL A, 1994, NAT GENET, V7, P64, DOI 10.1038/ng0594-64; Gorlin RJ, 1990, PLAST RECONSTR SURG; GUSELLA JF, 1983, NATURE, V306, P234, DOI 10.1038/306234a0; HECHT JT, 1987, AM J HUM GENET, V41, P454; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; LEMERRER M, 1994, NAT GENET, V6, P318; LERMAN LS, 1987, METHOD ENZYMOL, V155, P482; Lyons Jones K., 1988, SMITHS RECOGNIZABLE; MACDONALD ME, 1991, SOMAT CELL MOLEC GEN, V17, P421, DOI 10.1007/BF01233067; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MYERS RM, 1987, METHOD ENZYMOL, V155, P501; OBERKLAID F, 1979, J MED GENET, V16, P140, DOI 10.1136/jmg.16.2.140; ORNITZ DM, 1992, J BIOL CHEM, V267, P16305; ORRURTREGER A, 1993, DEV BIOL, V158, P475, DOI 10.1006/dbio.1993.1205; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; PASQUALE EB, 1990, P NATL ACAD SCI USA, V87, P5812, DOI 10.1073/pnas.87.15.5812; PAULI RM, 1983, AM J MED GENET, V16, P459, DOI 10.1002/ajmg.1320160404; PETERS K, 1993, DEV BIOL, V155, P423, DOI 10.1006/dbio.1993.1040; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHEFFIELD VC, 1989, P NATL ACAD SCI USA, V86, P232, DOI 10.1073/pnas.86.1.232; SHIANG R, 1993, NAT GENET, V5, P351, DOI 10.1038/ng1293-351; STANESCU R, 1990, AM J MED GENET, V37, P412, DOI 10.1002/ajmg.1320370323; THOMPSON LM, 1991, GENOMICS, V11, P1133, DOI 10.1016/0888-7543(91)90041-C; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VELINOV M, 1994, NAT GENET, V6, P314, DOI 10.1038/ng0394-314; WEBER B, 1991, NUCLEIC ACIDS RES, V19, P6263, DOI 10.1093/nar/19.22.6263; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; ZUO JA, 1993, HUM MOL GENET, V2, P889, DOI 10.1093/hmg/2.7.889	39	964	1039	4	85	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 29	1994	78	2					335	342		10.1016/0092-8674(94)90302-6	http://dx.doi.org/10.1016/0092-8674(94)90302-6			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NZ242	7913883				2022-12-24	WOS:A1994NZ24200016
J	ROSEN, SD; PAULESU, E; FRITH, CD; FRACKOWIAK, RSJ; DAVIES, GJ; JONES, T; CAMICI, PG				ROSEN, SD; PAULESU, E; FRITH, CD; FRACKOWIAK, RSJ; DAVIES, GJ; JONES, T; CAMICI, PG			CENTRAL NERVOUS PATHWAYS MEDIATING ANGINA-PECTORIS	LANCET			English	Article							CORTEX; BRAIN; PAIN; LOCALIZATION; RAT	The central nervous pathways of angina pectoris have never been identified in vivo in man. We used positron emission tomography to examine the changes in regional cerebral blood flow associated with angina pectoris. Dynamic positron emission tomography with O-15-labelled water was used in 12 patients with angina and angiographically proven coronary artery disease to measure regional cerebral blood flow changes during angina induced by intravenous dobutamine. All subjects had typical retrosternal chest pain accompanied by ischaemic electrocardiographic changes during dobutamine infusion. Compared to the resting state, angina was associated with increased regional cerebral blood flow in the hypothalamus (percentage change in regional cerebral blood now +6.5 and Z score 7.2) periaquaductal grey (+2.6 and 4.0), bilaterally in the thalamus (left: +2.7 and 4.3; right + 3.7 and 4.7) and lateral prefrontal cortex (left +11.5 and 7.6; right +8.5 and 7.8) and left inferior anterocaudal cingulate cortex (+9.4 and 6.6). In contrast, it was reduced bilaterally in the mid-rostrocaudal cingulate cortex (left -3.7 and 6.3; right -4.7 and 4.6) and fusiform gyrus (left -3.2 and 4.0; right -3.3 and 3.7), right posterior cingulate (-3.9 and 5.8) and left parietal cortices(-4.8 and 6.3). Several minutes after stopping dobutamine infusion, when the patients no longer experienced angina and the electrocardiographic changes had resolved, thalamic, but not cortical activation could be seen. We propose that the central structures activated constitute the pathways for perception of anginal pain and that the thalamus may act as a gate to afferent pain signals, with cortical activation being necessary for the sensation of pain. This method of investigation may form a basis for research into anomalies of visceral pain perception such as silent myocardial ischaemia.	HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,LONDON W12 0HS,ENGLAND	Imperial College London	ROSEN, SD (corresponding author), MRC,CTR CLIN SCI,CYCLOTRON UNIT,LONDON W12 0HS,ENGLAND.		Frackowiak, Richard/H-4383-2011; Frith, Chris D/A-2171-2009; Rosen, Stuart/AAE-4649-2020; Camici, Paolo/AAN-1959-2020; Frackowiak, Richard S/I-1809-2013; PAULESU, ERALDO/C-2737-2017	Frackowiak, Richard/0000-0002-3151-822X; Frith, Chris D/0000-0002-8665-0690; Camici, Paolo/0000-0001-5584-0750; PAULESU, ERALDO/0000-0002-9224-754X				[Anonymous], 1993, NEUROBIOLOGY CINGULA; AVERSANO T, 1993, PAIN, V32, P93; CAMICI P, 1986, CIRCULATION, V74, P81, DOI 10.1161/01.CIR.74.1.81; FRANCOISFRANCK CA, 1899, B ACAD MED, V41, P565; FRISTON KJ, 1990, J CEREBR BLOOD F MET, V10, P458, DOI 10.1038/jcbfm.1990.88; FRISTON KJ, 1991, J CEREBR BLOOD F MET, V11, P690, DOI 10.1038/jcbfm.1991.122; FRISTON KJ, 1989, J CEREBR BLOOD F MET, V9, P690, DOI 10.1038/jcbfm.1989.97; GABRIEL M, 1991, EXP BRAIN RES, V86, P585; Heberden W., 1786, MED T COLL PHYSICIAN, V2, P59; Hill J A, 1986, Cardiol Clin, V4, P621; HURLEY KM, 1991, J COMP NEUROL, V308, P249, DOI 10.1002/cne.903080210; JONES AKP, 1991, P ROY SOC B-BIOL SCI, V244, P39, DOI 10.1098/rspb.1991.0048; Keefer CS, 1928, ARCH INTERN MED, V41, P769, DOI 10.1001/archinte.1928.00130180002001; MALLIANI A, 1989, TXB PAIN, P128; MALLIANI A, 1987, SILENT ISCHEMIA CURR, P19; MELLER ST, 1992, NEUROSCIENCE, V48, P501, DOI 10.1016/0306-4522(92)90398-L; MORECRAFT RJ, 1992, J COMP NEUROL, V323, P341, DOI 10.1002/cne.903230304; OPIE LH, 1991, DRUGS HEART, P14; Raichle M. E., 1987, HDB PHYSL NERVOUS SY, V1, P643; SPINKS TJ, 1992, PHYS MED BIOL, V37, P1637, DOI 10.1088/0031-9155/37/8/002; TAKAO Y, 1992, EUR J PHARMACOL, V215, P245, DOI 10.1016/0014-2999(92)90034-2; Talairach I., 1988, COPLANAR STEREOTACTI; TALBOT JD, 1991, SCIENCE, V251, P1355, DOI 10.1126/science.2003220; TERREBERRY RR, 1983, BRAIN RES, V278, P245, DOI 10.1016/0006-8993(83)90246-9; WHITE JC, 1957, CIRCULATION, V16, P644, DOI 10.1161/01.CIR.16.4.644	25	194	201	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 16	1994	344	8916					147	150		10.1016/S0140-6736(94)92755-3	http://dx.doi.org/10.1016/S0140-6736(94)92755-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW810	7912763				2022-12-24	WOS:A1994NW81000007
J	PALMER, JP				PALMER, JP			WHAT IS THE BEST WAY TO PREDICT IDDM	LANCET			English	Editorial Material							GLUTAMIC-ACID DECARBOXYLASE; INSULIN; RELATIVES; AUTOANTIBODIES; ASSAY		UNIV WASHINGTON,DEPT MED,SEATTLE,WA	University of Washington; University of Washington Seattle	PALMER, JP (corresponding author), VET AFFAIRS MED CTR,SEATTLE,WA 98108, USA.							ATKINSON MA, 1993, J CLIN INVEST, V91, P350, DOI 10.1172/JCI116192; BJORK E, 1994, DIABETES, V43, P161, DOI 10.2337/diabetes.43.1.161; GIANANI R, 1992, DIABETES, V41, P347, DOI 10.2337/diabetes.41.3.347; GREENBAUM CJ, 1992, J CLIN ENDOCR METAB, V74, P1040, DOI 10.1210/jc.74.5.1040; HAGOPIAN WA, 1993, J CLIN INVEST, V91, P368, DOI 10.1172/JCI116195; HARRISON LC, 1993, LANCET, V341, P1365, DOI 10.1016/0140-6736(93)90940-I; KRISCHER JP, 1993, J CLIN ENDOCR METAB, V77, P743, DOI 10.1210/jc.77.3.743; PALMER JP, 1993, DIABETES REV, V1, P104; ROBERT JJ, 1991, DIABETES CARE, V14, P718, DOI 10.2337/diacare.14.8.718	9	9	10	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 4	1994	343	8910					1377	1378		10.1016/S0140-6736(94)92519-4	http://dx.doi.org/10.1016/S0140-6736(94)92519-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NP955	7910879				2022-12-24	WOS:A1994NP95500005
J	HULL, HF; WARD, NA; HULL, BP; MILSTIEN, JB; DEQUADROS, C				HULL, HF; WARD, NA; HULL, BP; MILSTIEN, JB; DEQUADROS, C			PARALYTIC POLIOMYELITIS - SEASONED STRATEGIES, DISAPPEARING DISEASE	LANCET			English	Article							ORAL POLIO VACCINE; ERADICATION; EFFICACY; PROGRESS; COUNTRIES; BRAZIL	With more than 2 years having elapsed since the last case of paralytic poliomyelitis occurred in the Western Hemisphere, significant progress has been made towards the global eradication of wild polioviruses. Poliomyelitis is disappearing from Europe, North Africa, Southern Africa, the Middle East, China, and the Pacific. Reported poliomyelitis cases declined to 15 587 cases in 1992. Current eradication strategies recommended by the World Health Organization include national mass campaigns administering oral poliovaccine to all children under 5 years of age, enhanced surveillance to detect cases of acute flaccid paralysis, creating a network of laboratories for viral diagnosis, and targeted immunisation to areas and populations where poliovirus transmission is likely to persist. The major obstacles to eradication include inadequate political support for eradication and insufficient funding, especially for the purchase of vaccine. With additional support for the international eradication effort, epidemics of poliomyelitis will cease in developing countries, and industrialised countries will be able to save the large sums spent each year on poliovaccine and rehabilitation.	CTR DIS CONTROL & PREVENT, NATL IMMUNIZAT PROGRAM, ATLANTA, GA 30341 USA; WHO, BIOL UNIT, CH-1211 GENEVA, SWITZERLAND; PAN AMER HLTH ORG, EXPANDED PROGRAMME IMMUNIZAT, WASHINGTON, DC USA	Centers for Disease Control & Prevention - USA; World Health Organization; Pan American Health Organization	HULL, HF (corresponding author), WHO, EXPANDED PROGRAMME IMMUNIZAT, CH-1211 GENEVA 4, SWITZERLAND.							ANDRUS JK, 1992, B WORLD HEALTH ORGAN, V70, P591; [Anonymous], 1992, Wkly Epidemiol Rec, V67, P341; BIELLIK RJ, 1992, B WORLD HEALTH ORGAN, V70, P79; CHOPRA K, 1989, J TROP PEDIATRICS, V35, P19, DOI 10.1093/tropej/35.1.19; CRUZ RR, 1984, REV INFECT DIS, V6, pS408; DEMING MS, 1992, AM J EPIDEMIOL, V135, P393, DOI 10.1093/oxfordjournals.aje.a116300; DEQUADROS CA, 1991, PEDIATR INFECT DIS J, V10, P222, DOI 10.1097/00006454-199103000-00011; Expanded programme on immunization, 1993, WKLY EPIDEMIOL REC, V68, P297; FOX JP, 1984, REV INFECT DIS, V6, pS352; GEAR JHS, 1984, REV INFECT DIS, V6, pS379; JOHN TJ, 1976, BRIT MED J, V1, P812, DOI 10.1136/bmj.1.6013.812; LEMON SM, 1991, PROG MED VIROL, V38, P42; Mandke B V, 1990, Indian J Public Health, V34, P200; MCBEAN AM, 1988, AM J EPIDEMIOL, V128, P615, DOI 10.1093/oxfordjournals.aje.a115009; MELNICK JL, 1984, REV INFECT DIS, V6, pS387; MELNICK JL, 1992, EPIDEMIOL INFECT, V108, P1; MODLIN JF, 1991, PEDIATR INFECT DIS J, V10, P976, DOI 10.1097/00006454-199112000-00031; ONORATO IM, 1991, J INFECT DIS, V163, P1, DOI 10.1093/infdis/163.1.1; ORENSTEIN WA, 1985, B WORLD HEALTH ORGAN, V63, P1055; PATRIARCA PA, 1988, LANCET, V1, P429; PATRIARCA PA, 1993, LANCET, V342, P1461, DOI 10.1016/0140-6736(93)92936-N; PATRIARCA PA, 1991, REV INFECT DIS, V13, P926; PLOTKIN SA, 1991, PEDIATR INFECT DIS J, V10, P979, DOI 10.1097/00006454-199112000-00032; RICHARDSON G, 1993, RD P ICAAC WASH; RISI JB, 1984, REV INFECT DIS, V6, pS400; SABIN AB, 1980, B WORLD HEALTH ORGAN, V58, P141; SABIN AB, 1960, JAMA-J AM MED ASSOC, V173, P1521, DOI 10.1001/jama.1960.03020320001001; SATTAR SA, 1991, VIRUSES WASTEWATER T, P91; STREBEL PM, 1992, CLIN INFECT DIS, V14, P568, DOI 10.1093/clinids/14.2.568; SUTTER RW, 1991, LANCET, V338, P715, DOI 10.1016/0140-6736(91)91442-W; TULCHINSKY T, 1989, AM J PUBLIC HEALTH, V79, P1648, DOI 10.2105/AJPH.79.12.1648; 1984, 1984 BELL C NEW YORK; 1993, WKLY EPIDEMIOL REC, V68, P222; 1993, CAN COMMUN DIS REP, V19, P57; 1993, B PAHO, V27, P287; 1992, WKLY EPIDEMIOL REC, V67, P336	36	167	169	0	23	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 28	1994	343	8909					1331	1337		10.1016/S0140-6736(94)92472-4	http://dx.doi.org/10.1016/S0140-6736(94)92472-4			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NN217	7910329				2022-12-24	WOS:A1994NN21700015
J	KATAMINE, S; MORIUCHI, R; YAMAMOTO, T; TERADA, K; EGUCHI, K; TSUJI, Y; YAMABE, T; MIYAMOTO, T; HINO, S				KATAMINE, S; MORIUCHI, R; YAMAMOTO, T; TERADA, K; EGUCHI, K; TSUJI, Y; YAMABE, T; MIYAMOTO, T; HINO, S			HTLV-I PROVIRAL DNA IN UMBILICAL-CORD BLOOD OF BABIES BORN TO CARRIER MOTHERS	LANCET			English	Note							CELL LEUKEMIA-VIRUS; POLYMERASE CHAIN-REACTION; TO-CHILD TRANSMISSION; ANTIBODY; ANTIGEN; MILK	Human T-lymphotropic virus type I (HTLV-I) in cord blood raises the possibility of intrauterine transmission as an alternative pathway to transmission via breast milk. However, none of 7 children with HTLV-I proviral DNA positive cord blood had seroconverted by 24-48 months. Contamination of cord blood by maternal blood was precluded on the basis of viral load and IgA concentration. Thus cord blood proviral DNA is not a hallmark of intrauterine infection. Moreover, none of the cord blood samples of 9 formula-fed children later confirmed to be infected was positive for HTLV-I, indicating that intrauterine infection is not a likely candidate as an alternative pathway.	NAGASAKI UNIV,SCH MED,DEPT INTERNAL MED 1,NAGASAKI 852,JAPAN; NAGASAKI UNIV,SCH MED,DEPT PAEDIAT,NAGASAKI 852,JAPAN; NAGASAKI UNIV,SCH MED,DEPT OBSTET & GYNAECOL,NAGASAKI 852,JAPAN; TOTTORI UNIV,FAC MED,DEPT VIROL,YONAGO,TOTTORI 683,JAPAN	Nagasaki University; Nagasaki University; Nagasaki University; Tottori University	KATAMINE, S (corresponding author), NAGASAKI UNIV,SCH MED,DEPT BACTERIOL,1-12-4 SAKAMOTO,NAGASAKI 852,JAPAN.							HINO S, 1987, LANCET, V2, P158; HINO S, 1985, JPN J CANCER RES, V76, P474; KAWASE K, 1992, JPN J CANCER RES, V83, P968, DOI 10.1111/j.1349-7006.1992.tb02009.x; KUGA T, 1988, JPN J CANCER RES, V79, P1168, DOI 10.1111/j.1349-7006.1988.tb01541.x; OKOCHI K, 1984, VOX SANG, V46, P245, DOI 10.1111/j.1423-0410.1984.tb00083.x; SAITO S, 1990, JPN J CANCER RES, V81, P890, DOI 10.1111/j.1349-7006.1990.tb02663.x; SATOW YI, 1991, LANCET, V338, P915, DOI 10.1016/0140-6736(91)91775-P; TAKAHASHI K, 1991, INT J CANCER, V49, P673, DOI 10.1002/ijc.2910490508	8	22	22	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 28	1994	343	8909					1326	1327		10.1016/S0140-6736(94)92469-4	http://dx.doi.org/10.1016/S0140-6736(94)92469-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NN217	7910326				2022-12-24	WOS:A1994NN21700012
J	SHAH, NM; MARCHIONNI, MA; ISAACS, I; STROOBANT, P; ANDERSON, DJ				SHAH, NM; MARCHIONNI, MA; ISAACS, I; STROOBANT, P; ANDERSON, DJ			GLIAL GROWTH-FACTOR RESTRICTS MAMMALIAN NEURAL CREST STEM-CELLS TO A GLIAL FATE	CELL			English	Article							RAT SCHWANN-CELLS; NEURONAL DIFFERENTIATION; DORSAL-ROOT; COMMITMENT; LINEAGE; GLUCOCORTICOIDS; IDENTIFICATION; DERIVATIVES; POPULATIONS; SEGREGATION	Growth factors and cytokines are thought to influence the development of uncommitted progenitor cell populations, but the issue of how these factors act on individual cells remains controversial. Such factors may act simply as selective mitogens or survival factors for cells that undergo lineage restrictions stochastically. Alternatively, they may instruct or bias multipotent cells to choose one lineage at the expense of others. Here we show that glial growth factor (GGF), previously defined as a Schwann cell mitogen, strongly suppresses neuronal differentiation of rat neural crest stem cells while promoting or allowing glial differentiation. Quantitative clonal analysis suggests that the action of GGF is likely to be instructive rather than selective. Taken together with the expression pattern of GGF, these data suggest a lateral signaling model for the diversification of cell types within developing peripheral ganglia.	CAMBRIDGE NEUROSCI INC, CAMBRIDGE, MA 02139 USA; LUDWIG INST CANC RES, LONDON W1P 8BT, ENGLAND	Ludwig Institute for Cancer Research	SHAH, NM (corresponding author), CALTECH, HOWARD HUGHES MED INST, DIV BIOL 216-76, PASADENA, CA 91125 USA.							Anderson D J, 1993, Curr Opin Neurobiol, V3, P8, DOI 10.1016/0959-4388(93)90028-W; ANDERSON DJ, 1993, ANNU REV NEUROSCI, V16, P129, DOI 10.1146/annurev.ne.16.030193.001021; BAROFFIO A, 1992, J CELL SCI, V103, P581; CHANDLER CE, 1984, J BIOL CHEM, V259, P6882; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CIMENT G, 1990, COMMENTS DEV NEUROBI, V1, P207; DAVIS JB, 1990, J CELL BIOL, V110, P1353, DOI 10.1083/jcb.110.4.1353; DEXTER TM, 1990, PHILOS T ROY SOC B, V327, P85, DOI 10.1098/rstb.1990.0045; DOUPE AJ, 1985, J NEUROSCI, V5, P2143; DOUPE AJ, 1985, J NEUROSCI, V5, P2119; DUFF RS, 1991, DEV BIOL, V147, P451, DOI 10.1016/0012-1606(91)90303-K; FAIRBAIRN LJ, 1993, CELL, V74, P823, DOI 10.1016/0092-8674(93)90462-Y; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; FRANK E, 1991, DEVELOPMENT, V111, P895; FRASER SE, 1991, DEVELOPMENT, V112, P913; GHYSEN A, 1993, GENE DEV, V7, P723, DOI 10.1101/gad.7.5.723; GREENWALD IS, 1983, CELL, V34, P435, DOI 10.1016/0092-8674(83)90377-X; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; HILL RJ, 1992, NATURE, V358, P470, DOI 10.1038/358470a0; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HOLTON B, 1982, DEV BIOL, V89, P72, DOI 10.1016/0012-1606(82)90295-0; JESSELL TM, 1992, CELL, V68, P257, DOI 10.1016/0092-8674(92)90469-S; JESSEN KR, 1991, GLIA, V4, P185, DOI 10.1002/glia.440040210; JIN JJ, 1993, CELL GROWTH DIFFER, V4, P227; JOHNSON JE, 1990, NATURE, V346, P858, DOI 10.1038/346858a0; JOHNSON JE, 1992, P NATL ACAD SCI USA, V89, P3596, DOI 10.1073/pnas.89.8.3596; JUST U, 1991, CELL, V64, P1163, DOI 10.1016/0092-8674(91)90271-Y; Le Douarin N.M., 1982, NEURAL CREST; LEDOUARIN NM, 1986, SCIENCE, V231, P1515, DOI 10.1126/science.3952494; LEDOUARIN NM, 1993, DEV BIOL, V159, P24, DOI 10.1006/dbio.1993.1219; LEMKE GE, 1984, J NEUROSCI, V4, P75; LO LC, 1991, GENE DEV, V5, P1524, DOI 10.1101/gad.5.9.1524; LO LC, 1991, DEV BIOL, V145, P139, DOI 10.1016/0012-1606(91)90220-W; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; METCALF D, 1991, P NATL ACAD SCI USA, V88, P11310, DOI 10.1073/pnas.88.24.11310; METCALF D, 1980, P NATL ACAD SCI-BIOL, V77, P5327, DOI 10.1073/pnas.77.9.5327; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MEYER D, 1994, P NATL ACAD SCI USA, V91, P1064, DOI 10.1073/pnas.91.3.1064; NAWA H, 1990, COLD SH Q B, V55, P247; OGAWA M, 1993, BLOOD, V81, P2844; PATTERSON PH, 1977, DEV BIOL, V56, P263, DOI 10.1016/0012-1606(77)90269-X; PATTERSON PH, 1993, CELL, V72, P123, DOI 10.1016/S0092-8674(05)80032-7; PATTERSON PH, 1990, CELL, V62, P1035, DOI 10.1016/0092-8674(90)90379-S; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; RIDLEY AJ, 1989, J CELL BIOL, V109, P3419, DOI 10.1083/jcb.109.6.3419; ROBEY EA, 1991, CELL, V64, P99, DOI 10.1016/0092-8674(91)90212-H; SELLECK MAJ, 1993, DEV BIOL, V159, P1, DOI 10.1006/dbio.1993.1217; SIEBERBLUM M, 1991, NEURON, V6, P949, DOI 10.1016/0896-6273(91)90235-R; STEMPLE DL, 1988, NEURON, V1, P517, DOI 10.1016/0896-6273(88)90182-1; STEMPLE DL, 1993, DEV BIOL, V159, P12, DOI 10.1006/dbio.1993.1218; STEMPLE DL, 1992, CELL, V71, P973, DOI 10.1016/0092-8674(92)90393-Q; WEINMASTER G, 1991, DEVELOPMENT, V113, P199; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; WESTON JA, 1991, CURR TOP DEV BIOL, V25, P133; YAMAMORI T, 1989, SCIENCE, V246, P1412, DOI 10.1126/science.2512641	58	445	455	0	14	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 6	1994	77	3					349	360		10.1016/0092-8674(94)90150-3	http://dx.doi.org/10.1016/0092-8674(94)90150-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NK970	7910115				2022-12-24	WOS:A1994NK97000006
J	LIENS, D; DELMAS, PD; MEUNIER, PJ				LIENS, D; DELMAS, PD; MEUNIER, PJ			LONG-TERM EFFECTS OF INTRAVENOUS PAMIDRONATE IN FIBROUS DYSPLASIA OF BONE	LANCET			English	Note								Nine patients with symptomatic and severe fibrous dysplasia were treated with intravenous pamidronate (60 mg per day over 3 days every sixth month), and were followed up for 18-48 months. The major effect was decreased bone pain (complete remission in 12 of 14 sites). Radiological changes were seen in four patients, with thickening of cortices, refilling of osteolytic lesions, or both. The initial increased bone remodelling was reduced, as shown by decrease of raised serum alkaline phosphatase and urinary hydroxyproline. The treatment was well tolerated, but a 13-year-old patient showed widening of knee growth-plates which is consistent with a transient mineralisation defect.	HOP EDOUARD HERRIOT,INSERM,U403,PAVILLON F,F-69437 LYON,FRANCE	CHU Lyon; Institut National de la Sante et de la Recherche Medicale (Inserm)								ADAMSON BB, 1993, LANCET, V342, P1459, DOI 10.1016/0140-6736(93)92935-M; BELL NH, 1970, J CLIN ENDOCR METAB, V31, P283, DOI 10.1210/jcem-31-3-283; COLE DEC, 1983, AM J MED GENET, V14, P725, DOI 10.1002/ajmg.1320140414; Fleisch H, 1989, Recent Results Cancer Res, V116, P1; HJELMSTEDT A, 1979, ACTA ORTHOP SCAND, V50, P251, DOI 10.3109/17453677908989764; JIANG Y, 1993, CALCIF TISSUE INT S2, V52, pS44; LONG A, 1988, IRISH J MED SCI, V157, P229, DOI 10.1007/BF02949307; MORII H, 1971, ENDOCRINOL JAPON, V18, P81; YAMAMOTO K, 1983, ENDOCRINOL JAPON, V30, P651	9	156	160	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 16	1994	343	8903					953	954		10.1016/S0140-6736(94)90069-8	http://dx.doi.org/10.1016/S0140-6736(94)90069-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF700	7909013				2022-12-24	WOS:A1994NF70000013
J	MCNULTY, A; KALDOR, JM; MCDONALD, AM; BAUMGART, K; COOPER, DA				MCNULTY, A; KALDOR, JM; MCDONALD, AM; BAUMGART, K; COOPER, DA			ACQUIRED IMMUNODEFICIENCY WITHOUT EVIDENCE OF HIV-INFECTION - NATIONAL RETROSPECTIVE SURVEY	BRITISH MEDICAL JOURNAL			English	Article									UNIV NEW S WALES,NATL CTR HIV EPIDEMIOL & CLIN RES,SYDNEY,NSW,AUSTRALIA; UNIV SYDNEY,CENTENARY INST CANC MED & CELL BIOL,SYDNEY,NSW 2006,AUSTRALIA; TAYLOR SQ PRIVATE CLIN,DARLINGHURST,NSW,AUSTRALIA	University of New South Wales Sydney; Kirby Institute; University of Sydney; Centenary Institute			Kaldor, John M/D-4545-2011					GATENBY PA, 1989, LANCET, V1, P1027, DOI 10.1016/S0140-6736(89)92677-9; KALDOR J, 1993, MED J AUSTRALIA, V158, P10, DOI 10.5694/j.1326-5377.1993.tb121640.x; LAURENCE J, 1993, ANN INTERN MED, V119, P55, DOI 10.7326/0003-4819-119-1-199307010-00010; MULLER J, 1990, MYCOSES IN AIDS PATIENTS, P123; 1992, MMWR, V41, P541	5	16	16	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 26	1994	308	6932					825	826		10.1136/bmj.308.6932.825	http://dx.doi.org/10.1136/bmj.308.6932.825			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ND243	7909464	Green Published			2022-12-24	WOS:A1994ND24300024
J	BENDELAC, A; KILLEEN, N; LITTMAN, DR; SCHWARTZ, RH				BENDELAC, A; KILLEEN, N; LITTMAN, DR; SCHWARTZ, RH			A SUBSET OF CD4(+) THYMOCYTES SELECTED BY MHC CLASS-I MOLECULES	SCIENCE			English	Article							CD8+ T-CELLS; CYTOPLASMIC TAIL; BINDING-SITE; IMMATURE THYMOCYTES; THYMIC SELECTION; ALPHA-3 DOMAIN; DEFICIENT MICE; GENE FAMILY; LINEAGE; CD4+	To complete their maturation, most immature thymocytes depend on the simultaneous engagement of their antigen receptor [alpha beta T cell receptor (TCR)] and their CD4 or CD8 coreceptors with major histocompatibility complex class II or I ligands, respectively. However, a normal subset of mature alpha beta TCR(+) thymocytes did not follow these rules. These thymocytes expressed NK1.1 and a restricted set of alpha beta TCRs that are intrinsically class I-reactive because their positive selection was class I-dependent but CD8-independent. These cells were CD4(+) and CD4(-)8(-) but never CD8(+), because the presence of CD8 caused negative selection. Thus, neither CD4 nor CD8 contributes signals that direct their maturation into the CD4(+) and CD4(-)8(-) lineages.	UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	BENDELAC, A (corresponding author), NIAID,CELLULAR & MOLEC IMMUNOL LAB,BETHESDA,MD 20892, USA.							ARASE H, 1992, P NATL ACAD SCI USA, V89, P6506, DOI 10.1073/pnas.89.14.6506; AUPHAN N, 1992, INT IMMUNOL, V4, P1419, DOI 10.1093/intimm/4.12.1419; BENDELAC A, 1991, NATURE, V353, P68, DOI 10.1038/353068a0; BENDELAC A, 1992, J EXP MED, V175, P731, DOI 10.1084/jem.175.3.731; Bendelac A, 1992, Semin Immunol, V4, P187; BENDELAC A, UNPUB; BIKOFF EK, 1993, J EXP MED, V177, P1699, DOI 10.1084/jem.177.6.1699; BIX M, 1993, J EXP MED, V178, P901, DOI 10.1084/jem.178.3.901; BIX M, 1992, NATURE, V359, P330, DOI 10.1038/359330a0; BORGULYA P, 1991, EMBO J, V10, P913, DOI 10.1002/j.1460-2075.1991.tb08024.x; BUDD RC, 1987, J EXP MED, V166, P577, DOI 10.1084/jem.166.2.577; CAMMAROTA G, 1992, NATURE, V356, P799, DOI 10.1038/356799a0; CHAN IT, 1993, SCIENCE, V261, P1581, DOI 10.1126/science.8372352; CHAN SH, 1993, CELL, V73, P225, DOI 10.1016/0092-8674(93)90225-F; CONNOLLY JM, 1990, P NATL ACAD SCI USA, V87, P2137, DOI 10.1073/pnas.87.6.2137; COSGROVE D, 1991, CELL, V66, P1051, DOI 10.1016/0092-8674(91)90448-8; DAVIS CB, 1993, CELL, V73, P237, DOI 10.1016/0092-8674(93)90226-G; FISCHER M, 1991, J IMMUNOL, V146, P3452; FOWLKES BJ, 1987, NATURE, V329, P251, DOI 10.1038/329251a0; FUNGLEUNG WP, 1991, CELL, V65, P443, DOI 10.1016/0092-8674(91)90462-8; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; GRUSBY MJ, 1991, SCIENCE, V253, P1417, DOI 10.1126/science.1910207; HAYAKAWA K, 1992, J EXP MED, V176, P269, DOI 10.1084/jem.176.1.269; KARLHOFER FM, 1992, NATURE, V358, P66, DOI 10.1038/358066a0; KATIV I, 1993, J EXP MED, V177, P1429; KILLEEN N, 1993, NATURE, V364, P729, DOI 10.1038/364729a0; KILLEEN N, 1993, EMBO J, V12, P1547, DOI 10.1002/j.1460-2075.1993.tb05798.x; KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266; KONIG R, 1992, NATURE, V356, P796, DOI 10.1038/356796a0; KRUISBEEK AM, 1985, J EXP MED, V161, P1029, DOI 10.1084/jem.161.5.1029; LANTZ O, UNPUB; LEVITSKY HI, 1991, J IMMUNOL, V146, P1113; LOCKSLEY RM, 1993, SCIENCE, V261, P1448, DOI 10.1126/science.8367726; MARUSICGALESIC S, 1988, NATURE, V333, P180, DOI 10.1038/333180a0; MATZINGER P, 1993, IMMUNOL REV, V135, P81, DOI 10.1111/j.1600-065X.1993.tb00645.x; MICELI MC, 1991, P NATL ACAD SCI USA, V88, P2623, DOI 10.1073/pnas.88.7.2623; MOZES E, 1993, SCIENCE, V261, P91, DOI 10.1126/science.8316860; RAHEMTULLA A, 1991, NATURE, V353, P180, DOI 10.1038/353180a0; RAMSDELL F, 1989, J IMMUNOL, V143, P1467; RAPOPORT MJ, 1993, J EXP MED, V178, P87, DOI 10.1084/jem.178.1.87; ROBEY EA, 1991, CELL, V64, P99, DOI 10.1016/0092-8674(91)90212-H; SALTER RD, 1990, NATURE, V345, P41, DOI 10.1038/345041a0; SAWADA S, UNPUB; SEONG RH, 1992, NATURE, V356, P718, DOI 10.1038/356718a0; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; SYKES M, 1990, J IMMUNOL, V145, P3209; TAKAHAMA Y, 1992, SCIENCE, V258, P1456, DOI 10.1126/science.1439838; TAKAHAMA Y, 1991, J IMMUNOL, V147, P2883; TAKEDA K, 1993, J EXP MED, V177, P155, DOI 10.1084/jem.177.1.155; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VANMEERWIJK JPM, 1993, SCIENCE, V261, P911, DOI 10.1126/science.8102208; VIVILLE S, 1993, CELL, V72, P635, DOI 10.1016/0092-8674(93)90081-Z; VONBOEHMER H, 1991, J EXP MED, V176, P699; ZAMOYSKA R, 1989, NATURE, V342, P278, DOI 10.1038/342278a0; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0; ZUNIGAPFLUCKER JC, 1989, J EXP MED, V169, P2085, DOI 10.1084/jem.169.6.2085	56	461	461	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 25	1994	263	5154					1774	1778		10.1126/science.7907820	http://dx.doi.org/10.1126/science.7907820			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NC040	7907820				2022-12-24	WOS:A1994NC04000039
J	GERLACH, H; ROSSAINT, R; PAPPERT, D; KNORR, M; FALKE, KJ				GERLACH, H; ROSSAINT, R; PAPPERT, D; KNORR, M; FALKE, KJ			AUTOINHALATION OF NITRIC-OXIDE AFTER ENDOGENOUS SYNTHESIS IN NASOPHARYNX	LANCET			English	Note								Exogenous nitric oxide (NO) reduces pulmonary vascular resistance after low-dose inhalation in patients. To estimate endogenous NO synthesis in the upper respiratory tract, we measured inhaled and exhaled NO in volunteers and patients during spontaneous or controlled ventilation, respectively. 20.3 nmol per min NO was synthesised in the nasopharnyx of non-smoking volunteers, leading to autoinhalation of 0.07-0.13 NO parts per million during inspiration; smokers had reduced NO synthesis. In volunteers, 50-70% of the NO was resorbed by the lungs; ventilated patients were deprived of NO autoinhalation. Bacteria in the nose may take part in endogenous NO synthesis.			GERLACH, H (corresponding author), FREE UNIV BERLIN,CLIN RUDOLF VIRCHOW,ANAESTHESIOL & INTENS CARE MED CLIN,D-13353 BERLIN,GERMANY.		Knorr, Michael/Q-3109-2019					CANNONS AC, 1993, J BIOL CHEM, V268, P3268; GERLACH H, 1993, INTENS CARE MED, V19, P443, DOI 10.1007/BF01711084; GERLACH H, 1993, EUR J CLIN INVEST, V23, P499, DOI 10.1111/j.1365-2362.1993.tb00797.x; GUSTAFSSON LE, 1991, BIOCHEM BIOPH RES CO, V181, P852, DOI 10.1016/0006-291X(91)91268-H; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; ROSSAINT R, 1993, NEW ENGL J MED, V328, P399, DOI 10.1056/NEJM199302113280605; SUTTORP N, 1993, J EXP MED, V178, P337, DOI 10.1084/jem.178.1.337	7	221	225	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 26	1994	343	8896					518	519		10.1016/S0140-6736(94)91465-6	http://dx.doi.org/10.1016/S0140-6736(94)91465-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MX888	7906764				2022-12-24	WOS:A1994MX88800013
J	JAKEMAN, P; SMITH, WCS				JAKEMAN, P; SMITH, WCS			THALIDOMIDE IN LEPROSY REACTION	LANCET			English	Editorial Material											JAKEMAN, P (corresponding author), LEPROSY MISSION EVALUAT UNIT,SINGAPORE,SINGAPORE.							GHIGLIOTTI G, 1993, J AM ACAD DERMATOL, V28, P271, DOI 10.1016/S0190-9622(08)81153-X; GUTIERREZRODRIGUEZ O, 1989, J RHEUMATOL, V16, P158; HASTINGS R C, 1980, Ethiopian Medical Journal, V18, P65; Jadhav V H, 1990, Indian J Lepr, V62, P316; MAKONKAWKEYOON S, 1993, P NATL ACAD SCI USA, V90, P5974, DOI 10.1073/pnas.90.13.5974; REA TH, 1978, ARCH DERMATOL, V114, P1023, DOI 10.1001/archderm.114.7.1023; SAGHER F, 1969, LEPROSY REV, V40, P126; Sheskin J, 1975, Med Cutan Ibero Lat Am, V3, P81; SHESKIN J, 1968, ISRAEL J MED SCI, V4, P901; TAMURA F, 1990, TRANSPLANTATION, V49, P20, DOI 10.1097/00007890-199001000-00005; 1993, THALIDOMIDE DRUG CAM; 1988, WHO TECH REP SER, V768	12	28	28	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 19	1994	343	8895					432	433		10.1016/S0140-6736(94)92686-7	http://dx.doi.org/10.1016/S0140-6736(94)92686-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW690	7905950				2022-12-24	WOS:A1994MW69000004
J	BARR, CS; NAAS, A; FREEMAN, M; LANG, CC; STRUTHERS, AD				BARR, CS; NAAS, A; FREEMAN, M; LANG, CC; STRUTHERS, AD			QT DISPERSION AND SUDDEN UNEXPECTED DEATH IN CHRONIC HEART-FAILURE	LANCET			English	Article							PLASMA NOREPINEPHRINE; INTERVAL PROLONGATION; PROGNOSTIC IMPORTANCE; MORTALITY; PREDICTORS; RISK	Death in chronic heart failure (CHF) can be from progression of disease or sudden and unexpected. We have attempted to identify factors that predict sudden death in CHF. We followed up 44 patients with CHF for 12-50 (mean 36) months. 4 patients died of non-cardiovascular causes and were excluded from analysis. There were 7 sudden deaths (symptoms for less than 1 h in a previously stable patient) and 12 from progressive CHF. Patients who died of progressive CHF had lower left-ventricular ejection fractions and higher concentrations of atrial natriuretic factor than the 21 survivors, but there were no differences in these variables between survivors and those who died suddenly. However, the sudden death group had significantly (p<0.05) greater inter-lead variability in the QT interval on the electrocardiogram (QT dispersion; 98.6 [95% CI 79.1-118] ms1/2) than survivors (53.1 [41.9-64.3] ms1/2) or the group who died from progressive CHF (66.7 [51.8-81.6] ms%). QT dispersion is a marker of myocardial electrical instability. The association of increased QT dispersion with sudden death suggests that patients at high risk of such death could be identified by means of this simple, reproducible test. This group might benefit from more intensive treatment.			BARR, CS (corresponding author), UNIV DUNDEE,NINEWELLS HOSP & MED SCH,DEPT CLIN PHARMACOL,DUNDEE DD1 9SY,SCOTLAND.			Lang, Chim/0000-0002-4530-3078; Struthers, Allan/0000-0002-2926-2528				ALGRA A, 1991, CIRCULATION, V83, P1888, DOI 10.1161/01.CIR.83.6.1888; BUJA G, 1993, AM J CARDIOL, V72, P973, DOI 10.1016/0002-9149(93)91118-2; CLELAND JGF, 1987, BRIT HEART J, V58, P572; COHN JN, 1984, NEW ENGL J MED, V311, P819, DOI 10.1056/NEJM198409273111303; COHN JN, 1988, AM J CARDIOL, V62, pA25, DOI 10.1016/S0002-9149(88)80081-X; DAY CP, 1990, BRIT HEART J, V63, P342; DAY CP, 1993, LANCET, V341, P1423; FRANCIS GS, 1990, CARDIOSCIENCE, V1, P29; GOTTLIEB SS, 1990, J AM COLL CARDIOL, V16, P827, DOI 10.1016/S0735-1097(10)80329-8; GOTTLIEB SS, 1989, J AM COLL CARDIOL, V13, P1534, DOI 10.1016/0735-1097(89)90344-6; GRADMAN A, 1989, J AM COLL CARDIOL, V14, P564, DOI 10.1016/0735-1097(89)90093-4; Higham P. D., 1993, European Heart Journal, V14, P86; HINKLE LE, 1982, CIRCULATION, V65, P457, DOI 10.1161/01.CIR.65.3.457; HO KKL, 1993, J AM COLL CARDIOL, V22, pA6, DOI 10.1016/0735-1097(93)90455-A; MERX W, 1977, AM HEART J, V94, P603, DOI 10.1016/S0002-8703(77)80130-0; PACKER M, 1987, AM J MED, V82, P4, DOI 10.1016/0002-9343(87)90126-4; Potratz J., 1993, European Heart Journal, V14, P254; PUDDU PE, 1986, J ELECTROCARDIOL, V19, P203, DOI 10.1016/S0022-0736(86)80030-9; PUDDU PE, 1982, J ELECTROCARDIOL, V15, P15, DOI 10.1016/S0022-0736(82)80040-X; SCHOUTEN EG, 1991, CIRCULATION, V84, P1516, DOI 10.1161/01.CIR.84.4.1516; STEVENSON WG, 1988, AM HEART J, V116, P1447, DOI 10.1016/0002-8703(88)90727-2	21	641	646	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 5	1994	343	8893					327	329		10.1016/S0140-6736(94)91164-9	http://dx.doi.org/10.1016/S0140-6736(94)91164-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MU985	7905146				2022-12-24	WOS:A1994MU98500010
J	AYANIAN, JZ; HAUPTMAN, PJ; GUADAGNOLI, E; ANTMAN, EM; PASHOS, CL; MCNEIL, BJ				AYANIAN, JZ; HAUPTMAN, PJ; GUADAGNOLI, E; ANTMAN, EM; PASHOS, CL; MCNEIL, BJ			KNOWLEDGE AND PRACTICES OF GENERALIST AND SPECIALIST PHYSICIANS REGARDING DRUG-THERAPY FOR ACUTE MYOCARDIAL-INFARCTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RANDOMIZED CLINICAL-TRIALS; HEALTH-CARE REFORM; UNSTABLE ANGINA; MANAGEMENT; INFORMATION; SERVICES; DISSEMINATION; GUIDELINES; LIDOCAINE; PATTERNS	Background. The respective roles of generalist and specialist physicians in the care of patients are currently a matter of debate. Information is limited about the knowledge and practices of generalist and specialist physicians regarding conditions that both groups treat, such as myocardial infarction. Methods. We therefore surveyed 1211 cardiologists, internists, and family practitioners in the states of New York and Texas about four treatments demonstrated by randomized clinical trials to be associated with improved survival after myocardial infarction (thrombolytic therapy, immediate and long-term use of aspirin, and long-term use of beta-blockers) and two treatments for which such evidence is lacking (diltiazem for patients with pulmonary congestion and prophylactic lidocaine). We asked physicians about the effect of each treatment on survival and the likelihood that they would prescribe each class of drugs. Results. For the four beneficial treatments, the cardiologists believed more strongly than the internists and family physicians that survival was improved by the treatment, and they were more likely to prescribe these drugs (P<0.001). For example, 94.1 percent of cardiologists said they were very likely to prescribe thrombolytic agents to treat an acute myocardial infarction, as compared with 82.0 percent of internists and 77.3 percent of family practitioners. Conversely, for the two treatments for which trials showed no evidence of a survival benefit, cardiologists were less likely than internists and family practitioners to think there was such a benefit and less likely to prescribe the drugs (P<0.001). For example, 4.7 percent of cardiologists reported that they were very likely to use prophylactic lidocaine, as compared with 13.1 percent of internists, and 16.5 percent of family practitioners. When we used logistic regression to adjust for potential confounders, all the differences between the cardiologists and the internists and family practitioners remained significant (P<0.02). Conclusions. Internists and family practitioners are less aware of or less certain about key advances in the treatment of myocardial infarction than are cardiologists. This finding underscores the need to improve the dissemination of information from clinical trials to generalist physicians, particularly if they are to have an enlarged role in the evolving health care system.	BRIGHAM & WOMENS HOSP, DIV GEN MED, HLTH SERV & POLICY RES SECT, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT RADIOL, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT MED, DIV CARDIOVASC, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital	AYANIAN, JZ (corresponding author), HARVARD UNIV, SCH MED,DEPT HLTH CARE POLICY,25 SHATTUCK ST, PARCEL B, 1ST FL, BOSTON, MA 02115 USA.				AHRQ HHS [HS06341] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ADAY LA, 1989, DESIGNING CONDUCTING, P121; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, LANCET, V1, P397; [Anonymous], 1988, BRIT MED J, V296, P320; ANTMAN EM, 1992, JAMA-J AM MED ASSOC, V268, P240, DOI 10.1001/jama.268.2.240; BEHAR S, 1988, EUR HEART J, V9, P354; CHASSIN MR, 1987, JAMA-J AM MED ASSOC, V258, P2533, DOI 10.1001/jama.258.18.2533; COHEN JJ, 1993, NEW ENGL J MED, V329, P1810, DOI 10.1056/NEJM199312093292412; ELKHATIB A, 1993, CIRCULATION, V88, P608; FRANKS P, 1993, JAMA-J AM MED ASSOC, V270, P1449, DOI 10.1001/jama.270.12.1449; FRIEDMAN LM, 1982, JAMA-J AM MED ASSOC, V247, P1707; GRAVES EJ, 1993, DHHS PHS931250 NAT C; GRECO PJ, 1993, NEW ENGL J MED, V329, P1271, DOI 10.1056/NEJM199310213291714; Gunnar R M, 1990, Circulation, V82, P664; GUNNAR RM, 1990, J AM COLL CARDIOL, V16, P249, DOI 10.1016/0735-1097(90)90575-A; GURWITZ JH, 1992, AM J MED, V93, P605, DOI 10.1016/0002-9343(92)90192-E; HANSEN JF, 1984, EUR HEART J, V5, P516; HELD PH, 1989, BMJ-BRIT MED J, V299, P1187, DOI 10.1136/bmj.299.6709.1187; HINE LK, 1989, ARCH INTERN MED, V149, P2694, DOI 10.1001/archinte.149.12.2694; HLATKY MA, 1988, AM J CARDIOL, V61, P510, DOI 10.1016/0002-9149(88)90755-2; HLATKY MA, 1988, AM J CARDIOL, V61, P515, DOI 10.1016/0002-9149(88)90756-4; HUTCHISON SJ, 1987, BRIT MED J, V294, P1261, DOI 10.1136/bmj.294.6582.1261; KIMBALL HR, 1994, JAMA-J AM MED ASSOC, V271, P315, DOI 10.1001/jama.271.4.315; KINDIG DA, 1993, JAMA-J AM MED ASSOC, V270, P1069; LAMAS GA, 1992, NEW ENGL J MED, V327, P241, DOI 10.1056/NEJM199207233270405; LAU J, 1992, NEW ENGL J MED, V327, P248, DOI 10.1056/NEJM199207233270406; MACMAHON S, 1988, JAMA-J AM MED ASSOC, V260, P1910, DOI 10.1001/jama.260.13.1910; MITCHELL JRA, 1982, BRIT MED J, V285, P1140, DOI 10.1136/bmj.285.6349.1140; MOSS AJ, 1988, NEW ENGL J MED, V319, P385; NAYLOR CD, 1990, CAN MED ASSOC J, V142, P1069; PASHOS CL, 1994, J AM COLL CARDIOL, V23, P1023, DOI 10.1016/0735-1097(94)90585-1; PEDERSEN TR, 1981, NEW ENGL J MED, V304, P801; SOUMERAI SB, 1989, MILBANK Q, V67, P268, DOI 10.2307/3350142; STARFIELD B, 1993, JAMA-J AM MED ASSOC, V269, P3136, DOI 10.1001/jama.269.24.3136; STINSON ER, 1980, JAMA-J AM MED ASSOC, V243, P140, DOI 10.1001/jama.243.2.140; STROSS JK, 1979, JAMA-J AM MED ASSOC, V241, P2622, DOI 10.1001/jama.241.24.2622; STROSS JK, 1981, JAMA-J AM MED ASSOC, V246, P360, DOI 10.1001/jama.246.4.360; THOMPSON PL, 1992, MED J AUSTRALIA, V157, P87, DOI 10.5694/j.1326-5377.1992.tb137032.x; TOGNONI G, 1990, STAT MED, V9, P17, DOI 10.1002/sim.4780090108; WEINER JP, 1994, JAMA-J AM MED ASSOC, V272, P222; WENNBERG JE, 1987, LANCET, V1, P1185, DOI 10.1016/s0140-6736(87)92152-0; WENNBERG JE, 1993, HEALTH AFFAIR, V12, P89, DOI 10.1377/hlthaff.12.2.89; YOUNG MJ, 1987, HEALTH SERV RES, V22, P623; YUSUF S, 1988, JAMA-J AM MED ASSOC, V260, P2088, DOI 10.1001/jama.260.14.2088; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; 1993, PHYSICIAN CHARACTERI; 1990, SAS STAT USERS GUIDE; 1991, DHHS PHS911232 NAT C; 1993, STATISTICAL ABSTRACT, P33	49	340	340	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 27	1994	331	17					1136	1142		10.1056/NEJM199410273311707	http://dx.doi.org/10.1056/NEJM199410273311707			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN065	7935639				2022-12-24	WOS:A1994PN06500007
J	DOLLERY, CM; SULLIVAN, ID; BAURAIND, O; BULL, C; MILLA, PJ				DOLLERY, CM; SULLIVAN, ID; BAURAIND, O; BULL, C; MILLA, PJ			THROMBOSIS AND EMBOLISM IN LONG-TERM CENTRAL VENOUS ACCESS FOR PARENTERAL-NUTRITION	LANCET			English	Article							CATHETER; COMPLICATIONS; CHILDREN	Although the use of silicone catheters for long-term central venous access is widespread, little is known about the incidence of pulmonary thromboembolic complications. We studied clinical events, lung perfusion scans, and echocardiographic screens in 34 children and adolescents with gut failure who had received cyclical parenteral nutrition for 2 months to 9 years. Major thrombosis and/or embolism was identified in 12 patients and 4 died as a consequence. Actuarial survival free from thrombosis was 53% at 5 years (95% Cl, 30-77%). Survival free from fatal pulmonary thromboembolic events was 74% at 5 years (48-99%). 3 patients required surgery to remove right atrial thrombus or pulmonary emboli. Major right atrial thrombosis and pulmonary embolism are common and potentially fatal complications of parenteral nutrition by long-term venous access in childhood. Anticoagulation is recommended.	HOSP SICK CHILDREN,CARDIOTHORAC UNIT,LONDON WC1N 3JH,ENGLAND; HOSP SICK CHILDREN,GASTROENTEROL UNIT,LONDON WC1N 3JH,ENGLAND	University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust								BISSET WM, 1992, ARCH DIS CHILD, V67, P109, DOI 10.1136/adc.67.1.109; BRISMAR B, 1982, ARCH SURG-CHICAGO, V117, P1196; EMERY JL, 1961, SURGERY, V50, P309; LEIBY JM, 1989, AM J MED, V86, P228, DOI 10.1016/0002-9343(89)90276-3; MOUKARZEL A, 1991, JPEN-PARENTER ENTER, V15, P551, DOI 10.1177/0148607191015005551; MUGHAL MM, 1989, BRIT J SURG, V76, P15, DOI 10.1002/bjs.1800760107; RYAN JA, 1974, NEW ENGL J MED, V290, P757, DOI 10.1056/NEJM197404042901401; SCHMIDTSOMMERFELD E, 1990, JPEN-PARENTER ENTER, V14, P148, DOI 10.1177/0148607190014002148; SHIBA E, 1992, EUR J SURG, V158, P59	9	120	120	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 15	1994	344	8929					1043	1045		10.1016/S0140-6736(94)91707-8	http://dx.doi.org/10.1016/S0140-6736(94)91707-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL852	7934444				2022-12-24	WOS:A1994PL85200007
J	CROSS, CE; VANDERVLIET, A; ONEILL, CA; EISERICH, JP				CROSS, CE; VANDERVLIET, A; ONEILL, CA; EISERICH, JP			REACTIVE OXYGEN SPECIES AND THE LUNG	LANCET			English	Article							OXIDATIVE STRESS; RESPIRATORY-TRACT; INJURY; ACID; CELL; GLUTATHIONE; RECEPTORS; TOXICITY; DISEASE		UNIV CALIF DAVIS,DEPT INTERNAL MED,DAVIS,CA; UNIV CALIF DAVIS,DEPT HUMAN PHYSIOL,DAVIS,CA	University of California System; University of California Davis; University of California System; University of California Davis	CROSS, CE (corresponding author), UNIV CALIF DAVIS,DIV PULM CRIT CARE,PROFESS BLDG,4301 X ST,ROOM 2120,SACRAMENTO,CA 95817, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047628, T32HL007013] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL07013, HL47628] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADLER KB, 1990, J CLIN INVEST, V85, P75, DOI 10.1172/JCI114436; ALBELDA SM, 1994, FASEB J, V8, P504, DOI 10.1096/fasebj.8.8.8181668; ANGGARD E, 1994, LANCET, V343, P1199, DOI 10.1016/S0140-6736(94)92405-8; BALLA G, 1992, J BIOL CHEM, V267, P18148; BARNARD ML, 1993, AM J PHYSIOL, V265, pL340, DOI 10.1152/ajplung.1993.265.4.L340; BARNES PJ, 1990, FREE RADICAL BIO MED, V9, P235, DOI 10.1016/0891-5849(90)90034-G; BRITIGAN BE, 1991, J CLIN INVEST, V88, P1092, DOI 10.1172/JCI115408; BROWN LAS, 1994, AM J PHYSIOL, V266, pL172, DOI 10.1152/ajplung.1994.266.2.L172; BUCCA C, 1989, RESPIRATION, V55, P214, DOI 10.1159/000195737; BUHL R, 1994, CHEM-BIOL INTERACT, V91, P147, DOI 10.1016/0009-2797(94)90035-3; CLARK S, 1993, BIOCHEM J, V292, P217, DOI 10.1042/bj2920217; CLERCH LB, 1994, J CLIN INVEST, V93, P2482, DOI 10.1172/JCI117257; CROSS CE, IN PRESS ENV HLTH PE; CRYSTAL RG, 1991, AM J MED, V91, pS39, DOI 10.1016/0002-9343(91)90282-3; GARNIER P, 1994, AM J RESP CRIT CARE, V149, pA148; GHIO AJ, 1994, AM J PHYSIOL, V266, pL382, DOI 10.1152/ajplung.1994.266.4.L382; HALLIWELL B, 1992, J LAB CLIN MED, V119, P598; HOLROYD KJ, 1993, THORAX, V48, P985, DOI 10.1136/thx.48.10.985; JANSSEN YMW, 1993, LAB INVEST, V69, P261; KOOY NW, 1994, AM J RESP CRIT CARE, V149, pA814; LEWISMOLOCK Y, 1994, AM J RESP CELL MOL, V10, P133, DOI 10.1165/ajrcmb.10.2.8110468; MERCER RR, 1994, AM J RESP CELL MOL, V10, P613, DOI 10.1165/ajrcmb.10.6.8003339; MULLIGAN MS, 1991, P NATL ACAD SCI USA, V88, P6338, DOI 10.1073/pnas.88.14.6338; MUNDAY R, 1989, FREE RADICAL BIO MED, V7, P659, DOI 10.1016/0891-5849(89)90147-0; NATANSON C, 1994, ANN INTERN MED, V120, P771, DOI 10.7326/0003-4819-120-9-199405010-00009; ORRENIUS S, 1992, ANN NEUROL, V32, pS33, DOI 10.1002/ana.410320708; PEDEN DB, 1993, AM REV RESPIR DIS, V148, P455, DOI 10.1164/ajrccm/148.2.455; PRICE LT, 1993, PEDIATR RES, V34, P577, DOI 10.1203/00006450-199311000-00005; PRITCHARD RJ, 1994, AM J RESP CRIT CARE, V149, pA840; ROUM JH, 1993, J APPL PHYSIOL, V75, P2419, DOI 10.1152/jappl.1993.75.6.2419; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; SCHWARTZ J, 1994, AM J CLIN NUTR, V59, P110, DOI 10.1093/ajcn/59.1.110; SHI M, 1994, AM J RESPIR CRIT CAR, V149, pA569; SMITH LJ, 1993, AM REV RESPIR DIS, V147, P1461, DOI 10.1164/ajrccm/147.6_Pt_1.1461; STOCKER R, 1990, FREE RADICAL RES COM, V9, P101, DOI 10.3109/10715769009148577; VANDERVLIET A, 1992, CHEM-BIOL INTERACT, V85, P95, DOI 10.1016/0009-2797(92)90055-P; YOO JH, 1994, J CLIN INVEST, V93, P297, DOI 10.1172/JCI116959	38	102	105	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 1	1994	344	8927					930	933		10.1016/S0140-6736(94)92275-6	http://dx.doi.org/10.1016/S0140-6736(94)92275-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PJ287	7934352				2022-12-24	WOS:A1994PJ28700016
J	ROOKUS, MA; VANLEEUWEN, FE				ROOKUS, MA; VANLEEUWEN, FE			ORAL-CONTRACEPTIVES AND RISK OF BREAST-CANCER IN WOMEN AGED 20-54 YEARS	LANCET			English	Article							YOUNG-WOMEN; METAANALYSIS	Although the use of oral contraceptives (OCs) is not generally associated with increased risk of breast cancer, higher risks have been reported for some subgroups of users. We have carried out a population-based case-control study in the Netherlands to assess the effect of timing and duration of OC use on the risk of breast cancer developing at various ages. 918 women with breast cancer (20-54 years at diagnosis) were pair-matched by age with controls randomly selected from municipal registries. Information on OC use obtained from women and their prescribers was combined according to standard decision rules. Overall, long-term use of OCs (greater than or equal to 12 years) had an associated relative risk (RR) of 1.3 (95% CI 0.9-1.9; test for trend in risk with months of use p = 0.03). This positive trend was found in both the youngest (<36 years; p = 0.08) and the oldest (46-54 years, p = 0.004) age groups, but not in women aged 36-45 years. The RR of developing breast cancer before age 36 was 2.1 (1.0-4.5) for 4 or more years of OC use compared with shorter use. In women younger than 36, risk increased for longer OC use before age 20 (1.44 per year, p = 0.04). Recent use (previous 3 years) was associated with increased risk in women of 46-54 (RR 1.9 [0.9-4.1], p = 0.02). We conclude that 4 or more years of OC use, especially if partly before age 20, is associated with an increased risk of breast cancer developing at an early age. There is limited evidence that the excess risk disappears as the cohort of young OC users ages, but this issue needs confirmation.	NETHERLANDS CANC INST,DEPT EPIDEMIOL,1066 CX AMSTERDAM,NETHERLANDS	Netherlands Cancer Institute								BERNSTEIN L, 1990, ORAL CONTRACEPTIVES, P169; BRESLOW NE, 1980, STATISTICAL METHODS; DELGADORODRIGUEZ M, 1991, REV EPIDEMIOL SANTE, V39, P165; EWERTZ M, 1992, EUR J CANCER, V28A, P1176, DOI 10.1016/0959-8049(92)90481-G; KOLS A, 1982, POPULATION REP, V10, pA189; MALONE KE, 1993, EPIDEMIOL REV, V15, P80, DOI 10.1093/oxfordjournals.epirev.a036119; MCPHERSON K, 1986, J EPIDEMIOL COMMUN H, V40, P289, DOI 10.1136/jech.40.4.289; MCPHERSON K, 1987, BRIT J CANCER, V56, P653, DOI 10.1038/bjc.1987.261; MEIRIK O, 1986, LANCET, V2, P650; NISCHAN P, 1993, AM J EPIDEMIOL, V138, P697, DOI 10.1093/oxfordjournals.aje.a116907; PAUL C, 1990, INT J CANCER, V46, P366, DOI 10.1002/ijc.2910460305; PIKE MC, 1981, BRIT J CANCER, V43, P72, DOI 10.1038/bjc.1981.10; PIKE MC, 1983, LANCET, V2, P926; ROMIEU I, 1990, CANCER-AM CANCER SOC, V66, P2253, DOI 10.1002/1097-0142(19901201)66:11<2253::AID-CNCR2820661102>3.0.CO;2-G; ROMIEU I, 1989, JNCI-J NATL CANCER I, V81, P1313, DOI 10.1093/jnci/81.17.1313; RUSHTON L, 1992, BRIT J OBSTET GYNAEC, V99, P239, DOI 10.1111/j.1471-0528.1992.tb14506.x; SKEGG DCG, 1988, AM J EPIDEMIOL, V127, P205, DOI 10.1093/oxfordjournals.aje.a114796; STADEL BV, 1986, AM J EPIDEMIOL, V123, P373, DOI 10.1093/oxfordjournals.aje.a114252; THOMAS DB, 1991, CONTRACEPTION, V43, P597, DOI 10.1016/0010-7824(91)90006-2; THOMAS DB, 1992, BRIT J CANCER, V65, P108, DOI 10.1038/bjc.1992.20; THOMAS DB, 1991, CANCER CAUSE CONTROL, V2, P309; VANDERVANGE N, 1987, CONTEMP OBSTET GYNEC, P315; VANLEEUWEN FE, 1992, CONTRACEPTION, V45, P399, DOI 10.1016/0010-7824(92)90154-L; VESSEY MP, 1989, BRIT J CANCER, V59, P613, DOI 10.1038/bjc.1989.124; VESSEY MP, 1990, ORAL CONTRACEPTIVES, P121; WINGO PA, 1991, OBSTET GYNECOL, V78, P161; WINGO PA, 1990, ORAL CONTRACEPTIVES, P67; 1989, LANCET, V1, P973; 1987, TNM CLASSIFICATION M	29	91	92	0	10	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 24	1994	344	8926					844	851		10.1016/S0140-6736(94)92826-6	http://dx.doi.org/10.1016/S0140-6736(94)92826-6			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PH253	7916400				2022-12-24	WOS:A1994PH25300010
J	VANNIEKERK, ABW; VRIES, JB; BAARD, J; SCHOUB, BD; CHEZZI, C; BLACKBURN, NK				VANNIEKERK, ABW; VRIES, JB; BAARD, J; SCHOUB, BD; CHEZZI, C; BLACKBURN, NK			OUTBREAK OF PARALYTIC POLIOMYELITIS IN NAMIBIA	LANCET			English	Article							SOUTH-AFRICA; VACCINE; POLIOVIRUSES	The last confirmed case of poliomyelitis in Namibia had been reported in 1988. However, between Nov 8, 1993, and Jan 7, 1994, 27 cases of paralytic poliomyelitis were confirmed in the country. The outbreak was limited to the south health region; at least 80% of infants in this region have received four doses of oral poliovaccine (OPV) by the age of 1 year. Acute flaccid paralysis (AFP) was the predominant clinical presentation during the outbreak. The patients' ages ranged from 13 months to 12 years; 24 were younger than 5 years. Of the 26 patients whose vaccine status was known, 14 had received four doses of OPV, 6 had one or two doses, and 6 no vaccine. Genotypic analysis showed 86% homology of outbreak isolates with a 1982 Namibian isolate and west African isolates. Factors that may have had a role in the outbreak include establishment of a pool of susceptible people, rapid urbanisation, inadequate sanitation, poor water supply, and possible endemicity of poliovirus in neighbouring areas. Epidemics can occur in areas of high vaccine coverage. Our findings emphasise the need to improve AFP surveillance activities and the estimation of vaccine coverage to identify areas of potential susceptibility for outbreaks.	KATATURA HOSP,DEPT PAEDIAT,WINDHOEK,NAMIBIA; NAMIBIAN MINIST HLTH & SOCIAL SERV,WINDHOEK,NAMIBIA		VANNIEKERK, ABW (corresponding author), NATL INST VIROL,PRIVATE BAG X4,JOHANNESBURG 2131,SOUTH AFRICA.							HESSE RR, 1987, VIROLOGY, V160, P311; JOHNSON S, 1984, T ROY SOC TROP MED H, V78, P26, DOI 10.1016/0035-9203(84)90166-4; KIMFARLEY RJ, 1984, LANCET, V2, P1322; NOTTAY BK, 1981, VIROLOGY, V108, P405, DOI 10.1016/0042-6822(81)90448-7; OTTEN MW, 1992, AM J EPIDEMIOL, V135, P381, DOI 10.1093/oxfordjournals.aje.a116299; PATRIARCA PA, 1991, REV INFECT DIS, V13, P926; SCHOUB BD, 1992, T ROY SOC TROP MED H, V86, P83, DOI 10.1016/0035-9203(92)90453-J; SCHOUB BD, 1988, J INFECT DIS, V157, P836, DOI 10.1093/infdis/157.4.836; SLATER PE, 1990, LANCET, V335, P1192, DOI 10.1016/0140-6736(90)92705-M; SUTTER RW, 1991, LANCET, V338, P715, DOI 10.1016/0140-6736(91)91442-W; YANG CF, 1991, VIRUS RES, V20, P159; 1991, EPI NEWSLETTER, V13, P5; 1992, WEEKLY EPIDEMIOL REC, V67, P113; 1993, WEEKLY EPIDEMIOL REC, V68, P225; 1992, WEEKLY EPIDEMIOL REC, V67, P325; 1989, MANUAL MANAGERS IMMU; 1991, WEEKLY EPIDEMIOL REC, V66, P49; 1988, WEEKLY EPIDEMIOL REC, V63, P161	18	34	35	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 3	1994	344	8923					661	664		10.1016/S0140-6736(94)92090-7	http://dx.doi.org/10.1016/S0140-6736(94)92090-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PE386	7915353				2022-12-24	WOS:A1994PE38600015
J	MOYA, C; ANTO, JM; TAYLOR, AJN; COSTA, A; FENOLLAR, J; MAYORDOMO, C; DOMENECH, E; MITJANS, L; VANACLOCHA, H; MARTI, JV; SALAS, D; SANTOLARIA, E; VILLANUEVA, V; GOBERNA, R; MORELL, F; PARKER, JB; POZO, F; SUNYER, J; GIL, J; HERNANDEZ, L; MARTIN, C; ROMERO, S; ARANDA, I; ANDREO, L; SOLE, A; VILAR, JL; CORRIN, B				MOYA, C; ANTO, JM; TAYLOR, AJN; COSTA, A; FENOLLAR, J; MAYORDOMO, C; DOMENECH, E; MITJANS, L; VANACLOCHA, H; MARTI, JV; SALAS, D; SANTOLARIA, E; VILLANUEVA, V; GOBERNA, R; MORELL, F; PARKER, JB; POZO, F; SUNYER, J; GIL, J; HERNANDEZ, L; MARTIN, C; ROMERO, S; ARANDA, I; ANDREO, L; SOLE, A; VILAR, JL; CORRIN, B			OUTBREAK OF ORGANIZING PNEUMONIA IN TEXTILE PRINTING SPRAYERS	LANCET			English	Article							ORGANIZING PNEUMONIA	Eight textile printing factories in Valencia, Spain, with a total workforce of 257 using spraying techniques were investigated as a result of severe interstitial lung disease occurring in three employees, one of whom died. Clinical and radiological data together with biopsy from 71 (27.6%) workers with abnormal respiratory features indicated the occurrence of an outbreak of organising pneumonia resulting in 6 deaths. Epidemiological analysis included the 22 workers who fulfilled the radiological case definition based on chest radiograph and computed tomographic scan showing widespread nodular opacities or confluent patchy consolidation with a lung biopsy corresponding to organising pneumonia. The overall attach rate was 8.9%. Only 2 of the 22 cases never worked in factories A or B. Those who had only worked in factory A had the highest risk of being a case (RR = 24.3; 95% CI = 5.7 - 104.4). The relationship of case status to period of employment suggested an abrupt change in exposure conditions in the period when Acramin FWR was substituted by Acramin FWN. Although the precise toxicological mechanism is unknown, it is proposed that the lung disease was caused by spraying procedures delivered a respirable aerosol of Acramin FWN to distal airways and pulmonary parenchyma.	UNIV AUTONOMA BARCELONA,INST MUNICIPAL INVEST MED,DEPT EPIDEMIOL & PUBL HLTH,E-08003 BARCELONA,SPAIN; NATL HEART & LUNG INST,DEPT OCCUPAT & ENVIRONM MED,LONDON,ENGLAND; GEN VALENCLANA,CONSELLERIA SANIATAT & CONSUM,AREA SALUD ALCOI,VALENCIA,SPAIN; GEN VALENCLANA,CONSELLERIA SANIATAT & CONSUM,SERV EPIDEMIOL,VALENCIA,SPAIN; GEN VALENCLANA,CONSELLERIA SANIATAT & CONSUM,SERV PROGRAMMAS ESPECIALES,UNIDAD SALUD LABORAL,VALENCIA,SPAIN; GEN VALENCLANA,CONSELLERIA SANIATAT & CONSUM,DIRECCIO GEN SALUT PUBL,VALENCIA,SPAIN; GEN VALENCLANA,CONSELLERIA SANIATAT & CONSUM,SERV SEGURIDAD & HIGIENE,VALENCIA,SPAIN; HOSP GEN VALLE HEBRON,SERV PNEUMOL,BARCELONA,SPAIN; NIOSH,DIV RESP DIS STUDIES,CINCINNATI,OH; MINIST SANIDAD & CONSUMO,DIRECC GEN ORDENAC INVEST & FORMAC,MADRID,SPAIN; HOSP GEN ALICANTE,SECC NEUMOL,ALACANT,SPAIN; HOSP GEN ALICANTE,SERV ANAT PATOL,ALACANT,SPAIN; HOSP GEN ALICANTE,SERV IMMUNOL,ALACANT,SPAIN; HOSP VIRGEN LIRIOS,MED INTERNA SERV,ALACANT,SPAIN; HOSP VIRGEN LIRIOS,SERV RADIOL,ALACANT,SPAIN; HOSP LA FE,SERV NEUMOL,E-46009 VALENCIA,SPAIN; HOSP DR PESET,SERV RADIOL,VALENCIA,SPAIN; ROYAL BROMPTON NATL HEART & LUNG HOSP,DEPT LUNG PATHOL,LONDON SW3 6NP,ENGLAND	Autonomous University of Barcelona; Imperial College London; Hospital Universitari Vall d'Hebron; Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH); General University Hospital of Alicante; General University Hospital of Alicante; General University Hospital of Alicante; Hospital Universitari i Politecnic La Fe; Imperial College London			Sunyer, Jordi/G-6909-2014; Aranda, F. Ignacio/H-5029-2011; ARANDA, FRANCISCO I/L-5525-2015; Anto, J M/H-2676-2014	Sunyer, Jordi/0000-0002-2602-4110; Aranda, F. Ignacio/0000-0003-2338-2286; ARANDA, FRANCISCO I/0000-0003-2338-2286; Anto, J M/0000-0002-4736-8529				BRESLOW N, 1980, INT AGENCY RES CANCE, V32, P299; DAVISON AG, 1983, Q J MED, V52, P382; EPLER GR, 1992, CHEST, V102, pS2, DOI 10.1378/chest.102.1_Supplement.2S; EPLER GR, 1985, NEW ENGL J MED, V312, P152, DOI 10.1056/NEJM198501173120304; KHAN H, 1989, STATISTICAL METHODS; SANZ P, 1993, LANCET, V342, P240, DOI 10.1016/0140-6736(93)92330-V; SPITERI MA, 1992, LANCET, V340, P281, DOI 10.1016/0140-6736(92)92366-N; 1992, MMWR-MORBID MORTAL W, V41, P965; 1993, MMWR-MORBID MORTAL W, V42, P885	9	53	54	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 20	1994	344	8921					498	502		10.1016/S0140-6736(94)91896-1	http://dx.doi.org/10.1016/S0140-6736(94)91896-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PC535	7914612				2022-12-24	WOS:A1994PC53500007
J	SNOW, R; HAJRI, S; MASSAI, R; LI, XF				SNOW, R; HAJRI, S; MASSAI, R; LI, XF			CONCERNED ABOUT REPRODUCTIVE HEALTH - STRENGTHEN THE HRP	LANCET			English	Editorial Material									CTR RECH REPROD HUMAINE,TUNIS 2080,TUNISIA; INST CHILENO MED REPROD,SANTIAGO,CHILE; FAMILY PLANNING RES INST ZHEJIANG,HANGZHOU,PEOPLES R CHINA		SNOW, R (corresponding author), HARVARD UNIV,SCH PUBL HLTH,DEPT POPULAT & INT HLTH,BOSTON,MA 02115, USA.							Alexander N, 1992, STEROID HORMONES UTE; ELIAS CJ, 1993, 6 POP COUNC PROGR DI; Germaine A, 1994, POPULATION POLICIES, P27; MAULDIN WP, 1988, STUD FAMILY PLANN, V19, P335, DOI 10.2307/1966628; RICHTER J, 1994, POWER DECISION SOCIA, P205; Sen Gita, 1994, POPULATION POLICIES; TRUSSELL J, 1987, STUD FAMILY PLANN, V18, P237, DOI 10.2307/1966856; 1994, 3 INT C POP DEV PREP	8	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 13	1994	344	8920					459	460		10.1016/S0140-6736(94)91777-9	http://dx.doi.org/10.1016/S0140-6736(94)91777-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PB761	7914571				2022-12-24	WOS:A1994PB76100017
J	TRIOZZI, PL				TRIOZZI, PL			AUTOLOGOUS BONE-MARROW AND PERIPHERAL-BLOOD PROGENITOR TRANSPLANT FOR BREAST-CANCER	LANCET			English	Editorial Material							HIGH-DOSE CHEMOTHERAPY; SUPPORT; THERAPY				TRIOZZI, PL (corresponding author), OHIO STATE UNIV,CTR COMPREHENS CANC,COLUMBUS,OH 43210, USA.							ANTMAN K, 1992, J CLIN ONCOL, V10, P102, DOI 10.1200/JCO.1992.10.1.102; COIFFIER B, 1994, J CLIN ONCOL, V12, P226, DOI 10.1200/JCO.1994.12.1.226; DAVIDSON NE, 1992, J CLIN ONCOL, V10, P517, DOI 10.1200/JCO.1992.10.4.517; ECKHOLM E, 1993, NY TIMES        1230, pA12; ECKHOLM E, 1993, NEW YORK TIMES  0920, pA1; EDDY DM, 1992, J CLIN ONCOL, V10, P657, DOI 10.1200/JCO.1992.10.4.657; FREI E, 1989, J CLIN ONCOL, V7, P515, DOI 10.1200/JCO.1989.7.4.515; HENDERSON IC, 1988, J CLIN ONCOL, V6, P1501, DOI 10.1200/JCO.1988.6.9.1501; HRYNIUK WM, 1987, SEMIN ONCOL, V14, P65; NEIDHART JA, 1991, BREAST CANCER RES TR, V20, pS15, DOI 10.1007/BF01908240; PETERS WP, 1993, J CLIN ONCOL, V11, P1132, DOI 10.1200/JCO.1993.11.6.1132; 1993, AUTOLOGOUS BONE MARR; 1992, LANCET, V339, P71	13	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 13	1994	344	8920					418	419		10.1016/S0140-6736(94)91762-0	http://dx.doi.org/10.1016/S0140-6736(94)91762-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB761	7914559				2022-12-24	WOS:A1994PB76100002
J	RUETZ, S; GROS, P				RUETZ, S; GROS, P			PHOSPHATIDYLCHOLINE TRANSLOCASE - A PHYSIOLOGICAL-ROLE FOR THE MDR2 GENE	CELL			English	Article							MULTIDRUG-RESISTANCE GENE; EXCHANGING HOMOLOGOUS DOMAINS; PRODUCT P-GLYCOPROTEIN; PLASMA-MEMBRANE; MONOCLONAL-ANTIBODIES; CANALICULAR MEMBRANE; TRANSMEMBRANE DOMAIN; FUNCTIONAL-ANALYSIS; COMPLEMENTARY-DNA; SENSITIVE METHOD	P-glycoproteins (P-gps) encoded by the mouse mdr2 and mdr3 genes were expressed in secretory vesicles (SVs) from the yeast mutant sec6-4, and their capacity to function as a lipid translocase/flippase was tested. An assay that uses a fluorescent phosphatidylcholine (PC) analog was developed to quantitate asymmetric lipid distribution in the outer and inner leaflets of the lipid bilayer of these vesicles. Mdr2 expression in SVs caused a time- and temperature-dependent enhancement of PC translocation to the inner leaflet of the membrane. The Mdr2-mediated effect was specific since expression of Mdr3 in these vesicles was without effect on the membrane distribution of PC. Increased Mdr2-mediated PC translocation was strictly ATP and Mg2+ dependent, was abrogated by the ATPase inhibitor vanadate and the P-gp modulator verapamil, but was insensitive to the presence of excess of the multidrug resistance drugs colchicine and vinblastine.			RUETZ, S (corresponding author), MCGILL UNIV,DEPT BIOCHEM,3655 DRUMMOND ST,MONTREAL H3G 1Y6,PQ,CANADA.							ABRAHAM EH, 1993, P NATL ACAD SCI USA, V90, P312, DOI 10.1073/pnas.90.1.312; ARCECI RJ, 1988, P NATL ACAD SCI USA, V85, P4350, DOI 10.1073/pnas.85.12.4350; BERR F, 1993, J BIOL CHEM, V268, P3976; BISHOP WR, 1985, CELL, V42, P51, DOI 10.1016/S0092-8674(85)80100-8; BOYER JL, 1992, ANNU REV PHYSIOL, V54, P415, DOI 10.1146/annurev.ph.54.030192.002215; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUGGEMANN EP, 1992, J BIOL CHEM, V267, P21020; BUSCHMAN E, 1991, MOL CELL BIOL, V11, P595, DOI 10.1128/MCB.11.2.595; BUSCHMAN E, 1992, J BIOL CHEM, V267, P18093; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; COLEMAN R, 1987, BIOCHEM J, V244, P249, DOI 10.1042/bj2440249; CORDONCARDO C, 1990, J HISTOCHEM CYTOCHEM, V38, P1277, DOI 10.1177/38.9.1974900; DEVAULT A, 1990, MOL CELL BIOL, V10, P1652, DOI 10.1128/MCB.10.4.1652; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; DEVINE SE, 1992, P NATL ACAD SCI USA, V89, P4564, DOI 10.1073/pnas.89.10.4564; DHIR R, 1992, BIOCHEMISTRY-US, V31, P6103, DOI 10.1021/bi00141a021; FOJO AT, 1987, P NATL ACAD SCI USA, V84, P265, DOI 10.1073/pnas.84.1.265; FOOTE SJ, 1989, CELL, V57, P921, DOI 10.1016/0092-8674(89)90330-9; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GREENBERGER LM, 1993, J BIOL CHEM, V268, P11417; Gros P, 1993, Int Rev Cytol, V137C, P169; GROS P, 1986, NATURE, V323, P728, DOI 10.1038/323728a0; GROS P, 1991, P NATL ACAD SCI USA, V88, P7289, DOI 10.1073/pnas.88.16.7289; GROS P, 1988, MOL CELL BIOL, V8, P2770, DOI 10.1128/MCB.8.7.2770; HIGGINS CF, 1992, TRENDS BIOCHEM SCI, V17, P18, DOI 10.1016/0968-0004(92)90419-A; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cellbio.8.1.67; HIGGINS CF, 1994, CURR BIOL, V4, P259, DOI 10.1016/S0960-9822(00)00059-2; HSU SIH, 1990, MOL CELL BIOL, V10, P3596, DOI 10.1128/MCB.10.7.3596; JULIANO RL, 1976, BIOCHIM BIOPHYS ACTA, V455, P152, DOI 10.1016/0005-2736(76)90160-7; KAMIMOTO Y, 1989, J BIOL CHEM, V264, P11693; KREMER JMH, 1977, BIOCHEMISTRY-US, V16, P3932, DOI 10.1021/bi00636a033; LEE TW, 1993, J BIOL CHEM, V268, P3143; LOO TW, 1993, J BIOL CHEM, V268, P19965; LOWRY RR, 1974, LIPIDS, V9, P491, DOI 10.1007/BF02534277; MCGRATH JP, 1989, NATURE, V340, P400, DOI 10.1038/340400a0; MCINTYRE JC, 1991, BIOCHEMISTRY-US, V30, P11819, DOI 10.1021/bi00115a012; NAKAMOTO RK, 1991, J BIOL CHEM, V266, P7940; NICHOLS JW, 1988, BIOCHEMISTRY-US, V27, P1889, DOI 10.1021/bi00406a014; OLSON P, 1979, BIOCHIM BIOPHYS ACTA, V455, P12; RAYMOND M, 1992, SCIENCE, V256, P232, DOI 10.1126/science.1348873; RAYMOND M, 1990, MOL CELL BIOL, V10, P1642, DOI 10.1128/MCB.10.4.1642; RAYMOND M, 1994, MOL CELL BIOL, V14, P277, DOI 10.1128/MCB.14.1.277; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROEPE PD, 1993, BIOCHEMISTRY-US, V32, P11042, DOI 10.1021/bi00092a014; RUETZ S, 1993, P NATL ACAD SCI USA, V90, P11588, DOI 10.1073/pnas.90.24.11588; RUETZ S, 1994, J BIOL CHEM, V269, P12277; SCHINKEL AH, 1991, CANCER RES, V51, P2628; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735; UEDA K, 1987, P NATL ACAD SCI USA, V84, P3004, DOI 10.1073/pnas.84.9.3004; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; VANDERBLIEK AM, 1988, GENE, V71, P401, DOI 10.1016/0378-1119(88)90057-1; VANDERVALK P, 1990, ANN ONCOL, V1, P56; WALSORTH NC, 1987, J CELL BIOL, V105, P163; YOSHIMURA A, 1989, J BIOL CHEM, V264, P16282; YUSA K, 1989, CANCER RES, V49, P5002	56	549	562	0	20	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 1	1994	77	7					1071	1081		10.1016/0092-8674(94)90446-4	http://dx.doi.org/10.1016/0092-8674(94)90446-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NV425	7912658				2022-12-24	WOS:A1994NV42500015
J	EITAN, S; SOLOMON, A; LAVIE, V; YOLES, E; HIRSCHBERG, DL; BELKIN, M; SCHWARTZ, M				EITAN, S; SOLOMON, A; LAVIE, V; YOLES, E; HIRSCHBERG, DL; BELKIN, M; SCHWARTZ, M			RECOVERY OF VISUAL RESPONSE OF INJURED ADULT-RAT OPTIC NERVES TREATED WITH TRANSGLUTAMINASE	SCIENCE			English	Article							CENTRAL-NERVOUS-SYSTEM; AXONAL REGENERATION; NEURITE GROWTH; OLIGODENDROCYTES; MYELIN	Failure of axons of the central nervous system in adult mammals to regenerate spontaneously after injury is attributed in part to inhibitory molecules associated with oligodendrocytes. Regeneration of central nervous system axons in fish is correlated with the presence of a transglutaminase. This enzyme dimerizes interleukin-2, and the product is cytotoxic to oligodendrocytes in vitro. Application of this nerve-derived transglutaminase to rat optic nerves, in which the injury had caused the loss of visual evoked potential response to light, promoted the recovery of that response within 6 weeks after injury. Transmission electron microscopy analysis revealed the concomitant appearance of axons in the distal stump of the optic nerve.	WEIZMANN INST SCI,DEPT NEUROBIOL,IL-76100 REHOVOT,ISRAEL; TEL AVIV UNIV,SACKLER FAC MED,CHAIM SHEBA MED CTR,GOLDSCHLEGER EYE INST,TEL HASHOMER,ISRAEL	Weizmann Institute of Science; Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine			Belkin, Michael/AAK-4728-2020; Solomon, Arieh/AAF-4361-2021					AGUAYO AJ, 1990, J EXP BIOL, V153, P199; ASSIA E, 1989, BRAIN RES, V476, P205, DOI 10.1016/0006-8993(89)91240-7; BANDTLOW CE, 1993, SCIENCE, V259, P80, DOI 10.1126/science.8418499; CAJAL SRY, 1954, DEGENERATION REGENER, V1; DAVID S, 1990, NEURON, V5, P463, DOI 10.1016/0896-6273(90)90085-T; DORFMAN LJ, 1987, NEUROLOGY, V37, P123, DOI 10.1212/WNL.37.1.123; EITAN S, 1992, P NATL ACAD SCI USA, V89, P5442, DOI 10.1073/pnas.89.12.5442; EITAN S, 1993, SCIENCE, V261, P106, DOI 10.1126/science.8100369; EIZENBERG O, UNPUB; FACCHIANO F, 1993, TRENDS BIOCHEM SCI, V18, P327, DOI 10.1016/0968-0004(93)90066-V; FOLK JE, 1980, ANNU REV BIOCHEM, V49, P517, DOI 10.1146/annurev.bi.49.070180.002505; GRAFSTEIN B, 1982, EXP NEUROL, V76, P318, DOI 10.1016/0014-4886(82)90212-6; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; KEIRSTEAD SA, 1989, SCIENCE, V246, P255, DOI 10.1126/science.2799387; KIERNAN JA, 1979, BIOL REV, V54, P155, DOI 10.1111/j.1469-185X.1979.tb00871.x; LAVIE V, 1990, J COMP NEUROL, V298, P293, DOI 10.1002/cne.902980304; RICHARDSON PM, 1982, J NEUROCYTOL, V11, P949, DOI 10.1007/BF01148310; SCHNELL L, 1990, NATURE, V343, P269, DOI 10.1038/343269a0; SCHWAB ME, 1988, J NEUROSCI, V8, P2381; SCHWAB ME, 1985, J NEUROSCI, V5, P2415; SCHWARTZ M, 1985, SCIENCE, V228, P600, DOI 10.1126/science.3983646; SIVRON T, 1994, J COMP NEUROL, V343, P237, DOI 10.1002/cne.903430205; SO KF, 1985, BRAIN RES, V328, P349, DOI 10.1016/0006-8993(85)91047-9	23	111	115	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 17	1994	264	5166					1764	1768		10.1126/science.7911602	http://dx.doi.org/10.1126/science.7911602			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NR600	7911602				2022-12-24	WOS:A1994NR60000044
J	LUCAS, SB; DECOCK, KM; HOUNNOU, A; PEACOCK, C; DIOMANDE, M; HONDE, M; BEAUMEL, A; KESTENS, L; KADIO, A				LUCAS, SB; DECOCK, KM; HOUNNOU, A; PEACOCK, C; DIOMANDE, M; HONDE, M; BEAUMEL, A; KESTENS, L; KADIO, A			CONTRIBUTION OF TUBERCULOSIS TO SLIM DISEASE IN AFRICA	BRITISH MEDICAL JOURNAL			English	Article							AIDS; HIV; UGANDA; INFECTIONS; DIARRHEA	Objectives-To assess the contribution of tuberculosis to the aetiology of the HIV wasting syndrome (slim) in Africa, a condition usually considered an enteropathy. Methods-Clinical examination and representative necropsy study of adult patients positive for HIV. Setting-Hospital medical wards in Abidjan, Ivory Coast. Subjects-Adults positive for HIV. Main outcome measures-CD4 T lymphocyte counts before death, clinical and anthropometric data, and gross and microscopic pathology. Results-Necropsy was done on 212 HIV positive adults. Tuberculosis was found in 41 of 93 with the clinical HIV wasting syndrome and in 32 of 119 without (odds ratio 2.1, 95% confidence interval 1.2 to 4.0). A significant association existed between the prevalence of tuberculosis at necropsy and the degree of cadaveric wasting (no wasting 25% (15/59); moderate wasting 40% (23/58); skeletal wasting 44% (42/95); P=0.02). Wasting was also associated with a history of chronic diarrhoea, but no association existed between diarrhoea and tuberculosis. Median CD4 T lymphocyte counts were lowest in wasted patients irrespective of findings at necropsy and in those with chronic diarrhoea (<60x10(6)/l). Conclusion-Wasting and chronic diarrhoea are late stage manifestations of HIV disease in Africa. The importance of tuberculosis as a contributing factor in the pathogenesis of the slim syndrome has been underestimated. In nearly half of patients dying with severe wasting, tuberculosis was the dominant pathological finding.	CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV HIV AIDS,ATLANTA,GA 30341; PROJET RETRO CI,ABIDJAN,COTE IVOIRE; UNIV HOSP ABIDJAN,ABIDJAN,COTE IVOIRE; INST TROP MED,B-2000 ANTWERP,BELGIUM	Centers for Disease Control & Prevention - USA; Institute of Tropical Medicine (ITM)	LUCAS, SB (corresponding author), UNIV LONDON UNIV COLL,SCH MED,DEPT HISTOPATHOL,LONDON WC1E 6JJ,ENGLAND.							COLEBUNDERS R, 1988, GUT, V29, P1687, DOI 10.1136/gut.29.12.1687; COLEBUNDERS RL, 1991, AIDS, V5, pS103; CONLON CP, 1990, AM J TROP MED HYG, V42, P83, DOI 10.4269/ajtmh.1990.42.83; DEAN AD, 1990, EPI INFO; DECOCK KM, 1990, AIDS, V4, P875, DOI 10.1097/00002030-199009000-00007; DECOCK KM, 1993, LANCET, V342, P437, DOI 10.1016/0140-6736(93)92853-L; DECOCK KM, 1992, JAMA-J AM MED ASSOC, V268, P1581, DOI 10.1001/jama.1992.03490120095035; DECOCK KM, 1993, AM J PUBLIC HEALTH, V83, P1385, DOI 10.2105/AJPH.83.10.1385; GRUNFELD C, 1992, NEW ENGL J MED, V327, P329, DOI 10.1056/NEJM199207303270506; KAPEMBWA MS, 1991, CLIN SCI, V81, P327, DOI 10.1042/cs0810327; KESTENS L, 1992, AIDS, V6, P803, DOI 10.1097/00002030-199208000-00006; KEUSCH GT, 1990, ANNU REV NUTR, V10, P475, DOI 10.1146/annurev.nu.10.070190.002355; KOTLER DP, 1989, AM J CLIN NUTR, V50, P444, DOI 10.1093/ajcn/50.3.444; LUCAS SB, 1989, J CLIN PATHOL, V42, P885, DOI 10.1136/jcp.42.8.885-b; LUCS SB, 1993, AIDS, V7, P1569; NAHLEN BL, 1993, AIDS, V7, P183, DOI 10.1097/00002030-199302000-00005; NAMBUYA A, 1988, J CLIN PATHOL, V41, P93, DOI 10.1136/jcp.41.1.93; NELSON AM, 1993, AIDS, V7, P1241, DOI 10.1097/00002030-199309000-00014; Scalcini M, 1991, Bull Int Union Tuberc Lung Dis, V66, P37; SERWADDA D, 1985, LANCET, V2, P849, DOI 10.1016/S0140-6736(85)90122-9; SEWANKAMBO N, 1987, AIDS, V1, P9; SMITH PD, 1992, ANN INTERN MED, V116, P63, DOI 10.7326/0003-4819-116-1-63; World Health Organisation, 1986, WKLY EPIDEM REC, V61, P69	23	106	106	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 11	1994	308	6943					1531	1533		10.1136/bmj.308.6943.1531	http://dx.doi.org/10.1136/bmj.308.6943.1531			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NR110	7912597	Green Published			2022-12-24	WOS:A1994NR11000018
J	WANG, SX; HAZELRIGG, T				WANG, SX; HAZELRIGG, T			IMPLICATIONS FOR BCD MESSENGER-RNA LOCALIZATION FROM SPATIAL-DISTRIBUTION OF EXU PROTEIN IN DROSOPHILA OOGENESIS	NATURE			English	Article							MESSENGER-RNA LOCALIZATION; BICOID RNA; GENE; MICROTUBULES; DIFFERENTIATION; MORPHOGEN; TRANSPORT; GRADIENT; PATTERN; EMBRYOS	SUBCELLULAR RNA localization in different cell types leads to asymmetric distribution of proteins in these cells(1,2). The localization of bicoid (bcd) messenger RNA to the anterior pole of the developing Drosophila oocyte gives rise in embryogenesis to a steep concentration gradient of the bcd protein(3-6), a transcription factor that activates expression of zygotic genes needed for anterior development(7-9). The exuperantia (exu) gene is necessary for this localization of bcd mRNA(3,4). Here we express a chimaeric gene encoding a fusion between the Acquorea victoria green fluorescent protein (GPP)(10) and the exu protein (Exu) in female germ cells, and find that the fusion protein fluoresces strongly in both live and fixed cells during Drosophila oogenesis. The fusion protein rescues an exu null allele, restoring full fertility to females, and is expressed and localized in a temporal and spatial pattern similar to native Exu. The high sensitivity of the GFP tag provides important ne,v details on the subcellular localization of Exu. The fusion protein is found in particles concentrated at ring canals, where transport occurs between nurse cells and the oocyte. Drugs such as colchicine and taxol that affect microtubule stability alter localization of the particles. We propose that the particles are ribonucleoprotein complexes or vesicles which transport bcd mRNA along microtubules and target it to the anterior oocyte cortex.	COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027	Columbia University								AINGER K, 1993, J CELL BIOL, V123, P431, DOI 10.1083/jcb.123.2.431; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; DRIEVER W, 1989, NATURE, V340, P363, DOI 10.1038/340363a0; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; FRIGERIO G, 1986, CELL, V47, P735, DOI 10.1016/0092-8674(86)90516-7; GUTZEIT H, 1986, ROUX ARCH DEV BIOL, V195, P173, DOI 10.1007/BF02439435; KARESS RE, 1984, CELL, V38, P135, DOI 10.1016/0092-8674(84)90534-8; MACDONALD PM, 1991, GENE DEV, V5, P2455, DOI 10.1101/gad.5.12b.2455; MARCEY D, 1991, EMBO J, V10, P4259, DOI 10.1002/j.1460-2075.1991.tb05004.x; POKRYWKA NJ, 1991, DEVELOPMENT, V113, P55; PRASHER DC, 1992, GENE, V111, P229, DOI 10.1016/0378-1119(92)90691-H; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHRODER C, 1988, EMBO J, V7, P2881, DOI 10.1002/j.1460-2075.1988.tb03145.x; SCHUEPBACH T, 1986, Wilhelm Roux's Archives of Developmental Biology, V195, P302; SINGER R H, 1992, Current Opinion in Cell Biology, V4, P15, DOI 10.1016/0955-0674(92)90053-F; Spradling Allan C., 1993, P1; STJOHNSTON D, 1989, DEVELOPMENT, V107, P13; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; THEURKAUF WE, 1993, DEVELOPMENT, V118, P1169, DOI 10.1016/0168-9525(93)90134-4; THEURKAUF WE, 1992, DEVELOPMENT, V115, P923; Thummel CS, 1992, DROS INF SERV, V71, P150; WAM RM, 1986, EXP CELL RES, V157, P355; WILHELM JE, 1993, J CELL BIOL, V123, P269, DOI 10.1083/jcb.123.2.269	25	424	474	3	47	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 2	1994	369	6479					400	403		10.1038/369400a0	http://dx.doi.org/10.1038/369400a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NP174	7910952				2022-12-24	WOS:A1994NP17400057
J	SPRAY, DC				SPRAY, DC			CMTX1 - A GAP JUNCTION GENETIC-DISEASE	LANCET			English	Editorial Material							GROWTH; CELLS; INVIVO; CDNA		ALBERT EINSTEIN COLL MED,DEPT MED,BRONX,NY	Yeshiva University; Albert Einstein College of Medicine	SPRAY, DC (corresponding author), ALBERT EINSTEIN COLL MED,DEPT NEUROSCI,BRONX,NY, USA.			Spray, David/0000-0001-8368-5073				BAI S, 1993, BIOCHIM BIOPHYS ACTA, V1216, P197, DOI 10.1016/0167-4781(93)90145-4; BENNETT MVL, 1991, NEURON, V6, P305, DOI 10.1016/0896-6273(91)90241-Q; BERGOFFEN J, 1993, SCIENCE, V262, P2039, DOI 10.1126/science.8266101; CHANSON M, 1993, J GEN PHYSIOL, V102, P925, DOI 10.1085/jgp.102.5.925; DERMIETZEL R, 1993, TRENDS NEUROSCI, V16, P185; EGHBALI B, 1991, P NATL ACAD SCI USA, V88, P10701, DOI 10.1073/pnas.88.23.10701; FAIRWEATHER N, 1994, HUM MOL GENET, V3, P29, DOI 10.1093/hmg/3.1.29; IONASESCU V, 1994, HUM MOL GENET, V3, P355, DOI 10.1093/hmg/3.2.355; LOEWENSTEIN WR, 1979, BIOCHIM BIOPHYS ACTA, V560, P1, DOI 10.1016/0304-419X(79)90002-7; MESNIL M, 1993, PROG CELL R, V3, P311; NAUS CCG, 1992, CANCER RES, V52, P4208; SAFFITZ JE, 1993, CIRCULATION, V87, P1742, DOI 10.1161/01.CIR.87.5.1742; SPRAY DC, 1992, BIOPHYS J, V62, P48, DOI 10.1016/S0006-3495(92)81774-5; SPRAY DC, 1994, ION CHANNELS CARDIOV, P185; SU Y, 1993, P NATL ACAD SCI USA, V90, P10856, DOI 10.1073/pnas.90.22.10856; SUTER U, 1993, TRENDS NEUROSCI, V16, P50, DOI 10.1016/0166-2236(93)90015-E; TETZLAFF W, 1982, J NEUROCYTOL, V11, P839, DOI 10.1007/BF01153522; Warner A., 1992, Seminars in Cell Biology, V3, P81	18	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 7	1994	343	8906					1111	1112		10.1016/S0140-6736(94)90229-1	http://dx.doi.org/10.1016/S0140-6736(94)90229-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NK730	7910226				2022-12-24	WOS:A1994NK73000003
J	NGAI, J; DOWLING, MM; BUCK, L; AXEL, R; CHESS, A				NGAI, J; DOWLING, MM; BUCK, L; AXEL, R; CHESS, A			THE FAMILY OF GENES ENCODING ODORANT RECEPTORS IN THE CHANNEL CATFISH	CELL			English	Article							BETA-ADRENERGIC-RECEPTOR; SENSITIVE ADENYLATE-CYCLASE; LIGAND-BINDING SPECIFICITY; ACID OLFACTORY RECEPTOR; NUCLEOTIDE SUBSTITUTIONS; OVERDOMINANT SELECTION; AMINO-ACIDS; EXPRESSION; NEURONS; CILIA	The anatomical and numerical simplicity of the fish olfactory system has led us to examine the family of olfactory receptors expressed in the catfish. We have identified a family of genes encoding seven transmembrane domain receptors that share considerable homology with the odorant receptors of the rat. The size of the catfish receptor repertoire appears to be far smaller than in mammals. Analysis of the nucleotide sequences suggests that these receptor genes have undergone positive Darwinian selection to generate enhanced diversity within the putative odorant-binding domains. Individual receptor clones anneal with 0.5%-2% of the olfactory neurons, suggesting that a single cell expresses only a small subset of distinct odorant receptors. Each cell, therefore, possesses a unique identity defined by the receptors it expresses. These data suggest that the brain may discriminate among odors by determining which neurons have been activated.	COLUMBIA UNIV COLL PHYS & SURG,HOWARD HUGHES MED INST,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032	Columbia University; Howard Hughes Medical Institute			Dowling, Michael M./AAE-5263-2020	Dowling, Michael M./0000-0001-5058-6589; Axel, Richard/0000-0002-3141-4076	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007367] Funding Source: NIH RePORTER; NIGMS NIH HHS [T-32 GM07367] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOEKHOFF I, 1990, EMBO J, V9, P2453, DOI 10.1002/j.1460-2075.1990.tb07422.x; BREER H, 1990, NATURE, V345, P65, DOI 10.1038/345065a0; BRUCH RC, 1988, COMP BIOCHEM PHYS B, V91, P535, DOI 10.1016/0305-0491(88)90018-1; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; CAGAN RH, 1978, P NATL ACAD SCI USA, V75, P4679, DOI 10.1073/pnas.75.10.4679; CAPRIO J, 1989, J GEN PHYSIOL, V93, P245, DOI 10.1085/jgp.93.2.245; CAPRIO J, 1984, J GEN PHYSIOL, V84, P403, DOI 10.1085/jgp.84.3.403; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DHALLAN RS, 1990, NATURE, V347, P184, DOI 10.1038/347184a0; DIXON RAF, 1987, NATURE, V326, P73, DOI 10.1038/326073a0; Doving K.B., 1986, Progress in Sensory Physiology, V6, P39; FESENKO EE, 1983, BIOCHIM BIOPHYS ACTA, V759, P250, DOI 10.1016/0304-4165(83)90320-3; GOULDING EH, 1992, NEURON, V8, P45, DOI 10.1016/0896-6273(92)90107-O; HARA T J, 1975, Progress in Neurobiology (Oxford), V5, P271, DOI 10.1016/0301-0082(75)90014-3; HUGHES AL, 1988, NATURE, V335, P167, DOI 10.1038/335167a0; HUGHES AL, 1989, P NATL ACAD SCI USA, V86, P958, DOI 10.1073/pnas.86.3.958; JUKES T H, 1969, P21; KALINOSKI DL, 1992, BIOCHEM J, V281, P449, DOI 10.1042/bj2810449; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; LANCET D, 1986, ANNU REV NEUROSCI, V9, P329, DOI 10.1146/annurev.ne.09.030186.001553; LEVY NS, 1991, J STEROID BIOCHEM, V39, P633, DOI 10.1016/0960-0760(91)90262-4; LUDWIG J, 1990, FEBS LETT, V270, P24, DOI 10.1016/0014-5793(90)81226-E; MAEDA N, 1986, ANNU REV GENET, V20, P81; Maniatis T., 1982, MOL CLONING; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; NAKAMURA T, 1987, NATURE, V325, P442, DOI 10.1038/325442a0; NEI M, 1986, MOL BIOL EVOL, V3, P418; NEI M, 1989, MOL BIOL EVOL, V6, P290; NGAI J, 1993, CELL, V72; ODOWD BF, 1989, ANNU REV NEUROSCI, V12, P67, DOI 10.1146/annurev.ne.12.030189.000435; PACE U, 1985, NATURE, V316, P255, DOI 10.1038/316255a0; PARMENTIER M, 1992, NATURE, V355, P453, DOI 10.1038/355453a0; REED RR, 1992, NEURON, V8, P205, DOI 10.1016/0896-6273(92)90287-N; REHNBERG BG, 1986, J COMP PHYSIOL A, V159, P61, DOI 10.1007/BF00612496; RESTREPO D, 1990, SCIENCE, V249, P1166, DOI 10.1126/science.2168580; RHEIN LD, 1983, J NEUROCHEM, V41, P569, DOI 10.1111/j.1471-4159.1983.tb04777.x; SKLAR PB, 1986, J BIOL CHEM, V261, P5538; STRADER CD, 1989, FASEB J, V3, P1825, DOI 10.1096/fasebj.3.7.2541037; STRADER CD, 1987, P NATL ACAD SCI USA, V84, P4384, DOI 10.1073/pnas.84.13.4384; TANAKA T, 1989, MOL BIOL EVOL, V6, P447; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7; WILKINSON DG, 1987, DEVELOPMENT, V99, P493; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	44	327	345	0	19	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 12	1993	72	5					657	666						10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KR436	7916654	Bronze			2022-12-24	WOS:A1993KR43600003
J	TODD, NW				TODD, NW			IMAGES IN CLINICAL MEDICINE - CHOLESTEATOMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											TODD, NW (corresponding author), EMORY UNIV,ATLANTA,GA 30322, USA.								0	0	0	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 17	1994	331	20					1347	1347						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PR216	7935704				2022-12-24	WOS:A1994PR21600005
J	GEORGOPOULOS, K; BIGBY, M; WANG, JH; MOLNAR, A; WU, P; WINANDY, S; SHARPE, A				GEORGOPOULOS, K; BIGBY, M; WANG, JH; MOLNAR, A; WU, P; WINANDY, S; SHARPE, A			THE IKAROS GENE IS REQUIRED FOR THE DEVELOPMENT OF ALL LYMPHOID LINEAGES	CELL			English	Article							HEMATOPOIETIC STEM-CELLS; NATURAL-KILLER-CELLS; DENDRITIC EPIDERMAL-CELLS; BONE-MARROW; PRECURSOR CELLS; LYMPHOCYTES-T; EXPRESSION; THYMUS; MOUSE; MICE	The Ikaros gene encodes a family of early hematopoietic- and lymphocyte-restricted transcription factors. Mice homozygous for a germline mutation in the Ikaros DNA-binding domain lack not only T and B lymphocytes and natural killer cells but also their earliest defined progenitors. In contrast, the erythroid and myeloid lineages were intact in these mutant mice. We propose that Ikaros promotes differentiation of pluripotential hematopoietic stem cell(s) into the lymphocyte pathways. In the absence of a functional Ikaros gene, these stem cells are exclusively diverted into the erythroid and myeloid lineages.	HARVARD UNIV,SCH MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT PATHOL,DIV IMMUNOL RES,BOSTON,MA 02114	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	GEORGOPOULOS, K (corresponding author), MASSACHUSETTS GEN HOSP,CUTANEOUS BIOL RES CTR,BOSTON,MA 02129, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033062] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR039795] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI033062, R01-AI33062-62] Funding Source: Medline; NIAMS NIH HHS [AR39795-04] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ARDAVIN C, 1993, NATURE, V362, P761, DOI 10.1038/362761a0; ASNARNOW DM, 1988, CELL, V55, P837; BIGBY M, 1987, J INVEST DERMATOL, V89, P495, DOI 10.1111/1523-1747.ep12460983; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; CLEVERS HC, 1993, IMMUNOL TODAY, V14, P591, DOI 10.1016/0167-5699(93)90198-T; FIFE A, 1994, J CLIN PATHOL, V47, P82, DOI 10.1136/jcp.47.1.82; FLEMING WH, 1993, J CELL BIOL, V122, P897, DOI 10.1083/jcb.122.4.897; GARNIWAGNER BA, 1993, J IMMUNOL, V151, P60; GEORGOPOULOS K, 1992, MOL CELL BIOL, V12, P747, DOI 10.1128/MCB.12.2.747; GEORGOPOULOS K, 1992, SCIENCE, V258, P808, DOI 10.1126/science.1439790; GODFREY DI, 1993, IMMUNOL TODAY, V14, P547, DOI 10.1016/0167-5699(93)90186-O; HACKETT J, 1986, J IMMUNOL, V136, P3124; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HARDY RR, 1986, IMMUNOL REV, V93, P53, DOI 10.1111/j.1600-065X.1986.tb01502.x; HAVRAN WL, 1990, NATURE, V344, P68, DOI 10.1038/344068a0; HAVRAN WL, 1988, NATURE, V335, P443, DOI 10.1038/335443a0; HESTDAL K, 1991, J IMMUNOL, V147, P22; HODGSON GS, 1979, NATURE, V281, P381, DOI 10.1038/281381a0; IKUTA K, 1992, ANNU REV IMMUNOL, V10, P759; KARASUYAMA H, 1994, CELL, V77, P133, DOI 10.1016/0092-8674(94)90241-0; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LI YS, 1993, J EXP MED, V178, P951, DOI 10.1084/jem.178.3.951; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; NILSSON SK, 1994, EXP HEMATOL, V22, P377; PEARSE M, 1989, P NATL ACAD SCI USA, V86, P1614, DOI 10.1073/pnas.86.5.1614; RAULET DH, 1991, IMMUNOL REV, V120, P185, DOI 10.1111/j.1600-065X.1991.tb00592.x; RODEWALD HR, 1992, CELL, V69, P139, DOI 10.1016/0092-8674(92)90125-V; ROLINK A, 1991, CELL, V66, P1081, DOI 10.1016/0092-8674(91)90032-T; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; SKEATH JB, 1992, GENE DEV, V6, P2606, DOI 10.1101/gad.6.12b.2606; SPANGRUDE GJ, 1989, IMMUNOL TODAY, V10, P344, DOI 10.1016/0167-5699(89)90192-8; VISSER JWM, 1983, CELL TISSUE KINET, V16, P385; WARD HP, 1971, MEDICINE, V50, P357, DOI 10.1097/00005792-197109000-00001; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; WU L, 1991, J EXP MED, V174, P1617, DOI 10.1084/jem.174.6.1617; WU L, 1991, NATURE, V349, P71, DOI 10.1038/349071a0	36	753	772	0	17	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 7	1994	79	1					143	156		10.1016/0092-8674(94)90407-3	http://dx.doi.org/10.1016/0092-8674(94)90407-3			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PK585	7923373				2022-12-24	WOS:A1994PK58500015
J	ASSEMAN, P; MCFADDEN, E; BAUCHART, JJ; LOUBEYRE, C; THERY, C				ASSEMAN, P; MCFADDEN, E; BAUCHART, JJ; LOUBEYRE, C; THERY, C			WHY DO BETA-BLOCKERS HELP IN IDIOPATHIC DILATED CARDIOMYOPATHY - FREQUENCY MISMATCH	LANCET			English	Article							HUMAN HEART-FAILURE; HUMAN VENTRICULAR MYOCARDIUM; FAILING HUMAN MYOCARDIUM; CALCIUM; EXPRESSION; CONTRACTILITY; METOPROLOL; BLOCKADE				ASSEMAN, P (corresponding author), UNIV LILLE,HOP CARDIOIOG,F-59037 LILLE,FRANCE.							BEUCKELMANN DJ, 1992, CIRCULATION, V85, P1046, DOI 10.1161/01.CIR.85.3.1046; BREALL JA, 1993, J AM COLL CARDIOL, V21, P471, DOI 10.1016/0735-1097(93)90691-S; CORABOEUF E, 1992, THERAPIE, V47, P171; EISING GP, 1994, J AM COLL CARDIOL, V23, P97; FOWLER MB, 1986, CIRCULATION, V74, P1290, DOI 10.1161/01.CIR.74.6.1290; GILBERT EM, 1991, CIRCULATION S2, V84, P1868; GO LW, 1993, CIRCULATION, V88, P624; GWATHMEY JK, 1990, J CLIN INVEST, V85, P1599, DOI 10.1172/JCI114611; GWATHMEY JK, 1987, CIRC RES, V61, P70, DOI 10.1161/01.RES.61.1.70; HAJJAR RJ, 1992, CIRCULATION, V86, P1819, DOI 10.1161/01.CIR.86.6.1819; HASENFUSS G, 1993, CIRCULATION, V88, P407; HASENFUSS G, 1992, CIRC RES, V70, P1226; HEILBRUNN SM, 1989, CIRCULATION, V79, P483, DOI 10.1161/01.CIR.79.3.483; LECHAT P, IN PRESS CIRCULATION; MANN DL, 1992, CIRCULATION, V85, P790, DOI 10.1161/01.CIR.85.2.790; MORAVEC CS, 1993, CIRCULATION, V88, P408; MULIERI LA, 1992, CIRCULATION, V85, P1743, DOI 10.1161/01.CIR.85.5.1743; PIESKE B, 1993, CIRCULATION, V88, P373; RASMUSSEN RP, 1990, BIOCHEM PHARMACOL, V39, P691, DOI 10.1016/0006-2952(90)90147-D; REINECKE H, 1993, CIRCULATION, V88, P408; SATO H, 1993, CIRCULATION, V88, P2215, DOI 10.1161/01.CIR.88.5.2215; VAHL CF, 1994, CIRC RES, V74, P952, DOI 10.1161/01.RES.74.5.952; WAAGSTEIN F, 1975, BRIT HEART J, V37, P1022; WAAGSTEIN F, 1993, LANCET, V342, P1441, DOI 10.1016/0140-6736(93)92930-R	24	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 17	1994	344	8925					803	804		10.1016/S0140-6736(94)92350-7	http://dx.doi.org/10.1016/S0140-6736(94)92350-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PG178	7916082				2022-12-24	WOS:A1994PG17800019
J	TURKASPA, I; MAOR, Y; DOR, J; MASHIACH, S				TURKASPA, I; MAOR, Y; DOR, J; MASHIACH, S			FREQUENCY OF INTERCOURSE FOR COUPLES TRYING TO CONCEIVE	LANCET			English	Editorial Material							OLIGOZOOSPERMIC MEN; SEMEN CHARACTERISTICS; INFERTILE MEN; PARAMETERS; INTERVAL; MOTILE; SPERM				TURKASPA, I (corresponding author), TEL AVIV UNIV,CHAIM SHEBA MED CTR,DEPT OBSTET & GYNECOL,INFERTIL & INVITRO FERTILIZAT UNIT,IL-52621 TEL HASHOMER,ISRAEL.			Maor, Yasmin/0000-0001-7258-3434				ACOSTA AA, 1988, OBSTET GYNECOL SURV, V44, P1; BAKER HWG, 1981, INT J ANDROL, V4, P609, DOI 10.1111/j.1365-2605.1981.tb00743.x; BRASCH JG, 1994, FERTIL STERIL, V62, P150; CHECK JH, 1985, FERTIL STERIL, V44, P416; COOPER TG, 1993, HUM REPROD, V8, P1251, DOI 10.1093/oxfordjournals.humrep.a138236; GLASS RH, 1986, REPRODUCTIVE ENDOCRI, P571; GULMEZ I, 1991, ANDROLOGIA, V23, P167; HORNSTEIN MD, 1992, FERTIL STERIL, V58, P433; Hotchkiss RS, 1941, J UROLOGY, V45, P875, DOI 10.1016/S0022-5347(17)71125-1; MATILSKY M, 1993, HUM REPROD, V8, P71, DOI 10.1093/oxfordjournals.humrep.a137877; SILBER SJ, 1989, HUM REPROD, V4, P947, DOI 10.1093/oxfordjournals.humrep.a137018; TURKASPA I, 1990, FERTIL STERIL, V54, P906; TURKASPA I, 1994, FERTIL STERIL, V62, P370	13	3	3	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 17	1994	344	8925					766	766		10.1016/S0140-6736(94)92334-5	http://dx.doi.org/10.1016/S0140-6736(94)92334-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PG178	7916066				2022-12-24	WOS:A1994PG17800003
J	BERKOWITZ, CD				BERKOWITZ, CD			HOMEOPATHT - KEEPING AN OPEN MIND	LANCET			English	Editorial Material											BERKOWITZ, CD (corresponding author), UNIV CALIF LOS ANGELES,LOS ANGELES CTY HARBOR MED CTR,DEPT PEDIAT,TORRANCE,CA 90509, USA.							CRETICOS PS, 1987, JAMA-J AM MED ASSOC, V258, P2874, DOI 10.1001/jama.258.20.2874; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; JACOBS J, 1994, PEDIATRICS, V93, P719; PACHTER LM, 1994, JAMA-J AM MED ASSOC, V271, P690, DOI 10.1001/jama.271.9.690; PALAFOX N, 1980, CROSS CULTURAL CARIN; REILLY DT, 1986, LANCET, V2, P881; WAPNIR RA, 1991, J PEDIATR, V118, P553; 1981, PUBLIC HLTH LETT, V3, P37	8	10	10	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 10	1994	344	8924					701	702		10.1016/S0140-6736(94)92203-9	http://dx.doi.org/10.1016/S0140-6736(94)92203-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PF187	7915771				2022-12-24	WOS:A1994PF18700005
J	CLARKE, KW; GRAY, D; KEATING, NA; HAMPTON, JR				CLARKE, KW; GRAY, D; KEATING, NA; HAMPTON, JR			DO WOMEN WITH ACUTE MYOCARDIAL-INFARCTION RECEIVE THE SAME TREATMENT AS MEN	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; THROMBOLYSIS; MORTALITY; PROGNOSIS; GENDER; POLICY	Objective-To determine whether women with acute myocardial infarction in the Nottingham health district receive the same therapeutic interventions as their male counterparts. Design-Retrospective study. Setting-University and City Hospitals, Nottingham. Patients-All patients admitted with a suspected myocardial infarction during 1989 and 1990. Main outcome measures-Route and timing of admission to hospital, ward of admission, treatment, interventions in hospital, and mortality. Results-Women with myocardial infarction took longer to arrive in hospital than men. They were less likely to be admitted to the coronary care unit and were therefore also less likely to receive thrombolytic treatment. They seemed to have more severe infarcts, with higher Killip classes, and had a slightly higher mortality during admission. They were less likely than men to receive secondary prophylaxis by being discharged taking beta blockers or aspirin. Conclusions-Survival chances both in hospital and after discharge in women with acute myocardial infarction are reduced because they do not have the same opportunity for therapeutic intervention as men.	UNIV NOTTINGHAM, BRITISH HEART FDN, DEPT MATH, CARDIOVASC STAT UNIT, NOTTINGHAM NG7 2RD, ENGLAND	University of Nottingham	CLARKE, KW (corresponding author), UNIV NOTTINGHAM HOSP, NOTTINGHAM NG7 2UH, ENGLAND.							ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, Lancet, V1, P397; [Anonymous], 1986, Lancet, V2, P57; DITTRICH H, 1988, AM J CARDIOL, V62, P1, DOI 10.1016/0002-9149(88)91356-2; GRAY D, 1993, LANCET, V341, P654, DOI 10.1016/0140-6736(93)90420-L; GRAY D, 1993, INT J EPIDEMIOL, V22, P222, DOI 10.1093/ije/22.2.222; HAMPTON JR, 1985, MED INT, P848; KANNEL WB, 1987, CORONARY HEART DISEA, P208; KILLIP T, 1967, AM J CARDIOL, V20, P457, DOI 10.1016/0002-9149(67)90023-9; LERNER DJ, 1986, AM HEART J, V111, P383, DOI 10.1016/0002-8703(86)90155-9; MULCAHY R, 1993, BRIT J CARDIOLOGY, V1, P35; PETTICREW M, 1993, BMJ-BRIT MED J, V306, P1164, DOI 10.1136/bmj.306.6886.1164; ROBINSON K, 1988, J AM COLL CARDIOL, V11, P932, DOI 10.1016/S0735-1097(98)90048-1; ROWLEY JM, 1992, BRIT HEART J, V67, P255; TOFLER GH, 1987, J AM COLL CARDIOL, V9, P473, DOI 10.1016/S0735-1097(87)80038-4; VEMURA K, 1988, WORLD HLTH STAT Q, V41, P155; WEINBLATT E, 1973, AM J PUBLIC HEALTH, V63, P577, DOI 10.2105/AJPH.63.7.577; 1993, MORTALITY STATISTICS	19	158	162	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 3	1994	309	6954					563	566		10.1136/bmj.309.6954.563	http://dx.doi.org/10.1136/bmj.309.6954.563			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PF330	7916228	Green Published			2022-12-24	WOS:A1994PF33000014
J	EISENBERG, M				EISENBERG, M			IMPROVING OUT-OF-HOSPITAL RESUSCITATION	LANCET			English	Editorial Material							AMERICAN-HEART-ASSOCIATION; CARDIAC-ARREST; HEALTH-PROFESSIONALS; STATEMENT; SURVIVAL				EISENBERG, M (corresponding author), UNIV WASHINGTON,MED CTR,EMERGENCY MED SERV,SEATTLE,WA 98195, USA.							BECKER LB, 1991, ANN EMERG MED, V20, P355, DOI 10.1016/S0196-0644(05)81654-3; BENSON NH, 1994, ANN EMERG MED, V23, P1047, DOI 10.1016/S0196-0644(94)70102-4; CLARK JJ, 1994, ANN EMERG MED, V23, P1022, DOI 10.1016/S0196-0644(94)70097-4; CUMMINS RO, 1991, CIRCULATION, V84, P960, DOI 10.1161/01.CIR.84.2.960; CUMMINS RO, 1991, CIRCULATION, V83, P1832, DOI 10.1161/01.CIR.83.5.1832; DULL SM, 1994, ANN EMERG MED, V23, P997, DOI 10.1016/S0196-0644(94)70093-1; EISENBERG MS, 1990, ANN EMERG MED, V19, P179, DOI 10.1016/S0196-0644(05)81805-0; EISENBERG MS, 1994, ANN EMERG MED, V23, P1049, DOI 10.1016/S0196-0644(94)70103-2; LARSEN MP, 1993, ANN EMERG MED, V22, P1652, DOI 10.1016/S0196-0644(05)81302-2; PARTRIDGE JF, 1967, LANCET, V2, P271; PEPE PE, 1994, ANN EMERG MED, V23, P1037, DOI 10.1016/S0196-0644(94)70100-8; ROTTENBERG EM, 1994, ANN EMERG MED, V23, P1027, DOI 10.1016/S0196-0644(94)70098-2; SHUSTER M, 1994, ANN EMERG MED, V23, P1014, DOI 10.1016/S0196-0644(94)70096-6; SOSNA DP, 1994, ANN EMERG MED, V23, P1042, DOI 10.1016/S0196-0644(94)70101-6; WHITE RD, 1994, ANN EMERG MED, V23, P1009, DOI 10.1016/S0196-0644(94)70095-8	15	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 27	1994	344	8922					561	562		10.1016/S0140-6736(94)91961-5	http://dx.doi.org/10.1016/S0140-6736(94)91961-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD424	7914956				2022-12-24	WOS:A1994PD42400005
J	FROMMEL, D; TEKLEHAIMANOT, R; VERDIER, M; NEGESSE, Y; BULTO, T; DENIS, F				FROMMEL, D; TEKLEHAIMANOT, R; VERDIER, M; NEGESSE, Y; BULTO, T; DENIS, F			HIV-INFECTION AND LEPROSY - A 4-YEAR SURVEY IN ETHIOPIA	LANCET			English	Note							VIRUS	Between 1988 and 1992 three cross-sectional surveys for antibodies to HIV were done in 644 Ethiopian patients with histologically proven leprosy. Whereas the frequency of HIV-1 infection gradually increased from 3.2% to 6.5%, the clinical presentation, number of new patients, and frequency of relapse did not differ between HIV negative and positive patients. Thus HIV appears unlikely to have a significant impact on the incidence of leprosy in sub-Sahelian populations.	UNIV ADDIS ABABA,FAC MED,DEPT MED,ADDIS ABABA,ETHIOPIA; CHU LIMOGES,DEPT VIROL,LIMOGES,FRANCE; ALL AFRICA LEPROSY & REHABIL TRAINING CTR,ADDIS ABABA,ETHIOPIA; INST PASTEUR,CNRS,URA 1459,LYON,FRANCE	Addis Ababa University; CHU Limoges; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	FROMMEL, D (corresponding author), ARMAUER HANSEN RES INST,POB 1005,ADDIS ABABA,ETHIOPIA.			VERDIER, Mireille/0000-0002-8162-4856				DUNCAN ME, 1981, LEPROSY REV, V52, P245; FROMMEL D, 1993, AM J TROP MED HYG, V49, P435, DOI 10.4269/ajtmh.1993.49.435; KHOD, 1993, KHODAKEVICH L, P319; LEONARD G, 1990, J ACQ IMMUN DEF SYND, V3, P1109; LUCAS S, 1993, LEPROSY REV, V64, P97; TEKLEHAIMANOT R, 1991, AIDS, V5, P108, DOI 10.1097/00002030-199101000-00019; 1993, ETHIOP J HLTH DEV, V7, P33; 1992, LEPROSY CONTROL ETHI; 1988, LEPROSY CONTROL ETHI	9	30	31	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 16	1994	344	8916					165	166		10.1016/S0140-6736(94)92760-X	http://dx.doi.org/10.1016/S0140-6736(94)92760-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW810	7912768				2022-12-24	WOS:A1994NW81000012
J	RUSSELL, JA				RUSSELL, JA			CANCER-THERAPY - TIME TO LEARN THE IMMUNOBABBLE	LANCET			English	Editorial Material							HIGH-DOSE INTERLEUKIN-2; TUMOR-INFILTRATING LYMPHOCYTES; ACTIVATED KILLER-CELLS; TRIAL				RUSSELL, JA (corresponding author), TOM BAKER CANC CLIN,CALGARY,AB,CANADA.							ATKINS MB, 1993, J CLIN ONCOL, V11, P661, DOI 10.1200/JCO.1993.11.4.661; CURTI BD, 1993, J CLIN ONCOL, V11, P652, DOI 10.1200/JCO.1993.11.4.652; KIM JA, 1993, 37TH ANN C ADV BIOL; LARSON SM, 1993, ACTA ONCOL, V32, P709, DOI 10.3109/02841869309096125; MARINCOLA FM, 1993, J IMMUNOTHER, V13, P282, DOI 10.1097/00002371-199305000-00008; ROSENBERG SA, 1993, JNCI-J NATL CANCER I, V85, P622, DOI 10.1093/jnci/85.8.622; ROSENBERG SA, 1987, NEW ENGL J MED, V316, P889, DOI 10.1056/NEJM198704093161501; ROSENBERG SA, 1986, SCIENCE, V233, P1318, DOI 10.1126/science.3489291; UCHIDA A, 1993, CANCER IMMUNOL IMMUN, V11, P75; YEUNG AW, 1994, CANCER, V71, P3633	10	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 16	1994	344	8916					145	146		10.1016/S0140-6736(94)92753-7	http://dx.doi.org/10.1016/S0140-6736(94)92753-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW810	7912761				2022-12-24	WOS:A1994NW81000005
J	LIFSON, AR				LIFSON, AR			PREVENTING HIV - HAVE WE LOST OUR WAY	LANCET			English	Editorial Material							RISK-FACTORS; DRUG-USERS; AIDS; TRANSMISSION; PROSTITUTES				LIFSON, AR (corresponding author), UNIV MINNESOTA,SCH PUBL HLTH,DIV EPIDEMIOL,MINNEAPOLIS,MN 55455, USA.							[Anonymous], 1990, Wkly Epidemiol Rec, V65, P221; [Anonymous], 1993, MMWR, V42, P869; BINSON D, 1993, FAM PLANN PERSPECT, V25, P268, DOI 10.2307/2136144; DESJARLAIS DC, 1992, AIDS, V6, P1053, DOI 10.1097/00002030-199210000-00001; HAYS RB, 1990, AIDS, V4, P901, DOI 10.1097/00002030-199009000-00011; LAGA M, 1993, AIDS, V7, P95, DOI 10.1097/00002030-199301000-00015; MANN JM, 1992, AIDS WORLD CAMBRIDGE; MICHAELS D, 1992, JAMA-J AM MED ASSOC, V268, P3456, DOI 10.1001/jama.268.24.3456; NICOLOSI A, 1992, AM J EPIDEMIOL, V135, P225, DOI 10.1093/oxfordjournals.aje.a116275; SIMOES EAF, 1993, J ACQ IMMUN DEF SYND, V6, P1030; SIRAPRAPASIRI T, 1991, AIDS, V5, P579, DOI 10.1097/00002030-199105000-00017; STALL R, 1990, J ACQ IMMUN DEF SYND, V3, P1181; 1993, SOCIAL IMPACT AIDS U; 1992, MMWR, V41, P1; 1994, MMWR, V43, P155	15	4	4	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 28	1994	343	8909					1306	1308		10.1016/S0140-6736(94)92462-7	http://dx.doi.org/10.1016/S0140-6736(94)92462-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NN217	7910319				2022-12-24	WOS:A1994NN21700005
J	SCHINKEL, AH; SMIT, JJM; VANTELLINGEN, O; BEIJNEN, JH; WAGENAAR, E; VANDEEMTER, L; MOL, CAAM; VANDERVALK, MA; ROBANUSMAANDAG, EC; TERIELE, HPJ; BERNS, AJM; BORST, P				SCHINKEL, AH; SMIT, JJM; VANTELLINGEN, O; BEIJNEN, JH; WAGENAAR, E; VANDEEMTER, L; MOL, CAAM; VANDERVALK, MA; ROBANUSMAANDAG, EC; TERIELE, HPJ; BERNS, AJM; BORST, P			DISRUPTION OF THE MOUSE MDR1A P-GLYCOPROTEIN GENE LEADS TO A DEFICIENCY IN THE BLOOD-BRAIN-BARRIER AND TO INCREASED SENSITIVITY TO DRUGS	CELL			English	Article							MULTIDRUG-RESISTANCE GENE; PERFORMANCE LIQUID-CHROMATOGRAPHY; BACTERIAL TRANSPORT PROTEINS; MONOCLONAL-ANTIBODIES; CHINESE-HAMSTER; CELLS; EXPRESSION; VINBLASTINE; VINCRISTINE; FAMILY	We have generated mice homozygous for a disruption of the mdr1a (also called mdr3) gene, encoding a drug-transporting P-glycoprotein. The mice were viable and fertile and appeared phenotypically normal, but they displayed an increased sensitivity to the centrally neurotoxic pesticide ivermectin (100-fold) and to the carcinostatic drug vinblastine (3-fold). By comparison of mdr1a (+/+) and (-/-) mice, we found that the mdr1a P-glycoprotein is the major P-glycoprotein in the blood-brain barrier and that its absence results in elevated drug levels in many tissues (especially in brain) and in decreased drug elimination. Our findings explain some of the side effects in patients treated with a combination of carcinostatics and P-glycoprotein inhibitors and indicate that these inhibitors might be useful in selectively enhancing the access of a range of drugs to the brain.	NETHERLANDS CANC INST,DEPT CLIN CHEM,1066 CX AMSTERDAM,NETHERLANDS; SLOTERVAART HOSP,DEPT PHARM,1066 EC AMSTERDAM,NETHERLANDS	Netherlands Cancer Institute; Slotervaart Hospital	SCHINKEL, AH (corresponding author), NETHERLANDS CANC INST,DIV MOLEC BIOL,PLESMANLAAN 121,1066 CX AMSTERDAM,NETHERLANDS.		Van Tellingen, Olaf/A-1344-2014	Van Tellingen, Olaf/0000-0002-1037-6269				AMES BN, 1990, P NATL ACAD SCI USA, V87, P7782, DOI 10.1073/pnas.87.19.7782; ARCECI RJ, 1988, P NATL ACAD SCI USA, V85, P4350, DOI 10.1073/pnas.85.12.4350; BRADBURY MWB, 1985, CIRC RES, V57, P213, DOI 10.1161/01.RES.57.2.213; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; BRADLEY G, 1990, J CELL PHYSIOL, V145, P398, DOI 10.1002/jcp.1041450303; CALLAGHAN R, 1993, J BIOL CHEM, V268, P16059; Campbell WW, 1989, IVERMECTIN ABAMECTIN; CEFALU WT, 1985, J NEUROCHEM, V45, P1954, DOI 10.1111/j.1471-4159.1985.tb10557.x; CHAN HSL, 1991, NEW ENGL J MED, V325, P1608, DOI 10.1056/NEJM199112053252304; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CORDONCARDO C, 1989, P NATL ACAD SCI USA, V86, P695, DOI 10.1073/pnas.86.2.695; CROOP JM, 1989, MOL CELL BIOL, V9, P1346, DOI 10.1128/MCB.9.3.1346; DEVAULT A, 1990, MOL CELL BIOL, V10, P1652, DOI 10.1128/MCB.10.4.1652; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FISHER MH, 1992, ANNU REV PHARMACOL, V32, P537, DOI 10.1146/annurev.pa.32.040192.002541; FORD JM, 1990, PHARMACOL REV, V42, P155; GEORGES E, 1990, P NATL ACAD SCI USA, V87, P152, DOI 10.1073/pnas.87.1.152; GOLDSTEIN GW, 1986, SCI AM, V255, P70; GOLDSTEIN LJ, 1989, J NATL CANCER I, V81, P116, DOI 10.1093/jnci/81.2.116; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GREIG NH, 1990, CANCER CHEMOTH PHARM, V26, P263, DOI 10.1007/BF02897227; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; GROS P, 1986, NATURE, V323, P728, DOI 10.1038/323728a0; GROS P, 1991, P NATL ACAD SCI USA, V88, P7289, DOI 10.1073/pnas.88.16.7289; GROS P, 1988, MOL CELL BIOL, V8, P2770, DOI 10.1128/MCB.8.7.2770; HORTON JK, 1989, BIOCHEM PHARMACOL, V38, P1727, DOI 10.1016/0006-2952(89)90405-X; HSU SIH, 1989, J BIOL CHEM, V264, P12053; JULIANO RL, 1976, BIOCHIM BIOPHYS ACTA, V455, P152, DOI 10.1016/0005-2736(76)90160-7; KASTER KR, 1983, NUCLEIC ACIDS RES, V11, P6895, DOI 10.1093/nar/11.19.6895; LADURON PM, 1979, BIOCHEM PHARMACOL, V28, P2161, DOI 10.1016/0006-2952(79)90198-9; LEVIN VA, 1980, J MED CHEM, V23, P682, DOI 10.1021/jm00180a022; PULLIAM JD, 1985, VET MED-US, V80, P33; RAYMOND M, 1990, MOL CELL BIOL, V10, P1642, DOI 10.1128/MCB.10.4.1642; RAYMOND M, 1989, P NATL ACAD SCI USA, V86, P6488, DOI 10.1073/pnas.86.17.6488; RONINSON IB, 1986, P NATL ACAD SCI USA, V83, P4538, DOI 10.1073/pnas.83.12.4538; SAEKI T, 1993, J BIOL CHEM, V268, P6077; Sambrook J., 1989, MOL CLONING LAB MANU; SCHINKEL AH, 1991, CANCER RES, V51, P2628; SIKIC BI, 1993, J CLIN ONCOL, V11, P1629, DOI 10.1200/JCO.1993.11.9.1629; SLATER LM, 1986, J CLIN INVEST, V77, P1405, DOI 10.1172/JCI112450; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; SUGAWARA I, 1988, CANCER RES, V48, P1926; TANIGAWARA Y, 1992, J PHARMACOL EXP THER, V263, P840; TATSUTA T, 1992, J BIOL CHEM, V267, P20383; TAYLOR HR, 1990, SCIENCE, V250, P116, DOI 10.1126/science.2218502; TEETER LD, 1990, MOL CELL BIOL, V10, P5728, DOI 10.1128/MCB.10.11.5728; THIEBAUT F, 1989, J HISTOCHEM CYTOCHEM, V37, P159, DOI 10.1177/37.2.2463300; THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735; TREZISE AEO, 1992, EMBO J, V11, P4291, DOI 10.1002/j.1460-2075.1992.tb05528.x; TSURUO T, 1981, CANCER RES, V41, P1967; UEDA K, 1987, P NATL ACAD SCI USA, V84, P3004, DOI 10.1073/pnas.84.9.3004; UEDA K, 1992, J BIOL CHEM, V267, P24248; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; VANDERBLIEK AM, 1988, GENE, V71, P401, DOI 10.1016/0378-1119(88)90057-1; VANDERLUGT N, 1991, GENE, V105, P263, DOI 10.1016/0378-1119(91)90161-4; VANDOMMELEN FS, 1986, BIOCHEM J, V236, P771, DOI 10.1042/bj2360771; VANTELLINGEN O, 1993, CANCER CHEMOTH PHARM, V32, P286, DOI 10.1007/BF00686174; VANTELLINGEN O, 1993, CANCER RES, V53, P2061	58	1917	1980	1	131	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 20	1994	77	4					491	502		10.1016/0092-8674(94)90212-7	http://dx.doi.org/10.1016/0092-8674(94)90212-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NM832	7910522				2022-12-24	WOS:A1994NM83200005
J	MULDER, DW; NUNN, AJ; KAMALI, A; NAKIYINGI, J; WAGNER, HU; KENGEYAKAYONDO, JF				MULDER, DW; NUNN, AJ; KAMALI, A; NAKIYINGI, J; WAGNER, HU; KENGEYAKAYONDO, JF			2-YEAR HIV-1-ASSOCIATED MORTALITY IN A UGANDAN RURAL-POPULATION	LANCET			English	Article							IMMUNODEFICIENCY VIRUS-INFECTION; HIV INFECTION; AFRICAN CITY; AIDS; ZAIRE; EMPLOYEES; KINSHASA	The mortality in 15 villages in South-West Uganda was studied in relation to HIV infection. After a population census, serum samples were tested for antibodies to HIV-1. Deaths were ascertained over 2 years. Unequivocal HIV-1 serology results were available for 9389 individuals. The prevalence of infection was 4.8% for all ages and 8.2% for adults (aged 13 or more). 198 deaths were recorded during 15725 person years of observation. Mortality among seronegative adults was 7.7 per 1000 and among seropositive adults 115.9 per 1000. The excess annual death rate associated with HIV-1 infection was 5.3 per 1000 and in adults 7.9 per 1000. Highest excess mortality was 16.9 per 1000 in the age group 25-34. Among adults, half of all deaths and among those aged 13-44 over 80% of deaths were attributable to HIV-1 infection. These results show the strong im pact that HIV-1 infection is having on mortality in a rural area of Uganda where the overall HIV-1 adult prevalence rate is below 10%-a rate lower than in many other parts of East Africa.	UGANDA VIRUS RES INST,ENTEBBE,UGANDA	Uganda Virus Research Institute	MULDER, DW (corresponding author), MRC UK,ODA,UVRI,PROGRAMME AIDS UGANDA,POB 49,ENTEBBE,UGANDA.			Nunn, Andrew/0000-0002-9158-4595				ANDERSON RM, 1991, AIDS, V5, pS37; ANZALA A, 1991, 7 INT C AIDS FLOR; BONGAARTS J, 1989, STAT MED, V8, P103, DOI 10.1002/sim.4780080111; COLEBUNDERS RL, 1991, AIDS, V5, pS103; DECOCK KM, 1990, SCIENCE, V249, P793, DOI 10.1126/science.2167515; GOEDERT JJ, 1989, NEW ENGL J MED, V321, P1141, DOI 10.1056/NEJM198910263211701; HIRA SK, 1990, J ACQ IMMUN DEF SYND, V3, P87; KNOWANE BM, 1991, AIDS, V5, pS7; LEE CA, 1989, BRIT J HAEMATOL, V73, P228, DOI 10.1111/j.1365-2141.1989.tb00257.x; LINDAN CP, 1992, ANN INTERN MED, V116, P320, DOI 10.7326/0003-4819-116-4-320; MANN JM, 1986, JAMA-J AM MED ASSOC, V255, P3255, DOI 10.1001/jama.255.23.3255; MULDER DW, 1994, AIDS, V8, P87, DOI 10.1097/00002030-199401000-00013; NELSON AM, 1991, AIDS, V5, P583, DOI 10.1097/00002030-199105000-00018; NGALY B, 1988, NEW ENGL J MED, V319, P1123, DOI 10.1056/NEJM198810273191704; NUNK AJ, 1994, IN PRESS METH INFORM, V33; NUNN AJ, 1993, AIDS, V7, P1057, DOI 10.1097/00002030-199308000-00005; PIOT P, 1991, AIDS, V5, pS1; RYDER RW, 1990, AIDS, V4, P725, DOI 10.1097/00002030-199008000-00002; SERWADDA D, 1992, AIDS, V6, P983, DOI 10.1097/00002030-199209000-00012; WAY PO, 1992, 8 INT C AIDS AMST; 1990, CURRENT FUTURE DIMEN; 1986, WKLY EPID REC, V61, P72	22	111	112	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 23	1994	343	8904					1021	1023		10.1016/S0140-6736(94)90133-3	http://dx.doi.org/10.1016/S0140-6736(94)90133-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NG682	7909054				2022-12-24	WOS:A1994NG68200015
J	FANG, JWS; BIRD, GLA; NAKAMURA, T; DAVIS, GL; LAU, JYN				FANG, JWS; BIRD, GLA; NAKAMURA, T; DAVIS, GL; LAU, JYN			HEPATOCYTE PROLIFERATION AS AN INDICATOR OF OUTCOME IN ACUTE ALCOHOLIC HEPATITIS	LANCET			English	Article							LIVER-DISEASE; THERAPY; GROWTH; TRIAL; DNA	To determine whether clinical outcome in patients with acute alcoholic hepatitis is related to the regenerative capability of the liver, liver biopsy specimens from 25 prospectively recruited patients with acute alcoholic hepatitis were studied for hepatic expression of mRNA for two proliferation markers, proliferating cell nuclear antigen and human histone, and for transforming growth factor alpha (TGFalpha) and TGFbeta1 and hepatocyte growth factor (HGF), which regulate hepatocyte proliferation. Proliferation markers were detected to varying degrees in 0-80% of hepatocytes and occasionally in sinusoidal cells and bile-duct epithelium in 19 patients (76%). Patients who survived for 6 months had greater expression of proliferation markers than those who did not survive (p < 0.01). TGFalpha was detected in hepatocytes and bile-duct epithelium, whereas TGFbeta1 was detected mainly in sinusoidal cells and was associated with perivenular fibrosis. Patients who survived for 6 months had greater expression of TGFs than non-survivors (p < 0.02). HGF was detected in sinusoidal cells in 7 patients and correlated with survival (p < 0.01). These data indicate that hepatocyte proliferation, which is possibly related to the pattern of hepatotrophic factor expression, is a good indicator of outcome in acute alcoholic hepatitis.	UNIV FLORIDA,DEPT MED,HEPATOBILIARY DIS SECT,POB 100214 JHMHC,GAINESVILLE,FL 32610; OSAKA UNIV,SCH MED,SUITA,OSAKA 565,JAPAN; GARTNAVEL ROYAL HOSP,MED UNIT A,GLASGOW G12 0YN,SCOTLAND	State University System of Florida; University of Florida; Osaka University; Gartnavel Royal Hospital								BAKER AL, 1981, GASTROENTEROLOGY, V80, P1410; BAPTISTA A, 1981, Lancet, V1, P707; BIRD GLA, 1988, MOL ASPECTS MED, V10, P97, DOI 10.1016/0098-2997(88)90017-9; CASTILLA A, 1991, NEW ENGL J MED, V324, P933, DOI 10.1056/NEJM199104043241401; DALKE DD, 1990, HEPATOLOGY, V12, P1085, DOI 10.1002/hep.1840120502; FAIRMAN MP, 1990, J CELL SCI, V95, P1; FAUSTO N, 1989, LAB INVEST, V60, P4; LAU JYN, 1991, J CLIN PATHOL, V44, P905, DOI 10.1136/jcp.44.11.905; MADDREY WC, 1978, GASTROENTEROLOGY, V75, P193; SCHUMPERLI D, 1986, CELL, V45, P471, DOI 10.1016/0092-8674(86)90277-1; SIERRA F, 1982, P NATL ACAD SCI-BIOL, V79, P1795, DOI 10.1073/pnas.79.6.1795; THEODOSSI A, 1982, GUT, V23, P75, DOI 10.1136/gut.23.1.75	12	61	63	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 2	1994	343	8901					820	823		10.1016/S0140-6736(94)92025-7	http://dx.doi.org/10.1016/S0140-6736(94)92025-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ND792	7908077				2022-12-24	WOS:A1994ND79200008
J	WHEELER, T; SOLLERO, C; ALDERMAN, S; LANDEN, J; ANTHONY, F; OSMOND, C				WHEELER, T; SOLLERO, C; ALDERMAN, S; LANDEN, J; ANTHONY, F; OSMOND, C			RELATION BETWEEN MATERNAL HEMOGLOBIN AND PLACENTAL HORMONE CONCENTRATIONS IN EARLY-PREGNANCY	LANCET			English	Article							HIGH-ALTITUDES; HYPOXIA; FETAL	Environmental factors that influence placental development are of particular interest because of the reported association between adult hypertension, low birthweight, and large placental size. Maternal anaemia is one environmental factor that is associated with an increase in placental size at birth. We have examined the relation between haematological status and plasma concentrations of chorionic gonadotropin (hCG) and placental lactogen (hPL) in 175 women at about 10 weeks of pregnancy. There were significant negative correlations between maternal haemoglobin concentration and the levels of hCG (p=0.03) and hPL (p=0.02). Although 21% of women had low iron stores (ferritin < 13 mu g/L), no relation was found between serum ferritin and the two placental hormones. There was no association between plasma volume (calculated from maternal weight and height) and hCG or hPL concentrations.	SOUTHAMPTON GEN HOSP, MRC, ENVIRONM EPIDEMIOL UNIT, SOUTHAMPTON SO9 4XY, HANTS, ENGLAND	University of Southampton	WHEELER, T (corresponding author), UNIV SOUTHAMPTON, PRINCESS ANNE HOSP, DEPT OBSTET & GYNAECOL, SOUTHAMPTON, HANTS, ENGLAND.			Osmond, Clive/0000-0002-9054-4655				BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; BEISCHER N A, 1970, Journal of Obstetrics and Gynaecology of the British Commonwealth, V77, P398; BERNSTEIN L, 1989, BRIT J OBSTET GYNAEC, V96, P92, DOI 10.1111/j.1471-0528.1989.tb01582.x; CLAPP JF, 1988, AM J OBSTET GYNECOL, V159, P1456, DOI 10.1016/0002-9378(88)90574-1; FLETCHER J, 1969, CLIN SCI, V36, P209; FOX H, 1970, AM J OBSTET GYNECOL, V107, P1058, DOI 10.1016/0002-9378(70)90629-0; GODFREY KM, 1991, BRIT J OBSTET GYNAEC, V98, P886, DOI 10.1111/j.1471-0528.1991.tb13510.x; Gregory F., 1990, DIETARY NUTR SURVEY; HAY DL, 1988, BRIT J OBSTET GYNAEC, V95, P1268, DOI 10.1111/j.1471-0528.1988.tb06817.x; HOWE D, IN PRESS J PHYSL; HUSTIN J, 1992, 1ST 12 WEEKS GESTATI, P97; JACKSON MR, 1987, J ANAT, V152, P173; KRUGER H, 1970, AM J OBSTET GYNECOL, V106, P586; LUND CJ, 1967, AM J OBSTET GYNECOL, V98, P393, DOI 10.1016/0002-9378(67)90160-3; MAYHEW TM, 1990, PLACENTA, V11, P493, DOI 10.1016/S0143-4004(05)80195-X; PARKER DJP, 1992, J EPIDEMIOL COMMUN H, V46, P8, DOI 10.1136/jech.46.1.8; RESHETNIKOVA OS, 1993, J PHYSIOL-LONDON, V459, pP308; RODESCH F, 1992, OBSTET GYNECOL, V80, P283; RYBO G, 1973, CLIN HAEMATOL, P269; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; WHITTAKER PG, 1993, BRIT J OBSTET GYNAEC, V100, P587, DOI 10.1111/j.1471-0528.1993.tb15315.x	21	35	35	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 26	1994	343	8896					511	513		10.1016/S0140-6736(94)91461-3	http://dx.doi.org/10.1016/S0140-6736(94)91461-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MX888	7906760				2022-12-24	WOS:A1994MX88800009
J	CAFORIO, ALP; KEELING, PJ; ZACHARA, E; MESTRONI, L; CAMERINI, F; MANN, JM; BOTTAZZO, GF; MCKENNA, WJ				CAFORIO, ALP; KEELING, PJ; ZACHARA, E; MESTRONI, L; CAMERINI, F; MANN, JM; BOTTAZZO, GF; MCKENNA, WJ			EVIDENCE FROM FAMILY STUDIES FOR AUTOIMMUNITY IN DILATED CARDIOMYOPATHY	LANCET			English	Article							I DIABETES-MELLITUS; CARDIAC ANTIBODIES; AUTOANTIBODIES; ASSOCIATION	Organ-specific antibodies are found in patients with autoimmune disease and their symptom-free relatives many years before clinical onset. Organ-specific cardiac antibodies can be found in patients with dilated cardiomyopathy (DCM) and their relatives, which supports the idea that DCM is an autoimmune disease. We did non-invasive cardiological assessment and antibody screening in 342 symptom-free relatives (170 male, 172 female, mean [SD] age 31 [16] years). 177 relatives were from 33 families with more than 1 affected individual (familial DCM) and 165 relatives from 31 families with only 1 affected member (non-familial DCM). The frequency of cardiac antibodies was higher among relatives of DCM patients than in controls (20% vs 3.5%, p = 0.0001). In 37 (58%) of the families studied, cardiac antibodies were found in the proband and/or in at least 1 family member and were more common in familial than in non-familial DCM (24% vs 15%, p = 0.036). Antibody-positive relatives were younger (26 [15] vs 33 [17] years, p = 0.01) and had a larger mean echocardiographic left ventricular end-systolic dimension (35 [6] vs 32 [6], p = 0.01 mm) and reduced percentage fractional shortening compared with antibody-negative relatives (31 [6] vs 34 [6], p = 0.008). Presence of cardiac-specific autoantibodies in symptom-free DCM relatives provides evidence of autoimmunity in a subset of our patients (58%), including familial and nonfamilial forms of DCM. These antibodies are associated with mild left ventricular systolic dysfunction on echocardiography and may be early markers for relatives at risk of DCM.	ST GEORGE HOSP,SCH MED,DEPT CARDIOL SCI,LONDON SW17 0RE,ENGLAND; ST GEORGE HOSP,SCH MED,DEPT CARDIOVASC PATHOL,LONDON SW17 0RE,ENGLAND; UNIV PADUA,INST CLIN MED,DEPT CARDIOL,PADUA,ITALY; LONDON HOSP,COLL MED,DEPT IMMUNOL,LONDON E1 1BB,ENGLAND; SAN CAMILLO HOSP,ROME,ITALY; INT CTR GENET ENGN & BIOTECHNOL,I-34012 TRIESTE,ITALY; UNIV HOSP TRIESTE,TRIESTE,ITALY	St Georges University London; St Georges University London; University of Padua; University of London; Queen Mary University London; International Center for Genetic Engineering & Biotechnology (ICGEB)			Caforio, Alida/AAC-3223-2019; McKenna, William J/C-3243-2008	McKenna, William J/0000-0001-7994-2460; Mestroni, Luisa/0000-0003-1116-2286; Caforio, Alida Linda Patrizia/0000-0002-4901-5655				Aretz HT, 1985, AM J CARDIOL PATHOL, V1, P1; BRANDENBURG RO, 1981, CIRCULATION, V64, pA437; CAFORIO ALP, 1992, TISSUE ANTIGENS, V39, P236, DOI 10.1111/j.1399-0039.1992.tb01941.x; CAFORIO ALP, 1992, CIRCULATION, V85, P1734, DOI 10.1161/01.CIR.85.5.1734; CAFORIO ALP, 1991, LANCET, V337, P1111, DOI 10.1016/0140-6736(91)92784-Y; CAFORIO ALP, 1990, J AM COLL CARDIOL, V15, P1527, DOI 10.1016/0735-1097(90)92821-I; CARLQUIST JF, 1991, CIRCULATION, V83, P515, DOI 10.1161/01.CIR.83.2.515; FUSTER V, 1981, AM J CARDIOL, V47, P525, DOI 10.1016/0002-9149(81)90534-8; HENRY WL, 1980, CIRCULATION, V62, P1054, DOI 10.1161/01.CIR.62.5.1054; KARJALAINEN J, 1989, NEW ENGL J MED, V320, P881, DOI 10.1056/NEJM198904063201401; KLEIN R, 1984, CLIN EXP IMMUNOL, V58, P283; LIMAS CJ, 1989, CIRC RES, V64, P97, DOI 10.1161/01.RES.64.1.97; MAGNUSSON Y, 1990, J CLIN INVEST, V86, P1658, DOI 10.1172/JCI114888; MAISCH B, 1983, AM J CARDIOL, V52, P1072, DOI 10.1016/0002-9149(83)90535-0; MANOLIO TA, 1992, AM J CARDIOL, V69, P1458, DOI 10.1016/0002-9149(92)90901-A; MESTRONI L, 1990, AM J CARDIOL, V65, P1449, DOI 10.1016/0002-9149(90)91353-8; MICHELS VV, 1992, NEW ENGL J MED, V326, P77, DOI 10.1056/NEJM199201093260201; NEUMANN DA, 1990, J AM COLL CARDIOL, V16, P839; SCHULTHEISS HP, 1985, J MOL CELL CARDIOL, V17, P603, DOI 10.1016/S0022-2828(85)80029-8; SOKOLOW M, 1949, AM HEART J, V37, P161, DOI 10.1016/0002-8703(49)90562-1; SRIKANTA S, 1983, NEW ENGL J MED, V308, P322, DOI 10.1056/NEJM198302103080607; ZACHARA E, 1993, BRIT HEART J, V69, P129; 1978, AM J CARDIOL, V0041, P00130	23	124	126	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 17	1994	344	8925					773	777		10.1016/S0140-6736(94)92339-6	http://dx.doi.org/10.1016/S0140-6736(94)92339-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PG178	7916071				2022-12-24	WOS:A1994PG17800008
J	WEISS, APC				WEISS, APC			THERMAL REGULATORY TESTING FOR PAIN DYSFUNCTION SYNDROMES	LANCET			English	Editorial Material							REFLEX SYMPATHETIC DYSTROPHY				WEISS, APC (corresponding author), BROWN UNIV,SCH MED,DEPT ORTHOPED,PROVIDENCE,RI 02912, USA.							AMADIO PC, 1988, J BONE JOINT SURG AM, V70A, P944, DOI 10.2106/00004623-198870060-00024; COOKE ED, 1993, J ROY SOC MED, V86, P690; HOLDER LE, 1984, RADIOLOGY, V152, P517, DOI 10.1148/radiology.152.2.6739825; KOMAN LA, 1984, J HAND SURG-AM, V9A, P305, DOI 10.1016/S0363-5023(84)80214-2; LINSON MA, 1983, J HAND SURG-AM, V8, P153, DOI 10.1016/S0363-5023(83)80006-9; POCHACZEVSKY R, 1987, AM J SPORT MED, V15, P243, DOI 10.1177/036354658701500309; POLLOCK FE, 1993, J HAND SURG-AM, V18A, P847; WERNER R, 1989, J HAND SURG-AM, V14A, P520, DOI 10.1016/S0363-5023(89)80016-4; 1986, PAIN S3, V26, pS29	9	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 23	1994	344	8917					209	210		10.1016/S0140-6736(94)92990-4	http://dx.doi.org/10.1016/S0140-6736(94)92990-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY060	7913150				2022-12-24	WOS:A1994NY06000002
J	CAPLICE, NM; WEST, MJ; CAMPBELL, GR; CAMPBELL, J				CAPLICE, NM; WEST, MJ; CAMPBELL, GR; CAMPBELL, J			INHIBITION OF HUMAN VASCULAR SMOOTH-MUSCLE CELL-GROWTH BY HEPARIN	LANCET			English	Note							EXPRESSION	We examined the inhibitory effect of heparin on vascular smooth muscle cell (VSMC) outgrowth from cultured coronary artery explants of primary atherosclerotic lesions and of undiseased regions from the same patients, compared with explant outgrowth from control patients (idiopathic cardiomyopathy) with no evidence of atherosclerosis. For undiseased tissue regardless of origin, heparin significantly delayed half-maximum percentage explant outgrowth time (mean difference from control treatment 2.1 [SE 0.8] days for atherosclerosis patients and 2.3 [1.0] days for control patients). For plaque tissue, hepa rin had no such effect. Thus the proliferative state of the cells involved in outgrowth may influence the activity of heparin.	UNIV QUEENSLAND,DEPT ANAT SCI,VASC BIOL RES CTR,BRISBANE,QLD,AUSTRALIA	University of Queensland	CAPLICE, NM (corresponding author), UNIV QUEENSLAND,PRINCE CHARLES HOSP,DEPT MED,BRISBANE,QLD 4032,AUSTRALIA.		CAMPBELL, GORDON/AAK-7979-2021; west, malcolm J/C-9425-2009	CAMPBELL, GORDON/0000-0003-1263-1988; west, malcolm J/0000-0002-7629-5277; Caplice, Noel/0000-0001-5445-1016				AU YPT, 1992, CIRC RES, V70, P1062, DOI 10.1161/01.RES.70.5.1062; CASTELLOT JJ, 1985, J CELL PHYSIOL, V124, P21, DOI 10.1002/jcp.1041240105; CHAMLEYCAMPBELL J, 1979, PHYSIOL REV, V59, P1, DOI 10.1152/physrev.1979.59.1.1; CHAN P, 1993, LANCET, V341, P341, DOI 10.1016/0140-6736(93)90139-8; CLOWES AW, 1988, J CELL BIOL, V107, P1939, DOI 10.1083/jcb.107.5.1939; CLOWES AW, 1992, CIRC RES, V70, P1128, DOI 10.1161/01.RES.70.6.1128; LEVINE S, 1985, AM J CARDIOL, V55, P673, DOI 10.1016/0002-9149(85)90134-1; SCHWARTZ SM, 1986, CIRC RES, V58, P427, DOI 10.1161/01.RES.58.4.427	8	29	29	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 9	1994	344	8915					97	98		10.1016/S0140-6736(94)91283-1	http://dx.doi.org/10.1016/S0140-6736(94)91283-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NV732	7912394				2022-12-24	WOS:A1994NV73200011
J	PAWLIKOWSKA, T; CHALDER, T; HIRSCH, SR; WALLACE, P; WRIGHT, DJM; WESSELY, S				PAWLIKOWSKA, T; CHALDER, T; HIRSCH, SR; WALLACE, P; WRIGHT, DJM; WESSELY, S			POPULATION-BASED STUDY OF FATIGUE AND PSYCHOLOGICAL DISTRESS	BRITISH MEDICAL JOURNAL			English	Article							PRIMARY CARE; PREVALENCE; BEHAVIOR	Objectives-To determine the prevalence of fatigue in the general population and the factors associated with fatigue. Design-Postal survey. Setting-Six general practices in southern England. Subjects-31 651 men and women aged 18-45 years registered with the practices. Main outcome measures-Responses to the 12 item general health questionnaire and a fatigue questionnaire which included self reported measures of duration, severity, and causes of fatigue. Results-15 283 valid questionnaires were returned, giving a response rate of 48.3%, (64% after adjustment for inaccuracies in the practice registers). 2798 (18.3%) of respondents reported substantial fatigue lasting six months or longer. Fatigue and psychological morbidity were moderately correlated (r = 0.62). Women were more likely to complain of fatigue than men, even after adjustment for psychological distress. The commonest cited reasons for fatigue were psychosocial (40% of patients). Of 2798 patients with excessive tiredness, only 38 (1.4%) attributed this to the chronic fatigue syndrome. Conclusion-Fatigue is distributed as a continuous variable in the community and is closely associated with psychological morbidity.	KINGS COLL, SCH MED & DENT, DEPT PSYCHOL MED, LONDON SE5 9RS, ENGLAND; ST MARYS HOSP, SCH MED, DEPT GEN PRACTICE, LONDON, ENGLAND; CHARING CROSS HOSP, SCH MED, DEPT MED MICROBIOL, LONDON, ENGLAND; CHARING CROSS HOSP, SCH MED, DEPT PSYCHIAT, LONDON, ENGLAND; ROYAL FREE HOSP, SCH MED, DEPT GEN PRACTICE, LONDON NW3, ENGLAND	University of London; King's College London; Imperial College London; Imperial College London; Imperial College London; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School			Wessely, Simon C/A-8713-2008; Chalder, Trudie/A-5717-2011	Chalder, Trudie/0000-0003-0775-1045; Wessely, Simon Charles/0000-0002-6743-9929				BEHAN P, 1988, CRIT REV NEURBIOL, V42, P157; BICKLER G, 1993, BRIT MED J, V306, P1167, DOI 10.1136/bmj.306.6886.1167; BUTLER S, 1991, J NEUROL NEUROSUR PS, V54, P153, DOI 10.1136/jnnp.54.2.153; CATHEBRAS PJ, 1992, J GEN INTERN MED, V7, P276, DOI 10.1007/BF02598083; CHALDER T, 1993, H PSYCHOSOMATIC RES, V37, P147; CROFT P, 1993, J RHEUMATOL, V20, P710; DAVID A, 1990, BMJ-BRIT MED J, V301, P1199, DOI 10.1136/bmj.301.6762.1199; DAVID AS, 1988, BRIT MED J, V296, P696, DOI 10.1136/bmj.296.6623.696; DAVID AS, 1991, BRIT MED BULL, V47, P966, DOI 10.1093/oxfordjournals.bmb.a072524; Goldberg DPW, 1988, USERS GUIDE GEN HLTH; JONES R, 1992, BRIT MED J, V304, P87, DOI 10.1136/bmj.304.6819.87; KATON W, 1992, ARCH INTERN MED, V152, P1604, DOI 10.1001/archinte.152.8.1604; KROENKE K, 1988, JAMA-J AM MED ASSOC, V260, P929, DOI 10.1001/jama.260.7.929; LEWIS G, 1992, J EPIDEMIOL COMMUN H, V46, P92, DOI 10.1136/jech.46.2.92; MANU P, 1988, ARCH INTERN MED, V148, P2213, DOI 10.1001/archinte.148.10.2213; MCDONALD E, 1993, PSYCHOL MED, V23, P987, DOI 10.1017/S0033291700026453; SHARPE M, 1992, BRIT MED J, V302, P347; SHARPE MC, 1991, J ROY SOC MED, V84, P118, DOI 10.1177/014107689108400224; WESSELY S, 1989, J NEUROL NEUROSUR PS, V52, P940, DOI 10.1136/jnnp.52.8.940	19	465	472	0	19	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 19	1994	308	6931					763	766		10.1136/bmj.308.6931.763	http://dx.doi.org/10.1136/bmj.308.6931.763			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NC348	7908238	Green Published			2022-12-24	WOS:A1994NC34800024
J	WITTEMAN, JCM; GROBBEE, DE; VALKENBURG, HA; VANHEMERT, AM; STIJNEN, T; BURGER, H; HOFMAN, A				WITTEMAN, JCM; GROBBEE, DE; VALKENBURG, HA; VANHEMERT, AM; STIJNEN, T; BURGER, H; HOFMAN, A			J-SHAPED RELATION BETWEEN CHANGE IN DIASTOLIC BLOOD-PRESSURE AND PROGRESSION OF AORTIC ATHEROSCLEROSIS	LANCET			English	Article							CORONARY HEART-DISEASE; MYOCARDIAL-INFARCTION; CALCIFICATION; MORTALITY; RISK	The J-shaped relation between diastolic blood pressure and mortality from coronary heart disease continues to provoke controversy. We examined the association between diastolic blood pressure and progression of aortic atherosclerosis in a population-based cohort of 855 women, aged 45-64 years at baseline. The women were examined radiographically for calcified deposits in the abdominal aorta, which have been shown to reflect intimal atherosclerosis. After 9 years of follow-up, slight progression of atherosclerosis was noted in 19% of women and substantial progression in 16%. The age-adjusted relative risk of substantial atherosclerotic progression in women with a decrease in diastolic pressure of 10 mm Hg or more was 2.5 (95% CI 1.3-5.6), compared with the reference group of women who had a smaller decrease or no change. The excess risk in this group was confined to women whose increase in pulse pressure was above the median (3.9 [1.5-9.9] vs 1.1 [0.3-4.2] in women with an increase in pulse pressure below the median). The relative risks for women with rises in diastolic pressure of 1-9 mm Hg and 10 mm Hg or more were 2.2 (1.1-4.3) and 3.5 (1.6-8.0), respectively. These findings suggest that a decline in diastolic blood pressure indicates vessel wall stiffening associated with atherosclerotic progression. They support the hypothesis that in low-risk subjects progression of atherosclerosis may be accompanied by a decrease in diastolic blood pressure rather than the opposing idea that low diastolic blood pressure precipitates the occurrence of atherosclerotic events.	UNIV HOSP LEIDEN,DEPT PSYCHIAT,LEIDEN,NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC)	WITTEMAN, JCM (corresponding author), ERASMUS UNIV ROTTERDAM,SCH MED,DEPT EPIDEMIOL & BIOSTAT,POB 1738,3000 DR ROTTERDAM,NETHERLANDS.		Grobbee, Diederick/C-7651-2014	Grobbee, Diederick/0000-0003-4472-4468				BOTS ML, 1993, ATHEROSCLEROSIS, V102, P99, DOI 10.1016/0021-9150(93)90088-C; COOPE J, 1988, J HUM HYPERTENS, V2, P79; CRUICKSHANK JM, 1988, BMJ-BRIT MED J, V297, P1227, DOI 10.1136/bmj.297.6658.1227; CRUICKSHANK JM, 1987, LANCET, V1, P581; DAGOSTINO RB, 1991, BRIT MED J, V303, P385, DOI 10.1136/bmj.303.6799.385; Dixon W. J., 1990, BMDP STATISTICAL SOF; FARNETT L, 1991, JAMA-J AM MED ASSOC, V265, P489, DOI 10.1001/jama.265.4.489; Fineberg MH, 1927, AM J MED SCI, V173, P835; FLETCHER AE, 1992, NEW ENGL J MED, V326, P251; HYMAN JB, 1954, AM HEART J, V47, P540; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MEGNIEN JL, 1992, CIRCULATION, V85, P1799, DOI 10.1161/01.CIR.85.5.1799; SLEIGHT P, 1988, LANCET, V1, P235; TAYLOR JO, 1991, AM J EPIDEMIOL, V134, P489, DOI 10.1093/oxfordjournals.aje.a116121; VANHEMERT AM, 1990, AM J EPIDEMIOL, V132, P123, DOI 10.1093/oxfordjournals.aje.a115624; VANMERODE T, 1988, ULTRASOUND MED BIOL, V14, P563, DOI 10.1016/0301-5629(88)90122-6; Wiggers CJ, 1932, ANN INTERN MED, V6, P12, DOI 10.7326/0003-4819-6-1-12; WITTEMAN JCM, 1986, LANCET, V2, P1120; WITTEMAN JCM, 1990, AM J CARDIOL, V66, P1060, DOI 10.1016/0002-9149(90)90505-U; WITTEMAN JCM, 1993, CIRCULATION, V88, P2156, DOI 10.1161/01.CIR.88.5.2156	20	218	223	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 26	1994	343	8896					504	507		10.1016/S0140-6736(94)91459-1	http://dx.doi.org/10.1016/S0140-6736(94)91459-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MX888	7906758	Green Submitted			2022-12-24	WOS:A1994MX88800007
J	TANG, MLK; KEMP, AS; THORBURN, J; HILL, DJ				TANG, MLK; KEMP, AS; THORBURN, J; HILL, DJ			REDUCED INTERFERON-GAMMA SECRETION IN NEONATES AND SUBSEQUENT ATOPY	LANCET			English	Article							CORD BLOOD IGE; IMMUNOGLOBULIN-E; NATURAL-HISTORY; EARLY-CHILDHOOD; DISEASE; DERMATITIS; PREDICTION; CHILDREN; INTERLEUKIN-4; RECEPTOR	Low interferon-gamma (IFN-gamma) secretion has been found in individuals with active atopic disease. Whether this is a cause or result of the disease process is uncertain. Cord blood IFN-gamma secretion was examined in 35 neonates who were then prospectively followed up for 1 year for the development of atopic disease. Infants who developed either symptoms of atopic disease or a positive IgE-mediated skin prick test at 12 months of age produced significantly less IFN-gamma at birth compared with those who did not (p = 0.005). This reduced secretion of IFN-gamma at birth indicates that the defect in interferon secretion is a primary component of the atopic state rather than an effect of the disease process.	ROYAL CHILDRENS HOSP,DEPT IMMUNOL,MELBOURNE,VIC,AUSTRALIA; ROYAL CHILDRENS HOSP,DEPT ALLERGY,MELBOURNE,VIC,AUSTRALIA; MERCY MATERN HOSP,DEPT NEONATAL PEDIAT,MELBOURNE,VIC,AUSTRALIA	Royal Children's Hospital Melbourne; Royal Children's Hospital Melbourne				Tang, Mimi/0000-0002-3839-5293				BUSINCO L, 1983, CLIN ALLERGY, V13, P503, DOI 10.1111/j.1365-2222.1983.tb02631.x; DELPRETE G, 1988, J IMMUNOL, V140, P4193; DING AH, 1988, J IMMUNOL, V141, P2407; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; HANIFIN JM, 1991, PEDIATR CLIN N AM, V38, P763; HIDE DW, 1991, CLIN EXP ALLERGY, V21, P739, DOI 10.1111/j.1365-2222.1991.tb03204.x; JUJO K, 1992, J ALLERGY CLIN IMMUN, V90, P323, DOI 10.1016/S0091-6749(05)80010-7; KJELLMAN NIM, 1984, ANN ALLERGY, V53, P167; LIPTAY S, 1992, CLIN PEDIATR, V31, P241, DOI 10.1177/000992289203100411; MERRETT T, 1992, CLIN EXP ALLERGY, V22, P506, DOI 10.1111/j.1365-2222.1992.tb00155.x; MICHEL FB, 1980, J ALLERGY CLIN IMMUN, V65, P422, DOI 10.1016/0091-6749(80)90234-1; REINHOLD U, 1990, LANCET, V335, P1282, DOI 10.1016/0140-6736(90)91347-D; REINHOLD U, 1988, INT ARCH ALLER A IMM, V87, P120, DOI 10.1159/000234661; Rinas U, 1993, Pediatr Allergy Immunol, V4, P60, DOI 10.1111/j.1399-3038.1993.tb00068.x; RUIZ RGG, 1990, LANCET, V336, P808, DOI 10.1016/0140-6736(90)93267-S; RUIZ RGG, 1991, CLIN EXP ALLERGY, V21, P467, DOI 10.1111/j.1365-2222.1991.tb01687.x; TANG M, 1993, CLIN EXP IMMUNOL, V92, P120; TANG MLK, 1994, IN PRESS CLIN EXP IM; VANASPEREN PP, 1989, ACTA PAEDIATR SCAND, V78, P239; VERCELLI D, 1989, J EXP MED, V169, P1295, DOI 10.1084/jem.169.4.1295; WARNER JA, 1994, CLIN EXP ALLERGY, V24, P423, DOI 10.1111/j.1365-2222.1994.tb00930.x	21	367	371	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 8	1994	344	8928					983	985		10.1016/S0140-6736(94)91641-1	http://dx.doi.org/10.1016/S0140-6736(94)91641-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PK978	7934430				2022-12-24	WOS:A1994PK97800009
J	YIN, JCP; WALLACH, JS; DELVECCHIO, M; WILDER, EL; ZHOU, H; QUINN, WG; TULLY, T				YIN, JCP; WALLACH, JS; DELVECCHIO, M; WILDER, EL; ZHOU, H; QUINN, WG; TULLY, T			INDUCTION OF A DOMINANT-NEGATIVE CREB TRANSGENE SPECIFICALLY BLOCKS LONG-TERM-MEMORY IN DROSOPHILA	CELL			English	Article							APLYSIA SENSORY NEURONS; LEUCINE ZIPPER; TRANSCRIPTION FACTORS; PROTEIN-SYNTHESIS; BINDING-PROTEINS; CDNA CLONES; GENE; MELANOGASTER; ELEMENT; FACILITATION	Consolidated memory after olfactory learning in Drosophila consists of two components, a cycloheximide-sensitive, long-term memory (LTM) and a cycloheximide-insensitive, anesthesia-resistant memory (ARM). Using an inducible transgene that expresses a dominant negative member of the fly CREB family, LTM was specifically and completely blocked only after induction, while ARM and learning were unaffected. These results suggest that LTM formation requires de novo gene expression probably mediated by CREB family genes.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; HARVARD UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT GENET,BOSTON,MA 02115	Massachusetts Institute of Technology (MIT); Harvard University; Harvard Medical School; Howard Hughes Medical Institute	YIN, JCP (corresponding author), COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724, USA.				NICHD NIH HHS [HD32245] Funding Source: Medline; NINDS NIH HHS [NS25621] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD032245] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS025621] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AGRANOFF BERNARD W., 1966, BRAIN RES, V1, P303, DOI 10.1016/0006-8993(66)90095-3; ALBERINI CM, 1994, CELL, V76, P1099, DOI 10.1016/0092-8674(94)90386-7; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BACKSAI BJ, 1993, SCIENCE, V260, P222; BADDELEY A, 1976, PSYCHOL MEMORY; BARONDES SH, 1968, NATURE, V218, P271; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; BOYNTON S, 1992, GENETICS, V131, P655; BYERS D, 1981, NATURE, V289, P79, DOI 10.1038/289079a0; BYRNE JH, 1993, ADV SEC MESS PHOSPH, V27, P47; CHEN CN, 1986, P NATL ACAD SCI USA, V83, P9313, DOI 10.1073/pnas.83.24.9313; DASH PK, 1990, NATURE, V345, P718, DOI 10.1038/345718a0; DAVIS HP, 1984, PSYCHOL BULL, V96, P518, DOI 10.1037/0033-2909.96.3.518; DEGROOT RP, 1993, MOL ENDOCRINOL, V7, P145, DOI 10.1210/me.7.2.145; DRAIN P, 1991, NEURON, V6, P71, DOI 10.1016/0896-6273(91)90123-H; DUDAI Y, 1976, P NATL ACAD SCI USA, V73, P1684, DOI 10.1073/pnas.73.5.1684; DURA JM, 1993, J NEUROGENET, V9, P1, DOI 10.3109/01677069309167272; DWARKI VJ, 1990, EMBO J, V9, P225, DOI 10.1002/j.1460-2075.1990.tb08099.x; Ebbinghaus, 1885, GEDACHTNIS; FOLKERS E, 1993, P NATL ACAD SCI USA, V90, P8123, DOI 10.1073/pnas.90.17.8123; FOULKES NS, 1992, CELL, V68, P411, DOI 10.1016/0092-8674(92)90178-F; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; FREY U, 1993, SCIENCE, V260, P1661, DOI 10.1126/science.8389057; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HOVEMANN B, 1988, NUCLEIC ACIDS RES, V16, P3175, DOI 10.1093/nar/16.8.3175; Huang Y Y, 1994, Learn Mem, V1, P74; KAANG BK, 1993, NEURON, V10, P427, DOI 10.1016/0896-6273(93)90331-K; KANDEL ER, 1982, SCIENCE, V218, P433, DOI 10.1126/science.6289442; KANDEL ER, 1987, SYNAPTIC FUNCTION, P471; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEVIN LR, 1992, CELL, V68, P479, DOI 10.1016/0092-8674(92)90185-F; LIVINGSTONE MS, 1984, CELL, V37, P205, DOI 10.1016/0092-8674(84)90316-7; MONTAROLO PG, 1986, SCIENCE, V234, P1249, DOI 10.1126/science.3775383; PARKER VP, 1985, MOL CELL BIOL, V5, P3058, DOI 10.1128/MCB.5.11.3058; QUINN WG, 1974, P NATL ACAD SCI USA, V71, P708, DOI 10.1073/pnas.71.3.708; ROSENZWEIG MR, 1984, NEUROBIOLOGY LEARNIN, P263; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SCHACHER S, 1988, SCIENCE, V240, P1667, DOI 10.1126/science.2454509; SKOULAKIS EMC, 1993, NEURON, V11, P197, DOI 10.1016/0896-6273(93)90178-T; Sokal R. R, 1981, BIOMETRY; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; TULLY T, 1994, CELL, V79, P35, DOI 10.1016/0092-8674(94)90398-0; TULLY T, 1985, J COMP PHYSIOL A, V157, P263, DOI 10.1007/BF01350033; TULLY T, 1993, J NEUROGENET, V9, P65; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0	49	796	828	2	42	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 7	1994	79	1					49	58		10.1016/0092-8674(94)90399-9	http://dx.doi.org/10.1016/0092-8674(94)90399-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PK585	7923376				2022-12-24	WOS:A1994PK58500007
J	FRESHNEY, NW; RAWLINSON, L; GUESDON, F; JONES, E; COWLEY, S; HSUAN, J; SAKLATVALA, J				FRESHNEY, NW; RAWLINSON, L; GUESDON, F; JONES, E; COWLEY, S; HSUAN, J; SAKLATVALA, J			INTERLEUKIN-1 ACTIVATES A NOVEL PROTEIN-KINASE CASCADE THAT RESULTS IN THE PHOSPHORYLATION OF HSP27	CELL			English	Article							TUMOR-NECROSIS-FACTOR; HEAT-SHOCK PROTEIN; FACTOR INCREASE PHOSPHORYLATION; SIGNAL TRANSDUCTION; PHORBOL ESTER; SKELETAL-MUSCLE; MAPKAP KINASE-2; CELLS; FIBROBLASTS; IDENTIFICATION	An IL-1-stimulated protein kinase cascade resulting in phosphorylation of the small heat shock protein hsp27 has been identified in KB cells. It is distinct from the p42 MAP kinase cascade. An upstream activator kinase phosphorylated a 40 kDa kinase (p40) upon threonine and tyrosine residues, which in turn phosphorylated a 50 kDa kinase (p50) upon threonine (and some serine) residues. p50 phosphorylated hsp27 upon serine. p40 and p50 were purified to near homogeneity. All three components were inactivated by protein phosphatase 2A, and p40 was inactivated by protein tyrosine phosphatase 1B. The substrate specificity of p40 differed from that of p42 and p54 MAP kinases. The upstream activator was not a MAP kinase kinase. p50 resembled MAPKAPK-2 and may be identical.	BABRAHAM INST,DEPT DEV & SIGNALLING,CYTOKINE LAB,CAMBRIDGE CB2 4AT,CAMBS,ENGLAND; INST CANC RES,CHESTER BEATTY LABS,LONDON SW3 6JB,ENGLAND; LUDWIG INST CANC RES,LONDON W1P 8BT,ENGLAND	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Ludwig Institute for Cancer Research			Hsuan, Justin/C-8825-2009	Hsuan, Justin/0000-0001-6083-7564; Freshney, Norman/0000-0002-6342-341X; Cowley, Sally/0000-0003-0297-6675				ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; BARFORD D, 1994, J MOL BIOL, V239, P726, DOI 10.1006/jmbi.1994.1409; BIRD TA, 1989, J IMMUNOL, V142, P126; BIRD TA, 1990, J BIOL CHEM, V265, P235; BIRD TA, 1994, FEBS LETT, V338, P31, DOI 10.1016/0014-5793(94)80111-8; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; CARPER SW, 1990, NUCLEIC ACIDS RES, V18, P6457, DOI 10.1093/nar/18.21.6457; COHEN P, 1988, METHOD ENZYMOL, V159, P390; COHEN P, 1993, BIOCHEM SOC T, V21, P555, DOI 10.1042/bst0210555; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DIGIOVINE FS, 1990, IMMUNOL TODAY, V11, P13; DINARELLO CA, 1991, BLOOD, V77, P1627; FEUERSTEIN N, 1983, J BIOL CHEM, V258, P786; GAESTEL M, 1991, J BIOL CHEM, V266, P14721; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GUESDON F, 1993, J BIOL CHEM, V268, P4236; GUY GR, 1991, J BIOL CHEM, V266, P14343; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HICKEY E, 1986, NUCLEIC ACIDS RES, V14, P4127, DOI 10.1093/nar/14.10.4127; JAKOB U, 1993, J BIOL CHEM, V268, P1517; KATO K, 1992, J BIOL CHEM, V267, P7718; KAUR P, 1989, FEBS LETT, V258, P269, DOI 10.1016/0014-5793(89)81671-0; KAUR P, 1988, FEBS LETT, V241, P6, DOI 10.1016/0014-5793(88)81019-6; KOSAKO H, 1993, EMBO J, V12, P787, DOI 10.1002/j.1460-2075.1993.tb05713.x; KRACHT M, 1994, IN PRESS BIOCH J; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANDRY J, 1992, J BIOL CHEM, V267, P794; LANDRY J, 1989, J CELL BIOL, V109, P7, DOI 10.1083/jcb.109.1.7; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LAVOIE JN, 1993, J BIOL CHEM, V268, P24210; LAVOIE JN, 1993, J BIOL CHEM, V268, P3420; LIU J, 1994, J BIOL CHEM, V269, P3047; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; MIZEL SB, 1990, IMMUNOL TODAY, V11, P390, DOI 10.1016/0167-5699(90)90154-2; NEBREDA AR, 1993, FEBS LETT, V333, P183, DOI 10.1016/0014-5793(93)80401-F; OKUSAWA S, 1988, J CLIN INVEST, V81, P1162, DOI 10.1172/JCI113431; ONEILL LAJ, 1990, IMMUNOL TODAY, V11, P392, DOI 10.1016/0167-5699(90)90155-3; RAPP UR, 1991, ONCOGENE, V6, P495; ROSSOMANDO A, 1992, P NATL ACAD SCI USA, V89, P5221, DOI 10.1073/pnas.89.12.5221; SAKLATVALA J, 1993, FEBS LETT, V334, P189, DOI 10.1016/0014-5793(93)81709-9; SAKLATVALA J, 1991, BIOCHEM J, V277, P635, DOI 10.1042/bj2770635; SATO N, 1986, J NATL CANCER I, V76, P113; SHIROO M, 1990, Cytokine, V2, P13, DOI 10.1016/1043-4666(90)90038-U; STOKOE D, 1993, BIOCHEM J, V296, P843, DOI 10.1042/bj2960843; STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; WELCH WJ, 1985, J BIOL CHEM, V260, P3058; XHOU M, 1993, J BIOL CHEM, V268, P35	48	795	818	0	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 23	1994	78	6					1039	1049		10.1016/0092-8674(94)90278-X	http://dx.doi.org/10.1016/0092-8674(94)90278-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PJ294	7923354				2022-12-24	WOS:A1994PJ29400014
J	MCMENAMIN, C; PIMM, C; MCKERSEY, M; HOLT, PG				MCMENAMIN, C; PIMM, C; MCKERSEY, M; HOLT, PG			REGULATION OF IGE RESPONSES TO INHALED ANTIGEN IN MICE BY ANTIGEN-SPECIFIC GAMMA-DELTA T-CELLS	SCIENCE			English	Article							NATURAL IMMUNE-RESPONSE; ALPHA-BETA; INTRAEPITHELIAL LYMPHOCYTES; PROTEIN ANTIGENS; SUPPRESSION; INHALATION; SENSITIZATION; TOLERANCE; INDUCTION; RECEPTOR	Indirect evidence implicates gamma delta T cells in the cross-regulation of CD4 alpha beta T cell responses. Adoptive transfer of small numbers of gamma delta T cells from ovalbumin (OVA)-tolerant mice selectively suppressed T(H)2- dependent immunoglobulin E (IgE) antibody production without affecting parallel IgG responses. Challenge of these gamma delta T cells in vitro with specific antigen resulted in production of high levels of interferon gamma. The effects of the gamma delta T cells may be mediated by direct inhibition of OVA-specific CD4(+) T(H)2 cell proliferation or selection for specific CD4 T(H)2 cells.	INST CHILD HLTH RES,DIV CELL BIOL,PERTH,WA 6872,AUSTRALIA	Telethon Kids Institute; University of Western Australia			Holt, Patrick G/H-1548-2011	Holt, Patrick G/0000-0003-1193-0935				AUGUSTIN A, 1989, NATURE, V340, P239, DOI 10.1038/340239a0; CARDING SR, 1990, J EXP MED, V172, P1225, DOI 10.1084/jem.172.4.1225; DIALYNAS DP, 1983, J IMMUNOL, V131, P2445; DOHERTY PC, 1992, ANNU REV IMMUNOL, V10, P123; FINKELMAN FD, 1990, ANNU REV IMMUNOL, V8, P303, DOI 10.1146/annurev.iy.08.040190.001511; FOX PC, 1981, IMMUNOLOGY, V43, P227; FUJIHASHI K, 1992, J EXP MED, V175, P695, DOI 10.1084/jem.175.3.695; GOODMAN T, 1988, NATURE, V333, P855, DOI 10.1038/333855a0; GORCZYNSKI RM, 1994, IMMUNOLOGY, V81, P27; HOLT PG, 1987, IMMUNOLOGY, V60, P97; HOLT PG, 1981, IMMUNOLOGY, V42, P409; HOLT PG, 1989, CLIN EXP ALLERGY, V19, P255, DOI 10.1111/j.1365-2222.1989.tb02380.x; HOLT PG, 1987, IMMUNOL TODAY, V8, P14, DOI 10.1016/0167-5699(87)90825-5; KAUFMANN SHE, 1993, P NATL ACAD SCI USA, V90, P9620, DOI 10.1073/pnas.90.20.9620; KUBO R, 1989, J IMMUNOL, V142, P2236; LEDBETTER JA, 1980, J EXP MED, V152, P280, DOI 10.1084/jem.152.2.280; MASON DW, 1988, IMMUNOLOGY, V65, P249; MCMENAMIN C, 1993, J EXP MED, V178, P889, DOI 10.1084/jem.178.3.889; MCMENAMIN C, 1991, IMMUNOLOGY, V74, P234; MILLER A, 1991, J EXP MED, V174, P791, DOI 10.1084/jem.174.4.791; MILLER A, 1992, P NATL ACAD SCI USA, V89, P421, DOI 10.1073/pnas.89.1.421; MOWAT AM, 1987, IMMUNOL TODAY, V8, P93, DOI 10.1016/0167-5699(87)90853-X; NUSSENBLATT RB, 1990, J IMMUNOL, V144, P1689; PTAK W, 1992, J IMMUNOL, V149, P3503; ROMAGNANI S, 1992, IMMUNOL TODAY, V13, P379, DOI 10.1016/0167-5699(92)90083-J; SEDGWICK JD, 1985, CELL IMMUNOL, V94, P182, DOI 10.1016/0008-8749(85)90095-4; SKEEN MJ, 1993, J EXP MED, V178, P985, DOI 10.1084/jem.178.3.985; STEWART GA, 1987, INT ARCH ALLER A IMM, V83, P44, DOI 10.1159/000234329; YAMAMOTO S, 1993, INFECT IMMUN, V61, P2154, DOI 10.1128/IAI.61.5.2154-2161.1993	29	362	366	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 23	1994	265	5180					1869	1871		10.1126/science.7916481	http://dx.doi.org/10.1126/science.7916481			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PH258	7916481				2022-12-24	WOS:A1994PH25800034
J	DEVITT, JE				DEVITT, JE			BREAST-CANCER - HAVE WE MISSED THE FOREST BECAUSE OF THE TREE	LANCET			English	Editorial Material																		EVANS I, 1994, LANCET, V343, P1085; MILLER AB, 1992, CAN MED ASSOC J, V147, P1459	2	11	11	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 10	1994	344	8924					734	735		10.1016/S0140-6736(94)92214-4	http://dx.doi.org/10.1016/S0140-6736(94)92214-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PF187	7915782				2022-12-24	WOS:A1994PF18700016
J	HOFFSTEIN, V				HOFFSTEIN, V			BLOOD-PRESSURE, SNORING, OBESITY, AND NOCTURNAL HYPOXEMIA	LANCET			English	Article							SLEEP-APNEA SYNDROME; CARDIOVASCULAR RISK-FACTORS; SYSTEMIC HYPERTENSION; MEN; HYPOXEMIA; DISEASE; SNORERS	The association between snoring and blood pressure is still a matter for debate, partly because of uncertainty about the definition of snoring and partly because confounding factors may affect systemic blood pressure such as obesity, sleep apnoea, and nocturnal hypoxaemia. To isolate the contribution of each of these factors, 1415 patients (389 females, 1026 males) referred to a sleep disorders centre were studied. A full history was obtained with particular attention to cardiovascular disease and medications. The patients had nocturnal polysomnography including objective measurement of snorning, and blood pressure was measured in the morning. 18% of non-snorers had hypertension as did 20% of heavy snorers (not significantly different). Multivariate linear regression analysis showed that snoring was not a significant determinant of blood pressure. Only age, male sex, apnoea/hypopnoea index, and body mass index contributed significantly to the variability of blood pressure. We conclude that snoring in the absence of sleep apnoea is not associated with raised blood pressure.			HOFFSTEIN, V (corresponding author), ST MICHAELS HOSP, DEPT MED, 30 BOND ST, TORONTO M5B 1W8, ON, CANADA.							ALI NJ, 1992, CHEST, V101, P526; GISLASON T, 1987, ACTA MED SCAND, V222, P415; GISLASON T, 1993, CHEST, V103, P1147, DOI 10.1378/chest.103.4.1147; HEDNER JA, 1992, AM REV RESPIR DIS, V146, P1240, DOI 10.1164/ajrccm/146.5_Pt_1.1240; HOFFSTEIN V, IN PRESS SLEEP; IWASE N, 1992, AM REV RESPIR DIS, V146, P1402, DOI 10.1164/ajrccm/146.6.1402; JENNUM P, 1992, CHEST, V102, P1371, DOI 10.1378/chest.102.5.1371; JENNUM P, 1993, INT J EPIDEMIOL, V22, P439, DOI 10.1093/ije/22.3.439; KOSKENVUO M, 1987, BRIT MED J, V294, P16, DOI 10.1136/bmj.294.6563.16; KOSKENVUO M, 1985, LANCET, V1, P893; LUGARESI E, 1980, SLEEP, V3, P221, DOI 10.1093/sleep/3.3-4.221; MARRONE O, 1993, CHEST, V103, P722, DOI 10.1378/chest.103.3.722; MATEIKA JH, 1992, AM REV RESPIR DIS, V145, P141, DOI 10.1164/ajrccm/145.1.141; PARTINEN M, 1985, LANCET, V2, P1325; RAUSCHER H, 1992, CHEST, V102, P367, DOI 10.1378/chest.102.2.367; RINGLER J, 1990, J APPL PHYSIOL, V69, P2143, DOI 10.1152/jappl.1990.69.6.2143; SCHMIDTNOWARA WW, 1990, ARCH INTERN MED, V150, P597, DOI 10.1001/archinte.150.3.597; SERIES F, 1993, CHEST, V103, P1769, DOI 10.1378/chest.103.6.1769; STOOHS R, 1992, J APPL PHYSIOL, V72, P583, DOI 10.1152/jappl.1992.72.2.583; STRADLING JR, 1990, BRIT MED J, V300, P75, DOI 10.1136/bmj.300.6717.75; TILKIAN AG, 1976, ANN INTERN MED, V85, P714, DOI 10.7326/0003-4819-85-6-714; WALLER PC, 1989, LANCET, V1, P143	22	53	72	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 3	1994	344	8923					643	645		10.1016/S0140-6736(94)92084-2	http://dx.doi.org/10.1016/S0140-6736(94)92084-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PE386	7915347				2022-12-24	WOS:A1994PE38600009
J	SCHLUGER, NW; CONDOS, R; LEWIS, S; ROM, WN				SCHLUGER, NW; CONDOS, R; LEWIS, S; ROM, WN			AMPLIFICATION OF DNA OF MYCOBACTERIUM-TUBERCULOSIS FROM PERIPHERAL-BLOOD OF PATIENTS WITH PULMONARY TUBERCULOSIS	LANCET			English	Note							POLYMERASE CHAIN-REACTION; IMMUNODEFICIENCY-VIRUS INFECTION; DIAGNOSIS	Sputum examination for rapid diagnosis of pulmonary tuberculosis is not always satisfactory. We examined peripheral blood with the polymerase chain reaction (PCR). Blood samples were collected from 8 consecutive patients with suspected pulmonary tuberculosis and from 18 healthy controls, half of whom were tuberculin skin-test positive. All 8 patients had evidence of circulating Mycobacterium tuberculosis DNA in the lymphocyte fraction of peripheral blood, and positive sputum cultures indicating active pulmonary tuberculosis. None of the healthy controls had positive PCR results. This PCR technique may prove useful for the rapid diagnosis of tuberculosis.	NYU,MED CTR,BELLEVUE CHEST SERV,NEW YORK,NY; NYU,MED CTR,DIV PULM & CRIT CARE MED,NEW YORK,NY	New York University; New York University			Schluger, Neil/ABA-1793-2021	Rom, William/0000-0002-8793-7028; Lewis, Stuart/0000-0001-5418-9388	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI008743] Funding Source: NIH RePORTER; NIAID NIH HHS [AI08743-01] Funding Source: Medline; PHS HHS [M01-0096] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		COUSINS DV, 1992, J CLIN MICROBIOL, V30, P255, DOI 10.1128/JCM.30.1.255-258.1992; EISENACH KD, 1991, AM REV RESPIR DIS, V144, P1160, DOI 10.1164/ajrccm/144.5.1160; FUJIWARA H, 1986, AM REV RESPIR DIS, V133, P73, DOI 10.1164/arrd.1986.133.1.73; KRAMER F, 1990, AM J MED, V89, P451, DOI 10.1016/0002-9343(90)90375-N; Mattar S, 1992, Enferm Infecc Microbiol Clin, V10, P29; SCHLUGER NW, 1994, CHEST, V105, P1116, DOI 10.1378/chest.105.4.1116; SHAFER RW, 1991, MEDICINE, V70, P384, DOI 10.1097/00005792-199111000-00004; TOOSSI Z, 1990, J CLIN INVEST, V85, P1777, DOI 10.1172/JCI114635; WALKER DA, 1992, THORAX, V47, P690, DOI 10.1136/thx.47.9.690	9	59	60	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 23	1994	344	8917					232	233		10.1016/S0140-6736(94)92999-8	http://dx.doi.org/10.1016/S0140-6736(94)92999-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY060	7913158				2022-12-24	WOS:A1994NY06000011
J	MARSH, JCW; SOCIE, G; SCHREZENMEIER, H; TICHELLI, A; GLUCKMAN, E; LJUNGMAN, P; MCCANN, SR; RAGHAVACHAR, A; MARIN, P; HOWS, JM; BACIGALUPO, A				MARSH, JCW; SOCIE, G; SCHREZENMEIER, H; TICHELLI, A; GLUCKMAN, E; LJUNGMAN, P; MCCANN, SR; RAGHAVACHAR, A; MARIN, P; HOWS, JM; BACIGALUPO, A			HEMATOPOIETIC GROWTH-FACTORS IN APLASTIC-ANEMIA - A CAUTIONARY NOTE	LANCET			English	Article							BONE-MARROW TRANSPLANTATION; COLONY-STIMULATING FACTOR; SAA WORKING PARTY; ANTILYMPHOCYTE GLOBULIN; ANEMIA; GRANULOCYTE; METHYLPREDNISOLONE	We are concerned about the inappropriate use of haemopoietic growth factors in patients with severe aplastic anaemia (SAA). The treatment of choice for this disorder is bone-marrow transplantation from an HLA-identical sibling donor if the patient is younger than 45 years, but it must be done soon after onset before the patient becomes sensitised by multiple red-cell and platelet transfusions. Other patients should immunosuppressive therapy with antithymocyte alone or with cyclosporin or oxymetholone. Haemopoietic growth factors may have a role in stimulation of granulopoiesis after immunosuppressive therapy, but there is no evidence that they can correct the underlying stem-cell defect in SAA, and therefore no justification for their use alone in newly diagnosed SAA. Such treatment is harmful because it delays bone-marrow transplantation, or immunosuppressive therapy in older patients and those without suitable donors, thus reducing the chances of a successful outcome.	HOP ST LOUIS,SERV HEMATOL,PARIS,FRANCE; UNIV ULM,MED KLIN & POLIKLIN,W-7900 ULM,GERMANY; UNIV BASEL HOSP,CH-4031 BASEL,SWITZERLAND; HUDDINGE SJUKHUS,MED KLINIKEN,HUDDINGE,SWEDEN; ST JAMES HOSP,DEPT HAEMATOL,DUBLIN 8,IRELAND; HOSP CLIN BARCELONA,SERV HEMATOL,BARCELONA,SPAIN; SOUTHMEAD GEN HOSP,DEPT HAEMATOL,BRISTOL,AVON,ENGLAND; OSPED SAN MARTINO GENOVA,DIV EMATOL 2,GENOA,ITALY	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Ulm University; University of Basel; Trinity College Dublin; University of Barcelona; Hospital Clinic de Barcelona; Southmead Hospital; University of Genoa; IRCCS AOU San Martino IST	MARSH, JCW (corresponding author), UNIV LONDON ST GEORGES HOSP,SCH MED,DEPT HAEMATOL,CRANMER TERRACE,LONDON SW17 0RE,ENGLAND.		Ljungman, Per/M-4946-2019					BACIGALUPO A, 1993, BRIT J HAEMATOL, V83, P145, DOI 10.1111/j.1365-2141.1993.tb04645.x; BACIGALUPO A, 1993, EXP HEMATOL, V21, P1081; CAMITTA BM, 1976, BLOOD, V48, P63; CHAMPLIN RE, 1989, BLOOD, V73, P694; CHAMPLIN RE, 1989, BLOOD, V73, P601; DEPLANQUE MM, 1989, BRIT J HAEMATOL, V73, P121; FRICKHOFEN N, 1991, NEW ENGL J MED, V324, P1297, DOI 10.1056/NEJM199105093241901; GANSER A, 1990, BLOOD, V76, P1287; HIRAYAMA Y, 1994, BR JHAEMATOL, V85, P676; HOWS JM, 1991, IMMUNOL LETT, V29, P77, DOI 10.1016/0165-2478(91)90204-N; KOJIMA S, 1991, BLOOD, V77, P937; KOJIMA S, 1992, NEW ENGL J MED, V326, P1294; KOJIMA S, 1992, BLOOD, V79, P2256; RAGHAVACHAR A, 1992, CYTOKINES HEMOPOIESI, V2, P555; SCHREZENMEIER H, 1993, BRIT J HAEMATOL, V85, P371, DOI 10.1111/j.1365-2141.1993.tb03181.x; SCHREZENMEIER H, 1993, BLOOD S1, V82, P1455; SOCIE G, 1993, NEW ENGL J MED, V329, P1152, DOI 10.1056/NEJM199310143291603; STARK R, 1993, BRIT J HAEMATOL, V83, P560, DOI 10.1111/j.1365-2141.1993.tb04691.x; STEWARD WP, 1993, LANCET, V342, P153, DOI 10.1016/0140-6736(93)91350-U; STORB R, 1991, BONE MARROW TRANSPL, V8, P69; STORB R, 1980, ANN INTERN MED, V91, P30; TICHELLI A, 1992, BLOOD, V80, P337; 1992, LANCET, V339, P395	23	41	42	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 16	1994	344	8916					172	173		10.1016/S0140-6736(94)92763-4	http://dx.doi.org/10.1016/S0140-6736(94)92763-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW810	7912771				2022-12-24	WOS:A1994NW81000015
J	GIANNAKOULOPOULOS, X; SEPULVEDA, W; KOURTIS, P; GLOVER, V; FISK, NM				GIANNAKOULOPOULOS, X; SEPULVEDA, W; KOURTIS, P; GLOVER, V; FISK, NM			FETAL PLASMA-CORTISOL AND BETA-ENDORPHIN RESPONSE TO INTRAUTERINE NEEDLING	LANCET			English	Article							GESTATIONAL-AGE; INTRAHEPATIC VEIN; BLOOD-GASES; CORD; SURGERY; STRESS; FETUS; PH; ANESTHESIA; FENTANYL	The purpose of this study was to investigate whether the fetus mounts a hormonal stress response to a potentially painful procedure, intrauterine needling. Cortisol and beta-endorphin concentrations in fetal plasma obtained during uncomplicated fetal blood sampling or intrauterine transfusions by needling the fetal intra-abdominal portion of the umbilical vein (intrahepatic vein) were compared to hormone concentrations in fetal plasma obtained by the conventional technique of needling the placental cord insertion, which is not innervated. Cortisol and beta-endorphin concentrations did not increase within 10 minutes of fetal abdominal needling (n = 15). However, more prolonged needling during transfusion at the intrahepatic vein was associated with an increase in fetal plasma cortisol (median increase 48 nmol/L; 95% Cl, 23-86) and beta-endorphin (207 pg/mL; 113-307) concentrations compared to transfusion at the placental cord insertion (p < 0.005 for both hormones). The magnitude of rise in hormone increased linearly with the duration of needling (cortisol, r = 0.80; beta-endorphin, r = 0.88; p < 0.05 for both). These data suggest that the fetus mounts a hormonal stress response to invasive procedures. They raise the possibility that the human fetus feels pain in utero, and may benefit from anaesthesia or analgesia for invasive procedures.	QUEEN CHARLOTTES & CHELSEA HOSP,ROYAL POSTGRAD MED SCH,INST OBSTET & GYNAECOL,CTR FETAL CARE,LONDON W6 0XG,ENGLAND; QUEEN CHARLOTTES & CHELSEA HOSP,ROYAL POSTGRAD MED SCH,INST OBSTET & GYNAECOL,DEPT CHEM PATHOL,LONDON W6 0XG,ENGLAND	Imperial College London; Imperial College London			Fisk, Nicholas/B-2126-2009	Fisk, Nicholas/0000-0003-0031-7975				ANAND KJS, 1992, NEW ENGL J MED, V326, P1, DOI 10.1056/NEJM199201023260101; ANAND KJS, 1987, LANCET, V1, P243; ANAND KJS, 1987, NEW ENGL J MED, V317, P1321, DOI 10.1056/NEJM198711193172105; COULTER CL, 1993, J CLIN ENDOCR METAB, V76, P1234, DOI 10.1210/jc.76.5.1234; DAFFOS F, 1985, AM J OBSTET GYNECOL, V153, P655, DOI 10.1016/S0002-9378(85)80254-4; DAWES GS, 1988, CAN J PHYSIOL PHARM, V66, P541, DOI 10.1139/y88-084; DONALDSON A, 1991, CLIN ENDOCRINOL, V35, P1; ECONOMIDES D L, 1988, Fetal Therapy, V3, P158; FISK NM, 1989, FETAL MONITORING, P46; FITZGERALD M, 1987, NATURE, V326, P603, DOI 10.1038/326603a0; FITZGERALD M, 1988, DEV MED CHILD NEUROL, V30, P520; FOX SB, 1990, PLACENTA, V11, P59, DOI 10.1016/S0143-4004(05)80443-6; GENSER G, 1976, ANN J OBSTET GYNECOL, V124, P43; GHIDINI A, 1993, AM J OBSTET GYNECOL, V168, P1139; HANNA CE, 1993, J CLIN ENDOCR METAB, V76, P384, DOI 10.1210/jc.76.2.384; LACOUMENTA S, 1987, BRIT J ANAESTH, V59, P713, DOI 10.1093/bja/59.6.713; MAURI A, 1990, ACTA ENDOCRINOL-COP, V123, P637, DOI 10.1530/acta.0.1230637; NICOLAIDES KH, 1987, AM J OBSTET GYNECOL, V157, P50, DOI 10.1016/S0002-9378(87)80344-7; NICOLAIDES KH, 1989, AM J OBSTET GYNECOL, V161, P996, DOI 10.1016/0002-9378(89)90770-9; NICOLINI U, 1988, PRENATAL DIAG, V8, P665, DOI 10.1002/pd.1970080906; NICOLINI U, 1990, OBSTET GYNECOL, V76, P47; PEPE GJ, 1990, ENDOCR REV, V11, P151, DOI 10.1210/edrv-11-1-151; RADUNOVIC N, 1992, AM J OBSTET GYNECOL, V167, P740, DOI 10.1016/S0002-9378(11)91581-6; ROGERS MC, 1992, NEW ENGL J MED, V326, P55, DOI 10.1056/NEJM199201023260109; RUTH V, 1993, AM J PERINAT, V10, P115, DOI 10.1055/s-2007-994641; STARK RI, 1986, ENDOCRINOLOGY, V119, P755, DOI 10.1210/endo-119-2-755; VENN RF, 1990, J CONTROL RELEASE, V13, P113, DOI 10.1016/0168-3659(90)90002-B; WARDLAW SL, 1979, J CLIN ENDOCR METAB, V49, P888, DOI 10.1210/jcem-49-6-888; WOLF AR, 1993, LANCET, V342, P319, DOI 10.1016/0140-6736(93)91468-2; ZOSMER N, 1993, OBSTET GYNECOL, V82, P504	30	166	179	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 9	1994	344	8915					77	81		10.1016/S0140-6736(94)91279-3	http://dx.doi.org/10.1016/S0140-6736(94)91279-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NV732	7912391				2022-12-24	WOS:A1994NV73200007
J	COGGON, D; INSKIP, H; WINTER, P; PANNETT, B				COGGON, D; INSKIP, H; WINTER, P; PANNETT, B			LOBAR PNEUMONIA - AN OCCUPATIONAL-DISEASE IN WELDERS	LANCET			English	Article							MORTALITY; SHIPYARD	We have used data from three analyses of occupational mortality for England and Wales to investigate a suspected hazard of pneumonia in welders. Mortality from the disease was consistently raised in welders aged 15-64, with standardised mortality ratios of 184 (95% Cl 150-224) in 1959-63 and 157 (121-200) in 1970-72. Analysis of data for 1979-80 and 1982-90 showed that the increased risk is attributable mainly to an excess of pneumococcal and unspecified lobar pneumonia (proportional mortality ratio 255, 95% Cl 192-332). No excess occurred in men above retirement age (65). A possible explanation of these findings is that welding fume reversibly increases the susceptibility of the lung to pneumonic infection. The observation of a similar mortality pattern in moulders and coremakers points to the metallic component of the fume as a possible culprit, but ozone or oxides of nitrogen could also be implicated. There are grounds for lobar pneumonia to be considered an occupational disease in welders.			COGGON, D (corresponding author), UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,MRC,ENVIRONM EPIDEMIOL UNIT,SOUTHAMPTON S09 4XY,ENGLAND.		Inskip, Hazel/L-5467-2018	Inskip, Hazel/0000-0001-8897-1749				[Anonymous], 1980, CLASSIFICATION OCCUP; BEAUMONT JJ, 1980, AM J EPIDEMIOL, V112, P775; COFFIN DL, 1968, ARCH ENVIRON HEALTH, V16, P633, DOI 10.1080/00039896.1968.10665119; COLLEN MF, 1947, J IND HYG TOXICOL, V29, P113; COTES JE, 1989, BRIT J IND MED, V46, P292; DOIG A. T., 1964, ANN OCCUP HYG, V7, P223; EHRLICH R, 1966, BACTERIOL REV, V30, P604, DOI 10.1128/MMBR.30.3.604-614.1966; FAWER RF, 1982, BRIT J IND MED, V39, P149; MCMILLAN GHG, 1983, J SOC OCCUP MED, V33, P75; MILHAM S, 1983, DHHS NIOSH83116 PUBL; NEWHOUSE ML, 1985, BRIT J IND MED, V42, P406; PARKES WR, 1982, OCCUPATIONAL LUNG DI; POLEDNAK AP, 1981, ARCH ENVIRON HEALTH, V36, P235, DOI 10.1080/00039896.1981.10667630; Puntoni R, 1979, Ann N Y Acad Sci, V330, P353, DOI 10.1111/j.1749-6632.1979.tb18738.x; 1971, ENGLAND WALES 1961 O; 1958, ENGLAND WALES 1951 2, V1; 1978, OCCUPATIONAL MORTALI	17	81	82	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 2	1994	344	8914					41	43		10.1016/S0140-6736(94)91056-1	http://dx.doi.org/10.1016/S0140-6736(94)91056-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU917	7912307				2022-12-24	WOS:A1994NU91700019
J	SMALL, PM; HOPEWELL, PC; SINGH, SP; PAZ, A; PARSONNET, J; RUSTON, DC; SCHECTER, GF; DALEY, CL; SCHOOLNIK, GK				SMALL, PM; HOPEWELL, PC; SINGH, SP; PAZ, A; PARSONNET, J; RUSTON, DC; SCHECTER, GF; DALEY, CL; SCHOOLNIK, GK			THE EPIDEMIOLOGY OF TUBERCULOSIS IN SAN-FRANCISCO - A POPULATION-BASED STUDY USING CONVENTIONAL AND MOLECULAR METHODS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RESISTANT MYCOBACTERIUM-TUBERCULOSIS; HUMAN-IMMUNODEFICIENCY-VIRUS; LENGTH-POLYMORPHISM ANALYSIS; COMPLEX STRAINS; TRANSMISSION; OUTBREAK; TOOL; INFECTION; SEQUENCE; IS6110	Background. The epidemiology of tuberculosis in urban populations is changing. Combining conventional epidemiologic techniques with DNA fingerprinting of Mycobacterium tuberculosis can improve the understanding of how tuberculosis is transmitted. Methods. We used restriction-fragment-length polymorphism (RFLP) analysis to study M. tuberculosis isolates from all patients reported to the tuberculosis registry in San Francisco during 1991 and 1992. These results were interpreted along with clinical, demographic, and epidemiologic data. Patients infected with the same strains were identified according to their RFLP patterns, and patients with identical patterns were grouped in clusters. Risk factors for being in a cluster were analyzed. Results. Of 473 patients studied, 191 appeared to have active tuberculosis as a result of recent infection. Tracing of patients' contacts with the use of conventional methods identified links among only 10 percent of these patients. DNA fingerprinting, however, identified 44 clusters, 20 of which consisted of only 2 persons and the largest of which consisted of 30 persons. In patients under 60 years of age, Hispanic ethnicity (odds ratio, 3.3; P = 0.02), black race (odds ratio, 2.3; P = 0.02), birth in the United States (odds ratio, 5.8; P < 0.001), and a diagnosis of the acquired immunodeficiency syndrome (odds ratio, 1.8; P = 0.04) were independently associated with being in a cluster. Further study of patients in clusters confirmed that poorly compliant patients with infectious tuberculosis have a substantial adverse effect on the control of this disease. Conclusions. Despite an efficient tuberculosis-control program, nearly a third of new cases of tuberculosis in San Francisco are the result of recent infection. Few of these instances of transmission are identified by conventional contact tracing.	STANFORD UNIV,SCH MED,HOWARD HUGHES MED INST,STANFORD,CA 94305; SAN FRANCISCO GEN HOSP,MED SERV,SAN FRANCISCO,CA 94110; UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94143; SAN FRANCISCO DEPT PUBL HLTH,DIV TB CONTROL,SAN FRANCISCO,CA	Howard Hughes Medical Institute; Stanford University; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; San Francisco Department of Public Health	SMALL, PM (corresponding author), STANFORD UNIV,BECKMAN CTR,SCH MED,DEPT MED,DIV INFECT DIS & GEOG MED,RM 251,STANFORD,CA 94305, USA.		Daley, Charles L./AAC-3231-2021	Parsonnet, Julie/0000-0001-7342-5366	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI001137, R01AI034238] Funding Source: NIH RePORTER; NIAID NIH HHS [R0I-AI34238-01, K08 AI01137-01] Funding Source: Medline; PHS HHS [U52-CCU 900454] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BECKSAGUE C, 1992, JAMA-J AM MED ASSOC, V268, P1280, DOI 10.1001/jama.268.10.1280; BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745, DOI 10.1164/ajrccm/144.4.745; CAVE MD, 1991, MOL CELL PROBE, V5, P73, DOI 10.1016/0890-8508(91)90040-Q; CHEVRELDELLAGI D, 1993, J CLIN MICROBIOL, V31, P2446, DOI 10.1128/JCM.31.9.2446-2450.1993; CORONADO VG, 1993, J INFECT DIS, V168, P1052, DOI 10.1093/infdis/168.4.1052; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; Davis W, 1980, IARC SCI PUBL, V32, P192; DWYER B, 1993, J INFECT DIS, V167, P490, DOI 10.1093/infdis/167.2.490; EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302; GENEWEIN A, 1993, LANCET, V342, P841, DOI 10.1016/0140-6736(93)92698-S; GODFREYFAUSSETT P, 1992, BRIT MED J, V305, P221, DOI 10.1136/bmj.305.6847.221; HERMANS PWM, 1991, INFECT IMMUN, V59, P2695, DOI 10.1128/IAI.59.8.2695-2705.1991; HERMANS PWM, 1990, J CLIN MICROBIOL, V28, P2051, DOI 10.1128/JCM.28.9.2051-2058.1990; HORWITZ O, 1973, HEALTH SERV REP, V88, P493, DOI 10.2307/4594837; OTAL I, 1991, J CLIN MICROBIOL, V29, P1252, DOI 10.1128/JCM.29.6.1252-1254.1991; PEARSON ML, 1992, ANN INTERN MED, V117, P191, DOI 10.7326/0003-4819-117-3-191; RASTOGI N, 1992, EUR J CLIN MICROBIOL, V11, P901, DOI 10.1007/BF01962370; SMALL PM, 1993, NEW ENGL J MED, V328, P1137, DOI 10.1056/NEJM199304223281601; SMALL PM, 1993, J CLIN MICROBIOL, V31, P1677, DOI 10.1128/JCM.31.7.1677-1682.1993; TABET SR, 1994, J INFECT DIS, V169, P189, DOI 10.1093/infdis/169.1.189; TAKAHASHI M, 1993, MICROBIOL IMMUNOL, V37, P289, DOI 10.1111/j.1348-0421.1993.tb03212.x; VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406, DOI 10.1128/JCM.31.2.406-409.1993; VANSOOLINGEN D, 1991, J CLIN MICROBIOL, V29, P2578, DOI 10.1128/JCM.29.11.2578-2586.1991; YUEN LKW, 1993, J CLIN MICROBIOL, V31, P1615, DOI 10.1128/JCM.31.6.1615-1618.1993; 1993, AM REV RESPIR DIS, V146, P1623; 1991, MMWR-MORBID MORTAL W, V40, P585; 1992, MMWR-MORBID MORTAL W, V41, P507; 1993, TUBERCULOSIS STATIST	28	1027	1057	1	32	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 16	1994	330	24					1703	1709		10.1056/NEJM199406163302402	http://dx.doi.org/10.1056/NEJM199406163302402			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NR109	7910661				2022-12-24	WOS:A1994NR10900002
J	HOPKINS, KD; LEHMANN, ED; GOSLING, RG				HOPKINS, KD; LEHMANN, ED; GOSLING, RG			AORTIC COMPLIANCE MEASUREMENTS - A NONINVASIVE INDICATOR OF ATHEROSCLEROSIS	LANCET			English	Editorial Material							WAVE VELOCITY; CORONARY		ST THOMAS HOSP,DIV MED,LONDON,ENGLAND; GUYS HOSP,DIV RADIOL SCI,LONDON SE1 9RT,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; Guy's & St Thomas' NHS Foundation Trust	HOPKINS, KD (corresponding author), GUYS HOSP,DEPT OBSTET & GYNAECOL,LONDON SE1 9RT,ENGLAND.							CRAVEN TE, 1990, CIRCULATION, V82, P1230, DOI 10.1161/01.CIR.82.4.1230; CROUSE JR, 1993, CIRCULATION, V87, P17; FARRAR DJ, 1991, CIRCULATION, V83, P1754, DOI 10.1161/01.CIR.83.5.1754; FURBERG CD, 1993, CIRCULATION, V87, P82; HIRAI T, 1989, CIRCULATION, V80, P78, DOI 10.1161/01.CIR.80.1.78; Kelly R, 1989, J VASC MED BIOL, V3, P142; LEHMANN ED, 1993, ULTRASOUND MED BIOL, V19, P683, DOI 10.1016/0301-5629(93)90087-5; MOHIADDIN RH, 1993, J APPL PHYSIOL, V74, P492, DOI 10.1152/jappl.1993.74.1.492; PEARSON TA, 1993, CIRCULATION, V87, P2; PROBSTFIELD JL, 1993, CIRCULATION, V87, P74; ROBERTS JC, 1959, CIRCULATION, V20, P511, DOI 10.1161/01.CIR.20.4.511; TANGANELLI P, 1993, ARTERIOSCLER THROMB, V13, P1700, DOI 10.1161/01.ATV.13.11.1700	12	40	41	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 11	1994	343	8911					1447	1447		10.1016/S0140-6736(94)92577-1	http://dx.doi.org/10.1016/S0140-6736(94)92577-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NQ415	7911173				2022-12-24	WOS:A1994NQ41500004
J	CONNELL, WR; KAMM, MA; DICKSON, M; BALKWILL, AM; RITCHIE, JK; LENNARDJONES, JE				CONNELL, WR; KAMM, MA; DICKSON, M; BALKWILL, AM; RITCHIE, JK; LENNARDJONES, JE			LONG-TERM NEOPLASIA RISK AFTER AZATHIOPRINE TREATMENT IN INFLAMMATORY BOWEL-DISEASE	LANCET			English	Article							CROHNS-DISEASE; HUMAN PAPILLOMAVIRUS; ULCERATIVE-COLITIS; CANCER	The incidence of various cancers, especially non-Hodgkin lymphoma (NHL), is higher among patients who receive azathioprine for immunosuppression after organ transplants than in the general population. We have studied the risk of neoplasia after azathioprine in 755 patients treated for inflammatory bowel disease. The patients received 2 mg/kg daily for a median of 12.5 months (range 2 days to 15 years) between 1962 and 1991; median follow-up was 9 years (range 2 weeks to 29 years). Overall there was no significant excess of cancer: 31 azathioprine-treated patients developed cancer before age 85 compared with 24.3 expected from rates in the general population (observed/expected ratio 1.27, p=0.186). There was a difference in the frequency of colorectal (13) and anal (2) carcinomas (expected 2.27; ratio 6.7, p=0.00001); these tumours are recognised complications of chronic inflammatory bowel disease. There were 2 cases of invasive cervical cancer (expected 0.5), but no case of NHL. Among patients with extensive chronic ulcerative colitis there was no difference in cancer frequency between 86 who had received azathioprine and 180 matched patients who had never received it. Thus, azathioprine treatment does not substantially increase the risk of cancer in inflammatory bowel disease.	ST MARKS HOSP,LONDON EC1V 2PS,ENGLAND; UNIV OXFORD,RADCLIFFE INFIRM,DEPT PUBL HLTH,CANC RES CAMPAIGN,EPIDEMIOL GRP,OXFORD,ENGLAND	Imperial College London; Radcliffe Infirmary; University of Oxford								ALLOUB MI, 1989, BMJ-BRIT MED J, V298, P153, DOI 10.1136/bmj.298.6667.153; CHURCH JM, 1985, DIS COLON RECTUM, V26, P361; EKBOM A, 1990, LANCET, V336, P357, DOI 10.1016/0140-6736(90)91889-I; Gelb A, 1983, Am J Gastroenterol, V78, P316; GLICK SN, 1984, RADIOLOGY, V153, P337, DOI 10.1148/radiology.153.2.6484163; GREENSTEIN AJ, 1981, CANCER, V48, P2742, DOI 10.1002/1097-0142(19811215)48:12<2742::AID-CNCR2820481231>3.0.CO;2-P; GYDE SN, 1988, GUT, V29, P206, DOI 10.1136/gut.29.2.206; GYDE SN, 1980, GUT, V21, P1024, DOI 10.1136/gut.21.12.1024; HALPERT R, 1986, OBSTET GYNECOL, V68, P251; HOOVER R, 1973, LANCET, V2, P55; KINLEN LJ, 1979, BRIT MED J, V2, P1461, DOI 10.1136/bmj.2.6203.1461; KINLEN LJ, 1985, AM J MED, V78, P44, DOI 10.1016/0002-9343(85)90245-1; KINLEN LJ, 1992, AUTOIMMUNITY, V5, P363; KORELITZ BI, 1983, AM J GASTROENTEROL, V78, P44; PRESENT DH, 1989, ANN INTERN MED, V111, P641, DOI 10.7326/0003-4819-111-8-641; SLATER G, 1984, ANN SURG, V199, P348, DOI 10.1097/00000658-198403000-00016; SOMERVILLE KW, 1984, GUT, V25, P1124, DOI 10.1136/gut.25.10.1124; WEEDON DD, 1973, NEW ENGL J MED, V289, P1099, DOI 10.1056/NEJM197311222892101	18	412	416	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 21	1994	343	8908					1249	1252		10.1016/S0140-6736(94)92150-4	http://dx.doi.org/10.1016/S0140-6736(94)92150-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NM144	7910274				2022-12-24	WOS:A1994NM14400008
J	FARROW, S				FARROW, S			ALLELIC VARIATION AND THE VITAMIN-D RECEPTOR	LANCET			English	Editorial Material							MESSENGER-RNA; EXPRESSION				FARROW, S (corresponding author), UCL, SCH MED, DEPT MED, LONDON W1N 8AA, ENGLAND.							BAKER AR, 1988, P NATL ACAD SCI USA, V85, P3294, DOI 10.1073/pnas.85.10.3294; MORRISON NA, 1994, NATURE, V367, P284, DOI 10.1038/367284a0; MORRISON NA, 1992, P NATL ACAD SCI USA, V89, P6665, DOI 10.1073/pnas.89.15.6665; MURPHY D, 1992, MOL CELL BIOL, V12, P2624, DOI 10.1128/MCB.12.6.2624; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; TEWARI M, 1991, MOL ENDOCRINOL, V5, P653, DOI 10.1210/mend-5-5-653	6	30	33	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAY 21	1994	343	8908					1242	1242		10.1016/S0140-6736(94)92147-4	http://dx.doi.org/10.1016/S0140-6736(94)92147-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NM144	7910271				2022-12-24	WOS:A1994NM14400005
J	MCSHANE, R; HOPE, T; WILKINSON, J				MCSHANE, R; HOPE, T; WILKINSON, J			TRACKING PATIENTS WHO WANDER - ETHICS AND TECHNOLOGY	LANCET			English	Editorial Material									JOHN RADCLIFFE HOSP,OXFORD PRACTICE SKILLS PROJECT,OXFORD,ENGLAND; RADCLIFFE INFIRM,OXFORD,ENGLAND; OXFORDSHIRE DEPT SOCIAL SERV,ABINGDON,OXON,ENGLAND	University of Oxford; Radcliffe Infirmary								BALLARD CG, 1987, INT J GERIATRIC PSYC, V2, P207; Beauchamp T, 1989, PRINCIPLES BIOMEDICA; HOPE RA, 1990, INT J GERIATR PSYCH, V5, P239, DOI 10.1002/gps.930050406; LANGLEY GE, 1981, BRIT MED J, V283, P1376, DOI 10.1136/bmj.283.6303.1376; PITT B, 1987, INT J GERIATR PSYCH, V2, P207, DOI 10.1002/gps.930020402; SANFORD J, 1975, BRIT MED J, V3, P473; 1993, PEOPLE NOT PARCELS D	7	37	38	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 21	1994	343	8908					1274	1274		10.1016/S0140-6736(94)92159-8	http://dx.doi.org/10.1016/S0140-6736(94)92159-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NM144	7910283				2022-12-24	WOS:A1994NM14400017
J	FIRTH, HV; BOYD, P; CHAMBERLAIN, P; MACKENZIE, I; MORRISSKAY, GM; HUSON, SM				FIRTH, HV; BOYD, P; CHAMBERLAIN, P; MACKENZIE, I; MORRISSKAY, GM; HUSON, SM			ANALYSIS OF LIMB REDUCTION DEFECTS IN BABIES EXPOSED TO CHRONIC VILLUS SAMPLING	LANCET			English	Article							ABNORMALITIES; CVS	In 1991 we reported a cluster of babies with limb abnormalities and suggested that chorionic villus sampling (CVS) was aetiologically associated with these defects. To address the issue more objectively, we have assessed reported limb reduction defects in 75 babies exposed to CVS in utero. 13 babies had an absent limb or a defect through the humerus or femur; 9 had defects through the radius or tibia; 22 defects of the carpus, tarsus, metacarpus, or metatarsus; 25 defects of the digits; and 6 defects of the terminal phalanx or nail only. There was a strong correlation between the severity of the defects and the duration of gestation when CVS was done. The median gestational age at CVS ranged from 56 (range 49-65) postmenstrual days for the most severe category to 72 (51-98) days for the least severe. The relation was seen for both isolated limb defects and for cases with oromandibular-limb hypogenesis syndromes. This relation is further evidence that CVS has an aetiological role in some limb reduction anomalies.	JOHN RADCLIFFE HOSP,OXFORD REG PRENATAL DIAG SERV,OXFORD,ENGLAND; JOHN RADCLIFFE HOSP,NUFFIELD DEPT OBSTET & GYNAECOL,OXFORD OX3 9DU,ENGLAND; UNIV OXFORD,DEPT HUMAN ANAT,OXFORD OX1 3QX,ENGLAND	University of Oxford; University of Oxford; University of Oxford	FIRTH, HV (corresponding author), CHURCHILL HOSP,OXFORD REG GENET SERV,OXFORD OX3 7LJ,ENGLAND.							BRAMBATI B, 1992, PRENATAL DIAG, V12, P789, DOI 10.1002/pd.1970121004; BURTON BK, 1992, OBSTET GYNECOL, V79, P726; BURTON BK, 1993, PEDIATRICS, V91, P989; CHRISTIAENS GCML, 1989, PRENATAL DIAG, V9, P67, DOI 10.1002/pd.1970090110; CORLISS CE, 1976, PATTENS HUMAN EMBRYO; DOLK H, 1992, LANCET, V339, P876, DOI 10.1016/0140-6736(92)90325-W; FIRTH HV, 1991, LANCET, V337, P762, DOI 10.1016/0140-6736(91)91374-4; FIRTH HV, 1991, LANCET, V338, P51, DOI 10.1016/0140-6736(91)90036-O; FROSTERISKENIUS UG, 1989, TERATOLOGY, V39, P127, DOI 10.1002/tera.1420390205; GHIRARDINI G, 1991, LANCET, V338, P695, DOI 10.1016/0140-6736(91)91271-U; HSIEH FJ, 1991, LANCET, V337, P1092; IBBA RM, 1992, PRENATAL DIAGN S, V12, pS98; JACKSON LG, 1991, LANCET, V337, P1423; Lin S. P., 1992, American Journal of Human Genetics, V51, pA261; LOS FJ, 1993, LANCET, V342, P1559, DOI 10.1016/S0140-6736(05)80137-0; MAHONEY MJ, 1991, LANCET, V337, P1422, DOI 10.1016/0140-6736(91)93117-R; MASTROIACOVO P, 1992, AM J MED GENET, V44, P856, DOI 10.1002/ajmg.1320440639; MONNI G, 1991, LANCET, V337, P1091; PLANTEYDT HT, 1986, LANCET, V2, P756; QUINTERO RA, 1992, LANCET, V339, P193, DOI 10.1016/0140-6736(92)90272-5; RICHMAN JM, 1992, DEV BIOL, V154, P299, DOI 10.1016/0012-1606(92)90069-S; RODECK CH, 1993, LANCET, V341, P500, DOI 10.1016/0140-6736(93)90259-J; SCHLOO R, 1992, AM J MED GENET, V42, P404, DOI 10.1002/ajmg.1320420338; SMIDTJENSEN S, 1992, LANCET, V340, P1237, DOI 10.1016/0140-6736(92)92946-D; WEBSTER WS, 1987, TERATOLOGY, V35, P253, DOI 10.1002/tera.1420350212; WILSON RD, 1992, AM J HUMAN GENET S, V51, pS176	26	115	124	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 30	1994	343	8905					1069	1071		10.1016/S0140-6736(94)90182-1	http://dx.doi.org/10.1016/S0140-6736(94)90182-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NJ694	7909100				2022-12-24	WOS:A1994NJ69400010
J	SHEHADEH, N; CALCINARO, F; BRADLEY, BJ; BRUCHLIM, I; VARDI, P; LAFFERTY, KJ				SHEHADEH, N; CALCINARO, F; BRADLEY, BJ; BRUCHLIM, I; VARDI, P; LAFFERTY, KJ			EFFECT OF ADJUVANT THERAPY ON DEVELOPMENT OF DIABETES IN MOUSE AND MAN	LANCET			English	Note							NOD MICE; PREVENTION	Freund's complete adjuvant (CFA) and BCG vaccine modulate the development of type 1 diabetes in animal models. In non-obese diabetic mice, CFA and BCG significantly reduced the proportion developing diabetes compared with controls. Histological examination showed that autoimmune disease still developed but had been diverted to become nondestructive. In a preliminary trial in 17 newly diagnosed, type 1 diabetic patients, intracutaneous administration of 0.1 mL of BCG 1 mg/mL led to clinical remission in 11 (65%)-by week 4 in 6. Remission has been sustained in 3 for 6-10 months. No side-effects were reported. A double-blind trial of BCG is warranted.	RAMBAM MED CTR,JUVENLLE DIABET CTR,HAIFA,ISRAEL; BARBARA DAVIS CTR CHILDHOOD DIABET,DENVER,CO	Rambam Health Care Campus; Technion Israel Institute of Technology					NIDDK NIH HHS [DK46621] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046621] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		GUYTINGCO R, 1991, DIABETES, V40, pA152; LAKEY JRT, 1992, TRANSPLANT P, V24, P2848; MCINERNEY MF, 1991, DIABETES, V40, P715, DOI 10.2337/diabetes.40.6.715; QIN HY, 1993, J IMMUNOL, V150, P2072; SHEHADEH NN, 1993, J AUTOIMMUN, V6, P291, DOI 10.1006/jaut.1993.1025; WANG T, 1992, DIABETES, V41, P114, DOI 10.2337/diabetes.41.1.114	6	140	149	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 19	1994	343	8899					706	707		10.1016/S0140-6736(94)91583-0	http://dx.doi.org/10.1016/S0140-6736(94)91583-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NB809	7907682				2022-12-24	WOS:A1994NB80900012
J	KOMBIAN, SB; MALENKA, RC				KOMBIAN, SB; MALENKA, RC			SIMULTANEOUS LTP OF NON-NMDA-RECEPTER-MEDIATED AND LTD OF NMDA-RECEPTER-MEDIATED RESPONSES IN THE NUCLEUS-ACCUMBENS	NATURE			English	Article							LONG-TERM DEPRESSION; MOLECULAR MECHANISMS; MEMBRANE-PROPERTIES; NEURONS INVITRO; AREA CA1; RAT; HIPPOCAMPUS; POTENTIALS; ASPARTATE; DOPAMINE	THE nucleus accumbens (NA), a ventral extension of the striatum, plays a role in several complex behaviour patterns(1) and also is a major site of action of drugs of abuse such as cocaine(1-3). Intrinsic NA cells are predominantly quiescent(4,5) and their activity depends on excitatory input from cortical and subcortical limbic afferents(6,7). Here we examine the mechanisms of synaptic plasticity at the synapse between prelimbic cortical afferents and cells in the core region of the NA(8-10). Manipulations that induce a Ca2+- dependent long-term potentiation (LTP) of non-NMDA (N-methyl-D-aspartate)-receptor-mediated responses also produce a simultaneous long-term depression (LTD) of NMDA-receptor-mediated responses. These results indicate that in a single cell the same change in postsynaptic Ca2+ concentration can have opposite effects on non-NMDA- and NMDA-receptor-mediated synaptic responses. This may be particularly important in the NA, where NMDA receptors are critical for mediating the behavioural actions of drugs of abuse(11-13).	UNIV CALIF SAN FRANCISCO,DEPT PSYCHIAT,LPPI,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco								ARTOLA A, 1993, TRENDS NEUROSCI, V16, P480, DOI 10.1016/0166-2236(93)90081-V; Bear M F, 1993, Curr Opin Neurobiol, V3, P197, DOI 10.1016/0959-4388(93)90210-P; BLANTON MG, 1989, J NEUROSCI METH, V30, P203, DOI 10.1016/0165-0270(89)90131-3; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; CHANG HT, 1986, BRAIN RES, V366, P392, DOI 10.1016/0006-8993(86)91326-0; CHEN L, 1992, NATURE, V356, P521, DOI 10.1038/356521a0; CHRISTIE MJ, 1987, NEUROSCIENCE, V22, P425, DOI 10.1016/0306-4522(87)90345-9; DUDEK SM, 1992, P NATL ACAD SCI USA, V89, P4363, DOI 10.1073/pnas.89.10.4363; HESTRIN S, 1990, J PHYSIOL-LONDON, V422, P203, DOI 10.1113/jphysiol.1990.sp017980; KELLEY AE, 1992, BRAIN RES BULL, V29, P247, DOI 10.1016/0361-9230(92)90034-U; KOOB GF, 1988, SCIENCE, V242, P715, DOI 10.1126/science.2903550; LISMAN J, 1989, P NATL ACAD SCI USA, V86, P9574, DOI 10.1073/pnas.86.23.9574; MALENKA RC, 1989, NATURE, V340, P554, DOI 10.1038/340554a0; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MCBAIN CJ, 1993, J PHYSIOL-LONDON, V462, P373, DOI 10.1113/jphysiol.1993.sp019560; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MULKEY RM, 1992, NEURON, V9, P967, DOI 10.1016/0896-6273(92)90248-C; NESTLER EJ, 1992, J NEUROSCI, V12, P2439; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; ODONNELL P, 1993, SYNAPSE, V13, P135, DOI 10.1002/syn.890130206; PENNARTZ CMA, 1991, EXP BRAIN RES, V86, P190, DOI 10.1007/BF00231053; PENNARTZ CMA, 1993, EUR J NEUROSCI, V5, P107, DOI 10.1111/j.1460-9568.1993.tb00475.x; PENNARTZ CMA, 1992, NEUROSCI LETT, V136, P109, DOI 10.1016/0304-3940(92)90660-Y; PERKEL DJ, 1993, J PHYSIOL-LONDON, V471, P481, DOI 10.1113/jphysiol.1993.sp019911; PHILLIPSON OT, 1985, NEUROSCIENCE, V16, P275, DOI 10.1016/0306-4522(85)90002-8; PULVIRENTI L, 1992, BRAIN RES, V594, P327, DOI 10.1016/0006-8993(92)91145-5; PULVIRENTI L, 1991, PHARMACOL BIOCHEM BE, V40, P841, DOI 10.1016/0091-3057(91)90095-J; SWERDLOW NR, 1987, BEHAV BRAIN SCI, V10, P197, DOI 10.1017/S0140525X00047488; UCHIMURA N, 1991, J PHARMACOL EXP THER, V258, P663; UCHIMURA N, 1989, J NEUROPHYSIOL, V61, P769, DOI 10.1152/jn.1989.61.4.769	30	172	175	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 17	1994	368	6468					242	246		10.1038/368242a0	http://dx.doi.org/10.1038/368242a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NA870	7908412				2022-12-24	WOS:A1994NA87000055
J	CACCIATORE, B; STENMAN, UH; YLOSTALO, P				CACCIATORE, B; STENMAN, UH; YLOSTALO, P			EARLY SCREENING FOR ECTOPIC PREGNANCY IN HIGH-RISK SYMPTOM-FREE WOMEN	LANCET			English	Note								We screened 225 symptom-free pregnantwomen at increased risk for ectopic pregnancy with transvaginal sonography and human chorionic gonadotropin (hCG) assays. Among 55 (24.4%), who proved to have an ectopic pregnancy, 46 (84%) cases were diagnosed at the initial screening at a median of 37 days of gestation, and the rest at repeated scans. The false-positive rate was 1.2%. Early diagnosis prevented tubal rupture, substantial haemorrhage, and the need for emergency care, allowing elective treatment. Such early surveillance reduced the risk of complications and facilitated treatment, and should be offered to at-risk women.	HELSINKI UNIV,CENT HOSP,DEPT OBSTET & GYNAECOL 2,SF-00290 HELSINKI,FINLAND	University of Helsinki; Helsinki University Central Hospital	CACCIATORE, B (corresponding author), HELSINKI UNIV,CENT HOSP,DEPT OBSTET & GYNAECOL 1,HAARTMANINKATU 2,SF-00290 HELSINKI,FINLAND.							CACCIATORE B, 1990, BRIT J OBSTET GYNAEC, V97, P904, DOI 10.1111/j.1471-0528.1990.tb02445.x; CARSON SA, 1993, NEW ENGL J MED, V329, P1174; GRUDZINSKAS JG, 1993, BRIT J OBSTET GYNAEC, V100, P510, DOI 10.1111/j.1471-0528.1993.tb15298.x; LOWER AM, 1992, HUM REPROD, V7, P711, DOI 10.1093/oxfordjournals.humrep.a137723; SHEPHERD RW, 1990, OBSTET GYNECOL, V75, P417; Stabile I, 1990, Obstet Gynecol Surv, V45, P335, DOI 10.1097/00006254-199006000-00001; YLOSTALO P, 1992, OBSTET GYNECOL, V80, P345	7	62	64	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 26	1994	343	8896					517	518		10.1016/S0140-6736(94)91464-8	http://dx.doi.org/10.1016/S0140-6736(94)91464-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MX888	7906763				2022-12-24	WOS:A1994MX88800012
J	SHORT, RV				SHORT, RV			DARWIN, HAVE I FAILED YOU	LANCET			English	Editorial Material											SHORT, RV (corresponding author), MONASH UNIV,DEPT PHYSIOL,CLAYTON,VIC 3168,AUSTRALIA.							DAWKIN R, 1986, BLIND WATCHMAKER; DIAMOND J, 1991, RISE FALL 3RD CHIMPA; 1992, CAMBRIDGE ENCYCLOPAE; 1991, MANS PLACE EVOLUTION	4	5	5	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 26	1994	343	8896					528	529		10.1016/S0140-6736(94)91469-9	http://dx.doi.org/10.1016/S0140-6736(94)91469-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MX888	7906767				2022-12-24	WOS:A1994MX88800017
J	OCONNOR, JJ; ROWAN, MJ; ANWYL, R				OCONNOR, JJ; ROWAN, MJ; ANWYL, R			LONG-LASTING ENHANCEMENT OF NMDA RECEPTOR-MEDIATED SYNAPTIC TRANSMISSION BY METABOTROPIC GLUTAMATE-RECEPTOR ACTIVATION	NATURE			English	Article							TERM POTENTIATION; TRANS-ACPD; TRANS-1-AMINOCYCLOPENTANE-1,3-DICARBOXYLIC ACID; RAT HIPPOCAMPUS; CURRENTS; SLICES; CELLS; RESPONSES; AGONIST	SYNAPTIC transmission mediated by the N-methyl-D-aspartate (NMDA) glutamate receptor plays a key role in a range of plastic processes in the nervous system. These include long-term potentiation of synaptic transmission mediated by the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) receptor, neuronal development, excitotoxicity and certain learning tasks1,2. Recently, long-term potentiation of NMDA receptor-mediated synaptic transmission was found to occur following high-frequency (tetanic) stimulation via an unknown mechanism3-7. We show here that activation of metabotropic glutamate (mGlu) receptors by neurally released transmitter underlies this type of long-term potentiation. The whole-cell patch-clamp technique in the 'thick' slice of the rat dentate gyrus was used to measure NMDA receptor-mediated excitatory postsynaptic currents. We have found that mGlu receptor activation by a selective agonist produced a long-lasting enhancement which was mutually exclusive with long-term potentiation of these NMDA currents. Moreover, both forms of potentiation were greatly reduced by the mGlu receptor antagonists L-2-amino-3-phosphonopropionate and (R,S)-alpha-methyl-4-carboxyphenylglycine.	UNIV DUBLIN TRINITY COLL, DEPT PHARMACOL & THERAPEUT, DUBLIN 2, IRELAND; UNIV DUBLIN TRINITY COLL, DEPT PHYSIOL, DUBLIN 2, IRELAND	Trinity College Dublin; Trinity College Dublin				O'Connor, John/0000-0001-8229-8602; Rowan, Michael Joseph/0000-0002-3867-9536	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANIKSZTEJN L, 1992, EUR J NEUROSCI, V4, P500, DOI 10.1111/j.1460-9568.1992.tb00900.x; ASZTELY F, 1992, EUR J NEUROSCI, V4, P681, DOI 10.1111/j.1460-9568.1992.tb00177.x; BASHIR ZI, 1991, NATURE, V349, P156, DOI 10.1038/349156a0; BASHIR ZI, 1993, NATURE, V363, P347, DOI 10.1038/363347a0; BASKYS A, 1991, J PHYSIOL-LONDON, V444, P687, DOI 10.1113/jphysiol.1991.sp018901; BEHNISCH T, 1991, NEUROREPORT, V2, P386, DOI 10.1097/00001756-199107000-00008; BERETTA N, 1991, EUR J NEUROSCI, V3, P850; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BORTOLOTTO ZA, 1993, NEUROPHARMACOLOGY, V32, P1, DOI 10.1016/0028-3908(93)90123-K; CERNE R, 1992, NEUROSCI LETT, V144, P180, DOI 10.1016/0304-3940(92)90745-S; COLLINGRIDGE GL, 1989, PHARMACOL REV, V41, P143; COLLINGRIDGE GL, 1992, INT ACAD B, V2, P41; COLLINS GGS, 1993, BRIT J PHARMACOL, V108, P422, DOI 10.1111/j.1476-5381.1993.tb12820.x; HESTRIN S, 1990, J PHYSIOL-LONDON, V422, P203, DOI 10.1113/jphysiol.1990.sp017980; KELLER BU, 1991, J PHYSIOL-LONDON, V435, P275, DOI 10.1113/jphysiol.1991.sp018510; LLANO I, 1991, J PHYSIOL-LONDON, V434, P183, DOI 10.1113/jphysiol.1991.sp018465; LOVINGER DM, 1991, NEUROSCI LETT, V129, P17, DOI 10.1016/0304-3940(91)90710-B; MCGUINNESS N, 1991, NEUROREPORT, V2, P688, DOI 10.1097/00001756-199111000-00014; MCGUINNESS N, 1991, EUR J PHARMACOL, V197, P231, DOI 10.1016/0014-2999(91)90529-Y; MULLER D, 1992, HIPPOCAMPUS, V2, P29, DOI 10.1002/hipo.450020105; MUSGRAVE MA, 1993, NEUROREPORT, V4, P171, DOI 10.1097/00001756-199302000-00014; NICOLETTI F, 1986, J NEUROCHEM, V46, P40, DOI 10.1111/j.1471-4159.1986.tb12922.x; PALMER E, 1989, EUR J PHARMACOL, V166, P585, DOI 10.1016/0014-2999(89)90383-X; XIE X, 1992, NEUROPHYSIOL, V67, P1009	24	160	162	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 10	1994	367	6463					557	559		10.1038/367557a0	http://dx.doi.org/10.1038/367557a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MV863	7906392				2022-12-24	WOS:A1994MV86300058
J	FRANTZ, TD; RASGON, BM; QUESENBERRY, CP				FRANTZ, TD; RASGON, BM; QUESENBERRY, CP			ACUTE EPIGLOTTITIS IN ADULTS - ANALYSIS OF 129 CASES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note								Objective.-To characterize the clinical features of acute epiglottitis in adults and to identify factors associated with airway intervention. Design.-Case series. Setting.-Northern California health maintenance organization. Participants.-A total of 129 patients aged 18 years or older with laryngoscopically confirmed acute epiglottitis admitted from November 1986 through October 1991. Results.-The mean patient age was 47 years (range, 18 to 85 years) and the male-to-female ratio was 1.8 to 1.0 (P<.001). The most common symptoms were sore throat (95% and odynophagia (94%); the most common signs were muffled voice and evidence of pharyngitis. Nineteen patients (15%) received airway intervention, including seven with tracheotomy and 12 with endotracheal intubation. The remaining 110 patients recovered fully without airway intervention. In multivariate analysis, factors associated with airway intervention were strider (relative risk [RR], 6.2; 95% confidence interval [CI], 1.7 to 22.9) and sitting erect (RR, 4.8; 95% CI, 1.3 to 16.1). Six (12%) of 52 blood cultures yielded Haemophilus influenzae type b. Major complications occurred in six patients (5%), but no deaths occurred. Conclusion.-Most adults who have acute epiglottitis can be managed conservatively and have low morbidity and mortality.	KAISER PERMANENTE MED CTR,DEPT HEAD & NECK SURG,OAKLAND,CA 94611; KAISER PERMANENTE MED CARE PROGRAM,DIV RES,OAKLAND,CA 94611	Kaiser Permanente; Kaiser Permanente								BAXTER FJ, 1988, CAN J ANAESTH, V35, P428, DOI 10.1007/BF03010869; DEEB ZE, 1985, LARYNGOSCOPE, V95, P289; FRANTZ TD, 1993, OTOLARYNG HEAD NECK, V109, P457, DOI 10.1177/019459989310900311; KHILANANI U, 1984, AM J MED SCI, V287, P65, DOI 10.1097/00000441-198401000-00022; OSSOFF RH, 1980, LARYNGOSCOPE, V90, P1155, DOI 10.1288/00005537-198007000-00011; SHAPIRO J, 1988, JAMA-J AM MED ASSOC, V259, P563, DOI 10.1001/jama.259.4.563; SHEIKH KH, 1989, WESTERN J MED, V151, P520; SHIH L, 1988, ANN OTO RHINOL LARYN, V97, P527, DOI 10.1177/000348948809700517; SMITH MFM, 1986, NEW ENGL J MED, V314, P1133; STANLEY RE, 1988, J LARYNGOL OTOL, V102, P1017, DOI 10.1017/S0022215100107157; WOLF M, 1990, LARYNGOSCOPE, V100, P183	11	118	120	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 2	1994	272	17					1358	1360		10.1001/jama.272.17.1358	http://dx.doi.org/10.1001/jama.272.17.1358			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PP020	7933397				2022-12-24	WOS:A1994PP02000031
J	SONG, YH; CONNOR, E; LI, YX; ZOROVICH, B; BALDUCCI, P; MACLAREN, N				SONG, YH; CONNOR, E; LI, YX; ZOROVICH, B; BALDUCCI, P; MACLAREN, N			THE ROLE OF TYROSINASE IN AUTOIMMUNE VITILIGO	LANCET			English	Article							MELANOCYTE AUTOANTIBODIES; DIABETES-MELLITUS; ANTIBODIES; SEQUENCE; CLONE	Vitiligo is a common depigmenting skin disease, associated with certain autoimmune endocrinopathies, and autoantibodies to several antigens can be found in melanoma cells. We set out to identify the antigens. We examined 26 patients with vitiligo and associated endocrine disease. Of these, 18 patients (77%) and 8 immediate family members had autoantibodies specific for a 69 kDa protein in HTB-70 human melanoma cells that was not seen in control cells. The autoantibody-positive patient sera reacted with recombinant human tyrosinase expressed in Escherichia cell seen by western blots, as did antibodies raised in rabbits against hamster tyrosinase, but not to recombinant tyrosinase-related protein. Not one of 31 normal controls or 8 patients with alopecia or systemic lupus erythematosus had tyrosinase autoantibodies but a small proportion (12%) of 42 patients with autoimmune endocrine disease without a history of vitiligo had them. The results show that tyrosinase, an enzyme important in melanin formation, is a principal autoantigen of autoimmune vitiligo.	UNIV FLORIDA,COLL MED,DEPT PATHOL & LAB MED,GAINESVILLE,FL 32610; UNIV FLORIDA,COLL MED,DEPT PEDIAT,GAINESVILLE,FL 32610	State University System of Florida; University of Florida; State University System of Florida; University of Florida			Song, Yao-Hua/A-2516-2011	Connor, Ellen/0000-0002-9667-7002	NICHD NIH HHS [R01HD19469] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD019469] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AHONEN P, 1990, NEW ENGL J MED, V322, P1829, DOI 10.1056/NEJM199006283222601; ATKINSON MA, 1990, LANCET, V335, P1357, DOI 10.1016/0140-6736(90)91241-2; AUSTIN LM, 1992, CLIN IMMUNOL IMMUNOP, V64, P112, DOI 10.1016/0090-1229(92)90188-T; BADRI M, 1993, J PATHOL, V170, P149; BROSTOFF J, 1969, LANCET, V2, P177; COHEN T, 1990, NUCLEIC ACIDS RES, V18, P2807, DOI 10.1093/nar/18.9.2807; CUI J, 1993, J INVEST DERMATOL, V100, P812, DOI 10.1111/1523-1747.ep12476636; GOUDIE RB, 1990, LANCET, V335, P316, DOI 10.1016/0140-6736(90)90607-7; GOULD IM, 1985, BRIT J DERMATOL, V113, P153, DOI 10.1111/j.1365-2133.1985.tb02057.x; HERTZ KC, 1977, NEW ENGL J MED, V297, P634, DOI 10.1056/NEJM197709222971204; HOWITZ J, 1971, LANCET, V1, P1331; JIMENEZ M, 1989, J BIOL CHEM, V264, P3397; KWON BS, 1987, P NATL ACAD SCI USA, V84, P7473, DOI 10.1073/pnas.84.21.7473; LAMONT SJ, 1981, CLIN IMMUNOL IMMUNOP, V21, P407, DOI 10.1016/0090-1229(81)90229-4; LEPOOLE IC, 1993, J INVEST DERMATOL, V100, P816, DOI 10.1111/1523-1747.ep12476645; LORINI R, 1992, AUTOIMMUNITY, V11, P255, DOI 10.3109/08916939209035163; MACLAREN NK, 1985, DIABETES CARE, V8, P34, DOI 10.2337/diacare.8.1.S34; MOELLMANN GE, 1985, J INVEST DERMATOL, V84, P333; NAUGHTON GK, 1983, J INVEST DERMATOL, V81, P540, DOI 10.1111/1523-1747.ep12522891; NAUGHTON GK, 1983, J EXP MED, V158, P246, DOI 10.1084/jem.158.1.246; NEUFELD M, 1981, MEDICINE, V60, P355, DOI 10.1097/00005792-198109000-00003; NORRIS DA, 1988, J INVEST DERMATOL, V90, P783, DOI 10.1111/1523-1747.ep12461505; Sambrook J., 1989, MOL CLONING LAB MANU; SEARLE EA, 1993, PIGM CELL RES, V6, P145, DOI 10.1111/j.1600-0749.1993.tb00594.x	24	151	165	3	12	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 15	1994	344	8929					1049	1052		10.1016/S0140-6736(94)91709-4	http://dx.doi.org/10.1016/S0140-6736(94)91709-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL852	7934446				2022-12-24	WOS:A1994PL85200009
J	PARRATT, J; TAGGART, M; WRAY, S				PARRATT, J; TAGGART, M; WRAY, S			ABOLITION OF CONTRACTIONS IN THE MYOMETRIUM BY ACIDIFICATION IN-VITRO	LANCET			English	Note							METABOLIC INHIBITION; INTRACELLULAR PH; FORCE PRODUCTION; UTERINE; RAT	Uterine dystocia, often of unknown cause, remains one of the commonest causes of emergency caesarean section. We have tested the hypothesis that small acidic changes in pH, that can occur during labour contractions, can decrease contractions and contribute to dystocia. We simultaneously recorded intracellular pH (pH(i)) and force in human myometrium: acidification abolished contractions. Such effects of pH(i) on uterine contractile acitivity may be of clinical significance. Blood flow reduces during each uterine contraction; the resulting fall in pH(i) could lead to inefficient uterine action in some labours and failure to progress (ie, dystocia).	UNIV LIVERPOOL,DEPT PHYSIOL,LIVERPOOL L69 3BX,ENGLAND	University of Liverpool			Taggart, Michael/A-1288-2012; wray, susan/B-1197-2009	Taggart, Michael/0000-0002-9981-2783; Wray, Susan/0000-0002-0086-1359				BEISCHER NA, 1986, OBSTETRICS NEWBORN, P443; BRAR HS, 1988, AM J OBSTET GYNECOL, V158, P952, DOI 10.1016/0002-9378(88)90100-7; GREISS FC, 1965, AM J OBSTET GYNECOL, V93, P917, DOI 10.1016/0002-9378(65)90150-X; HARRISON N, 1994, J PHYSIOL-LONDON, V476, P349, DOI 10.1113/jphysiol.1994.sp020136; PHOENIX J, 1993, J REPROD FERTIL, V97, P507; TAGGART M, 1993, PFLUG ARCH EUR J PHY, V423, P527, DOI 10.1007/BF00374951; TAGGART MJ, 1993, J PHYSIOL-LONDON, V472, P23, DOI 10.1113/jphysiol.1993.sp019933; WRAY S, 1990, J PHYSIOL-LONDON, V423, P411, DOI 10.1113/jphysiol.1990.sp018030; WRAY S, 1992, EXP PHYSIOL, V77, P307, DOI 10.1113/expphysiol.1992.sp003590; WRAY S, 1993, AM J PHYSIOL, V264, pC1, DOI 10.1152/ajpcell.1993.264.1.C1	10	31	32	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 10	1994	344	8924					717	718		10.1016/S0140-6736(94)92209-8	http://dx.doi.org/10.1016/S0140-6736(94)92209-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PF187	7915777				2022-12-24	WOS:A1994PF18700011
J	COLOVER, J				COLOVER, J			FUNCTIONAL DUALISM IN THE NERVOUS-SYSTEM	LANCET			English	Editorial Material							VISUAL-SYSTEM; ORGANIZATION; CELLS				COLOVER, J (corresponding author), UNITED MED & DENT SCH, RAYNE INST, DEPT IMMUNOL, ST THOMAS CAMPUS, LONDON SE1 7EH, ENGLAND.							BEHAN M, 1992, J COMP NEUROL, V315, P230, DOI 10.1002/cne.903150209; BEHRMAN S, 1958, BRAIN, V81, P529, DOI 10.1093/brain/81.4.529; Cushing H, 1916, J NERV MENT DIS, V44, P312; Hartline HK, 1938, AM J PHYSIOL, V121, P400, DOI 10.1152/ajplegacy.1938.121.2.400; Head H, 1905, BRAIN, V28, P99, DOI 10.1093/brain/28.2.99; HUBEL DH, 1985, NATURE, V315, P325, DOI 10.1038/315325a0; IKEDA H, 1988, DOC OPHTHALMOL, V69, P175, DOI 10.1007/BF00153699; IKEDA H, 1972, J PHYSIOL-LONDON, V227, P769, DOI 10.1113/jphysiol.1972.sp010058; IKEDA T, 1985, POLAR BIOL, V4, P1, DOI 10.1007/BF00286811; JAIN KK, 1993, J ROY SOC MED, V86, P133; MCCONNELL SK, 1986, J COMP NEUROL, V250, P109, DOI 10.1002/cne.902500110; SCHILLER PH, 1992, TRENDS NEUROSCI, V15, P86, DOI 10.1016/0166-2236(92)90017-3; SHIPP S, 1985, NATURE, V315, P322, DOI 10.1038/315322a0; ZEKI S, 1990, COLD SPRING HARB SYM, V55, P651	14	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 3	1994	344	8923					670	671		10.1016/S0140-6736(94)92092-3	http://dx.doi.org/10.1016/S0140-6736(94)92092-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PE386	7915355				2022-12-24	WOS:A1994PE38600017
J	YUSUF, S; ZUCKER, D; PEDUZZI, P; FISHER, LD; TAKARO, T; KENNEDY, JW; DAVIS, K; KILLIP, T; PASSAMANI, E; NORRIS, R; MORRIS, C; MATHUR, V; VARNAUSKAS, E; CHALMERS, TC				YUSUF, S; ZUCKER, D; PEDUZZI, P; FISHER, LD; TAKARO, T; KENNEDY, JW; DAVIS, K; KILLIP, T; PASSAMANI, E; NORRIS, R; MORRIS, C; MATHUR, V; VARNAUSKAS, E; CHALMERS, TC			EFFECT OF CORONARY-ARTERY BYPASS GRAFT-SURGERY ON SURVIVAL - OVERVIEW OF 10-YEAR RESULTS FROM RANDOMIZED TRIALS BY THE CORONARY-ARTERY BYPASS GRAFT-SURGERY TRIALISTS COLLABORATION	LANCET			English	Article							DISEASE	We carried out a systematic overview using individual patient data from the seven randomised trials that have compared a strategy of initial coronary artery bypass graft (CABG) surgery with one of initial medical therapy to assess the effects on mortality in patients with stable coronary heart disease (stable angina not severe enough to necessitate surgery on grounds of symptoms alone, or myocardial infarction). 1324 patients were assigned CABG surgery and 1325 medical management between 1972 and 1984. The proportion of patients in the medical treatment group who had undergone CABG surgery was 25% at 5 years, 33% at 7 years, and 41% at 10 years: 93.7% of patients assigned to the surgery group underwent CABG surgery. The CABG group had significantly lower mortality than the medical treatment group at 5 years (10.2 vs 15.8%; odds ratio 0.61 [95% CI 0.48-0.77], p=0.0001), 7 years (15.8 vs 21.7%; 0.68 [0.56-0.83], p<0.001), and 10 years (26.4 vs 30.5%; 0.83 [0.70-0.98]; p=0.03). The risk reduction was greater in patients with left main artery disease than in those with disease in three vessels or one or two vessels (odds ratios at 5 years 0.32, 0.58, and 0.77, respectively). Although relative risk reductions in subgroups defined by other baseline characteristics were similar, the absolute benefits of CABG surgery were most pronounced in patients in the highest risk categories. This effect was most evident when several prognostically important clinical and angiographic risk factors were integrated to stratify patients by risk levels and the extension of survival at 10 years was examined (change in survival -1.1 [SE 3.1] months in low-risk group, 5.0 [4.2] months in moderate-risk group, and 8.8 [5.4] months in high-risk group; p for trend < 0.003). A strategy of initial CABG surgery is associated with lower mortality than one of medical management with delayed surgery if necessary, especially in high-risk and medium-risk patients with stable coronary heart disease. In low-risk patients, the limited data show a non-significant trend towards greater mortality with CABG.	NHLBI,BETHESDA,MD; MCMASTER UNIV,HAMILTON,ON,CANADA; HEBREW UNIV JERUSALEM,JERUSALEM,ISRAEL; VET AFFAIRS COOPERAT STUDIES PROGRAM,W HAVEN,CT; UNIV WASHINGTON,SEATTLE,WA; BETH ISRAEL HOSP,NEW YORK,NY; GREEN LANE HOSP,AUCKLAND,NEW ZEALAND; OREGON HLTH SCI UNIV,PORTLAND,OR; TEXAS HEART INST,HOUSTON,TX; GOTHENBURG UNIV,GOTHENBURG,SWEDEN; HARVARD UNIV,SCH PUBL HLTH,BOSTON,MA 02115; TUFTS UNIV,BOSTON,MA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); McMaster University; Hebrew University of Jerusalem; University of Washington; University of Washington Seattle; Oregon Health & Science University; Texas Heart Institute; University of Gothenburg; Harvard University; Harvard T.H. Chan School of Public Health; Tufts University				Yusuf, Salim/0000-0003-4776-5601				BICKELL NA, 1992, ANN INTERN MED, V116, P791, DOI 10.7326/0003-4819-116-10-791; CALIFF RM, 1989, JAMA-J AM MED ASSOC, V261, P2077, DOI 10.1001/jama.261.14.2077; Favaloro R G, 1968, Ann Thorac Surg, V5, P334; HARRELL FE, 1984, STAT MED, V3, P143, DOI 10.1002/sim.4780030207; IRWIN JO, 1949, J HYG-CAMBRIDGE, V47, P188, DOI 10.1017/S0022172400014443; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KENNEDY JN, 1992, CIRCULATION, V86, P1; KLOSTER FE, 1979, NEW ENGL J MED, V300, P149, DOI 10.1056/NEJM197901253000401; LOOP FD, 1986, NEW ENGL J MED, V314, P1, DOI 10.1056/NEJM198601023140101; Mathur V S, 1977, Cardiovasc Clin, V8, P131; MUHLBAIER LH, 1992, CIRCULATION, V86, P198; NORRIS RM, 1981, CIRCULATION, V63, P785, DOI 10.1161/01.CIR.63.4.785; PEDUZZI PN, 1982, CONTROL CLIN TRIALS, V3, P47, DOI 10.1016/0197-2456(82)90018-6; TAKARO T, 1976, CIRCULATION, V54, P107; VARNAUSKAS E, 1988, NEW ENGL J MED, V319, P332, DOI 10.1056/NEJM198808113190603; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; 1985, NEW ENGL J MED, V393, P217; 1988, BRIT MED J, V296, P320; 1983, CIRCULATION, V68, P939; 1984, NEW ENGL J MED, V311, P1333	20	1542	1620	0	34	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 27	1994	344	8922					563	570		10.1016/S0140-6736(94)91963-1	http://dx.doi.org/10.1016/S0140-6736(94)91963-1			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD424	7914958				2022-12-24	WOS:A1994PD42400007
J	EKBOM, A; WAKEFIELD, AJ; ZACK, M; ADAMI, HO				EKBOM, A; WAKEFIELD, AJ; ZACK, M; ADAMI, HO			PERINATAL MEASLES INFECTION AND SUBSEQUENT CROHNS-DISEASE	LANCET			English	Article							INFLAMMATORY BOWEL-DISEASE; MORTALITY	Although the aetiology of Crohn's disease is unknown, morphological and epidemiological studies have implicated measles virus as a potential component cause, particularly when exposure occurs in utero or early in life. An increased incidence of Crohn's disease among people born during measles epidemics would support this hypothesis. We identified all individuals born in four counties in central Sweden in 1945-54 who had had Crohn's disease diagnosed before the age of 30 years. Yearly reports compiled in these counties revealed that five measles epidemics had affected all four counties during the trial period. After adjusting for monthly differences in the number of livebirths in the four counties, we calculated the expected number of patients with Crohn's disease and ulcerative colitis born during the 3-month period after the peaks of the epidemics. The number of people with Crohn's disease significantly exceeded that expected: 57 versus 39.0 (standardised incidence ratio 1.46, 95% CI 1.11-1.89). For patients with ulcerative colitis, the observed number (42) was close to that expected (46.8). Our results strengthen the hypothesis that measles is related to Crohn's disease and that the perinatal period is a time of vulnerability.	HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115; ROYAL FREE HOSP,SCH MED,INFLAMMATORY BOWEL DIS STUDY GRP,LONDON,ENGLAND; CTR DIS CONTROL & PREVENT,NATL CTR CHRON DIS PREVENT & HLTH PROMOT,ATLANTA,GA 30341	Harvard University; Harvard T.H. Chan School of Public Health; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; Centers for Disease Control & Prevention - USA	EKBOM, A (corresponding author), UNIV UPPSALA HOSP,CANC EPIDEMIOL UNIT,S-75185 UPPSALA,SWEDEN.							AABY P, 1988, LANCET, V1, P516; EKBOM A, 1990, AM J EPIDEMIOL, V132, P1111, DOI 10.1093/oxfordjournals.aje.a115754; EKBOM A, 1991, GASTROENTEROLOGY, V100, P350, DOI 10.1016/0016-5085(91)90202-V; EKBOM A, 1991, AM J EPIDEMIOL, V134, P876, DOI 10.1093/oxfordjournals.aje.a116162; EVANS JG, 1965, GUT, V6, P311, DOI 10.1136/gut.6.4.311; GARLAND CF, 1981, GASTROENTEROLOGY, V81, P1115; LOCKHARTMUMMERY HE, 1960, GUT, V1, P87, DOI 10.1136/gut.1.2.87; LUNDEE AS, 1980, DHHS PHS801358 PUBL; MORGAN KL, 1987, LANCET, V1, P1017; NORLEN BJ, 1970, SCAND J GASTROENTERO, V5, P385; ORHOLM M, 1991, NEW ENGL J MED, V324, P84, DOI 10.1056/NEJM199101103240203; POSER CM, 1990, J NEUROL SCI, V95, P214; REMINGTON JS, 1983, INFECT DIS, P45; Samuelsson S., 1976, THESIS U UPPSALA UPP; SONNENBERG A, 1986, DIS COLON RECTUM, V29, P854, DOI 10.1007/BF02555363; WAKEFIELD AJ, 1993, J MED VIROL, V39, P345, DOI 10.1002/jmv.1890390415; 1945, UNTITLED NATALITY ST	17	133	133	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 20	1994	344	8921					508	510		10.1016/S0140-6736(94)91898-8	http://dx.doi.org/10.1016/S0140-6736(94)91898-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PC535	7914614				2022-12-24	WOS:A1994PC53500009
J	FALLOWFIELD, LJ; HALL, A; MAGUIRE, P; BAUM, M; AHERN, RPA				FALLOWFIELD, LJ; HALL, A; MAGUIRE, P; BAUM, M; AHERN, RPA			PSYCHOLOGICAL EFFECTS OF BEING OFFERED CHOICE OF SURGERY FOR BREAST-CANCER	BRITISH MEDICAL JOURNAL			English	Article									CHRISTIE HOSP, CANC RES CAMPAIGN, PSYCHOL MED GRP, MANCHESTER M20 9BX, LANCS, ENGLAND; ROYAL MARSDEN HOSP, LONDON SW3 6JJ, ENGLAND	Christie NHS Foundation Trust; Christie Hospital; Royal Marsden NHS Foundation Trust	FALLOWFIELD, LJ (corresponding author), UCL, SCH MED,DEPT ONCOL,CANC RES CAMPAIGN, COMMUN & COUNSELLING RES CTR, 3RD FLOOR, LONDON W1P 7PL, ENGLAND.			A'Hern, Roger/0000-0003-0593-8391; Fallowfield, Lesley/0000-0003-0577-4518				ASHCROFT JJ, 1985, J ROY SOC MED, V78, P43; FALLOWFIELD LJ, 1990, BRIT MED J, V301, P575, DOI 10.1136/bmj.301.6752.575; LUKER K, 1993, PREFERENCES INFORMAT; MORRIS J, 1988, SOC SCI MED, V26, P583, DOI 10.1016/0277-9536(88)90021-4; WILSON RG, 1988, BMJ-BRIT MED J, V297, P1167, DOI 10.1136/bmj.297.6657.1167	5	166	167	1	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 13	1994	309	6952					448	448		10.1136/bmj.309.6952.448	http://dx.doi.org/10.1136/bmj.309.6952.448			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PC404	7920129	Green Published			2022-12-24	WOS:A1994PC40400019
J	GOUGH, AKS; LILLEY, J; EYRE, S; HOLDER, RL; EMERY, P				GOUGH, AKS; LILLEY, J; EYRE, S; HOLDER, RL; EMERY, P			GENERALIZED BONE LOSS IN PATIENTS WITH EARLY RHEUMATOID-ARTHRITIS	LANCET			English	Article							LOW-DOSE CORTICOSTEROIDS; DISEASE-ACTIVITY; MINERAL DENSITY; FRACTURE; CALCIUM; WOMEN; MASS	Generalised osteoporosis is a feature of established rheumatoid arthritis but whether this is a consequence of treatment, immobility, or disease activity has been unclear. We estimated bone mineral density by dual energy x-ray absorptiometry on 148 patients with early rheumatoid arthritis before treatment with corticosteroids or disease-modifying drugs and 730 normal controls. Scans were done at 12-month intervals in patients and at 0 and 12 months an 50 of the controls matched for menopausal status. At presentation, bone mineral density of patients did not differ from controls. However, patients with disease for less than 6 months had significantly higher spinal bone mineral density than those of longer duration. Over the next 12 months, bone mineral density loss was greater in patients with rheumatoid arthritis compared with controls; significantly so for early disease (eg, - 2.4 [0.8] vs - 0.6 [0.4] g/cm(2), p < 0.05 in the spine and - 4.3 [0.8] vs - 0.4 [0.5] g/cm(2), p < 0.001 in the trochanter). For the lumbar spine, only disease activity was significantly associated with this bone mineral density loss. For patients with active disease over 2 years, mean bone mineral density loss at each site was between 5.5 and 10% (p < 0.01 compared to patients with inactive disease). Suppression of disease activity stabilised this bone loss. In patients with rheumatoid arthritis significant amounts of generalised skeletal bone were test early in the disease and the loss was associated with disease activity. These findings have implications for the management of patients with rheumatoid arthritis and possibly other inflammatory diseases.	UNIV BIRMINGHAM,DEPT RHEUMATOL,BIRMINGHAM B15 2TT,ENGLAND; UNIV BIRMINGHAM,DEPT MATH & STAT,BIRMINGHAM,ENGLAND; QUEEN ELIZABETH HOSP,DEPT NUCL MED,BIRMINGHAM,W MIDLANDS,ENGLAND	University of Birmingham; University of Birmingham; University of Birmingham			emery, paul/B-3560-2013					ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; BEAT AM, 1991, J RHEUMATOL, V18, P804; BROZIK M, 1992, J RHEUMATOL, V19, P63; COMPSTON JE, 1988, ANN RHEUM DIS, V47, P660, DOI 10.1136/ard.47.8.660; COMPSTON JE, 1987, GUT, V28, P410, DOI 10.1136/gut.28.4.410; EGGELMEIJER F, 1993, BRIT J RHEUMATOL, V32, P387; FELDER M, 1991, RHEUMATOL INT, V11, P41, DOI 10.1007/BF00290250; FILLIBEN JJ, 1975, TECHNOMETRICS, V17, P111, DOI 10.2307/1268008; FRIES JF, 1982, J RHEUMATOL, V74, P786; GOUGH AKS, 1994, ANN RHEUM DIS, V53, P14, DOI 10.1136/ard.53.1.14; GOWEN M, 1983, NATURE, V306, P378, DOI 10.1038/306378a0; HOOYMAN JR, 1984, ARTHRITIS RHEUM-US, V27, P1353, DOI 10.1002/art.1780271205; KENNEDY AC, 1975, SCAND J RHEUMATOL, V4, P73, DOI 10.3109/03009747509095618; LAAN RFJM, 1993, ANN RHEUM DIS, V52, P21, DOI 10.1136/ard.52.1.21; LAAN RFJM, 1992, BRIT J RHEUMATOL, V31, P91; LEBOFF MS, 1991, J RHEUMATOL, V18, P339; Lilley J, 1991, Osteoporos Int, V1, P141, DOI 10.1007/BF01625443; MCCONKEY B, 1962, Q J MED, V124, P419; MELLISH RWE, 1987, ANN RHEUM DIS, V46, P830, DOI 10.1136/ard.46.11.830; NG KC, 1984, ANN RHEUM DIS, V43, P370, DOI 10.1136/ard.43.3.370; OKA M, 1975, SCAND J RHEUMATOL, V4, P28; REID DM, 1982, BMJ-BRIT MED J, V285, P330, DOI 10.1136/bmj.285.6338.330; RITCHIE DM, 1968, Q J MED, V37, P393; SAMBROOK PN, 1987, ARTHRITIS RHEUM, V30, P721, DOI 10.1002/art.1780300701; SAMBROOK PN, 1989, ANN RHEUM DIS, V48, P535, DOI 10.1136/ard.48.7.535; SAMBROOK PN, 1985, ANN RHEUM DIS, V44, P580, DOI 10.1136/ard.44.9.580; SPECTOR TD, 1993, BRIT MED J, V306, P558, DOI 10.1136/bmj.306.6877.558; STEINBROCKER O, 1949, JAMA-J AM MED ASSOC, V140, P659, DOI 10.1001/jama.1949.02900430001001; VERSTRAETEN A, 1986, ANN RHEUM DIS, V45, P852, DOI 10.1136/ard.45.10.852; VERSTRAETEN A, 1989, CLIN EXP RHEUMATOL, V7, P351	30	570	586	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 2	1994	344	8914					23	27		10.1016/S0140-6736(94)91049-9	http://dx.doi.org/10.1016/S0140-6736(94)91049-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU917	7912297				2022-12-24	WOS:A1994NU91700012
J	BURNS, DN; GELLERT, GA; CRONE, RK				BURNS, DN; GELLERT, GA; CRONE, RK			TUBERCULOSIS IN EASTERN-EUROPE AND THE FORMER SOVIET-UNION - HOW CONCERNED SHOULD WE BE	LANCET			English	Editorial Material									PROJECT HOPE,CTR HLTH SCI EDUC,MILLWOOD,VA		BURNS, DN (corresponding author), NIH,BETHESDA,MD 20892, USA.							BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055; CHEN LC, 1992, LANCET, V339, P1465, DOI 10.1016/0140-6736(92)92044-G; ELLNER JJ, 1993, J INFECT DIS, V168, P537, DOI 10.1093/infdis/168.3.537; MURRAY CJL, 1991, LANCET, V338, P1305, DOI 10.1016/0140-6736(91)92600-7; NEVILLE K, 1994, CHEST, V105, P45, DOI 10.1378/chest.105.1.45; RAVIGLIONE MC, 1993, B WORLD HEALTH ORGAN, V71, P297; RAVIGLIONE MC, 1994, WHOTB94176 DOC; 1993, MMWR-MORBID MORTAL W, V42, P696	8	17	17	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 11	1994	343	8911					1445	1446		10.1016/S0140-6736(94)92576-3	http://dx.doi.org/10.1016/S0140-6736(94)92576-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NQ415	7911172				2022-12-24	WOS:A1994NQ41500003
J	BANATVALA, JE; CHRYSTIE, IL				BANATVALA, JE; CHRYSTIE, IL			HIV SCREENING IN PREGNANCY - UK TAGS	LANCET			English	Editorial Material											BANATVALA, JE (corresponding author), UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,ST THOMAS HOSP,DEPT VIROL,LONDON,ENGLAND.							ADES AE, 1993, BRIT MED J, V306, P1296, DOI 10.1136/bmj.306.6888.1296; BARBACCI M, 1991, LANCET, V337, P709, DOI 10.1016/0140-6736(91)90286-X; Chrystie I, 1992, Health Trends, V24, P13; DAVISON CF, 1993, AIDS CARE, V5, P135, DOI 10.1080/09540129308258593; GOUDEAU A, 1989, PARS TOURS COOPERATI; HOWARD LC, 1989, BRIT J OBSTET GYNAEC, V96, P135, DOI 10.1111/j.1471-0528.1989.tb01651.x; LINDGREN S, 1993, BRIT MED J, V307, P1447, DOI 10.1136/bmj.307.6917.1447; MEADOWS J, 1990, AIDS Care, V2, P229, DOI 10.1080/09540129008257735; MEADOWS J, 1992, LANCET, V339, P622; SIMMONDS RJ, 1992, 41ST EP INT SERV ANN, P35; 1992, IMMUNISATION INFECTI, P114; 1994, CLIN ALERT IMPORTANT; 1992, DEP HLTH GUIDANCE PL; 1993, AIDS SURVEILLANCE EU, V37, P20	14	8	8	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 7	1994	343	8906					1113	1114		10.1016/S0140-6736(94)90230-5	http://dx.doi.org/10.1016/S0140-6736(94)90230-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NK730	7910227				2022-12-24	WOS:A1994NK73000004
J	GODFREY, R				GODFREY, R			THE NOSE AND THE LOWER AIRWAYS	LANCET			English	Editorial Material							EXERCISE; ASTHMA				GODFREY, R (corresponding author), SOUTHAMPTON GEN HOSP,DEPT MED,SOUTHAMPTON,ENGLAND.							ANDERSEN I, 1974, ARCH ENVIRON HEALTH, V28, P31, DOI 10.1080/00039896.1974.10666429; BRODER I, 1974, J ALLERGY CLIN IMMUN, V54, P100, DOI 10.1016/0091-6749(74)90038-4; GILBERT IA, 1988, J APPL PHYSIOL, V64, P2167, DOI 10.1152/jappl.1988.64.5.2167; Proctor DF, 1982, NOSE UPPER AIRWAY PH; RUBINSTEIN I, 1988, AM REV RESPIR DIS, V138, P1164, DOI 10.1164/ajrccm/138.5.1164; SCHUMACHER MJ, 1986, J ALLERGY CLIN IMMUN, V78, P30, DOI 10.1016/0091-6749(86)90111-9; SERRABATLLES J, 1994, THORAX, V49, P128, DOI 10.1136/thx.49.2.128; WIDDICOMBE JG, 1990, EUR RESPIR J S12, V3, P564	8	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 23	1994	343	8904					991	992		10.1016/S0140-6736(94)90122-8	http://dx.doi.org/10.1016/S0140-6736(94)90122-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NG682	7909089				2022-12-24	WOS:A1994NG68200005
J	WILKINSON, D				WILKINSON, D			HIGH-COMPLIANCE TUBERCULOSIS TREATMENT PROGRAM IN A RURAL-COMMUNITY	LANCET			English	Note								The global tuberculosis epidemic is being fuelled by dual infection with human immunodeficiency virus type I, Short-course chemotherapy is effective but usually fails for operational reasons. A community-based treatment programme of twice-weekly fully-supervised treatment is described in which 89% of surviving patients completed treatment under programme conditions. Half the patients were successfully supervised by non-health workers. New approaches are needed to combat the global tuberculosis epidemic.	HLABLSA HOSP,HLABLSA 3937,SOUTH AFRICA				Wilkinson, David/A-6207-2008	Wilkinson, David/0000-0002-7265-9846	PHS HHS [1-D43-T200231-01] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Chaulet P, 1987, Tubercle, V68, P19, DOI 10.1016/0041-3879(87)90016-X; CHOWDHURY AMR, 1992, LANCET, V339, P1181, DOI 10.1016/0140-6736(92)90788-5; CUNEO WD, 1989, CLIN CHEST MED, V10, P375; ELLIOTT AM, 1992, TROP DOCT, V22, P147, DOI 10.1177/004947559202200402; FOX W, 1981, BRIT J DIS CHEST, V75, P331, DOI 10.1016/0007-0971(81)90022-X; ISEMAN MD, 1993, NEW ENGL J MED, V328, P576, DOI 10.1056/NEJM199302253280811; KOCHI A, 1991, TUBERCLE, V72, P1, DOI 10.1016/0041-3879(91)90017-M; LEOWSKI J, 1988, M WORKING GROUP SHOR; NARAIN JP, 1992, TUBERCLE LUNG DIS, V73, P311, DOI 10.1016/0962-8479(92)90033-G; RODRIGUES LC, 1990, T ROY SOC TROP MED H, V84, P739, DOI 10.1016/0035-9203(90)90172-B; SUTHERLAND I, 1988, BRIT MED BULL, V44, P665, DOI 10.1093/oxfordjournals.bmb.a072275; 1992, TUBERCULOSIS TREATME	12	135	136	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 12	1994	343	8898					647	648		10.1016/S0140-6736(94)92640-9	http://dx.doi.org/10.1016/S0140-6736(94)92640-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NA093	7906815				2022-12-24	WOS:A1994NA09300013
J	JACKSON, R				JACKSON, R			WHICH HYPERTENSIVE PATIENTS SHOULD BE TREATED	LANCET			English	Editorial Material							CORONARY				JACKSON, R (corresponding author), UNIV AUCKLAND,DEPT COMMUNITY HLTH,AUCKLAND,NEW ZEALAND.			Jackson, Rod/0000-0001-5914-6934				ANDERSON KM, 1991, CIRCULATION, V83, P356, DOI 10.1161/01.CIR.83.1.356; [Anonymous], 1993, BMJ, V307, P1541; BEARD K, 1992, BMJ-BRIT MED J, V304, P412, DOI 10.1136/bmj.304.6824.412; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; JACKSON R, 1993, BRIT MED J, V307, P107, DOI 10.1136/bmj.307.6896.107; MACMAHON S, IN PRESS J VASC MED; SEVER P, 1993, BMJ-BRIT MED J, V306, P983, DOI 10.1136/bmj.306.6883.983; 1993, ARCH INTERN MED, V153, P154; 1988, ARCH INTERN MED, V148, P1023	9	15	15	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 26	1994	343	8896					496	497		10.1016/S0140-6736(94)91456-7	http://dx.doi.org/10.1016/S0140-6736(94)91456-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MX888	7906755				2022-12-24	WOS:A1994MX88800004
J	VANLEEUWEN, FE; BENRAADT, J; COEBERGH, JWW; KIEMENEY, LALM; GIMBRERE, CHF; OTTER, R; SCHOUTEN, LJ; DAMHUIS, RAM; BONTENBAL, M; DIEPENHORST, FW; VANDENBELTDUSEBOUT, AW; VANTINTEREN, H				VANLEEUWEN, FE; BENRAADT, J; COEBERGH, JWW; KIEMENEY, LALM; GIMBRERE, CHF; OTTER, R; SCHOUTEN, LJ; DAMHUIS, RAM; BONTENBAL, M; DIEPENHORST, FW; VANDENBELTDUSEBOUT, AW; VANTINTEREN, H			RISK OF ENDOMETRIAL CANCER AFTER TAMOXIFEN TREATMENT OF BREAST-CANCER	LANCET			English	Article							ADJUVANT TAMOXIFEN; VAGINAL EPITHELIUM; PREVENTION; THERAPY; RADIOTHERAPY; DISEASE	Since large trials have been set up to assess whether tamoxifen decreases the risk of breast cancer in healthy women, it has become important to investigate the drug's potential adverse effects, including occurrence of endometrial cancer. We undertook a case-control study in the Netherlands to assess the effect of tamoxifen on the risk of endometrial cancer after breast cancer. Through the population-based Netherlands Cancer Registry and two older, hospital-based, registries, we identified 98 patients who had endometrial cancer diagnosed at least 3 months after a diagnosis of primary breast cancer. Detailed information about treatment was obtained for all these patients, and for 285 controls, who were matched to the cases for age, year of breast cancer diagnosis, and survival time with intact uterus. Tamoxifen had been used by 24% of patients with subsequent endometrial cancer and 20% of controls (relative risk 1.3 [95% Cl 0.7-2.4]). Women who had used tamoxifen for more than 2 years had a 2.3 (0.9-5.9) times greater risk of endometrial cancer than never users. There was a significant trend of increasing risk of endometrial cancer with duration of tamoxifen use (p=0.049), and also with cumulative dose (p=0.046). The duration-response trends were similar with daily doses of 40 mg or 30 mg and less. These findings support the hypothesis that tamoxifen use increases the risk of endometrial cancer. This oestrogenic effect on the endometrium was not related to the dose intensity. Physicians should be aware of the higher risk of endometrial cancer in tamoxifen users.	COMPREHENS CANC CTR,AMSTERDAM,NETHERLANDS; COMPREHENS CANC CTR S NETHERLANDS,EINDHOVEN,NETHERLANDS; COMPREHENS CANC CTR MIDDLE NETHERLANDS,UTRECHT,NETHERLANDS; COMPREHENS CANC CTR,LIMBURG,NETHERLANDS; COMPREHENS CANC CTR,ROTTERDAM,NETHERLANDS; COMPREHENS CANC CTR STEDENDRIEHOEK,TWENTE,NETHERLANDS; DR DANIEL DEN HOED CANC CTR,ROTTERDAM,NETHERLANDS	Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute	VANLEEUWEN, FE (corresponding author), NETHERLANDS CANC INST,DEPT EPIDEMIOL,PLESMANLAAN 121,1066 CX AMSTERDAM,NETHERLANDS.		Schouten, Leo J/G-3713-2012; Schouten, Leo J/AAB-2275-2019; Kiemeney, Lambertus A./D-3357-2009	Schouten, Leo J/0000-0003-3361-7560; Kiemeney, Lambertus A./0000-0002-2368-1326; Coebergh, Jan Willem/0000-0002-2419-3930				ANDERSSON M, 1992, ACTA ONCOL, V31, P259, DOI 10.3109/02841869209088912; ANDERSSON M, 1991, J NATL CANCER I, V83, P1013, DOI 10.1093/jnci/83.14.1013; BOCCARDO F, 1981, ONCOLOGY, V38, P281, DOI 10.1159/000225571; BOCCARDO F, 1984, TUMORI, V70, P61, DOI 10.1177/030089168407000110; Breslow N, 1980, STATISTICAL METHODS, V32; BURING JE, 1986, AM J EPIDEMIOL, V124, P434, DOI 10.1093/oxfordjournals.aje.a114414; COLLETTE HJA, 1984, LANCET, V1, P1224; COLLINS J, 1980, LANCET, V2, P961; CREASMAN WT, 1990, OBSTET GYNECOL, V75, P287; DEMUYLDER X, 1991, INT J GYNECOL OBSTET, V36, P127, DOI 10.1016/0020-7292(91)90767-Y; Early Breast Cancer Trialists' Collaborative Group, 1992, LANCET, V339, P1; ELWOOD JM, 1980, GYNECOL ONCOL, V10, P173, DOI 10.1016/0090-8258(80)90079-7; FERRAZZI E, 1977, BRIT MED J, V1, P1351, DOI 10.1136/bmj.1.6072.1351-e; FISHER B, 1991, J NATL CANCER I, V83, P1278, DOI 10.1093/jnci/83.18.1278; FISHER B, 1989, NEW ENGL J MED, V320, P489; FORNANDER T, 1989, LANCET, V1, P117; FUGHBERMAN A, 1992, LANCET, V340, P1143, DOI 10.1016/0140-6736(92)93161-F; GOTTARDIS MM, 1988, CANCER RES, V48, P812; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; MAGRIPLES U, 1993, J CLIN ONCOL, V11, P485, DOI 10.1200/JCO.1993.11.3.485; MUIR C, 1987, CANCER INCIDENCE 5 C, V5; NAYFIELD SG, 1991, J NATL CANCER I, V83, P1450, DOI 10.1093/jnci/83.20.1450; NEVEN P, 1993, LANCET, V342, P452, DOI 10.1016/0140-6736(93)91590-I; POWLES TJ, 1992, LANCET, V340, P1145, DOI 10.1016/0140-6736(92)93162-G; POWLES TJ, 1990, EUR J CANCER, V26, P680, DOI 10.1016/0277-5379(90)90116-B; STEWART HJ, 1989, LANCET, V1, P375; SUNDERLAND MC, 1991, J CLIN ONCOL, V9, P1283, DOI 10.1200/JCO.1991.9.7.1283; 1988, BRIT J CANCER, V57, P604; 1992, INCIDENCE CANCER NET; 1992, LANCET, V339, P71	30	492	498	0	12	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 19	1994	343	8895					448	452		10.1016/S0140-6736(94)92692-1	http://dx.doi.org/10.1016/S0140-6736(94)92692-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW690	7905955	Green Submitted			2022-12-24	WOS:A1994MW69000010
J	SAWIN, CT; GELLER, A; WOLF, PA; BELANGER, AJ; BAKER, E; BACHARACH, P; WILSON, PWF; BENJAMIN, EJ; DAGOSTINO, RB				SAWIN, CT; GELLER, A; WOLF, PA; BELANGER, AJ; BAKER, E; BACHARACH, P; WILSON, PWF; BENJAMIN, EJ; DAGOSTINO, RB			LOW SERUM THYROTROPIN CONCENTRATIONS AS A RISK FACTOR FOR ATRIAL-FIBRILLATION IN OLDER PERSONS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							THYROID-STIMULATING-HORMONE; GRAVES-DISEASE; THYROTOXICOSIS; ASSAY; STROKE; TSH; HYPERTHYROIDISM; PREVALENCE; EMBOLISM; CARE	Background, Low serum thyrotropin concentrations are a sensitive indicator of hyperthyroidism but can also occur in persons who have no clinical manifestations of the disorder. We studied whether low serum thyrotropin concentrations in clinically euthyroid older persons are a risk factor for Subsequent atrial fibrillation. Methods. We studied 2007 persons (814 men and 1193 women) 60 years of age or older who did not have atrial fibrillation in order to determine the frequency of this arrhythmia during a 10-year follow-up period. The subjects were classified according to their serum thyrotropin concentrations: those with low values (less than or equal to 0.1 mU per liter; 61 subjects); those with slightly low values (> 0.1 to 0.4 mU per liter; 187 subjects); those with normal values (> 0.4 to 5.0 mU per liter; 1576 subjects); and those with high values (> 5.0 mU per liter; 183 subjects). Results. During the 10-year follow-up period, atrial fibrillation occurred in 13 persons with low initial values for serum thyrotropin, 23 with slightly low values, 133 with normal values, and 23 with high values. The cumulative incidence of atrial fibrillation at 10 years was 28 percent among the subjects with low serum thyrotropin values (less than or equal to 0.1 mU per liter), as compared with 11 percent among those with normal values; the age-adjusted incidence of atrial fibrillation was 28 per 1000 person-years among those with low values and 10 per 1000 person-years among those with normal values (P = 0.005). After adjustment for other known risk factors, the relative risk of atrial fibrillation in elderly subjects with low serum thyrotropin concentrations, as compared with those with normal concentrations, was 3.1 (95 percent confidence interval, 1.7 to 5.5; P < 0.001), The 10-year incidence of atrial fibrillation in the groups with slightly low and high serum thyrotropin values was not significantly different from that in the group with normal values. Conclusions. Among people 60 years of age or older, a low serum thyrotropin concentration is associated with a threefold higher risk that atrial fibrillation will develop in the subsequent decade.	VET AFFAIRS MED CTR,MED RES SERV,BOSTON,MA; BOSTON UNIV,EVANS MEM DEPT CLIN RES,PREVENT MED & EPIDEMIOL SECT,BOSTON,MA; BOSTON UNIV,DEPT NEUROL,BOSTON,MA; BOSTON UNIV,DEPT MATH,BOSTON,MA; BOSTON UNIV,DEPT MED,BOSTON,MA; FRAMINGHAM HEART DIS EPIDEMIOL STUDY,FRAMINGHAM,MA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Boston University; Boston University; Boston University; Boston University; Framingham Heart Study	SAWIN, CT (corresponding author), VET AFFAIRS MED CTR,MED SERV,150 S HUNTINGTON AVE,BOSTON,MA 02130, USA.		Wilson, Peter W.F./J-2455-2016; Benjamin, Emelia/E-7103-2011	Benjamin, Emelia/0000-0003-4076-2336; Wolf, Philip/0000-0002-3628-301X	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC038038] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040423] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017950] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL40423-04, N01-HC-38038] Funding Source: Medline; NINDS NIH HHS [2-R01-NS-17950-12] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAGCHI N, 1990, ARCH INTERN MED, V150, P785, DOI 10.1001/archinte.150.4.785; COX DR, 1972, J R STAT SOC B, V34, P187; DALY JG, 1982, BMJ-BRIT MED J, V285, P1574; EGGERTSEN R, 1988, BRIT MED J, V297, P1586, DOI 10.1136/bmj.297.6663.1586; FAGERBERG B, 1990, CLIN CHEM, V36, P620; FRIEDMAN D, 1992, AGE, V15, P9, DOI 10.1007/BF02434907; FURSZYFER J, 1970, MAYO CLIN PROC, V45, P636; KALBFLEISCH JD, 1980, STAT ANAL FAILURE TI, P199; KANNEL WB, 1982, NEW ENGL J MED, V306, P1018, DOI 10.1056/NEJM198204293061703; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LEESE GP, 1992, CLIN ENDOCRINOL, V37, P500, DOI 10.1111/j.1365-2265.1992.tb01480.x; LUNDGREN E, 1990, CLIN ENDOCRINOL, V33, P133, DOI 10.1111/j.1365-2265.1990.tb00473.x; NORDYKE RA, 1988, ARCH INTERN MED, V148, P626, DOI 10.1001/archinte.148.3.626; PARLE JV, 1991, CLIN ENDOCRINOL, V34, P77; PEKARY AE, 1975, J CLIN ENDOCR METAB, V41, P676, DOI 10.1210/jcem-41-4-676; PETERSEN P, 1988, STROKE, V19, P15, DOI 10.1161/01.STR.19.1.15; PETERSEN P, 1984, ACTA MED SCAND, V216, P5; PHILLIPS DIW, 1985, CLIN ENDOCRINOL, V23, P283, DOI 10.1111/j.1365-2265.1985.tb00225.x; PRESTI CF, 1989, AM HEART J, V117, P976, DOI 10.1016/0002-8703(89)90642-X; ROSS DS, 1990, J CLIN ENDOCR METAB, V71, P764, DOI 10.1210/jcem-71-3-764; SANDLER G, 1959, Q J MED, V52, P347; SAWIN CT, 1991, ARCH INTERN MED, V151, P165, DOI 10.1001/archinte.151.1.165; SIEBERS MJ, 1992, ARCH INTERN MED, V152, P2063, DOI 10.1001/archinte.152.10.2063; SINGER DE, 1992, NEW ENGL J MED, V327, P1451, DOI 10.1056/NEJM199211123272009; STAFFURTH JS, 1977, BRIT MED J, V2, P688, DOI 10.1136/bmj.2.6088.688; SUNDBECK G, 1991, ARCH INTERN MED, V151, P549, DOI 10.1001/archinte.151.3.549; TENERZ A, 1990, J INTERN MED, V228, P229; TIBALDI JM, 1986, AM J MED, V81, P619, DOI 10.1016/0002-9343(86)90547-4; WEEKS I, 1984, CLIN ENDOCRINOL, V20, P489, DOI 10.1111/j.1365-2265.1984.tb03446.x; White PD, 1918, ARCH INTERN MED, V22, P766; WOLF PA, 1983, STROKE, V14, P664, DOI 10.1161/01.STR.14.5.664; WOLF PA, 1987, ARCH INTERN MED, V147, P1561, DOI 10.1001/archinte.147.9.1561	32	855	889	0	12	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 10	1994	331	19					1249	1252		10.1056/NEJM199411103311901	http://dx.doi.org/10.1056/NEJM199411103311901			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PP752	7935681				2022-12-24	WOS:A1994PP75200001
J	HAY, RJ				HAY, RJ			OF IMAGING AND SKIN	LANCET			English	Editorial Material											HAY, RJ (corresponding author), GUYS HOSP,ST JOHNS INST DERMATOL,LONDON,ENGLAND.							DERIGAL J, 1989, J INVEST DERMATOL, V93, P621, DOI 10.1111/1523-1747.ep12319741; GASSENMAIER G, 1990, HAUTARZT, V41, P360; GOETTMANN S, 1994, BRIT J DERMATOL, V130, P701, DOI 10.1111/j.1365-2133.1994.tb03405.x; KIRSNER RS, 1993, BRIT J DERMATOL, V128, P99, DOI 10.1111/j.1365-2133.1993.tb00156.x; PEREDNIA DA, 1991, J AM ACAD DERMATOL, V25, P89, DOI 10.1016/0190-9622(91)70178-5	5	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 29	1994	344	8931					1174	1174		10.1016/S0140-6736(94)90504-5	http://dx.doi.org/10.1016/S0140-6736(94)90504-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN803	7934536				2022-12-24	WOS:A1994PN80300005
J	MARK, DB; NAYLOR, CD; HLATKY, MA; CALIFF, RM; TOPOL, EJ; GRANGER, CB; KNIGHT, JD; NELSON, CL; LEE, KL; CLAPPCHANNING, NE; SUTHERLAND, W; PILOTE, L; ARMSTRONG, PW				MARK, DB; NAYLOR, CD; HLATKY, MA; CALIFF, RM; TOPOL, EJ; GRANGER, CB; KNIGHT, JD; NELSON, CL; LEE, KL; CLAPPCHANNING, NE; SUTHERLAND, W; PILOTE, L; ARMSTRONG, PW			USE OF MEDICAL RESOURCES AND QUALITY-OF-LIFE AFTER ACUTE MYOCARDIAL-INFARCTION IN CANADA AND THE UNITED-STATES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INDEX	Background. Much attention has been directed to the use of medical resources and to patients' outcomes in Canada as compared with the United States. We compared U.S. and Canadian patients with respect to their use of medical resources and their quality of life during the year after acute myocardial infarction. Methods. A total of 2600 U.S. and 400 Canadian patients were randomly selected from the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) trial. Base-line data from their initial hospitalizations were analyzed, and the patients were then interviewed by telephone 30 days, 6 months, and 1 year after myocardial infarction to determine their use of medical care and quality of life. Results. The Canadian patients typically stayed in the hospital one day longer (P = 0.009) than the U.S. patients but had a much lower rate of cardiac catheterization (25 percent vs. 72 percent, P<0.001), coronary angioplasty (11 percent vs. 29 percent, P<0.001), and coronary bypass surgery (3 percent vs. 14 percent, P<0.001). At one year 24 percent of the Canadian and 53 percent of the U.S. patients had undergone angioplasty or bypass surgery at least once (P<0.001). The Canadians had more visits to physicians during the follow-up year (P<0.001), but fewer visits to specialists (P<0.001). At 30 days, functional status was equivalent in the patients from the two countries. However, after one year the U.S. patients had substantially more improvement than the Canadian patients (P<0.001). The prevalence of chest pain and dyspnea at one year was higher among the Canadian patients (34 percent vs. 21 percent and 45 percent vs. 29 percent, respectively; P<0.001). Conclusions. The Canadian patients had more cardiac symptoms and worse functional status one year after acute myocardial infarction than the U.S. patients. The Canadian patients also underwent fewer invasive cardiac procedures and had fewer visits to specialist physicians. These results suggest, but do not prove, that the more aggressive pattern of care in the United States may have been responsible for the better quality of life.	DUKE UNIV, MED CTR, CLIN TRIALS COORDINATING CTR, DURHAM, NC 27708 USA; DUKE UNIV, MED CTR, DIV CARDIOL, DURHAM, NC 27708 USA; DUKE UNIV, MED CTR, DEPT MED, DURHAM, NC 27708 USA; DUKE UNIV, MED CTR, DEPT FAMILY & COMMUNITY MED, DIV BIOMETRY, DURHAM, NC 27708 USA; UNIV TORONTO, DEPT MED, TORONTO, ON, CANADA; INST CLIN EVALUAT SCI, TORONTO, ON, CANADA; UNIV ALBERTA, DEPT MED, EDMONTON, AB, CANADA; STANFORD UNIV, MED CTR, DEPT HLTH RES & POLICY, DIV HLTH SERV RES, STANFORD, CA 94305 USA; CLEVELAND CLIN, DEPT CARDIOL, CLEVELAND, OH USA	Duke University; Duke University; Duke University; Duke University; University of Toronto; University of Toronto; University of Alberta; Stanford University; Cleveland Clinic Foundation	MARK, DB (corresponding author), DUKE UNIV, MED CTR, ECON & QUAL LIFE RES GRP, POB 3485, DURHAM, NC 27708 USA.		Granger, Christopher B/D-3458-2014	Granger, Christopher B/0000-0002-0045-3291; Topol, Eric/0000-0002-1478-4729; Mark, Daniel/0000-0001-6340-8087; Armstrong, Paul/0000-0002-0460-3445; Hlatky, Mark/0000-0003-4686-9441; Pilote, Louise/0000-0002-6159-0628	AHRQ HHS [HS-05635, HS-06503] Funding Source: Medline; NHLBI NIH HHS [HL-36587] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R18HS005635] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036587] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON GM, 1993, JAMA-J AM MED ASSOC, V269, P1661; COX DR, 1972, J R STAT SOC B, V34, P187; HLATKY MA, 1989, AM J CARDIOL, V64, P651, DOI 10.1016/0002-9149(89)90496-7; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KATZ S, 1970, GERONTOLOGIST, V10, P20, DOI 10.1093/geront/10.1_Part_1.20; KOENIG HG, 1992, INT J PSYCHIAT MED, V22, P183, DOI 10.2190/M1F5-F40P-C4KD-YPA3; MARK DB, IN PRESS ACUTE CORON; PILOTE L, 1994, ARCH INTERN MED, V154, P1090, DOI 10.1001/archinte.154.10.1090; ROOS LL, 1990, JAMA-J AM MED ASSOC, V263, P2453, DOI 10.1001/jama.263.18.2453; Rose GA, 1982, WHO MONOGRAPH SERIES, V56; ROULEAU JL, 1993, NEW ENGL J MED, V328, P779, DOI 10.1056/NEJM199303183281108; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; TORRANCE GW, 1987, J CHRON DIS, V40, P593, DOI 10.1016/0021-9681(87)90019-1; TSEVAT J, 1990, J CLIN EPIDEMIOL, V43, pS73, DOI 10.1016/0895-4356(90)90224-D; 1991, CIRCULATION S5, V84, P1; 1992, DHHS PHS921232 NAT C	16	319	322	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 27	1994	331	17					1130	1135		10.1056/NEJM199410273311706	http://dx.doi.org/10.1056/NEJM199410273311706			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN065	7935638				2022-12-24	WOS:A1994PN06500006
J	DOWNEY, GP; BAVIN, PJ; DEERY, ARS; CROW, J; GRIFFITHS, PD; EMERY, VC; WALKER, PG				DOWNEY, GP; BAVIN, PJ; DEERY, ARS; CROW, J; GRIFFITHS, PD; EMERY, VC; WALKER, PG			RELATION BETWEEN HUMAN PAPILLOMAVIRUS TYPE-16 AND POTENTIAL FOR PROGRESSION OF MINOR-GRADE CERVICAL DISEASE	LANCET			English	Article							INTRAEPITHELIAL NEOPLASIA; INFECTION; SMEAR; ATYPIA; DNA; CANCER; WOMEN; RISK	We have previously reported that among 200 women referred for colposcopy with smears suggesting mild dyskaryosis, medium or high copy numbers of human papiliomavirus type 16 (HPV16) DNA identified patients with current high-grade cervical disease. We have followed up 95 women from that group who had histologically proven mild-grade cervical disease (cervical intraepithelial neoplasia grade 1, n = 37) or wart virus infection (n = 12) or who had no evidence of cervical abnormality at study entry (n = 43). Kaplan-Meier survival analysis of the 70 months' follow-up was used to identify baseline features that might affect the risk of progression. 3 women were lost to follow-up; data were available for the remaining 92. Among the whole group the probability of remaining free of high-grade cervical disease was 0.71. Women with a histological diagnosis of minor-grade disease were more likely to progress to high-grade disease than those with no evidence of abnormality (proportion disease-free 0.52 vs 0.90, p=0.004). Stratification of the group according to median age (28 years) revealed a weak association between age and disease progression (p=0.04). There was no difference in disease-free probability between HPV16-positive and HPV16-negative women (0.75 vs 0.65, p=0.19). Nor was there a significant difference in disease-free probability when the group was stratified by HPV16 viral burden. These data show that a histological diagnosis of minor grade cervical disease is a better long-term predictor of disease progression than is HPV16 positivity, irrespective of copy number. These findings do not support the simple view that HPV16 alone is the cause of high-grade cervical disease, including cancer.	ROYAL FREE HOSP, SCH MED, DIV COMMUN DIS, LONDON NW3 2QG, ENGLAND; ROYAL FREE HOSP, SCH MED, DEPT OBSTET & GYNAECOL, LONDON NW3 2QG, ENGLAND; ROYAL FREE HOSP, SCH MED, DEPT CYTOL, LONDON NW3 2QG, ENGLAND; ROYAL FREE HOSP, SCH MED, DEPT HISTOPATHOL, LONDON NW3 2QG, ENGLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School			Emery, Vincent/G-8928-2013	Emery, Vincent/0000-0001-5893-9756				BAVIN PJ, 1993, BRIT J CANCER, V67, P602, DOI 10.1038/bjc.1993.110; BUXTON EJ, 1991, BRIT J OBSTET GYNAEC, V98, P1273, DOI 10.1111/j.1471-0528.1991.tb15401.x; CAMPION MJ, 1986, LANCET, V2, P237; CRUM CP, 1984, INT J GYNECOL PATHOL, V3, P376; CUZICK J, 1992, LANCET, V339, P959, DOI 10.1016/0140-6736(92)91532-D; EVANS AS, 1985, BRIT J OBSTET GYNAEC, V92, P165, DOI 10.1111/j.1471-0528.1985.tb01069.x; GILES JA, 1989, BRIT J OBSTET GYNAEC, V96, P1067, DOI 10.1111/j.1471-0528.1989.tb03382.x; GISSMANN L, 1984, CANCER SURV, V3, P161; HAUSEN HZ, 1984, PROG MED VIROL, V30, P170; HIRSCHOWITZ L, 1992, BRIT MED J, V304, P1209, DOI 10.1136/bmj.304.6836.1209; KOSS LG, 1963, CANCER, V16, P1160, DOI 10.1002/1097-0142(196309)16:9<1160::AID-CNCR2820160910>3.0.CO;2-4; KOUTSKY LA, 1992, NEW ENGL J MED, V327, P1272, DOI 10.1056/NEJM199210293271804; MCCORMICK JS, 1989, LANCET, V2, P207; MCINDOE WA, 1984, OBSTET GYNECOL, V64, P451; MITCHELL H, 1986, LANCET, V1, P573; NUOVO GJ, 1990, OBSTET GYNECOL, V75, P1006; NUOVO GJ, 1989, OBSTET GYNECOL, V74, P673; ROBERTSON JH, 1988, BRIT MED J, V297, P18, DOI 10.1136/bmj.297.6640.18; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SHAFI MI, 1991, BRIT J OBSTET GYNAEC, V98, P490, DOI 10.1111/j.1471-0528.1991.tb10349.x; WALKER EM, 1986, LANCET, V2, P672	21	26	26	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 13	1994	344	8920					432	435		10.1016/S0140-6736(94)91768-X	http://dx.doi.org/10.1016/S0140-6736(94)91768-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB761	7914563				2022-12-24	WOS:A1994PB76100008
J	WERLER, MM; LOUIK, C; SHAPIRO, S; MITCHELL, AA				WERLER, MM; LOUIK, C; SHAPIRO, S; MITCHELL, AA			OVULATION INDUCTION AND RISK OF NEURAL-TUBE DEFECTS	LANCET			English	Note							CLOMIPHENE	The relation between use of ovulation-inducing drugs and risk of neural tube defects (NTDs) was studied in a case-control surveillance programme. The frequency of any use of such drugs during the 6 months before the last menstrual period or during pregnancy was 3.0% for 1034 mothers of infants and fetuses with NTDs (cases) and 2.8% for 4081 mothers of those with other major congenital malformations (controls) (relative risk 1.1, 95% CI 0.8-1.7). Relative risks for clomiphene and for hormones were 0.8 (0.5-1.3) and 1.5 (0.7-3.4), respectively. These data suggest that use of ovulation-inducing drugs before conception does not increase the risk of NTDs.			WERLER, MM (corresponding author), BOSTON UNIV,SCH PUBL HLTH,SLONE EPIDEMIOL UNIT,1371 BEACON ST,BROOKLINE,MA 02146, USA.			Werler, Martha/0000-0003-3392-6814; Mitchell, Allen/0000-0003-0950-6799; Louik, Carol/0000-0001-5429-5084	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD027697] Funding Source: NIH RePORTER; NICHD NIH HHS [NICHD R01-HD27697] Funding Source: Medline; PHS HHS [MCJ-2505667] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		CUCKLE H, 1989, LANCET, V2, P1281; FIELD B, 1974, LANCET, V2, P1511; GLASSNER MJ, 1990, J REPROD MED, V35, P175; HARLAP S, 1976, LANCET, V2, P961; MILI F, 1991, AM J EPIDEMIOL, V134, P748; MILLS LJ, 1990, LANCET, V335, P103; MILUNSKY A, 1990, TERATOLOGY, V42, P467, DOI 10.1002/tera.1420420502; ROBERT E, 1991, REPROD TOXICOL, V5, P83, DOI 10.1016/0890-6238(91)90115-V; SINGH M, 1978, J PEDIATR-US, V93, P152, DOI 10.1016/S0022-3476(78)80634-9	9	16	16	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 13	1994	344	8920					445	446		10.1016/S0140-6736(94)91772-8	http://dx.doi.org/10.1016/S0140-6736(94)91772-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB761	7914567				2022-12-24	WOS:A1994PB76100012
J	ALVAREZ, FJ; DELRIO, MC				ALVAREZ, FJ; DELRIO, MC			DRUGS AND DRIVING	LANCET			English	Editorial Material											ALVAREZ, FJ (corresponding author), UNIV VALLADOLID,FAC MED,DEPT PHARMACOL & THERAPEUT,DRUGS & ALCOHOL RES GRP,VALLADOLID,SPAIN.		Alvarez, Francisco/GZL-1953-2022; Alvarez, F. Javier/E-7204-2016; Alvarez, F. Javier/X-2294-2019	Alvarez, F. Javier/0000-0002-7566-5678; Alvarez, F. Javier/0000-0002-7566-5678				DEGIER JJ, 1993, IHP9339 U LIMB I HUM; 1985, JAMA-J AM MED ASSOC, V257, P2618; 1985, EUROPEAN HLTH ALL SE, V1; 1991, OFF J EEC; 1991, III916390EN; 1986, JAMA-J AM MED ASSOC, V255, P522; 1992, OFF J EEC; 1992, EUROPEAN COMMISSION	8	24	26	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 30	1994	344	8918					282	282						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NZ233	7914258				2022-12-24	WOS:A1994NZ23300004
J	COWLEY, S; PATERSON, H; KEMP, P; MARSHALL, CJ				COWLEY, S; PATERSON, H; KEMP, P; MARSHALL, CJ			ACTIVATION OF MAP KINASE KINASE IS NECESSARY AND SUFFICIENT FOR PC12 DIFFERENTIATION AND FOR TRANSFORMATION OF NIH 3T3 CELLS	CELL			English	Article							NERVE GROWTH-FACTOR; SIGNAL-REGULATED KINASE; RAF-1 PROTEIN-KINASE; MONOCLONAL-ANTIBODIES; TRANSCRIPTION FACTOR; TYROSINE KINASE; IN-VITRO; RAS; TRANSDUCTION; CASCADE	The MAP kinase pathway is activated by a wide variety of external signals leading to cell proliferation or differentiation. However, it is not clear whether activation of this pathway is required for cellular responses or whether it is only one branch point in signal transduction. To investigate these questions, we generated constitutively activated and interfering mutants of MAP kinase kinase 1. The activated mutants stimulated PC12 cell neuronal differentiation and transformed NIH 3T3 cells. The interfering mutants inhibited growth factor-induced PC12 differentiation, growth factor stimulation of proliferation, and reverted v-src- and ras-transformed cells. These results therefore show that, depending on cellular context, activation of MAP kinase kinase is necessary and sufficient for cell differentiation or proliferation.			COWLEY, S (corresponding author), INST CANC RES,CHESTER BEATTY LABS,DEPT CELL & MOLEC BIOL,237 FULHAM RD,LONDON SW3 6JB,ENGLAND.			Cowley, Sally/0000-0003-0297-6675				ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; BURGERING BMT, 1993, MOL CELL BIOL, V13, P7248, DOI 10.1128/MCB.13.12.7248; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COUGHLIN SR, 1989, SCIENCE, V243, P1191; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DELARCO JE, 1978, P NATL ACAD SCI USA, V75, P4001; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HACCARD O, 1993, SCIENCE, V262, P1262, DOI 10.1126/science.8235656; HANCOCK JF, 1988, ONCOGENE, V3, P187; HEMPSTEAD BL, 1992, NEURON, V9, P883, DOI 10.1016/0896-6273(92)90241-5; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUGHES DA, 1993, SCIENCE, V260, P1937; KUNG HF, 1986, EXP CELL RES, V162, P363, DOI 10.1016/0014-4827(86)90341-1; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAU AF, 1979, P NATL ACAD SCI USA, V76, P3904, DOI 10.1073/pnas.76.8.3904; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LEEVES SJ, 1993, THESIS U LONDON; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; LLOYD AC, 1989, EMBO J, V8, P1099, DOI 10.1002/j.1460-2075.1989.tb03479.x; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MACPHERSON I, 1964, VIROLOGY, V23, P291, DOI 10.1016/0042-6822(64)90301-0; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1985, PROC R SOC SER B-BIO, V226, P99, DOI 10.1098/rspb.1985.0084; MASHALL C, 1994, CURR OPIN CELL BIOL, V4, P82; MILLER J, 1986, J EXP MED, V164, P1478, DOI 10.1084/jem.164.5.1478; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; NODA M, 1983, P NATL ACAD SCI-BIOL, V80, P5602, DOI 10.1073/pnas.80.18.5602; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SAITO Y, 1994, FEBS LETT, V341, P119, DOI 10.1016/0014-5793(94)80252-1; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SETH A, 1991, J BIOL CHEM, V266, P23521; SHIN SI, 1975, P NATL ACAD SCI USA, V72, P4435, DOI 10.1073/pnas.72.11.4435; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TRAHEY M, 1987, MOL CELL BIOL, V7, P541, DOI 10.1128/MCB.7.1.541; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; TSUDA L, 1993, CELL, V72, P407, DOI 10.1016/0092-8674(93)90117-9; VANHOOFF COM, 1989, J CELL BIOL, V108, P1115, DOI 10.1083/jcb.108.3.1115; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WU J, 1993, P NATL ACAD SCI USA, V90, P173, DOI 10.1073/pnas.90.1.173; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZHENG CF, 1993, J BIOL CHEM, V268, P11435; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	57	1905	1951	1	98	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 17	1994	77	6					841	852		10.1016/0092-8674(94)90133-3	http://dx.doi.org/10.1016/0092-8674(94)90133-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NT331	7911739				2022-12-24	WOS:A1994NT33100009
J	WILLIAMS, NS; HUGHES, SF; STUCHFIELD, B				WILLIAMS, NS; HUGHES, SF; STUCHFIELD, B			CONTINENT COLONIC CONDUIT FOR RECTAL EVACUATION IN SEVERE CONSTIPATION	LANCET			English	Article							IDIOPATHIC CONSTIPATION; OUTLET OBSTRUCTION; ANISMUS; PROCTOCOLECTOMY; APPENDIX; SURGERY; ENEMA	We describe a new operation for the treatment of rectal evacuatory disorders: a continent colonic conduit, incorporating an intussuscepted valve, was constructed from the sigmoid colon. Intubation of the conduit allowed irrigation and evacuation of the distal colon and rectum. Initially all 10 patients reported a reduction in time taken and the discomfort involved in completing evacuation. The number of stools passed per week increased in 9 out of 10 patients, from a median of 1.5 (range 0.25-7) to a median of 7 (range 3-7) postoperatively. Subsequently, 3 patients developed complications, 2 of whom required conversion to an ileostomy. Overall, the colonic conduit procedure was successful in treating the rectal evacuatory disorder in 7 patients, failed in 2, and 1 patient has a temporary defunctioning ileostomy. The procedure is a relatively simple surgical alternative for the treatment of a condition which is often resistant to conservative measures.			WILLIAMS, NS (corresponding author), ROYAL LONDON HOSP,SURG UNIT,LONDON E1 1BB,ENGLAND.							DUDLEY HAF, 1980, BRIT J SURG, V67, P80, DOI 10.1002/bjs.1800670203; HALLAN RI, 1988, LANCET, V2, P714; HOSIE KB, 1990, BRIT J SURG, V77, P801, DOI 10.1002/bjs.1800770726; HUGHES ESR, 1981, AUST NZ J SURG, V51, P144, DOI 10.1111/j.1445-2197.1981.tb05926.x; KAMM MA, 1988, BRIT J SURG, V75, P661, DOI 10.1002/bjs.1800750713; KOCK NG, 1969, ARCH SURG-CHICAGO, V99, P223; LESTAR B, 1991, INT J COLORECTAL DIS, V6, P202, DOI 10.1007/BF00341391; MALONE PS, 1990, LANCET, V336, P1217, DOI 10.1016/0140-6736(90)92834-5; MARTELLI H, 1978, GASTROENTEROLOGY, V75, P623; MITROFANOFF P, 1980, CHIR PEDIATR, V21, P297; NICHOLLS RJ, 1988, DIS COLON RECTUM, V31, P968, DOI 10.1007/BF02554897; PRESTON DM, 1985, DIGEST DIS SCI, V30, P413, DOI 10.1007/BF01318172; RYAN JA, 1985, AM J SURG, V149, P636, DOI 10.1016/S0002-9610(85)80145-8; SQUIRE R, 1993, J PEDIATR SURG, V28, P1012, DOI 10.1016/0022-3468(93)90505-F; TAYLOR T, 1989, BRIT MED J, V299, P300, DOI 10.1136/bmj.299.6694.300; WASSERMAN I F, 1964, Dis Colon Rectum, V7, P87, DOI 10.1007/BF02616902; WEXNER SD, 1991, DIS COLON RECTUM, V34, P851, DOI 10.1007/BF02049695; WHEELER RA, 1991, BRIT J SURG, V78, P1283, DOI 10.1002/bjs.1800781103; WILLIAMS NS, 1980, BRIT MED J, V281, P107, DOI 10.1136/bmj.281.6233.107; WILLIAMS NS, SURGICAL THERAPY CON, P757; YOSHIOKA K, 1987, BRIT J SURG, V74, P373, DOI 10.1002/bjs.1800740516	21	40	40	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 28	1994	343	8909					1321	1324		10.1016/S0140-6736(94)92467-8	http://dx.doi.org/10.1016/S0140-6736(94)92467-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NN217	7910324				2022-12-24	WOS:A1994NN21700010
J	ROUSSEAUXPREVOST, R; LESUR, P; COLLIER, F; RIGOT, JM; VENEZIA, ND; POL, PS; DELAUNAY, J; GAUTHIER, A; ROUSSEAUX, J				ROUSSEAUXPREVOST, R; LESUR, P; COLLIER, F; RIGOT, JM; VENEZIA, ND; POL, PS; DELAUNAY, J; GAUTHIER, A; ROUSSEAUX, J			ABNORMAL EXPRESSION OF PROTEIN-4.1 IN SPERMATOZOA OF INFERTILE MEN WITH TERATOSPERMIA	LANCET			English	Note							SPERM	Molecular defects responsible for morphologically abnormal spermatozoa (teratospermia) associated with male sterility are largely unknown. We report defective expression of protein 4.1, a cytoskeletal protein initially recognised in red cells. In some patients with severely amorphous sperm heads, protein 4.1 had an abnormal sub-cellular localisation (tail instead of head) and appeared as high-molecular-weight isoforms, especially a 135 kDa species instead of the 82 kDa isoform seen in fertile sperm. Because the 135 kDa isoform is characteristic of immature germ cells from testis, its presence in teratospermia suggests profoundly disturbed sperm differentiation.	LAB ANAL MED LIBERTE, LILLE, FRANCE; CTR HOSP REG & UNIV LILLE, SERV GYNECOL SOCLALE, LILLE, FRANCE; CTR HOSP REG & UNIV LILLE, SERV UROL, LILLE, FRANCE; CNRS, URA 1171, LYON, FRANCE; CTR HOSP REG & UNIV LILLE, CECOS NORD, LILLE, FRANCE	Universite de Lille - ISITE; CHU Lille; Universite de Lille - ISITE; CHU Lille; Centre National de la Recherche Scientifique (CNRS); Universite de Lille - ISITE; CHU Lille	ROUSSEAUXPREVOST, R (corresponding author), INST RECH CANC LILLE, PL VERDUN, F-59045 LILLE, FRANCE.		VENEZIA, Nicole DALLA/C-6542-2017	VENEZIA, Nicole DALLA/0000-0002-4553-3535				ARBOLEDA CE, 1988, DEV BIOL, V125, P217, DOI 10.1016/0012-1606(88)90075-9; BACCETTI B, 1988, J SUBMICR CYTOL PATH, V20, P209; CHEVAILLIER P, 1987, LANCET, V2, P806; CONBOY JG, 1993, SEMIN HEMATOL, V30, P58; ESCALIER D, 1990, International Journal of Developmental Biology, V34, P287; MIRANDA PV, 1992, MOL REPROD DEV, V33, P443, DOI 10.1002/mrd.1080330411; VENEZIA ND, 1992, J CLIN INVEST, V90, P1713, DOI 10.1172/JCI116044; VIRTANEN I, 1984, J CELL BIOL, V99, P1083, DOI 10.1083/jcb.99.3.1083	8	13	13	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 26	1994	343	8900					764	765		10.1016/S0140-6736(94)91840-6	http://dx.doi.org/10.1016/S0140-6736(94)91840-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NC351	7907733				2022-12-24	WOS:A1994NC35100012
J	ELIAS, D; COHEN, IR				ELIAS, D; COHEN, IR			PEPTIDE THERAPY FOR DIABETES IN NOD MICE	LANCET			English	Note							PROTEIN; MOUSE	NOD mice spontaneously develop autoimmune diabetes that mimics insulin-dependent diabetes mellitus (IDDM) in man. A peptide of the 60 kDa heat shock protein (hsp60), designated p277, can serve as a target for diabetogenic T-cell clones, and diabetes was prevented by using the p277 peptide to turn off anti-p277 immunity early in life. We report that the p277 peptide, administered once, can arrest the autoimmune process even after it is far advanced. Successful therapy was associated with down-regulation of the autoimmune process and regression of islet inflammation. Thus the immune system is responsive to manipulation by a specific signal even in the face of a virulent, full-blown autoimmune process.	WEIZMANN INST SCI,DEPT CELL BIOL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science			Cohen, Irun R/B-3542-2009					BENDELAC A, 1987, J EXP MED, V166, P823, DOI 10.1084/jem.166.4.823; BRUDZYNSKI K, 1992, DIABETOLOGIA, V35, P316, DOI 10.1007/BF00401198; CASTANO L, 1990, ANNU REV IMMUNOL, V8, P647, DOI 10.1146/annurev.iy.08.040190.003243; COHEN IR, 1992, IMMUNOL TODAY, V13, P490, DOI 10.1016/0167-5699(92)90024-2; COHEN IR, 1992, IMMUNOL TODAY, V13, P441, DOI 10.1016/0167-5699(92)90071-E; ELIAS D, 1991, P NATL ACAD SCI USA, V88, P3088, DOI 10.1073/pnas.88.8.3088; KARJALAINEN J, 1992, NEW ENGL J MED, V327, P302, DOI 10.1056/NEJM199207303270502; LIDER O, 1988, SCIENCE, V239, P181, DOI 10.1126/science.2447648; TISCH R, 1993, NATURE, V366, P72, DOI 10.1038/366072a0; ZHANG JW, 1993, SCIENCE, V261, P1451, DOI 10.1126/science.7690157	10	176	191	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 19	1994	343	8899					704	706		10.1016/S0140-6736(94)91582-2	http://dx.doi.org/10.1016/S0140-6736(94)91582-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NB809	7907681				2022-12-24	WOS:A1994NB80900011
J	WILSON, R; AINSCOUGH, R; ANDERSON, K; BAYNES, C; BERKS, M; BURTON, J; CONNELL, M; BONFIELD, J; COPSEY, T; COOPER, J; COULSON, A; CRAXTON, M; DEAR, S; DU, Z; DURBIN, R; FAVELLO, A; FRASER, A; FULTON, L; GARDNER, A; GREEN, P; HAWKINS, T; HILLIER, L; JIER, M; JOHNSTON, L; JONES, M; KERSHAW, J; KIRSTEN, J; LAISSTER, N; LATREILLE, P; LLOYD, C; MORTIMORE, B; OCALLAGHAN, M; PARSONS, J; PERCY, C; RIFKEN, L; ROOPRA, A; SAUNDERS, D; SHOWNKEEN, R; SIMS, M; SMALDON, N; SMITH, A; SMITH, M; SONNHAMMER, E; STADEN, R; SULSTON, J; THIERRYMIEG, J; THOMAS, K; VAUDIN, M; VAUGHAN, K; WATERSTON, R; WATSON, A; WEINSTOCK, L; WILKINSONSPROAT, J; WOHLDMAN, P				WILSON, R; AINSCOUGH, R; ANDERSON, K; BAYNES, C; BERKS, M; BURTON, J; CONNELL, M; BONFIELD, J; COPSEY, T; COOPER, J; COULSON, A; CRAXTON, M; DEAR, S; DU, Z; DURBIN, R; FAVELLO, A; FRASER, A; FULTON, L; GARDNER, A; GREEN, P; HAWKINS, T; HILLIER, L; JIER, M; JOHNSTON, L; JONES, M; KERSHAW, J; KIRSTEN, J; LAISSTER, N; LATREILLE, P; LLOYD, C; MORTIMORE, B; OCALLAGHAN, M; PARSONS, J; PERCY, C; RIFKEN, L; ROOPRA, A; SAUNDERS, D; SHOWNKEEN, R; SIMS, M; SMALDON, N; SMITH, A; SMITH, M; SONNHAMMER, E; STADEN, R; SULSTON, J; THIERRYMIEG, J; THOMAS, K; VAUDIN, M; VAUGHAN, K; WATERSTON, R; WATSON, A; WEINSTOCK, L; WILKINSONSPROAT, J; WOHLDMAN, P			2.2 MB OF CONTIGUOUS NUCLEOTIDE-SEQUENCE FROM CHROMOSOME-III OF C-ELEGANS	NATURE			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; EDITING PROGRAM; DNA; GENOME; GENES; ENCODES; SIMILARITY; PROTEIN; LIN-12; RNA	As part of our effort to sequence the 100-megabase (Mb) genome of the nematode Caenorhabditis elegans, we have completed the nucleotide sequence of a contiguous 2,181,032 base pairs in the central gene cluster of chromosome III. Analysis of the finished sequence has indicated an average density of about one gene per five kilobases; comparison with the public sequence databases reveals similarities to previously known genes for about one gene in three. In addition, the genomic sequence contains several intriguing features, including putative gene duplications and a variety of other repeats with potential evolutionary implications.	WASHINGTON UNIV,SCH MED,CTR GENOME SEQUENCING,ST LOUIS,MO 63110; MRC,MOLEC BIOL LAB,CAMBRIDGE CB10 1RQ,CAMBS,ENGLAND; SANGER CTR,CAMBRIDGE CB10 1RQ,CAMBS,ENGLAND; CNRS,CTR RECH BIOCHIM MACROMOLEC & PHYS MATH,F-34033 MONTPELLIER,FRANCE	Washington University (WUSTL); MRC Laboratory Molecular Biology; Wellcome Trust Sanger Institute; Centre National de la Recherche Scientifique (CNRS)	WILSON, R (corresponding author), WASHINGTON UNIV,SCH MED,DEPT GENET,ST LOUIS,MO 63110, USA.		Durbin, Richard/AAE-7178-2019; Wilson, Richard K./AAF-4139-2019; THIERRY-MIEG, Jean/F-1975-2017; Smith, Andy/A-7512-2011; Cooper, John/D-4448-2014	Durbin, Richard/0000-0002-9130-1006; Wilson, Richard K./0000-0002-1992-1358; THIERRY-MIEG, Jean/0000-0002-0396-6789; Smith, Andy/0000-0001-8580-278X; Sonnhammer, Erik/0000-0002-9015-5588; Bonfield, James/0000-0002-6447-4112; Cooper, John/0000-0002-0933-4571				Alschul S F, 1990, J Mol Biol, V215, P403; BANKIER AT, 1983, TECHNIQUES NUCLEIC B, V5, P1; BRENNER S, 1974, GENETICS, V77, P71; BURGLIN TR, 1991, NATURE, V351, P703, DOI 10.1038/351703a0; CAMPBELL HD, 1993, P NATL ACAD SCI USA, V90, P11386, DOI 10.1073/pnas.90.23.11386; CHISHOLM A, 1991, DEVELOPMENT, V111, P921; CLARK SG, 1993, CELL, V74, P43, DOI 10.1016/0092-8674(93)90293-Y; COLLINS J, 1989, GENETICS, V121, P47; CONNELL C, 1987, BIOTECHNIQUES, V5, P342; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7821, DOI 10.1073/pnas.83.20.7821; COULSON A, 1988, NATURE, V335, P184, DOI 10.1038/335184a0; COULSON A, 1991, BIOESSAYS, V13, P413, DOI 10.1002/bies.950130809; CRAXTON M, 1991, Methods (Orlando), V3, P20, DOI 10.1016/S1046-2023(05)80159-8; Dear S, 1992, DNA Seq, V3, P107, DOI 10.3109/10425179209034003; DEAR S, 1991, NUCLEIC ACIDS RES, V19, P3907, DOI 10.1093/nar/19.14.3907; DEININGER PL, 1983, ANAL BIOCHEM, V129, P216, DOI 10.1016/0003-2697(83)90072-6; DU ZJ, 1993, METHOD ENZYMOL, V218, P104; FICHANT GA, 1991, J MOL BIOL, V220, P659, DOI 10.1016/0022-2836(91)90108-I; FINNEY M, 1988, CELL, V55, P757, DOI 10.1016/0092-8674(88)90132-8; GLEESON T, 1991, NUCLEIC ACIDS RES, V19, P6481, DOI 10.1093/nar/19.23.6481; GLEESON TJ, 1991, COMPUT APPL BIOSCI, V7, P398; GREEN P, 1993, SCIENCE, V259, P1711, DOI 10.1126/science.8456298; GUO XD, 1991, NATURE, V349, P707, DOI 10.1038/349707a0; HALLORAN N, 1992, METHOD MOL BIOL, V10, P297; HAWKINS TL, 1992, ELECTROPHORESIS, V13, P552, DOI 10.1002/elps.11501301113; HILLENBRAND C, 1991, J ROY ASIATIC SOC, V1, P124, DOI 10.1017/S1356186300000201; KOOP BF, 1993, BIOTECHNIQUES, V14, P442; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; LEE LG, 1992, NUCLEIC ACIDS RES, V20, P2471, DOI 10.1093/nar/20.10.2471; MCCOMBIE WR, 1992, NAT GENET, V1, P124, DOI 10.1038/ng0592-124; NAITO M, 1992, NUCLEIC ACIDS RES, V20, P2967, DOI 10.1093/nar/20.12.2967; PATEL N, 1993, P NATL ACAD SCI USA, V90, P9181, DOI 10.1073/pnas.90.19.9181; SCHRIEFER LA, 1990, NUCLEIC ACIDS RES, V18, P7455, DOI 10.1093/nar/18.24.7455; SMITH LM, 1986, NATURE, V321, P674, DOI 10.1038/321674a0; STRAUSS EC, 1986, ANAL BIOCHEM, V154, P353, DOI 10.1016/0003-2697(86)90536-1; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; SULSTON J, 1992, NATURE, V357, P106; SULSTON JE, 1974, GENETICS, V77, P95; UBER DC, 1991, BIOTECHNIQUES, V11, P642; WANG BB, 1993, CELL, V74, P29, DOI 10.1016/0092-8674(93)90292-X; WATERSTON R, 1992, NAT GENET, V1, P114, DOI 10.1038/ng0592-114; WATERSTON RH, 1978, NATURE, V275, P715, DOI 10.1038/275715a0; WATERSTON RH, 1990, GENBANK LOCUS CESUP5; WATSON A, 1993, NATURE, V362, P569, DOI 10.1038/362569a0; WESTON K, 1989, NUCLEIC ACIDS RES, V17, P2138, DOI 10.1093/nar/17.5.2138; Wood WB, 1988, NEMATODE CAENORHABDI; YOCHEM J, 1989, CELL, V58, P553, DOI 10.1016/0092-8674(89)90436-4; YOCHEM J, 1988, NATURE, V335, P547, DOI 10.1038/335547a0; YUAN JY, 1991, P NATL ACAD SCI USA, V88, P3334, DOI 10.1073/pnas.88.8.3334	49	1297	1685	0	26	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 3	1994	368	6466					32	38		10.1038/368032a0	http://dx.doi.org/10.1038/368032a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MY569	7906398				2022-12-24	WOS:A1994MY56900044
J	STERN, RS				STERN, RS			DRUG PROMOTION FOR AN UNLABELED INDICATION - THE CASE OF TOPICAL TRETINOIN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									HARVARD UNIV,SCH MED,BOSTON,MA	Harvard University; Harvard Medical School	STERN, RS (corresponding author), BETH ISRAEL HOSP,DEPT DERMATOL,330 BROOKLINE AVE,BOSTON,MA 02215, USA.							DELOZIER JE, 1987, DHHS PHS821364 NAT C; HOROWITZ GL, 1981, NEW ENGL J MED, V305, P924, DOI 10.1056/NEJM198110153051605; KESSLER DA, 1991, NEW ENGL J MED, V325, P201, DOI 10.1056/NEJM199107183250310; KRIPKE ML, 1980, J AM ACAD DERMATOL, V2, P439, DOI 10.1016/S0190-9622(80)80373-2; LIMERICK Z, 1977, READERS GUIDE PERIOD, V36; RANDALL T, 1991, JAMA-J AM MED ASSOC, V266, P11, DOI 10.1001/jama.266.1.11; SCHAPPERT SM, 1993, DHHS PHS931250 NAT C; WEISS JS, 1988, JAMA-J AM MED ASSOC, V259, P527, DOI 10.1001/jama.259.4.527; Weiss JS, 1988, JAMA-J AM MED ASSOC, V260, P926; WEISS JS, 1988, JAMA-J AM MED ASSOC, V259, P3274; 1987, DRUG TOPICS RED BOOK; 1985, J AM ACAD DERMATOL, V13, pA60; 1989, J AM ACAD DERMATOL, V20, pA100; 1980, VITAL HLTH STATIST 2, V90; 1991, DRUG TOPICS RED BOOK; 1991, FDC REPORTS PINK SHE, V53; 1978, NY TIMES INDEX BOOK, V65; 1978, FDA DRUG B, V8, P26	18	13	13	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 17	1994	331	20					1348	1349		10.1056/NEJM199411173312006	http://dx.doi.org/10.1056/NEJM199411173312006			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PR216	7935705				2022-12-24	WOS:A1994PR21600006
J	FOX, R				FOX, R			RED-LIGHT ON CALCUTTA - HEALTH VIA SCHOOLS IN ANDHRA-PRADESH	LANCET			English	Editorial Material																		JANA S, 1994, 10TH INT C AIDS YOK	1	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 15	1994	344	8929					1038	1038		10.1016/S0140-6736(94)91705-1	http://dx.doi.org/10.1016/S0140-6736(94)91705-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PL852	7934442				2022-12-24	WOS:A1994PL85200005
J	TULLY, T; PREAT, T; BOYNTON, SC; DELVECCHIO, M				TULLY, T; PREAT, T; BOYNTON, SC; DELVECCHIO, M			GENETIC DISSECTION OF CONSOLIDATED MEMORY IN DROSOPHILA	CELL			English	Article							APLYSIA SENSORY NEURONS; PROTEIN KINASE-A; INDUCED RETROGRADE-AMNESIA; LONG-TERM FACILITATION; WITHDRAWAL REFLEX; ADENYLATE-CYCLASE; MUTANT DROSOPHILA; OLFACTORY MEMORY; GILL-WITHDRAWAL; MUSHROOM BODIES	Behavioral and pharmacological experiments in many animal species have suggested that memory is consolidated from an initial, disruptable form into a longlasting, stable form within a few hours after training. We combined these traditional approaches with genetic analyses in Drosophila to show that consolidated memory of conditioned (learned) odor avoidance 1 day after extended training consisted of two genetically distinct, functionally independent memory components: anesthesia-resistant memory (ARM) and longterm memory (LTM). ARM decayed away within 4 days, was resistant to hypothermic disruption, was insensitive to the protein synthesis inhibitor cycloheximide (CXM), and was disrupted by the radish single-gene mutation. LTM showed no appreciable decay over 7 days, was sensitive to CXM, and was not disrupted by the radish mutation.	BRANDEIS UNIV,DEPT BIOL,WALTHAM,MA 02254	Brandeis University	TULLY, T (corresponding author), COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724, USA.			Preat, Thomas/0000-0001-9976-1763	NICHD NIH HHS [HD32245] Funding Source: Medline; NIGMS NIH HHS [P01-GM33205] Funding Source: Medline; NINDS NIH HHS [NS25621] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD032245] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM033205] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS025621] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Agranoff BW, 1981, BASIC NEUROCHEMISTRY, P801; AKAHANE R, 1983, J INSECT PHYSIOL, V29, P331, DOI 10.1016/0022-1910(83)90034-3; ALBERINI CM, 1994, CELL, V76, P1099, DOI 10.1016/0092-8674(94)90386-7; ALLWEIS C, 1984, BEHAV BRAIN RES, V11, P117, DOI 10.1016/0166-4328(84)90134-7; ALLWEIS C, 1991, NEURAL BEHAV PLASTIC, P370; Andrew RJ, 1980, ADV STUD BEHAV, P337; ARMSTRONG RC, 1993, ANNU REV NEUROSCI, V16, P17, DOI 10.1146/annurev.ne.16.030193.000313; ASZODI A, 1991, P NATL ACAD SCI USA, V88, P5832, DOI 10.1073/pnas.88.13.5832; BACSKAI BJ, 1993, SCIENCE, V260, P222, DOI 10.1126/science.7682336; BADDELEY A, 1976, PSYCHOL MEMORY; BAILEY CH, 1994, SEMIN NEUROSCI, V6, P35; BERGOLD PJ, 1992, NEURON, V8, P387, DOI 10.1016/0896-6273(92)90304-V; BERMAN RF, 1978, BRAIN RES, V158, P171, DOI 10.1016/0006-8993(78)90013-6; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; BOYNTON S, 1992, GENETICS, V131, P655; BOYNTON S, 1990, BIOL MEMORY, P91; BUONOMANO DV, 1990, SCIENCE, V249, P420, DOI 10.1126/science.2165631; CAREW TJ, 1972, SCIENCE, V175, P451, DOI 10.1126/science.175.4020.451; CASTELLUCCI VF, 1989, J NEUROBIOL, V20, P1, DOI 10.1002/neu.480200102; CHEN CN, 1986, P NATL ACAD SCI USA, V83, P9313, DOI 10.1073/pnas.83.24.9313; CROW T, 1993, J NEUROPHYSIOL, V69, P636, DOI 10.1152/jn.1993.69.2.636; DANIELS D, 1971, J COMP PHYSIOL PSYCH, V76, P110, DOI 10.1037/h0031044; DASH PK, 1990, NATURE, V345, P718, DOI 10.1038/345718a0; DAVIS HP, 1984, PSYCHOL BULL, V96, P518, DOI 10.1037/0033-2909.96.3.518; DAVIS RL, 1993, NEURON, V11, P1, DOI 10.1016/0896-6273(93)90266-T; DEBELLE JS, 1994, SCIENCE, V263, P692, DOI 10.1126/science.8303280; DRAIN P, 1991, NEURON, V6, P71, DOI 10.1016/0896-6273(91)90123-H; DUDAI Y, 1976, P NATL ACAD SCI USA, V73, P1684, DOI 10.1073/pnas.73.5.1684; DUDAI Y, 1983, P NATL ACAD SCI-BIOL, V80, P5445, DOI 10.1073/pnas.80.17.5445; DUDAI Y, 1988, J COMP PHYSIOL A, V162, P101, DOI 10.1007/BF01342707; DURA JM, 1993, J NEUROGENET, V9, P1, DOI 10.3109/01677069309167272; EMPTAGE NJ, 1993, SCIENCE, V262, P253, DOI 10.1126/science.8211146; ERBER J, 1976, J COMP PHYSIOL PSYCH, V90, P41, DOI 10.1037/h0077258; FLOOD JF, 1977, BEHAV BIOL, V21, P307, DOI 10.1016/S0091-6773(77)90101-8; FOLKERS E, 1993, P NATL ACAD SCI USA, V90, P8123, DOI 10.1073/pnas.90.17.8123; FRECKLETON WC, 1968, PSYCHON SCI, V12, P179; FRIEDER B, 1978, BEHAV BIOL, V22, P178, DOI 10.1016/S0091-6773(78)92200-9; FROST WN, 1985, P NATL ACAD SCI USA, V82, P8266, DOI 10.1073/pnas.82.23.8266; GAILEY DA, 1991, J COMP PHYSIOL A, V169, P685; GALL CM, 1991, MEMORY ORG LOCUS CHA, P301; GELLER A, 1968, PSYCHON SCI, V12, P169; GLICKMAN SE, 1961, PSYCHOL BULL, V58, P218, DOI 10.1037/h0044212; GREENOUGH WT, 1984, TRENDS NEUROSCI, V7, P229, DOI 10.1016/S0166-2236(84)80211-8; Hintzman D. L., 1974, THEORIES COGNITIVE P, P77; HIRSCH J, 1956, PSYCHOL BULL, V53, P402, DOI 10.1037/h0040715; JAFFE K, 1980, PHYSIOL BEHAV, V25, P367, DOI 10.1016/0031-9384(80)90275-9; James W., 1890, PRINCIPLES PSYCHOL; KAANG BK, 1993, NEURON, V10, P427, DOI 10.1016/0896-6273(93)90331-K; KESNER RP, 1981, BRAIN RES, V209, P159, DOI 10.1016/0006-8993(81)91178-1; KNOWLTON BJ, 1993, SCIENCE, V262, P1747, DOI 10.1126/science.8259522; LEVIN LR, 1992, CELL, V68, P479, DOI 10.1016/0092-8674(92)90185-F; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; LISMAN JE, 1985, P NATL ACAD SCI USA, V82, P3055, DOI 10.1073/pnas.82.9.3055; LIVINGSTONE MS, 1984, CELL, V37, P205, DOI 10.1016/0092-8674(84)90316-7; MALDONADO H, 1980, J INSECT PHYSIOL, V26, P339, DOI 10.1016/0022-1910(80)90002-5; MCDONALD RJ, 1993, BEHAV NEUROSCI, V107, P3, DOI 10.1037/0735-7044.107.1.3; MCGAUGH JL, 1966, SCIENCE, V153, P1351, DOI 10.1126/science.153.3742.1351; MCGAUGH JL, 1972, MEMORY CONSOLIDATION; MENZEL R, 1993, NATURWISSENSCHAFTEN, V80, P380, DOI 10.1007/BF01138799; MENZEL R, 1990, BRAIN PERCEPTION COG, P111; MIZUMORI SJY, 1985, BEHAV NEUROSCI, V99, P220, DOI 10.1037/0735-7044.99.2.220; MONTAROLO PG, 1986, SCIENCE, V234, P1249, DOI 10.1126/science.3775383; NAGY ZM, 1993, B PSYCHONOMIC SOC, V31, P225, DOI 10.3758/BF03337330; NAZIF FA, 1991, BRAIN RES, V539, P324, DOI 10.1016/0006-8993(91)91638-H; PRUZAN A, 1977, PHARMACOL BIOCHEM BE, V6, P355, DOI 10.1016/0091-3057(77)90037-5; QUINN WG, 1976, NATURE, V262, P576, DOI 10.1038/262576a0; QUINN WG, 1974, P NATL ACAD SCI USA, V71, P708, DOI 10.1073/pnas.71.3.708; RIBOT TA, 1892, DICT PSYCHOL MED; Riccio D. C., 1981, INFORMATION PROCESSI, P291; RIEGE WH, 1974, BEHAV BIOL, V12, P477, DOI 10.1016/S0091-6773(74)92291-3; ROSE SPR, 1991, TRENDS NEUROSCI, V14, P390, DOI 10.1016/0166-2236(91)90027-R; ROSE SPR, 1987, BEHAV NEURAL BIOL, V48, P246, DOI 10.1016/S0163-1047(87)90808-9; ROSE SPR, 1984, BEHAV NEURAL BIOL, V42, P663; ROSENZWEIG MR, 1984, NEUROBIOLOGY LEARNIN, P263; SKOULAKIS EMC, 1993, NEURON, V11, P197, DOI 10.1016/0896-6273(93)90178-T; Sokal R. R, 1981, BIOMETRY; Squire L. R., 1987, MEMORY BRAIN; SQUIRE LR, 1980, SCIENCE, V209, P836, DOI 10.1126/science.7190729; STAUBLI U, 1985, BEHAV NEURAL BIOL, V43, P287, DOI 10.1016/S0163-1047(85)91632-2; STEWART MG, 1991, NEURAL BEHAVIOURAL P, P305; TEMPEL BL, 1983, P NATL ACAD SCI-BIOL, V80, P1482, DOI 10.1073/pnas.80.5.1482; TULLY T, 1986, J NEUROGENET, V3, P33, DOI 10.3109/01677068609106893; TULLY T, 1990, COLD SH Q B, V55, P203; TULLY T, 1985, J COMP PHYSIOL A, V157, P263, DOI 10.1007/BF01350033; TULLY T, 1993, J NEUROGENET, V9, P55, DOI 10.3109/01677069309167275; TULLY T, 1988, MODULATION SYNAPTIC, P401; Tully T., 1991, NEUROBIOLOGY LEARNIN, P29; WILLMUND R, 1979, NATURWISSENSCHAFTEN, V66, P318, DOI 10.1007/BF00441282; YAMADA A, 1992, J NEUROSCI, V12, P729; YIN JCP, 1994, CELL, V79, P49, DOI 10.1016/0092-8674(94)90399-9; ZOLAMORGAN S, 1993, ANNU REV NEUROSCI, V16, P547, DOI 10.1146/annurev.ne.16.030193.002555	91	707	721	0	59	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 7	1994	79	1					35	47		10.1016/0092-8674(94)90398-0	http://dx.doi.org/10.1016/0092-8674(94)90398-0			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PK585	7923375				2022-12-24	WOS:A1994PK58500006
J	MCGUIRE, W; HILL, AVS; ALLSOPP, CEM; GREENWOOD, BM; KWIATKOWSKI, D				MCGUIRE, W; HILL, AVS; ALLSOPP, CEM; GREENWOOD, BM; KWIATKOWSKI, D			VARIATION IN THE TNF-ALPHA PROMOTER REGION ASSOCIATED WITH SUSCEPTIBILITY TO CEREBRAL MALARIA	NATURE			English	Article							TUMOR-NECROSIS-FACTOR; MAJOR HISTOCOMPATIBILITY COMPLEX; B-CELL LINES; FALCIPARUM-MALARIA; PLASMODIUM-FALCIPARUM; GENE-REGULATION; T-CELL; POLYMORPHISM; PROTECTION; CACHECTIN	TUMOUR-necrosis factor-alpha (TNF-alpha) is believed to have an important role in the pathogenesis of severe infectious disease(1) and fatal cerebral malaria is associated with high circulating levels of this cytokine(2,3). In a large case-control study in Cambian children we find that homozygotes for the TNF2 allele, a variant of the TNF-alpha gene promoter region(4), have a relative risk of 7 for death or severe neurological sequelae due to cerebral malaria. Although the TNF2 allele is in linkage disequilibrium with several neighbouring HLA alleles, we show that this disease association is independent of HLA class I and class II variation. These data suggest that regulatory polymorphisms of cytokine genes can affect the outcome of severe infection. The maintenance of the TNF2 allele at a gene frequency of 0.16 in The Gambia implies that the increased risk of cerebral malaria in homozygotes is counterbalanced by some biological advantage.	JOHN RADCLIFFE HOSP,INST MOLEC MED,MOLEC IMMUNOL GRP,OXFORD OX3 9DU,ENGLAND; MRC LABS,FAJARA,SENEGAL	University of Oxford	MCGUIRE, W (corresponding author), JOHN RADCLIFFE HOSP,DEPT PAEDIAT,OXFORD OX3 9DU,ENGLAND.		HILL, Adrian V>S>/C-1306-2008	Kwiatkowski, Dominic/0000-0002-5023-0176; McGuire, William/0000-0001-8572-3467	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALFONSO SD, 1994, IMMUNOGENETICS, V30, P150; ALLSOPP CEM, 1991, HUM IMMUNOL, V30, P105, DOI 10.1016/0198-8859(91)90078-N; BERENDT AR, 1989, NATURE, V341, P57, DOI 10.1038/341057a0; BEUTLER B, 1986, NATURE, V320, P584, DOI 10.1038/320584a0; BREWSTER DR, 1990, LANCET, V336, P1039, DOI 10.1016/0140-6736(90)92498-7; CLARK IA, 1987, PARASITOL TODAY, V3, P300, DOI 10.1016/0169-4758(87)90187-6; CLARK IA, 1992, LANCET, V340, P8994; DUNHAM I, 1987, P NATL ACAD SCI USA, V84, P7237, DOI 10.1073/pnas.84.20.7237; GOLDFELD AE, 1991, J EXP MED, V174, P73, DOI 10.1084/jem.174.1.73; GOLDFELD AE, 1990, P NATL ACAD SCI USA, V87, P9769, DOI 10.1073/pnas.87.24.9769; GRAU GE, 1989, NEW ENGL J MED, V320, P1586, DOI 10.1056/NEJM198906153202404; GRAU GE, 1987, SCIENCE, V237, P1210, DOI 10.1126/science.3306918; GRAU GE, 1992, TUMOUR NECROSIS FACT, V1, P329; HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0; HILL AVS, 1992, NATURE, V360, P434, DOI 10.1038/360434a0; HILL AVS, 1992, P NATL ACAD SCI USA, V89, P2277, DOI 10.1073/pnas.89.6.2277; JACOB CO, 1990, P NATL ACAD SCI USA, V87, P1233, DOI 10.1073/pnas.87.3.1233; KERN P, 1989, AM J MED, V87, P139, DOI 10.1016/S0002-9343(89)80688-6; KWIATKOWSKI D, 1989, CLIN EXP IMMUNOL, V77, P361; KWIATKOWSKI D, 1990, LANCET, V336, P1201, DOI 10.1016/0140-6736(90)92827-5; KWIATKOWSKI D, 1992, CURR OPIN IMMUNOL, V4, P425, DOI 10.1016/S0952-7915(06)80034-8; MOLVIG J, 1988, SCAND J IMMUNOL, V27, P7025; NEDOSPASOV SA, 1986, COLD SPRING HARB SYM, V51, P611, DOI 10.1101/SQB.1986.051.01.073; PICOT F, 1993, EUR J IMMUNOL, V23, P224; RHOADES KL, 1992, J BIOL CHEM, V267, P22102; TITUS RG, 1991, PARASITOL TODAY, V12, pA13; Wilson A. G., 1992, Human Molecular Genetics, V1, P353, DOI 10.1093/hmg/1.5.353; WILSON AG, 1993, J EXP MED, V177, P557, DOI 10.1084/jem.177.2.557; WILSON AG, 1994, BR J RHEUMATOL S1, V33, P89; WONG FHW, 1992, TUMOR NECROSIS FACTO, V1, P371	30	1050	1078	1	26	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 6	1994	371	6497					508	511		10.1038/371508a0	http://dx.doi.org/10.1038/371508a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PK589	7935762				2022-12-24	WOS:A1994PK58900053
J	GREENBERGER, NJ; MINER, PB				GREENBERGER, NJ; MINER, PB			IS MAINTENANCE THERAPY EFFECTIVE IN CROHNS-DISEASE	LANCET			English	Editorial Material							PREDNISOLONE				GREENBERGER, NJ (corresponding author), UNIV KANSAS,MED CTR,DEPT MED,KANSAS CITY,KS 66103, USA.							EWE K, 1993, GASTROENTEROLOGY, V105, P367, DOI 10.1016/0016-5085(93)90709-L; GENDRE JP, 1993, GASTROENTEROLOGY, V104, P435, DOI 10.1016/0016-5085(93)90411-5; HANAUER SB, 1993, AM J GASTROENTEROL, V88, P1343; MESSORI A, 1994, AM J GASTROENTEROL, V89, P692; MODIGLIANI R, 1990, GASTROENTEROLOGY, V98, P811, DOI 10.1016/0016-5085(90)90002-I; SINGLETON JW, 1993, GASTROENTEROLOGY, V104, P1292; SUMMERS RW, 1979, GASTROENTEROLOGY, V77, P847; SUTHERLAND L, 1991, GUT, V32, P1071, DOI 10.1136/gut.32.9.1071	8	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 1	1994	344	8927					900	901		10.1016/S0140-6736(94)92261-6	http://dx.doi.org/10.1016/S0140-6736(94)92261-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PJ287	7934340				2022-12-24	WOS:A1994PJ28700002
J	MANZONI, OJ; MANABE, T; NICOLL, RA				MANZONI, OJ; MANABE, T; NICOLL, RA			RELEASE OF ADENOSINE BY ACTIVATION OF NMDA RECEPTORS IN THE HIPPOCAMPUS	SCIENCE			English	Article							GLUTAMATE-EVOKED RELEASE; EXCITATORY AMINO-ACIDS; RAT CORTICAL SLICES; SYNAPTIC TRANSMISSION; PRESYNAPTIC INHIBITION; ENDOGENOUS ADENOSINE; POSTTETANIC DEPRESSION; CEREBRAL-CORTEX; BRAIN-SLICES; AREA CA1	Adenosine is present in the mammalian brain in large amounts and has patent effects on neuronal activity, but its role in neural signaling is poorly understood. The glutamate receptor agonist N-methyl-D-aspartate (NMDA) caused a presynaptic depression of excitatory synaptic transmission in the CA1 region of guinea pig hippocampal slices. This depression was blocked by an adenosine A1 receptor antagonist, which suggests that activation of the NMDA subtype of glutamate receptor raises the concentration of extracellular adenosine, which acts on presynaptic inhibitory A1 receptors. Strong tetanic stimulation caused a heterosynaptic inhibition that was blocked by both NMDA and A1 receptor antagonists. Enkephalin, which selectively inhibits interneurons, antagonized the heterosynaptic inhibition. These findings suggest that synaptically released glutamate activates NMDA receptors, which in turn releases adenosine, at least in part from interneurons, that acts at a distance to inhibit presynaptically the release of glutamate from excitatory synapses. Thus, interneurons may mediate a widespread purinergic presynaptic inhibition.	UNIV CALIF SAN FRANCISCO, DEPT PHARMACOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT PHYSIOL, SAN FRANCISCO, CA 94143 USA; UNIV TOKYO, FAC MED, INST BRAIN RES, DEPT NEUROPHYSIOL, TOKYO 113, JAPAN	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Tokyo			Manzoni, Olivier/M-7899-2016	Manzoni, Olivier/0000-0002-5579-6208				BASHIR ZI, 1992, EUR J NEUROSCI, V4, P485, DOI 10.1111/j.1460-9568.1992.tb00898.x; BLANTON MG, 1989, J NEUROSCI METH, V30, P203, DOI 10.1016/0165-0270(89)90131-3; BOUITON CL, 1993, J PHYSIOL-LONDON, V467, pP181; CAPOGNA M, 1993, J PHYSIOL-LONDON, V470, P539, DOI 10.1113/jphysiol.1993.sp019874; COHEN GA, 1992, NEURON, V9, P325, DOI 10.1016/0896-6273(92)90171-9; COLEMAN PA, 1989, J NEUROPHYSIOL, V61, P218, DOI 10.1152/jn.1989.61.1.218; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; CRAIG CG, 1993, J NEUROCHEM, V60, P1073, DOI 10.1111/j.1471-4159.1993.tb03256.x; CULLCANDY SG, 1991, ANN NY ACAD SCI, V633, P458; CUNHA RA, 1992, J NEUROCHEM, V59, P657, DOI 10.1111/j.1471-4159.1992.tb09420.x; DUNWIDDIE TV, 1985, J PHYSIOL-LONDON, V369, P365, DOI 10.1113/jphysiol.1985.sp015907; DUNWIDDIE TV, 1985, INT REV NEUROBIOL, V27, P63, DOI 10.1016/S0074-7742(08)60556-5; EAST SJ, 1991, NEUROSCI LETT, V123, P17, DOI 10.1016/0304-3940(91)90147-L; GROVER LM, 1993, SYNAPSE, V15, P149, DOI 10.1002/syn.890150207; GROVER LM, 1993, NEUROSCI LETT, V154, P39, DOI 10.1016/0304-3940(93)90166-I; HAAS HL, 1988, N-S ARCH PHARMACOL, V337, P561; HOEHN K, 1990, J NEUROCHEM, V54, P256, DOI 10.1111/j.1471-4159.1990.tb13309.x; HOEHN K, 1990, J NEUROCHEM, V54, P1716, DOI 10.1111/j.1471-4159.1990.tb01226.x; ISAACSON JS, 1993, NEURON, V10, P165, DOI 10.1016/0896-6273(93)90308-E; KAUER JA, 1988, NATURE, V334, P250, DOI 10.1038/334250a0; LUPICA CR, 1992, J NEUROSCI, V12, P3753; MADISON DV, 1988, J PHYSIOL-LONDON, V398, P123, DOI 10.1113/jphysiol.1988.sp017033; MANABE T, 1992, NATURE, V355, P50, DOI 10.1038/355050a0; MITCHELL JB, 1993, J NEUROSCI, V13, P3439; NICOLL RA, 1980, NATURE, V287, P22, DOI 10.1038/287022a0; NICOLL RA, 1981, J NEUROSCI METH, V4, P153, DOI 10.1016/0165-0270(81)90049-2; PHILLIS JW, 1981, PROG NEUROBIOL, V16, P187, DOI 10.1016/0301-0082(81)90014-9; PONS F, 1980, J NEUROCHEM, V34, P1319, DOI 10.1111/j.1471-4159.1980.tb09977.x; PRINCE DA, 1992, P NATL ACAD SCI USA, V89, P8586, DOI 10.1073/pnas.89.18.8586; PULL I, 1973, BIOCHEM J, V136, P893, DOI 10.1042/bj1360893; SAH P, 1990, J PHYSIOL-LONDON, V430, P605, DOI 10.1113/jphysiol.1990.sp018310; SCANZIANI M, 1992, NEURON, V9, P919, DOI 10.1016/0896-6273(92)90244-8; SCHOLZ KP, 1992, NEURON, V8, P1139, DOI 10.1016/0896-6273(92)90134-Y; SEKINO Y, 1992, NEUROSCI LETT, V148, P109, DOI 10.1016/0304-3940(92)90816-P; SILINSKY EM, 1984, J PHYSIOL-LONDON, V346, P243, DOI 10.1113/jphysiol.1984.sp015019; USOWICZ MM, 1989, NATURE, V339, P380, DOI 10.1038/339380a0; WYLLIE DJA, 1991, J PHYSIOL-LONDON, V432, P235, DOI 10.1113/jphysiol.1991.sp018383; ZETTERSTROM T, 1982, NEUROSCI LETT, V29, P111, DOI 10.1016/0304-3940(82)90338-X; ZIEGLGANSBERGER W, 1979, SCIENCE, V205, P415, DOI 10.1126/science.451610	39	252	257	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 30	1994	265	5181					2098	2101		10.1126/science.7916485	http://dx.doi.org/10.1126/science.7916485			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PJ912	7916485				2022-12-24	WOS:A1994PJ91200032
J	AVNER, ED				AVNER, ED			GENE TIME FOR POLYCYSTIC KIDNEY-DISEASE	LANCET			English	Editorial Material											AVNER, ED (corresponding author), CHILDRENS HOSP & MED CTR,DIV PEDIAT NEPHROL,SEATTLE,WA 98105, USA.							AVNER ED, 1993, SEMIN NEPHROL, V13, P427; KIMBERLING WJ, 1993, GENOMICS, V18, P467, DOI 10.1016/S0888-7543(11)80001-7; MCDONALD RA, 1991, SEMIN NEPHROL, V11, P632; MOYER JH, 1994, SCIENCE, V264, P1329, DOI 10.1126/science.8191288; REEDERS ST, 1985, NATURE, V317, P542, DOI 10.1038/317542a0; WOO DDL, 1994, NATURE, V368, P750, DOI 10.1038/368750a0; ZERRES K, 1994, NAT GENET, V7, P429, DOI 10.1038/ng0794-429; 1994, CELL, V77, P1	8	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 24	1994	344	8926					833	834		10.1016/S0140-6736(94)92820-7	http://dx.doi.org/10.1016/S0140-6736(94)92820-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PH253	7916394				2022-12-24	WOS:A1994PH25300004
J	LU, Z; MACKINNON, R				LU, Z; MACKINNON, R			ELECTROSTATIC TUNING OF MG2+ AFFINITY IN AN INWARD-RECTIFIER K+ CHANNEL	NATURE			English	Article							GUINEA-PIG HEART; POTASSIUM CHANNEL; FUNCTIONAL EXPRESSION; VENTRICULAR CELLS; MAGNESIUM BLOCK; INTERNAL MG-2+; RECTIFICATION; ACTIVATION; IONS	INWARD-RECTIFIER potassium channels conduct K+ across the cell membrane more efficiently in the inward than outward direction. This unusual conduction property is directly related to the biological action of these channels(1-6). One basis for inward rectification is voltage-dependent blockade by intracellular Mg2+ (refs 1, 7-9): strong inward-rectifier channels are so sensitive to intracellular Mg2+ that no outward K+ current is measurable under physiological conditions; weak inward rectifiers are less sensitive and allow some K+ to flow outwards. Background K1 channels and acetylcholine-regulated K+ channels from the heart are examples of strong inward rectifiers and ATP-sensitive K+ channels are weak rectifiers(1,7-10). Here we show that mutations at one position in the second transmembrane segment can alter the Mg2+ affinity and convert a weakly rectifying channel (ROMK1) into a strong rectifier. The amino acid at this position exposes its side chain to the aqueous pore and affects Mg2+ blockade as well as K+ conduction through an electrostatic mechanism.			LU, Z (corresponding author), HARVARD UNIV,SCH MED,DEPT NEUROBIOL,220 LONGWOOD AVE,BOSTON,MA 02115, USA.							ASHCROFT FM, 1990, BIOCHEM SOC T, V18, P109, DOI 10.1042/bst0180109; CHOI KL, 1993, NEURON, V10, P533, DOI 10.1016/0896-6273(93)90340-W; Creighton T. E., 1993, PROTEINS STRUCTURES; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P1025; Goldman DE, 1943, J GEN PHYSIOL, V27, P37, DOI 10.1085/jgp.27.1.37; GRAHAME DC, 1947, CHEM REV, V41, P441, DOI 10.1021/cr60130a002; Hille B., 1991, IONIC CHANNELS EXCIT; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; HORIE M, 1987, J PHYSIOL-LONDON, V387, P251, DOI 10.1113/jphysiol.1987.sp016572; ISHIHARA K, 1989, J PHYSIOL-LONDON, V419, P297, DOI 10.1113/jphysiol.1989.sp017874; KIRSCH GE, 1993, NEURON, V11, P503, DOI 10.1016/0896-6273(93)90154-J; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; KURACHI Y, 1985, J PHYSIOL-LONDON, V366, P365, DOI 10.1113/jphysiol.1985.sp015803; LOPEZ GA, 1994, NATURE, V367, P179, DOI 10.1038/367179a0; MACKINNON R, 1988, NEURON, V1, P997, DOI 10.1016/0896-6273(88)90156-0; MATSUDA H, 1991, J PHYSIOL-LONDON, V435, P83, DOI 10.1113/jphysiol.1991.sp018499; MATSUDA H, 1987, NATURE, V325, P156, DOI 10.1038/325156a0; MILLER C, 1991, SCIENCE, V252, P1092, DOI 10.1126/science.252.5009.1092; NICHOLS CG, 1994, J PHYSIOL-LONDON, V476, P399, DOI 10.1113/jphysiol.1994.sp020141; NOMA A, 1983, PFLUGERS ARCH, V400, P424; SAKMANN B, 1983, NATURE, V303, P250, DOI 10.1038/303250a0; SEOJIMA M, 1984, PFLUGERS ARCH, V400, P424; SILVER MR, 1990, J GEN PHYSIOL, V96, P109, DOI 10.1085/jgp.96.1.109; SLESINGER PA, 1993, NEURON, V11, P739, DOI 10.1016/0896-6273(93)90083-4; STANFIELD PR, 1994, J PHYSIOL-LONDON, V475, P1; TAGLIALATELA M, 1994, SCIENCE, V264, P844, DOI 10.1126/science.8171340; TRAUTWEIN W, 1958, PFLUG ARCH GES PHYS, V266, P324, DOI 10.1007/BF00416781; VANDENBERG CA, 1987, P NATL ACAD SCI USA, V84, P2560, DOI 10.1073/pnas.84.8.2560	29	273	278	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 15	1994	371	6494					243	246		10.1038/371243a0	http://dx.doi.org/10.1038/371243a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PG290	7915826				2022-12-24	WOS:A1994PG29000051
J	PHILIPP, T; DURAZZO, M; TRAUTWEIN, C; ALEX, B; STRAUB, P; LAMB, JG; JOHNSON, EF; TUKEY, RH; MANNS, MP				PHILIPP, T; DURAZZO, M; TRAUTWEIN, C; ALEX, B; STRAUB, P; LAMB, JG; JOHNSON, EF; TUKEY, RH; MANNS, MP			RECOGNITION OF URIDINE-DIPHOSPHATE GLUCURONOSYL TRANSFERASES BY LKM-3 ANTIBODIES IN CHRONIC HEPATITIS-D	LANCET			English	Article							BILIRUBIN UDP-GLUCURONOSYLTRANSFERASE; CRIGLER-NAJJAR SYNDROME; DELTA-VIRUS-INFECTION; AUTOIMMUNE HEPATITIS; MICROSOMAL AUTOANTIBODIES; DEVELOPMENTAL EXPRESSION; RAT; CYTOCHROME-P-450; SEQUENCE; GENE	Patients with chronic hepatitis D often have liver-kidney microsoma I a nti bod ies type 3 (LKM-3). These a nti bod ies react with several microsomal antigens that have a molecular weight of 55 KDa and an isoelectric point of about 8. We studied the molecular nature of the antigen and, by immunoscreening a human liver cDNA expression library with KM-3 sera, found that uridine diphosphate glucuronosyl transferases (UGT) appeared as candidate antigens. We confirmed the identity of UGT as an antigen by reacting the sera with recombinant rabbit liver UGT proteins. Some sera reacted with rabbit UGT-2 proteins, but UGT-1 proteins were more sensitive and specific in detecting LKM-3 autoantibodies in patient sera. Anti-UGT-1 antibodies were detected in all LKM-3 positive sera from patients with hepatitis D and 1 out of 11 patients with autoimmune hepatitis type 2. Sera from patients who had hepatitis B only did not react with UGT proteins. The UGT proteins are part of the phase II enzymes of drug metabolism and a re the fi rst such enzymes to be identified as human autoantigens.	HANNOVER MED SCH, DEPT GASTROENTEROL & HEPATOL, HANNOVER, GERMANY; UNIV TURIN, IST MED INTERNA, TURIN, ITALY; UNIV CALIF SAN DIEGO, CTR CANC, DEPT PHARMACOL, SAN DIEGO, CA 92103 USA; SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, LA JOLLA, CA 92093 USA	Hannover Medical School; University of Turin; University of California System; University of California San Diego; Scripps Research Institute				DURAZZO, Marilena/0000-0003-2450-5911	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049135, R01GM031001] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM31001, GM49135] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMENGUAL MJ, 1989, CLIN EXP IMMUNOL, V78, P80; BEAUNE P, 1987, P NATL ACAD SCI USA, V84, P551, DOI 10.1073/pnas.84.2.551; BOSMA PJ, 1993, GASTROENTEROLOGY, V105, P216, DOI 10.1016/0016-5085(93)90029-C; BURCHELL B, 1991, DNA CELL BIOL, V10, P487, DOI 10.1089/dna.1991.10.487; COUGHTRIE MWH, 1988, MOL PHARMACOL, V34, P729; CRIVELLI O, 1983, CLIN EXP IMMUNOL, V54, P232; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; HAQUE SJ, 1991, DNA CELL BIOL, V10, P515, DOI 10.1089/dna.1991.10.515; IYANAGI T, 1986, J BIOL CHEM, V261, P5607; KIRKPATRICK RB, 1988, HEPATOLOGY, V8, P353, DOI 10.1002/hep.1840080227; MACKENZIE PI, 1992, J STEROID BIOCHEM, V43, P1099, DOI 10.1016/0960-0760(92)90338-J; MACKENZIE PI, 1990, J BIOL CHEM, V265, P11328; MANNS MP, 1989, J CLIN INVEST, V83, P1066, DOI 10.1172/JCI113949; MANNS MP, 1991, J CLIN INVEST, V88, P1370, DOI 10.1172/JCI115443; MANNS MP, 1990, ARCH BIOCHEM BIOPHYS, V280, P229, DOI 10.1016/0003-9861(90)90541-6; MICHEL G, 1992, LANCET, V339, P267, DOI 10.1016/0140-6736(92)91332-3; NORMAN RL, 1978, J BIOL CHEM, V253, P8640; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; RITTER JK, 1992, J CLIN INVEST, V90, P150, DOI 10.1172/JCI115829; RITTER JK, 1992, J BIOL CHEM, V267, P3257; ROBERTSON KJ, 1991, J INHERIT METAB DIS, V14, P563, DOI 10.1007/BF01797927; Schwab GE., 1987, MAMMALIAN CYTOCHROME, VI, P55; STRAUB P, 1993, J BIOL CHEM, V268, P21997; SUTHERLAND L, 1992, FEBS LETT, V308, P161, DOI 10.1016/0014-5793(92)81266-O; TUKEY RH, 1993, J BIOL CHEM, V268, P15260; VERGANI D, 1993, GASTROENTEROLOGY, V104, P1870, DOI 10.1016/0016-5085(93)90673-Z; WANG KS, 1986, NATURE, V323, P508, DOI 10.1038/323508a0; WESIERSKAGADEK J, 1990, HEPATOLOGY, V12, P1129; WOOSTER R, 1991, BIOCHEM J, V278, P465, DOI 10.1042/bj2780465; ZANGER UM, 1988, P NATL ACAD SCI USA, V85, P8256, DOI 10.1073/pnas.85.21.8256; ZAULI D, 1986, J CLIN PATHOL, V39, P897, DOI 10.1136/jcp.39.8.897; ZUBER MX, 1986, SCIENCE, V234, P1258, DOI 10.1126/science.3535074	32	104	107	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 27	1994	344	8922					578	581		10.1016/S0140-6736(94)91966-6	http://dx.doi.org/10.1016/S0140-6736(94)91966-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD424	7914961				2022-12-24	WOS:A1994PD42400010
J	SMYTH, JF; MOSSMAN, J; HALL, R; HEPBURN, S; PINKERTON, R; RICHARDS, M; THATCHER, N; BOX, J				SMYTH, JF; MOSSMAN, J; HALL, R; HEPBURN, S; PINKERTON, R; RICHARDS, M; THATCHER, N; BOX, J			CONDUCTING CLINICAL RESEARCH IN THE NEW NHS - THE MODEL OF CANCER	BRITISH MEDICAL JOURNAL			English	Article								The United Kingdom Coordinating Committee on Cancer Research represents the major organisations funding cancer research in the United Kingdom. The deliberations of a working party convened by the committee to evaluate recently expressed concerns that the changes in the NHS threaten research, especially clinical trials to evaluate new treatments, are reported. A survey of contributors to trials coordinated by the committee showed that half are now experiencing difficulties in continuing to participate in clinical trials. The two major problems identified were lack of time and of staff, especially for NHS staff in non-teaching hospitals. Recent changes in junior doctors' hours and proposed reductions in the length of time for training will exacerbate this. It is possible to identify the direct and indirect excess costs of conducting research in the NHS, but currently the mechanism does not exist to designate funds specifically for this purpose. Consultation with the regional directors of research and development confirmed that the service increment for teaching and research is not the solution for this, Proposals are made to secure future clinical research in the NHS, including finance, indemnity, the licensing of new drugs, the greater use of nurse counsellors, and the value of cancer registries.	UNITED KINGDOM COORDINATING COMM CANC RES,LONDON WC2A 3PX,ENGLAND; FREEMAN RD HOSP,DEPT UROL,NEWCASTLE TYNE NE7 7DN,TYNE & WEAR,ENGLAND; ROYAL MARSDEN HOSP,SUTTON SM2 5PT,SURREY,ENGLAND; GUYS HOSP,IMPERIAL CANC RES FUND,BREAST CANC UNIT,LONDON SE1 9RT,ENGLAND; CHRISTIE HOSP,DEPT MED ONCOL,MANCHESTER M20 9BX,LANCS,ENGLAND; MRC,LONDON W1N 4AL,ENGLAND	Newcastle Freeman Hospital; Royal Marsden NHS Foundation Trust; Cancer Research UK; Guy's & St Thomas' NHS Foundation Trust; Christie NHS Foundation Trust; Christie Hospital	SMYTH, JF (corresponding author), UNIV EDINBURGH,WESTERN GEN HOSP,DEPT CLIN ONCOL,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.		pinkerton, ross/I-4808-2014					1992, ASSESSING EFFECTS HL	1	41	41	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 13	1994	309	6952					457	461		10.1136/bmj.309.6952.457	http://dx.doi.org/10.1136/bmj.309.6952.457			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PC404	7920132	Green Published			2022-12-24	WOS:A1994PC40400024
J	TILLOTSON, SL; FUGGLE, PW; SMITH, I; ADES, AE; GRANT, DB				TILLOTSON, SL; FUGGLE, PW; SMITH, I; ADES, AE; GRANT, DB			RELATION BETWEEN BIOCHEMICAL SEVERITY AND INTELLIGENCE IN EARLY TREATED CONGENITAL HYPOTHYROIDISM - A THRESHOLD EFFECT	BRITISH MEDICAL JOURNAL			English	Article							FETAL HYPOTHYROIDISM; MENTAL-DEVELOPMENT; THYROXINE; CHILDREN; PARAMETERS; INFANTS; TESTS; AGE	Objectives-To assess whether early treatment of congenital hypothyroidism fully prevents intellectual impairment. Design-A national register of children with congenital hypothyroidism who were compared with unaffected children from the same school classes and matched for age, sex, social class, and first language. Setting-First three years (1982-4) of a neonatal screening programme in England, Wales, and Northern Ireland. Subjects-361 children with congenital hypothyroidism given early treatment and 315 control children. Main outcome measures-Intelligence quotient (IQ) measured at school entry at 5 years of age with the Wechsler preschool and primary scale of intelligence. Results-There was a discontinuous relation between IQ and plasma thyroxine concentration at diagnosis, with a threshold at 42.8 nmol/l (95% confidence interval 35.2 to 47.1 nmol/l). Hypothyroid children with thyroxine values below 42.8 nmol/l had a mean IQ 10.3 points (6.9 to 13.7 points) lower than those with higher values and than controls. None of the measures of quality of treatment (age at start of treatment (range 1-173 days), average thyoxine dose (12-76 mu g in the first year), average thyroxine concentration during treatment (79-234 nmol/l in the first year), and thyroxine concentration 103 nmol/l less than at least once during the first year) influenced IQ at age 5. Conclusions-Despite early treatment in congenital hypothyroidism the disease severity has a threshold effect on brain development, probably determined prenatally. The 55% of infants with more severe disease continue to show clinically significant intellectual impairment; infants with milder disease show no such impairment. The findings predict that	INST CHILD HLTH, MRC, REGISTER CHILDREN HYPOTHYROIDISM, MED UNIT, LONDON WC1N 1EH, ENGLAND; INST CHILD HLTH, DEPT EPIDEMIOL & BIOSTAT, LONDON WC1H 1EH, ENGLAND	University of London; University College London; University of London; University College London								DAVIDSON R, 1981, ECONOMETRICA, V49, P781, DOI 10.2307/1911522; DEONA CR, 1988, PEDIATR RES, V24, P588, DOI 10.1203/00006450-198811000-00010; FISHER DA, 1979, J PEDIATR-US, V94, P700, DOI 10.1016/S0022-3476(79)80133-X; FLYNN JR, 1987, PSYCHOL BULL, V101, P171, DOI 10.1037/0033-2909.101.2.171; FUGGLE PW, 1992, J CHILD PSYCHOL PSYC, V33, P1241, DOI 10.1111/j.1469-7610.1992.tb00942.x; FUGGLE PW, 1991, EUR J PEDIATR, V150, P570, DOI 10.1007/BF02072209; GLORIEUX J, 1983, J PEDIATR-US, V102, P19, DOI 10.1016/S0022-3476(83)80279-0; GLORIEUX J, 1988, PEDIATR RES, V24, P6, DOI 10.1203/00006450-198807000-00003; GRANT DB, 1993, ARCH DIS CHILD, V69, P555, DOI 10.1136/adc.69.5.555; GRANT DB, 1992, ARCH DIS CHILD, V67, P87, DOI 10.1136/adc.67.1.87; GRANT DB, 1988, BRIT MED J, V296, P1355, DOI 10.1136/bmj.296.6633.1355; HEYERDAHL S, 1991, J PEDIATR-US, V118, P850, DOI 10.1016/S0022-3476(05)82194-8; HULSE JA, 1984, ARCH DIS CHILD, V59, P23, DOI 10.1136/adc.59.1.23; ILICKI A, 1991, ACTA PAEDIATR SCAND, V80, P199, DOI 10.1111/j.1651-2227.1991.tb11834.x; ILLIG R, 1987, ARCH DIS CHILD, V62, P1050, DOI 10.1136/adc.62.10.1050; KLEIN AH, 1972, J PEDIATR-US, V81, P912, DOI 10.1016/S0022-3476(72)80542-0; KOMIANOU F, 1988, EUR J PEDIATR, V147, P275, DOI 10.1007/BF00442694; LARSEN PR, 1989, NEW ENGL J MED, V321, P44, DOI 10.1056/NEJM198907063210108; MATTHEWS DE, 1988, BIOMETRIKA, V75, P139; ROCHICCIOLI P, 1984, ARCH FR PEDIATR, V41, P329; ROVET J, 1987, J PEDIATR-US, V110, P700, DOI 10.1016/S0022-3476(87)80005-7; ROYSTON P, IN PRESS BIOMETRICS; TILLOTSON SL, 1992, J CLIN PATHOL, V45, P819, DOI 10.1136/jcp.45.9.819; VIRTANEN M, 1989, ACTA PAEDIATR SCAND, V78, P405, DOI 10.1111/j.1651-2227.1989.tb11100.x; VULSMA T, 1989, NEW ENGL J MED, V321, P13, DOI 10.1056/NEJM198907063210103; 1984, J PEDIATR, V104, P539; 1981, LANCET, V2, P1095; 1990, J PEDIATR, V116, P27; 1990, LABOUR FORCE SURVEY; 1982, 1981 CENSUS NATIONAL	30	144	148	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 13	1994	309	6952					440	445		10.1136/bmj.309.6952.440	http://dx.doi.org/10.1136/bmj.309.6952.440			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PC404	7920127	Green Published			2022-12-24	WOS:A1994PC40400017
J	HAN, J; LEE, JD; BIBBS, L; ULEVITCH, RJ				HAN, J; LEE, JD; BIBBS, L; ULEVITCH, RJ			A MAP KINASE TARGETED BY ENDOTOXIN AND HYPEROSMOLARITY IN MAMMALIAN-CELLS	SCIENCE			English	Article							PROTEIN-TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION PATHWAY; MACROPHAGES; FAMILY; YEAST; GENES; TAXOL; CD14	Mammalian cells respond to endotoxic lipopolysaccharide (LPS) by activation of protein kinase cascades that lead to new gene expression. A protein kinase, p38, that was tyrosine phosphorylated in response to LPS, was cloned. The p38 enzyme and the product of the Saccharomyces cerevisiae HOG 1 gene, which are both members of the mitogen-activated protein (MAP) kinase family, have sequences at and adjacent to critical phosphorylation sites that distinguish these proteins from most other MAP kinase family members. Both HOG1 and p38 are tyrosine phosphorylated after extracellular changes in osmolarity. These findings link a signaling pathway in mammalian cells with a pathway in yeast that is responsive to physiological stress.	SCRIPPS RES INST, MICROCHEM FACIL, LA JOLLA, CA 92037 USA	Scripps Research Institute	HAN, J (corresponding author), SCRIPPS RES INST, DEPT IMMUNOL, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.		Ulevitch, Richard J/Q-3393-2017; Han, J/G-4671-2010		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015136] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028485, P01GM037696, R37GM028485] Funding Source: NIH RePORTER; NIAID NIH HHS [AI15136] Funding Source: Medline; NIGMS NIH HHS [GM28485, GM37696] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; CORRADIN SB, 1992, J LEUKOCYTE BIOL, V52, P363, DOI 10.1002/jlb.52.4.363; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DING AH, 1990, SCIENCE, V248, P370, DOI 10.1126/science.1970196; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P255, DOI 10.1016/0003-2697(92)90336-6; GLAUSER MP, 1991, LANCET, V338, P732, DOI 10.1016/0140-6736(91)91452-Z; GLENNEY JR, 1991, METHOD ENZYMOL, V201, P92; GONZALEZ FA, 1992, FEBS LETT, V304, P170, DOI 10.1016/0014-5793(92)80612-K; GUSTIN M, COMMUNICATION; Han J., UNPUB; HAN JH, 1993, J BIOL CHEM, V268, P25009; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEE JD, 1993, P NATL ACAD SCI USA, V90, P9930, DOI 10.1073/pnas.90.21.9930; MANTHEY CL, 1992, J IMMUNOL, V149, P2459; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; SCHILD D, 1990, P NATL ACAD SCI USA, V87, P2916, DOI 10.1073/pnas.87.8.2916; TILLY BC, 1993, J BIOL CHEM, V268, P19919; Tracey K J, 1990, Adv Surg, V23, P21; ULEVITCH RJ, 1994, CURR OPIN IMMUNOL, V6, P125, DOI 10.1016/0952-7915(94)90043-4; ULEVITCH RJ, 1993, ADV IMMUNOL, V53, P267, DOI 10.1016/S0065-2776(08)60502-7; WEINSTEIN SL, 1992, J BIOL CHEM, V267, P14955; WEINSTEIN SL, 1991, P NATL ACAD SCI USA, V88, P4148, DOI 10.1073/pnas.88.10.4148; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0	26	2398	2539	3	73	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 5	1994	265	5173					808	811		10.1126/science.7914033	http://dx.doi.org/10.1126/science.7914033			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PA372	7914033				2022-12-24	WOS:A1994PA37200041
J	HEYM, B; HONORE, N; TRUFFOTPERNOT, C; BANERJEE, A; SCHURRA, C; JACOBS, WR; VANEMBDEN, JD; GROSSET, JH; COLE, ST				HEYM, B; HONORE, N; TRUFFOTPERNOT, C; BANERJEE, A; SCHURRA, C; JACOBS, WR; VANEMBDEN, JD; GROSSET, JH; COLE, ST			IMPLICATIONS OF MULTIDRUG-RESISTANCE FOR THE FUTURE OF SHORT-COURSE CHEMOTHERAPY OF TUBERCULOSIS - A MOLECULAR STUDY	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; NEW-YORK-CITY; MYCOBACTERIUM-TUBERCULOSIS; STREPTOMYCIN RESISTANCE; PULMONARY TUBERCULOSIS; GENE; RIFAMPIN; SINGLE; MUTATIONS; LEPRAE	Tuberculosis-control programmes are compromised by the increased frequency of multidrug-resistant strains of Mycobacterium tuberculosis. We used the polymerase chain reaction (PCR) and single-strand conformation polymorphism (SSCP) analysis techniques to establish the molecular basis of resistance in 37 drug-resistant isolates of M tuberculosis, and correlated these findings with clinical and antibiotic-sensitivity data. Resistance to isoniazid was found in 36 strains, 16 of which were also resistant to ethionamide. Of the 36 isoniazid-resistant strains, 23 had mutations in the katG gene, and 5 of these also had mutations in the inhA gene. A further 5 strains had alterations in the inhA locus without the katG gene being mutated. Rifampicin resistance was less frequent (13 strains) and usually associated with isoniazid resistance (11 of 13 strains). Mutations in the rpoB gene were detected for all these rifampicin-resistant isolates. Mutations in the rpsL and rrs genes, associated with streptomycin resistance, were found in 13 of 25 and 2 of 25 streptomycin-resistant strains, respectively. The same chromosomal mutations, or combinations of mutations, were found in strains displaying single or multidrug resistance, from cases of both primary and secondary resistance, and from patients infected with human immunodeficiency virus. Thus, multidrug resistance is not due to a novel mechanism and tuberculosis chemotherapy is not subject to a new threat.	INST PASTEUR,UNITE GENET MOLEC BACTERIENNE,F-75724 PARIS 15,FRANCE; UNIV PARIS 06,PARIS,FRANCE; ALBERT EINSTEIN COLL MED,HOWARD HUGHES MED INST,NEW YORK,NY; NATL INST PUBL HLTH & HYG,BILTHOVEN,NETHERLANDS	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Sorbonne Universite; Howard Hughes Medical Institute; Yeshiva University				Jacobs, William/0000-0003-3321-3080				BANERJEE A, 1994, SCIENCE, V263, P227, DOI 10.1126/science.8284673; BARNES PF, 1991, NEW ENGL J MED, V324, P1644, DOI 10.1056/NEJM199106063242307; BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055; BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745, DOI 10.1164/ajrccm/144.4.745; DOOLEY SW, 1992, JAMA-J AM MED ASSOC, V267, P2632, DOI 10.1001/jama.267.19.2632; FINKEN M, 1993, MOL MICROBIOL, V9, P1239, DOI 10.1111/j.1365-2958.1993.tb01253.x; FRIEDEN TR, 1993, NEW ENGL J MED, V328, P521, DOI 10.1056/NEJM199302253280801; GOBLE M, 1993, NEW ENGL J MED, V328, P527, DOI 10.1056/NEJM199302253280802; HEYM B, 1993, J BACTERIOL, V175, P4255, DOI 10.1128/JB.175.13.4255-4259.1993; HONORE N, 1994, ANTIMICROB AGENTS CH, V38, P238, DOI 10.1128/AAC.38.2.238; HONORE N, 1993, ANTIMICROB AGENTS CH, V37, P414, DOI 10.1128/AAC.37.3.414; Imboden Paul, 1993, P519; ISEMAN MD, 1993, NEW ENGL J MED, V329, P784, DOI 10.1056/NEJM199309093291108; JACOBS WR, 1993, SCIENCE, V260, P819, DOI 10.1126/science.8484123; MARTIN C, 1990, MOL BIOL MYCOBACTERI, P121; MCCLATCHY JK, 1986, ANTIBIOTICS LABORATO, P181; MITCHISON DA, 1986, AM REV RESPIR DIS, V133, P423; NAIR J, 1993, MOL MICROBIOL, V10, P521, DOI 10.1111/j.1365-2958.1993.tb00924.x; NIKAIDO H, 1994, SCIENCE, V264, P382, DOI 10.1126/science.8153625; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; SNIDER DE, 1992, NEW ENGL J MED, V326, P703, DOI 10.1056/NEJM199203053261011; TAKIFF HE, 1994, ANTIMICROB AGENTS CH, V38, P773, DOI 10.1128/AAC.38.4.773; TELENTI A, 1993, LANCET, V341, P647, DOI 10.1016/0140-6736(93)90417-F; TELENTI A, 1993, ANTIMICROB AGENTS CH, V37, P2054, DOI 10.1128/AAC.37.10.2054; WOODS SA, 1989, FEMS MICROBIOL LETT, V65, P305; ZHANG Y, 1992, NATURE, V358, P591, DOI 10.1038/358591a0; 1992, MMWR-MORBID MORTAL W, V42, P5; 1991, MMWR-MORBID MORTAL W, V40, P585; 1993, MMWR-MORBID MORTAL W, V42, P1	29	240	261	0	13	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 30	1994	344	8918					293	298		10.1016/S0140-6736(94)91338-2	http://dx.doi.org/10.1016/S0140-6736(94)91338-2			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NZ233	7914261				2022-12-24	WOS:A1994NZ23300007
J	KUNST, CB; WARREN, ST				KUNST, CB; WARREN, ST			CRYPTIC AND POLAR VARIATION OF THE FRAGILE-X REPEAT COULD RESULT IN PREDISPOSING NORMAL ALLELES	CELL			English	Article							FMR-I LOCUS; MYOTONIC-DYSTROPHY; FOUNDER CHROMOSOMES; RNA-BINDING; CGG-REPEAT; CTG REPEAT; CAG REPEAT; GENE; DNA; INSTABILITY	Fragile X syndrome results from the expansion of a CGG repeat that is normally interrupted by occasional AGG triplets. Linkage disequilibrium suggests that certain normal haplotypes may contribute unequally to the pool of fragile X chromosomes. Sequence analysis of normal alleles demonstrates haplotype-specific variation of the cryptic nature of the repeat. Variation occurs principally at the 3' end of the repeat, suggesting stability differences between the leading and lagging strands of DNA replication. Normal alleles with greater than 24 perfect 3' CGG repeats appear more frequently on haplotypes overrepresented among fragile X chromosomes. Such alleles are found in 2% of normal chromosomes and could comprise the ancestral allelic pool from which fragile X chromosomes are derived. These data also may imply that equilibrium between certain predisposed alleles and fragile X expansions has not yet been attained, indicating ongoing evolutionary change at this locus.	EMORY UNIV,SCH MED,DEPT BIOCHEM,ATLANTA,GA 30322; EMORY UNIV,SCH MED,DEPT PEDIAT,ATLANTA,GA 30322	Emory University; Emory University	KUNST, CB (corresponding author), EMORY UNIV,SCH MED,HOWARD HUGHES MED INST,ATLANTA,GA 30322, USA.		Warren, Stephen T/A-2498-2012		NICHD NIH HHS [HD20521] Funding Source: Medline; OHS HRSA HHS [ST32 GM08367] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD020521, R01HD020521] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); OHS HRSA HHS; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ARMOUR JAL, 1993, HUM MOL GENET, V2, P1137, DOI 10.1093/hmg/2.8.1137; ASHLEY CT, 1993, NAT GENET, V4, P244, DOI 10.1038/ng0793-244; ASHLEY CT, 1993, SCIENCE, V262, P563, DOI 10.1126/science.7692601; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; BROWN TC, 1987, CELL, V50, P945, DOI 10.1016/0092-8674(87)90521-6; BROWN WT, 1993, JAMA-J AM MED ASSOC, V270, P1569, DOI 10.1001/jama.270.13.1569; BURHANS WC, 1990, CELL, V62, P955, DOI 10.1016/0092-8674(90)90270-O; CHAKRAVARTI A, 1992, NAT GENET, V1, P237, DOI 10.1038/ng0792-237; CHUNG MY, 1993, NAT GENET, V5, P254, DOI 10.1038/ng1193-254; DAVIES J, 1992, CELL, V68, P799; ECKHART M, 1993, AM J HUM GENET, V53, pA796; FAIRMAN R, 1988, BIOCHEMISTRY-US, V27, P560, DOI 10.1021/bi00402a009; FU YH, 1992, SCIENCE, V255, P1256, DOI 10.1126/science.1546326; FU YH, 1991, CELL, V67, P1047, DOI 10.1016/0092-8674(91)90283-5; GLOVER TW, 1987, AM J HUM GENET, V41, P882; HORNSTRA IK, 1993, HUM MOL GENET, V2, P1659; HYRIEN O, 1993, EMBO J, V12, P4511, DOI 10.1002/j.1460-2075.1993.tb06140.x; IMBERT G, 1993, NAT GENET, V4, P72, DOI 10.1038/ng0593-72; KELLY R, 1989, GENOMICS, V5, P844, DOI 10.1016/0888-7543(89)90126-2; KNIGHT SJL, 1993, CELL, V74, P127, DOI 10.1016/0092-8674(93)90300-F; KOIDE R, 1994, NAT GENET, V6, P9, DOI 10.1038/ng0194-9; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; MACDONALD ME, 1992, NAT GENET, V1, P99, DOI 10.1038/ng0592-99; MAHADEVAN M, 1992, SCIENCE, V255, P1253, DOI 10.1126/science.1546325; MCCONKIEROSELL A, 1993, AM J HUM GENET, V53, P800; MORTON NE, 1992, P NATL ACAD SCI USA, V89, P4215, DOI 10.1073/pnas.89.9.4215; NAGAFUCHI S, 1994, NAT GENET, V6, P14, DOI 10.1038/ng0194-14; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; ORR HT, 1993, NAT GENET, V4, P221, DOI 10.1038/ng0793-221; OUDET C, 1993, AM J HUM GENET, V52, P297; PETES TD, 1991, GENOME DYNAMICS PROT, V1; PIERETTI M, 1991, CELL, V66, P817, DOI 10.1016/0092-8674(91)90125-I; RICHARDS RI, 1994, NAT GENET, V6, P114, DOI 10.1038/ng0294-114; RICHARDS RI, 1992, NAT GENET, V1, P257, DOI 10.1038/ng0792-257; RICHARDS RI, 1992, CELL, V70, P709, DOI 10.1016/0092-8674(92)90302-S; ROUSSEAU F, 1993, AM J HUM GENET, V53, pA3; SIOMI H, 1993, CELL, V74, P291, DOI 10.1016/0092-8674(93)90420-U; SMITS APT, 1993, J MED GENET, V30, P94, DOI 10.1136/jmg.30.2.94; SNOW K, 1993, AM J HUM GENET, V53, P1217; STARR C, 1984, BIOL UNITY DIVERSITY; STIENBACH P, 1993, HUM GENET, V92, P491; Sutcliffe James S., 1992, Human Molecular Genetics, V1, P397, DOI 10.1093/hmg/1.6.397; SZABO P, 1984, P NATL ACAD SCI-BIOL, V81, P7855, DOI 10.1073/pnas.81.24.7855; TRINH TQ, 1991, NATURE, V352, P544, DOI 10.1038/352544a0; VAUTE X, 1993, SCIENCE, V261, P598; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; WARREN ST, 1994, JAMA-J AM MED ASSOC, V271, P536, DOI 10.1001/jama.271.7.536; WEBER JL, 1990, GENOMICS, V7, P524, DOI 10.1016/0888-7543(90)90195-Z; WOHRLE D, 1992, HUM GENET, V89, P114, DOI 10.1007/BF00207057; WOHRLE D, 1993, NAT GENET, V4, P140, DOI 10.1038/ng0693-140; YU S, 1992, AM J HUM GENET, V50, P968; 1993, CELL, V72, P971	53	334	337	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 17	1994	77	6					853	861		10.1016/0092-8674(94)90134-1	http://dx.doi.org/10.1016/0092-8674(94)90134-1			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NT331	7911740				2022-12-24	WOS:A1994NT33100010
J	QUEIROZ, DMM; MOURA, SB; MENDES, EN; ROCHA, GA; BARBOSA, AJA; DECARVALHO, AST				QUEIROZ, DMM; MOURA, SB; MENDES, EN; ROCHA, GA; BARBOSA, AJA; DECARVALHO, AST			EFFECT OF HELICOBACTER-PYLORI ERADICATION ON G-CELL AND D-CELL DENSITY IN CHILDREN	LANCET			English	Article							CAMPYLOBACTER-PYLORI; DUODENAL-ULCER; UREASE ACTIVITY; GASTRIN; SOMATOSTATIN; HYPERGASTRINEMIA; AMOXYCILLIN; ACID	Helicobacter pylori infection is associated with abnormalities in serum gastrin concentration, antral gastrin and somatostatin content, and D-cell density in adults. We have studied the effects of H pylori infection in children. We studied 13 children positive for H pylori and 7 negative children. The median antral somatostatin content was significantly lower in the positive than in the negative group (0.69 [range 0.35-0.91] vs 1.31 [0.73-1.67] ng/mg, p = 0.007). Both antral and serum gastrin concentrations were significantly higher in the positive group (30.1 [15.3-83.6] vs 14.8 [13.8-28.8] ng/mg, p = 0.008; and 89.9 [59.4-313.2] vs 29.5 [13.9-71.1] pg/mL, p = 0.006). Treatment to eradicate H pylori was successful in 11 of the 13 positive patients. With eradication antral somatostatin increased to within the normal range (by a median of 0.41 [0.21-0.86] ng/mg to 1.10 [0.81-1.55] ng/mg, p = 0.016). Serum and antral gastrin decreased (by 37.1 [5.5-265.2] pg/mL to 52.8 [21.4-267.5] ng/mg, p = 0.001; and by 8.0 [2.0-47.2] ng/mg to 22.1 [10.9-37.5] ng/mg, p = 0.001). Eradication of H pylori also significantly increased antral D-cell density (8 [5-22] to 15 [9-22] cells per mm, p = 0.031) and decreased G-cell density (138 [89-161] to 88 [33-121] cells per mm, p = 0.016). The hypergastrinaemia in children positive for H pylori may be due to a deficiency of antral somatostatin, which inhibits gastrin synthesis and release.	UNIV FED MINAS GERAIS, FAC MED, DEPT PATHOL, BELO HORIZONTE, MG, BRAZIL; UNIV FED MINAS GERAIS, FAC MED, DEPT PEDIAT, BELO HORIZONTE, MG, BRAZIL	Universidade Federal de Minas Gerais; Universidade Federal de Minas Gerais	QUEIROZ, DMM (corresponding author), UNIV FED MINAS GERAIS, FAC MED, RES BACTERIOL LAB, AVE ALFREDO BALENA 190-464, BR-30130100 BELO HORIZONTE, MG, BRAZIL.		Moura, Sílvia B/K-7344-2012; Queiroz, Dulciene/AAU-9386-2020; Rocha, Gifone A/N-6913-2018	Queiroz, Dulciene/0000-0003-1334-9423; Rocha, Gifone A/0000-0002-1858-3166				ARNOLD R, 1980, CLIN GASTROENTEROL, V9, P733; BRYANT MG, 1982, RADIOIMMUNOASSAY GUT, P336; CARVALHO AST, 1991, BRAZ J MED BIOL RES, V24, P163; CHITTAJALLU RS, 1991, GUT, V32, P1286, DOI 10.1136/gut.32.11.1286; ELNUJUMI AM, 1991, GUT, V32, P866, DOI 10.1136/gut.32.8.866; ELOMAR E, 1993, GUT, V34, P1060, DOI 10.1136/gut.34.8.1060; GRAHAM DY, 1993, GASTROENTEROLOGY, V104, P1655, DOI 10.1016/0016-5085(93)90642-P; GRAHAM DY, 1990, AM J GASTROENTEROL, V85, P394; KANEKO H, 1992, DIGEST DIS SCI, V37, P409, DOI 10.1007/BF01307736; Kramling H J, 1987, Adv Exp Med Biol, V216A, P427; LEVI S, 1989, LANCET, V1, P1167; MAHONY MJ, 1990, ARCH DIS CHILD, V65, P1212; MCCOLL KEL, 1989, LANCET, V2, P499; MOSS SF, 1992, LANCET, V340, P930, DOI 10.1016/0140-6736(92)92816-X; NAKANISHI T, 1993, AM J GASTROENTEROL, V88, P440; ODERDA G, 1989, ARCH DIS CHILD, V64, P326, DOI 10.1136/adc.64.3.326; ODERDA G, 1989, LANCET, V1, P690; QUEIROZ DMM, 1993, SCAND J GASTROENTERO, V28, P858, DOI 10.3109/00365529309103125; QUEIROZ DMM, 1987, J CLIN MICROBIOL, V25, P2378, DOI 10.1128/JCM.25.12.2378-2379.1987; SCHUSDZIARRA V, 1983, SCAND J GASTROENTERO, V18, P69; SMITH JTL, 1990, GUT, V31, P522, DOI 10.1136/gut.31.5.522; STERNBERG LA, 1986, IMMUNOCYTOCHEMISTRY; WILLIAMS G, 1988, HORM METAB RES, V20, P668, DOI 10.1055/s-2007-1010913; WOLFE MM, 1988, NEW ENGL J MED, V319, P1707; YEUNG CK, 1990, J PEDIATR GASTR NUTR, V10, P357, DOI 10.1097/00005176-199004000-00016	25	49	51	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 14	1994	343	8907					1191	1193		10.1016/S0140-6736(94)92401-5	http://dx.doi.org/10.1016/S0140-6736(94)92401-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NL175	7909869				2022-12-24	WOS:A1994NL17500010
J	MARKHAM, RB; COBERLY, J; RUFF, AJ; HOOVER, D; GOMEZ, J; HOLT, E; DESORMEAUX, J; BOULOS, R; QUINN, TC; HALSEY, NA				MARKHAM, RB; COBERLY, J; RUFF, AJ; HOOVER, D; GOMEZ, J; HOLT, E; DESORMEAUX, J; BOULOS, R; QUINN, TC; HALSEY, NA			MATERNAL IGG1 AND IGA ANTIBODY TO V3 LOOP CONSENSUS SEQUENCE AND MATERNAL-INFANT HIV-1 TRANSMISSION	LANCET			English	Note							HUMAN-IMMUNODEFICIENCY-VIRUS; GP120; MOTHERS	Maternal-infant transmission of HIV-1 occurs in 13-40% of pregnancies. Studies on transmission of maternal immunity to HIV antigens have used antigens from viruses not representative of clinical isolates and have been conflicting. Using a consensus peptide sequence based on HIV isolates found in Haiti, we found that Haitian mothers who transmitted infection to their offspring had significantly higher mean concentrations of IgG1 antibodies to the V3 loop of the primary neutralising domain of the viral envelope (gp 160) than non-transmitters (p = 0.02). Concentrations of IgA antibody to this domain were similar in transmitters and non-transmitters.	JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT INT HLTH,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT EPIDEMIOL,BALTIMORE,MD 21205; CTR DEV & HLTH,PORT AU PRINCE,HAITI	Johns Hopkins University; Johns Hopkins University	MARKHAM, RB (corresponding author), JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT IMMUNOL & INFECT DIS,615 N WOLFE ST,BALTIMORE,MD 21205, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI028748, R01AI032468] Funding Source: NIH RePORTER; NIAID NIH HHS [AI32468, P30 AI28748] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		DEVASH Y, 1990, P NATL ACAD SCI USA, V87, P3445, DOI 10.1073/pnas.87.9.3445; HALSEY NA, 1992, J ACQ IMMUN DEF SYND, V5, P153; HALSEY NA, 1990, JAMA-J AM MED ASSOC, V264, P2088, DOI 10.1001/jama.264.16.2088; LAROSA GJ, 1990, SCIENCE, V249, P932, DOI 10.1126/science.2392685; PAREKH BS, 1991, AIDS, V5, P1179, DOI 10.1097/00002030-199110000-00004; ROSSI P, 1989, P NATL ACAD SCI USA, V86, P8055, DOI 10.1073/pnas.86.20.8055; WESTERVELT P, 1992, J VIROL, V66, P2577, DOI 10.1128/JVI.66.4.2577-2582.1992; YERLY S, 1992, J INFECT DIS, V166, P269, DOI 10.1093/infdis/166.2.269; 1992, J ACQUIR IMMUN DEFIC, V5, P1019	9	31	33	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 12	1994	343	8894					390	391		10.1016/S0140-6736(94)91225-4	http://dx.doi.org/10.1016/S0140-6736(94)91225-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW283	7905554	hybrid			2022-12-24	WOS:A1994MW28300011
J	GOODEVE, AC; PRESTON, FE; PEAKE, IR				GOODEVE, AC; PRESTON, FE; PEAKE, IR			FACTOR-VIII GENE REARRANGEMENTS IN PATIENTS WITH SEVERE HEMOPHILIA-A	LANCET			English	Note							HEMOPHILIA-A	Sequences within intron 22 of the factor VIII (FVIII) gene have been implicated in the cause of haemophilia in almost 50% of severely affected patients. The changes result from intrachromosomal rearrangements of the tip of the long arm of the X chromosome, one break-point being within intron 22 of the FVIII gene. The rearrangements can be identified by Southern blot and we report use of this procedure to detect rearrangements in 11 of 23 unrelated families with severe haemophilia A. Of 22 patients studied, none of the 10 with the gene rearrangement had at any time developed inhibitors to FVIII, compared with 7 of 12 lacking the rearrangement.	ROYAL HALLAMSHIRE HOSP,DEPT MED & PHARMACOL,HAEMATOL SECT,SHEFFIELD S10 2JF,S YORKSHIRE,ENGLAND; ROYAL HALLAMSHIRE HOSP,DEPT MED & PHARMACOL,MOLEC GENET SECT,SHEFFIELD S10 2JF,S YORKSHIRE,ENGLAND	University of Sheffield; University of Sheffield				Goodeve, Anne/0000-0002-6177-7062				HIGUCHI M, 1991, P NATL ACAD SCI USA, V88, P7405, DOI 10.1073/pnas.88.16.7405; LAKICH D, 1993, NAT GENET, V5, P236, DOI 10.1038/ng1193-236; MILLAR DS, 1990, HUM GENET, V86, P219; NAYLOR J, 1993, HUM MOL GENET, V2, P1773, DOI 10.1093/hmg/2.11.1773; NAYLOR JA, 1993, HUM MOL GENET, V2, P11, DOI 10.1093/hmg/2.1.11; PEAKE IR, 1993, BLOOD COAGUL FIBRIN, V4, P313, DOI 10.1097/00001721-199304000-00013; WION KL, 1986, NUCLEIC ACIDS RES, V14, P4553	7	66	66	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 5	1994	343	8893					329	330		10.1016/S0140-6736(94)91165-7	http://dx.doi.org/10.1016/S0140-6736(94)91165-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MU985	7905147				2022-12-24	WOS:A1994MU98500011
J	NOORDERMEER, J; KLINGENSMITH, J; PERRIMON, N; NUSSE, R				NOORDERMEER, J; KLINGENSMITH, J; PERRIMON, N; NUSSE, R			DISHEVELLED AND ARMADILLO ACT IN THE WINGLESS SIGNALING PATHWAY IN DROSOPHILA	NATURE			English	Article							POLARITY GENE ARMADILLO; PROTEIN; EXPRESSION; PRODUCT; ENCODES; EMBRYOGENESIS; REQUIREMENTS; SECRETION; EPIDERMIS; HEDGEHOG	THE Wnt genes encode conserved secreted proteins that play a role in normal development and tumorigenesis1,2. Little is known about the signal transduction pathways of Wnt gene products. One of the best characterized Wnt family members is the Drosophila segment polarity gene wingless3-6. We have investigated whether segment polarity genes with a wingless-like phenotype mediate the wingless signal. We used a wingless transgene controlled by a heat-shock promoter for genetic epistasis experiments. We show that wingless acts through dishevelled and armadillo to affect the expression of the homeobox gene engrailed and cuticle differentiation.	STANFORD UNIV, HOWARD HUGHES MED INST, STANFORD, CA 94305 USA; STANFORD UNIV, DEPT DEV BIOL, STANFORD, CA 94305 USA; HARVARD UNIV, SCH MED, HOWARD HUGHES MED INST, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT GENET, BOSTON, MA 02115 USA	Howard Hughes Medical Institute; Stanford University; Stanford University; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Harvard Medical School				Perrimon, Norbert/0000-0001-7542-472X				ARIAS AM, 1988, DEVELOPMENT, V103, P157; BAKER NE, 1987, EMBO J, V6, P1765, DOI 10.1002/j.1460-2075.1987.tb02429.x; BEJSOVEC A, 1991, DEVELOPMENT, V113, P471; BOUROUIS M, 1990, EMBO J, V9, P2877, DOI 10.1002/j.1460-2075.1990.tb07477.x; CABRERA CV, 1987, CELL, V50, P659, DOI 10.1016/0092-8674(87)90039-0; CHOU TB, 1992, GENETICS, V131, P643; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; DOUGAN S, 1992, NATURE, V360, P347, DOI 10.1038/360347a0; EBERL DF, 1992, GENETICS, V130, P569; GONZALEZ F, 1991, MECH DEVELOP, V35, P43, DOI 10.1016/0925-4773(91)90040-D; HEEMSKERK J, 1991, NATURE, V352, P404, DOI 10.1038/352404a0; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; KANIA MA, 1990, GENE DEV, V4, P1701, DOI 10.1101/gad.4.10.1701; KLINGENSMITH J, 1989, DEV BIOL, V134, P130, DOI 10.1016/0012-1606(89)90084-5; KLINGENSMITH J, IN PRESS GENES DEV; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; MCMAHON AP, 1992, TRENDS GENET, V8, P236, DOI 10.1016/0168-9525(92)90122-K; MOHLER J, 1988, GENETICS, V120, P1061; NOORDERMEER J, 1992, DEVELOPMENT, V116, P711; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; PERRIMON N, 1987, DEV BIOL, V119, P587, DOI 10.1016/0012-1606(87)90061-3; RIGGLEMAN B, 1990, CELL, V63, P549, DOI 10.1016/0092-8674(90)90451-J; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; SAMPEDRO J, 1993, DEVELOPMENT, V117, P677; SIEGFRIED E, 1992, CELL, V71, P1167, DOI 10.1016/S0092-8674(05)80065-0; SIEGFRIED E, 1990, NATURE, V345, P825, DOI 10.1038/345825a0; SIEGFRIED E, 1994, NATURE, V367, P76, DOI 10.1038/367076a0; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; VANDENHEUVEL M, IN PRESS EMBO J; WIESCHAUS E, 1987, CELL, V49, P177, DOI 10.1016/0092-8674(87)90558-7; Wieschaus E., 1986, DROSOPHILA PRACTICAL	33	332	335	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 6	1994	367	6458					80	83		10.1038/367080a0	http://dx.doi.org/10.1038/367080a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MP865	7906389				2022-12-24	WOS:A1994MP86500064
J	HORIE, S; HIGASHIHARA, E; NUTAHARA, K; MIKAMI, Y; OKUBO, A; KANO, M; KAWABE, K				HORIE, S; HIGASHIHARA, E; NUTAHARA, K; MIKAMI, Y; OKUBO, A; KANO, M; KAWABE, K			MEDIATION OF RENAL CYST FORMATION BY HEPATOCYTE GROWTH-FACTOR	LANCET			English	Note							CELLS	Hepatocyte growth factor (HGF) is a potent mitogen for renal tubular cells, and HGF and its receptor (c-met proto-oncogene product, Met) can induce lumen formation in epithelial cells. We measured the concentration of HGF in cyst fluids from patients with renal cystic diseases. The concentration of HGF was high in proximal cyst fluid (mean 2.45 vs 0.42 ng/mL in distal cysts). Cyclic AMP concentration was higher in distal than in proximal cysts (663 vs 6.0 pmol/L). mRNA of HGF and Met were cc-expressed in cyst walls from cases with polycystic kidney disease. These findings suggest that HGF is a growth factor that may mediate human renal cyst genesis.	UNIV TOKYO,FAC MED,DEPT LAB MED,TOKYO 113,JAPAN; KYORIN UNIV,FAC MED,DEPT UROL,TOKYO,JAPAN	University of Tokyo; Kyorin University	HORIE, S (corresponding author), UNIV TOKYO,FAC MED,DEPT UROL,BUNKYO KU,7-3-1 HONGO,TOKYO 113,JAPAN.							GRANTHAM JJ, 1993, ADV INTERNAL MED, V38, P409; HUSEMAN R, 1980, KIDNEY INT, V18, P375, DOI 10.1038/ki.1980.148; Maniatis T., 1982, MOL CLONING; MATSUMOTO K, 1992, Critical Reviews in Oncogenesis, V3, P27; MATSUNAGA T, 1994, EXP CELL RES, V210, P326, DOI 10.1006/excr.1994.1045; NEUFELD TK, 1992, KIDNEY INT, V41, P1222, DOI 10.1038/ki.1992.184; TSARFATY I, 1994, SCIENCE, V263, P98, DOI 10.1126/science.7505952; TSARFATY I, 1992, SCIENCE, V152, P802; TSUBOUCHI H, 1992, LANCET, V340, P307, DOI 10.1016/0140-6736(92)92396-W; WILSON SE, 1993, INVEST OPHTH VIS SCI, V34, P2544	10	48	49	1	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 17	1994	344	8925					789	791		10.1016/S0140-6736(94)92344-2	http://dx.doi.org/10.1016/S0140-6736(94)92344-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PG178	7916076				2022-12-24	WOS:A1994PG17800013
J	ADAM, IJ; MOHAMDEE, MO; MARTIN, IG; SCOTT, N; FINAN, PJ; JOHNSTON, D; DIXON, MF; QUIRKE, P				ADAM, IJ; MOHAMDEE, MO; MARTIN, IG; SCOTT, N; FINAN, PJ; JOHNSTON, D; DIXON, MF; QUIRKE, P			ROLE OF CIRCUMFERENTIAL MARGIN INVOLVEMENT IN THE LOCAL RECURRENCE OF RECTAL-CANCER	LANCET			English	Article							MESORECTAL EXCISION; SURVIVAL; RESECTION; CLEARANCE; SURGERY; SPREAD	Local recurrence after resection for rectal cancer remains common despite growing acceptance that inadequate local excision may be implicated. In a prospective study of 190 patients with rectal cancer, we examined the circumferential margin of excision of resected specimens for tumour presence, to examine its frequency and its relation to subsequent local recurrence. Tumour involvement of the circumferential margin was seen in 25% (35/141) of specimens for which the surgeon thought the resection was potentially curative, and in 36% (69/190) of all cases. After a median 5 years' follow-up (range 3.0-7.7 years), the frequency of local recurrence after potentially curative resection was 25% (95% Cl 18-33%). The frequency of local recurrence was significantly higher for patients who had had tumour involvement of the circumferential margin than for those without such involvement (78 [95% Cl 62-94] vs 10 [4-16]%). By Cox's regression analysis tumour involvement of the circumferential margin independently influenced both local recurrence (hazard ratio=12.2 [4.4-34.6]) and survival (3.2 [1.6-6.53]). These results show the importance of wide local excision during resection for rectal cancer, and the need for routine assessment of the circumferential margin to assess significant influence on survival, whereas the other prognosis.	GEN INFIRM,CTR DIGEST DIS,ACAD UNIT PATHOL SCI,LEEDS LS1 3EX,W YORKSHIRE,ENGLAND; GEN INFIRM,CTR DIGEST DIS,ACAD SURG UNIT,LEEDS LS1 3EX,W YORKSHIRE,ENGLAND	Leeds General Infirmary; University of Leeds; Leeds General Infirmary; University of Leeds			Quirke, Philip/AAI-1362-2019	Quirke, Philip/0000-0002-3597-5444				ABULAFI AM, 1994, BRIT J SURG, V81, P7, DOI 10.1002/bjs.1800810106; CAWTHORN SJ, 1990, LANCET, V335, P1055, DOI 10.1016/0140-6736(90)92631-Q; CHAN KW, 1985, HISTOPATHOLOGY, V9, P1319, DOI 10.1111/j.1365-2559.1985.tb02813.x; COX DR, 1972, J R STAT SOC B, V34, P187; DUKES CE, 1932, J PATHOL BACTERIOL, V35, P330; FIELDING LP, 1978, LANCET, V2, P778; FISHER B, 1988, JNCI-J NATL CANCER I, V80, P21, DOI 10.1093/jnci/80.1.21; Gordon-Watson C, 1938, LANCET, V1, P239; HEALD RJ, 1986, LANCET, V1, P1479; JASS JR, 1987, LANCET, V1, P1303; MACFARLANE JK, 1993, LANCET, V341, P457, DOI 10.1016/0140-6736(93)90207-W; MCARDLE CS, 1991, BRIT MED J, V302, P1501, DOI 10.1136/bmj.302.6791.1501; MORSON BC, 1963, BMJ-BRIT MED J, P13, DOI 10.1136/bmj.2.5348.13; NG IOL, 1993, CANCER-AM CANCER SOC, V71, P1972, DOI 10.1002/1097-0142(19930315)71:6<1972::AID-CNCR2820710608>3.0.CO;2-V; PETO R, 1973, BIOMETRICS, V29, P579, DOI 10.2307/2529177; PHILLIPS RKS, 1984, BRIT J SURG, V71, P12, DOI 10.1002/bjs.1800710104; POWERS WE, 1964, NATURE, V201, P172; QUIRKE P, 1986, LANCET, V2, P996, DOI 10.1016/s0140-6736(86)92612-7; QUIRKE P, 1988, INT J COLORECTAL DIS, V3, P127, DOI 10.1007/BF01645318; WILLIAMSON RCN, 1982, GUT, V23, P316, DOI 10.1136/gut.23.4.316; 1987, AM J CLIN ONCOL-CANC, V10, P369; 1990, LANCET, V335, P1067	22	772	794	0	15	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 10	1994	344	8924					707	711		10.1016/S0140-6736(94)92206-3	http://dx.doi.org/10.1016/S0140-6736(94)92206-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PF187	7915774				2022-12-24	WOS:A1994PF18700008
J	MARSHALL, H; STUDER, M; POPPERL, H; APARICIO, S; KUROIWA, A; BRENNER, S; KRUMLAUF, R				MARSHALL, H; STUDER, M; POPPERL, H; APARICIO, S; KUROIWA, A; BRENNER, S; KRUMLAUF, R			A CONSERVED RETINOIC ACID RESPONSE ELEMENT REQUIRED FOR EARLY EXPRESSION OF THE HOMEOBOX GENE HOXB-1	NATURE			English	Article							CENTRAL-NERVOUS-SYSTEM; XENOPUS EMBRYOS; MOUSE HINDBRAIN; PATTERN; IDENTIFICATION; HOX-2.9; TRANSFORMATION; SEGMENTATION; RHOMBOMERES; RECEPTORS	WITHIN the Herb homeobox gene complex, Hoxb-1 is the earliest member expressed in the mesoderm and neuroectoderm of primitive streak and presomite embryos, preceding rhombomere-restricted expression in the hindbrain(1-7). Ectopic exposure of embryos to retinoic acid alters spatial aspects of Hox gene expression patterns(8-15). However, the role of retinoids in regulating these genes during normal development is unclear. We have now identified two enhancers, 3' of the mouse Hoxb-1 gene, which together reconstruct the early endogenous expression pattern and mediate the early ectopic response to retinoic acid. Furthermore, these regions are functionally conserved in both chicken and pufferfish (Fugu rubripes)(16) Hoxb-1 genes. The enhancer that controls the retinoic acid response, and regulates expression predominantly in neuroectoderm, contains a retinoic acid response element (RARE). Point mutations in the RARE abolish expression in neuroectoderm. Therefore, this RARE is not only involved in the ectopic response to retinoic acid, but is also essential for establishing aspects of the early Hoxb-1 expression pattern.	NATL INST MED RES,DEV NEUROBIOL LAB,LONDON NW7 1AA,ENGLAND; UNIV CAMBRIDGE,ADDENBROOKES HOSP,SCH CLIN,MOLEC GENET UNIT,CAMBRIDGE CB2 2QQ,ENGLAND; UNIV CAMBRIDGE,ADDENBROOKES HOSP,SCH CLIN,DEPT MED,CAMBRIDGE CB2 2QQ,ENGLAND; NAGOYA UNIV,SCH SCI,DEPT MOLEC BIOL,CHIKUSA KU,NAGOYA 46401,JAPAN	MRC National Institute for Medical Research; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Nagoya University			Krumlauf, Robb/AAH-5012-2019; Studer, Michele/P-4580-2016	Krumlauf, Robb/0000-0001-9102-7927; Studer, Michele/0000-0001-7105-2957; Aparicio, Samuel/0000-0002-0487-9599; Kuroiwa, Atsushi/0000-0001-7710-4041				ALTABA ARI, 1991, GENE DEV, V5, P175, DOI 10.1101/gad.5.2.175; ALTABA ARI, 1991, DEVELOPMENT, V112, P945; BRENNER S, 1993, NATURE, V366, P265, DOI 10.1038/366265a0; CONLON RA, 1992, DEVELOPMENT, V116, P357; DOLLE P, 1989, NATURE, V342, P767, DOI 10.1038/342767a0; DURSTON AJ, 1989, NATURE, V340, P140, DOI 10.1038/340140a0; FROHMAN MA, 1990, DEVELOPMENT, V110, P589; GUTHRIE S, 1992, NATURE, V356, P157, DOI 10.1038/356157a0; HOLDER N, 1991, DEVELOPMENT, V113, P1159; IZPISUABELMONTE JC, 1991, NATURE, V350, P585, DOI 10.1038/350585a0; KESSEL M, 1993, NEURON, V10, P379, DOI 10.1016/0896-6273(93)90328-O; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; LANGSTON AW, 1992, MECH DEVELOP, V38, P217, DOI 10.1016/0925-4773(92)90055-O; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; MADEN M, 1991, DEVELOPMENT, V111, P35; MARSHALL H, 1992, NATURE, V360, P737, DOI 10.1038/360737a0; MORRISSKAY GM, 1991, EMBO J, V10, P2985, DOI 10.1002/j.1460-2075.1991.tb07849.x; MURPHY P, 1989, NATURE, V341, P156, DOI 10.1038/341156a0; MURPHY P, 1991, DEVELOPMENT, V111, P61; PAPALOPULU N, 1991, DEVELOPMENT, V113, P1145; POPPERL H, 1993, MOL CELL BIOL, V13, P257; SIVE HL, 1991, GENE DEV, V5, P1321, DOI 10.1101/gad.5.8.1321; SIVE HL, 1990, GENE DEV, V4, P932, DOI 10.1101/gad.4.6.932; STUNNENBERG HG, 1993, BIOESSAYS, V15, P309, DOI 10.1002/bies.950150504; SUNDIN O, 1992, DEVELOPMENT, V114, P841; SUNDIN OH, 1990, GENE DEV, V4, P1267, DOI 10.1101/gad.4.8.1267; WHITING J, 1991, GENE DEV, V5, P2048, DOI 10.1101/gad.5.11.2048; WILKINSON DG, 1989, NATURE, V341, P405, DOI 10.1038/341405a0; YEE SP, 1993, GENE DEV, V7, P1277, DOI 10.1101/gad.7.7a.1277	30	388	390	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 18	1994	370	6490					567	571		10.1038/370567a0	http://dx.doi.org/10.1038/370567a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PC537	7914354				2022-12-24	WOS:A1994PC53700058
J	HUTTON, JL; COOKE, T; PHAROAH, POD				HUTTON, JL; COOKE, T; PHAROAH, POD			LIFE EXPECTANCY IN CHILDREN WITH CEREBRAL-PALSY	BRITISH MEDICAL JOURNAL			English	Article							MENTAL-RETARDATION; BIRTH-WEIGHT; TRENDS; SURVIVAL; HANDICAPS; FINLAND; PEOPLE; AGE	Objective-To determine life expectancy of children with cerebral palsy. Design-Cohort analysis, by means of register compiled from multiple sources of ascertainment, of all children with cerebral palsy born during 1966-84 to mothers resident in Mersey region. Status of children was determined by flagging through NHS central register. Subjects-1258 subjects with idiopathic cerebral palsy, of whom 1251 were traced and included in analysis. Main outcome measures-Effect of functional ability (ambulation, manual dexterity, and mental ability), sex, birth weight, and gestational age on survival. Results-20 year survival for whole cohort was 89.3% for females and 86.9% for males. For subjects with no severe functional disabilities 20 year survival was 99% (95% confidence interval 98% to 100%), while subjects severely disabled in all three functional groups had 20 year survival of 50% (42% to 58%). Subjects with birth weight less than or equal to 2500 g had 20 year survival of 92% (89% to 95%), while those with birth weight >2500 g had survival of 87% (84% to 89%). Subjects with gestational age of >37 weeks had 20 year survival of 93% (91% to 96%), white those with gestational age greater than or equal to 37 weeks had survival of 85% (83% to 88%). Birth weight and gestational age were less predictive of survival than functional disability. Best statistical model used gestational age and number of severe functional disabilities as predictors. Conclusions-Life expectancy of this cohort of children with cerebral palsy was greater than has been suggested in some previous studies. This has important implications for social, educational, and health services.	UNIV LIVERPOOL,DEPT PUBL HLTH,LIVERPOOL L69 3BX,ENGLAND; UNIV LIVERPOOL,DEPT STAT,LIVERPOOL L69 3BX,ENGLAND; UNIV LIVERPOOL,DEPT COMPUTAT MATH,LIVERPOOL L69 3BX,ENGLAND	University of Liverpool; University of Liverpool; University of Liverpool								BAIRD PA, 1987, J PEDIATR-US, V110, P849, DOI 10.1016/S0022-3476(87)80395-5; BALAKRISHNAN TR, 1976, AM J MENT DEF, V80, P650; COX DR, 1984, ANAL SURVIVAL DATA, P53; COX DR, 1982, THEORETICAL STATISTI, P92; Dayton NA, 1932, NEW ENGL J MED, V206, P555, DOI 10.1056/NEJM193203172061103; DOWDING VM, 1988, IRISH MED J, V81, P25; EVANS PM, 1990, ARCH DIS CHILD, V65, P1329, DOI 10.1136/adc.65.12.1329; EYMAN RK, 1993, AM J DIS CHILD, V147, P329, DOI 10.1001/archpedi.1993.02160270091029; EYMAN RK, 1990, NEW ENGL J MED, V323, P584, DOI 10.1056/NEJM199008303230906; HAGBERG B, 1989, ACTA PAEDIATR SCAND, V78, P283, DOI 10.1111/j.1651-2227.1989.tb11071.x; HAGBERG B, 1984, ACTA PAEDIATR SCAND, V73, P433, DOI 10.1111/j.1651-2227.1984.tb09951.x; KUDRJAVCEV T, 1985, NEUROLOGY, V35, P900, DOI 10.1212/WNL.35.6.900; PHAROAH POD, 1990, ARCH DIS CHILD, V65, P602, DOI 10.1136/adc.65.6.602; PHAROAH POD, 1987, ARCH DIS CHILD, V62, P379, DOI 10.1136/adc.62.4.379; RIIKONEN R, 1989, ACTA PAEDIATR SCAND, V78, P581, DOI 10.1111/j.1651-2227.1989.tb17940.x; SAHAMOTO Y, 1986, AKAIKE INFORMATION C; STANLEY FJ, 1992, BRIT MED J, V304, P1658, DOI 10.1136/bmj.304.6843.1658; VONWENDT L, 1985, ANN CLIN RES, V17, P156; 1979, OPCS SERIES DS, V2; 1989, SAS STAT USERS GUIDE, V2, P997	20	119	125	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 13	1994	309	6952					431	435		10.1136/bmj.309.6952.431	http://dx.doi.org/10.1136/bmj.309.6952.431			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PC404	7920125	Green Published			2022-12-24	WOS:A1994PC40400015
J	WINLAW, DS; SMYTHE, GA; KEOGH, AM; SCHYVENS, CG; SPRATT, PM; MACDONALD, PS				WINLAW, DS; SMYTHE, GA; KEOGH, AM; SCHYVENS, CG; SPRATT, PM; MACDONALD, PS			INCREASED NITRIC-OXIDE PRODUCTION IN HEART-FAILURE	LANCET			English	Note								The role of nitric oxide in heart failure is unknown. The high-capacity inducible isoform of nitric oxide synthase is present in the myocardium of patients with idiopathic dilated cardiomyopathy. Plasma nitrate, the stable end-product of nitric oxide production, was significantly increased in patients with heart failure compared with normal controls (means 51.3 and 24.6 mu mol/L). Vasodilation caused by increased nitric oxide may compensate for the vasoconstrictor effect of neurohumoral adaptions to heart failure. Alternatively, excess production may be detrimental to the heart by a direct negative inotropic effect.	ST VINCENTS HOSP,VICTOR CHANG CARDIAC RES INST,DEPT CARDIOPULM TRANSPLANTAT,SYDNEY,NSW 2010,AUSTRALIA; ST VINCENTS HOSP,VICTOR CHANG CARDIAC RES INST,DEPT CHEM PATHOL,SYDNEY,NSW 2010,AUSTRALIA	St Vincents Hospital Sydney; Victor Chang Cardiac Research Institute; St Vincents Hospital Sydney; Victor Chang Cardiac Research Institute			Macdonald, Peter/Q-3188-2019; Winlaw, David S/F-8365-2016; Winlaw, David/B-9405-2019	Winlaw, David S/0000-0001-8005-3361; Winlaw, David/0000-0001-8005-3361				DEBELDER AJ, 1993, LANCET, V341, P84, DOI 10.1016/0140-6736(93)92559-C; DREXLER H, 1992, AM J CARDIOL, V69, P1596, DOI 10.1016/0002-9149(92)90710-G; EVANS HG, 1993, CARDIOVASC RES, V27, P1486, DOI 10.1093/cvr/27.8.1486; FINKEL MS, 1992, SCIENCE, V257, P387, DOI 10.1126/science.1631560; GREEN LC, 1981, P NATL ACAD SCI-BIOL, V78, P7764, DOI 10.1073/pnas.78.12.7764; LANGREHR JM, 1992, J CLIN INVEST, V90, P679, DOI 10.1172/JCI115911; LEVINE B, 1990, NEW ENGL J MED, V323, P236, DOI 10.1056/NEJM199007263230405; MONCADA S, 1992, ACTA PHYSIOL SCAND, V145, P201, DOI 10.1111/j.1748-1716.1992.tb09359.x; TAKAHASHI H, 1992, J CARDIOVASC PHARM, V20, pS214, DOI 10.1097/00005344-199204002-00061	9	217	223	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 6	1994	344	8919					373	374		10.1016/S0140-6736(94)91403-6	http://dx.doi.org/10.1016/S0140-6736(94)91403-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PA303	7914309				2022-12-24	WOS:A1994PA30300012
J	TAS, S; ABDELLA, NA				TAS, S; ABDELLA, NA			BLOOD-PRESSURE, CORONARY-ARTERY DISEASE, AND GLYCEMIC CONTROL IN TYPE-2 DIABETES-MELLITUS - RELATION TO APOLIPOPROTEIN-CIII GENE POLYMORPHISM	LANCET			English	Note							APO-CIII; HYPERTRIGLYCERIDEMIA; MECHANISM	The apolipoprotein CIII allele S2 is associated with hypertriglyceridaemia and myocardial infarction. 15 subjects with type 2 diabetes mellitus and the S2 allele had significantly greater systolic blood pressure than 48 without this allele (mean 142 [SD 10]) vs 129 [14] mm Hg), despite being on antihypertensives more frequently. S2 patients showed better glycaemic control (glycated haemoglobin [HbA(1C)] 8.4 [2.0] vs 9.9 [2.0]%). Stepwise multiple regression indicated S2 as an independent predictor of both blood pressure and HbA(1C). These findings suggest mechanisms for relations between glucose and triglyceride metabolism and blood pressure.	KUWAIT UNIV,FAC MED,DEPT PATHOL,KUWAIT,KUWAIT; KUWAIT UNIV,FAC MED,DEPT MED,KUWAIT,KUWAIT; MUBARAK AL KABEER HOSP,DEPT CLIN LABS,KUWAIT,KUWAIT; MUBARAK AL KABEER HOSP,DEPT MED,KUWAIT,KUWAIT	Kuwait University; Kuwait University; Mubarak Al-Kabeer Hospital; Mubarak Al-Kabeer Hospital								AALTOSETALA K, 1992, J CLIN INVEST, V90, P1889, DOI 10.1172/JCI116066; DAMMERMAN M, 1993, P NATL ACAD SCI USA, V90, P4562, DOI 10.1073/pnas.90.10.4562; DEFRONZO RA, 1991, DIABETES CARE, V14, P173, DOI 10.2337/diacare.14.3.173; FELBER JP, 1990, HORM METAB RES, V22, P11; GINSBERG HN, 1986, J CLIN INVEST, V78, P1287, DOI 10.1172/JCI112713; OBRIEN T, 1993, MAYO CLIN PROC, V68, P141, DOI 10.1016/S0025-6196(12)60161-X; SHOULDERS CC, 1991, ATHEROSCLEROSIS, V87, P239, DOI 10.1016/0021-9150(91)90026-Y; TAS S, 1989, CLIN CHEM, V35, P256; TAS S, 1991, LANCET, V337, P113, DOI 10.1016/0140-6736(91)90770-P; TAS S, 1990, CLIN CHEM, V36, P1825	10	22	22	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 14	1994	343	8907					1194	1195		10.1016/S0140-6736(94)92402-3	http://dx.doi.org/10.1016/S0140-6736(94)92402-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NL175	7909870				2022-12-24	WOS:A1994NL17500011
J	KANKI, PJ; TRAVERS, KU; MBOUP, S; HSIEH, CC; MARLINK, RG; GUEYENDIAYE, A; SIBY, T; THIOR, I; HERNANDEZAVILA, M; SANKALE, JL; NDOYE, I; ESSEX, ME				KANKI, PJ; TRAVERS, KU; MBOUP, S; HSIEH, CC; MARLINK, RG; GUEYENDIAYE, A; SIBY, T; THIOR, I; HERNANDEZAVILA, M; SANKALE, JL; NDOYE, I; ESSEX, ME			SLOWER HETEROSEXUAL SPREAD OF HIV-2 THAN HIV-1	LANCET			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-2; VERTICAL TRANSMISSION; WEST-AFRICA; AIDS; INFECTION	Because of the similar virological properties of HIV types 1 and 2, HIV-2 was assumed to be as infectious and capable of inducing AIDS as HIV-1. Seroepidemiological studies have shown significant rates of HIV-2 infection in West Africa, and surveys from other regions of the world indicate that the spread of HIV-2 infection continues. However the pathogenic potential of HIV-2 is considered to be lower than that of HIV-1. It is therefore important to understand the transmission properties of HIV-2 and its contribution to the AIDS pandemic. Since 1985, we have prospectively studied 1452 registered female prostitutes in Dakar, Senegal, with sequential evaluation of their antibody status to HIV-1 and HIV-2. During the study the overall incidence of HIV-1 and HIV-2 was the same (1-11 per 100 person-years of observation [pyo]). However, the annual incidence of HIV-1 increased substantially: there was a 1.4-fold increased risk per year and thus a 12-fold increase in risk over the entire study period. The incidence of HIV-2 remained stable, despite higher HIV-2 prevalence. In our population the heterosexual spread of HIV-2 is significantly slower than that of HIV-1, which strongly suggests differences in the viruses' infectivity potential.	NATL INST PUBL HLTH,CUERNAVACA,MEXICO; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115; UNIV CHEIKH ANTA DIOP,VIROL & BACTERIOL LAB,DAKAR,SENEGAL; INST SOCIAL HYG,DAKAR,SENEGAL	Instituto Nacional de Salud Publica; Harvard University; Harvard T.H. Chan School of Public Health; University Cheikh Anta Diop Dakar	KANKI, PJ (corresponding author), HARVARD UNIV,SCH PUBL HLTH,DEPT CANC BIOL,BOSTON,MA 02115, USA.			Travers, Karin/0000-0002-9097-1710; Essex, M./0000-0002-4576-7841	NCI NIH HHS [CA 39805] Funding Source: Medline; PHS HHS [P01 A1 30795] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA039805] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON RM, 1989, AIDS, V3, P333, DOI 10.1097/00002030-198906000-00001; ANDERSON RM, 1988, NATURE, V333, P514, DOI 10.1038/333514a0; Breslow NE, 1987, STATISTICAL METHODS, P1; CLAVEL F, 1987, NEW ENGL J MED, V316, P1180, DOI 10.1056/NEJM198705073161903; GAYLE HD, 1992, J ACQ IMMUN DEF SYND, V5, P513; KANKI P, 1992, AM J EPIDEMIOL, V136, P895, DOI 10.1093/aje/136.7.895; KINGSLEY LA, 1991, AM J EPIDEMIOL, V134, P331, DOI 10.1093/oxfordjournals.aje.a116094; MARLINK RG, 1988, AIDS RES HUM RETROV, V4, P137, DOI 10.1089/aid.1988.4.137; Marlink Richard, 1994, P47; MATHERON S, 1990, LANCET, V335, P1103, DOI 10.1016/0140-6736(90)92682-8; PLUMMER FA, 1991, J INFECT DIS, V163, P233, DOI 10.1093/infdis/163.2.233; POULSEN AG, 1992, J ACQ IMMUN DEF SYND, V5, P25; ROMIEU I, 1990, J ACQ IMMUN DEF SYND, V3, P220; WINKELSTEIN W, 1987, AM J PUBLIC HEALTH, V76, P685; 1990, WKLY EPIDEMIOL REC, V65, P281	15	282	290	0	16	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 16	1994	343	8903					943	946		10.1016/S0140-6736(94)90065-5	http://dx.doi.org/10.1016/S0140-6736(94)90065-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF700	7909009				2022-12-24	WOS:A1994NF70000009
J	STEEL, C; GUINEA, A; MCCARTHY, JS; OTTESEN, EA				STEEL, C; GUINEA, A; MCCARTHY, JS; OTTESEN, EA			LONG-TERM EFFECT OF PRENATAL EXPOSURE TO MATERNAL MICROFILAREMIA ON IMMUNE RESPONSIVENESS TO FILARIAL PARASITE ANTIGENS	LANCET			English	Article							LYMPHATIC FILARIASIS; ONCHOCERCA-VOLVULUS; ENDEMIC FILARIASIS; BRUGIA-PAHANGI; PACIFIC ISLAND; INFECTION; UNRESPONSIVENESS; SENSITIZATION; RESPONSES; TOLERANCE	To identify long-term effects of prenatal exposure to maternal filarial-parasite infection, we assessed lymphocyte responses in 21 Polynesian children born 17-19 years previously to mothers diagnosed as being microfilaraemic or infection-free. All children lived on an island endemic for bancroftian filariasis but were free from infection at the ti me of study. While children (n = 10) of infection-free mothers responded vigorously to microfilarial antigen with lymphocyte proliferation, production of interleukin 2 (IL-2), IL-5, IL-10, granulocyte macrophage colony-stimulating factor (GM-CSF), and interferon gamma (IFN-gamma), cellular hyporesponsiveness was seen in children (n = 11) born to microfilaraemic mothers. The hyporesponsiveness appeared restricted to microfilarial antigens and did not extend to non-parasite antigens. These findings suggest that hyporesponsiveness resulted from in-utero acquisition of tolerance to microfilarial antigens in chronically-infected mothers.	HLTH DEPT,MAUKE,COOK ISLANDS		STEEL, C (corresponding author), NIH,PARASIT DIS LAB,BLDG 4 ROOM 126,BETHESDA,MD 20892, USA.		McCarthy, James S/C-1681-2009	McCarthy, James/0000-0001-6596-9718				BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; ELOISANTOS SM, 1989, J CLIN INVEST, V84, P1028, DOI 10.1172/JCI114225; GIMMI CD, 1993, P NATL ACAD SCI USA, V90, P6586, DOI 10.1073/pnas.90.14.6586; GUSMAO RD, 1981, EXP PARASITOL, V52, P147, DOI 10.1016/0014-4894(81)90070-9; HAQUE A, 1988, EUR J IMMUNOL, V18, P1167, DOI 10.1002/eji.1830180804; HAQUE A, 1982, NATURE, V299, P361, DOI 10.1038/299361a0; KAUSHAL NA, 1984, CLIN EXP IMMUNOL, V56, P567; KING CL, 1992, J CLIN INVEST, V89, P1403, DOI 10.1172/JCI115729; KING CL, 1993, J CLIN INVEST, V92, P1667, DOI 10.1172/JCI116752; KLEI TR, 1986, T ROY SOC TROP MED H, V80, P214, DOI 10.1016/0035-9203(86)90014-3; KLION AD, 1991, J INFECT DIS, V163, P1318, DOI 10.1093/infdis/163.6.1318; LAMMIE PJ, 1991, LANCET, V337, P1005, DOI 10.1016/0140-6736(91)92661-K; NUTMAN TB, 1987, J CLIN INVEST, V79, P1516, DOI 10.1172/JCI112982; NUTMAN TB, 1987, J IMMUNOL, V138, P3954; OTTESEN E A, 1989, American Journal of Tropical Medicine and Hygiene, V41, P9; OTTESEN EA, 1977, IMMUNOLOGY, V33, P413; OTTESEN EA, 1981, ACTA TROP, V38, P205; OTTESEN EA, 1985, J IMMUNOL, V134, P2707; OTTESEN EA, 1982, AM J TROP MED HYG, V31, P953, DOI 10.4269/ajtmh.1982.31.953; PARTONO F, 1978, AM J TROP MED HYG, V27, P910, DOI 10.4269/ajtmh.1978.27.910; PETRALANDA I, 1988, AM J TROP MED HYG, V38, P372, DOI 10.4269/ajtmh.1988.38.372; PIESSENS WF, 1980, J CLIN INVEST, V65, P172, DOI 10.1172/JCI109648; PROST A, 1979, TROPENMED PARASITOL, V30, P477; RAGHAVAN N. G. S., 1958, Bulletin of the National Society of India for Malaria and Other Mosquito-Borne Diseases, V6, P147; STEEL C, 1991, J INFECT DIS, V164, P581, DOI 10.1093/infdis/164.3.581; WARTMAN WB, 1947, MEDICINE, V12, P181; WEIL GJ, 1983, J CLIN INVEST, V71, P1124, DOI 10.1172/JCI110862; WEIL GJ, 1987, J INFECT DIS, V156, P350, DOI 10.1093/infdis/156.2.350; WELLER PF, 1982, AM J TROP MED HYG, V31, P942, DOI 10.4269/ajtmh.1982.31.942; ZIMMERMAN PA, 1993, NUCLEIC ACIDS RES, V21, P4541, DOI 10.1093/nar/21.19.4541	30	134	134	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 9	1994	343	8902					890	893		10.1016/S0140-6736(94)90009-4	http://dx.doi.org/10.1016/S0140-6736(94)90009-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF213	7908359				2022-12-24	WOS:A1994NF21300009
J	VANEIJCK, CHJ; KRENNING, EP; BOOTSMA, A; OEI, HY; VANPEL, R; LINDEMANS, J; JEEKEL, J; REUBI, JC; LAMBERTS, SWJ				VANEIJCK, CHJ; KRENNING, EP; BOOTSMA, A; OEI, HY; VANPEL, R; LINDEMANS, J; JEEKEL, J; REUBI, JC; LAMBERTS, SWJ			SOMATOSTATIN RECEPTOR SCINTIGRAPHY IN PRIMARY BREAST-CANCER	LANCET			English	Article							EPIDERMAL GROWTH-FACTOR; ENDOCRINE TUMORS; LOCALIZATION; CARCINOMAS; INHIBITION; HORMONE; INVIVO; ANALOG; SANDOSTATIN; TISSUE	Somatostatin-receptor (SS-R) scintigraphy successfully shows primary cancers and distant metastases in most patients with carcinoids, islet cells tumours, and paragangliomas. Previous in-vitro studies indicated that somatostatin receptors are present in human breast cancers. We report positive scintigraphy with [In-111-DTPA-D-Phe(1)]-octreotide in 39 of 52 primary breast cancers (75%). Parallel in-vitro autoradiography with [I-125-Tyr(3)]-octreotide of 30 of these showed a corresponding somatostatin-receptor status in 28. Significantly more invasive ductal cancers could be shown than invasive lobular carcinomas (85% vs 56%; p < 0.05). Also the number of T-1 cancers which were shown was higher than T-1 (86% vs 61%; p < 0.05). Imaging of the axillae showed non-palpable cancer-containing lymphnodes in 4 of 13 patients with subsequently histologically-proven metastases. In the follow-up after a mean of 2.5 yr, SS-R scintigraphy in 28 of the 37 patients with an originally SS-R-positive cancer, was positive in the 2 patients with clinically-recognised metastases, as well as in 6 of the remaining 26 patients who were symptom-free. Raised carcinoembryonic antigent (CEA) and CA 15-3 values were observed in only 2 and 1, respectively, of these patients. Most primary breast cancers can be shown by SS-R scintigraphy, especially invasive ductal cancers. This technique may be of value in selecting patients for clinical trials with somatostatin analogues or other medical treatments. Furthermore, SS-R scintigraphy is more sensitive than measurements of the usual serum cancer markers for detecting recurrences of SS-R-positive breast cancer.	ERASMUS UNIV ROTTERDAM,DEPT MED,ROTTERDAM,NETHERLANDS; ERASMUS UNIV ROTTERDAM,DEPT NUCL MED,ROTTERDAM,NETHERLANDS; ERASMUS UNIV ROTTERDAM,DEPT CLIN CHEM,ROTTERDAM,NETHERLANDS; ERASMUS UNIV ROTTERDAM,DEPT PATHOL,ROTTERDAM,NETHERLANDS; UNIV BERN,INST PATHOL,BERN,SWITZERLAND	Erasmus University Rotterdam; Erasmus University Rotterdam; Erasmus University Rotterdam; Erasmus University Rotterdam; University of Bern	VANEIJCK, CHJ (corresponding author), UNIV HOSP DIJKZIGT,DEPT SURG,40 DR MOLEWATERPLEIN,3015 GD ROTTERDAM,NETHERLANDS.		van Eijck, casper/K-5983-2019; Krenning, Eric P/L-1064-2013; Van Eijck, Casper/ABD-1655-2020					BAKKER WH, 1991, LIFE SCI, V49, P1583, DOI 10.1016/0024-3205(91)90052-D; BUSSOLATI G, 1985, AM J PATHOL, V120, P186; COLOMER R, 1989, CANCER, V64, P1674, DOI 10.1002/1097-0142(19891015)64:8<1674::AID-CNCR2820640820>3.0.CO;2-V; FEKETE M, 1989, J CLIN LAB ANAL, V3, P137, DOI 10.1002/jcla.1860030302; FOEKENS JA, 1989, CANCER RES, V49, P7002; HAYNES DF, 1986, J CLIN ONCOL, V4, P1542; KRENNING EP, 1993, EUR J NUCL MED, V20, P716, DOI 10.1007/BF00181765; KRENNING EP, 1989, LANCET, V1, P242; LAMBERTS SWJ, 1990, J CLIN ENDOCR METAB, V71, P566, DOI 10.1210/jcem-71-3-566; LAMBERTS SWJ, 1990, NEW ENGL J MED, V323, P1246, DOI 10.1056/NEJM199011013231805; LAMBERTS SWJ, 1990, METABOLISM, V39, P152, DOI 10.1016/0026-0495(90)90235-5; NELSON J, 1989, BRIT J CANCER, V59, P739, DOI 10.1038/bjc.1989.154; PAPOTTI M, 1989, INT J CANCER, V43, P365, DOI 10.1002/ijc.2910430302; REUBI JC, 1987, CANCER RES, V47, P5758; REUBI JC, 1987, J CLIN ENDOCR METAB, V65, P1127, DOI 10.1210/jcem-65-6-1127; REUBI JC, 1989, CANCER, V64, P1254, DOI 10.1002/1097-0142(19890915)64:6<1254::AID-CNCR2820640615>3.0.CO;2-D; REUBI JC, 1987, CANCER RES, V47, P551; REUBI JC, 1986, NEUROSCIENCE, V18, P329, DOI 10.1016/0306-4522(86)90158-2; REUBI JC, 1990, METABOLISM, V39, P78, DOI 10.1016/0026-0495(90)90217-Z; REUBI JC, 1992, INT J CANCER, V47, P416; SCAMBIA G, 1988, J CANCER RES CLIN, V114, P306, DOI 10.1007/BF00405839; SETYONOHAN B, 1987, CANCER RES, V47, P1566; SZENDE B, 1989, BREAST CANCER RES TR, V14, P307, DOI 10.1007/BF01806302; VANBONMARTENS MJH, 1992, NED TIJDSCHR GENEES, V134, P287; WEBER C, 1989, SURGERY, V106, P416	25	126	128	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 12	1994	343	8898					640	643		10.1016/S0140-6736(94)92637-9	http://dx.doi.org/10.1016/S0140-6736(94)92637-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NA093	7906813	Green Submitted			2022-12-24	WOS:A1994NA09300010
J	LI, G; REGUNATHAN, S; BARROW, CJ; ESHRAGHI, J; COOPER, R; REIS, DJ				LI, G; REGUNATHAN, S; BARROW, CJ; ESHRAGHI, J; COOPER, R; REIS, DJ			AGMATINE - AN ENDOGENOUS CLONIDINE-DISPLACING SUBSTANCE IN THE BRAIN	SCIENCE			English	Article							BIOSYNTHETIC ARGININE DECARBOXYLASE; IMIDAZOLINE-PREFERRING RECEPTORS; VENTROLATERAL MEDULLA; ESCHERICHIA-COLI; BINDING-SITES; ALPHA-2-ADRENERGIC RECEPTOR; BOVINE BRAIN; PURIFICATION; RILMENIDINE; CDS	Clonidine, an antihypertensive drug, binds to alpha(2)-adrenergic and imidazoline receptors. The endogenous ligand for imidazoline receptors may be a clonidine-displacing substance, a small molecule isolated from bovine brain. This clonidine-displacing substance was purified and determined by mass spectroscopy to be agmatine (decarboxylated arginine), here-tofore not detected in brain. Agmatine binds to alpha(2)-adrenergic and imidazoline receptors and stimulates release of catecholamines from adrenal chromaffin cells. Its biosynthetic enzyme, arginine decarboxylase, is present in brain. Agmatine, locally synthesized, is an endogenous agonist at imidazoline receptors, a noncatecholamine ligand at alpha(2)-adrenergic receptors and may act as a neurotransmitter.	CORNELL UNIV,COLL MED,DEPT NEUROL & NEUROSCI,DIV NEUROBIOL,NEW YORK,NY 10021; STERLING WINTHROP PHARMACEUT RES DIV,MALVERN,PA 19355	Cornell University					NHLBI NIH HHS [HL18974] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018974] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ATLAS D, 1991, BIOCHEM PHARMACOL, V41, P1541, DOI 10.1016/0006-2952(91)90152-U; ATLAS D, 1984, EUR J BIOCHEM, V144, P287, DOI 10.1111/j.1432-1033.1984.tb08462.x; BUCH JK, 1985, J BACTERIOL, V163, P522, DOI 10.1128/JB.163.2.522-527.1985; COUPRY I, 1990, J PHARMACOL EXP THER, V252, P293; DIAMANT S, 1987, EUR J PHARMACOL, V144, P247, DOI 10.1016/0014-2999(87)90377-3; DIAMANT S, 1986, BIOCHEM BIOPH RES CO, V134, P184, DOI 10.1016/0006-291X(86)90545-0; EINARSSON S, 1983, J CHROMATOGR, V282, P609, DOI 10.1016/S0021-9673(00)91638-8; ERNSBERGER P, 1990, J PHARMACOL EXP THER, V253, P408; ERNSBERGER P, 1993, J PHARMACOL EXP THER, V264, P172; ERNSBERGER P, 1987, EUR J PHARMACOL, V134, P1, DOI 10.1016/0014-2999(87)90125-7; ERNSBERGER P, 1990, AM J HYPERTENS, V3, P90, DOI 10.1093/ajh/3.2.90; ERNSBERGER P, 1988, BRAIN RES, V441, P309, DOI 10.1016/0006-8993(88)91409-6; FELSEN D, 1987, EUR J PHARMACOL, V142, P453, DOI 10.1016/0014-2999(87)90087-2; GOMEZ RE, 1991, EUR J PHARMACOL, V195, P181, DOI 10.1016/0014-2999(91)90534-W; HIMSWICH WA, 1969, HDB NEUROCHEMISTRY, V1, P33; IVERSEN L, 1969, HDB NEUROCHEMISTRY, V4, P197; KAMISAKI Y, 1990, BRAIN RES, V514, P15, DOI 10.1016/0006-8993(90)90430-J; KAWABATA T, 1978, J AGR FOOD CHEM, V26, P334, DOI 10.1021/jf60216a038; LORING RH, 1990, BRIT J PHARMACOL, V99, P207, DOI 10.1111/j.1476-5381.1990.tb14680.x; MAJUMDER S, 1992, J PARASITOL, V78, P371, DOI 10.2307/3283493; MEELEY MP, 1986, LIFE SCI, V38, P1119, DOI 10.1016/0024-3205(86)90248-1; MEELEY MP, 1989, SOC NEUR ABSTR, V15, P1159; MICHEL MC, 1989, TRENDS PHARMACOL SCI, V10, P342, DOI 10.1016/0165-6147(89)90002-3; MICHEL MC, 1992, TRENDS PHARMACOL SCI, V13, P369; MOORE RC, 1990, J BACTERIOL, V172, P4631, DOI 10.1128/jb.172.8.4631-4640.1990; NICHOLS AJ, 1991, MOL BIOL BIOCH PHARM, P75; PARINI A, 1989, J BIOL CHEM, V264, P11874; QUIK M, 1985, BRAIN RES, V325, P79, DOI 10.1016/0006-8993(85)90304-X; REGUNATHAN S, 1993, BIOCHEM PHARMACOL, V45, P1667, DOI 10.1016/0006-2952(93)90308-J; REGUNATHAN S, 1993, J NEUROSCI RES, V34, P681, DOI 10.1002/jnr.490340611; REGUNATHAN S, 1991, MOL PHARMACOL, V40, P884; SCHAEFFER JM, 1990, BIOCHEM J, V270, P599, DOI 10.1042/bj2700599; SENER A, 1989, BIOCHEM PHARMACOL, V38, P327, DOI 10.1016/0006-2952(89)90044-0; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TESSON F, 1991, J BIOL CHEM, V266, P155; TIBIRICA E, 1991, EUR J PHARMACOL, V209, P213, DOI 10.1016/0014-2999(91)90172-M; WANG H, 1992, MOL PHARMACOL, V42, P762; WEITZEL G, 1980, HOPPESEYLERS Z PHYSL, V36, P51; WIKBERG JES, 1992, PHARMACOL TOXICOL, V70, P208; WU WH, 1973, J BIOL CHEM, V248, P1687	40	653	698	4	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 18	1994	263	5149					966	969		10.1126/science.7906055	http://dx.doi.org/10.1126/science.7906055			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MX165	7906055				2022-12-24	WOS:A1994MX16500035
J	ESRIG, D; ELMAJIAN, D; GROSHEN, S; FREEMAN, JA; STEIN, JP; CHEN, SC; NICHOLS, PW; SKINNER, DG; JONES, PA; COTE, RJ				ESRIG, D; ELMAJIAN, D; GROSHEN, S; FREEMAN, JA; STEIN, JP; CHEN, SC; NICHOLS, PW; SKINNER, DG; JONES, PA; COTE, RJ			ACCUMULATION OF NUCLEAR P53 AND TUMOR PROGRESSION IN BLADDER-CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DISEASE PROGRESSION; ALTERED EXPRESSION; GENE-PRODUCT; MUTATIONS; PROTEIN; OVEREXPRESSION; CHEMOTHERAPY; CYSTECTOMY; CARCINOMA	Background. We have previously demonstrated a strong association between nuclear accumulation of p53 protein, as determined by immunohistochemical analysis, and mutations in the p53 gene. The purpose of this study was to determine the relation between nuclear accumulation of p53 and tumor progression in transitional-cell carcinoma of the bladder. Methods. Histologic specimens of transitional-cell carcinoma of the bladder (stages Pa, noninvasive disease, to P4, disease with direct extension into adjacent organs or structures) from 243 patients who were treated by radical cystectomy were examined for the immunohistochemical detection of p53 protein. Nuclear p53 reactivity was then analyzed in relation to time to recurrence and overall survival. Results. The detection of nuclear p53 was significantly associated with an increased risk of recurrence of bladder cancer (P < 0.001) and with decreased overall survival (P < 0.001). In patients with cancer confined to the bladder, the rates of recurrence for stage P1, P2, and P3a tumors that had no detectable nuclear p53 reactivity at five years were 7, 12, and 11 percent, respectively, as compared with 62, 56, and 80 percent, respectively, for tumors that had p53 immunoreactivity. Similar results were obtained when the presence or absence of p53 in the nuclei of the tumor cells was studied in relation to overall survival. In a multivariable analysis stratified according to grade, pathological stage, and lymph-node status, nuclear p53 status was an independent predictor (and in cancer confined to the bladder, the only independent predictor) of recurrence and overall survival (P < 0.001). Conclusions. In patients with transitional-cell carcinoma confined to the bladder, an accumulation of p53 in the tumor-cell nuclei detected by immunohistochemical methods predicts a significantly increased risk of recurrence and death, independently of tumor grade, stage, and lymph-node status. Patients with transitional-cell carcinoma confined to the bladder that demonstrates nuclear p53 reactivity should be considered for protocols of adjuvant treatment.	UNIV SO CALIF,KENNETH NORRIS JR COMPREHENS CANC CTR,SCH MED,DEPT PATHOL,LOS ANGELES,CA 90033; UNIV SO CALIF,SCH MED,DEPT UROL,LOS ANGELES,CA; UNIV SO CALIF,SCH MED,DEPT PREVENT MED,LOS ANGELES,CA	University of Southern California; University of Southern California; University of Southern California					NCI NIH HHS [P30 CA 14089, R35 CA49758] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA049758, P30CA014089] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bergkvist A, 1965, Acta Chir Scand, V130, P371; CORDONCARDO C, 1994, CANCER RES, V54, P794; CORDONCARDO C, 1992, J NATL CANCER I, V84, P1251, DOI 10.1093/jnci/84.16.1251; ESRIG D, 1993, AM J PATHOL, V143, P1389; FIENBERG SE, 1977, ANAL CROSS CLASSIFIE, P9; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; HERMANEK P, 1987, TNM CLASSIFICATION M, P133; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KASTAN MB, 1991, CANCER RES, V51, P6304; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LIPPONEN PK, 1993, INT J CANCER, V53, P365, DOI 10.1002/ijc.2910530304; LOGOTHETIS CJ, 1992, J NATL CANCER I, V84, P1256, DOI 10.1093/jnci/84.16.1256; MILLER RG, 1981, SURVIVAL ANAL, P44; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; SARKIS AS, 1993, INT J ONCOL, V3, P355; SARKIS AS, 1993, J NATL CANCER I, V85, P53, DOI 10.1093/jnci/85.1.53; SIDRANSKY D, 1992, UROL CLIN N AM, V19, P629; SIDRANSKY D, 1991, SCIENCE, V252, P706, DOI 10.1126/science.2024123; SKINNER DG, 1982, J UROLOGY, V128, P34, DOI 10.1016/S0022-5347(17)52740-8; SKINNER DG, 1991, J UROLOGY, V145, P459, DOI 10.1016/S0022-5347(17)38368-4; SPRUCK CH, 1994, CANCER RES, V54, P784; STOCKLE M, 1992, J UROLOGY, V148, P302, DOI 10.1016/S0022-5347(17)36578-3	23	673	682	0	17	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 10	1994	331	19					1259	1264		10.1056/NEJM199411103311903	http://dx.doi.org/10.1056/NEJM199411103311903			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PP752	7935683				2022-12-24	WOS:A1994PP75200003
J	GHOSH, A; TANG, MHY; LAM, YH; FUNG, E; CHAN, V				GHOSH, A; TANG, MHY; LAM, YH; FUNG, E; CHAN, V			ULTRASOUND MEASUREMENT OF PLACENTAL THICKNESS TO DETECT PREGNANCIES AFFECTED BY HOMOZYGOUS ALPHA-THALASSEMIA-1	LANCET			English	Note							ALPHA-THALASSEMIA; HYDROPS-FETALIS; DIAGNOSIS	Homozygous alpha-thalessaemia-1, a common cause of hydrops fetalis, is usually diagnosed invasively. We measured placental thickness by ultrasound at 10-21 weeks' gestation in 231 at-risk pregnancies. 60 were affected (by DNA analysis). The sensitivity and specificity in detecting affected pregnancies at cut-off of mean placental thickness plus 2 SD before 12 weeks' gestation were 0.72 (95% Cl 0.52-0.93) and 0.97 (0.9-1.0). After 12 weeks sensitivity increased to 0.95 (0.89-1.0) and by 18 weeks reached 1.0 (0.60-0.99) without change in specificity. Selection of pregnancies at risk by measurement of placental thickness will reduce the number of invasive diagnostic procedures.	QUEEN MARY HOSP,DEPT MED,HONG KONG,HONG KONG	University of Hong Kong	GHOSH, A (corresponding author), UNIV HONG KONG,TSAN YUK HOSP,DEPT OBSTET & GYNAECOL,HOSP RD,HONG KONG,HONG KONG.		Tang, Mary Hoi Yin/A-7638-2013; Chan, Vivian/C-4217-2009					CHAN V, 1984, BMJ-BRIT MED J, V288, P1327, DOI 10.1136/bmj.288.6427.1327; GHOSH A, 1987, PRENATAL DIAG, V7, P307, DOI 10.1002/pd.1970070503; HSIEH FJ, 1989, OBSTET GYNECOL, V74, P722; KANOKPONGSAKDI S, 1990, PRENATAL DIAG, V10, P809, DOI 10.1002/pd.1970101208; LEIINJO LE, 1962, BLOOD, V20, P581; LIANG ST, 1985, BRIT J OBSTET GYNAEC, V92, P680, DOI 10.1111/j.1471-0528.1985.tb01447.x; RUBIN EM, 1985, LANCET, V1, P75; THUMASATHIT B, 1986, J PEDIATR, V73, P132; TODD D, 1967, BRIT MED J, V3, P347, DOI 10.1136/bmj.3.5561.347; WEATHERALL DJ, 1970, BRIT J HAEMATOL, V18, P357, DOI 10.1111/j.1365-2141.1970.tb01449.x	10	53	56	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 8	1994	344	8928					988	989		10.1016/S0140-6736(94)91644-6	http://dx.doi.org/10.1016/S0140-6736(94)91644-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PK978	7934433				2022-12-24	WOS:A1994PK97800012
J	JOHN, TJ				JOHN, TJ			LEARNING FROM PLAGUE IN INDIA	LANCET			English	Editorial Material											JOHN, TJ (corresponding author), CHRISTIAN MED COLL & HOSP,DEPT MICROBIOL & VIROL,VELLORE 632004,TAMIL NADU,INDIA.							1994, LANCET, V344, P941	1	13	13	1	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 8	1994	344	8928					972	972		10.1016/S0140-6736(94)91637-3	http://dx.doi.org/10.1016/S0140-6736(94)91637-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PK978	7934426				2022-12-24	WOS:A1994PK97800005
J	SCULLY, C; MORTIMER, P				SCULLY, C; MORTIMER, P			GNASHINGS OF HIV	LANCET			English	Editorial Material							INFECTED DENTIST; DENTAL PRACTICE; TRANSMISSION		PUBL HLTH LAB SERV, LONDON, ENGLAND	Public Health England	SCULLY, C (corresponding author), UCL EASTMAN DENT INST ORAL HEALTHCARE SCI, LONDON, ENGLAND.							ARNOW PM, 1993, PUBLIC HEALTH REP, V108, P273; BLANK S, 1994, LANCET, V344, P512, DOI 10.1016/S0140-6736(94)91900-3; CHANT K, 1993, LANCET, V342, P1548, DOI 10.1016/S0140-6736(05)80112-6; CIESIELSKI C, 1992, ANN INTERN MED, V116, P798, DOI 10.7326/0003-4819-116-10-798; DEBRY RW, 1993, NATURE, V361, P691, DOI 10.1038/361691a0; DICKINSON GM, 1993, JAMA-J AM MED ASSOC, V269, P1802, DOI 10.1001/jama.269.14.1802; GORE SM, 1994, J INFECTION, V28, P209, DOI 10.1016/S0163-4453(94)95740-1; HILLIS DM, 1994, NATURE, V369, P24, DOI 10.1038/369024a0; NACCACHE H, 1993, AIDS PATIENT CARE, V7, P134, DOI 10.1089/apc.1993.7.134; OU CY, 1992, SCIENCE, V256, P1165, DOI 10.1126/science.256.5060.1165; PORTER SR, 1993, BRIT DENT J, V175, P254, DOI 10.1038/sj.bdj.4808292; SCULLY C, 1993, BRIT DENT J, V175, P381, DOI 10.1038/sj.bdj.4808330; SCULLY C, 1993, BRIT MED J, V306, P1754, DOI 10.1136/bmj.306.6894.1754-a; SCULLY C, 1990, BRIT DENTAL J LONDON, P142; SCULLY C, 1994, HLTH TRENDS, V26, P15; YORK AK, 1993, J AM DENT ASSOC, V124, P74, DOI 10.14219/jada.archive.1993.0141	16	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	OCT 1	1994	344	8927					904	904		10.1016/S0140-6736(94)92265-9	http://dx.doi.org/10.1016/S0140-6736(94)92265-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PJ287	7934343				2022-12-24	WOS:A1994PJ28700006
J	STUDER, M; POPPERL, H; MARSHALL, H; KUROIWA, A; KRUMLAUF, R				STUDER, M; POPPERL, H; MARSHALL, H; KUROIWA, A; KRUMLAUF, R			ROLE OF A CONSERVED RETINOIC ACID RESPONSE ELEMENT IN RHOMBOMERE RESTRICTION OF HOXB-1	SCIENCE			English	Article							ZINC-FINGER GENE; SEGMENT-SPECIFIC EXPRESSION; HOMEOBOX-CONTAINING GENES; EMBRYONIC EXPRESSION; CHICK HINDBRAIN; MOUSE HINDBRAIN; VERTEBRATE HEAD; NERVOUS-SYSTEM; NEURAL CREST; HOX-1.6	After activation in mesoderm and neuroectoderm, expression of the Hoxb-1 gene is progressively restricted to rhombomere (r) 4 in the hindbrain. Analysis of the chick and mouse Hoxb-1 genes identified positive and negative regulatory regions that cooperate to mediate segment-restricted expression during rhombomere formation. An enhancer generates expression extending into r3 and r5, and a repressor limits this domain to r4. The repressor contains a conserved retinoic acid response element, point mutations in which allow expression to spread into adjacent rhombomeres. Retinoids and their nuclear receptors may therefore participate in sharpening segment-restricted expression of Hoxb-1 during rhombomere boundary formation.	NATL INST MED RES, DEV NEUROBIOL LAB, LONDON NW7 1AA, ENGLAND; NAGOYA UNIV, SCH SCI, DEPT MOLEC BIOL, NAGOYA 46401, JAPAN	MRC National Institute for Medical Research; Nagoya University			Krumlauf, Robb/AAH-5012-2019; Studer, Michele/P-4580-2016	Krumlauf, Robb/0000-0001-9102-7927; Studer, Michele/0000-0001-7105-2957; Kuroiwa, Atsushi/0000-0001-7710-4041				CARPENTER EM, 1993, DEVELOPMENT, V118, P1063; CHISAKA O, 1992, NATURE, V355, P516, DOI 10.1038/355516a0; CONLON RA, 1992, DEVELOPMENT, V116, P357; DOLLE P, 1993, P NATL ACAD SCI USA, V90, P7666, DOI 10.1073/pnas.90.16.7666; FJOSE A, 1993, EMBO J, V12, P1403, DOI 10.1002/j.1460-2075.1993.tb05784.x; FRASER S, 1990, NATURE, V344, P431, DOI 10.1038/344431a0; FROHMAN MA, 1993, DEVELOPMENT, V117, P925; FROHMAN MA, 1990, DEVELOPMENT, V110, P589; GAUNT SJ, 1987, DEVELOPMENT, V101, P51; GEADA AMC, 1992, DEVELOPMENT, V116, P497; GUTHRIE S, 1991, DEVELOPMENT, V112, P221; GUTHRIE S, 1993, DEVELOPMENT, V118, P527; GUTHRIE S, 1992, NATURE, V356, P157, DOI 10.1038/356157a0; Hogan B., 1986, MANIPULATING MOUSE E; HUNT P, 1991, NATURE, V353, P861, DOI 10.1038/353861a0; HUNT P, 1991, DEVELOPMENT, V112, P43; IP YT, 1992, J CELL SCI, P33; JACKLE H, 1992, J CELL SCI, P39; KESSEL M, 1993, NEURON, V10, P379, DOI 10.1016/0896-6273(93)90328-O; KIMMEL CB, 1988, DEVELOPMENT, V104, P197; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; LUMSDEN A, 1989, NATURE, V337, P424, DOI 10.1038/337424a0; MADEN M, 1991, DEVELOPMENT, V111, P35; MARK M, 1993, DEVELOPMENT, V119, P319; MARSHALL H, 1994, NATURE, V370, P567, DOI 10.1038/370567a0; MARSHALL H, 1992, NATURE, V360, P737, DOI 10.1038/360737a0; MENDELSOHN C, 1994, MECH DEVELOP, V45, P227, DOI 10.1016/0925-4773(94)90010-8; MORRISSKAY G, 1993, BIOESSAYS, V15, P9, DOI 10.1002/bies.950150103; MORRISSKAY GM, 1991, EMBO J, V10, P2985, DOI 10.1002/j.1460-2075.1991.tb07849.x; MURPHY P, 1989, NATURE, V341, P156, DOI 10.1038/341156a0; MURPHY P, 1991, DEVELOPMENT, V111, P61; POPPERL H, 1993, MOL CELL BIOL, V13, P257; RUBOCK MJ, 1990, P NATL ACAD SCI USA, V87, P4751, DOI 10.1073/pnas.87.12.4751; SCHNEIDERMAUNOURY S, 1993, CELL, V75, P1199, DOI 10.1016/0092-8674(93)90329-O; SHAM MH, 1992, EMBO J, V11, P1825, DOI 10.1002/j.1460-2075.1992.tb05234.x; SHAM MH, 1993, CELL, V72, P183, DOI 10.1016/0092-8674(93)90659-E; STUNNENBERG HG, 1993, BIOESSAYS, V15, P309, DOI 10.1002/bies.950150504; SUNDIN O, 1992, DEVELOPMENT, V114, P841; SUNDIN OH, 1990, GENE DEV, V4, P1267, DOI 10.1101/gad.4.8.1267; SWIATEK PJ, 1993, GENE DEV, V7, P2071, DOI 10.1101/gad.7.11.2071; WHITING J, 1991, GENE DEV, V5, P2048, DOI 10.1101/gad.5.11.2048; WILKINSON DG, 1989, NATURE, V341, P405, DOI 10.1038/341405a0; WILKINSON DG, 1989, NATURE, V337, P461, DOI 10.1038/337461a0; YEE SP, 1993, GENE DEV, V7, P1277, DOI 10.1101/gad.7.7a.1277	46	247	248	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 16	1994	265	5179					1728	1732		10.1126/science.7916164	http://dx.doi.org/10.1126/science.7916164			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PG284	7916164				2022-12-24	WOS:A1994PG28400037
J	MALMBERG, P				MALMBERG, P			COKING TO DEATH	LANCET			English	Editorial Material											MALMBERG, P (corresponding author), NATL INST OCCUPAT HLTH,S-17184 SOLNA,SWEDEN.							ANDERSSON K, 1993, HYGIEA, V102, P120; BHOPAL RS, 1994, J EPIDEMIOL COMMUN H, V48, P237, DOI 10.1136/jech.48.3.237; NORLEN U, 1993, INDOOR CLIMATE SWE D, V10; STENBERG B, 1993, JUL P INDOOR AIR HEL, P399	4	4	4	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 3	1994	344	8923					632	632		10.1016/S0140-6736(94)92081-8	http://dx.doi.org/10.1016/S0140-6736(94)92081-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PE386	7915346				2022-12-24	WOS:A1994PE38600006
J	GUENDELMAN, S				GUENDELMAN, S			MEXICAN WOMEN IN THE UNITED-STATES	LANCET			English	Editorial Material							INFANT-MORTALITY; BIRTH				GUENDELMAN, S (corresponding author), UNIV CALIF BERKELEY,SCH PUBL HLTH,BERKELEY,CA 94720, USA.							BALCAZAR H, 1994, AM J PUBLIC HEALTH, V84, P462, DOI 10.2105/AJPH.84.3.462; BECERRA JE, 1991, JAMA-J AM MED ASSOC, V265, P217, DOI 10.1001/jama.265.2.217; FRISBIE P, 1989, INT REV COMP PUBL PO, V1, P65; GUENDELMAN S, IN PRESS AM J PUBL H; HAHN RA, 1992, JAMA-J AM MED ASSOC, V267, P259, DOI 10.1001/jama.267.2.259; HEDDERSON J, 1982, SOC SCI J, V199, P68; MENDOZA F, 1991, JAMA-J AM MED ASSOC, V265, P277; SCRIBNER R, 1989, AM J PUBLIC HEALTH, V79, P1263, DOI 10.2105/AJPH.79.9.1263; VEGA WA, 1990, J MARRIAGE FAM, V52, P1015, DOI 10.2307/353316; 1992, 1990 CPH L 90 1990 C; 1994, ADV DATA VITAL HLTH, V241	11	10	10	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 6	1994	344	8919					352	352		10.1016/S0140-6736(94)91397-8	http://dx.doi.org/10.1016/S0140-6736(94)91397-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PA303	7914303				2022-12-24	WOS:A1994PA30300006
J	KUMAR, L				KUMAR, L			CAN MOLECULAR MONITORING IMPROVE OUTCOME IN LEUKEMIA	LANCET			English	Editorial Material							BONE-MARROW TRANSPLANTATION; POLYMERASE CHAIN-REACTION; ACUTE LYMPHOBLASTIC-LEUKEMIA; MINIMAL RESIDUAL DISEASE; B-CELL LYMPHOMA; RELAPSE				KUMAR, L (corresponding author), ALL INDIA INST MED SCI,INST ROTARY CANC HOSP,NEW DELHI,INDIA.							BASH RO, 1993, BLOOD, V81, P2110; BRENNER MK, 1993, LANCET, V341, P85, DOI 10.1016/0140-6736(93)92560-G; BRISCO MJ, 1994, LANCET, V343, P196, DOI 10.1016/S0140-6736(94)90988-1; CRIST WM, 1990, BLOOD, V76, P117; CROSS NCP, 1993, BLOOD, V82, P1929; DROBYSKI WR, 1993, BLOOD, V81, P551; GRIBBEN JG, 1993, BLOOD, V81, P3449; GRIBBEN JG, 1991, NEW ENGL J MED, V325, P1525, DOI 10.1056/NEJM199111283252201; LION T, 1993, LANCET, V341, P275, DOI 10.1016/0140-6736(93)92619-5; MILLER WH, 1993, BLOOD, V82, P1689; NIZET Y, 1993, BLOOD, V82, P1618; ROTH MS, 1992, BLOOD, V79, P276; WEISDORF DJ, 1993, TRANSPLANTATION, V55, P61, DOI 10.1097/00007890-199301000-00012	13	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 6	1994	344	8919					348	349		10.1016/S0140-6736(94)91393-5	http://dx.doi.org/10.1016/S0140-6736(94)91393-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PA303	7914299				2022-12-24	WOS:A1994PA30300002
J	HUTCHINSON, CM; HOOK, EW; SHEPHERD, M; VERLEY, J; ROMPALO, AM				HUTCHINSON, CM; HOOK, EW; SHEPHERD, M; VERLEY, J; ROMPALO, AM			ALTERED CLINICAL PRESENTATION OF EARLY SYPHILIS IN PATIENTS WITH HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION	ANNALS OF INTERNAL MEDICINE			English	Article							TREPONEMA-PALLIDUM ANTIGENS; SECONDARY SYPHILIS; HIV-INFECTION; HOMOSEXUAL MEN; MANIFESTATIONS; ASSOCIATION; DIAGNOSIS; SARCOMA; RISK	Objectives: To compare clinical presentations of patients with early syphilis who did or did not have human immunodeficiency virus (HIV) infection. Design: Case-control study. Setting: The sexually transmitted diseases clinics of the Baltimore City Health Department. Patients: Patients with newly diagnosed primary, secondary, or early latent syphilis who had voluntary HIV testing from January 1990 to November 1991. Measurements: Data on sexual history, risk behaviors, and physical findings (before knowledge of HIV or syphilis serologic test results) were extracted from clinical records. Diagnoses of syphilis were confirmed by reactive syphilis serologic tests. Rapid plasma reagin titers reported to the disease registry of the Baltimore City Health Department were abstracted to determine therapeutic response. Patients positive for HIV who returned for follow-up had further counseling, staging, and CD4 lymphocyte testing. Results: Data were available on 309 of 527 patients with early syphilis: 108 patients with primary syphilis, 116 with secondary syphilis, and 85 with early latent syphilis. Seventy (23%) patients had concurrent HIV infection. Patients with HIV infection presented more often with secondary syphilis than did patients with syphilis who were HIV seronegative (53% [37 of 70] compared with 33% [79 of 239]; P = 0.01). The same was true for heterosexual men with HIV infection (46% [16 of 35]) compared with heterosexual men without infection (25% [35 of 142]; P < 0.03). Among those who denied intravenous drug use, 59% (22 of 37) of patients with HIV infection presented with secondary syphilis compared with 33% (65 of 198) of patients without infection (P < 0.01). Among patients with first episodes of syphilis, patients positive for HIV who had secondary syphilis were more likely to present with persistent chancres (43% [9 of 21] compared with 15% [11 of 72]; P = 0.01). The rate of decline in the rapid plasma reagin titers during a 12-month period after treatment did not differ between patients with and without HIV infection (P = 0.15). Conclusions.- The clinical presentation of syphilis in patients with HIV infection differs from that of patients without HIV infection in that patients with HIV infection present more often in the secondary stage and those with secondary syphilis are more likely to have chancres.	JOHNS HOPKINS UNIV, SCH MED, BALTIMORE, MD USA; BALTIMORE CITY DEPT HLTH, BALTIMORE, MD USA; UNIV ALABAMA, BIRMINGHAM, AL USA	Johns Hopkins University; University of Alabama System; University of Alabama Birmingham					NIAID NIH HHS [R01-AI27727-03] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027727] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERRY CD, 1987, NEW ENGL J MED, V316, P1587, DOI 10.1056/NEJM198706183162507; BLOUNT JH, 1978, BIOL PARSITIC SPIROC, P157; DARROW WW, 1987, AM J PUBLIC HEALTH, V77, P479, DOI 10.2105/AJPH.77.4.479; FIUMARA NJ, 1980, JAMA-J AM MED ASSOC, V243, P2500, DOI 10.1001/jama.243.24.2500; GOUREVITCH MN, 1993, ANN INTERN MED, V118, P350, DOI 10.7326/0003-4819-118-5-199303010-00005; HAAS JS, 1990, J INFECT DIS, V162, P862, DOI 10.1093/infdis/162.4.862; HICKS CB, 1987, ANN INTERN MED, V107, P492, DOI 10.7326/0003-4819-107-4-492; HUTCHINSON CM, 1991, JAMA-J AM MED ASSOC, V266, P253, DOI 10.1001/jama.266.2.253; HUTCHINSON CM, 1991, ARCH INTERN MED, V151, P511, DOI 10.1001/archinte.151.3.511; JAFFE HW, 1975, ANN INTERN MED, V83, P846, DOI 10.7326/0003-4819-83-6-846; JAFFE HW, 1983, ANN INTERN MED, V99, P145, DOI 10.7326/0003-4819-99-2-145; JOHNS DR, 1987, NEW ENGL J MED, V316, P1569, DOI 10.1056/NEJM198706183162503; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; KREISS JK, 1989, J INFECT DIS, V160, P380, DOI 10.1093/infdis/160.3.380; LUKEHART SA, 1980, J IMMUNOL, V124, P454; LUKEHART SA, 1988, ANN INTERN MED, V109, P855, DOI 10.7326/0003-4819-109-11-855; MAGNUSON HJ, 1956, MEDICINE, V35, P33, DOI 10.1097/00005792-195602000-00002; MARRA CM, 1992, J INFECT DIS, V165, P1020, DOI 10.1093/infdis/165.6.1020; QUINN TC, 1988, NEW ENGL J MED, V318, P197, DOI 10.1056/NEJM198801283180401; QUINN TC, 1990, ARCH INTERN MED, V150, P1297, DOI 10.1001/archinte.150.6.1297; RADOLF JD, 1988, J AM ACAD DERMATOL, V18, P423, DOI 10.1016/S0190-9622(88)70062-6; ROMPALO AM, 1992, J INFECT DIS, V165, P1124, DOI 10.1093/infdis/165.6.1124; ROSENBERG ZF, 1992, SEXUALLY TRANSMITTED, P165; SCHROETER AL, 1972, J AMER MED ASSOC, V221, P471, DOI 10.1001/jama.221.5.471; STOKES JH, 1944, MODERN CLIN SYPHILOL; STOUMBOS VD, 1987, AM J OPHTHALMOL, V103, P103, DOI 10.1016/S0002-9394(14)74179-0; 1989, MMWR MORB MORTAL WKL, V38; 1988, MMWR-MORBID MORTAL W, V37, P755; 1988, MMWR-MORBID MORTAL W, V37, P35; 1988, MMWR-MORBID MORTAL W, V37, P486	30	111	118	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1994	121	2					94	99		10.7326/0003-4819-121-2-199407150-00003	http://dx.doi.org/10.7326/0003-4819-121-2-199407150-00003			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW186	7912483				2022-12-24	WOS:A1994NW18600003
J	HARRISON, P; DEGEN, SJF; WILLIAMS, R; FARZANEH, F				HARRISON, P; DEGEN, SJF; WILLIAMS, R; FARZANEH, F			HEPATIC EXPRESSION OF HEPATOCYTE-GROWTH-FACTOR-LIKE MACROPHAGE-STIMULATING PROTEIN MESSENGER-RNA IN FULMINANT HEPATIC-FAILURE	LANCET			English	Note							GENE	We investigated whether impaired Kupffer cell phagocytosis in fulminant hepatic failure could be due to reduced synthesis of hepatocyte-growth-factor-like/macrophage-stimulating protein (HGFL/MSP), a serum protein synthesised predominantly in hepatocytes and required by tissue macrophages for phagocytosis. Hepatic expression of the 3.0 kb HGFL/MSP mRNA, assessed by northern hybridisation, was lower in nine patients with fulminant hepatic failure undergoing liver transplantation than in three liver grafts as controls (median absorbance units 97 [range 15-1200] versus 1114 [1100-1120], respectively; p < 0.05). Decreased hepatic HGFL/MSP production might cause impaired Kupffer cell phagocytosis in fulminant hepatic failure.	UNIV LONDON KINGS COLL,SCH MED & DENT,INST LIVER STUDIES,LONDON SE5 9PJ,ENGLAND; CHILDRENS HOSP RES FDN,DIV BASIC SCI RES,CINCINNATI,OH 45229	University of London; King's College London; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation	HARRISON, P (corresponding author), UNIV LONDON KINGS COLL,SCH MED & DENT,DEPT MOLEC MED,BESSEMER RD,LONDON SE5 9PJ,ENGLAND.		Farzaneh, Farzin/B-4902-2009; Harrison, Phillip M/D-5374-2009	Farzaneh, Farzin/0000-0002-9275-2415; opoku, anita/0000-0001-7243-8157				BEZERRA JA, 1993, HEPATOLOGY, V18, P394, DOI 10.1016/0270-9139(93)90024-H; CANALESE J, 1982, GUT, V23, P265, DOI 10.1136/gut.23.4.265; HAN S, 1991, BIOCHEMISTRY-US, V30, P9768, DOI 10.1021/bi00104a029; HUGHES RD, 1986, EUR J CLIN INVEST, V16, P352, DOI 10.1111/j.1365-2362.1986.tb01008.x; LEONARD EJ, 1976, EXP CELL RES, V102, P434, DOI 10.1016/0014-4827(76)90065-3; ROLANDO N, 1990, HEPATOLOGY, V11, P49, DOI 10.1002/hep.1840110110; SKEEL A, 1991, J EXP MED, V173, P1227, DOI 10.1084/jem.173.5.1227; YOSHIMURA T, 1993, J BIOL CHEM, V268, P15461	8	13	14	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 2	1994	344	8914					27	28		10.1016/S0140-6736(94)91050-2	http://dx.doi.org/10.1016/S0140-6736(94)91050-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU917	7912298				2022-12-24	WOS:A1994NU91700013
J	OTSUKI, Y; MISAKI, O; SUGIMOTO, O; ITO, Y; TSUJIMOTO, Y; AKAO, Y				OTSUKI, Y; MISAKI, O; SUGIMOTO, O; ITO, Y; TSUJIMOTO, Y; AKAO, Y			CYCLIC BCL-2 GENE-EXPRESSION IN HUMAN UTERINE ENDOMETRIUM DURING MENSTRUAL-CYCLE	LANCET			English	Note							TISSUES	To investigate an apoptotic role for bcl-2 in menses, we studied bcl-2 protein production throughout the cycle. Bcl-2 protein was observed in endometrial glandular, stromal and myometrial smooth-muscle cells. Glandular cells expressed bcl-2 at proliferative through early secretory phases but not at late secretory through menstrual phases. This cyclic expression of bcl-2 gene was similar to that of oestrogen and progesterone receptors. Thus bcl-2 expression in glandular cells may be regulated by ovarian hormones. The disappearance of bcl-2 expression in glandular cells at late secretory phase was consistent with the appearance of apoptotic cells in the same phase.	OSAKA MED COLL,DEPT OBSTET & GYNAECOL,TAKATSUKI,OSAKA,JAPAN; OSAKA UNIV,SCH MED,BIOMED RES CTR,OSAKA 553,JAPAN	Osaka Medical College; Osaka University	OTSUKI, Y (corresponding author), OSAKA MED COLL,DEPT ANAT & BIOL,2-7 DIAGAKU MACHI,TAKATSUKI,OSAKA 569,JAPAN.							ADACHI M, 1990, ONCOGENE, V5, P1653; AKAO Y, 1994, CANCER RES, V84, P2468; GARCIA I, 1992, SCIENCE, V258, P303; HOPWOOD D, 1976, J PATHOL, V119, P159; LEBRUN DP, 1993, AM J PATHOL, V142, P743; LU QL, 1993, J PATHOL, V169, P431, DOI 10.1002/path.1711690408; MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000; SATYASWAROOP PG, 1979, J CLIN ENDOCR METAB, V48, P639, DOI 10.1210/jcem-48-4-639; TSUJIMOTO Y, 1989, ONCOGENE, V4, P1331	9	177	184	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 2	1994	344	8914					28	29						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU917	7912299				2022-12-24	WOS:A1994NU91700014
J	PEDRINELLI, R; GIAMPIETRO, O; CARMASSI, F; MELILLO, E; DELLOMO, G; CATAPANO, G; MATTEUCCI, E; TALARICO, L; MORALE, M; DENEGRI, F; DIBELLO, V				PEDRINELLI, R; GIAMPIETRO, O; CARMASSI, F; MELILLO, E; DELLOMO, G; CATAPANO, G; MATTEUCCI, E; TALARICO, L; MORALE, M; DENEGRI, F; DIBELLO, V			MICROALBUMINURIA AND ENDOTHELIAL DYSFUNCTION IN ESSENTIAL-HYPERTENSION	LANCET			English	Article							LEFT-VENTRICULAR HYPERTROPHY; VONWILLEBRAND-FACTOR; CARDIOVASCULAR-DISEASE; RISK-FACTORS; ATHEROSCLEROSIS; LIPOPROTEIN; MECHANISMS; INHIBITION; FIBRINOGEN; PRESSURE	Microalbuminuria (urinary albumin excretion between 20 and 200 mu g/min) and endothelial dysfunction coexist in patients with essential hypertension. To evaluate whether the two phenomena are related and the determinants of that association, we recruited 10 untreated males with essential hypertension and microalbuminuria without diabetes to be compared with an equal number of matched patients with essential hypertension excreting albumin in normal amounts and 10 normal controls. The status of endothelial function was inferred from circulating von Willebrand Factor antigen (vWF), a glycoprotein secreted in greater amounts when the vascular endothelium is damaged. vWF concentrations were higher in hypertensive patients with microalbuminuria than in hypertensive patients without and controls. Individual vWF and urine albumin-excretion values were correlated (r = 0.55, p < 0.002). Blood pressure correlated with both urinary albumin excretion and vWF. Left ventricular mass index and minimal forearm vascular resistances were comparable in patients with hypertension and higher than in controls; total and low-density lipoprotein cholesterol, triglycerides, lipoprotein-a, Factor VII, and plasminogen activator inhibitor-1 did not differ. Fibrinogen was higher and creatinine clearance lower in microalbuminurics. Albuminuria in essential hypertension may reflect systemic dysfunction of the vascular endothelium, a structure intimately involved in permeability, haemostasis, fibrinolysis, and blood pressure control. This abnormality may have important physiopathological implications and expose these patients to increased cardiovascular risk.	UNIV PISA,MED CLIN 2,I-56100 PISA,ITALY; UNIV PISA,REPARTO MED INTERNA,I-56100 PISA,ITALY	University of Pisa; University of Pisa	PEDRINELLI, R (corresponding author), UNIV PISA,MED CLIN 1,USL 12,I-56100 PISA,ITALY.			Carmassi, Franco/0000-0003-2244-4430				BIGAZZI R, 1992, NEPHRON, V61, P94, DOI 10.1159/000186842; BLANN A D, 1991, Medical Science Research, V19, P535; BLANN AD, 1993, J HUM HYPERTENS, V7, P107; CARMASSI F, 1992, THROMB RES, V67, P643, DOI 10.1016/0049-3848(92)90068-L; CERASOLA G, 1992, REV LAT CARDIOL, V13, P3; Christensen C K, 1983, J Hypertens, V1, P45; CONLAN MG, 1993, THROMB HAEMOSTASIS, V70, P380; CORRADI L, 1993, J HYPERTENS, V11, pS190; DAHLOF B, 1992, AM J HYPERTENS, V5, P95, DOI 10.1093/ajh/5.2.95; GIAMPIETRO O, 1992, ACTA DIABETOL, V28, P239, DOI 10.1007/BF00779006; JANSSON JH, 1991, BRIT HEART J, V66, P351; JENSEN T, 1988, DIABETOLOGIA, V31, P142, DOI 10.1007/BF00276846; KANNEL WB, 1987, JAMA-J AM MED ASSOC, V258, P1183, DOI 10.1001/jama.258.9.1183; LINDEMAN RD, 1984, KIDNEY INT, V26, P861, DOI 10.1038/ki.1984.229; METTINGER KL, 1982, THROMB RES, V26, P183, DOI 10.1016/0049-3848(82)90139-6; MITROPOULOS KA, 1989, ATHEROSCLEROSIS, V76, P203, DOI 10.1016/0021-9150(89)90104-4; NICHOLS TC, 1990, ARTERIOSCLEROSIS, V10, P449, DOI 10.1161/01.ATV.10.3.449; NITENBERG A, 1993, AM J MED, V95, P71, DOI 10.1016/0002-9343(93)90234-G; PANZA JA, 1990, NEW ENGL J MED, V323, P22, DOI 10.1056/NEJM199007053230105; PARVING HH, 1973, CIRC RES, V32, P643, DOI 10.1161/01.RES.32.5.643; PEDRINELLI R, 1990, J HYPERTENS, V8, P467, DOI 10.1097/00004872-199005000-00012; PEDRINELLI R, 1993, ARTERIOSCLER THROMB, V13, P900, DOI 10.1161/01.ATV.13.6.900; PHILLIPS GB, 1993, J HYPERTENS, V11, P699, DOI 10.1097/00004872-199307000-00003; PICKERING TG, 1990, HYPERTENSION PATHOPH, P1397; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; SALAZAR FJ, 1992, HYPERTENSION, V20, P113, DOI 10.1161/01.HYP.20.1.113; SCANU AM, 1990, J CLIN INVEST, V85, P1709, DOI 10.1172/JCI114625; SUFFREDINI AF, 1989, NEW ENGL J MED, V320, P1165, DOI 10.1056/NEJM198905043201802; VANE JR, 1990, NEW ENGL J MED, V323, P27; VIBERTI GC, 1990, ACTA DIABETOL LAT, V27, P267, DOI 10.1007/BF02581339; WILLIAMS RR, 1990, HYPERTENSION PATHOPH, V9, P127; YUDKIN JS, 1988, LANCET, V2, P531	32	353	369	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 2	1994	344	8914					14	18		10.1016/S0140-6736(94)91047-2	http://dx.doi.org/10.1016/S0140-6736(94)91047-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU917	7912295				2022-12-24	WOS:A1994NU91700010
J	KUSS, BJ; DEELEY, RG; COLE, SPC; WILLMAN, CL; KOPECKY, KJ; WOLMAN, SR; EYRE, HJ; LANE, SA; NANCARROW, JK; WHITMORE, SA; CALLEN, DF				KUSS, BJ; DEELEY, RG; COLE, SPC; WILLMAN, CL; KOPECKY, KJ; WOLMAN, SR; EYRE, HJ; LANE, SA; NANCARROW, JK; WHITMORE, SA; CALLEN, DF			DELETION OF GENE FOR MULTIDRUG-RESISTANCE IN ACUTE MYELOID-LEUKEMIA WITH INVERSION IN CHROMOSOME-16 - PROGNOSTIC IMPLICATIONS	LANCET			English	Article							ACUTE NONLYMPHOCYTIC LEUKEMIA; CANCER CELL-LINE; P-GLYCOPROTEIN; ACCUMULATION; ASSOCIATION; TRANSPORTER; MECHANISMS	Acute myeloid leukaemia (AML) associated with an inversion in chromosome 16 has a relatively favourable prognosis. The AML subclass most commonly associated with this chromosomal abnormality is acute myelomonocytic leukaemia with abnormal eosinophils. In some AML patients with inversion 16 the chromosomal lesion results in deletion of MRP, the gene for multidrug resistance associated protein. This gene is proximal to the primary breakpoint and loss of its function may play a key role in determining the favourable outcome in inversion 16 AML. We have demonstrated deletion of MRP by in situ hybridisation, by gene dosage studies and by studying loss of heterogeneity of a flanking microsatellite marker. Among 13 AML patients with inversion 16 MRP deletion was detected in 5 while 7 had no deletion. Deletion of MRP gene was associated with longer time from diagnosis until death or relapse from complete remission (p=0.007). These findings provide important insight into the biology of inversion 16 leukaemia and suggest that MRP deletion, as detected by molecular analysis, may,have a key role in determining outcome in patients with inversion 16 AML.	QUEENS UNIV,CANC RES LABS,KINGSTON,ON,CANADA; CTR MOLEC & CELLULAR DIAGNOST,CTR CANC,ALBUQUERQUE,NM; FRED HUTCHINSON CANC RES CTR,SEATTLE,WA; MICHIGAN CANC FDN,DETROIT,MI; ONCOR,GAITHERSBURG,MD; SW ONCOL GRP,LEUKAEMIA BIOL PROGRAM,SAN ANTONIO,TX	Queens University - Canada; Fred Hutchinson Cancer Center; Southwest Oncology Group	KUSS, BJ (corresponding author), WOMENS & CHILDRENS HOSP,CTR MED GENET,DEPT CYTOGENET & MOLEC GENET,KING WILLIAM RD,ADELAIDE,SA 5006,AUSTRALIA.		Deeley, Roger/J-4828-2012; Cole, Susan P.C./I-6389-2017; Callen, David F/G-1975-2012	Cole, Susan P.C./0000-0001-6571-6884; Callen, David/0000-0002-6189-9991	NCI NIH HHS [CA32102] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U10CA032102] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARTHUR DC, 1983, BLOOD, V61, P994; BAE SC, 1993, ONCOGENE, V8, P809; BARRAND MA, 1993, BR J CANCER S20, V67, P77; CALLEN DF, 1992, GENOMICS, V13, P1178, DOI 10.1016/0888-7543(92)90035-Q; CALLEN DF, 1990, ANN GENET-PARIS, V33, P219; CAMPBELL LJ, 1991, GENE CHROMOSOME CANC, V3, P55, DOI 10.1002/gcc.2870030110; CAMPOS L, 1992, EUR J HAEMATOL, V48, P254; COLE SPC, 1989, BRIT J CANCER, V59, P42, DOI 10.1038/bjc.1989.9; COLE SPC, 1991, CANCER RES, V51, P3345; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; Cole Susan P. C., 1993, Proceedings of the American Association for Cancer Research Annual Meeting, V34, P579; DACHARY D, 1986, CANCER GENET CYTOGEN, V20, P241, DOI 10.1016/0165-4608(86)90079-8; DAUWERSE JG, 1993, HUM MOL GENET, V2, P1527, DOI 10.1093/hmg/2.10.1527; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GRANT CE, IN PRESS CANCER RES; HART SM, 1993, BLOOD S, pA258; KRISHNAMACHARY N, 1993, CANCER RES, V53, P3658; LARSON RA, 1986, BLOOD, V68, P1242; LEBEAU MM, 1983, NEW ENGL J MED, V309, P630, DOI 10.1056/NEJM198309153091103; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; MARQUARDT D, 1992, CANCER RES, V52, P3157; MARQUARDT D, 1990, CANCER RES, V50, P1426; OHYASHIKI K, 1988, LEUKEMIA, V2, P398; RAIMONDI SC, 1989, CANCER GENET CYTOGEN, V40, P13, DOI 10.1016/0165-4608(89)90141-6; ROSS DD, 1993, BLOOD, V82, P1288; SLOVAK ML, 1993, CANCER RES, V53, P3221; ZHAO S, 1993, BLOOD S, pA258	27	108	113	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 18	1994	343	8912					1531	1534		10.1016/S0140-6736(94)92938-6	http://dx.doi.org/10.1016/S0140-6736(94)92938-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NR329	7911871				2022-12-24	WOS:A1994NR32900008
J	DAVIES, MH; MUTIMER, D; LOWES, J; ELIAS, E; NEUBERGER, J				DAVIES, MH; MUTIMER, D; LOWES, J; ELIAS, E; NEUBERGER, J			RECOVERY DESPITE IMPAIRED CEREBRAL PERFUSION IN FULMINANT HEPATIC-FAILURE	LANCET			English	Note							LIVER-TRANSPLANTATION	We report 4 patients with fulminant hepatic failure who developed prolonged intracranial hypertension (> 35 mm Hg for 24-38 h) that was refractpty to standard therapy and associated with impaired cerebral perfusion pressure (< 50 mm Hg for 2-72 h). All survived with complete neurological recovery. Refractory elevation of intracranial pressure and reduced cerebral perfusion pressure are generally thought to contra-indicate liver transplantation in hepatic failure and are indications to withdraw support. Our observations challenge this concept.	QUEEN ELIZABETH HOSP,LIVER UNIT,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND	University of Birmingham			Neuberger, James/ABG-3010-2020					ALMDAL T, 1989, SCAND J GASTROENTERO, V24, P299, DOI 10.3109/00365528909093050; DONOVAN JP, 1992, HEPATOLOGY, V16, P267, DOI 10.1002/hep.1840160138; EMOND JC, 1989, GASTROENTEROLOGY, V96, P1583, DOI 10.1016/0016-5085(89)90530-1; Kanter M J, 1991, Neurosurg Clin N Am, V2, P257; LLIDOFSKY SD, 1992, HEPATOLOGY, V16, P1; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; MUNOZ SJ, 1993, TRANSPLANTATION, V55, P1071, DOI 10.1097/00007890-199305000-00025; MUNOZ SJ, 1993, SEMIN LIVER DIS, V13, P395; OGRADY JG, 1989, GASTROENTEROLOGY, V97, P439, DOI 10.1016/0016-5085(89)90081-4	9	44	45	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 28	1994	343	8909					1329	1330		10.1016/S0140-6736(94)92471-6	http://dx.doi.org/10.1016/S0140-6736(94)92471-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NN217	7910328				2022-12-24	WOS:A1994NN21700014
J	PRESANT, CA; WOLF, W; WALUCH, V; WISEMAN, C; KENNEDY, P; BLAYNEY, D; BRECHNER, RR				PRESANT, CA; WOLF, W; WALUCH, V; WISEMAN, C; KENNEDY, P; BLAYNEY, D; BRECHNER, RR			ASSOCIATION OF INTRATUMORAL PHARMACOKINETICS OF FLUOROURACIL WITH CLINICAL-RESPONSE	LANCET			English	Article							MAGNETIC-RESONANCE SPECTROSCOPY; 5-FLUOROURACIL; INVIVO; METABOLISM; TOXICITY	In-vivo fluorine-19 nuclear magnetic resonance spectroscopy (NMRS) allows non-invasive, real-time, chemical identification of specific fluorinated compounds inside human tumours after administration of fluorouracil (5-fluorouracil). Kinetic measures of the administered drug and metabolites allow estimation of the tumoral half-life of fluorouracil. We studied 57 patients by F-19 NMRS immediately after they had received 600 mg/m(2) fluorouracil intravenously. Serial spectra were acquired with the surface coil positioned on the shin above the tumour. We defined an intratumoral half-life of fluorouracil of 20 min or more as indicating trapping of the drug, based on the blood half-life of 8-12 min. 19 patients had intratumoral half-lives indicating trapping of fluorouracil, 27 had half-lives less than 20 min, and 11 had no detectable fluorouracil in their rumours. 8 of 9 evaluable patients whose tumours showed trapping had partial responses to chemotherapy that included fluorouracil compared with only 2 of 25 patients whose tumours did not trap the drug (p = 0.000021). F-19 NMRS can identify patients likely to respond to chemotherapy with fluorouracil and could be used clinically to tailor optimum treatment.	ST VINCENTS MED CTR,MRI SECT,LOS ANGELES,CA; UNIV SO CALIF,RADIOPHARM PROGRAM,LOS ANGELES,CA; UNIV SO CALIF,DEPT MED,LOS ANGELES,CA; UNIV SO CALIF,DEPT RADIOL,LOS ANGELES,CA; CENT LOS ANGELES COMMUNITY CLIN ONCOL PROGRAM,LOS ANGELES,CA	University of Southern California; University of Southern California; University of Southern California	PRESANT, CA (corresponding author), ST VINCENTS MED CTR,LOS ANGELES ONCOL INST,CTR NONINVAS PHARMACOL,BOX 57992,2131 W 3RD ST,LOS ANGELES,CA 90057, USA.		Blayney, Douglas/AAK-2920-2020; Wiseman MD, Charles/AHC-6808-2022	Blayney, Douglas/0000-0002-7931-4533; 	NATIONAL CANCER INSTITUTE [U10CA035200, R01CA056138, R55CA048255] Funding Source: NIH RePORTER; NCI NIH HHS [CA-35200, 1-R55-CA-48255, CA-56138] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOLGER M, 1987, OPERATIONAL INSTRUCT; COHEN JL, 1974, CANCER CHEMOTH REP 1, V58, P723; COUSTERE C, 1991, CANCER CHEMOTH PHARM, V28, P123, DOI 10.1007/BF00689701; ELTAHTAWY A, 1991, CANCER RES, V51, P5806; FINDLAY MPN, 1993, ANN ONCOL, V4, P597, DOI 10.1093/oxfordjournals.annonc.a058595; GUERQUIN-KERN JL, 1991, CANCER RES, V51, P5770; MCSHEEHY PMJ, 1989, BRIT J CANCER, V60, P303, DOI 10.1038/bjc.1989.275; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; PRESANT CA, 1990, J CLIN ONCOL, V8, P1868, DOI 10.1200/JCO.1990.8.11.1868; PRESANT CA, 1993, P AM CLIN ONCOL, V11, P501; SCHLEMMER HP, 1991, RADIOLOGY, V181, P210; VALLABHAJOSULA SR, 1982, EUR J NUCL MED, V7, P462; WALUCH V, 1992, P ANN M SOC MAGNETIC, V11, P3616; WOHLHUETER RM, 1980, J CELL PHYSIOL, V104, P309, DOI 10.1002/jcp.1041040305; WOLF W, 1987, MAGN RESON IMAGING, V5, P165, DOI 10.1016/0730-725X(87)90016-6; WOLF W, 1990, P NATL ACAD SCI USA, V87, P492, DOI 10.1073/pnas.87.1.492; WOLF W, 1993, P AACR, V34, P2365	17	162	164	1	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 14	1994	343	8907					1184	1187		10.1016/S0140-6736(94)92399-X	http://dx.doi.org/10.1016/S0140-6736(94)92399-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NL175	7909867				2022-12-24	WOS:A1994NL17500008
J	BENTON, EC				BENTON, EC			WARTS IN BUTCHERS - A CAUSE FOR CONCERN	LANCET			English	Editorial Material											BENTON, EC (corresponding author), ROYAL INFIRM,DEPT DERMATOL,EDINBURGH,SCOTLAND.							COGGON D, 1989, BRIT J IND MED, V46, P188; DEVILLIERS EM, 1989, ARCH DERMATOL, V125, P1590, DOI 10.1001/archderm.125.11.1590; KEEFE M, 1994, BRIT J DERMATOL, V130, P15, DOI 10.1111/j.1365-2133.1994.tb06875.x; KEEFE M, 1994, BRIT J DERMATOL, V130, P9, DOI 10.1111/j.1365-2133.1994.tb06874.x; MELCHERS W, 1993, J CLIN MICROBIOL, V31, P2547, DOI 10.1128/JCM.31.9.2547-2549.1993; RUDLINGER R, 1989, BRIT J DERMATOL, V120, P375, DOI 10.1111/j.1365-2133.1989.tb04163.x; STEHRGREEN PA, 1993, INT J EPIDEMIOL, V22, P294, DOI 10.1093/ije/22.2.294; YOUSEM SA, 1992, CANCER-AM CANCER SOC, V69, P693, DOI 10.1002/1097-0142(19920201)69:3<693::AID-CNCR2820690316>3.0.CO;2-Y	8	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 7	1994	343	8906					1114	1114		10.1016/S0140-6736(94)90231-3	http://dx.doi.org/10.1016/S0140-6736(94)90231-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NK730	7910228				2022-12-24	WOS:A1994NK73000005
J	MALLIDIS, C; LIM, TC; HILL, ST; SKINNER, DJ; BROWN, DJ; JOHNSTON, WIH; BAKER, HWG				MALLIDIS, C; LIM, TC; HILL, ST; SKINNER, DJ; BROWN, DJ; JOHNSTON, WIH; BAKER, HWG			COLLECTION OF SEMEN FROM MEN IN ACUTE-PHASE OF SPINAL-CORD INJURY	LANCET			English	Note							ELECTROEJACULATION; STATE; ART	In chronic spinal cord injury, semen obtained by assisted ejaculation is usually abnormal. We have assessed electroejaculation early after injury in seven patients. There were no adverse effects. Initial samples contained few or no spermatozoa but as patients emerged from spinal shock, semen improved and five had specimens cryopreserved. Thereafter sperm motility and viability decreased towards the pattern of chronic spinal cord injury by day 16. Cryopreservation was not possible in one patient with many medical complications and another who started electroejaculation 15 days after injury. Semen storage within the first 2 weeks after spinal cord injury is recommended for future fertility treatment.	AUSTIN HOSP,SPINAL INJURIES UNIT,MELBOURNE,VIC 3084,AUSTRALIA; UNIV MELBOURNE,DEPT OBSTET & GYNECOL,MELBOURNE,VIC,AUSTRALIA; ROYAL WOMENS HOSP,REPROD BIOL UNIT,CARLTON,AUSTRALIA; MELBOURNE IVF,MELBOURNE,AUSTRALIA	Austin Research Institute; Florey Institute of Neuroscience & Mental Health; University of Melbourne				Mallidis, Con/0000-0001-9531-3808				BRINDLEY GS, 1981, J NEUROL NEUROSUR PS, V44, P9, DOI 10.1136/jnnp.44.1.9; HALSTEAD LS, 1987, PARAPLEGIA, V25, P120, DOI 10.1038/sc.1987.21; LIM TC, 1994, PARAPLEGIA, V32, P142, DOI 10.1038/sc.1994.27; Linsenmeyer T A, 1991, J Am Paraplegia Soc, V14, P116; SARKARATI M, 1987, J UROLOGY, V138, P59, DOI 10.1016/S0022-5347(17)42988-0; SHERMAN JK, 1973, FERTIL STERIL, V24, P397; SIOSTEEN A, 1990, PARAPLEGIA, V20, P96; TALBOT HS, 1955, J UROLOGY, V73, P91, DOI 10.1016/S0022-5347(17)67370-1; WOLF DP, 1989, J IN VITRO FERTIL EM, V6, P325, DOI 10.1007/BF01138770; 1992, WHO LABORATORY MANUA	10	41	42	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 30	1994	343	8905					1072	1073		10.1016/S0140-6736(94)90183-X	http://dx.doi.org/10.1016/S0140-6736(94)90183-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NJ694	7909101				2022-12-24	WOS:A1994NJ69400011
J	NIEHRS, C; STEINBEISSER, H; DEROBERTIS, EM				NIEHRS, C; STEINBEISSER, H; DEROBERTIS, EM			MESODERMAL PATTERNING BY A GRADIENT OF THE VERTEBRATE HOMEOBOX GENE GOOSECOID	SCIENCE			English	Article							XENOPUS-LAEVIS; EMBRYOS; EXPRESSION; TRANSCRIPTION; ORGANIZER; ACTIVIN; HOMOLOG; ACTIVATION; INDUCTION; DOMAIN	Amphibian mesoderm arises from the marginal zone of the early gastrula and generates various tissues such as notochord, muscle, kidney, and blood. Small changes (twofold) in the amount of microinjected messenger RNA encoding the goosecoid (gsc) homeodomain protein resulted in marked changes in the differentiation of mesoderm in Xenopus laevis. At least three thresholds were observed, which were sufficient to specify four mesodermal cell states. Endogenous gsc messenger RNA was expressed in the marginal zone in a graded fashion that is congruent with a role for this gene in dorso-ventral patterning of mesoderm at the early gastrula stage.	UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT CHEM,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles				De Robertis, Edward/0000-0002-7843-1869	NICHD NIH HHS [HD21502-08] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD021502, R37HD021502] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; BLUMBERG B, 1991, SCIENCE, V253, P194, DOI 10.1126/science.1677215; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; CHRISTIAN JL, 1993, GENE DEV, V7, P13, DOI 10.1101/gad.7.1.13; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; CUNLIFFE V, 1992, NATURE, V358, P427, DOI 10.1038/358427a0; DALE L, 1987, DEVELOPMENT, V100, P279; DIRKSEN ML, 1992, GENE DEV, V6, P599, DOI 10.1101/gad.6.4.599; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; GREEN JBA, 1992, CELL, V71, P731, DOI 10.1016/0092-8674(92)90550-V; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; MOHUN TJ, 1984, NATURE, V311, P716, DOI 10.1038/311716a0; NIEHRS C, 1993, CELL, V72, P491, DOI 10.1016/0092-8674(93)90069-3; NIEHRS C, UNPUB; NUSSLEINVOLHARD C, 1901, DEVELOPMENT S, V1, P1; PATIENT RK, 1982, NUCLEIC ACIDS RES, V10, P7935, DOI 10.1093/nar/10.24.7935; PERRY M, 1985, J MOL BIOL, V185, P479, DOI 10.1016/0022-2836(85)90065-8; RUPP RAW, 1991, CELL, V65, P927, DOI 10.1016/0092-8674(91)90545-A; SATO SM, 1990, DEV BIOL, V137, P135, DOI 10.1016/0012-1606(90)90014-A; SCHULTEMERKER S, IN PRESS DEVELOPMENT; SLACK JMW, 1993, MECH DEVELOP, V41, P91, DOI 10.1016/0925-4773(93)90040-5; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SMITH WC, 1993, NATURE, V361, P547, DOI 10.1038/361547a0; STEINBEISSER H, 1993, CR ACAD SCI III-VIE, V316, P966; TAIRA M, 1992, GENE DEV, V6, P356, DOI 10.1101/gad.6.3.356; WILSON D, 1993, GENE DEV, V7, P2120, DOI 10.1101/gad.7.11.2120	27	149	149	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 11	1994	263	5148					817	820		10.1126/science.7905664	http://dx.doi.org/10.1126/science.7905664			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MV866	7905664				2022-12-24	WOS:A1994MV86600038
J	EBENS, AJ; GARREN, H; CHEYETTE, BNR; ZIPURSKY, SL				EBENS, AJ; GARREN, H; CHEYETTE, BNR; ZIPURSKY, SL			THE DROSOPHILA ANACHRONISM LOCUS - A GLYCOPROTEIN SECRETED BY GLIA INHIBITS NEUROBLAST PROLIFERATION	CELL			English	Article							POSTEMBRYONIC NEUROBLASTS; DEVELOPMENTAL SWITCH; 44-45 REGION; MELANOGASTER; GENE; NEUROGENESIS; MUTAGENESIS; PROTEIN; PATTERN; BRIDE	The Drosophila anachronism (ana) locus controls the proliferation of neuroblasts, neuronal stem cells that give rise to the central nervous system. In ana mutants, quiescent postembryonic central brain and optic lobe neuroblasts enter S phase precociously. ana encodes a novel secreted protein of 474 amino acids that is expressed not in the affected neuroblasts, but rather in a subclass of neighboring glial cells. These studies argue for an important role for glia in negatively regulating proliferation of neuronal precursor cells, thereby controlling the timing of postembryonic neurogenesis.	UNIV CALIF LOS ANGELES, SCH MED, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	EBENS, AJ (corresponding author), UNIV CALIF LOS ANGELES, SCH MED, DEPT COORDINATED SCI, HOWARD HUGHES MED INST, LOS ANGELES, CA 90024 USA.		Cheyette, Benjamin/K-5535-2014	Cheyette, Benjamin/0000-0001-9934-7941; Zipursky, Stephen/0000-0001-5630-7181	NIGMS NIH HHS [GM-07104] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMBROS V, 1989, CELL, V57, P49, DOI 10.1016/0092-8674(89)90171-2; ASHBURNER M, 1989, DROSOPHILA LABORATOR; Bauer V, 1904, ZOOL JB ABT ANAT ONT, V20, P123; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; COOLEY L, 1988, SCIENCE, V239, P1121, DOI 10.1126/science.2830671; ENVER T, 1990, NATURE, V344, P309, DOI 10.1038/344309a0; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GAO WQ, 1991, NEURON, V6, P705, DOI 10.1016/0896-6273(91)90168-Y; GREEN P, 1993, IN PRESS CELL TISSUE; HART AC, 1990, GENE DEV, V4, P1835, DOI 10.1101/gad.4.11.1835; HARTENSTEIN V, 1987, ROUX ARCH DEV BIOL, V196, P473, DOI 10.1007/BF00399871; HARTENSTEIN V, 1984, ROUX ARCH DEV BIOL, V193, P308, DOI 10.1007/BF00848159; HEISENBERG M, 1979, Z NATURFORSCH C, V34, P143; HOFBAUER A, 1990, ROUX ARCH DEV BIOL, V198, P264, DOI 10.1007/BF00377393; ITO K, 1992, DEV BIOL, V149, P134, DOI 10.1016/0012-1606(92)90270-Q; KONEV AY, 1991, GENETIKA+, V27, P77; KONEV AY, 1991, GENETIKA+, V27, P667; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; Maniatis T., 1982, MOL CLONING; MEINERTZHAGEN IA, 1973, DEV NEUROBIOLOGY ART, P51; MOSER MH, 1991, TRENDS PHARMACOL SCI, V12, P304, DOI 10.1016/0165-6147(91)90582-D; OKANE CJ, 1987, P NATL ACAD SCI USA, V84, P9123, DOI 10.1073/pnas.84.24.9123; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; Pardue ML, 1986, DROSOPHILA PRACTICAL, P111; PERLMAN D, 1983, J MOL BIOL, V167, P391, DOI 10.1016/S0022-2836(83)80341-6; PROKOP A, 1991, DEVELOPMENT, V111, P79; REINKE R, 1988, CELL, V55, P321, DOI 10.1016/0092-8674(88)90055-4; RUVKUN G, 1989, NATURE, V338, P313, DOI 10.1038/338313a0; SAIKI R. K., 1990, PCR PROTOCOLS GUIDE, P13; SNOW PM, 1989, CELL, V59, P313, DOI 10.1016/0092-8674(89)90293-6; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TOLBERT LP, 1989, TRENDS NEUROSCI, V12, P70, DOI 10.1016/0166-2236(89)90139-2; TRUMAN JW, 1988, DEV BIOL, V125, P145, DOI 10.1016/0012-1606(88)90067-X; VERNADAKIS A, 1988, INT REV NEUROBIOL, V30, P149	38	173	174	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 16	1993	74	1					15	27		10.1016/0092-8674(93)90291-W	http://dx.doi.org/10.1016/0092-8674(93)90291-W			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LN625	7916657				2022-12-24	WOS:A1993LN62500004
J	SACHSENMAIER, C; RADLERPOHL, A; ZINCK, R; NORDHEIM, A; HERRLICH, P; RAHMSDORF, HJ				SACHSENMAIER, C; RADLERPOHL, A; ZINCK, R; NORDHEIM, A; HERRLICH, P; RAHMSDORF, HJ			INVOLVEMENT OF GROWTH-FACTOR RECEPTORS IN THE MAMMALIAN UVC RESPONSE	CELL			English	Article							C-FOS PROMOTER; TYROSINE KINASES; PROTEIN-KINASE; TERNARY COMPLEX; TRANSCRIPTIONAL ACTIVATION; AUTOCRINE TRANSFORMATION; ENHANCER ELEMENT; PHORBOL ESTER; FACTOR P62TCF; JUN ACTIVITY	Irradiation of HeLa cells with short-wavelength ultraviolet light (UVC) induces the modification and activation of the preexisting transcription factors c-fos-c-Jun (AP-1) and TCF/Elk-1, as well as the protein synthesis independent transcriptional activation of the c-fos and c-jun genes. This response to UVC is mediated via obligatory cytoplasmic signal transduction, involving Pas and Raf, Src, and MAP kinases. The UVC response is inhibited by prior down-modulation of growth factor receptor signaling upon growth factor prestimulation, by suramin (an inhibitor of receptor activation) or by expression of a dominant negative epidermal growth factor (EGF) receptor mutant. These data suggest the involvement of several growth factor receptors in the UVC response. Indeed, UVC induces the suramin-inhibitable immediate tyrosine phosphorylation of the EGF receptor.	HANNOVER MED SCH,INST MOLEK BIOL,D-30623 HANNOVER,GERMANY	Hannover Medical School	SACHSENMAIER, C (corresponding author), KERNFORSCHUNGSZENTRUM KARLSRUHE GMBH,INST GENET,D-76021 KARLSRUHE,GERMANY.							ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; BETSHOLTZ C, 1986, P NATL ACAD SCI USA, V83, P6440, DOI 10.1073/pnas.83.17.6440; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BUSCHER M, 1988, ONCOGENE, V3, P301; COCHET C, 1984, J BIOL CHEM, V259, P2553; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; ELLEM KAO, 1988, CARCINOGENESIS, V9, P797, DOI 10.1093/carcin/9.5.797; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HERRLICH P, 1992, REV PHYSIOL BIOCH P, V119, P187; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HUANG SS, 1988, J BIOL CHEM, V263, P12608; JANKNECHT R, 1992, NUCLEIC ACIDS RES, V20, P3317, DOI 10.1093/nar/20.13.3317; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JANKNECHT R, 1994, ONCOGENE, V9, P1273; JOHNSON RM, 1989, SCIENCE, V246, P121, DOI 10.1126/science.2506643; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KRAFT AS, 1982, J BIOL CHEM, V257, P13193; KRAMER M, 1993, J BIOL CHEM, V268, P6734; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MATTHIAS P, 1989, NUCLEIC ACIDS RES, V17, P6418, DOI 10.1093/nar/17.15.6418; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; OBERMEIER A, 1993, EMBO J, V12, P933, DOI 10.1002/j.1460-2075.1993.tb05734.x; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PINGOUD V, 1994, IN PRESS J BIOL CHEM; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; Rahmsdorf H., 1992, INDUCED EFFECTS GENO, P141; REDEMANN N, 1992, MOL CELL BIOL, V12, P491, DOI 10.1128/MCB.12.2.491; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; SACHSENMAIER C, 1994, BIOCHEM PHARMACOL, V47, P129, DOI 10.1016/0006-2952(94)90446-4; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SCHORPP M, 1984, CELL, V37, P861, DOI 10.1016/0092-8674(84)90421-5; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; STEIN B, 1992, PHOTOCHEM PHOTOBIOL, V55, P409, DOI 10.1111/j.1751-1097.1992.tb04255.x; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; WASILENKO WJ, 1990, MOL CELL BIOL, V10, P1254, DOI 10.1128/MCB.10.3.1254; YAROSH DB, 1993, J INVEST DERMATOL, V100, P790, DOI 10.1111/1523-1747.ep12476573; YAYON A, 1990, P NATL ACAD SCI USA, V87, P5346, DOI 10.1073/pnas.87.14.5346; ZINCK R, 1993, EMBO J, V12, P2377, DOI 10.1002/j.1460-2075.1993.tb05892.x	53	414	422	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 23	1994	78	6					963	972		10.1016/0092-8674(94)90272-0	http://dx.doi.org/10.1016/0092-8674(94)90272-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PJ294	7923365				2022-12-24	WOS:A1994PJ29400008
J	SOGAARD, M; TANI, K; YE, RR; GEROMANOS, S; TEMPST, P; KIRCHHAUSEN, T; ROTHMAN, JE; SOLLNER, T				SOGAARD, M; TANI, K; YE, RR; GEROMANOS, S; TEMPST, P; KIRCHHAUSEN, T; ROTHMAN, JE; SOLLNER, T			A RAB PROTEIN IS REQUIRED FOR THE ASSEMBLY OF SNARE COMPLEXES IN THE DOCKING OF TRANSPORT VESICLES	CELL			English	Article							INTEGRAL MEMBRANE-PROTEIN; BINDING YPT1 PROTEIN; VESICULAR TRANSPORT; ENDOPLASMIC-RETICULUM; SECRETORY PATHWAY; GOLGI-COMPLEX; SYNAPTIC VESICLES; NEUROTRANSMITTER RELEASE; SACCHAROMYCES-CEREVISIAE; FUSION PROTEIN	Rab proteins are generally required for transport vesicle docking. We have exploited yeast secretion mutants to demonstrate that a rab protein is required for v-SNAREs and t-SNAREs to assemble. The absence of the rab protein in the docking complex suggests that, in a broad sense, rab proteins participate in a reaction catalyzing SNARE complex assembly. In so doing, mb proteins could help impart an additional layer of specificity to vesicle docking. This mechanism likely involves the Sec1 homolog Sly1, which we identified in isolated docking complexes. We also report the identification of a novel v-SNARE (Ykt6p) component of the yeast ER-Golgi docking complex that has a CAAX box and is predicted to be lipid anchored. The surprising finding that docking complexes can contain many distinct species of SNAREs (Sed5p, Bos1p, Sec22p, Ykt6p, and likely Bet1p, p28, and p14) suggests that multimeric interactions are features of the fusion machinery, and may also improve the fidelity of vesicle targeting.	MEM SLOAN KETTERING CANC CTR,PROGRAM MOLEC BIOL,NEW YORK,NY 10021; HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,CTR BLOOD RES,BOSTON,MA 02115	Memorial Sloan Kettering Cancer Center; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School	SOGAARD, M (corresponding author), MEM SLOAN KETTERING CANC CTR,CELLULAR BIOCHEM & BIOPHYS PROGRAM,1275 YORK AVE,NEW YORK,NY 10021, USA.				NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NCI NIH HHS [5 P30 CA08748-29] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AALTO MK, 1992, CELL, V68, P181, DOI 10.1016/0092-8674(92)90462-L; AALTO MK, 1993, EMBO J, V12, P4095, DOI 10.1002/j.1460-2075.1993.tb06093.x; BANFIELD D, 1994, IN PRESS J CELL BIOL; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BAUMERT M, 1989, EMBO J, V8, P379, DOI 10.1002/j.1460-2075.1989.tb03388.x; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BENNETT MK, 1994, ANNU REV BIOCHEM, V63, P63, DOI 10.1146/annurev.bi.63.070194.000431; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BLASI J, 1993, NATURE, V365, P160, DOI 10.1038/365160a0; BLASI J, 1993, EMBO J, V12, P4821, DOI 10.1002/j.1460-2075.1993.tb06171.x; BRENNWALD P, 1993, NATURE, V362, P560, DOI 10.1038/362560a0; CAIN CC, 1992, J BIOL CHEM, V267, P11681; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; DASCHER C, 1991, MOL CELL BIOL, V11, P872, DOI 10.1128/MCB.11.2.872; DUJON B, 1994, NATURE, V369, P371, DOI 10.1038/369371a0; DUNN B, 1993, NATURE, V362, P563, DOI 10.1038/362563a0; ELICONE C, 1994, J CHROMATOGR A, V676, P121, DOI 10.1016/0021-9673(94)00089-1; EVAN GI, 1984, MOL CELL BIOL, V4, P2843, DOI 10.1128/MCB.4.12.2843; FERRONOVICK S, 1993, ANNU REV CELL BIOL, V9, P575; GALLWITZ D, 1983, NATURE, V306, P704, DOI 10.1038/306704a0; GARCIA EP, 1994, P NATL ACAD SCI USA, V91, P2003, DOI 10.1073/pnas.91.6.2003; GEROMANOS S, 1994, TECHNIQUES PROTEIN C, V5, P143; GRIFF IC, 1992, J BIOL CHEM, V267, P12106; HARDWICK KG, 1992, J CELL BIOL, V119, P513, DOI 10.1083/jcb.119.3.513; HARLOW E, 1988, ANTIBODIES LABORATOR; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; KNUDSEN KA, 1985, ANAL BIOCHEM, V147, P285, DOI 10.1016/0003-2697(85)90273-8; LIAN JP, 1993, CELL, V73, P735, DOI 10.1016/0092-8674(93)90253-M; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; NEWMAN AP, 1990, MOL CELL BIOL, V10, P3405, DOI 10.1128/MCB.10.7.3405; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; ORCI L, 1989, CELL, V56, P357, DOI 10.1016/0092-8674(89)90239-0; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; PEVSNER J, 1994, P NATL ACAD SCI USA, V91, P1445, DOI 10.1073/pnas.91.4.1445; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; PLUTNER H, 1991, J CELL BIOL, V115, P31, DOI 10.1083/jcb.115.1.31; PROTOPOPOV V, 1993, CELL, V74, P855, DOI 10.1016/0092-8674(93)90465-3; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; REISS Y, 1991, P NATL ACAD SCI USA, V88, P732, DOI 10.1073/pnas.88.3.732; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SALAMA NR, 1993, EMBO J, V12, P4073, DOI 10.1002/j.1460-2075.1993.tb06091.x; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; SEGEV N, 1991, SCIENCE, V252, P1553, DOI 10.1126/science.1904626; SHIM J, 1991, J CELL BIOL, V113, P55, DOI 10.1083/jcb.113.1.55; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; TEMPST P, 1990, ELECTROPHORESIS, V11, P537, DOI 10.1002/elps.1150110704; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749; TRIMBLE WS, 1988, P NATL ACAD SCI USA, V85, P4538, DOI 10.1073/pnas.85.12.4538; VONMOLLARD GF, 1991, NATURE, V349, P79, DOI 10.1038/349079a0; WADA Y, 1990, MOL CELL BIOL, V10, P2214, DOI 10.1128/MCB.10.5.2214; WATERS MG, 1986, J CELL BIOL, V102, P1543, DOI 10.1083/jcb.102.5.1543; WHITE JM, 1992, SCIENCE, V258, P917, DOI 10.1126/science.1439803; WHITEHEART SW, 1993, NATURE, V362, P353, DOI 10.1038/362353a0; WILSON DW, 1992, J CELL BIOL, V117, P531, DOI 10.1083/jcb.117.3.531; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0	62	465	470	2	20	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 23	1994	78	6					937	948		10.1016/0092-8674(94)90270-4	http://dx.doi.org/10.1016/0092-8674(94)90270-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PJ294	7923363				2022-12-24	WOS:A1994PJ29400006
J	TAKAHAMA, Y; SUZUKI, H; KATZ, KS; GRUSBY, MJ; SINGER, A				TAKAHAMA, Y; SUZUKI, H; KATZ, KS; GRUSBY, MJ; SINGER, A			POSITIVE SELECTION OF CD4+ T-CELLS BY TCR LIGATION WITHOUT AGGREGATION EVEN IN THE ABSENCE OF MHC	NATURE			English	Article							CD3/T-CELL RECEPTOR COMPLEX; CLASS-II MOLECULES; MONOCLONAL-ANTIBODY; ANTIGEN RECEPTOR; IMMATURE THYMOCYTES; NEGATIVE SELECTION; TRANSGENIC MICE; CROSS-LINKING; THYMUS; BETA	THE developmental fate of immature thymocytes is determined by the specificity of their T-cell antigen receptors (TCRs). Immature CD4(+)8(+) thymocytes are positively selected to differentiate into mature T cells by recognition of peptides associated with major histocompatibility complex (MHC) encoded molecules(7-10) on But neither the identity of molecules transducing positive selection signals nor the nature of the signals themselves is fully known. Here we report that direct ligation of TCR molecules by monoclonal antibodies specific for either clonotypic or CD3 chains can signal immature thymocytes to differentiate into mature CD4(+)8(-) T cells, even in the absence of MHC expression and MHC-dependent CD4 co-receptor signalling. Moreover, we show that TCR engagement induces positive selection signals only in the absence of TCR aggregation and that TCR aggregation is inhibitory for positive selection. Thus, low valency of TCR crosslinking is a critical parameter(15), distinguishing positive selection from other TCR-mediated signalling events.	NCI, EXPTL IMMUNOL BRANCH, BETHESDA, MD 20892 USA; SYNTEX INST IMMUNOL, NIIHARI 30041, JAPAN; HARVARD UNIV, SCH PUBL HLTH, DEPT CANC BIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT RHEUMATOL, BOSTON, MA 02115 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School			Takahama, Yousuke/A-5863-2010; Suzuki, Harumi/L-1271-2013	Takahama, Yousuke/0000-0002-4992-9174; Suzuki, Harumi/0000-0003-3616-9361				ANDERSON G, 1993, NATURE, V362, P70, DOI 10.1038/362070a0; ASHTONRICKARDT PG, 1993, CELL, V73, P1041, DOI 10.1016/0092-8674(93)90281-T; ASHTONRICKARDT PG, 1994, CELL, V76, P651, DOI 10.1016/0092-8674(94)90505-3; BERG LJ, 1989, CELL, V58, P1035, DOI 10.1016/0092-8674(89)90502-3; BLACKMAN M, 1990, SCIENCE, V248, P1335, DOI 10.1126/science.1972592; BLUMBERG RS, 1990, P NATL ACAD SCI USA, V87, P7220, DOI 10.1073/pnas.87.18.7220; BORN W, 1987, J IMMUNOL, V138, P999; CHAN SH, 1993, CELL, V73, P225, DOI 10.1016/0092-8674(93)90225-F; COSGROVE D, 1991, CELL, V66, P1051, DOI 10.1016/0092-8674(91)90448-8; COULIE PG, 1991, EUR J IMMUNOL, V21, P1703, DOI 10.1002/eji.1830210718; DELAHERA A, 1991, J EXP MED, V173, P7, DOI 10.1084/jem.173.1.7; DINTZIS HM, 1976, P NATL ACAD SCI USA, V73, P3671, DOI 10.1073/pnas.73.10.3671; DOYLE C, 1987, NATURE, V330, P256, DOI 10.1038/330256a0; FINKEL TH, 1989, CELL, V58, P1047, DOI 10.1016/0092-8674(89)90503-5; GRUSBY MJ, 1993, P NATL ACAD SCI USA, V90, P3913, DOI 10.1073/pnas.90.9.3913; GRUSBY MJ, 1991, SCIENCE, V253, P1417, DOI 10.1126/science.1910207; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; HUGO P, 1992, NATURE, V360, P679, DOI 10.1038/360679a0; HUNIG T, 1988, EUR J IMMUNOL, V18, P2089, DOI 10.1002/eji.1830181234; KAYE J, 1992, CELL, V71, P423, DOI 10.1016/0092-8674(92)90512-B; KILLEEN N, 1993, NATURE, V364, P729, DOI 10.1038/364729a0; KOURILSKY P, 1989, CELL, V56, P327, DOI 10.1016/0092-8674(89)90233-X; KUBO RT, 1989, J IMMUNOL, V142, P2736; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LO D, 1986, NATURE, V319, P672, DOI 10.1038/319672a0; MANDEL TE, 1978, IMMUNOLOGY, V35, P317; MARRACK P, 1989, NATURE, V338, P503, DOI 10.1038/338503a0; MCCONKEY DJ, 1989, J IMMUNOL, V143, P1801; MCDUFFIE M, 1986, P NATL ACAD SCI USA, V83, P8728, DOI 10.1073/pnas.83.22.8728; MULLER KP, 1993, EUR J IMMUNOL, V23, P1661, DOI 10.1002/eji.1830230740; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; NAKAYAMA T, 1991, P NATL ACAD SCI USA, V88, P9949, DOI 10.1073/pnas.88.22.9949; PIRCHER H, 1989, NATURE, V342, P559, DOI 10.1038/342559a0; PUNT JA, 1993, J IMMUNOL, V151, P1290; PUNT JA, 1994, J EXP MED, V180, P587, DOI 10.1084/jem.180.2.587; ROBINSON JH, 1976, CLIN EXP IMMUNOL, V23, P347; SEBZDA E, 1994, SCIENCE, V263, P1615, DOI 10.1126/science.8128249; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; SINGER A, 1987, TRANSPLANT P, V19, P107; Singer A., 1986, PROG IMMUNOL, V6, P60; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; SWAIN SL, 1983, IMMUNOL REV, V74, P129, DOI 10.1111/j.1600-065X.1983.tb01087.x; TAKAHAMA Y, 1992, SCIENCE, V258, P1456, DOI 10.1126/science.1439838; TEH HS, 1988, NATURE, V335, P229, DOI 10.1038/335229a0; VUKMANOVIC S, 1992, NATURE, V359, P729, DOI 10.1038/359729a0; YACHELINI P, 1990, J IMMUNOL, V145, P1382	46	77	77	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 1	1994	371	6492					67	70		10.1038/371067a0	http://dx.doi.org/10.1038/371067a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PE381	7915400				2022-12-24	WOS:A1994PE38100052
J	CAO, XY; JIANG, XM; KAREEM, A; DOU, ZH; RAKEMAN, MA; ZHANG, ML; MA, T; ODONNELL, K; DELONG, N; DELONG, GR				CAO, XY; JIANG, XM; KAREEM, A; DOU, ZH; RAKEMAN, MA; ZHANG, ML; MA, T; ODONNELL, K; DELONG, N; DELONG, GR			IODINATION OF IRRIGATION WATER AS A METHOD OF SUPPLYING IODINE TO A SEVERELY IODINE-DEFICIENT POPULATION IN XINJIANG, CHINA	LANCET			English	Article								Severe iodine deficiency still occurs in many countries, and causes cretinism and mental impairment. In southern Xinjiang province, China, after usual methods of iodine supplementation had failed, we iodinated irrigation water to increase iodine in soil, crops, animals, and human beings. 5% potassium iodate solution, dripped into an irrigation canal for 12 or 24 days, increased soil iodine 3-fold, and crop and animal iodine 2-fold. Median urinary iodine excretion in children increased from 18 to 49 mu g/L (two groups of similar age). The cost for iodine was US $0.05 per person per year. Soil iodine remained stable over one winter, and dripping of iodine during the second year (US $0.12 per person per year) resulted in a further 4-fold increase in soil iodine and a 1.8-fold increase in iodine in crops. We conclude that iodination of irrigation water is an advantageous and cost-effective method of supplying iodine in southern Xinjiang, and may be useful in other areas dependent on irrigation.	DUKE UNIV, MED CTR, DURHAM, NC 27710 USA; XINJIANG HLTH & ANTIEPIDEM STN, XINJIANG, PEOPLES R CHINA; INST ENDEM DIS CONTROL & RES, XINJIANG, PEOPLES R CHINA; TIANJIN MED COLL, TIANJIN, PEOPLES R CHINA	Duke University; Tianjin Medical University								ANKE M, 1991, ELIMINATION IODINE D, P1; DELANGE F, 1990, ACTA CLIN BELG, V45, P394, DOI 10.1080/17843286.1990.11718117; DELANGE FM, 1981, FETAL BRAIN DISORDER, P285; Delong G. Robeert, 1993, American Journal of Clinical Nutrition, V57, p286S, DOI 10.1093/ajcn/57.2.286S; DELONG GR, 1989, IODINE BRAIN; Delong R., 1986, PREVENTION CONTROL I, P49; Dunn JT., 1987, PREVENTION CONTROL I, P135; FISHER KD, 1974, PB233599; HALPERN JP, 1991, BRAIN, V114, P825, DOI 10.1093/brain/114.2.825; HEMKEN RW, 1972, J DAIRY SCI, V55, P931, DOI 10.3168/jds.S0022-0302(72)85599-1; Hetzel B.S., 1986, TRACE ELEMENTS HUMAN, P139; 1980, MINERAL TOLERANCE DO, P227	12	69	74	1	13	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 9	1994	344	8915					107	110		10.1016/S0140-6736(94)91286-6	http://dx.doi.org/10.1016/S0140-6736(94)91286-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NV732	7912349				2022-12-24	WOS:A1994NV73200014
J	WEDEGAERTNER, PB; BOURNE, HR				WEDEGAERTNER, PB; BOURNE, HR			ACTIVATION AND DEPALMITOYLATION OF G(S-ALPHA)	CELL			English	Article							HUMAN BETA-2-ADRENERGIC RECEPTOR; BETA-ADRENERGIC RECEPTORS; G-PROTEIN; ALPHA-SUBUNIT; ADENYLATE-CYCLASE; PLASMA-MEMBRANE; PALMITOYLATION; STIMULATION; MUTATION; BINDING	[H-3]palmitate attached to mutationally activated alpha(s) (alpha(s)-R201C) turns over rapidly, compared with palmitate linked to normal alpha(s) (t(1/2) approximate to 2 min versus 90 min); although alpha(s)-R201C (unlike normal alpha(s)) is predominantly found in the cytosol, [3H]palmitate is linked only to the membrane-bound pool of alpha(s), normal or mutant. Similarly, activation of wild-type alpha(s) by isoproterenol, a beta-adrenoceptor agonist that also induces membrane-to-cytosol translocation of alpha(s), dramatically accelerates depalmitoylation of alpha(s). Thus, activation-induced removal of palmitate provides an explanation for activation-induced shifts of alpha(s) to the cytosol. Regulated palmitoylation cycles provide a potential general mechanism for controlling reversible changes in the cellular location and activity of a protein.	UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,DEPT MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	WEDEGAERTNER, PB (corresponding author), UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,DEPT PHARMACOL,SAN FRANCISCO,CA 94143, USA.				NCI NIH HHS [CA-54427] Funding Source: Medline; NIGMS NIH HHS [GM-27800] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054427] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027800, R37GM027800] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; BIGAY J, 1985, FEBS LETT, V191, P181, DOI 10.1016/0014-5793(85)80004-1; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; BOMSEL M, 1993, J BIOL CHEM, V268, P25824; BOMSEL M, 1992, MOL BIOL CELL, V3, P1317, DOI 10.1091/mbc.3.12.1317; BOURNE HR, 1981, MOL PHARMACOL, V20, P435; CAMP LA, 1993, J BIOL CHEM, V268, P22566; DEGTYAREV MY, 1993, J BIOL CHEM, V268, P23769; DEGTYAREV MY, 1993, BIOCHEMISTRY-US, V32, P8057, DOI 10.1021/bi00083a001; Grassie Morag A., 1993, Biochemical Society Transactions, V21, p499S; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HUANG EM, 1989, BIOCHIM BIOPHYS ACTA, V1011, P134, DOI 10.1016/0167-4889(89)90200-0; JAMES G, 1990, BIOCHEMISTRY-US, V29, P2623, DOI 10.1021/bi00463a001; JAMES G, 1989, J BIOL CHEM, V264, P20998; JOCHEN A, 1991, BIOCHEM BIOPH RES CO, V177, P797, DOI 10.1016/0006-291X(91)91859-B; KAHN RA, 1993, CELL, V75, P1045, DOI 10.1016/0092-8674(93)90314-G; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LEE E, 1992, J BIOL CHEM, V267, P1212; LEVIS MJ, 1992, J CELL BIOL, V119, P1297, DOI 10.1083/jcb.119.5.1297; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; MILLER RT, 1988, NATURE, V334, P712, DOI 10.1038/334712a0; MOFFETT S, 1993, EMBO J, V12, P349, DOI 10.1002/j.1460-2075.1993.tb05663.x; MOUILLAC B, 1992, J BIOL CHEM, V267, P21733; NEGISHI M, 1992, J BIOL CHEM, V267, P2367; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; PARENTI M, 1993, BIOCHEM J, V291, P349, DOI 10.1042/bj2910349; PEITZSCH RM, 1993, BIOCHEMISTRY-US, V32, P10436, DOI 10.1021/bi00090a020; PIMLIKAR SW, 1993, NATURE, V362, P456; RANSNAS LA, 1989, P NATL ACAD SCI USA, V86, P7900, DOI 10.1073/pnas.86.20.7900; SALOMON MR, 1981, MOL PHARMACOL, V19, P109; SUDO Y, 1992, EMBO J, V11, P2095, DOI 10.1002/j.1460-2075.1992.tb05268.x; WEDEGAERTNER PB, 1993, J BIOL CHEM, V268, P25001; ZUBER MX, 1989, NATURE, V341, P345, DOI 10.1038/341345a0	35	321	321	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 1	1994	77	7					1063	1070		10.1016/0092-8674(94)90445-6	http://dx.doi.org/10.1016/0092-8674(94)90445-6			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NV425	7912657				2022-12-24	WOS:A1994NV42500014
J	NIGRO, G; ZERBINI, M; KRZYSZTOFIAK, A; GENTILOMI, G; PORCARO, MA; MANGO, T; MUSIANI, M				NIGRO, G; ZERBINI, M; KRZYSZTOFIAK, A; GENTILOMI, G; PORCARO, MA; MANGO, T; MUSIANI, M			ACTIVE OR RECENT PARVOVIRUS B19 INFECTION IN CHILDREN WITH KAWASAKI-DISEASE	LANCET			English	Note								Because parvovirus B19 occasionally causes some of the features typical of Kawasaki disease, we investigated B19 involvement in 15 children with Kawasaki disease. Active or recent B19 infection, as shown by B19-DNAaemia, positive B19-specific IgM antibodies, or both, was diagnosed in 10 patients (67%). A high frequency of all major criteria for diagnosis of Kawasaki disease (60%), anaemia (60%), coronary aneurysms (30%), and arthropathy (30%) was found in children with B19-associated Kawasaki disease. Thus B19 may have a pathogenic role in the development of Kawasaki disease, with other predisposing factors.	UNIV ROMA LA SAPIENZA,INST PAEDIAT,ROME,ITALY; CNR,INST EXPTL MED,ROME,ITALY; UNIV BOLOGNA,INST MICROBIOL,BOLOGNA,ITALY	Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR); University of Bologna								KATO H, 1992, LANCET, V340, P1127, DOI 10.1016/0140-6736(92)93152-D; KURTZMAN GJ, 1989, J CLIN INVEST, V84, P1114, DOI 10.1172/JCI114274; LEVIN M, 1991, ARCH DIS CHILD, V66, P1369, DOI 10.1136/adc.66.12.1369; MORTIMER PP, 1985, LANCET, V2, P730; MUSIANI M, 1993, J MED VIROL, V40, P157, DOI 10.1002/jmv.1890400214; NIGRO G, 1993, AIDS, V7, P288, DOI 10.1097/00002030-199302000-00026; PLUMMER FA, 1985, NEW ENGL J MED, V313, P74, DOI 10.1056/NEJM198507113130203; ROWLEY AH, 1991, ADV PEDIATR, P51; ZERBINI M, 1993, J VIROL METHODS, V40, P157	9	112	115	1	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 21	1994	343	8908					1260	1261		10.1016/S0140-6736(94)92154-7	http://dx.doi.org/10.1016/S0140-6736(94)92154-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NM144	7910278				2022-12-24	WOS:A1994NM14400012
J	SHIMELL, MJ; SIMON, J; BENDER, W; OCONNOR, MB				SHIMELL, MJ; SIMON, J; BENDER, W; OCONNOR, MB			ENHANCER POINT MUTATION RESULTS IN A HOMEOTIC TRANSFORMATION IN DROSOPHILA	SCIENCE			English	Article							BITHORAX COMPLEX; ANTENNAPEDIA GENE; EXPRESSION; HUNCHBACK; ULTRABITHORAX; SEGMENTATION; PRODUCTS; PROTEINS; EMBRYOS; KRUPPEL	In Drosophila, the misexpression or altered activity of genes from the bithorax complex results in homeotic transformations. One of these genes, abd-A, normally specifies the identity of the second through fourth abdominal segments (A2 to A4). In the dominant Hyperabdominal mutations (Hab), portions of the third thoracic segment (T3) are transformed toward A2 as the result of ectopic abd-A expression. Sequence analysis and deoxyribonuclease I footprinting demonstrate that the misexpression of abd-A in two independent Hab mutations results from the same single base change in a binding site for the gap gene Kruppel protein. These results establish that the spatial limits of the homeotic genes are directly regulated by gap gene products.	UNIV CALIF IRVINE,DEPT MOLEC BIOL & BIOCHEM,IRVINE,CA 92717; UNIV CALIF IRVINE,CTR DEV BIOL,IRVINE,CA 92717; UNIV MINNESOTA,DEPT BIOCHEM,ST PAUL,MN 55108; HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115	University of California System; University of California Irvine; University of California System; University of California Irvine; University of Minnesota System; University of Minnesota Twin Cities; Harvard University; Harvard Medical School			O'Connor, Michael B/C-9977-2014	O'Connor, Michael B/0000-0002-3067-5506				Bencini DA, 1984, BIOTECHNIQUES, V2, P4; BERRY M, 1992, NATURE, V358, P499, DOI 10.1038/358499a0; CELNIKER SE, 1989, GENE DEV, V3, P1424, DOI 10.1101/gad.3.9.1424; CELNIKER SE, 1993, P NATL ACAD SCI USA, V90, P1566, DOI 10.1073/pnas.90.4.1566; CRIBBS DL, 1992, GENETICS, V132, P699; CURTIS D, 1989, GENETICS, V122, P653; DRIEVER W, 1989, NATURE, V340, P363, DOI 10.1038/340363a0; DUNCAN I, 1987, ANNU REV GENET, V21, P285, DOI 10.1146/annurev.ge.21.120187.001441; DUNCAN I, COMMUNICATION; FRISCHER LE, 1986, CELL, V47, P1017, DOI 10.1016/0092-8674(86)90816-0; GYURKOVICS H, 1990, EMBO J, V9, P2579, DOI 10.1002/j.1460-2075.1990.tb07439.x; HARDING K, 1988, EMBO J, V7, P205, DOI 10.1002/j.1460-2075.1988.tb02801.x; HOEY T, 1988, NATURE, V332, P858, DOI 10.1038/332858a0; IRISH VF, 1989, EMBO J, V8, P1527, DOI 10.1002/j.1460-2075.1989.tb03537.x; JIANG J, 1991, GENE DEV, V5, P1881, DOI 10.1101/gad.5.10.1881; JORGENSEN EM, 1987, GENE DEV, V1, P544, DOI 10.1101/gad.1.6.544; KARCH F, 1990, GENE DEV, V4, P1573, DOI 10.1101/gad.4.9.1573; KARCH F, UNPUB; Kaufman T C, 1990, Adv Genet, V27, P309; KAZAZIAN HH, 1986, COLD SPRING HARB SYM, V51, P371, DOI 10.1101/SQB.1986.051.01.045; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; Lewis Edith, COMMUNICATION; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; MANN RS, 1990, CELL, V60, P597, DOI 10.1016/0092-8674(90)90663-Y; Pankratz Michael J., 1993, P467; PEIFER M, 1987, GENE DEV, V1, P891, DOI 10.1101/gad.1.9.891; QIAN S, 1991, EMBO J, V10, P1415, DOI 10.1002/j.1460-2075.1991.tb07662.x; QIAN S, 1993, EMBO J, V12, P3865, DOI 10.1002/j.1460-2075.1993.tb06065.x; REINITZ J, 1990, DEV BIOL, V140, P57, DOI 10.1016/0012-1606(90)90053-L; ROSENBERG UB, 1986, NATURE, V319, P336, DOI 10.1038/319336a0; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SAUER F, 1993, NATURE, V364, P454, DOI 10.1038/364454a0; SHIMELL M, UNPUB; SIMON J, 1990, EMBO J, V9, P3945, DOI 10.1002/j.1460-2075.1990.tb07615.x; SIMON J, UNPUB; SIMON J, 1993, DEV BIOL, V158, P134; STANOJEVIC D, 1989, NATURE, V341, P331, DOI 10.1038/341331a0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TREISMAN J, 1989, NATURE, V341, P335, DOI 10.1038/341335a0; WHITE RAH, 1986, CELL, V47, P311, DOI 10.1016/0092-8674(86)90453-8; WHITE RAH, 1985, NATURE, V318, P567, DOI 10.1038/318567a0; ZHANG CC, 1991, DEVELOPMENT, V113, P1171	43	77	77	1	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 13	1994	264	5161					968	971		10.1126/science.7909957	http://dx.doi.org/10.1126/science.7909957			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NK974	7909957				2022-12-24	WOS:A1994NK97400036
J	JOBST, KA; SMITH, AD; SZATMARI, M; ESIRI, MM; JASKOWSKI, A; HINDLEY, N; MCDONALD, B; MOLYNEUX, AJ				JOBST, KA; SMITH, AD; SZATMARI, M; ESIRI, MM; JASKOWSKI, A; HINDLEY, N; MCDONALD, B; MOLYNEUX, AJ			RAPIDLY PROGRESSING ATROPHY OF MEDIAL TEMPORAL-LOBE IN ALZHEIMERS-DISEASE	LANCET			English	Note							DEMENTIA; TOMOGRAPHY	The symptoms of Alzheimer's disease are associated with pathological change and loss of neurons in the medial temporal lobe. By yearly temporal-lobe-oriented computed tomograms the average rate of atrophy of the medial temporal lobe was 15.1% per year (95% CI 10.0, 20.2) in 20 patients with histopathologically, confirmed Alzheimer's disease and 1.5% (0.2, 2.8) in 47 healthy ageing controls. Such excessive atrophy presumably reflects the vulnerability of the medial temporal lobe to a catastrophic event, probably a pathological cascade process. Thus, Alzheimer's disease may not be due simply to an acceleration of normal ageing but, rather, is the consequence of a true disease process.	UNIV OXFORD,DEPT PHARMACOL,OXFORD PROJECT INVESTIGATE MEMORY & AGEING,OXFORD OX1 3QT,ENGLAND; UNIV OXFORD,DEPT CLIN NEUROL,OXFORD OX1 3QT,ENGLAND; RADCLIFFE INFIRM,DEPT NEUROPATHOL,OXFORD OX2 6HE,ENGLAND; RADCLIFFE INFIRM,DEPT NEURORADIOL,OXFORD OX2 6HE,ENGLAND	University of Oxford; University of Oxford; Radcliffe Infirmary; Radcliffe Infirmary			Smith, Anthony D./A-4233-2010	Smith, Anthony D./0000-0002-1095-6722				BOWEN DM, 1979, LANCET, V1, P11; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; BRAYNE C, 1988, LANCET, V1, P1265; DECARLI C, 1990, NEUROLOGY, V40, P872, DOI 10.1212/WNL.40.6.872; DECARLI C, 1992, NEUROLOGY, V42, P2029; DELEON MJ, 1989, LANCET, V2, P672; JOBST KA, 1992, LANCET, V340, P1179; JORM AF, 1990, EPIDEMIOLOGY ALZHEIM; LUXENBERG JS, 1987, NEUROLOGY, V37, P1135, DOI 10.1212/WNL.37.7.1135; MANN DMA, 1988, NEW ENGL J MED, V318, P789	10	189	190	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 2	1994	343	8901					829	830		10.1016/S0140-6736(94)92028-1	http://dx.doi.org/10.1016/S0140-6736(94)92028-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ND792	7908080				2022-12-24	WOS:A1994ND79200011
J	HUNTINGTON, J; CONNELL, FA				HUNTINGTON, J; CONNELL, FA			FOR EVERY DOLLAR SPENT - THE COST SAVINGS ARGUMENT FOR PRENATAL-CARE	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							LOW-BIRTH-WEIGHT; MEDICAID; PROJECT; IMPACT; INFANT; BARRIERS; WOMEN		UNIV WASHINGTON,SCH PUBL HLTH & COMMUNITY MED,DEPT HLTH SERV,SEATTLE,WA 98195; GRP HLTH COOPERAT PUGET SOUND,SEATTLE,WA 98112	University of Washington; University of Washington Seattle; Group Health Cooperative					PHS HHS [MCJ 9043] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BUESCHER PA, 1987, AM J OBSTET GYNECOL, V156, P204, DOI 10.1016/0002-9378(87)90239-0; CURRY M, 1987, ACCESS PRENATAL CARE; ENKIN M, 1982, CLIN DEV MED, V81, P266; GORSKY RD, 1989, HEALTH SERV RES, V24, P583; GUYER B, 1990, JAMA-J AM MED ASSOC, V264, P2264, DOI 10.1001/jama.264.17.2264; HAAS JS, 1993, JAMA-J AM MED ASSOC, V269, P87, DOI 10.1001/jama.269.1.87; HALL MH, 1980, LANCET, V2, P78; Huntington JL, 1913, BOSTON MED SURG J, V169, P763, DOI 10.1056/NEJM191311201692108; KORENBROT CC, 1984, MOBIUS, V4, P34; Lazarus E S, 1990, Med Anthropol, V12, P269; Leavitt J.W., 1986, BROUGHT BED CHILDBEA; Lennie J A, 1987, Health Care Financ Rev, V8, P83; LEPPERT PC, 1985, J NURSE-MIDWIFERY, V30, P285, DOI 10.1016/0091-2182(85)90044-8; LEVENO KJ, 1985, OBSTET GYNECOL, V66, P599; MOORE TR, 1986, AM J OBSTET GYNECOL, V154, P29, DOI 10.1016/0002-9378(86)90387-X; Morales W J, 1985, J Fla Med Assoc, V72, P852; OAKLEY A, 1990, BRIT J OBSTET GYNAEC, V97, P155, DOI 10.1111/j.1471-0528.1990.tb01741.x; PEOPLES MD, 1984, AM J PUBLIC HEALTH, V74, P549, DOI 10.2105/AJPH.74.6.549; PIPER JM, 1990, JAMA-J AM MED ASSOC, V264, P2219, DOI 10.1001/jama.264.17.2219; POLAND ML, 1987, AM J OBSTET GYNECOL, V157, P297, DOI 10.1016/S0002-9378(87)80156-4; SARDELL A, 1990, J HEALTH POLIT POLIC, V15, P271, DOI 10.1215/03616878-15-2-271; SCHRAMM WF, 1992, PUBLIC HEALTH REP, V107, P647; SCHWARTZ RM, 1989, FAM PLANN PERSPECT, V21, P170, DOI 10.2307/2135808; SOKOL RJ, 1980, OBSTET GYNECOL, V56, P150; STCLAIR PA, 1990, PUBLIC HEALTH REP, V105, P264; STROBINO DM, 1986, AM J PUBLIC HEALTH, V76, P274, DOI 10.2105/AJPH.76.3.274; Thompson JE, 1990, NEW PERSPECTIVES PAR, P9; Wertz Richard W., 1989, LYING HIST CHILDBIRT; WILSON AL, 1992, AM J PERINAT, V9, P281, DOI 10.1055/s-2007-994790; 1988, OTAH345 OFF TECHN AS; [No title captured]	31	70	71	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 10	1994	331	19					1303	1307		10.1056/NEJM199411103311910	http://dx.doi.org/10.1056/NEJM199411103311910			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PP752	7935689				2022-12-24	WOS:A1994PP75200010
J	AUBUCHON, JP; BIRKMEYER, JD				AUBUCHON, JP; BIRKMEYER, JD			SAFETY AND COST-EFFECTIVENESS OF SOLVENT-DETERGENT-TREATED PLASMA - IN SEARCH OF A ZERO-RISK BLOOD-SUPPLY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; FRESH-FROZEN PLASMA; ARTERY BYPASS-SURGERY; TRANSFUSION; HEPATITIS; INACTIVATION; INFECTION; DERIVATIVES; COMPONENTS; HIV	Objective.-To determine the public health and economic implications of Solvent-detergent-treated frozen plasma (SD FP). While this processing technique nearly eliminates the risk of transmitting lipid-enveloped viruses (hepatitis B and C and human immunodeficiency virus), it has associated costs and, because it requires pooling many plasma units, may increase risks of nonenveloped virus transmission. Design.-A previously published Markov decision analysis model was modified to assess transfusion-related outcomes in hypothetical cohorts of plasma recipients. In-hospital mortality and other characteristics were determined in 61 patients receiving plasma transfusions at a medium-sized tertiary care center to provide data for the model. Other parameters were obtained from the medical literature. Main Outcome Measures.-Expected SD FP costs, benefits, and cost-effectiveness, assessed as cost per quality-adjusted life-year saved. Results.-Compared with untreated plasma, a unit of SD FP produces a net benefit of 35 minutes in quality-adjusted life expectancy at a cost of about $19. Extrapolated to the 2.2 million plasma units transfused annually in the United States, SD FP would save 147 quality-adjusted life-years at a cost of $42.5 million. The marginal cost-effectiveness, $289 300 per quality-adjusted life-year saved in the baseline analysis, was most sensitive to estimates of SD treatment cost and the clinical setting of plasma use. In sensitivity analysis, the net benefit of SD FP was negated by the existence of even a minute risk of nonenveloped virus infection. Conclusions.-From a public health perspective, the relatively high costs and small benefits of reducing enveloped virus infection risks with SD FP (and the additional risks of nonenveloped virus transmission) do not appear to justify widespread implementation of this new technology.	DARTMOUTH COLL,HITCHCOCK MED CTR,DEPT SURG,LEBANON,NH 03756; DARTMOUTH COLL,HITCHCOCK MED CTR,CTR EVALUAT CLIN SCI,LEBANON,NH 03756	Dartmouth College; Dartmouth College	AUBUCHON, JP (corresponding author), DARTMOUTH COLL,HITCHCOCK MED CTR,DEPT PATHOL,1 MED CTR DR,LEBANON,NH 03756, USA.							ANDERSON LJ, 1991, CURR CLIN TOP INFECT, V11, P261; ARNO PS, 1989, JAMA-J AM MED ASSOC, V262, P1493, DOI 10.1001/jama.262.11.1493; AUBUCHON JP, 1992, CLIN LAB MED, V12, P787, DOI 10.1016/S0272-2712(18)30488-8; BECK JR, 1983, MED DECIS MAKING, V3, P419, DOI 10.1177/0272989X8300300403; BIRKMEYER JD, 1993, TRANSFUSION, V33, P544, DOI 10.1046/j.1537-2995.1993.33793325048.x; BIRKMEYER JD, 1994, ANN THORAC SURG, V57, P161, DOI 10.1016/0003-4975(94)90386-7; BLOOM BS, 1993, ANN INTERN MED, V118, P298, DOI 10.7326/0003-4819-118-4-199302150-00009; BOWDEN RA, 1991, BLOOD, V78, P246; BUSCH MP, 1991, NEW ENGL J MED, V325, P1, DOI 10.1056/NEJM199107043250101; COHEN BJ, 1990, J VIROL METHODS, V30, P233, DOI 10.1016/0166-0934(90)90065-N; CONTRERAS M, 1991, LANCET, V337, P753, DOI 10.1016/0140-6736(91)91370-A; CUMMING PD, 1989, NEW ENGL J MED, V321, P941, DOI 10.1056/NEJM198910053211405; DODD RY, 1992, NEW ENGL J MED, V327, P419, DOI 10.1056/NEJM199208063270610; DODD RY, 1990, TRANSFUSION MEDICINE IN THE 1990S, P223; DONAHUE JG, 1992, NEW ENGL J MED, V327, P869; EDDY DM, 1990, ANN INTERN MED, V113, P214, DOI 10.7326/0003-4819-113-3-214; EDWARDS CA, 1987, VOX SANG, V52, P53, DOI 10.1111/j.1423-0410.1987.tb02989.x; EVANS RW, 1986, SURG CLIN N AM, V66, P603; GERITZEN A, 1992, LANCET, V340, P1231; GOODNOUGH LT, 1991, JAMA-J AM MED ASSOC, V265, P86, DOI 10.1001/jama.265.1.86; HELLINGER FJ, 1993, JAMA-J AM MED ASSOC, V270, P474, DOI 10.1001/jama.270.4.474; HELLINGER FJ, 1990, PUBLIC HEALTH REP, V105, P1; HELLSTERN P, 1992, VOX SANG, V63, P178, DOI 10.1111/j.1423-0410.1992.tb05097.x; HOROWITZ B, 1990, YALE J BIOL MED, V63, P361; HOROWITZ B, 1985, TRANSFUSION, V25, P516, DOI 10.1046/j.1537-2995.1985.25686071422.x; HOROWITZ B, 1992, BLOOD, V79, P826; HOROWITZ B, 1985, TRANSFUSION, V25, P523, DOI 10.1046/j.1537-2995.1985.25686071423.x; HOROWITZ B, 1994, MAR FDA WORKSH ROL V; LEFRERE JJ, 1994, LANCET, V343, P211, DOI 10.1016/S0140-6736(94)90993-8; LEUSCHNER J, 1994, MAR FDA WORKSH ROL V; LONGINI IM, 1989, STAT MED, V8, P831, DOI 10.1002/sim.4780080708; MCOMISH F, 1993, J CLIN MICROBIOL, V31, P323, DOI 10.1128/JCM.31.2.323-328.1993; MENITOVE JE, 1990, ARCH PATHOL LAB MED, V114, P330; NELSON KE, 1992, ANN INTERN MED, V117, P554, DOI 10.7326/0003-4819-117-7-554; NORMANN A, 1992, LANCET, V340, P1232, DOI 10.1016/0140-6736(92)92938-C; PIET MPJ, 1990, TRANSFUSION, V30, P591, DOI 10.1046/j.1537-2995.1990.30790385516.x; PIQUET Y, 1992, VOX SANG, V63, P251, DOI 10.1111/j.1423-0410.1992.tb01230.x; SHANBERGE JN, 1992, TRANSFUSION MED, V2, P189, DOI 10.1111/j.1365-3148.1992.tb00154.x; SIMON TL, 1992, CLIN LAB MED, V12, P655, DOI 10.1016/S0272-2712(18)30479-7; SONNENBERG FA, 1988, 11TH P ANN S COMP AP; STANGE PV, 1978, NEW ENGL J MED, V298, P372, DOI 10.1056/NEJM197802162980705; SURGENOR D, 1994, MAR FDA WORKSH ROL V; VANDERPOEL CL, 1990, LANCET, V335, P558, DOI 10.1016/0140-6736(90)90347-8; WALLACE EL, 1993, TRANSFUSION, V33, P139, DOI 10.1046/j.1537-2995.1993.33293158046.x; WEINSTEIN MC, 1982, CIRCULATION, V66, P56; Weinstein MC, 1980, CLIN DECISION ANAL; WIEDING JU, 1993, ANN HEMATOL, V67, P259, DOI 10.1007/BF01696345; ZUCK TF, 1987, TRANSFUSION, V27, P447, DOI 10.1046/j.1537-2995.1987.27688071691.x; 1989, MMWR-MORBID MORTAL W, V38, P91; 1987, VITAL STATISTICS U A, V2, P8; 1991, MMWR-MORBID MORTAL W, V40, P1	51	64	64	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 19	1994	272	15					1210	1214		10.1001/jama.272.15.1210	http://dx.doi.org/10.1001/jama.272.15.1210			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL212	7933351				2022-12-24	WOS:A1994PL21200037
J	BESSER, RE; FEIKIN, DR; EBERHARTPHILLIPS, JE; MASCOLA, L; GRIFFIN, PM				BESSER, RE; FEIKIN, DR; EBERHARTPHILLIPS, JE; MASCOLA, L; GRIFFIN, PM			DIAGNOSIS AND TREATMENT OF CHOLERA IN THE UNITED-STATES - ARE WE PREPARED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note								Objective.-To assess cholera recognition and treatment by US health care workers in the largest cholera outbreak in the United States this century. Design.-We reviewed the medical records of passengers from a flight on which a cholera outbreak occurred. To determine the availability of oral rehydration solutions, we surveyed treatment facilities and referral pharmacies. Setting.-On February 14, 1992, more than 100 passengers on a flight from South America to Los Angeles, Calif, were infected with toxigenic Vibrio cholerae 01. Subjects.-Fifty-four of 67 passengers who sought care in California and Nevada. Results.-We reviewed the records of 54 passengers, including 39 with diarrhea and 15 without symptoms. All 17 persons who sought treatment before the outbreak was widely reported by the media had diarrhea. For 12 of these persons, recent travel to South America was noted, but only those four whose records listed cholera as a possible diagnosis were immediately hospitalized. Seven sought cars again within 3 days; three were dehydrated, two of these three were hospitalized, and one of these two died. None of the 26 patients suspected to have cholera received appropriate fluids; severely dehydrated patients did not receive Ringer's lactate solution and those not severely dehydrated did not receive an oral rehydration solution. None of the facilities and pharmacies involved stocked World Health Organization oral rehydration salts solution, the preferred solution for treating cho!era and other diarrheal diseases. Conclusions.-Treatment of cholera in the United States was suboptimal. Oral fluids appropriate for the treatment of cholera and other diarrheal diseases were generally unavailable. Widespread cholera in the developing world means that US physicians should be prepared to treat ''imported'' cases. Physicians evaluating patients with diarrhea should obtain a travel history, should consider cholera in patients returning from countries with endemic or epidemic cholera, and should instruct patients in appropriate use of World Health Organization oral rehydration salts solution or other oral rehydration solutions containing 75 to 90 mmol/L of sodium. Pharmacies and medical facilities should stock these solutions.	CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV BACTERIAL & MYCOT DIS,ATLANTA,GA 30341; CTR DIS CONTROL & PREVENT,EPIDEMIOL PROGRAM OFF,DIV FIELD EPIDEMIOL,ATLANTA,GA 30341; CTY LOS ANGELES DEPT HLTH SERV,LOS ANGELES,CA; CTR DIS CONTROL & PREVENT,EPIDEM INTELLIGENCE SERV,ATLANTA,GA 30341	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA								MAHALANABIS D, 1992, CHOLERA, P266; SWERDLOW DL, 1992, JAMA-J AM MED ASSOC, V267, P1495, DOI 10.1001/jama.267.11.1495; 1991, WHOSER9115 PROGR CON, P1; 1993, MMWR MORN MORTAL WKL, V42, P89; 1991, MMWR-MORBID MORTAL W, V40, P562; 1990, WHOSER802 PROGR CONT; 1992, MMWR-MORBID MORTAL W, V41, P1	7	22	23	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 19	1994	272	15					1203	1205		10.1001/jama.272.15.1203	http://dx.doi.org/10.1001/jama.272.15.1203			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL212	7933349				2022-12-24	WOS:A1994PL21200035
J	ALTOMARE, DF; REGINA, G; LOVREGLIO, R; MEMEO, V				ALTOMARE, DF; REGINA, G; LOVREGLIO, R; MEMEO, V			ACETYLCHOLINE SWEAT TEST - AN EFFECTIVE WAY TO SELECT PATIENTS FOR LUMBAR SYMPATHECTOMY	LANCET			English	Article								Although lumbar sympathectomy can benefit patients with critical limb ischaemia, many derive no benefit from the procedure. The poor prediction of outcome may be related to pre-existing damage to the sympathetic fibres. We assessed sympathetic nerve function with the acetylcholine sweatspot test before and after lumber sympathectomy in 31 patients with critical limb ischaemia. Of 9 patients with normal sympathetic function or minor denervation preoperatively (sweatspot score greater than or equal to 8), 8 showed improvement in pain and/or healing of ischaemic lesions after sympathectomy. The procedure did not achieve denervation in the patient without improvement, as shown by persisting sympathetic activity postoperatively. By contrast, among the 22 patients with lower sweatspot scores, indicating severe or complete sympathetic denervation, only 1 showed improvement (partial) after lumbar sympathectomy. 9 patients underwent oximetry before and after the operation; in this subgroup there was a positive correlation between preoperative sweatspot score and the change in tissue partial pressure of oxygen (r(2)=0.35). Preoperative assessment of sympathetic nerve function by means of a sensitive, quantitative test of autonomic integrity can predict the outcome of the procedure with high sensitivity and specificity. A postoperative test allows verification of sympathetic denervation. We recommend use of this simple test in selecting patients for lumbar sympathectomy.	UNIV BARI,CATTEDRA CHIRURG VASC,I-70124 BARI,ITALY; UNIV BARI,DERMATOL CLIN,I-70124 BARI,ITALY	Universita degli Studi di Bari Aldo Moro; Universita degli Studi di Bari Aldo Moro	ALTOMARE, DF (corresponding author), UNIV BARI,IST CLIN CHIRURG,CATTEDRA METODOL CLIN,PIAZZA G CESARE 11,I-70124 BARI,ITALY.			Altomare, Donato Francesco/0000-0001-8980-2752				ALTOMARE D, 1992, GUT, V33, P1539, DOI 10.1136/gut.33.11.1539; BAKER DM, 1993, BR J SURG S, V80, pA666; BROTHERS TE, 1993, SURGERY, V113, P433; COTTON LT, 1985, BRIT J SURG, V72, P678, DOI 10.1002/bjs.1800720903; IMPARATO AM, 1979, SURG CLIN N AM, V59, P719; KIM GE, 1976, ANN SURG, V183, P157, DOI 10.1097/00000658-197602000-00012; LINDENAUER SM, 1982, BRIT J SURG S, V69, P32; MORGAN RH, 1989, BRIT J SURG, V76, pA1340; PERSSON AV, 1985, SURG CLIN N AM, V65, P393; PLECHA FR, 1980, SURGERY, V88, P375; RYDER REJ, 1988, LANCET, V1, P1303, DOI 10.1016/S0140-6736(88)92120-4; SEEGER JM, 1977, AM J SURG, V134, P749, DOI 10.1016/0002-9610(77)90316-6; SMITHWICK RH, 1957, SURGERY, V42, P415; SZILAGYI DE, 1967, ARCH SURG-CHICAGO, V95, P753; WALKER PM, 1980, SURGERY, V87, P216; YAO JST, 1973, ARCH SURG-CHICAGO, V107, P676	16	6	6	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 8	1994	344	8928					976	978		10.1016/S0140-6736(94)91639-X	http://dx.doi.org/10.1016/S0140-6736(94)91639-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PK978	7934428				2022-12-24	WOS:A1994PK97800007
J	BURR, DC; MORRONE, MC; ROSS, J				BURR, DC; MORRONE, MC; ROSS, J			SELECTIVE SUPPRESSION OF THE MAGNOCELLULAR VISUAL PATHWAY DURING SACCADIC EYE-MOVEMENTS	NATURE			English	Article							MOTION PERCEPTION; MACAQUE MONKEY; SENSITIVITY; CONTRAST; IMAGE	VISUAL scientists have long sought to explain why the world remains stable during saccades, the ballistic eye-movements that continually displace the retinal image at fast but resolvable(1) velocities. An early suggestion was that vision may be actively suppressed during saccades(2), but experimental support has been variable(3-5). Here we present evidence that saccadic suppression does occur, but that it is selective for patterns modulated in luminance at low spatial frequencies. Patterns of higher Spatial frequency, and equiluminant patterns (modulated only in colour) at all spatial frequencies were not suppressed during saccades, but actually enhanced. The selectivity of the suppression suggests that it is confined to the colour-blind magnocellular stream (which provides the dominant input to motion centres and areas involved with attention), where it could dull the otherwise disturbing sense of Past low-spatial-frequency image motion. Masking studies suggest that the suppression precedes the site of contrast masking and may therefore occur early in visual processing, possibly as early as the lateral geniculate nucleus.	UNIV ROME, DEPT PSYCHOL, I-00185 ROME, ITALY; UNIV WESTERN AUSTRALIA, DEPT PSYCHOL, NEDLANDS, WA 6009, AUSTRALIA	Sapienza University Rome; University of Western Australia	BURR, DC (corresponding author), CNR, IST NEUROFISIOL, VIA S ZENO 51, I-56127 PISA, ITALY.		Morrone, Maria Concetta/C-6756-2014	Morrone, Maria Concetta/0000-0002-1025-0316; Burr, David/0000-0003-1541-8832				BONDS AB, 1991, NONLINEAR VISION DET, P329; Burr D. C., 1982, VISION RES, V23, P3567, DOI [10.1016/0042-6989(82)90196-1, DOI 10.1016/0042-6989(82)90196-1]; BURR DC, 1993, J OPT SOC AM A, V10, P1706, DOI 10.1364/JOSAA.10.001706; BURR DC, 1982, J PHYSIOL-LONDON, V333, P1; CORBETTA M, 1993, J NEUROSCI, V13, P1202; CROPPER SJ, 1988, PERCEPTION, V17, P353; DERRINGTON AM, 1984, VISION RES, V24, P1965, DOI 10.1016/0042-6989(84)90031-2; DEYOE EA, 1988, TRENDS NEUROSCI, V11, P219, DOI 10.1016/0166-2236(88)90130-0; Grusser O.J., 1991, VISION VISUAL DYSFUN, V12; Holt EB, 1903, PSYCHOL REV-MONOGR S, V4, P3; ILG UJ, 1993, VISION RES, V33, P211, DOI 10.1016/0042-6989(93)90159-T; KRAUSKOPF J, 1966, AM J PSYCHOL, V79, P73, DOI 10.2307/1420709; LATOUR PL, 1962, VISION RES, V2, P261, DOI 10.1016/0042-6989(62)90031-7; MACKAY DM, 1970, NATURE, V225, P90, DOI 10.1038/225872a0; MATIN E, 1974, PSYCHOL BULL, V81, P899, DOI 10.1037/h0037368; MAUNSELL JHR, 1990, J NEUROSCI, V10, P3323; MERIGAN WH, 1991, J NEUROSCI, V11, P3422; MERIGAN WH, 1991, J NEUROSCI, V11, P994; MERIGAN WH, 1993, ANNU REV NEUROSCI, V16, P369, DOI 10.1146/annurev.ne.16.030193.002101; MERIGAN WH, 1991, NATO ADV SCI I A-LIF, V203, P117; OHZAWA I, 1982, NATURE, V298, P5871; RIGGS LA, 1974, VISION RES, V14, P997, DOI 10.1016/0042-6989(74)90169-2; SCHILLER PH, 1990, NATURE, V343, P68, DOI 10.1038/343068a0; SCLAR G, 1990, VISION RES, V30, P1, DOI 10.1016/0042-6989(90)90123-3; SHIOIRI S, 1989, VISION RES, V29, P915, DOI 10.1016/0042-6989(89)90106-5; UCHIKAWA K, IN PRESS J OPT SOC A; UNGERLEIDER LG, 1986, J COMP NEUROL, V248, P147, DOI 10.1002/cne.902480202; WATSON AB, 1983, PERCEPT PSYCHOPHYS, V33, P113, DOI 10.3758/BF03202828; [No title captured]	29	483	491	0	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 6	1994	371	6497					511	513		10.1038/371511a0	http://dx.doi.org/10.1038/371511a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PK589	7935763				2022-12-24	WOS:A1994PK58900054
J	ASHTON, LJ; LEARMONT, J; LUO, K; WYLIE, B; STEWART, G; KALDOR, JM				ASHTON, LJ; LEARMONT, J; LUO, K; WYLIE, B; STEWART, G; KALDOR, JM			HIV-INFECTION IN RECIPIENTS OF BLOOD PRODUCTS FROM DONORS WITH KNOWN DURATION OF INFECTION	LANCET			English	Note							TRANSFUSION; AIDS; AUSTRALIA; PEOPLE	From a registry of people with transfusion-acquired HIV infection, 25 recipients were identified for whom the dates of HIV infection in the 8 corresponding donors could be established. Longer times to AIDS and to death in recipients were independently associated (p<0.01) with the receipt of blood from donors who developed AIDS more than 10 years after HIV infection, as well as with older age and fewer transfusions. Sex, zidovudine treatment, and severity of illness at transfusion were not significantly associated with survival.	UNIV NEW S WALES,NATL CTR HIV EPIDEMIOL & CLIN RES,SYDNEY,NSW 2010,AUSTRALIA; NEW S WALES RED CROSS,BLOOD TRANSFUS SERV,SYDNEY,NSW,AUSTRALIA; WESTMEAD HOSP,DEPT IMMUNOPATHOL,WESTMEAD,NSW 2145,AUSTRALIA	University of New South Wales Sydney; Kirby Institute; Australian Red Cross Blood Service; University of Sydney			Wylie, Bruce/H-3182-2014; Kaldor, John M/D-4545-2011	Wylie, Bruce/0000-0002-7374-1083; 				BLAXHULT A, 1990, AIDS, V4, P125, DOI 10.1097/00002030-199002000-00005; KALDOR J, 1993, MED J AUSTRALIA, V158, P10, DOI 10.5694/j.1326-5377.1993.tb121640.x; KOPECSCHRADER E, 1993, AIDS, V7, P1009, DOI 10.1097/00002030-199307000-00016; LEARMONT J, 1992, LANCET, V340, P863, DOI 10.1016/0140-6736(92)93281-Q; SWANSON CE, 1990, AIDS, V4, P749, DOI 10.1097/00002030-199008000-00006; WARD JW, 1989, NEW ENGL J MED, V321, P947, DOI 10.1056/NEJM198910053211406	6	25	27	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 10	1994	344	8924					718	720		10.1016/S0140-6736(94)92210-1	http://dx.doi.org/10.1016/S0140-6736(94)92210-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PF187	7915778				2022-12-24	WOS:A1994PF18700012
J	WULFF, HR				WULFF, HR			QUALITY-OF-LIFE AND TREATMENT FOR PROXIMAL DEEP-VEIN THROMBOSIS	LANCET			English	Editorial Material											WULFF, HR (corresponding author), HERLEV HOSP,DEPT MED C,HERLEV,DENMARK.							HARRIS J, 1987, J MED ETHICS, V13, P117, DOI 10.1136/jme.13.3.117; NAYLOR CD, 1994, J CLIN EPIDEMIOL, V47, P987; OMEARA JJ, 1994, NEW ENGL J MED, V330, P117; RAWLES J, 1989, J MED ETHICS, V15, P143, DOI 10.1136/jme.15.3.143; WEINSTEIN MC, 1980, CLIN DECISION ANAL, P199	5	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 13	1994	344	8920					420	421		10.1016/S0140-6736(94)91764-7	http://dx.doi.org/10.1016/S0140-6736(94)91764-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PB761	7914561				2022-12-24	WOS:A1994PB76100004
J	FASSATI, A; TEDESCHI, S; BORDONI, A; AMBONI, P; CURCIO, C; BRESOLIN, N; SCARLATO, G				FASSATI, A; TEDESCHI, S; BORDONI, A; AMBONI, P; CURCIO, C; BRESOLIN, N; SCARLATO, G			RAPID DIRECT DIAGNOSIS OF DELETIONS CARRIERS OF DUCHENNE AND BECKER MUSCULAR-DYSTROPHIES	LANCET			English	Note							POLYMERASE CHAIN-REACTION; INTRAGENIC RECOMBINATION; GENE	13 families and 34 women at risk of being carriers of Duchenne and Becker muscular dystrophies were analysed blind by restriction fragment length polymorphisms (RFLPs) and a new, non-radioactive direct test based on competitive polymerase-chain-reaction (PCR) amplification. All obligate carriers were correctly diagnosed by RFLPs and competitive PCR, and 7 women with a 99% risk of being carriers were also diagnosed carriers by competitive PCR. There were no false positives or false negatives. Only 1 PCR result was non-informative. Our test allows rapid, precise, and direct carrier diagnosis of women whose relatives have a known deletion of the dystrophin gene.	UNIV MILAN,IST CLIN NEUROL,I-20122 MILAN,ITALY; IST CLIN PERFEZIONAMENTO,MILAN,ITALY	University of Milan	FASSATI, A (corresponding author), UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,GUYS HOSP,DEPT EXPTL PATHOL,LONDON BRIDGE,LONDON SE1 9RT,ENGLAND.		CURCIO, CRISTINA/D-3898-2011; CURCIO, CRISTINA/AAO-1488-2020	CURCIO, CRISTINA/0000-0001-9275-3242; Bresolin, Nereo/0000-0001-6694-3595				ABBS S, 1990, GENOMICS, V7, P602, DOI 10.1016/0888-7543(90)90205-9; ABBS S, 1992, J MED GENET, V29, P191, DOI 10.1136/jmg.29.3.191; BEGGS AH, 1990, HUM GENET, V86, P45; BEGGS AH, 1990, NUCLEIC ACIDS RES, V18, P1931, DOI 10.1093/nar/18.7.1931; DENDUNNEN JT, 1989, AM J HUM GENET, V45, P835; Emery A.E.H., 1993, DUCHENNE MUSCULAR DY; GILLILAND G, 1990, P NATL ACAD SCI USA, V87, P2725, DOI 10.1073/pnas.87.7.2725; LATHROP GM, 1984, AM J HUM GENET, V36, P460; OUDET C, 1991, AM J HUM GENET, V49, P311; ROBERTS RG, 1989, NUCLEIC ACIDS RES, V17, P811, DOI 10.1093/nar/17.2.811	10	10	10	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 30	1994	344	8918					302	303		10.1016/S0140-6736(94)91340-4	http://dx.doi.org/10.1016/S0140-6736(94)91340-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NZ233	7914263				2022-12-24	WOS:A1994NZ23300009
J	MAEDA, N; WATANABE, K; NEGORO, T; ASO, K; OHKI, T; ITO, K; KATO, T				MAEDA, N; WATANABE, K; NEGORO, T; ASO, K; OHKI, T; ITO, K; KATO, T			EVOLUTIONAL CHANGES OF CORTICAL HYPOMETABOLISM IN WESTS SYNDROME	LANCET			English	Article							INFANTILE SPASMS; SURGICAL-TREATMENT	The pathophysiological basis of the epileptic encephalopathy West's syndrome remains unknown. We have done serial positron emission tomography (PET) with fluorine-18-labelled 2-deoxy-3-fluoro-D-glucose (FDG) in twelve patients with newly diagnosed West's syndrome. Throughout follow-up, PET revealed diffuse or focal cortical hypometabolism in eleven patients, whereas magnetic resonance imaging (MRI) showed morphological abnormalities in only five. At disease onset, PET showed cortical hypometabolism in eight patients (diffuse in three, focal in five). The second PET showed normal metabolism in six of these patients but focal abnormalities in three of the four with normal results on first PET. In all seven patients with normal findings on the second PET, tonic spasms ceased after initial treatment and no epileptic seizure occurred thereafter. In the five patients with cortical hypometabolism on the second PET, tonic spasms persisted or recurred, or partial seizures appeared. However, in two patients PET abnormalities disappeared in accordance with the later resolution of epileptic seizures. All patients with normal MRI and second PET results had normal psychomotor development. Diffuse or focal cortical hypometabolism that cannot be detected by MRI or computed tomography is common in patients with West's syndrome. However, this anomaly is not permanent and changes with clinical symptoms. These functional abnormalities in the cerebral cortex may be associated with the development of West's syndrome.	NAGOYA UNIV,SCH MED,DEPT RADIOL,NAGOYA 461,JAPAN	Nagoya University	MAEDA, N (corresponding author), NAGOYA UNIV,SCH MED,DEPT PEDIAT,SHOWA KU,65 TSURUMA CHO,NAGOYA,AICHI 466,JAPAN.							CHUGANI HT, 1990, ANN NEUROL, V27, P406, DOI 10.1002/ana.410270408; CHUGANI HT, 1992, ANN NEUROL, V31, P212, DOI 10.1002/ana.410310212; ENGEL J, 1993, NEUROLOGY, V43, P1612, DOI 10.1212/WNL.43.8.1612; MAEDA N, 1993, PEDIATR NEUROL, V9, P430, DOI 10.1016/0887-8994(93)90021-4; YAMAMOTO N, 1988, EPILEPSIA, V29, P34, DOI 10.1111/j.1528-1157.1988.tb05095.x; 1992, EPILEPSIA, V33, P195	6	39	39	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 25	1994	343	8913					1620	1623		10.1016/S0140-6736(94)93065-1	http://dx.doi.org/10.1016/S0140-6736(94)93065-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU354	7911927				2022-12-24	WOS:A1994NU35400018
J	MCGLAVE, PB; DEFABRITIIS, P; DEISSEROTH, A; GOLDMAN, J; BARNETT, M; REIFFERS, J; SIMONSSON, B; CARELLA, A; AEPPLI, D				MCGLAVE, PB; DEFABRITIIS, P; DEISSEROTH, A; GOLDMAN, J; BARNETT, M; REIFFERS, J; SIMONSSON, B; CARELLA, A; AEPPLI, D			AUTOLOGOUS TRANSPLANTS FOR CHRONIC MYELOGENOUS LEUKEMIA - RESULTS FROM 8 TRANSPLANT GROUPS	LANCET			English	Article							MARROW TRANSPLANTATION; LEUKEMIA; INTERFERON; CELLS; CML; PROGENITORS; GAMMA	Chronic myelogenous leukaemia (CML) can be cured by donor marrow transplant. Unfortunately, suitably HLA-matched related or unrelated donors are not available for the majority of patients. Transplant of stem cells derived from a patient's own marrow or peripheral blood (autologous transplant) avoids the need for an HLA-matched donor, is associated with a less complicated and shorter hospital course than donor transplantation, and has been successful in the treatment of other haematological malignancies. We report results of autologous transplants in 200 patients with CML at eight marrow transplant centres over seven yeats. This is the first multicentre analysis of autologous transplants for CML and reports on the largest number of patients studied to date. We show that autologous transplants provide a plateau in the survival curve not observed in conventional treatments. Autologous transplants are associated with a high engraftment rate, low mortality, and prompt return of both younger and older patients to normal activity levels. Our results suggest that autologous transplants provide an alternative to conventional treatment in the care of patients not eligible for donor transplant.	INST HEMATOL,ROME,ITALY; MD ANDERSON CANC CTR,DEPT HEMATOL,HOUSTON,TX 77030; HAMMERSMITH HOSP,DEPT HAEMATOL,LONDON,ENGLAND; VANCOUVER GEN HOSP,LEUKEMIA & BONE MARROW TRANSPLANTAT PROGRAM,VANCOUVER,BC,CANADA; HOSP HAUT LEVEQUE,UNITE GREFFE,BORDEAUX,FRANCE; UNIV UPPSALA HOSP,DEPT MED,UPPSALA,SWEDEN; OSPED SAN MARTINO GENOVA,GENOA,ITALY; UNIV MINNESOTA,SCH PUBL HLTH,MINNEAPOLIS,MN 55455	University of Texas System; UTMD Anderson Cancer Center; Imperial College London; University of British Columbia; CHU Bordeaux; Uppsala University; Uppsala University Hospital; University of Genoa; IRCCS AOU San Martino IST; University of Minnesota System; University of Minnesota Twin Cities	MCGLAVE, PB (corresponding author), UNIV MINNESOTA,SCH MED,DEPT MED,MARROW TRANSPLANT PROGRAM,MINNEAPOLIS,MN 55455, USA.			de Fabritiis, Paolo/0000-0002-1835-0581				BARNETT MJ, 1989, BONE MARROW TRANSPL, V4, P345; BAUM CM, 1992, P NATL ACAD SCI USA, V89, P2804, DOI 10.1073/pnas.89.7.2804; CARELLA AM, 1993, BONE MARROW TRANSPL, V12, P267; CARLOSTELLA C, 1991, BONE MARROW TRANSPL, V8, P265; DEFABRITIIS P, 1990, BONE MARROW TRANSPL, V6, P247; DEISSEROTH AB, IN PRESS BLOOD; ELAUDTJOHNSON RC, 1980, SURVIVAL MODELS DATA; GOLDMAN JM, 1993, IN PRESS BLOOD; HIGANO CS, 1992, BLOOD, V80, P1437; HOYLE C, 1994, BRIT J HAEMATOL, V86, P76, DOI 10.1111/j.1365-2141.1994.tb03255.x; Karnofsky DA, 1949, EVALUATION CHEMOTHER, P191; LEEMHUIS T, 1992, EXP HEMATOL, V20, P782; MCGLAVE P, 1987, EXP HEMATOL, V15, P331; MCGLAVE P, 1993, BLOOD, V81, P543; MCGLAVE PB, 1990, BONE MARROW TRANSPL, V6, P115; MCGLAVE PB, 1990, BONE MARROW TRANSPL, P235; REIFFERS J, 1991, BRIT J HAEMATOL, V77, P339, DOI 10.1111/j.1365-2141.1991.tb08581.x; SHPALL EJ, 1994, J CLIN ONCOL, V12, P28, DOI 10.1200/JCO.1994.12.1.28; SIMONSSON B, 1992, LEUKEMIA LYMPHOMA, V7, P55, DOI 10.3109/10428199209061566; SOKAL JE, 1985, BLOOD, V66, P1342; TURHAN AG, 1990, BLOOD, V76, P2402; VERFAILLIE CM, 1992, BLOOD, V79, P1003	22	195	197	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 11	1994	343	8911					1486	1488		10.1016/S0140-6736(94)92589-5	http://dx.doi.org/10.1016/S0140-6736(94)92589-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NQ415	7911185				2022-12-24	WOS:A1994NQ41500016
J	TREASURE, T				TREASURE, T			THE PULMONARY AUTOGRAFT AS AN AORTIC-VALVE REPLACEMENT	LANCET			English	Editorial Material											TREASURE, T (corresponding author), ST GEORGE HOSP,LONDON,ENGLAND.							ELKINS RC, 1994, NEW ENGL J MED, V330, P59, DOI 10.1056/NEJM199401063300111; KOUCHOUKOS NT, 1994, NEW ENGL J MED, V330, P1, DOI 10.1056/NEJM199401063300101; ROSS D, 1992, EUR J CARDIO-THORAC, V6, P113, DOI 10.1016/1010-7940(92)90115-E; ROSS D, 1991, ANN THORAC SURG, V52, P1346, DOI 10.1016/0003-4975(91)90032-L; ROSS DN, 1967, LANCET, V2, P956	5	1	1	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 28	1994	343	8909					1308	1308		10.1016/S0140-6736(94)92463-5	http://dx.doi.org/10.1016/S0140-6736(94)92463-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NN217	7910320				2022-12-24	WOS:A1994NN21700006
J	VINEIS, P; BARTSCH, H; CAPORASO, N; HARRINGTON, AM; KADLUBAR, FF; LANDI, MT; MALAVEILLE, C; SHIELDS, PG; SKIPPER, P; TALASKA, G; TANNENBAUM, SR				VINEIS, P; BARTSCH, H; CAPORASO, N; HARRINGTON, AM; KADLUBAR, FF; LANDI, MT; MALAVEILLE, C; SHIELDS, PG; SKIPPER, P; TALASKA, G; TANNENBAUM, SR			GENETICALLY BASED N-ACETYLTRANSFERASE METABOLIC POLYMORPHISM AND LOW-LEVEL ENVIRONMENTAL EXPOSURE TO CARCINOGENS	NATURE			English	Article							EXFOLIATED UROTHELIAL CELLS; HEMOGLOBIN ADDUCTS; DNA ADDUCTS; URINARY MUTAGENICITY; CIGARETTE SMOKERS; SMOKING; ACETYLATION; PHENOTYPE; CANCER	THE metabolic activation or inactivation of carcinogens varies considerably in human populations, and is partly genetically determined(1,2). Inter-individual variability in the susceptibility to carcinogens may be particularly important at low degrees of environmental exposure. Examples of probable human carcinogens that present widespread low-dose exposures are environmental tobacco smoke and diesel exhaust(3,4). We have determined levels of DNA adducts in bladder cells and of 4-aminobiphenyl-haemoglobin adducts in 97 volunteers, together with the N-acetylation non-inducible phenotype, the corresponding genotype, and the levels of nicotine-cotinine in the urine. We find that among the slow acetylators, 4-aminobiphenyl adducts were higher than in rapid acetylators at low or null nicotine-cotinine levels, whereas the difference between slow and rapid acetylators was less evident at increasing nicotine-cotinine levels. The N-acetyltransferase genotype is highly predictive of the acetylation phenotype. Our results indicate that the clearance of low-dose carcinogens is decreased in the genetically based slow-acetylator phenotype. Such genetic modulation of low-dose environmental risks is relevant to 'risk assessment' procedures.	MAIN HOSP,I-10126 TURIN,ITALY; GERMAN CANC RES CTR,D-69120 HEIDELBERG,GERMANY; NCI,GENET EPIDEMIOL BRANCH,ROCKVILLE,MD 20892; NCI,HUMAN CARCINOGENESIS LAB,BETHESDA,MD 20892; NATL CTR TOXICOL RES,JEFFERSON,AR 72079; UNIV MILAN,IST MED LAVORO,I-20122 MILAN,ITALY; INT AGCY RES CANC,F-69372 LYON,FRANCE; MIT,DEPT CHEM,CAMBRIDGE,MA 02139; UNIV CINCINNATI,DEPT ENVIRONM HLTH,CINCINNATI,OH	Helmholtz Association; German Cancer Research Center (DKFZ); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); US Food & Drug Administration (FDA); University of Milan; World Health Organization; International Agency for Research on Cancer (IARC); Massachusetts Institute of Technology (MIT); University System of Ohio; University of Cincinnati	VINEIS, P (corresponding author), UNIV TURIN,DIPARTIMENTO SCI BIOMED & ONCOL UMANA,CANC EPIDEMIOL UNIT,I-10126 TURIN,ITALY.		Shields, Peter G/I-1644-2012					[Anonymous], 1974, IARC MONOGRAPHS EVAL, V4; BARTSCH H, 1990, JNCI-J NATL CANCER I, V82, P1826, DOI 10.1093/jnci/82.23.1826; BELL DA, 1993, CARCINOGENESIS, V14, P1689, DOI 10.1093/carcin/14.8.1689; BLUM M, 1991, P NATL ACAD SCI USA, V88, P5237, DOI 10.1073/pnas.88.12.5237; BRYANT MS, 1988, P NATL ACAD SCI USA, V85, P9788, DOI 10.1073/pnas.85.24.9788; BUTLER MA, 1992, PHARMACOGENETICS, V2, P116, DOI 10.1097/00008571-199206000-00003; CAPORASO N, 1991, PHARMACOGENETICS, V1, P4, DOI 10.1097/00008571-199110000-00003; Case R A, 1966, Ann R Coll Surg Engl, V39, P213; SHIELDS PG, 1991, JAMA-J AM MED ASSOC, V266, P681, DOI 10.1001/jama.266.5.681; TALASKA G, 1990, CARCINOGENESIS, V11, P639, DOI 10.1093/carcin/11.4.639; TALASKA G, 1991, P NATL ACAD SCI USA, V88, P5350, DOI 10.1073/pnas.88.12.5350; TALASKA G, 1991, CANCER EPIDEM BIOMAR, V1, P61; VINEIS P, 1990, CANCER RES, V50, P3002; WOODWARD A, 1991, EUR J CANCER, V27, P1472, DOI 10.1016/0277-5379(91)90034-B; 1989, IARC MONOGRAPHS EVAL, V46	15	270	274	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 12	1994	369	6476					154	156		10.1038/369154a0	http://dx.doi.org/10.1038/369154a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NK971	7909916				2022-12-24	WOS:A1994NK97100051
J	DECOSAS, J				DECOSAS, J			FIGHTING AIDS OR RESPONDING TO THE EPIDEMIC - CAN PUBLIC-HEALTH FIND ITS WAY	LANCET			English	Editorial Material											DECOSAS, J (corresponding author), GTZ REG AIDS PROGRAMME W & CENT AFRICA,POB 9698,KOTOKA INT AIRPORT,ACCRA,GHANA.							SCHEPERHUGHES N, 1993, LANCET, V342, P965, DOI 10.1016/0140-6736(93)92006-F	1	1	1	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 7	1994	343	8906					1145	1146		10.1016/S0140-6736(94)90241-0	http://dx.doi.org/10.1016/S0140-6736(94)90241-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NK730	7910238				2022-12-24	WOS:A1994NK73000015
J	VANDERVIES, SM; GATENBY, AA; GEORGOPOULOS, C				VANDERVIES, SM; GATENBY, AA; GEORGOPOULOS, C			BACTERIOPHAGE-T4 ENCODES A CO-CHAPERONIN THAT CAN SUBSTITUTE FOR ESCHERICHIA-COLI GROES IN PROTEIN-FOLDING	NATURE			English	Article							RIBULOSE BISPHOSPHATE CARBOXYLASE; MORPHOGENESIS; INTERACTS; MUTATION; GENE-31; ATP	SEVERAL bacteriophages use the Escherichia coli GroES and GroEL chaperonins for folding and assembly of their morphogenetic structures1. Bacteriophage T4 is unusual in that it encodes a specialized protein (Gp31) that is thought to interact with the host GroEL and to be absolutely required for the correct assembly of the major capsid protein (Gp23) in vivo2-4. Here we show that despite the absence of amino-acid sequence similarity between Gp31 and GroES5,6 Gp31 can functionally substitute for the GroES co-chaperonin in the morphogenesis of bacteriophages lambda and T5, the in vivo and in vitro chaperonin-dependent assembly of ribulose bisphosphate carboxylase (Rubisco), as well as overall bacterial growth at the non-permissive temperature. Like GroES, the bacteriophage Gp31 protein forms a stable complex with the E. coli GroEL protein in the presence of Mg-ATP and inhibits the ATPase activity of GroEL in vitro.	DUPONT CO INC,CENT RES & DEV,DIV MOLEC BIOL,EXPTL STN,WILMINGTON,DE 19880	DuPont	VANDERVIES, SM (corresponding author), UNIV GENEVA,DEPT BIOCHIM MED,CH-1211 GENEVA 4,SWITZERLAND.							CASTILLO CJ, 1978, J BIOL CHEM, V253, P2132; FAYET O, 1986, MOL GEN GENET, V202, P435, DOI 10.1007/BF00333274; GATENBY AA, 1985, NATURE, V314, P617, DOI 10.1038/314617a0; GEORGOPOULOS CP, 1972, NATURE-NEW BIOL, V239, P38, DOI 10.1038/newbio239038a0; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; KEPPEL F, 1990, GENE, V86, P19, DOI 10.1016/0378-1119(90)90109-5; LAEMMLI UK, 1970, J MOL BIOL, V47, P69, DOI 10.1016/0022-2836(70)90402-X; LANDRY SJ, 1993, NATURE, V364, P255, DOI 10.1038/364255a0; LORIMER GH, 1977, ANAL BIOCHEM, V78, P65; NIVINSKAS R, 1988, GENE, V73, P251, DOI 10.1016/0378-1119(88)90332-0; STERNBERG N, 1973, J MOL BIOL, V76, P1, DOI 10.1016/0022-2836(73)90078-8; TAKANO T, 1972, NATURE-NEW BIOL, V239, P34, DOI 10.1038/newbio239034a0; TODD MJ, 1993, BIOCHEMISTRY-US, V32, P8560, DOI 10.1021/bi00084a024; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; VIITANEN PV, 1992, PROTEIN SCI, V1, P363; ZEILSTRARYALLS J, 1991, ANNU REV MICROBIOL, V45, P301, DOI 10.1146/annurev.mi.45.100191.001505	19	90	92	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 14	1994	368	6472					654	656		10.1038/368654a0	http://dx.doi.org/10.1038/368654a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NF392	7908418				2022-12-24	WOS:A1994NF39200066
J	ANKUM, WM; VONK, J				ANKUM, WM; VONK, J			THE SPRING BALANCE - A SIMPLE MONITORING-SYSTEM FOR FLUID OVERLOAD DURING HYSTEROSCOPIC SURGERY	LANCET			English	Article							ABSORPTION; ETHANOL	Fluid overload may arise during hysteroscopic surgery, caused by absorption of fluid used to distend the uterus. continuous monitoring of the fluid balance is required to prevent this serious complication. Commercial equipment does not serve this purpose adequately. We describe a simple solution. We weigh the inflow and outflow volumes together on a spring balance; this method provides information about fluid balance, since any fluid lost as spillage or by absorption is reflected by a loss of weight on the balance. The method is simple, accurate, and inexpensive, and the components can be purchased readily.			ANKUM, WM (corresponding author), UNIV AMSTERDAM,ACAD MED CTR,DEPT OBSTET & GYNAECOL,MELBERGDREEF 9,1105 AZ AMSTERDAM,NETHERLANDS.		Vonk, Judith M/ABA-3009-2020; Vonk, Judith/K-8477-2019	Vonk, Judith M/0000-0001-7531-4547; Vonk, Judith/0000-0001-7531-4547				DUFFY S, 1992, OBSTET GYNECOL, V79, P300; GARRY R, 1990, LANCET, V336, P1013, DOI 10.1016/0140-6736(90)92480-6; HARRISON RH, 1956, J UROLOGY, V75, P95, DOI 10.1016/S0022-5347(17)66783-1; HULTEN JO, 1986, SCAND J UROL NEPHROL, V20, P245, DOI 10.3109/00365598609024506; MACDONALD R, 1989, LANCET, V335, P1387; MAGOS AL, 1990, LANCET, V336, P44; MOLNAR BG, 1992, GYNAECOL ENDOSC, V1, P133; VULGAROPULOS SP, 1992, AM J OBSTET GYNECOL, V167, P386, DOI 10.1016/S0002-9378(11)91417-3; 1991, LANCET, V338, P606	9	7	12	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 2	1994	343	8901					836	837		10.1016/S0140-6736(94)92030-3	http://dx.doi.org/10.1016/S0140-6736(94)92030-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ND792	7908082				2022-12-24	WOS:A1994ND79200013
J	MOTT, MG; BOYSE, J; HEWITT, M; RADFORD, M				MOTT, MG; BOYSE, J; HEWITT, M; RADFORD, M			DO MUTATIONS AT THE GLYCOPHORIN-A LOCUS IN PATIENTS TREATED FOR CHILDHOOD HODGKINS-DISEASE PREDICT SECONDARY LEUKEMIA	LANCET			English	Note							SOMATIC MUTATIONS; SURVIVORS	Childhood Hodgkin's disease has a high cure rate but second cancers are common, related to treatment and perhaps genetic predisposition. The glycophorin-A (GPA) mutation assay measures the frequency of NO and NN mutant erythrocytes of MN blood-group heterozygous individuals. Mutant frequencies in Hodgkin's disease patients were compared with controls. No significant difference from controls was found pretreatment or in patients treated with radiotherapy only. Patients who received chemotherapy had a significantly increased frequency (total mutation frequency per 10(6) cells: 31 vs 11, p < 0.001), which may be relevant to their known increased risk of secondary leukaemia.	UNIV NOTTINGHAM HOSP,QUEENS MED CTR,NOTTINGHAM NG7 2UH,ENGLAND; SOUTHAMPTON GEN HOSP,DEPT CHILD HLTH,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND	University of Nottingham; University of Southampton	MOTT, MG (corresponding author), ROYAL HOSP SICK CHILDREN,INST CHILD HLTH,ST MICHAELS HILL,BRISTOL BS2 8BJ,ENGLAND.							BOICE JD, 1993, J NATL CANCER I, V85, P4, DOI 10.1093/jnci/85.1.4; CAGGANA M, 1991, ENVIRON MOL MUTAGEN, V18, P6, DOI 10.1002/em.2850180103; GLICKSMAN AS, 1982, CANCER TREAT REP, V66, P1035; HEWITT M, 1992, BRIT J CANCER, V66, P143, DOI 10.1038/bjc.1992.232; LANGLOIS RG, 1990, CYTOMETRY, V11, P513, DOI 10.1002/cyto.990110410; LANGLOIS RG, 1987, SCIENCE, V236, P445, DOI 10.1126/science.3563520; RADFORD M, 1991, MED PEDIATR ONCOL, V19, P400; SALATREPAT M, 1993, MUTAT RES, V289, P115, DOI 10.1016/0027-5107(93)90137-5; SWERDLOW AJ, 1992, BRIT MED J, V304, P1137, DOI 10.1136/bmj.304.6835.1137; TARBELL NJ, 1993, LANCET, V341, P1428, DOI 10.1016/0140-6736(93)90880-P	10	27	28	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 2	1994	343	8901					828	829		10.1016/S0140-6736(94)92027-3	http://dx.doi.org/10.1016/S0140-6736(94)92027-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ND792	7908079				2022-12-24	WOS:A1994ND79200010
J	MENNERICK, S; ZORUMSKI, CF				MENNERICK, S; ZORUMSKI, CF			GLIAL CONTRIBUTIONS TO EXCITATORY NEUROTRANSMISSION IN CULTURED HIPPOCAMPAL CELLS	NATURE			English	Article							ELECTROGENIC GLUTAMATE UPTAKE; METHYL-D-ASPARTATE; TIME COURSE; RECEPTORS; NEURONS; ACTIVATION; MEMBRANE; CURRENTS; CHANNEL; PATCHES	ALTHOUGH many glial cells possess neurotransmitter receptors and transporters(1-5), little is known about glial participation in neurotransmission. To explore this issue, we recorded neuronal autaptic(6,7) and glial responses from cultured hippocampal single-neuron micro-islands(6,7). Excitatory synaptic events activate rapid electrogenic glial glutamate transporter currents similar to those elicited by exogenous glutamate in other preparations. We show here that glial transporter responses may be used to sense changes in presynaptic efficacy and that glial uptake helps to remove synaptically released glutamate, thereby contributing to the termination of excitatory synaptic currents under certain conditions. These observations provide a framework for understanding the role of glia in both normal and pathological processes.	WASHINGTON UNIV,SCH MED,DEPT ANAT & NEUROBIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,PROGRAM NEUROSCI,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)	MENNERICK, S (corresponding author), WASHINGTON UNIV,SCH MED,DEPT PSYCHIAT,ST LOUIS,MO 63110, USA.		Mennerick, Steven/O-2806-2017	Mennerick, Steven/0000-0003-0868-0664				BARBOUR B, 1991, J PHYSIOL-LONDON, V436, P169, DOI 10.1113/jphysiol.1991.sp018545; BARRES BA, 1991, J NEUROSCI, V11, P3685; BEKKERS JM, 1991, P NATL ACAD SCI USA, V88, P7834, DOI 10.1073/pnas.88.17.7834; BREW H, 1987, NATURE, V327, P707, DOI 10.1038/327707a0; BRIDGES RJ, 1991, J MED CHEM, V34, P717, DOI 10.1021/jm00106a037; CLEMENTS JD, 1992, SCIENCE, V258, P1498, DOI 10.1126/science.1359647; COLQUHOUN D, 1992, J PHYSIOL-LONDON, V458, P261, DOI 10.1113/jphysiol.1992.sp019417; CORNELLBELL AH, 1990, SCIENCE, V247, P470, DOI 10.1126/science.1967852; ECCLES JC, 1958, PROC R SOC SER B-BIO, V148, P38, DOI 10.1098/rspb.1958.0003; FORSYTHE ID, 1990, J PHYSIOL-LONDON, V429, P1; HARRISON NL, 1990, J PHYSIOL-LONDON, V422, P433, DOI 10.1113/jphysiol.1990.sp017993; HESTRIN S, 1990, NEURON, V5, P247, DOI 10.1016/0896-6273(90)90162-9; HILLE B, 1972, J GEN PHYSIOL, V59, P637, DOI 10.1085/jgp.59.6.637; KARWOSKI CJ, 1989, SCIENCE, V244, P578, DOI 10.1126/science.2785716; KATZ B, 1965, PROC R SOC SER B-BIO, V161, P496, DOI 10.1098/rspb.1965.0017; KORN H, 1991, TRENDS NEUROSCI, V14, P439, DOI 10.1016/0166-2236(91)90042-S; LESTER RAJ, 1992, J NEUROSCI, V12, P635; LUCERO MT, 1990, J GEN PHYSIOL, V95, P523, DOI 10.1085/jgp.95.3.523; MURPHY TH, 1993, J NEUROSCI, V13, P2672, DOI 10.1523/JNEUROSCI.13-06-02672.1993; PATNEAU DK, 1990, J NEUROSCI, V10, P2385; PATNEAU DK, 1993, J NEUROSCI, V13, P3496; SARANTIS M, 1993, NEURON, V11, P541, DOI 10.1016/0896-6273(93)90158-N; SATHER W, 1992, J PHYSIOL-LONDON, V450, P643, DOI 10.1113/jphysiol.1992.sp019148; SEGAL MM, 1991, J NEUROPHYSIOL, V65, P761, DOI 10.1152/jn.1991.65.4.761; STEPHENS GJ, 1993, RECEPTOR CHANNEL, V1, P39; SZATKOWSKI M, 1990, NATURE, V348, P443, DOI 10.1038/348443a0; TRUSSELL LO, 1993, NEURON, V10, P1185, DOI 10.1016/0896-6273(93)90066-Z; WYLLIE DJA, 1991, J PHYSIOL-LONDON, V432, P235, DOI 10.1113/jphysiol.1991.sp018383; YAMADA KA, 1993, J NEUROSCI, V13, P3904; ZORUMSKI CF, 1993, NEURON, V10, P61, DOI 10.1016/0896-6273(93)90242-J	30	295	296	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 3	1994	368	6466					59	62		10.1038/368059a0	http://dx.doi.org/10.1038/368059a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MY569	7906399				2022-12-24	WOS:A1994MY56900052
J	STEWART, THM; RETSKY, MW; TSAI, SCJ; VERMA, S				STEWART, THM; RETSKY, MW; TSAI, SCJ; VERMA, S			DOSE-RESPONSE IN THE TREATMENT OF BREAST-CANCER	LANCET			English	Editorial Material							GROWTH-FACTOR; CARCINOMA; CELLS; GLUCOCORTICOIDS; THERAPY; CULTURE; INVITRO; INVIVO	We present evidence that drugs that are effective in causing regression of metastatic breast cancer in a dose-dependent fashion also cause a dose-dependent reduction of cytokines produced by the immune system. This may be an important factor in the occasional induction of a complete remission.	UNIV COLORADO, COLORADO SPRINGS, CO USA; ROCHE DIAGNOST SYST, BRANCHBURG, NJ USA; OTTAWA REG CANC CTR, OTTAWA, ON, CANADA	University of Colorado System; University of Colorado at Colorado Springs; Roche Holding; University of Ottawa; Ottawa Hospital Research Institute	STEWART, THM (corresponding author), OTTAWA GEN HOSP, ROOM LM-18, 501 SMYTH RD, OTTAWA K1H 8L6, ON, CANADA.							BASOLO F, 1992, INT J CANCER, V51, P634, DOI 10.1002/ijc.2910510421; BESCH GJ, 1986, CANCER RES, V46, P2306; COOPER KD, 1990, J AM ACAD DERMATOL, V23, P1318, DOI 10.1016/0190-9622(90)70360-T; DEMICHELI R, 1991, TUMORI J, V77, P189, DOI 10.1177/030089169107700302; DEMICHELI R, 1992, P AN M AM SOC CLIN, V11, P100; DODWELL DJ, 1993, LANCET, V341, P614, DOI 10.1016/0140-6736(93)90366-O; ENSOLI B, 1992, IMMUNOL REV, V127, P147, DOI 10.1111/j.1600-065X.1992.tb01412.x; HIRAOKA D, 1987, CANCER RES, V47, P6560; JORDAN VC, 1992, SEMIN ONCOL, V19, P299; KURTZ JM, 1990, J CLIN ONCOL, V8, P591, DOI 10.1200/JCO.1990.8.4.591; LARSSON EL, 1980, J IMMUNOL, V124, P2828; LIPPMAN M, 1976, CANCER RES, V36, P4602; MANTOVANI A, 1992, IMMUNOL TODAY, V13, P265, DOI 10.1016/0167-5699(92)90008-U; MCCULLOUGH JL, 1983, PSORIASIS CELL PROLI, P347; MEAKIN JW, 1979, CAN MED ASSOC J, V120, P1221; Meropol N J, 1992, Oncology (Williston Park), V6, P53; MICHIEL DF, 1992, CANCER BIOL, V3, P3; OLSEN GA, 1988, TRANSPLANTATION, V46, P57, DOI 10.1097/00007890-198807000-00009; PREHN RT, 1980, INSERM, V97, P297; RAMACHANDRA S, 1990, J PATHOL, V161, P7, DOI 10.1002/path.1711610104; RETSKY MW, 1993, ADJUVANT THERAPY BRE, P13; RUBENS RD, 1988, BRIT J CANCER, V58, P626, DOI 10.1038/bjc.1988.273; RUBENS RD, 1991, MED MANAGEMENT BREAS, P117; SHEARER WT, 1978, FED PROC, V37, P2385; SMITH KA, 1980, IMMUNOL REV, V51, P337, DOI 10.1111/j.1600-065X.1980.tb00327.x; STEWART THM, 1993, CLIN EXP METASTAS, V11, P295, DOI 10.1007/BF00058049; STEWART THM, 1992, CELLULAR IMMUNE MECHANISMS AND TUMOR DORMANCY, P213; STOLL BA, 1963, BMJ-BRIT MED J, P210, DOI 10.1136/bmj.2.5351.210; WAAGE A, 1990, EUR J IMMUNOL, V20, P2439, DOI 10.1002/eji.1830201112; WEETMAN AP, 1984, CLIN ENDOCRINOL, V21, P163, DOI 10.1111/j.1365-2265.1984.tb03456.x; WELTE K, 1984, BLOOD, V64, P380	31	15	15	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 12	1994	343	8894					402	404						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW283	7905558				2022-12-24	WOS:A1994MW28300015
J	BASLER, K; EDLUND, T; JESSELL, TM; YAMADA, T				BASLER, K; EDLUND, T; JESSELL, TM; YAMADA, T			CONTROL OF CELL PATTERN IN THE NEURAL-TUBE - REGULATION OF CELL-DIFFERENTIATION BY DORSALIN-1, A NOVEL TGF-BETA FAMILY MEMBER	CELL			English	Article							CENTRAL-NERVOUS-SYSTEM; FLOOR PLATE; CREST CELLS; MONOCLONAL-ANTIBODIES; CHICK-EMBRYO; DROSOPHILA EMBRYO; VENTRAL AXIS; NOTOCHORD; BONE; IDENTIFICATION	Distinct cell types differentiate along the dorsoventral axis of the neural tube. We have cloned and characterized a novel member of the TGFbeta gene family, dorsalin-1 (dsl-1), that appears to regulate cell differentiation within the neural tube. dsl-1 is expressed selectively in the dorsal neural tube, and its pattern of expression appears to be restricted by early signals from the notochord. Exposure of neural plate cells to dsl-1 promotes the differentiation of cells with neural crest-like properties and inhibits the induction of motor neurons by signals from the notochord and floor plate. These findings suggest that dsl-1 regulates the differentiation of cell types along the dorsoventral axis of the neural tube, acting in conjunction with distinct ventralizing signals from the notochord and floor plate.	UMEA UNIV, DEPT MICROBIOL, S-90187 UMEA, SWEDEN	Umea University	BASLER, K (corresponding author), COLUMBIA UNIV, CTR NEUROBIOL & BEHAV, DEPT BIOCHEM & MOLEC BIOPHYS, HOWARD HUGHES MED INST, NEW YORK, NY 10032 USA.			Basler, Konrad/0000-0003-3534-1529				ABO T, 1981, J IMMUNOL, V127, P1024; ALTABA AR, 1989, NATURE, V341, P33; ARTINGER KB, 1992, DEVELOPMENT, V116, P877; BAROFFIO A, 1988, P NATL ACAD SCI USA, V85, P5325, DOI 10.1073/pnas.85.14.5325; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BERND P, 1985, DEV BIOL, V112, P145, DOI 10.1016/0012-1606(85)90128-9; BRONNERFRASER M, 1988, NATURE, V335, P161, DOI 10.1038/335161a0; CELESTE AJ, 1990, P NATL ACAD SCI USA, V87, P9843, DOI 10.1073/pnas.87.24.9843; DAOPIN S, 1992, SCIENCE, V257, P369, DOI 10.1126/science.1631557; DARNELL DK, 1992, DEV DYNAM, V193, P389, DOI 10.1002/aja.1001930411; DELANNET M, 1992, DEVELOPMENT, V116, P275; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DODD J, 1988, NEURON, V1, P105, DOI 10.1016/0896-6273(88)90194-8; ERICSON J, 1992, SCIENCE, V256, P1555, DOI 10.1126/science.1350865; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FERGUSON EL, 1992, DEVELOPMENT, V114, P583; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; FURLEY AJ, 1990, CELL, V61, P157, DOI 10.1016/0092-8674(90)90223-2; GRABOWSKI CT, 1956, J EXP ZOOL, V133, P301, DOI 10.1002/jez.1401330207; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; GREEN JBA, 1992, CELL, V71, P731, DOI 10.1016/0092-8674(92)90550-V; GREVE JM, 1982, J CELL BIOCHEM, V18, P221, DOI 10.1002/jcb.1982.240180209; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; HATTA K, 1991, NATURE, V350, P339, DOI 10.1038/350339a0; HIRANO S, 1991, SCIENCE, V251, P310, DOI 10.1126/science.1987648; Hoffmann FM, 1991, CURR OPIN CELL BIOL, V3, P947, DOI 10.1016/0955-0674(91)90112-C; JONES CM, 1991, DEVELOPMENT, V111, P531; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; KLAR A, 1992, CELL, V69, P95, DOI 10.1016/0092-8674(92)90121-R; LEE SJ, 1991, P NATL ACAD SCI USA, V88, P4250, DOI 10.1073/pnas.88.10.4250; LEE SJ, 1990, MOL ENDOCRINOL, V4, P1034, DOI 10.1210/mend-4-7-1034; LYONS KM, 1991, TRENDS GENET, V7, P408, DOI 10.1016/0168-9525(91)90265-R; MAXWELL GD, 1988, NEURON, V1, P557, DOI 10.1016/0896-6273(88)90105-5; PLACZEK M, 1990, DEVELOPMENT, V110, P19; PLACZEK M, 1990, SCIENCE, V250, P985, DOI 10.1126/science.2237443; PLACZEK M, 1993, DEVELOPMENT, V117, P205; PLACZEK M, 1991, DEVELOPMENT, P105; RAY RP, 1991, DEVELOPMENT, V113, P35; ROGERS SL, 1992, DEV BIOL, V151, P192, DOI 10.1016/0012-1606(92)90226-7; SCHLUNEGGER MP, 1992, NATURE, V358, P430, DOI 10.1038/358430a0; SIEBERBLUM M, 1980, DEV BIOL, V80, P96, DOI 10.1016/0012-1606(80)90501-1; SMITH JL, 1989, J EXP ZOOL, V250, P49, DOI 10.1002/jez.1402500107; SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5; STEMPLE DL, 1992, CELL, V71, P973, DOI 10.1016/0092-8674(92)90393-Q; STJOHNSTON RD, 1987, EMBO J, V6, P2785, DOI 10.1002/j.1460-2075.1987.tb02574.x; STOCKER KM, 1991, DEVELOPMENT, V111, P635; TAKAHASHI Y, 1992, P NATL ACAD SCI USA, V89, P10237, DOI 10.1073/pnas.89.21.10237; TANAKA H, 1989, DEV BIOL, V132, P419, DOI 10.1016/0012-1606(89)90238-8; TANAKA H, 1984, DEV BIOL, V106, P26, DOI 10.1016/0012-1606(84)90057-5; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0; THIES RS, 1992, ENDOCRINOLOGY, V130, P1318, DOI 10.1210/en.130.3.1318; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; THOR S, 1991, NEURON, V7, P881, DOI 10.1016/0896-6273(91)90334-V; VANSTRAATEN HWM, 1988, ANAT EMBRYOL, V177, P317; VANSTRAATEN HWM, 1991, ANAT EMBRYOL, V184, P55; WHARTON KA, 1991, P NATL ACAD SCI USA, V88, P9214, DOI 10.1073/pnas.88.20.9214; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V; YAMADA T, 1993, CELL, V73, P673, DOI 10.1016/0092-8674(93)90248-O	61	320	356	1	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 21	1993	73	4					687	702		10.1016/0092-8674(93)90249-P	http://dx.doi.org/10.1016/0092-8674(93)90249-P			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LD830	7916656	Green Accepted			2022-12-24	WOS:A1993LD83000008
J	KUMAR, L				KUMAR, L			DONOR LEUKOCYTE INFUSIONS FOR RELAPSE IN CHRONIC MYELOGENOUS LEUKEMIA	LANCET			English	Editorial Material							BONE-MARROW TRANSPLANTATION; CHRONIC MYELOID-LEUKEMIA; LEUKOCYTE INFUSIONS; IMMUNOTHERAPY; TRANSFUSIONS				KUMAR, L (corresponding author), ALL INDIA INST MED SCI,INST ROTARY CANC HOSP,DEPT MED ONCOL,NEW DELHI,INDIA.							ANTIN JH, 1993, BLOOD, V82, P2273; ARCESE W, 1993, BLOOD, V82, P3211; BAR BMAM, 1993, J CLIN ONCOL, V11, P513; CULLIS JO, 1992, BLOOD, V79, P1379; DROBYSKI WR, 1993, BLOOD, V82, P2310; HERTENSTEIN B, 1993, TRANSPLANTATION, V56, P1114, DOI 10.1097/00007890-199311000-00013; KOLB HJ, 1993, SEMIN HEMATOL, V30, P37; KOLB HJ, 1990, BLOOD, V76, P2462, DOI 10.1182/blood.V76.12.2462.2462; KUMAR L, 1994, J CLIN ONCOL, V12, P1710, DOI 10.1200/JCO.1994.12.8.1710; MRSIC M, 1992, BONE MARROW TRANSPL, V9, P269; PORTER DL, 1994, NEW ENGL J MED, V330, P100, DOI 10.1056/NEJM199401133300204	11	9	9	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 22	1994	344	8930					1101	1102		10.1016/S0140-6736(94)90624-6	http://dx.doi.org/10.1016/S0140-6736(94)90624-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN066	7934489				2022-12-24	WOS:A1994PN06600003
J	DEGROOT, RP; BALLOU, LM; SASSONECORSI, P				DEGROOT, RP; BALLOU, LM; SASSONECORSI, P			POSITIVE REGULATION OF THE CAMP-RESPONSIVE ACTIVATOR CREM BY THE P70 S6 KINASE - AN ALTERNATIVE ROUTE TO MITOGEN-INDUCED GENE-EXPRESSION	CELL			English	Article							PROTEIN-KINASE; SIGNALING PATHWAYS; 70K-S6 KINASE; MAP KINASE; RAT-LIVER; T-CELLS; PHOSPHORYLATION; TRANSCRIPTION; BINDING; PROMOTER	Activation of the adenylyl cyclase signaling pathway elicits the induction of genes via activators binding to cAMP-responsive elements (CREs). Nuclear factor CRE modulator (CREM) is activated by PKA-mediated phosphorylation on a serine at position 117. We show that Ser-117 is also phosphorylated by the mitogen-activated p70 S6 kinase (p70(S6K)) in vitro. Activation of cellular p70(S6K) by serum factors enhances Ser-117 phosphorylation and CREM transactivation. Coexpression of p70(S6K) significantly increases transactivation by a GAL4-CREM fusion. The macrolide rapamycin, a potent and specific inhibitor of p70(S6K) in vivo, completely blocks CREM activation induced by serum and by p70(S6K). Thus, CREM constitutes a target for mitogenic signaling through p70(S6K) and may acts as a nuclear effector in which transduction pathways may converge and cross-talk.	FAC MED STRASBOURG,INST CHIM BIOL,CNRS,GENET MOLEC EUCARYOTES LAB,INSERM,U184,F-67085 STRASBOURG,FRANCE; RES INST MOLEC PATHOL,A-1030 VIENNA,AUSTRIA	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)								ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; BALLOU LM, 1991, NATURE, V349, P348, DOI 10.1038/349348a0; BANERJEE P, 1990, P NATL ACAD SCI USA, V87, P8550, DOI 10.1073/pnas.87.21.8550; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CAMBIER JC, 1987, NATURE, V327, P629, DOI 10.1038/327629a0; CHEN RH, 1992, MOL CELL BIOL, V12, P925; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DEAN DC, 1990, J BIOL CHEM, V265, P3522; DEGROOT RP, 1993, MOL ENDOCRINOL, V7, P145, DOI 10.1210/me.7.2.145; DEGROOT RP, 1994, ONCOGENE, V9, P463; DEGROOT RP, 1991, EMBO J, V10, P2523, DOI 10.1002/j.1460-2075.1991.tb07792.x; DEGROOT RP, 1993, EMBO J, V12, P3903, DOI 10.1002/j.1460-2075.1993.tb06068.x; DEGROOT RP, 1993, MOL ENDOCRINOL, V7, P1495, DOI 10.1210/me.7.11.1495; DELMAS V, 1993, MOL ENDOCRINOL, V7, P1502, DOI 10.1210/me.7.11.1502; DELMAS V, 1992, P NATL ACAD SCI USA, V89, P4226, DOI 10.1073/pnas.89.10.4226; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; FLOTOW H, 1992, J BIOL CHEM, V267, P3074; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; FOULKES NS, 1993, NATURE, V362, P264, DOI 10.1038/362264a0; FRANCO R, 1990, J BIOL CHEM, V265, P4321; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GROVE JR, 1991, MOL CELL BIOL, V11, P5541, DOI 10.1128/MCB.11.11.5541; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JENO P, 1988, P NATL ACAD SCI USA, V85, P406, DOI 10.1073/pnas.85.2.406; KOZMA SC, 1990, P NATL ACAD SCI USA, V87, P7365, DOI 10.1073/pnas.87.19.7365; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LALLI E, 1994, J BIOL CHEM, V269, P17359; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; LAOIDE BM, 1993, EMBO J, V12, P1179, DOI 10.1002/j.1460-2075.1993.tb05759.x; MACNICOL M, 1992, FEBS LETT, V304, P237, DOI 10.1016/0014-5793(92)80627-S; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MELLSTROM B, 1993, NEURON, V10, P655, DOI 10.1016/0896-6273(93)90167-P; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; MORICE WG, 1993, J BIOL CHEM, V268, P22737; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; PRICE DJ, 1989, J BIOL CHEM, V264, P13825; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; REINHARD C, 1992, P NATL ACAD SCI USA, V89, P4052, DOI 10.1073/pnas.89.9.4052; REINHARD C, 1994, EMBO J, V13, P1557, DOI 10.1002/j.1460-2075.1994.tb06418.x; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; STEHLE JH, 1993, NATURE, V365, P314, DOI 10.1038/365314a0; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; TAKAHASHI JS, 1993, NATURE, V365, P299, DOI 10.1038/365299a0; TERADA N, 1992, BIOCHEM BIOPH RES CO, V186, P1315, DOI 10.1016/S0006-291X(05)81549-9; TERADA N, 1993, J CELL PHYSIOL, V154, P7, DOI 10.1002/jcp.1041540103; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; YOSHIMASA T, 1987, NATURE, V327, P67, DOI 10.1038/327067a0	54	210	213	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 7	1994	79	1					81	91		10.1016/0092-8674(94)90402-2	http://dx.doi.org/10.1016/0092-8674(94)90402-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PK585	7923380				2022-12-24	WOS:A1994PK58500010
J	KOCISKO, DA; COME, JH; PRIOLA, SA; CHESEBRO, B; RAYMOND, GJ; LANSBURY, PT; CAUGHEY, B				KOCISKO, DA; COME, JH; PRIOLA, SA; CHESEBRO, B; RAYMOND, GJ; LANSBURY, PT; CAUGHEY, B			CELL-FREE FORMATION OF PROTEASE-RESISTANT PRION PROTEIN	NATURE			English	Article							SCRAPIE-ASSOCIATED FORM; CULTURED-CELLS; PRP; CONVERSION; DISEASES; FIBRILS; BIOLOGY; ACID	THE infectious agent (or 'prion') of the transmissible spongiform encephalopathies (TSEs) such as scrapie resembles a virus in that it replicates in vivo and has distinct strains(1), but it was postulated long ago to contain only protein(2-3). More recently, PrPSc, a pathogenic, scrapie-associated form of the host-encoded prion protein (PrP), was identified as a possible primary TSE agent protein(4-6). PrPSc is defined biochemically by its insolubility and resistance to proteases(7) and is derived post-translationally from normal, protease-sensitive PrP (PrPc)(8,9). The conversion seems to involve conformational change rather than covalent modification(10-13) However, the conversion mechanism and the relationship of PrPSc formation to TSE agent replication remain unclear. Here we report the conversion of PrPc to protease-resistant forms similar to PrPSc in a cell-free system composed of substantially purified constituents. This conversion was selective and required the presence of preexisting PrPSc, providing direct evidence that PrPSc derives from specific PrPc-PrPSc interactions.	MIT,DEPT CHEM,CAMBRIDGE,MA 02139; NIAID,ROCKY MT LABS,PERSISTENT VIRAL DIS LAB,HAMILTON,MT 59840	Massachusetts Institute of Technology (MIT); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)								AIKEN JM, 1990, MICROBIOL REV, V54, P242, DOI 10.1128/MMBR.54.3.242-246.1990; BOLTON DC, 1982, SCIENCE, V218, P1309, DOI 10.1126/science.6815801; BOLTON DC, 1988, NOVEL INFECTIOUS AGE, V1, P164; BORCHELT DR, 1990, J CELL BIOL, V110, P743, DOI 10.1083/jcb.110.3.743; BROWN P, 1991, LANCET, V337, P1019, DOI 10.1016/0140-6736(91)92670-W; CAUGHEY B, 1991, J BIOL CHEM, V266, P18217; CAUGHEY B, 1991, J VIROL, V65, P6597, DOI 10.1128/JVI.65.12.6597-6603.1991; CAUGHEY B, 1989, J VIROL, V63, P175, DOI 10.1128/JVI.63.1.175-181.1989; CAUGHEY B, 1993, J VIROL, V67, P643, DOI 10.1128/JVI.67.2.643-650.1993; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; CHESEBRO B, 1993, DEV BIOL STAND, V80, P131; COME JH, 1993, P NATL ACAD SCI USA, V90, P5959, DOI 10.1073/pnas.90.13.5959; DIRINGER H, 1983, NATURE, V306, P476, DOI 10.1038/306476a0; FRASER H, 1993, BRIT MED BULL, V49, P792, DOI 10.1093/oxfordjournals.bmb.a072647; GRIFFITH JS, 1967, NATURE, V215, P1043, DOI 10.1038/2151043a0; HOPE J, 1986, EMBO J, V5, P2591, DOI 10.1002/j.1460-2075.1986.tb04539.x; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; MEYER RK, 1986, P NATL ACAD SCI USA, V83, P2310, DOI 10.1073/pnas.83.8.2310; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; PATTISON IH, 1967, VET REC, V80, P2, DOI 10.1136/vr.80.1.2; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; PRUSINER SB, 1984, CELL, V38, P127, DOI 10.1016/0092-8674(84)90533-6; Riesner D., 1991, SEMIN VIROL, V2, P215; ROGERS M, 1993, P NATL ACAD SCI USA, V90, P3182, DOI 10.1073/pnas.90.8.3182; Rohwer R G, 1991, Curr Top Microbiol Immunol, V172, P195; SAFAR J, 1993, J BIOL CHEM, V268, P20276; SNOW AD, 1990, LAB INVEST, V63, P601; STAHL N, 1993, BIOCHEMISTRY-US, V32, P1991, DOI 10.1021/bi00059a016; TARABOULOS A, 1990, P NATL ACAD SCI USA, V87, P8262, DOI 10.1073/pnas.87.21.8262; WEISSMANN C, 1991, NATURE, V352, P679, DOI 10.1038/352679a0	30	766	802	1	38	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 11	1994	370	6489					471	474		10.1038/370471a0	http://dx.doi.org/10.1038/370471a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PB407	7913989	Green Published			2022-12-24	WOS:A1994PB40700059
J	CLEARY, MA; WALTER, JH; WRAITH, JE; JENKINS, JPR; ALANI, SM; TYLER, K; WHITTLE, D				CLEARY, MA; WALTER, JH; WRAITH, JE; JENKINS, JPR; ALANI, SM; TYLER, K; WHITTLE, D			MAGNETIC-RESONANCE-IMAGING OF THE BRAIN IN PHENYLKETONURIA	LANCET			English	Article							MULTIPLE-SCLEROSIS; EXPERIMENTAL HYPERPHENYLALANINEMIA; NEUROLOGICAL DETERIORATION; DIETARY-TREATMENT; ADOLESCENTS; STIMULATION; MR; INTELLIGENCE; MYELIN	Abnormalities of magnetic resonance imaging (MRI) of the brain occur in some patients with phenylketonuria but the clinical importance of this finding is not clear. In order to determine the frequency and functional significance of changes on MRI we investigated 77 adolescent and adult patients with phenylketonuria. Patients aged 14-49 years and taking a restricted diet of 1 g/kg protein underwent clinical examination, IQ testing, neurophysiological investigation, and MRI of the brain. Patients aged between 10-14 years taking a low phenylalanine diet with aminoacid supplements had MRI of the brain only. Biochemical control was assessed from: the lifetime blood phenylalanine determined from the mean blood concentration throughout life; the accumulated time for each patient that phenylalanine was < 120 mu mol/L; the accumulated time for each patient that phenylalanine was > 1200 mu mol/L); mean blood concentration in the first 4 years of life; and the mean blood phe concentration in the 5 years prior to imaging. MRI changes, compatible with a disturbance in the water content of white matter, were present in all but 1 patient. The severity of abnormality was most strongly associated with the blood phenylalanine concentration at the time of imaging. Clinical and neurophysiological abnormalities were less common and usually mild. 3 patients had prolonged central motor conduction time, 7 had prolonged visual evoked potentials, and 5 had impaired peripheral sensory nerve conduction. There was no significant association between the extent of MRI abnormalities and IQ, and the presence of neurophysiological, or clinical abnormalities. An abnormal brain scan in PKU may reflect present biochemical control rather than indicate significant neurological damage. As yet there is little evidence that in most patients with PKU these MRI changes are of clinical importance.	ROYAL MANCHESTER CHILDRENS HOSP,WILLINK BIOCHEM GENET UNIT,MANCHESTER M27 4HA,LANCS,ENGLAND; HOPE HOSP,SALFORD M6 8HD,LANCS,ENGLAND; MANCHESTER ROYAL INFIRM,DEPT CLIN RADIOL,MANCHESTER,ENGLAND	Royal Manchester Children's Hospital; University of Manchester								BICK U, 1991, EUR J PEDIATR, V150, P185, DOI 10.1007/BF01963563; BICK U, 1993, EUR J PEDIATR, V152, P1012, DOI 10.1007/BF01957228; BRANTZAWADZKI M, 1988, RADIOLOGY, V166, P1; DOBSON JC, 1977, PEDIATRICS, V60, P822; EISEN A, 1990, MUSCLE NERVE, V13, P146, DOI 10.1002/mus.880130211; HALLIDAY AM, 1973, BRIT MED J, V4, P661, DOI 10.1136/bmj.4.5893.661; HOMMES FA, 1982, J INHERIT METAB DIS, V5, P21, DOI 10.1007/BF01799750; INGRAM DA, 1988, J NEUROL NEUROSUR PS, V51, P487, DOI 10.1136/jnnp.51.4.487; KAMMAN RL, 1988, MAGNET RESON MED, V6, P265, DOI 10.1002/mrm.1910060304; KORINTHENBERG R, 1988, NEUROPEDIATRICS, V19, P175, DOI 10.1055/s-2008-1052440; LOU HC, 1992, J INHERIT METAB DIS, V15, P687, DOI 10.1007/BF01800008; LUDOLPH AC, 1992, ACTA NEUROL SCAND, V85, P243; MALAMUD N, 1966, J NEUROPATH EXP NEUR, V25, P254, DOI 10.1097/00005072-196604000-00006; MAYR N, 1991, NEUROLOGY, V41, P566, DOI 10.1212/WNL.41.4.566; MCDONALD WI, 1988, CLIN NEUROL NEUROSUR, V90, P3; PEARSEN KD, 1990, RADIOLOGY, V177, P437, DOI 10.1148/radiology.177.2.2217781; REYNOLDS R, 1992, EXP NEUROL, V115, P347, DOI 10.1016/0014-4886(92)90200-A; SAUDUBRAY JM, 1987, EUR J PEDIATR, V146, P20; SHAW DWW, 1990, J COMPUT ASSIST TOMO, V14, P458, DOI 10.1097/00004728-199005000-00026; SMITH I, 1990, ARCH DIS CHILD, V65, P472, DOI 10.1136/adc.65.5.472; SMITH I, 1985, GENETIC METABOLIC DI, P166; TAYLOR EH, 1983, INT J NEUROSCI, V20, P217, DOI 10.3109/00207458308986575; THOMPSON AJ, 1993, BRAIN, V116, P811, DOI 10.1093/brain/116.4.811; THOMPSON AJ, 1990, LANCET, V336, P602, DOI 10.1016/0140-6736(90)93401-A; TOMA P, 1991, NEUROPEDIATRICS, V22, P174; Valk J., 1989, MAGNETIC RESONANCE M; VILLASANA D, 1989, J INHERIT METAB DIS, V12, P451, DOI 10.1007/BF01802042; Waisbren S E, 1980, J Inherit Metab Dis, V3, P149, DOI 10.1007/BF02312549; WAISBREN SE, 1987, PEDIATRICS, V79, P351; WALTER JH, 1993, EUR J PEDIATR, V152, P822, DOI 10.1007/BF02073379	30	121	125	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 9	1994	344	8915					87	90		10.1016/S0140-6736(94)91281-5	http://dx.doi.org/10.1016/S0140-6736(94)91281-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NV732	7912392				2022-12-24	WOS:A1994NV73200009
J	NIGHTINGALE, SL				NIGHTINGALE, SL			TREATMENT IND FOR ADVANCED NON-SMALL-CELL LUNG-CANCER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 15	1994	271	23					1818	1818						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NP959	7910857				2022-12-24	WOS:A1994NP95900007
J	BERKOVITCH, M; LAXER, RM; INMAN, R; KOREN, G; PRITZKER, KPH; FRITZLER, MJ; OLIVIERI, NF				BERKOVITCH, M; LAXER, RM; INMAN, R; KOREN, G; PRITZKER, KPH; FRITZLER, MJ; OLIVIERI, NF			ARTHROPATHY IN THALASSEMIA PATIENTS RECEIVING DEFERIPRONE	LANCET			English	Note							IRON; L1	The iron chelator deferiprone (L1) reduces tissue iron stores in iron-loaded patients. Three of sixteen patients treated with deferiprone developed joint pain and swelling without evidence of systemic lupus erythematosus (SLE). Articular cartilage, synovial hypertrophy and iron deposition, and synovial lining cell proliferation, with no inflammatory or allergic reaction, were observed on synovial exploration and biopsy. Symptoms resolved partly or completely during continued drug administration. We hypothesise that deferiprone-induced shifts of iron to synovium resulted in tissue damage, accelerated by free-radical formation during incomplete complexation of iron and this bidentate chelator. This deferiprone-associated symptom complex is not associated with drug-induced SLE, and does not progress in severity during continued therapy.	HOSP SICK CHILDREN,DEPT PEDIAT,HAEMOGLOBINOPATHY PROGRAM,TORONTO M5G 1X8,ON,CANADA; UNIV TORONTO,TORONTO HOSP,DEPT MED,TORONTO,ON,CANADA; UNIV TORONTO,MT SINAI HOSP,DEPT PATHOL,TORONTO M5G 1X5,ON,CANADA; UNIV ALBERTA,MCCALG CTR JOINT INJURY & ARTHRITIS RES,CALGARY,AB,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Alberta			Olivieri, Nancy/AAI-2250-2020	Inman, Robert/0000-0002-4750-1422				AGARWAL MB, 1992, BRIT J HAEMATOL, V82, P460, DOI 10.1111/j.1365-2141.1992.tb06445.x; ALREFAIE FN, 1992, BLOOD, V80, P592; BERDOUKAS V, 1991, LANCET, V337, P672, DOI 10.1016/0140-6736(91)92483-I; BERKOVITCH M, 1992, BLOOD S1, V80, pA7; BLAKE DR, 1981, LANCET, V2, P1142; BRITTENHAM GM, 1992, BLOOD, V80, P569; GRATWICK GM, 1978, ANN INTERN MED, V88, P494, DOI 10.7326/0003-4819-88-4-494; HERSHKO C, 1991, BLOOD, V77, P2049; MAGARO M, 1990, ANN RHEUM DIS, V49, P268, DOI 10.1136/ard.49.4.268-b; MEHTA J, 1991, LANCET, V337, P298, DOI 10.1016/0140-6736(91)90906-6	10	59	61	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 11	1994	343	8911					1471	1472		10.1016/S0140-6736(94)92585-2	http://dx.doi.org/10.1016/S0140-6736(94)92585-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NQ415	7911181				2022-12-24	WOS:A1994NQ41500012
J	NITTI, VW				NITTI, VW			INTRAVESICAL CAPSAICIN FOR TREATMENT OF NEUROGENIC BLADDER	LANCET			English	Editorial Material							SPINAL-CORD INJURY; MICTURITION; REFLEX				NITTI, VW (corresponding author), SUNY HLTH SCI CTR,BROOKLYN,NY 11203, USA.			Nitti, Victor/0000-0002-1390-7053				FOWLER CJ, 1994, J NEUROL NEUROSUR PS, V57, P169, DOI 10.1136/jnnp.57.2.169; KOLDEWIJN EL, 1994, J UROLOGY, V151, P955, DOI 10.1016/S0022-5347(17)35133-9; MAGGI CA, 1989, J UROLOGY, V142, P150, DOI 10.1016/S0022-5347(17)38701-3; MAGGI CA, 1989, NEUROSCIENCE, V31, P745, DOI 10.1016/0306-4522(89)90438-7; MCGUIRE EJ, 1991, NEUROUROL URODYNAM, V10, P223, DOI 10.1002/nau.1930100302; MCGUIRE EJ, 1994, J UROLOGY, V151, P965, DOI 10.1016/S0022-5347(17)35135-2; MCGUIRE EJ, 1983, J UROLOGY, V129, P775, DOI 10.1016/S0022-5347(17)52357-5; SIRLS LT, 1994, J UROLOGY, V151, P946, DOI 10.1016/S0022-5347(17)35131-5	8	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 11	1994	343	8911					1448	1448		10.1016/S0140-6736(94)92578-X	http://dx.doi.org/10.1016/S0140-6736(94)92578-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NQ415	7911174				2022-12-24	WOS:A1994NQ41500005
J	HOWAT, WJ; MOORE, IE; JUDD, M; ROCHE, WR				HOWAT, WJ; MOORE, IE; JUDD, M; ROCHE, WR			PULMONARY IMMUNOPATHOLOGY OF SUDDEN-INFANT-DEATH-SYNDROME	LANCET			English	Article							MONOCLONAL-ANTIBODY; T-CELLS; ASSOCIATION; TEMPERATURE; RECOGNIZES; TISSUES; ANTIGEN	Sudden infant death syndrome (SIDS) is the most common cause of postneonatal mortality in the UK. Pathological investigations have shown evidence suggestive of respiratory obstruction with subsequent hypoxia leading to death. We examined 48 infants who died of SIDS and 30 who died of other, non-pulmonary, causes and identified pulmonary eosinophil and neutrophil leucocytes, mast cells, and T and B lymphocytes by immunocytochemistry. Positively stained cells were counted in the parenchyma and around the bronchi without knowledge of the tissue source. The results showed three times more eosinophils in the lungs of infants who died of SIDS (27.61 vs 7.91 [99% CI 1.76-5.87] cells/mm(2) for parenchyma) accompanied by increased T lymphocytes and B lymphocytes. There were more peribronchial mast cells in the SIDS group (22.1 vs 14.7 [1.03-2.10] cells/mm(2)) and insignificant differences in neutrophils and parenchymal mast cells. There were significant associations between eosinophil, B lymphocyte, and T lymphocyte numbers. These findings provide evidence for an abnormal T lymphocyte-mediated pulmonary inflammatory response In SIDS. Products of eosinophil degranulation can cause epithelial damage and pulmonary oedema, which could cause the respiratory obstruction and hypoxia associated with SIDS.	UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,DEPT PATHOL,SOUTHAMPTON S09 4XY,ENGLAND	University of Southampton								BECKWITH JB, 1970, SUDDEN INFANT DEATH, P83; BERRY PJ, 1992, J CLIN PATHOL S, V45, pS11; BONSER RSA, 1978, INT J EPIDEMIOL, V7, P335, DOI 10.1093/ije/7.4.335; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; CAMPBELL MJ, 1989, MED J AUSTRALIA, V151, P365, DOI 10.5694/j.1326-5377.1989.tb101216.x; CLARK JW, 1979, J PEDIATR-US, V95, P85, DOI 10.1016/S0022-3476(79)80094-3; COOMBS RRA, 1990, CLIN EXP ALLERGY, V20, P359, DOI 10.1111/j.1365-2222.1990.tb02794.x; COSTA JJ, 1993, J CLIN INVEST, V91, P2673, DOI 10.1172/JCI116506; CUNNINGHAM AS, 1975, J PEDIATR-US, V87, P426, DOI 10.1016/S0022-3476(75)80650-0; FLEMING PJ, 1990, BRIT MED J, V301, P85, DOI 10.1136/bmj.301.6743.85; HILTON JMN, 1989, PAEDIAT FORENSIC MED, P156; KAPSENBERG ML, 1992, CURR OPIN IMMUNOL, V4, P788, DOI 10.1016/0952-7915(92)90063-K; MASON DY, 1990, AM J PATHOL, V136, P1215; MASON DY, 1989, J CLIN PATHOL, V42, P1194, DOI 10.1136/jcp.42.11.1194; MIRCHANDANI HG, 1984, J FORENSIC SCI, V29, P425; NAEYE RL, 1976, AM J CLIN PATHOL, V66, P526, DOI 10.1093/ajcp/66.3.526; NELSON EAS, 1988, NEW ZEAL MED J, V101, P443; NORTON AJ, 1986, J CLIN PATHOL, V39, P399, DOI 10.1136/jcp.39.4.399; OPENSHAW PJM, 1992, INT IMMUNOL, V4, P493, DOI 10.1093/intimm/4.4.493; PULFORD KAF, 1988, J CLIN PATHOL, V41, P853, DOI 10.1136/jcp.41.8.853; RESNICK MB, 1993, AM J RESP CELL MOL, V8, P349, DOI 10.1165/ajrcmb/8.4.349; ROWEN JL, 1991, AM REV RESPIR DIS, V142, P215; SAITO H, 1988, P NATL ACAD SCI USA, V85, P2288, DOI 10.1073/pnas.85.7.2288; STEWART S, 1985, J PATHOL, V145, P53, DOI 10.1002/path.1711450105; STRIMER R, 1969, J AMER MED ASSOC, V209, P1493, DOI 10.1001/jama.209.10.1493; TAI PC, 1984, NATURE, V309, P182, DOI 10.1038/309182a0; UREN EC, 1980, MED J AUSTRALIA, V1, P417, DOI 10.5694/j.1326-5377.1980.tb134996.x; WALLS AF, 1990, J PATHOL, V162, P119, DOI 10.1002/path.1711620204; WILLIAMS AL, 1984, BRIT MED J, V288, P1491, DOI 10.1136/bmj.288.6429.1491; WOOD GS, 1981, J HISTOCHEM CYTOCHEM, V29, P1196, DOI 10.1177/29.10.7028859; 1992, OFFICE POPULATIO DH6	31	50	52	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 4	1994	343	8910					1390	1392		10.1016/S0140-6736(94)92523-2	http://dx.doi.org/10.1016/S0140-6736(94)92523-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NP955	7910883				2022-12-24	WOS:A1994NP95500009
J	LOUSSERTAJAKA, I; BRUNVEZINET, F; SIMON, F; LY, TD; CHAIX, ML; SARAGOSTI, S; COUROUCE, AM; INGRAND, D				LOUSSERTAJAKA, I; BRUNVEZINET, F; SIMON, F; LY, TD; CHAIX, ML; SARAGOSTI, S; COUROUCE, AM; INGRAND, D			HIV-1/HIV-2 SERONEGATIVITY IN HIV-1 SUBTYPE-O INFECTED PATIENTS	LANCET			English	Note								Nine patients with atypical HIV-1 western blot profiles were diagnosed as having HIV-1 subtype O infection. All the patients were living in France; eight originated from Cameroon and one from France. Lymphocyte DNA amplification by the polymerase chain reaction was only positive when HIV-1 subtype O specific primers were used. Preliminary sequence analysis of amplified products and serological reactivity against a specific subtype O synthetic env peptide confirmed HIV-1 subtype O infection. HIV-1/HIV-2 enzyme-linked immunosorbent assays, especially those based on env peptides or on the sandwich format, can be negative in HIV-1 subtype O infection.	BICHAT CLAUDE BERNARD HOSP,DEPT VIROL,VIROL LAB,F-75877 PARIS 18,FRANCE; ALFRED FOURNIER INST,PARIS,FRANCE; COCHIN HOSP,INSERM,U363,ICGM,PARIS,FRANCE; NATL BLOOD TRANSFUS INST,PARIS,FRANCE; ROBERT DEBRE HOSP,DEPT MICROBIOL,REIMS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Universite de Montpellier; CHU de Reims								AGUT H, 1992, LANCET, V340, P681, DOI 10.1016/0140-6736(92)92226-6; GURTLER LG, 1994, J VIROL, V68, P1581; MYERS G, 1993, HUMAN RETROVIRUSES A; NKENGASONG JN, 1993, AIDS, V7, P1536, DOI 10.1097/00002030-199311000-00026; VANDENHAESEVELDE M, 1994, J VIROL, V68, P1586, DOI 10.1128/JVI.68.3.1586-1596.1994	5	210	214	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 4	1994	343	8910					1393	1394		10.1016/S0140-6736(94)92524-0	http://dx.doi.org/10.1016/S0140-6736(94)92524-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NP955	7910884				2022-12-24	WOS:A1994NP95500010
J	TUOMILEHTO, J; ZIMMET, P; MACKAY, IR; KOSKELA, P; VIDGREN, G; TOIVANEN, L; TUOMILEHTOWOLF, E; KOHTAMAKI, K; STENGARD, J; ROWLEY, MJ				TUOMILEHTO, J; ZIMMET, P; MACKAY, IR; KOSKELA, P; VIDGREN, G; TOIVANEN, L; TUOMILEHTOWOLF, E; KOHTAMAKI, K; STENGARD, J; ROWLEY, MJ			ANTIBODIES TO GLUTAMIC-ACID DECARBOXYLASE AS PREDICTORS OF INSULIN-DEPENDENT DIABETES-MELLITUS BEFORE CLINICAL ONSET OF DISEASE	LANCET			English	Article							ISLET CELL ANTIBODIES; AUTOANTIBODIES; CHILDREN; MARKERS; GABA; MICE; GAD	We have done a study designed to ascertain the effectiveness of measuring antibodies to glutamic acid decarboxylase (anti-GAD) in predicting insulin-dependent diabetes mellitus (IDDM). Anti-GAD was measured-in prediabetic sera from 151 women aged 20-39 years with newly diagnosed diabetes mellitus who had been identified through a nationwide diabetes register. Multiple serum samples had been collected from these women up to 10 years before the clinical onset of diabetes during their earlier pregnancies. Anti-GAD was measured with a radioimmunoprecipitation assay. Anti-GAD was detected in 82% of 28 women with IDDM, in 36% of 11 women with non-insulin-dependent diabetes mellitus, and in 5% of 112 women with gestational diabetes mellitus. In a random sample of 100 non-diabetic young Finnish women, none had anti-GAD. The sensitivity of the anti-GAD assay for predicting IDDM was 82.1% and the specificity was 100%. The longest time of anti-GAD positivity before clinical onset of IDDM was 10 years. Once positive, anti-GAD levers remained stable and no patients became negative after a positive test during the prediabetic period. Anti-GAD is a valuable early predictive marker and is associated with a very high risk for development of IDDM.	INT DIABET INST,CAULFIELD,VIC,AUSTRALIA; MONASH UNIV,CTR MOLEC BIOL & MED,CLAYTON,VIC 3168,AUSTRALIA; NATL PUBL HLTH INST,OULU,FINLAND	Monash University; Finland National Institute for Health & Welfare	TUOMILEHTO, J (corresponding author), NATL PUBL HLTH INST,DEPT EPIDEMIOL & HLTH PROMOT,MANNERHELMINTIE 166,SF-00300 HELSINKI,FINLAND.		Mackay, Ian R/A-7228-2010; Zimmet, Paul/O-8486-2019	Zimmet, Paul/0000-0003-0627-0776				ATKINSON MA, 1990, LANCET, V335, P1357, DOI 10.1016/0140-6736(90)91241-2; BAEKKESKOV S, 1982, NATURE, V298, P167, DOI 10.1038/298167a0; BAEKKESKOV S, 1987, J CLIN INVEST, V79, P926, DOI 10.1172/JCI112903; BAEKKESKOV S, 1990, NATURE, V347, P151, DOI 10.1038/347151a0; BINGLEY PJ, 1993, DIABETES CARE, V16, P45, DOI 10.2337/diacare.16.1.45; BLOHME G, 1993, DIABETOLOGIA, V35, P56; BONNEVIENIELSEN V, 1981, DIABETES, V30, P424, DOI 10.2337/diabetes.30.5.424; CATALANO PM, 1990, DIABETES CARE, V13, P478, DOI 10.2337/diacare.13.5.478; CHEN QY, 1993, PEDIATR RES, V34, P785, DOI 10.1203/00006450-199312000-00018; CHRISTIE M, 1988, DIABETOLOGIA, V31, P597, DOI 10.1007/BF00264766; HAGOPIAN WA, 1993, J CLIN INVEST, V91, P368, DOI 10.1172/JCI116195; Harris M.I, 1992, INT TEXTB DIABETES M, P3; KAUFMAN DL, 1992, J CLIN INVEST, V89, P283, DOI 10.1172/JCI115573; KAUFMAN DL, 1993, NATURE, V366, P69, DOI 10.1038/366069a0; LANDINOLSSON M, 1993, DIABETOLOGIA, V36, pA99; LERNMARK A, 1978, NEW ENGL J MED, V299, P375, DOI 10.1056/NEJM197808242990802; PALMER JP, 1983, SCIENCE, V222, P1337, DOI 10.1126/science.6362005; REETZ A, 1991, EMBO J, V10, P1275, DOI 10.1002/j.1460-2075.1991.tb08069.x; ROWLEY MJ, 1992, DIABETES, V41, P548, DOI 10.2337/diabetes.41.4.548; SCOTT RS, 1991, DIABETIC MED, V8, P1; SERJEANTSON SW, 1993, HUM IMMUNOL, V38, P97, DOI 10.1016/0198-8859(93)90525-6; SERJEANTSON SW, 1992, DIABETOLOGIA, V35, P996, DOI 10.1007/BF00401432; THIVOLET C, 1992, DIABETOLOGIA, V35, P570, DOI 10.1007/BF00400486; TISCH R, 1993, NATURE, V366, P72, DOI 10.1038/366072a0; TUOMI T, 1993, DIABETES, V42, P359, DOI 10.2337/diabetes.42.2.359; TUOMILEHTOWOLF E, 1993, BRIT MED J, V307, P155, DOI 10.1136/bmj.307.6897.155; TUOMILEHTOWOLF E, 1991, ANN MED, V23, P481, DOI 10.3109/07853899109150507; WILKIN T, 1985, LANCET, V1, P480; ZIMMET PZ, 1994, DIABETIC MED, V11, P299, DOI 10.1111/j.1464-5491.1994.tb00275.x	29	161	164	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 4	1994	343	8910					1383	1385		10.1016/S0140-6736(94)92521-6	http://dx.doi.org/10.1016/S0140-6736(94)92521-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NP955	7910881				2022-12-24	WOS:A1994NP95500007
J	WATSON, BA; STARR, SE				WATSON, BA; STARR, SE			VARICELLA VACCINE FOR HEALTHY-CHILDREN	LANCET			English	Editorial Material											WATSON, BA (corresponding author), CHILDRENS HOSP PHILADELPHIA,DIV ALLERGY IMMUNOL & INFECT DIS,PHILADELPHIA,PA 19104, USA.							ASANO Y, 1985, PEDIATRICS, V75, P667; BERNSTEIN HH, 1993, PEDIATRICS, V92, P833; DUNKLE LM, 1991, NEW ENGL J MED, V325, P1539, DOI 10.1056/NEJM199111283252203; KUTER BJ, 1991, VACCINE, V9, P643, DOI 10.1016/0264-410X(91)90189-D; LIEU TA, 1994, JAMA-J AM MED ASSOC, V271, P375, DOI 10.1001/jama.271.5.375; PREBLUD SR, 1985, POSTGRAD MED J, V61, P17; WATSON B, 1974, J INFECT DIS, V164, P197; WATSON BM, 1993, PEDIATRICS, V91, P17; WHITE CJ, 1992, PEDIATR INFECT DIS J, V11, P19, DOI 10.1097/00006454-199201000-00006	9	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 16	1994	343	8903					928	929		10.1016/S0140-6736(94)90058-2	http://dx.doi.org/10.1016/S0140-6736(94)90058-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF700	7909003				2022-12-24	WOS:A1994NF70000002
J	THOMSON, AD				THOMSON, AD			ALCOHOLIC HEPATITIS	LANCET			English	Editorial Material											THOMSON, AD (corresponding author), GREENWICH DIST HOSP,DEPT MED,LONDON,ENGLAND.							ACHORD JL, 1993, AM J GASTROENTEROL, V88, P1822; BIRD GLA, 1990, ALCOHOL ALCOHOLISM, V25, P197, DOI 10.1093/oxfordjournals.alcalc.a044993; FANG JWS, 1994, LANCET, V343, P820, DOI 10.1016/S0140-6736(94)92025-7; LEEVY CM, 1973, LIVER REGENERATION M; SHERON N, 1993, HEPATOLOGY, V18, P41, DOI 10.1002/hep.1840180108; THOMSON AD, 1974, NATURE, V252, P721, DOI 10.1038/252721a0; THOMSON AD, 1991, GUT, P97	7	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 2	1994	343	8901					810	810		10.1016/S0140-6736(94)92022-2	http://dx.doi.org/10.1016/S0140-6736(94)92022-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ND792	7908075				2022-12-24	WOS:A1994ND79200005
J	GLEICHER, N				GLEICHER, N			AUTOANTIBODIES AND PREGNANCY LOSS	LANCET			English	Editorial Material							ANTIBODIES		FDN REPROD MED,CHICAGO,IL		GLEICHER, N (corresponding author), CTR HUMAN REPROD,CHICAGO,IL, USA.							AOKI K, 1993, AM J REPROD IMMUNOL, V29, P82, DOI 10.1111/j.1600-0897.1993.tb00570.x; BAKIMER R, 1992, J CLIN INVEST, V89, P1158; BLANK M, 1991, P NATL ACAD SCI USA, V88, P3069, DOI 10.1073/pnas.88.8.3069; CHRISTIANSEN OB, 1989, HUM REPROD, V4, P913, DOI 10.1093/oxfordjournals.humrep.a137011; CLARK DA, 1991, AM J REPROD IMMUNOL, V25, P18, DOI 10.1111/j.1600-0897.1991.tb01058.x; EROGLU GE, 1994, AM J REPROD IMMUNOL, V31, P1; GLEICHER N, 1992, AM J OBSTET GYNECOL, V167, P637, DOI 10.1016/S0002-9378(11)91563-4; GLINOER D, 1991, J CLIN ENDOCR METAB, V73, P421, DOI 10.1210/jcem-73-2-421; PRATT DE, 1993, FERTIL STERIL, V60, P1001; STAGNAROGREEN A, 1990, JAMA-J AM MED ASSOC, V264, P1422, DOI 10.1001/jama.264.11.1422; VONBOEHMER H, 1990, SCIENCE, V248, P1369, DOI 10.1126/science.1972594; XU L, 1990, AM J OBSTET GYNECOL, V163, P1493, DOI 10.1016/0002-9378(90)90612-B	12	21	21	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 26	1994	343	8900					747	748		10.1016/S0140-6736(94)91833-3	http://dx.doi.org/10.1016/S0140-6736(94)91833-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NC351	7907727				2022-12-24	WOS:A1994NC35100005
J	BEADLE, C; LONG, GW; WEISS, WR; MCELROY, PD; MARET, SM; OLOO, AJ; HOFFMAN, SL				BEADLE, C; LONG, GW; WEISS, WR; MCELROY, PD; MARET, SM; OLOO, AJ; HOFFMAN, SL			DIAGNOSIS OF MALARIA BY DETECTION OF PLASMODIUM-FALCIPARUM HRP-2 ANTIGEN WITH A RAPID DIPSTICK ANTIGEN-CAPTURE ASSAY	LANCET			English	Article							HISTIDINE-RICH PROTEINS; RADIOIMMUNOASSAY	Two field studies in Kenya and an experimental challenge study in the USA were done to assess the accuracy of a dipstick antigen-capture assay based on qualitative detection of Plasmodium falciparum histidine-rich protein 2 (PfHRP-2) in peripheral blood for diagnosis of P fafciparum infection. In these studies, the assay was 96.5-100% sensitive for detection of greater than 60 P falciparum asexual parasites/ mu L blood, 70-81% sensitive for 11-60 parasites/mu L blood, and 11-67% sensitive for 10 parasites or less/mu L blood. Specificity was 95% (95% CI 85-105%; n = 20) among naive American volunteers, 98% (96-101%; n=112) among volunteers exposed to the bite of P falciparium-infected mosquitoes, and 88% (84-92%; n=285) among Kenyans living in an area with holoendemic malaria. Our results also indicated that PfHRP-2 antigen was not detectable in blood 6 days after initiation of curative chemotherapy, and suggest that such circulating antigens rarely lead to false-positive tests. The dipstick assay's sensitivity, specificity, simplicity, and speed may make it an important tool in the battle against malaria.	USN,MED RES INST,MALARIA PROGRAM,ROCKVILLE,MD 20852; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,BALTIMORE,MD; USN,NAVAL MED RES INSST DETACHMENT,KISUMU,KENYA; USA,ARMY MED RES UNIT,KISUMU,KENYA; BECTON DICKINSON CO,DIV ADV DIAGNOST,BALTIMORE,MD; KENYA GOVT MED RES CTR,VECTOR BIOL & CONTROL CLIN RES CTR,KISUMU,KENYA	Naval Medical Research Center (NMRC); United States Department of Defense; United States Navy; Johns Hopkins University; Becton Dickinson; Kenya Medical Research Institute			Oloo, James Aggrey/CAF-3948-2022	Oloo, James Aggrey/0000-0001-7495-1827				[Anonymous], 1991, MALARIA OBSTACLES OP; AVIDOR B, 1985, J IMMUNOL METHODS, V82, P121, DOI 10.1016/0022-1759(85)90231-5; AVRAHAM H, 1983, AM J TROP MED HYG, V32, P11, DOI 10.4269/ajtmh.1983.32.11; BEIER JC, IN PRESS AM J TROP M; Fleiss JL, 1981, STAT METHODS RATES P, P218; HULLEY SB, 1988, DESIGNING CLIN RES E, P145; NAMSIRIPONGPUN V, 1993, T ROY SOC TROP MED H, V87, P32, DOI 10.1016/0035-9203(93)90410-R; PARRA ME, 1991, J CLIN MICROBIOL, V29, P1629, DOI 10.1128/JCM.29.8.1629-1634.1991; ROCK EP, 1987, PARASITOLOGY, V95, P209, DOI 10.1017/S0031182000057681; SPENCER H C, 1987, Annals of Tropical Medicine and Parasitology, V81, P13; TAYLOR DW, 1993, T ROY SOC TROP MED H, V87, P29, DOI 10.1016/0035-9203(93)90409-J; WELLEMS TE, 1986, P NATL ACAD SCI USA, V83, P6065, DOI 10.1073/pnas.83.16.6065	12	236	249	4	38	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 5	1994	343	8897					564	568		10.1016/S0140-6736(94)91520-2	http://dx.doi.org/10.1016/S0140-6736(94)91520-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY843	7906328	hybrid, Green Submitted			2022-12-24	WOS:A1994MY84300008
J	BRAATEN, BA; NOU, XW; KALTENBACH, LS; LOW, DA				BRAATEN, BA; NOU, XW; KALTENBACH, LS; LOW, DA			METHYLATION PATTERNS IN PAP REGULATORY DNA CONTROL PYELONEPHRITIS-ASSOCIATED PILI PHASE VARIATION IN ESCHERICHIA-COLI	CELL			English	Article							UROPATHOGENIC ESCHERICHIA-COLI; X-CHROMOSOME INACTIVATION; URINARY-TRACT; EXPRESSION; PROTEIN; MODEL; METHYLTRANSFERASE; TRANSPOSITION; REPLICATION; MECHANISM	We have examined the roles of pap DNA methylation patterns in the regulation of the switch between phase ON and OFF pyelonephritis-associated pill (Pap) expression states in E. coli. Two Dam methyltransferase sites, GATC(1028) and GATC(1130), were shown previously to be differentially methylated in phase ON versus phase OFF cells. In work presented here, these sites were mutated so that they could not be methylated, and the effects of these mutations on Pap phase variation were examined. Our results show that methylation of GATC(1028) blocks formation of the ON state by inhibiting the binding of Lrp and Papl regulatory proteins to this site. Conversely, methylation of GATC(1130) is required for the ON state. Evidence indicates that this occurs by the inhibition of binding of Lrp to sites overlapping the pilin promoter. A model describing how the transition between the phase ON and OFF methylation states might occur is presented.			BRAATEN, BA (corresponding author), UNIV UTAH, HLTH SCI CTR, DEPT PATHOL, DIV CELL BIOL & IMMUNOL, SALT LAKE CITY, UT 84132 USA.		Low, David A/M-7536-2014		NCI NIH HHS [5P30 CA42014-07] Funding Source: Medline; NIAID NIH HHS [2R01 AI23348, 5K04 AI881] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA042014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023348] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Antequera F., 1993, Experientia Supplementum (Basel), V64, P169; Ausubel F, 1989, MOL REPROD DEV, V1, P146; BAGA M, 1985, EMBO J, V4, P3887, DOI 10.1002/j.1460-2075.1985.tb04162.x; BAKKER A, 1989, J BACTERIOL, V171, P5738, DOI 10.1128/jb.171.10.5738-5742.1989; BLYN LB, 1989, EMBO J, V8, P613, DOI 10.1002/j.1460-2075.1989.tb03416.x; BLYN LB, 1990, EMBO J, V9, P4045, DOI 10.1002/j.1460-2075.1990.tb07626.x; BOYE E, 1990, CELL, V62, P981, DOI 10.1016/0092-8674(90)90272-G; BRAATEN BA, 1992, P NATL ACAD SCI USA, V89, P4250, DOI 10.1073/pnas.89.10.4250; BRAATEN BA, 1991, J BACTERIOL, V173, P1789, DOI 10.1128/jb.173.5.1789-1800.1991; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; CEDAR H, 1988, CELL, V53, P3, DOI 10.1016/0092-8674(88)90479-5; FEDOROFF N, 1989, BIOESSAYS, V10, P139, DOI 10.1002/bies.950100502; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GORANSSON M, 1989, MOL MICROBIOL, V3, P1557, DOI 10.1111/j.1365-2958.1989.tb00141.x; GORANSSON M, 1990, NATURE, V344, P682, DOI 10.1038/344682a0; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; Holliday R, 1993, EXS, V64, P452; Hultgren SJ, 1991, CURR OPIN GENET DEV, V1, P313, DOI 10.1016/S0959-437X(05)80293-X; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LOW D, 1987, MOL MICROBIOL, V1, P335, DOI 10.1111/j.1365-2958.1987.tb01940.x; MARINUS MG, 1984, GENE, V28, P123, DOI 10.1016/0378-1119(84)90095-7; MODRICH P, 1989, J BIOL CHEM, V264, P6597; NOU XW, 1993, MOL MICROBIOL, V7, P545, DOI 10.1111/j.1365-2958.1993.tb01145.x; OHANLEY P, 1985, J CLIN INVEST, V75, P347, DOI 10.1172/JCI111707; OHANLEY P, 1985, NEW ENGL J MED, V313, P414, DOI 10.1056/NEJM198508153130704; PETERSON KR, 1985, MOL GEN GENET, V201, P14, DOI 10.1007/BF00397979; RIGGS AD, 1992, TRENDS GENET, V8, P169, DOI 10.1016/0168-9525(92)90219-T; ROBERTS D, 1985, CELL, V43, P117, DOI 10.1016/0092-8674(85)90017-0; ROBERTS JA, 1989, INFECTION, V17, P401, DOI 10.1007/BF01645559; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIMONS RW, 1987, GENE, V53, P85, DOI 10.1016/0378-1119(87)90095-3; SWAIN JL, 1987, CELL, V50, P719, DOI 10.1016/0092-8674(87)90330-8; VANDERWOUDE MW, 1992, MOL MICROBIOL, V6, P2429; WANG MX, 1992, NATURE, V360, P606, DOI 10.1038/360606a0; WANG Q, 1993, J MOL BIOL, V229, P306, DOI 10.1006/jmbi.1993.1036; WANG Q, 1993, EMBO J, V12, P2495, DOI 10.1002/j.1460-2075.1993.tb05904.x; WILLINS DA, 1991, J BIOL CHEM, V266, P10768; WOLF SF, 1984, P NATL ACAD SCI-BIOL, V81, P2806, DOI 10.1073/pnas.81.9.2806	41	156	161	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 11	1994	76	3					577	588		10.1016/0092-8674(94)90120-1	http://dx.doi.org/10.1016/0092-8674(94)90120-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MX207	7906204				2022-12-24	WOS:A1994MX20700017
J	NEAL, KR; BRIJ, SO; SLACK, RCB; HAWKEY, CJ; LOGAN, RFA				NEAL, KR; BRIJ, SO; SLACK, RCB; HAWKEY, CJ; LOGAN, RFA			RECENT TREATMENT WITH H(2) ANTAGONISTS AND ANTIBIOTICS AND GASTRIC-SURGERY AS RISK-FACTORS FOR SALMONELLA INFECTION	BRITISH MEDICAL JOURNAL			English	Article									UNIV NOTTINGHAM,DIV GASTROENTEROL,NOTTINGHAM NG7 2UH,ENGLAND; NOTTINGHAM HLTH AUTHOR,DIV GASTROENTEROL,NOTTINGHAM NG3 5AF,ENGLAND	University of Nottingham	NEAL, KR (corresponding author), UNIV NOTTINGHAM,DEPT HLTH MED & EPIDEMIOL,NOTTINGHAM NG7 2UH,ENGLAND.							GIANNELLA RA, 1972, GUT, V13, P251, DOI 10.1136/gut.13.4.251; HOLT P, 1985, PRACTITIONER, V229, P1027; HOWDEN CW, 1987, GUT, V28, P96, DOI 10.1136/gut.28.1.96; NORDBRING F, 1962, ACTA MED SCAND, V171, P783; PAVIA AT, 1990, J INFECT DIS, V161, P255, DOI 10.1093/infdis/161.2.255	5	74	75	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 15	1994	308	6922					176	176						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MR974	7906170				2022-12-24	WOS:A1994MR97400020
J	BELL, BP; GOLDOFT, M; GRIFFIN, PM; DAVIS, MA; GORDON, DC; TARR, PI; BARTLESON, CA; LEWIS, JH; BARRETT, TJ; WELLS, JG; BARON, R; KOBAYASHI, J				BELL, BP; GOLDOFT, M; GRIFFIN, PM; DAVIS, MA; GORDON, DC; TARR, PI; BARTLESON, CA; LEWIS, JH; BARRETT, TJ; WELLS, JG; BARON, R; KOBAYASHI, J			A MULTISTATE OUTBREAK OF ESCHERICHIA-COLI-O157-H7 ASSOCIATED BLOODY DIARRHEA AND HEMOLYTIC-UREMIC-SYNDROME FROM HAMBURGERS - THE WASHINGTON EXPERIENCE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DAY-CARE-CENTER; HEMORRHAGIC COLITIS; O157-H7 STRAINS; NURSING-HOME; EPIDEMIOLOGY; 0157-H7; INFECTION; CHILDREN; DISEASE	Objective.-To determine the source of and describe a large outbreak of Escherichia coli O157:H7 infections in Washington State. Design.-Case-control study; environmental investigation; provider-based surveillance for E coli O157:H7 infections. Setting.-Chain of fast-food restaurants, hospitals, physician offices, local laboratories, and local health departments. Participants.-Patients with diarrhea and neighborhood controls. A case was defined as diarrhea with culture-confirmed E coli O157:H7 infection or postdiarrheal hemolytic uremic syndrome (HUS) occurring from December 1, 1992, through February 28, 1993, in a Washington State resident. Controls were age- and neighborhood-matched friends of the first 16 case patients. Interventions.-Announcement to the public; recall of implicated hamburger lots. Main Outcome Measure.-Abatement of outbreak due to E coli O157:H7. Results.-Infection was associated with eating at a fast-food chain (chain A) in the 10 days before symptoms began. Twelve (75%) of 16 case patients but no controls had eaten at chain A (matched odds ratio undefined; lower 95% confidence interval, 3.5; P<.001). In total, 501 cases were reported, including 151 hospitalizations (31%), 45 cases of HUS (9%), and three deaths. Forty-eight patients (10%) had secondary infections. Of the remaining 453 patients (90%), 398 (86%) reported eating at a Washington chain A restaurant; 92% of them reported eating a regular hamburger. The pulsed-field gel electrophoresis pattern of the E coli O157:H7 strains isolated from all regular hamburger lots of a single production date shipped to Washington was identical to that of the strains isolated from patients. Ten (63%) of 16 regular hamburgers cooked according to chain A policy had internal temperatures below 60 degrees C. Public health action removed more than 250 000 potentially contaminated hamburgers, preventing an estimated 800 cases. Conclusions.-This E coli O157:H7 outbreak, the largest reported, resulted from errors in meat processing and cooking. Public health surveillance through state-mandated reporting of E coli O157:H7 infection as is carried out in Washington State was critical for prompt outbreak recognition and control. Measures should be developed to reduce meat contamination. Consumers and food service workers should be educated about cooking hamburger meat thoroughly.	CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,FOODBORNE & DIARRHEAL DIS BRANCH,ATLANTA,GA 30333; CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,EPIDEM INTELLIGENCE SERV,ATLANTA,GA 30341; CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV FIELD EPIDEMIOL,EPIDEMIOL PROGRAM OFF,ATLANTA,GA 30341; WASHINGTON STATE DEPT HLTH,SEATTLE,WA; WASHINGTON STATE DEPT HLTH,OLYMPIA,WA; SEATTLE KING CTY DEPT PUBL HLTH,SEATTLE,WA; SNOHOMISH HLTH DIST,EVERETT,WA; UNIV WASHINGTON,SCH MED,DEPT PEDIAT,DIV GASTROENTEROL,SEATTLE,WA 98195; CHILDRENS HOSP & MED CTR,SEATTLE,WA 98105	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; University of Washington; University of Washington Seattle; Seattle Children's Hospital								BELONGIA EA, 1993, JAMA-J AM MED ASSOC, V269, P883, DOI 10.1001/jama.269.7.883; BESSER RE, 1993, JAMA-J AM MED ASSOC, V269, P2217, DOI 10.1001/jama.269.17.2217; BOHM H, 1992, J CLIN MICROBIOL, V30, P2169; CARTER AO, 1987, NEW ENGL J MED, V317, P1496, DOI 10.1056/NEJM198712103172403; DOYLE MP, 1984, APPL ENVIRON MICROB, V48, P855, DOI 10.1128/AEM.48.4.855-856.1984; DOYLE MP, 1987, APPL ENVIRON MICROB, V53, P2394, DOI 10.1128/AEM.53.10.2394-2396.1987; GRIFFIN PM, 1991, EPIDEMIOL REV, V13, P60, DOI 10.1093/oxfordjournals.epirev.a036079; MACDONALD KL, 1988, JAMA-J AM MED ASSOC, V259, P3567, DOI 10.1001/jama.259.24.3567; MACDONALD KL, 1993, JAMA-J AM MED ASSOC, V269, P2264, DOI 10.1001/jama.269.17.2264; MARTIN D, 1991, EPIDEMIOLOGY, V2, P359, DOI 10.1097/00001648-199109000-00008; OSTROFF SM, 1989, JAMA-J AM MED ASSOC, V262, P355, DOI 10.1001/jama.262.3.355; REMIS RS, 1984, ANN INTERN MED, V101, P624, DOI 10.7326/0003-4819-101-5-624; RILEY LW, 1983, NEW ENGL J MED, V308, P681, DOI 10.1056/NEJM198303243081203; ROWE PC, 1991, J PEDIATR-US, V119, P218, DOI 10.1016/S0022-3476(05)80730-9; RYAN CA, 1986, J INFECT DIS, V154, P631, DOI 10.1093/infdis/154.4.631; SAMADPOUR M, 1993, J CLIN MICROBIOL, V31, P3179, DOI 10.1128/JCM.31.12.3179-3183.1993; SPIKA JS, 1986, J PEDIATR-US, V109, P287, DOI 10.1016/S0022-3476(86)80386-9; STROCKBINE NA, 1992, MOL CELL PROBE, V6, P93, DOI 10.1016/0890-8508(92)90052-Y; SWERDLOW DL, 1992, ANN INTERN MED, V117, P812, DOI 10.7326/0003-4819-117-10-812; TARR PI, 1990, J INFECT DIS, V162, P553, DOI 10.1093/infdis/162.2.553; WEISSMAN JB, 1974, J PEDIATR-US, V84, P797, DOI 10.1016/S0022-3476(74)80750-X; WELLS JG, 1991, J CLIN MICROBIOL, V29, P985, DOI 10.1128/JCM.29.5.985-989.1991; WILSON R, 1981, J INFECT DIS, V143, P130, DOI 10.1093/infdis/143.1.130; 1976, US DHEW782081 US FOO, P28; 1993, MMWR-MORBID MORTAL W, V42, P258	25	513	536	0	72	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 2	1994	272	17					1349	1353		10.1001/jama.272.17.1349	http://dx.doi.org/10.1001/jama.272.17.1349			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PP020	7933395				2022-12-24	WOS:A1994PP02000029
J	SMITH, L; FOLKARD, S; POOLE, CJM				SMITH, L; FOLKARD, S; POOLE, CJM			INCREASED INJURIES ON NIGHT-SHIFT	LANCET			English	Article							PERFORMANCE	Concern over safety has resulted in legislation by, for example, the Commission of the European Union, to limit the number of hours worked at night, There is, however, no direct evidence that injuries a re more frequent at night. We analysed all 4645 injury incidents reported for a year on a rotating three-shift system in a large engineering company where the a-priori accident risk appeared to be constant. The relative risk of sustaining an injury was 1.23 (95% CI 1.14-1.31) higher on the night shift than on the morning shift, which showed the lowest incidence. The type of work (machine versus self-paced) affected the pattern and nature of injuries; for self-paced work the relative risk of more serious injury on the night shift compared with the morning shift was 1.82 (1.30-2.34).	DUDLEY HLTH AUTHOR,DEPT OCCUPAT HLTH,DUDLEY,W MIDLANDS,ENGLAND		SMITH, L (corresponding author), UNIV COLL SWANSEA,DEPT PSYCHOL,BODY RHYTHMS & SHIFTWORK CTR,SWANSEA SA2 8PP,W GLAM,WALES.							BARTON J, IN PRESS OCCU ENV ME; CARTER FA, 1982, SHIFTWORK ACCIDENTS; Drury C. G., 1990, EVALUATION HUMAN WOR; FOLKARD S, 1990, PHILOS T ROY SOC B, V327, P543, DOI 10.1098/rstb.1990.0097; FOLKARD S, 1979, HUM FACTORS, V21, P483, DOI 10.1177/001872087902100410; HARRINGTON JM, 1978, SHIFT WORK HLTH CRIT; KNAUTH P, 1993, ERGONOMICS, V36, P15, DOI 10.1080/00140139308967850; LAVIE P, 1991, SLEEP SLEEPINESS PER, P65; MITLER MM, 1988, SLEEP, V11, P100, DOI 10.1093/sleep/11.1.100; ONG CN, 1987, APPL ERGON, V18, P51, DOI 10.1016/0003-6870(87)90070-6; Waterhouse J.M, 1992, SHIFTWORK HLTH SAFET, P1978; 1993, DIRECTIVE WORKING TI; 1993, B EUR STUD TIME, V6, P46	13	160	162	3	12	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 22	1994	344	8930					1137	1139		10.1016/S0140-6736(94)90636-X	http://dx.doi.org/10.1016/S0140-6736(94)90636-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PN066	7934499				2022-12-24	WOS:A1994PN06600015
J	JACQ, X; BROU, C; LUTZ, Y; DAVIDSON, I; CHAMBON, P; TORA, L				JACQ, X; BROU, C; LUTZ, Y; DAVIDSON, I; CHAMBON, P; TORA, L			HUMAN TAF(II)30 IS PRESENT IN A DISTINCT TFIID COMPLEX AND IS REQUIRED FOR TRANSCRIPTIONAL ACTIVATION BY THE ESTROGEN-RECEPTOR	CELL			English	Article							RNA POLYMERASE-II; TATA-BINDING PROTEIN; CLONING; DOMAINS; PURIFICATION; STIMULATION; INITIATION; EXPRESSION; SEQUENCE; GAL-VP16	We showed previously that coactivators mediating stimulation by different activators were associated with the TATA-binding protein (TBP) in distinct TFIID complexes. We have characterized a human TBP-associated factor (TAF), hTAF(II)30, associated with a subset of TFIID complexes. hTAF(II)30 interacts with the AF-2-containing region E of the human estrogen receptor (ER), but not with ER AF-1 or VP16. An antibody against hTAF(II)30 inhibited transcriptional stimulation by the ER AF-2 without affecting basal or VP16-activated transcription and allowed the separation of TFIID complex(es) containing hTAF(II)30 from complexes mediating the activity of VP16. These results directly demonstrate the existence of functionally dis tinct TFIID populations that share common TAF(II)s but differ in specific TAF(II)s.			JACQ, X (corresponding author), FAC MED STRASBOURG,INST CHIM BIOL,CNRS,GENET MOLEC EUCARYOTES LAB,INSERM,U184,11 RUE HUMANN,F-67085 STRASBOURG,FRANCE.		Tora, Laszlo/E-9999-2018	Tora, Laszlo/0000-0001-7398-2250; Davidson, Irwin/0000-0001-5533-1171				BROU C, 1993, NUCLEIC ACIDS RES, V21, P5, DOI 10.1093/nar/21.1.5; BROU C, 1993, EMBO J, V12, P489, DOI 10.1002/j.1460-2075.1993.tb05681.x; BROU C, 1993, NUCLEIC ACIDS RES, V21, P4011, DOI 10.1093/nar/21.17.4011; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; Burton N, 1991, Protein Expr Purif, V2, P432, DOI 10.1016/1046-5928(91)90105-R; CHIANG CM, 1993, EMBO J, V12, P2749, DOI 10.1002/j.1460-2075.1993.tb05936.x; CHOY B, 1993, NATURE, V366, P531, DOI 10.1038/366531a0; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; DURAND B, 1994, IN PRESS EMBO J; DYNLACHT BD, 1993, NATURE, V363, P176, DOI 10.1038/363176a0; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; GRUNDY FJ, 1989, VIROLOGY, V172, P223, DOI 10.1016/0042-6822(89)90124-4; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HISATAKE K, 1993, NATURE, V362, P179, DOI 10.1038/362179a0; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; ING NH, 1992, J BIOL CHEM, V267, P17617; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LEES JA, 1989, NUCLEIC ACIDS RES, V17, P5477, DOI 10.1093/nar/17.14.5477; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LIEBERMAN PM, 1991, GENE DEV, V5, P2441, DOI 10.1101/gad.5.12b.2441; MARTIN KJ, 1990, NATURE, V346, P147, DOI 10.1038/346147a0; MONCOLLIN V, 1986, EMBO J, V5, P2577, DOI 10.1002/j.1460-2075.1986.tb04537.x; OREILLY DR, 1992, BACULOVIRUS EXPRESSI; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PIERRAT P, 1994, GENE, V143, P193; PUGH BF, 1992, J BIOL CHEM, V267, P679; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; RUPPERT S, 1993, NATURE, V362, P175, DOI 10.1038/362175a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; TASSET D, 1990, CELL, V62, P1177, DOI 10.1016/0092-8674(90)90394-T; TIMMERS HTM, 1991, GENE DEV, V5, P1946, DOI 10.1101/gad.5.11.1946; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; WEINZIERL ROJ, 1993, EMBO J, V12, P5303, DOI 10.1002/j.1460-2075.1993.tb06226.x; WHITE J, 1992, EMBO J, V11, P2229, DOI 10.1002/j.1460-2075.1992.tb05282.x; WHITE JH, 1991, P NATL ACAD SCI USA, V88, P7674, DOI 10.1073/pnas.88.17.7674; WHITE RJ, 1992, TRENDS GENET, V8, P284, DOI 10.1016/0168-9525(92)90255-3; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G; YOKOMORI K, 1993, GENE DEV, V7, P2587, DOI 10.1101/gad.7.12b.2587; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964; ZHOU Q, 1993, GENE DEV, V7, P180, DOI 10.1101/gad.7.2.180	47	359	365	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 7	1994	79	1					107	117		10.1016/0092-8674(94)90404-9	http://dx.doi.org/10.1016/0092-8674(94)90404-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PK585	7923369				2022-12-24	WOS:A1994PK58500012
J	HARRIS, GC; ASTONJONES, G				HARRIS, GC; ASTONJONES, G			INVOLVEMENT OF D2 DOPAMINE-RECEPTORS IN THE NUCLEUS-ACCUMBENS IN THE OPIATE WITHDRAWAL SYNDROME	NATURE			English	Article							LOCUS-COERULEUS NEURONS; CYCLIC-AMP FORMATION; RAT; MORPHINE; CLONIDINE; REWARD; SPECIFICITY; PROJECTIONS; ABSTINENCE; INHIBITION	THE nucleus accumbens is prominently implicated in the reinforcing effects of abused drugs(1-4), and is an important site for mediating aversive stimulus properties of opiate withdrawal(5). It is generally thought, however, that the role of the accumbens is negligible in the somatic signs of opiate withdrawal(5-7). Contrary to this assumption, we now report that D2 dopaminergic receptor activity in the accumbens area potently regulates somatic symptoms of opiate withdrawal. We find that activation of D2 receptors within the accumbens prevents somatic signs of naloxone-induced opiate withdrawal and, conversely, that blockade of accumbal D2 receptors in opiate-dependent animals elicits somatic withdrawal symptoms. These data indicate that dopamine in the accumbens not only is important in the rewarding effects of abused drugs, but also (via D2 receptors) plays a pivotal role in opiate withdrawal.	HAHNEMANN UNIV,DEPT MENTAL HLTH SCI,DIV BEHAV NEUROBIOL,PHILADELPHIA,PA 19102	Drexel University								AGHAJANIAN GK, 1978, NATURE, V276, P186, DOI 10.1038/276186a0; AKAOKA H, 1991, J NEUROSCI, V11, P3830; BOZARTH MA, 1984, SCIENCE, V224, P516, DOI 10.1126/science.6324347; DEOLMOS J, 1985, RAT NERVOUS SYSTEM, V1, P223; DWORKIN SI, 1988, PHARMACOL BIOCHEM BE, V29, P175, DOI 10.1016/0091-3057(88)90292-4; GERFEN CR, 1990, SCIENCE, V250, P1429, DOI 10.1126/science.2147780; GOLD MS, 1978, LANCET, V2, P599; HEIJNA MH, 1992, EUR J PHARMACOL, V229, P197, DOI 10.1016/0014-2999(92)90555-I; HEIMER L, 1991, NEUROSCIENCE, V41, P89, DOI 10.1016/0306-4522(91)90202-Y; HENSELMANS JML, 1993, NEUROSCI LETT, V158, P79, DOI 10.1016/0304-3940(93)90617-T; KELLY E, 1987, N-S ARCH PHARMACOL, V335, P508; KOOB GF, 1989, PSYCHOPHARMACOLOGY, V98, P530, DOI 10.1007/BF00441954; KOOB GF, 1988, SCIENCE, V242, P615; LEMOINE C, 1991, P NATL ACAD SCI USA, V88, P4205, DOI 10.1073/pnas.88.10.4205; Paxinos G., 1986, RAT BRAIN STEREOTAXI, V2nd; POTHOS E, 1991, BRAIN RES, V566, P348, DOI 10.1016/0006-8993(91)91724-F; RASMUSSEN K, 1990, J NEUROSCI, V10, P2308; ROSSETTI ZL, 1992, EUR J PHARMACOL, V221, P227, DOI 10.1016/0014-2999(92)90706-A; STINUS L, 1990, NEUROSCIENCE, V37, P767, DOI 10.1016/0306-4522(90)90106-E; Stoof JC, 1981, NATURE, V294, P366, DOI 10.1038/294366a0; STOOF JC, 1986, EUR J PHARMACOL, V129, P205, DOI 10.1016/0014-2999(86)90358-4; SURMEIER DJ, 1992, P NATL ACAD SCI USA, V89, P10178, DOI 10.1073/pnas.89.21.10178; SURMEIER DJ, 1993, TRENDS NEUROSCI, V16, P299, DOI 10.1016/0166-2236(93)90103-S; TERWILLIGER RZ, 1991, BRAIN RES, V548, P100, DOI 10.1016/0006-8993(91)91111-D; TUCKER DC, 1985, BRAIN RES, V360, P159, DOI 10.1016/0006-8993(85)91231-4; VACCARINO FJ, 1985, PSYCHOPHARMACOLOGY, V86, P37, DOI 10.1007/BF00431681; VANDERKOOY D, 1984, J COMP NEUROL, V224, P1, DOI 10.1002/cne.902240102; WEI E, 1973, J PHARMACOL EXP THER, V184, P398; WISE RA, 1989, NEUROSCI BIOBEHAV R, V13, P129, DOI 10.1016/S0149-7634(89)80021-1; ZAHM DS, 1992, NEUROSCIENCE, V50, P751, DOI 10.1016/0306-4522(92)90202-D	30	181	185	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 8	1994	371	6493					155	157		10.1038/371155a0	http://dx.doi.org/10.1038/371155a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PF191	7915401				2022-12-24	WOS:A1994PF19100063
J	YUSUF, SW; BAKER, DM; CHUTER, TAM; WHITAKER, SC; WENHAM, PW; HOPKINSON, BR				YUSUF, SW; BAKER, DM; CHUTER, TAM; WHITAKER, SC; WENHAM, PW; HOPKINSON, BR			TRANSFEMORAL ENDOLUMINAL REPAIR OF ABDOMINAL AORTIC-ANEURYSM WITH BIFURCATED GRAFT	LANCET			English	Note								Traditional open repair of abdominal aortic aneurysm has disadvantages. We present our experience of transfemoral endoluminal repair with a bifurcated graft system. 29 patients with aortic aneurysm over 5.5 cm in diameter and 1 with a 3.2 cm aneurysm and bilateral iliac stenosis were assessed; 5 were suitable for the procedure. The operation was successful in all the patients, without haemodynamic compromise or major complications. This technique has the potential to reduce morbidity and mortality from abdominal aortic aneurysm. Further modifications are required to make it applicable to most aneurysms.	COLUMBIA UNIV,COLL PHYS & SURG,DEPT SURG,NEW YORK,NY	Columbia University	YUSUF, SW (corresponding author), UNIV NOTTINGHAM HOSP,NOTTINGHAM NG7 2UH,ENGLAND.			Yusuf, Salim/0000-0003-4776-5601; Baker, Daryll/0000-0002-0098-405X				CHUTER TAM, 1994, THESIS U NOTTINGHAM; Clark NJ, 1994, ANESTHESIA, P1851; COLLIN J, 1988, LANCET, V2, P613; FOWKES FGR, 1989, BRIT MED J, V298, P33, DOI 10.1136/bmj.298.6665.33; GREENHALGH RM, 1990, BRIT MED J, V301, P136, DOI 10.1136/bmj.301.6744.136; Hertzer N R, 1987, Ann Vasc Surg, V1, P616, DOI 10.1016/S0890-5096(06)61452-0; JOHANSSON G, 1986, BRIT J SURG, V73, P101, DOI 10.1002/bjs.1800730205; Parodi J C, 1991, Ann Vasc Surg, V5, P491, DOI 10.1007/BF02015271; SCOTT RAP, 1994, LANCET, V343, P413, DOI 10.1016/S0140-6736(94)91247-5	9	88	100	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 3	1994	344	8923					650	651		10.1016/S0140-6736(94)92086-9	http://dx.doi.org/10.1016/S0140-6736(94)92086-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PE386	7915349				2022-12-24	WOS:A1994PE38600011
J	JORGENSEN, HS; NAKAYAMA, H; RAASCHOU, HO; OLSEN, TS				JORGENSEN, HS; NAKAYAMA, H; RAASCHOU, HO; OLSEN, TS			EFFECT OF BLOOD-PRESSURE AND DIABETES ON STROKE IN PROGRESSION	LANCET			English	Article							SYSTEM CEREBRAL INFARCTION; PROFILE CLINICAL COURSE; ISCHEMIC STROKE	Progression of acute stroke after arrival at hospital is frequent and the prognosis severe. However, risk factors and mechanisms behind progression are largely unknown. A prospective, community-based study of 868 patients with acute stroke was undertaken to discover factors of importance in the development of stroke in progression. Diagnosis of progression was based on the Scandinavian Neurological Stroke Scale, Patients were divided according to whether progression occurred early (within 36 hours from stroke onset) or late (with in the first week from onset). Results were analysed by comparing patients with and without progression. Marked progression developed in 32%. Risk factors for early progression were identified as systolic blood pressure on admission (decreased the relative risk by 0.66 per 20 mm Hg increase, 95% Cl 0.55-0.83) and diabetes (increased the relative risk by 1.9, 95% Cl 1.1-3.3). Stroke severity was the only risk factor found in late progression (OR 1.4 per 20-point increase in stroke severity, 95% Cl 1.1-1.7).These relations were independent of age, sex, blood glucose, heart disease, and other stroke risk factors. Early progression is related to systolic blood pressure and diabetes. Late progression is related to initial stroke severity. Although this study does not prove that a causal relationship exists between systolic blood pressure and the development of early progression, such a relationship would, however, explain our findings.	BISPEBJERG HOSP, DEPT RADIOL, DK-2400 COPENHAGEN NV, DENMARK	University of Copenhagen; Bispebjerg Hospital	JORGENSEN, HS (corresponding author), BISPEBJERG HOSP, DEPT NEUROL, DK-2400 COPENHAGEN NV, DENMARK.							[Anonymous], 1989, Stroke, V20, P1407; ASPLUND K, 1985, STROKE, V16, P885; ASPLUND K, 1992, CEREBROVASC DIS, V2, P317, DOI 10.1159/000109037; ASPLUND K, 1993, THROMBOLYTIC THERAPY, V2, P119; BENTSEN N, 1975, STROKE, V6, P497, DOI 10.1161/01.STR.6.5.497; BRITTON M, 1986, STROKE, V17, P861, DOI 10.1161/01.STR.17.5.861; BRITTON M, 1985, STROKE, V16, P629, DOI 10.1161/01.STR.16.4.629; DAVALOS A, 1990, NEUROLOGY, V40, P1865, DOI 10.1212/WNL.40.12.1865; GAUTIER JC, 1985, STROKE, V16, P729, DOI 10.1161/01.STR.16.4.729; HACHINSKI V, 1985, ACUTE STROKE, P123; JONES HR, 1976, STROKE, V7, P64, DOI 10.1161/01.STR.7.1.64; JONES HR, 1980, STROKE, V11, P173, DOI 10.1161/01.STR.11.2.173; JORGENSEN HS, 1994, STROKE, V25, P97, DOI 10.1161/01.STR.25.1.97; LINDENSTROM E, 1991, CEREBROVASC DIS, V1, P103, DOI 10.1159/000108825; MAHONEY F I, 1965, Md State Med J, V14, P61; MARCHAL G, 1993, LANCET, V341, P925, DOI 10.1016/0140-6736(93)91214-7; MILLIKAN CH, 1981, STROKE, V12, P397, DOI 10.1161/01.STR.12.4.397; Millikan CH, 1975, STROKE, V6, P564; OBRIEN MD, 1974, ARCH NEUROL-CHICAGO, V30, P461, DOI 10.1001/archneur.1974.00490360037008; OLSEN TS, 1983, STROKE, V14, P332, DOI 10.1161/01.STR.14.3.332; SHIMA T, 1983, J CEREB BLOOD FLO S1, V3, P620	21	252	258	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 16	1994	344	8916					156	159						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW810	7912765				2022-12-24	WOS:A1994NW81000009
J	THOMPSON, BT; COCKRILL, BA				THOMPSON, BT; COCKRILL, BA			RENAL-DOSE DOPAMINE - A SIREN SONG	LANCET			English	Editorial Material							BLOOD-FLOW; SHOCK				THOMPSON, BT (corresponding author), MASSACHUSETTS GEN HOSP,PULM & CRIT CARE UNIT,BOSTON,MA, USA.							BALDWIN L, 1994, ANN INTERN MED, V120, P744, DOI 10.7326/0003-4819-120-9-199405010-00004; BRESLOW MJ, 1987, AM J PHYSIOL, V252, pH291, DOI 10.1152/ajpheart.1987.252.2.H291; DASTA JF, 1986, PHARMACOTHERAPY, V6, P304; GIRAUD GD, 1984, J PHARMACOL EXP THER, V230, P214; GOLDBERG LI, 1972, PHARMACOL REV, V24, P1; GREENE SI, 1976, NEW ENGL J MED, V294, P114; ORME MLE, 1973, EUR J CLIN PHARMACOL, V6, P150, DOI 10.1007/BF00558278; PASS LJ, 1988, J THORAC CARDIOV SUR, V95, P608; PAWLIK W, 1976, AM HEART J, V75, P325; SCANNELL G, 1994, CRIT CARE MED, V22, pA187; SEGAL JM, 1992, J APPL PHYSIOL, V73, P1159, DOI 10.1152/jappl.1992.73.3.1159; SWYGERT TH, 1991, ANESTHESIOLOGY, V75, P571, DOI 10.1097/00000542-199110000-00005	12	78	78	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 2	1994	344	8914					7	8		10.1016/S0140-6736(94)91044-8	http://dx.doi.org/10.1016/S0140-6736(94)91044-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU917	7912346				2022-12-24	WOS:A1994NU91700007
J	ROEP, BO; HEIDENTHAL, E; DEVRIES, RRP; KOLB, H; MARTIN, S				ROEP, BO; HEIDENTHAL, E; DEVRIES, RRP; KOLB, H; MARTIN, S			SOLUBLE FORMS OF INTERCELLULAR-ADHESION MOLECULE-1 IN INSULIN-DEPENDENT DIABETES-MELLITUS	LANCET			English	Article							CARDIAC ALLOGRAFT; ICAM-1; ANTIBODIES; LFA-1; PROTEIN; INVIVO; INJURY; CELLS	Soluble adhesion molecules are detectable at low levels in healthy people but are increased in various disorders. However, their physiological role is unknown. Circulating intercellular adhesion molecule-1 (clCAM-1) may modulate inflammation or a rise as a consequence of inflammation. We have described elevated concentrations of clCAM-1 in subjects at risk of developing insulin-dependent diabetes mellitus (IDDM), compared with recent-onset IDDM patients and healthy controls. Here we tested the ability of a monomeric soluble recombinant form of ICAM-1 (rlCAM-1), to prevent the proliferation of T cells to islet-cell and other antigens. We also tested the ability of two multivalent ICAM-1-immunoglobulin (ICAM-1-Ig) fusion proteins to stop proliferation of T cells in vitro. Autoreactive T-cell proliferation was suppressed by monoclonal antibodies directed against ICAM-1 or lymphocyte-function antigen-1 (LFA-1). Furthermore, 100 mu mol rlCAM-1 blocked T-cell proliferation in response to an islet-cell autoantigen, and multivalent ICAM-1-Ig fusion proteins were approximately 1000-fold more effective. The usual interleukin-2-induced proliferation of T cells was unaffected by ICAM or ICAM-Ig. In addition, rlCAM-1 blocked primary T-cell responses from peripheral blood mononuclear cells of newly diagnosed IDDM patients in concentrations similar to elevated clCAM-1 concentrations in individuals at risk for the disease. Thus, naturally circulating ICAM-1 may downregulate inflammation in subjects at risk of developing IDDM. Ig-ICAM-1 fusion proteins may thus provide novel means to intervene in the pathogenesis of autoimmune diseases.	UNIV DUSSELDORF,DIABET RES INST,DEPT CLIN,D-40225 DUSSELDORF,GERMANY; UNIV LEIDEN HOSP,DEPT IMMUNOHAEMATOL,2300 RC LEIDEN,NETHERLANDS; UNIV LEIDEN HOSP,BLOOD BANK,2300 RC LEIDEN,NETHERLANDS	Heinrich Heine University Dusseldorf; Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC)			Roep, Bart/AAD-7609-2021					ALTMANN DM, 1989, NATURE, V338, P512, DOI 10.1038/338512a0; [Anonymous], 1988, DIABETES, V37, P1574, DOI 10.2337/diabetes.37.11.15742903105; ARGENBRIGHT LW, 1992, J CLIN INVEST, V89, P259, DOI 10.1172/JCI115570; ASSAN R, 1985, LANCET, V2, P119; ATKINSON MA, 1992, LANCET, V339, P458, DOI 10.1016/0140-6736(92)91061-C; BARTON RW, 1989, J IMMUNOL, V143, P1278; BECKER JC, 1991, J IMMUNOL, V147, P4398; COSIMI AB, 1990, J IMMUNOL, V144, P4604; DOUGHERTY GJ, 1988, EUR J IMMUNOL, V18, P35, DOI 10.1002/eji.1830180107; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; FLAVIN T, 1991, TRANSPLANT P, V23, P533; GEARING AJH, 1993, IMMUNOL TODAY, V14, P506, DOI 10.1016/0167-5699(93)90267-O; IIGO Y, 1991, J IMMUNOL, V147, P4167; ISOBE M, 1992, SCIENCE, V255, P1125, DOI 10.1126/science.1347662; KAKIMOTO K, 1992, CELL IMMUNOL, V142, P326, DOI 10.1016/0008-8749(92)90294-Y; LAMPETER ER, 1992, DIABETES, V41, P1668, DOI 10.2337/diabetes.41.12.1668; MARTIN S, 1993, J VIROL, V67, P3561, DOI 10.1128/JVI.67.6.3561-3568.1993; MIYAZAKI A, 1992, CLIN EXP IMMUNOL, V89, P52; NISHIKAWA K, 1993, J EXP MED, V177, P667, DOI 10.1084/jem.177.3.667; PATARROYO M, 1991, CLIN IMMUNOL IMMUNOP, V60, P333, DOI 10.1016/0090-1229(91)90091-N; ROEP BO, 1990, NATURE, V345, P632, DOI 10.1038/345632a0; ROEP BO, 1991, LANCET, V337, P1439, DOI 10.1016/0140-6736(91)93127-U; SETH R, 1991, LANCET, V338, P83, DOI 10.1016/0140-6736(91)90077-3; VANSEVENTER GA, 1990, J IMMUNOL, V144, P4579	24	96	99	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 25	1994	343	8913					1590	1593		10.1016/S0140-6736(94)93055-4	http://dx.doi.org/10.1016/S0140-6736(94)93055-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU354	7911918				2022-12-24	WOS:A1994NU35400008
J	CHRISTOFORI, G; NAIK, P; HANAHAN, D				CHRISTOFORI, G; NAIK, P; HANAHAN, D			A 2ND SIGNAL SUPPLIED BY INSULIN-LIKE GROWTH-FACTOR-II IN ONCOGENE-INDUCED TUMORIGENESIS	NATURE			English	Article							BETA-CELL TUMORS; TRANSGENIC MICE; INDUCTION; TISSUES; PROTEIN; LINEAGE; GENE	TRANSGENIC mice expressing the simian virus-40 large T-antigen (Tag) under the control of the insulin gene regulatory region offer a useful model for tumorigenesis(1,2). All the islets of Langerhans express Tag, although there is at first no aberrant proliferation. Over half of the islets become hyperplastic, however, and neovascularization of a further subset (about 10%)(3) leads eventually to formation of highly vascularized solid tumours in 1-2% of islets by about 14 weeks of age. Here we show that the initial proliferative switch is correlated with focal activation of insulin-like growth factor II (IGF-II). Transfection with an antisense oligonucleotide to the IGF-II messenger RNA interferes with tumour cell proliferation in vitro, and transgenic mice homozygous for a disruption of the IGF-II gene develop tumours with reduced malignancy and a higher incidence of apoptosis. Several signals, in this case including an oncoprotein and a growth/survival factor, thus appear to be needed to elicit hyperproliferation.	UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,HORMONE RES INST,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco								ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; ALPERT S, 1988, CELL, V53, P295, DOI 10.1016/0092-8674(88)90391-1; BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; BRETSCHER P, 1970, SCIENCE, V169, P1042, DOI 10.1126/science.169.3950.1042; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; DECHIARA TM, 1990, NATURE, V345, P75; EFRAT S, 1988, P NATL ACAD SCI USA, V85, P9037, DOI 10.1073/pnas.85.23.9037; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FERGUSONSMITH AC, 1991, NATURE, V351, P155; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; GARCIA RL, 1989, AM J PATHOL, V134, P733; HANAHAN D, 1989, SCIENCE, V246, P1265, DOI 10.1126/science.2686032; HANAHAN D, 1988, ANNU REV GENET, V22, P479, DOI 10.1146/annurev.ge.22.120188.002403; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; HARRINGTON EA, IN PRESS EMBO J; LACY PE, 1967, DIABETES, V16, P35, DOI 10.2337/diab.16.1.35; LEROITH D, 1991, INSULIN LIKE GROWTH; RAPPOLEE DA, 1992, GENE DEV, V6, P939, DOI 10.1101/gad.6.6.939; RECHLER MM, 1990, HDB EXPT PHARM, V95, P263; SCHOFIELD PN, 1992, INSULIN LIKE GROWTH; SHING Y, 1993, SCIENCE, V259, P1604, DOI 10.1126/science.8456283; SMITH KM, 1990, J LIPID RES, V31, P995; TEITELMAN G, 1988, CELL, V52, P97, DOI 10.1016/0092-8674(88)90534-X	24	383	396	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 2	1994	369	6479					414	418		10.1038/369414a0	http://dx.doi.org/10.1038/369414a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NP174	7910953				2022-12-24	WOS:A1994NP17400061
J	WRIGHT, EC				WRIGHT, EC			A LESSON IN NONCOMPLIANCE	LANCET			English	Editorial Material																		BABIKER IE, 1986, PSYCHIAT DEV, V4, P329; GREENBERG RN, 1984, CLIN THER, V65, P590; HAYNES RB, 1987, PATIENT EDUC COUNS, V10, P155, DOI 10.1016/0738-3991(87)90095-4; WALKER R, 1992, PHARM J, V249, P695; 1994, J PEDIATR, V124, P383	5	3	3	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 28	1994	343	8909					1305	1305		10.1016/S0140-6736(94)92460-0	http://dx.doi.org/10.1016/S0140-6736(94)92460-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NN217	7910317				2022-12-24	WOS:A1994NN21700003
J	KANDA, Y; SHIGENO, K; KINOSHITA, N; NAKAO, K; YANO, M; MATSUO, H				KANDA, Y; SHIGENO, K; KINOSHITA, N; NAKAO, K; YANO, M; MATSUO, H			SUDDEN HEARING-LOSS ASSOCIATED WITH INTERFERON	LANCET			English	Note							ALPHA-INTERFERON; DISEASE; CANCER	With the increasing long-term use of interferon, several new adverse effects have been recognised. We have prospectively assessed auditory function in 49 patients receiving interferon, after we saw a case of sudden sensorineural hearing loss during interferon therapy. Auditory disability (tinnitus, hearing loss, or both) occurred in 22 patients (45%) during treatment with audiometry-documented sensorineural hearing loss in 18 (37%). The auditory disability often developed in the late stage of treatment and resolved in all patients within 7-14 days after discontinuation of interferon.	NAGASAKI CHUO NATL HOSP,DEPT OTOLARYNGOL,NAGASAKI,JAPAN; NAGASAKI CHUO NATL HOSP,INST CLIN RES,NAGASAKI,JAPAN; JAPANESE RED CROSS,NAGASAKI ATOM BOMB HOSP,DEPT OTOLARYNGOL,NAGASAKI,JAPAN; JAPANESE RED CROSS,NAGASAKI ATOM BOMB HOSP,DEPT INTERNAL MED,NAGASAKI,JAPAN; JAPANESE RED CROSS,NAGASAKI ATOM BOMB HOSP,DEPT NEUROL,NAGASAKI,JAPAN	Japanese Red Cross Medical Center; Japanese Red Cross Medical Center; Japanese Red Cross Medical Center	KANDA, Y (corresponding author), NAGASAKI UNIV,SCH MED,DEPT OTOLARYNGOL,1-7-1 SAKAMOTO,NAGASAKI 852,JAPAN.							BURMAN P, 1985, LANCET, V2, P100; CALVET MC, 1979, NATURE, V278, P558, DOI 10.1038/278558a0; COLE RR, 1988, AM J OTOL, V9, P211; CONLON KC, 1990, CANCER, V65, P2237, DOI 10.1002/1097-0142(19900515)65:10<2237::AID-CNCR2820651013>3.0.CO;2-5; GUYER DR, 1993, ARCH OPHTHALMOL-CHIC, V111, P350, DOI 10.1001/archopht.1993.01090030068041; KIRKWOOD JM, 1984, J CLIN ONCOL, V2, P336, DOI 10.1200/JCO.1984.2.4.336; QUESADA JR, 1986, J CLIN ONCOL, V4, P234, DOI 10.1200/JCO.1986.4.2.234; RENAULT PF, 1989, SEMIN LIVER DIS, V9, P273, DOI 10.1055/s-2008-1040523; SCHATTNER A, 1988, AM J MED SCI, V295, P532, DOI 10.1097/00000441-198806000-00007	9	52	54	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 7	1994	343	8906					1134	1135		10.1016/S0140-6736(94)90237-2	http://dx.doi.org/10.1016/S0140-6736(94)90237-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NK730	7910234				2022-12-24	WOS:A1994NK73000011
J	TAKAHASHI, K; JUJI, T; MIYAMOTO, M; UCHIDA, S; AKAZA, T; TADOKORO, K; SHIBATA, Y; INO, T; HIDANO, A				TAKAHASHI, K; JUJI, T; MIYAMOTO, M; UCHIDA, S; AKAZA, T; TADOKORO, K; SHIBATA, Y; INO, T; HIDANO, A			ANALYSIS OF RISK-FACTORS FOR POSTTRANSFUSION GRAFT-VERSUS-HOST DISEASE IN JAPAN	LANCET			English	Article							ERYTHRODERMA; SURGERY	We distributed a questionnaire to highlight the effects of post transfusion graft-versus-host disease (PT-GVHD) and to elucidate the risk factors that would predispose people to the disease. The questionnaire described the pathogenesis and the clinical profiles of PT-GVHD and was distributed to doctors in Japan whose hospital conducted more than 1000 units of blood transfusions a year. Doctors were asked about their awareness and experience of PT-GVHD cases. Those who had seen cases of PT-GVHD were then asked to detail clinical course and laboratory data. Of the 14 083 doctors who replied to the first question, 47.4% did not realise that PT-GVHD could occur in immunocompetent hosts. From 304 cases where detailed information was supplied, 171 were considered clinically compatible with PT-GVHD. From these it seems that the risk factors linked to PT-GVHD are cardiovascular surgery, cancer, fresh and consanguineous blood transfusion, and being male. Patients with any of these factors should have some prophylactic therapy such as irradiation of blood before transfusion.	JAPANESE RED CROSS CENT BLOOD CTR,HIROO,TOKYO,JAPAN; UNIV TOKYO,FAC MED,DEPT TRANSFUS MED & IMMUNOHEMATOL,TOKYO,TOKYO,JAPAN; JICHI MED SCH,OOMLYA MED CTR,OMIYA,SAITAMA,JAPAN; TOKYO WOMENS COLL,FAC MED,DEPT DERMATOL,TOKYO,TOKYO,JAPAN	Japanese Red Cross Medical Center; University of Tokyo; Jichi Medical University; Tokyo Women's Medical University	TAKAHASHI, K (corresponding author), TORANOMON GEN HOSP,DEPT TRANSFUS MED & IMMUNOHEMATOL,MINATO KU,TORANOMON 2-2-2,TOKYO,TOKYO 105,JAPAN.							BUTTON LN, 1981, TRANSFUSION, V21, P419, DOI 10.1046/j.1537-2995.1981.21481275998.x; ITO K, 1988, LANCET, V1, P413; JUJI T, 1989, NEW ENGL J MED, V321, P56; LEITMANN SF, 1989, TRANSFUSION, V25, P293; MATSUSHITA H, 1988, VIRCHOWS ARCH B, V55, P237; OTSUKA S, 1989, TRANSFUSION, V29, P544, DOI 10.1046/j.1537-2995.1989.29689318456.x; SAKAKIBARA T, 1986, LANCET, V2, P1099; TAKAHASHI K, 1991, TRANSFUS SCI, V12, P281, DOI 10.1016/0955-3886(91)90108-F	8	37	38	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 19	1994	343	8899					700	702		10.1016/S0140-6736(94)91580-6	http://dx.doi.org/10.1016/S0140-6736(94)91580-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NB809	7907679				2022-12-24	WOS:A1994NB80900009
J	JAVITT, NB; BUDAI, K; MILLER, DG; CAHAN, AC; RAJU, U; LEVITZ, M				JAVITT, NB; BUDAI, K; MILLER, DG; CAHAN, AC; RAJU, U; LEVITZ, M			BREAST GUT CONNECTION - ORIGIN OF CHENODEOXYCHOLIC ACID IN BREAST CYST FLUID	LANCET			English	Article							BILE-ACIDS; CANCER; IDENTIFICATION; ETIOLOGY; SERUM	The notion that a breast-gut connection might modulate the microenvironment of breast tissue was supported by the finding that breast cyst fluid contains bile acids that are characteristically found in the intestines. To establish that the gut, rather than circulating steroid precursors, is the source of bile acids in breast cyst fluid, we gave two patients deuterium-labelled chenodeoxycholic acid (three 200 mg doses by mouth), starting 9 days before aspiration of breast cysts. The chenodeoxycholic acid concentration of seven samples of aspirated cyst fluid ranged from 42 to 94 mu mol/L. The corresponding plasma concentrations of chenodeoxycholic acid on the same day were 0.80 and 2.90 mu mol/L, of which the labelled compound comprised 13.0% (0.38 mu mol/L) and 28.2% (0.23 mu mol/L). The deuterated chenodeoxycholic acid concentrations in cyst fluid were 1.8 and 1.4 mu mol/L in two samples from patient 1 and 4.7 mu mol/L in patient 2; these values are equivalent to 11-17% of the plasma concentrations. This study shows that intestinal bile acids rapidly gain access to cyst fluid. Further studies should investigate the mechanisms that govern the exchange processes and the maintenance of the high cyst fluid to plasma concentration gradients, and the biological half-lives of individual constituents.	NYU MED CTR, DEPT OBSTET & GYNECOL, NEW YORK, NY 10016 USA; STRANG CANC PREVENT CTR, NEW YORK, NY USA	New York University	JAVITT, NB (corresponding author), NYU MED CTR, DIV HEPAT DIS, NEW YORK, NY 10016 USA.			Javitt, Norman B/0000-0001-9265-3508	NATIONAL CANCER INSTITUTE [R01CA002071] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032995] Funding Source: NIH RePORTER; NCI NIH HHS [CA02071] Funding Source: Medline; NIDDK NIH HHS [DK32995] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALI SS, 1970, CAN J BIOCHEM CELL B, V48, P1054, DOI 10.1139/o70-166; AXELSON M, 1988, J LIPID RES, V29, P629; BAKER PR, 1992, BRIT J CANCER, V65, P566, DOI 10.1038/bjc.1992.115; BAKER PR, 1988, BIOCHEM SOC T, V16, P741, DOI 10.1042/bst0160741; CHEAH PY, 1990, CANCER LETT, V49, P207, DOI 10.1016/0304-3835(90)90160-Y; DANIELSSON H, 1963, J BIOL CHEM, V238, P2299; GORBACH SL, 1984, REV INFECT DIS, V6, pS85; JAVITT NB, 1981, J BIOL CHEM, V256, P2644; JAVITT NB, 1989, BIOMED ENVIRON MASS, V18, P624, DOI 10.1002/bms.1200180820; MAHMOODA SK, 1982, CANCER RES, V42, P2792; MODAN B, 1977, CANCER-AM CANCER SOC, V40, P1887, DOI 10.1002/1097-0142(197710)40:4+<1887::AID-CNCR2820400819>3.0.CO;2-E; PETRAKIS NL, 1981, LANCET, V2, P1203; RAJU U, 1990, J CLIN ENDOCR METAB, V70, P1030, DOI 10.1210/jcem-70-4-1030; RANG EH, 1983, LANCET, V1, P1014	14	37	38	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 12	1994	343	8898					633	635		10.1016/S0140-6736(94)92635-2	http://dx.doi.org/10.1016/S0140-6736(94)92635-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NA093	7906811	hybrid			2022-12-24	WOS:A1994NA09300008
J	MELBYE, M; COTE, TR; KESSLER, L; GAIL, M; BIGGAR, RJ; LEMP, G; WEST, D; SINGLETON, J; YOUNG, J; KERNDT, P; DEAPEN, D; GINZBERG, M; ANTONCULVER, H; LIEB, S; HOPKINS, R; WILLIAMS, B; LIFF, J; MORGAN, D; PARKIN, W				MELBYE, M; COTE, TR; KESSLER, L; GAIL, M; BIGGAR, RJ; LEMP, G; WEST, D; SINGLETON, J; YOUNG, J; KERNDT, P; DEAPEN, D; GINZBERG, M; ANTONCULVER, H; LIEB, S; HOPKINS, R; WILLIAMS, B; LIFF, J; MORGAN, D; PARKIN, W			HIGH-INCIDENCE OF ANAL CANCER AMONG AIDS PATIENTS	LANCET			English	Article							IV HIV DISEASE; INTRAEPITHELIAL NEOPLASIA; PAPILLOMAVIRUS INFECTION; HUMAN IMMUNODEFICIENCY; HOMOSEXUAL MEN; MARITAL-STATUS; CARCINOMA; ASSOCIATION; PARALLEL	Until now, the only cancers that have been strongly associated with AIDS are Kaposi's sarcoma and non-Hodgkin lymphoma. We used a linkage between AIDS (50 050 reports) and cancer (859 398 reports) registries in seven health departments in the USA to investigate the association between HIV infection and epidermoid anal cancer. We compared the numbers of observed cases and expected cases, calculated from general population rates with adjustment for age, sex, and race. The relative risk of anal cancer at and after AIDS diagnosis was 84.1 (95% CI 46.4-152) among homosexual patients (11 cases) and 37.7 (9.4-151) among non-homosexual patients (2 cases). The relative risk of anal cancer up to 5 years before the AIDS diagnosis (23 cases) was also increased; it was 13.9 (6.6-29.2) in the period 2-5 years before AIDS and 27.4 (15.9-47.2) during the 2 years before AIDS diagnosis (p for trend = 0.004). Among homosexual men, the relative risk of anal cancer was inversely related to age at AIDS onset (p for trend < 0.001). Excess risks were found in all geographical areas. This study establishes a strikingly increased risk of anal cancer among people with AIDS, These data are consistent with a previously hypothesised association between HIV-induced immunodeficiency and anal cancer development, but because homosexual men were at increased risk of anal cancer even before the AIDS epidemic, we cannot say how much of the increased risk is attributable to HIV infection. Nevertheless, clinicians should be aware that AIDS patients have an increased risk of anal cancer.	NCI,DIV CANC ETIOL,VIRAL EPIDEMIOL BRANCH,ROCKVILLE,MD 20852; STATE SERUM INST,DANISH EPIDEMIOL SCI CTR,COPENHAGEN,DENMARK; NCI,DIV CANC PREVENT & CONTROL,APPL RES BRANCH,ROCKVILLE,MD 20852; NCI,DIV CANC ETIOL,BIOSTAT BRANCH,ROCKVILLE,MD 20852	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Aarhus University; Statens Serum Institut; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)				melbye, mads/0000-0001-8264-6785				ADAM YG, 1987, SURGERY, V101, P253; BIGGAR RJ, 1994, AM J EPIDEMIOL, V139, P362, DOI 10.1093/oxfordjournals.aje.a117008; BLOHME I, 1985, TRANSPLANTATION, V39, P23; Breslow NE., 1987, STATISTICAL METHODS, P48; CAUSSY D, 1990, INT J CANCER, V46, P214, DOI 10.1002/ijc.2910460212; COTE T, 1993, 9TH INT C AIDS BERL; COTE TR, 1993, J NATL CANCER I, V85, P1113; DALING JR, 1987, NEW ENGL J MED, V317, P973, DOI 10.1056/NEJM198710153171601; FELDMAN AR, 1986, NEW ENGL J MED, V315, P1394, DOI 10.1056/NEJM198611273152206; FRAZER IH, 1986, LANCET, V2, P657; FRISCH M, 1993, BMJ-BRIT MED J, V306, P419, DOI 10.1136/bmj.306.6875.419; GOLDMAN S, 1989, ACTA CHIR SCAND, V155, P191; HOLLY EA, 1989, JNCI-J NATL CANCER I, V81, P1726, DOI 10.1093/jnci/81.22.1726; KIVIAT N, 1990, J INFECT DIS, V162, P358, DOI 10.1093/infdis/162.2.358; MELBYE M, 1991, LANCET, V338, P657, DOI 10.1016/0140-6736(91)91233-K; MELBYE M, 1990, INT J CANCER, V46, P203, DOI 10.1002/ijc.2910460210; MELBYE M, 1940, IN PRESS AM J EPIDEM; PALEFSKY JM, 1990, JAMA-J AM MED ASSOC, V263, P2911, DOI 10.1001/jama.263.21.2911; PALEFSKY JM, 1992, J ACQ IMMUN DEF SYND, V5, P1258; PENN I, 1986, CANCER-AM CANCER SOC, V58, P611, DOI 10.1002/1097-0142(19860801)58:3<611::AID-CNCR2820580303>3.0.CO;2-M; PETERS RK, 1983, BRIT J CANCER, V48, P629, DOI 10.1038/bjc.1983.244; RABKIN CS, 1991, CANCER SURV, V10, P151; RABKIN CS, 1992, AM J EPIDEMIOL, V136, P54, DOI 10.1093/oxfordjournals.aje.a116420; RIES LG, 1983, JNCI-J NATL CANCER I, V70, P693; SCHOLEFIELD JH, 1989, LANCET, V2, P765; SCHOLEFIELD JH, 1992, LANCET, V340, P1271, DOI 10.1016/0140-6736(92)92961-E; SCHOLEFIELD JH, 1990, BRIT J CANCER, V62, P286, DOI 10.1038/bjc.1990.279; 1992, MMWR, V41, P1; 1980, INT CLASSIFICATION D	29	208	210	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 12	1994	343	8898					636	639		10.1016/S0140-6736(94)92636-0	http://dx.doi.org/10.1016/S0140-6736(94)92636-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NA093	7906812				2022-12-24	WOS:A1994NA09300009
J	ASTROW, AB				ASTROW, AB			RETHINKING CANCER	LANCET			English	Editorial Material											ASTROW, AB (corresponding author), ST VINCENTS HOSP & MED CTR,DEPT MED,NEW YORK,NY 10011, USA.							BAILAR JC, 1986, NEW ENGL J MED, V314, P1226, DOI 10.1056/NEJM198605083141905; CHABNER BA, 1986, J CLIN ONCOL, V4, P625; DEVITA VT, 1993, PRINCIPLES CHEMOTHER, P289; LEDER P, 1993, 35TH ANN M; SCHIPPER H, 1993, CAN J ONCOL, V3, P207; SCHIPPER H, 1993, CAN J ONCOL, V3, P220; SCHNIPPER LE, 1986, NEW ENGL J MED, V314, P1423; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; 1993, NIH OBSERVER, V4, P1	9	20	21	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 26	1994	343	8896					494	495		10.1016/S0140-6736(94)91454-0	http://dx.doi.org/10.1016/S0140-6736(94)91454-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MX888	7906753				2022-12-24	WOS:A1994MX88800002
J	SCHIMMEL, TW; CRUMM, KF				SCHIMMEL, TW; CRUMM, KF			IMAGES IN CLINICAL MEDICINE - MICROSURGICAL FERTILIZATION AND BLASTOMERE REMOVAL FOR GENETIC-ANALYSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											SCHIMMEL, TW (corresponding author), UNITED HOSP,IVF AMER PROGRAM,PORT CHESTER,NY 10573, USA.								0	2	2	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 3	1994	331	18					1200	1200						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN806	7935658				2022-12-24	WOS:A1994PN80600005
J	TRENITE, DGAKN				TRENITE, DGAKN			VIDEO-GAME EPILEPSY	LANCET			English	Editorial Material							PHOTOSENSITIVITY				TRENITE, DGAKN (corresponding author), INST EPILEPSIEBESTRIJDING MEER & BOSCH CRUQUIUSHOEVE,HEEMSTEDE,NETHERLANDS.		Trenite, Dorothee Nolst/ABG-5804-2020					FERRIE CD, 1994, J NEUROL NEUROSUR PS, V57, P925, DOI 10.1136/jnnp.57.8.925; FISH DR, 1994, NATIONAL SURVEY PHOT; GRAF WD, 1994, PEDIATRICS, V93, P551; HARDING GFA, 1993, BROADCASTING ADVERTI, V1; Jeavons P, 1975, PHOTOSENSITIVE EPILE; JEAVONS PM, 1986, EPILEPSIA, V27, P569, DOI 10.1111/j.1528-1157.1986.tb03586.x; TRENITE DGA, 1989, ACTA NEUROL SCAND, V47, P163; TRENITE DGAK, 1987, J NEUROL NEUROSUR PS, V50, P1546, DOI 10.1136/jnnp.50.11.1546; WILKINS AJ, 1979, ELECTROEN CLIN NEURO, V47, P163, DOI 10.1016/0013-4694(79)90218-9; WOLF P, 1986, J NEUROL NEUROSUR PS, V49, P1386, DOI 10.1136/jnnp.49.12.1386	10	18	18	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 22	1994	344	8930					1102	1103		10.1016/S0140-6736(94)90625-4	http://dx.doi.org/10.1016/S0140-6736(94)90625-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN066	7934490				2022-12-24	WOS:A1994PN06600004
J	MOORE, S; WOLFE, SM; LINDES, D; DOUGLAS, CE				MOORE, S; WOLFE, SM; LINDES, D; DOUGLAS, CE			EPIDEMIOLOGY OF FAILED TOBACCO CONTROL LEGISLATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To evaluate the influence of tobacco industry campaign donations, district location, and political party affiliation on tobacco control legislation among members of the US Congress. Design.-Data were obtained from the Federal Election Commission on money contributed by the 10 leading tobacco political action committees and by tobacco industry-aligned individuals to members of the US House of Representatives (1991-1992) and Senate (1987-1992). Logistic regression analyses were performed using recorded votes and cosponsorship activities concerning tobacco control legislation during the 102nd and 103rd Congresses and membership on the House Congressional Task Force on Tobacco and Health as the dependent variables and tobacco money received, party, district location, and caucus or committee membership as the independent variables. Setting.-United States Congress in 1991 and 1992. Interventions.-None. Main Outcome Measure.-Support for federal tobacco control legislation. Results.-The tobacco industry donated approximately $2.4 million to members of Congress from January 1991 through December 1992. House members received an average of $2943 (1991-1992) and senators received an average of $11593 (1937-1992). The more tobacco money a member received, the less likely the member was to support tobacco control legislation. In the Senate, on a vote to end the taxpayer subsidy of tobacco products in military stores, the odds ratio that senators in the top quartile of tobacco money recipients did not support the measure vs senators in the lowest quartile of tobacco money recipients was 42.2 (95% confidence interval, 4.1 to 430.0; P<.001). In the House, on a vote to end a $3.5 million subsidy to promote American tobacco abroad, the odds that House members in the top third of tobacco money recipients would oppose the legislation were 14.4 times greater (95% confidence interval, 5.5 to 39.0; P<.001) than for House members in the lowest third of tobacco money recipients. Receiving more tobacco money, being a member of the Republican party, and representing a tobacco producing state were all associated with decreased support for tobacco control issues. The amount of tobacco money received was the variable most strongly and consistently associated with a lack of support for tobacco control legislation, even when we controlled for additional factors such as district location and party. Conclusion.-Tobacco industry contributions to members of the US Congress strongly influence the federal tobacco policy process. Unless this influence is diminished through a combination of members refusing tobacco money and campaign finance reform, this process of contributing to death by thwarting tobacco control will continue to claim hundreds of thousands of lives a year.	PUBL CITIZENS HLTH RES GRP,WASHINGTON,DC 20036; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,PREVENT MED RESIDENCY PROGRAM,BALTIMORE,MD; WASHINGTON UNIV,ST LOUIS,MO; AMER CANC SOC,WASHINGTON,DC	Johns Hopkins University; Washington University (WUSTL); American Cancer Society								BEGAY ME, 1993, AM J PUBLIC HEALTH, V83, P1214, DOI 10.2105/AJPH.83.9.1214; MCGINNIS JM, 1993, JAMA-J AM MED ASSOC, V270, P2207, DOI 10.1001/jama.270.18.2207; MOORE S, 1993, CONTRIBUTING DEATH I; WOLFE SM, 1993, PUBLIC CITIZEN HLTH, V9, P1; 1992, STATISTICAL ABSTRACT, P733; 1993, SAVING LIVES RAISING	6	55	55	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 19	1994	272	15					1171	1175		10.1001/jama.272.15.1171	http://dx.doi.org/10.1001/jama.272.15.1171			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PL212	7933346				2022-12-24	WOS:A1994PL21200030
J	MANABE, T; NICOLL, RA				MANABE, T; NICOLL, RA			LONG-TERM POTENTIATION - EVIDENCE AGAINST AN INCREASE IN TRANSMITTER RELEASE PROBABILITY IN THE CA1 REGION OF THE HIPPOCAMPUS	SCIENCE			English	Article							PAIRED-PULSE; FACILITATION; TRANSMISSION; ENHANCEMENT; MECHANISMS; CURRENTS; INVITRO; NEURONS; SYNAPSE; SLICES	It is widely accepted that N-methyl-D-aspartate (NMDA)-receptor-dependent long-term potentiation (LTP) in the CA1 region of the hippocampus is triggered postsynaptically, but there is considerable debate as to the site at which the increase in synaptic strength is expressed. The irreversible open-channel blocking action of the NMDA receptor antagonist MK-801 has been used to test whether the probability of transmitter release (P-r) is increased during LTP. Although the rate of decline of the amplitude of the NMDA receptor-mediated excitatory postsynaptic current (EPSC) in the presence of MK-801 strongly depends on P-r, the rate of decline of the EPSC evoked at synapses expressing LTP is identical to that observed at synapses not expressing LTP. These findings are difficult to reconcile with models in which the expression of LTP is due to an increase in P-r.	UNIV CALIF SAN FRANCISCO,DEPT PHARMACOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV TOKYO,FAC MED,INST BRAIN RES,DEPT NEUROPHYSIOL,TOKYO 113,JAPAN	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Tokyo								BAUDRY M, 1991, LONG TERM POTENTIATI; BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; CREAGER R, 1980, J PHYSIOL-LONDON, V299, P409, DOI 10.1113/jphysiol.1980.sp013133; Foster T C, 1991, Hippocampus, V1, P79, DOI 10.1002/hipo.450010108; GUSTAFSSON B, 1988, NEUROSCI LETT, V85, P77, DOI 10.1016/0304-3940(88)90432-6; HESSLER NA, 1993, NATURE, V366, P569, DOI 10.1038/366569a0; HESTRIN S, 1990, NEURON, V5, P247, DOI 10.1016/0896-6273(90)90162-9; HUETTNER JE, 1988, P NATL ACAD SCI USA, V85, P1307, DOI 10.1073/pnas.85.4.1307; KULLMANN DM, 1992, NATURE, V357, P240, DOI 10.1038/357240a0; LARKMAN A, 1992, NATURE, V360, P70, DOI 10.1038/360070a0; LIAO D, 1992, NEURON, V9, P1089, DOI 10.1016/0896-6273(92)90068-O; MADISON DV, 1991, ANNU REV NEUROSCI, V14, P379, DOI 10.1146/annurev.ne.14.030191.002115; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MALINOW R, 1991, SCIENCE, V252, P722, DOI 10.1126/science.1850871; MALLART A, 1968, J PHYSIOL-LONDON, V196, P593, DOI 10.1113/jphysiol.1968.sp008525; MANABE T, 1993, J NEUROPHYSIOL, V70, P1451, DOI 10.1152/jn.1993.70.4.1451; MCNAUGHTON BL, 1982, J PHYSIOL-LONDON, V324, P249, DOI 10.1113/jphysiol.1982.sp014110; MULLER D, 1989, BRAIN RES, V479, P290, DOI 10.1016/0006-8993(89)91631-4; NICOLL RA, 1994, CELLULAR MOL MECHANI, P189; ROSENMUND C, 1993, SCIENCE, V262, P754, DOI 10.1126/science.7901909; VORONIN LL, 1990, NEUROSCI RES COMMUN, V6, P149; ZALUTSKY RA, 1990, SCIENCE, V248, P1619, DOI 10.1126/science.2114039; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.neuro.12.1.13	24	117	118	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 23	1994	265	5180					1888	1892		10.1126/science.7916483	http://dx.doi.org/10.1126/science.7916483			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PH258	7916483				2022-12-24	WOS:A1994PH25800040
J	OOSTVOGEL, PM; VANWIJNGAARDEN, JK; VANDERAVOORT, HGAM; MULDERS, MN; CONYNVANSPAENDONCK, MAE; RUMKE, HC; VANSTEENIS, G; VANLOON, AM				OOSTVOGEL, PM; VANWIJNGAARDEN, JK; VANDERAVOORT, HGAM; MULDERS, MN; CONYNVANSPAENDONCK, MAE; RUMKE, HC; VANSTEENIS, G; VANLOON, AM			POLIOMYELITIS OUTBREAK IN AN UNVACCINATED COMMUNITY IN THE NETHERLANDS, 1992-93	LANCET			English	Article							PARALYTIC POLIOMYELITIS; WILD POLIOVIRUS; EPIDEMIC; VACCINE	An outbreak of poliomyelitis occurred in the Netherlands between September, 1992, and February, 1993, after 14 years without endemic cases. The outbreak was due to pollovirus type 3 and involved 71 patients, of whom 2 died and 59 had paralysis. The patients were aged between 10 days and 61 years (median 18 years). None of the patients had been vaccinated, and all but 1 belonged to a socially and geographically clustered group of people who refuse vaccination for religious reasons. Control measures were taken within 5 days of notification of the first patient and included a wide offer of vaccination with the trivalent oral poliovirus vaccine to the population at risk. Sequence analysis of the viral genome showed closest similarity (96.7%) with a strain isolated in India in 1992, indicating that the virus probably originates from the Indian subcontinent. The difference, however, is still too large to assume direct import. Extensive outbreak investigation at schools, in the environment, at virus diagnostic laboratories, and in the general population showed no evidence of widespread circulation of the epidemic virus outside the groups at risk and area where these groups live. As in the previous outbreak in 1978, the general population, including the majority of unvaccinated people who live dispersed in the population, seemed to be well-protected against poliomyelitis.	NATL INST PUBL HLTH & ENVIRONM PROTECT,VIROL LAB,3720 BA BILTHOVEN,NETHERLANDS; NATL INST PUBL HLTH & ENVIRONM PROTECT,WHO,COLLABORATING CTR REFERENCE & RES POLIOMYELITIS,3720 BA BILTHOVEN,NETHERLANDS; NATL INST PUBL HLTH & ENVIRONM PROTECT,DEPT INFECT DIS EPIDEMIOL,3720 BA BILTHOVEN,NETHERLANDS; NATL INST PUBL HLTH & ENVIRONM PROTECT,CLIN VACCINE RES LAB,3720 BA BILTHOVEN,NETHERLANDS; NATL INST PUBL HLTH & ENVIRONM PROTECT,CONTROL BIOL PROD LAB,3720 BA BILTHOVEN,NETHERLANDS; MED INSPECTORATE HLTH,RIJSWIJK,NETHERLANDS	Netherlands National Institute for Public Health & the Environment; Netherlands National Institute for Public Health & the Environment; World Health Organization; Netherlands National Institute for Public Health & the Environment; Netherlands National Institute for Public Health & the Environment; Netherlands National Institute for Public Health & the Environment								BIJKERK H, 1984, REV INFECT DIS, V6, pS451; BIJKERK H, 1981, DEV BIOL STAND, V47, P233; DEMING MS, 1992, AM J EPIDEMIOL, V135, P393, DOI 10.1093/oxfordjournals.aje.a116300; Expanded programme on immunization, 1993, WKLY EPIDEMIOL REC, V68, P297; HOVI T, 1986, LANCET, V1, P1427; KIMFARLEY RJ, 1984, LANCET, V2, P1322; Nibbeling R, 1994, Clin Diagn Virol, V2, P113, DOI 10.1016/0928-0197(94)90044-2; RICOHESSE R, 1987, VIROLOGY, V160, P311, DOI 10.1016/0042-6822(87)90001-8; Rumke H C, 1993, Ned Tijdschr Geneeskd, V137, P1380; SCHAAP GJP, 1984, PROG MED VIROL, V29, P124; SLATER PE, 1990, LANCET, V335, P1192, DOI 10.1016/0140-6736(90)92705-M; SUTTER RW, 1991, LANCET, V338, P715, DOI 10.1016/0140-6736(91)91442-W; VANDENKERKHOF H, 1993, B INFECT, V4, P203; VANLOON AM, 1993, MEASLES POLIOMYELITI, P359; VANWEZEL AL, 1979, INTERVIROLOGY, V11, P1; VERBRUGGE HP, 1990, PEDIATRICS, V86, P1060; WHITE FMM, 1981, CANJ PUBL HLTH, V72, P119; WRIGHT PF, 1991, NEW ENGL J MED, V325, P1774, DOI 10.1056/NEJM199112193252504; YANG CF, 1991, VIRUS RES, V20, P159; 1979, MMWR-MORBID MORTAL W, V28, P345; 1993, CCDR, V19, P96; 1992, WKLY EPIDEMIOL REC, V67, P336	22	169	172	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 3	1994	344	8923					665	670		10.1016/S0140-6736(94)92091-5	http://dx.doi.org/10.1016/S0140-6736(94)92091-5			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PE386	7915354				2022-12-24	WOS:A1994PE38600016
J	ROZE, JC; STORME, L; ZUPAN, V; MORVILLE, P; DINHXUAN, AT; MERCIER, JC				ROZE, JC; STORME, L; ZUPAN, V; MORVILLE, P; DINHXUAN, AT; MERCIER, JC			ECHOCARDIOGRAPHIC INVESTIGATION OF INHALED NITRIC-OXIDE IN NEWBORN BABIES WITH SEVERE HYPOXEMIA	LANCET			English	Note							PERSISTENT PULMONARY-HYPERTENSION; RESPIRATORY-DISTRESS SYNDROME	Nitric oxide inhalation can benefit newborn babies with right-to-left extrapulmonary shunt (EPS). Using doppler ultrasound, we compared the effects of nitric oxide on systemic oxygenation and mean pulmonary-blood-flow velocity (MPBFV) in severely hypoxic babies with or without EPS. With a median (interquartile range) dose of 20 (32) parts per million, oxygenation index decreased significantly in both groups (EPS, 49 [19] vs 11 [9]; non-EPS, 40 [11] vs 20 [13]). The decrease was significantly greater in the EPS group. MPBFV increased significantly in the EPS group (18 [4] vs 29 [8] m/s) only. Nitric oxide may improve systemic oxygenation in neonates with severe hypoxaemia secondary to EPS by increasing pulmonary blood flow, and in those without EPS by improving ventilation-perfusion matching.	HOP UNIV NANTES,DEPT NEONATOL,NANTES,FRANCE; HOP UNIV LILLE,DEPT NEONATOL,LILLE,FRANCE; HOP ANTOINE BECLERE,DEPT NEONATOL,CLAMART,FRANCE; AMER MEM HOSP,DEPT NEONATOL,REIMS,FRANCE; HOP COCHIN,DEPT PHYSIOL,F-75674 PARIS,FRANCE; HOP ROBERT DEBRE,DEPT PEDIAT,F-75019 PARIS,FRANCE	Nantes Universite; CHU de Nantes; Universite de Lille - ISITE; CHU Lille; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Antoine-Beclere - APHP; CHU de Reims; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite			DINH-XUAN, Anh Tuan/A-9691-2008; Rozé, Jean-Christophe/AAS-1314-2021	DINH-XUAN, Anh Tuan/0000-0001-8651-5176; 				CHU J, 1967, PEDIATRICS, V40, P709; CORBET AJS, 1974, J APPL PHYSIOL, V36, P74, DOI 10.1152/jappl.1974.36.1.74; EVANS N, 1993, PEDIATRICS, V92, P737; KINSELLA JP, 1992, LANCET, V340, P819, DOI 10.1016/0140-6736(92)92687-B; MERCIER JC, 1993, LANCET, V342, P431, DOI 10.1016/0140-6736(93)92843-I; MUSEWE NN, 1990, J AM COLL CARDIOL, V15, P446, DOI 10.1016/S0735-1097(10)80076-2; PISON U, 1993, J APPL PHYSIOL, V74, P1287, DOI 10.1152/jappl.1993.74.3.1287; ROBERTS JD, 1992, LANCET, V340, P818, DOI 10.1016/0140-6736(92)92686-A; ROSSAINT R, 1993, NEW ENGL J MED, V328, P399, DOI 10.1056/NEJM199302113280605; WALTHER FJ, 1992, PEDIATRICS, V90, P899	10	56	56	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 30	1994	344	8918					303	305		10.1016/S0140-6736(94)91341-2	http://dx.doi.org/10.1016/S0140-6736(94)91341-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NZ233	7914264				2022-12-24	WOS:A1994NZ23300010
J	KURTZ, TW				KURTZ, TW			GENETIC MODELS OF HYPERTENSION	LANCET			English	Article							BLOOD-PRESSURE; ANIMAL-MODELS; LINKAGE; MOUSE; RENIN; RATS				KURTZ, TW (corresponding author), UNIV CALIF SAN FRANCISCO, LONG HOSP,MED CTR,DEPT LAB MED,ROOM 518, BOX 0134, SAN FRANCISCO, CA 94143 USA.							CICILA GT, 1993, NAT GENET, V3, P346, DOI 10.1038/ng0493-346; DENG YL, 1992, NAT GENET, V1, P267, DOI 10.1038/ng0792-267; GANTEN D, 1987, HYPERTENSION, V9, pI2; HILBERT P, 1991, NATURE, V353, P521, DOI 10.1038/353521a0; JACOB HJ, 1991, CELL, V67, P213, DOI 10.1016/0092-8674(91)90584-L; KURTZ TW, 1993, J CLIN INVEST, V91, P741, DOI 10.1172/JCI116291; MULLINS JJ, 1990, NATURE, V344, P541, DOI 10.1038/344541a0; OHKUBO H, 1990, P NATL ACAD SCI USA, V87, P5153, DOI 10.1073/pnas.87.13.5153; OKAMOTO KOZO, 1963, JAPAN CIRCULATION JOUR, V27, P282; PRAVENEC M, 1989, J HYPERTENS, V7, P217; RAPP JP, 1987, HYPERTENSION, V10, P7, DOI 10.1161/01.HYP.10.1.7; SMITHIES O, 1993, TRENDS GENET, V9, P112, DOI 10.1016/0168-9525(93)90204-U; SMITHIES O, 1994, P NATL ACAD SCI USA, V91, P3612, DOI 10.1073/pnas.91.9.3612; STLEZIN E, 1993, HYPERTENSION, V22, P421; STLEZIN EM, 1993, TRENDS CARDIOVAS MED, V3, P119, DOI 10.1016/1050-1738(93)90011-T; TURNER ME, 1991, HYPERTENSION, V17, P1097, DOI 10.1161/01.HYP.17.6.1097; YAMADA J, 1994, MAMM GENOME, V5, P63, DOI 10.1007/BF00292332	17	16	16	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 16	1994	344	8916					167	168		10.1016/S0140-6736(94)92761-8	http://dx.doi.org/10.1016/S0140-6736(94)92761-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW810	7912769				2022-12-24	WOS:A1994NW81000013
J	MAGUIRE, J; SANTORO, T; JENSEN, P; SIEBENLIST, U; YEWDELL, J; KELLY, K				MAGUIRE, J; SANTORO, T; JENSEN, P; SIEBENLIST, U; YEWDELL, J; KELLY, K			GEM - AN INDUCED, IMMEDIATE-EARLY PROTEIN BELONGING TO THE RAS FAMILY	SCIENCE			English	Article							MECHANISM; GROWTH; ACTIVATION; CLONES; CELLS	A gene encoding a 35-kilodalton guanosine triphosphate (GTP)-binding protein, Gem, was cloned from mitogen-induced human peripheral blood T cells. Gem and Rad, the product of a gene overexpressed in skeletal muscle in individuals with Type II diabetes, constitute a new family of Ras-related GTP-binding proteins. The distinct structural features of this family include the G3 GTP-binding motif, extensive amino- and carboxyl-terminal extensions beyond the Ras-related domain, and a motif that determines membrane association. Gem was transiently expressed in human peripheral blood T cells in response to mitogenic stimulation; the protein was phosphorylated on tyrosine residues and localized to the cytosolic face of the plasma membrane. Deregulated Gem expression prevented proliferation of normal and transformed 3T3 cells. These results suggest that Gem is a regulatory protein, possibly participating in receptor-mediated signal transduction at the plasma membrane.	NCI,PATHOL LAB,BETHESDA,MD 20892; NIAID,IMMUNOREGULAT LAB,BETHESDA,MD 20892; NIAID,VIRAL DIS LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			yewdell, jyewdell@nih.gov jonathan/A-1702-2012					ANDREWS PW, 1984, LAB INVEST, V50, P147; BARBACID M, 1981, J VIROL, V37, P518, DOI 10.1128/JVI.37.1.518-523.1981; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; FLETCHER BS, 1991, J BIOL CHEM, V266, P14511; GERRARD TL, 1983, CELL IMMUNOL, V82, P394, DOI 10.1016/0008-8749(83)90172-7; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HORGAN K, 1991, CURRENT PROTOCOLS IM, V1; HWANG YW, 1989, GUANINE NUCLEOTIDE B, P77; JAHNER D, 1991, MOL CELL BIOL, V11, P3682; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; MAGUIRE JM, UNPUB; MILLER RT, 1988, NATURE, V334, P712, DOI 10.1038/334712a0; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; REYNET C, 1993, SCIENCE, V262, P1441, DOI 10.1126/science.8248782; Sambrook J., 1989, MOL CLONING LAB MANU; SEKIYA T, 1984, P NATL ACAD SCI-BIOL, V81, P4771, DOI 10.1073/pnas.81.15.4771; ZIPFEL PF, 1989, MOL CELL BIOL, V9, P1041, DOI 10.1128/MCB.9.3.1041	20	165	172	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 8	1994	265	5169					241	244		10.1126/science.7912851	http://dx.doi.org/10.1126/science.7912851			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NV957	7912851	Green Submitted			2022-12-24	WOS:A1994NV95700039
J	MOFFATT, F; HILL, MR; CORNELIS, F; SCHOU, C; FAUX, JA; YOUNG, RP; JAMES, AL; RYAN, G; LESOUEF, P; MUSK, AW; HOPKIN, JM; COOKSON, WOCM				MOFFATT, F; HILL, MR; CORNELIS, F; SCHOU, C; FAUX, JA; YOUNG, RP; JAMES, AL; RYAN, G; LESOUEF, P; MUSK, AW; HOPKIN, JM; COOKSON, WOCM			GENETIC-LINKAGE OF T-CELL RECEPTOR ALPHA/DELTA COMPLEX TO SPECIFIC IGE RESPONSES	LANCET			English	Article							ALLELIC VARIATIONS; IMMUNOGLOBULIN-E; RELATIVE RISKS; REPERTOIRE; ADULTS	IgE responses to inhaled proteins underlie the clinical syndrome of allergic (atopic) asthma and rhinitis. We have investigated genetic linkage between specific IgE reactions to highly purified major allergens and the T-cell receptor (TCR) alpha: and beta gene complexes on chromosome 14 and 7, respectively. Antigens tested included highly purified proteins from the housedust mite Dermatophagoides pteronyssinus, the domestic cat and dog, grass pollen, and the mould Alternaria alternata. Affected sibling-pair methods were used in two independent sets of families, one in the UK and one in Australia, No linkage of IgE serotypes to TCR-beta was detected, but significant linkage to TCR-alpha was seen in both family groups, For several of the IgE phenotypes investigated (positive responses to whole allergen sources or purified antigens or serum IgE above the 70th percentile in the population) the affected sibling-pairs showed significant sharing of TCR-alpha microsatellite alleles from both parents. The results show that a gene (or genes) in the TCR-alpha region modifies specific IgE responses.	JOHN RADCLIFFE HOSP,NUFFIELD DEPT CLIN MED,OXFORD OX3 9DU,ENGLAND; INST MOLEC MED,MOLEC IMMUNOL GRP,OXFORD,ENGLAND; ALK LABS,HORSHOLM,DENMARK; SIR CHARLES GAIRDINER HOSP,DEPT RESP MED,PERTH,WA 6000,AUSTRALIA; UNIV WESTERN AUSTRALIA,PRINCESS MARGARET HOSP,DEPT PAEDIAT,PERTH,WA 6009,AUSTRALIA; CHURCHILL HOSP,OSLER CHEST UNIT,OXFORD OX3 7LJ,ENGLAND	University of Oxford; University of Oxford; University of Western Australia; University of Oxford			Hill, Michael/C-4861-2008; Le Souef, Peter N/H-5256-2014; Cookson, William/HHC-1790-2022	Le Souef, Peter/0000-0003-0930-1654	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BLACKWELDER W C, 1985, Genetic Epidemiology, V2, P85, DOI 10.1002/gepi.1370020109; COOKSON WOCM, 1991, CLIN EXP ALLERGY, V21, P473, DOI 10.1111/j.1365-2222.1991.tb01688.x; CORNELIS F, 1993, EUR J IMMUNOL, V23, P1277, DOI 10.1002/eji.1830230613; CORNELIS F, 1992, GENOMICS, V13, P820, DOI 10.1016/0888-7543(92)90159-P; DIZIER MH, 1993, GENET EPIDEMIOL, V10, P333; GERRARD JW, 1978, AM J HUM GENET, V30, P46; GULWANIAKOLKAR B, 1991, J EXP MED, V174, P1139, DOI 10.1084/jem.174.5.1139; H/CEPH Collaborative Mapping Group, 1992, SCIENCE, V258, P67; HEINZEL FP, 1991, P NATL ACAD SCI USA, V88, P7011, DOI 10.1073/pnas.88.16.7011; HOLFORDSTREVENS V, 1984, J ALLERGY CLIN IMMUN, V73, P516, DOI 10.1016/0091-6749(84)90363-4; Holt P G, 1991, Clin Exp Allergy, V21 Suppl 1, P148, DOI 10.1111/j.1365-2222.1991.tb01719.x; KJELLMAN NIM, 1976, CLIN ALLERGY, V6, P51, DOI 10.1111/j.1365-2222.1976.tb01411.x; LI YX, 1990, J EXP MED, V171, P221, DOI 10.1084/jem.171.1.221; LOVERIDGE JA, 1991, IMMUNOLOGY, V74, P246; MOHAPATRA SS, 1994, IMMUNOLOGY, V81, P15; MOSS PAH, 1993, EUR J IMMUNOL, V23, P1153, DOI 10.1002/eji.1830230526; ROBINSON MA, 1987, P NATL ACAD SCI USA, V84, P9089, DOI 10.1073/pnas.84.24.9089; SANDFORD AJ, 1993, LANCET, V341, P332, DOI 10.1016/0140-6736(93)90136-5; SEARS MR, 1989, CLIN EXP ALLERGY, V19, P419, DOI 10.1111/j.1365-2222.1989.tb02408.x; YOUNG RP, 1994, CLIN EXP ALLERGY, V24, P431, DOI 10.1111/j.1365-2222.1994.tb00931.x	20	177	181	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 25	1994	343	8913					1597	1600		10.1016/S0140-6736(94)93057-0	http://dx.doi.org/10.1016/S0140-6736(94)93057-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU354	7911920				2022-12-24	WOS:A1994NU35400010
J	HASLAM, PL; HUGHES, DA; MACNAUGHTON, PD; BAKER, CS; EVANS, TW				HASLAM, PL; HUGHES, DA; MACNAUGHTON, PD; BAKER, CS; EVANS, TW			SURFACTANT REPLACEMENT THERAPY IN LATE-STAGE ADULT-RESPIRATORY-DISTRESS-SYNDROME	LANCET			English	Note								In four adult patients with late-stage acute respiratory distress syndrome (ARDS), a single dose of the artificial surfactant ALEC was given by intrabronchial instillation. There was no sustained clinical improvement, but bronchoalveolar lavage measurements indicated that phosphatidylcholine (PC) at 24 h after treatment had increased up to 4.4 fold and phosphatidylglycerol up to 34.7 fold. However, PC relative to total phospholipid remained below normal, and protein contamination relative to PC remained above normal. Thus, therapeutic formulations and regimens to achieve greater and more sustained supplementation of PC may be required in patients with late-stage ARDS.	ROYAL BROMPTON NATL HEART & LUNG HOSP,ADULT INTENS CARE UNIT,LONDON SW3 6NP,ENGLAND	Imperial College London	HASLAM, PL (corresponding author), NATL HEART & LUNG INST,CELL BIOL UNIT,LONDON SW3 6LY,ENGLAND.							HUGHES DA, 1990, EUR RESPIR J, V3, P1128; IKEGAMI M, 1993, AM REV RESPIR DIS, V148, P837, DOI 10.1164/ajrccm/148.4_Pt_1.837; JOBE A, 1987, AM REV RESPIR DIS, V136, P1256, DOI 10.1164/ajrccm/136.5.1256; LACHMANN B, 1989, EUR RESPIR J S3, V2, pS98; LEWIS JF, 1993, AM REV RESPIR DIS, V147, P218, DOI 10.1164/ajrccm/147.1.218; Morley C J, 1989, Eur Respir J Suppl, V3, p81s; NOSAKA S, 1990, LANCET, V336, P947, DOI 10.1016/0140-6736(90)92325-C; RICHMAN PS, 1989, EUR RESPIR J S3, V2, pS109; SEEGER W, 1993, EUR RESPIR J, V6, P971; WIEDEMANN H, 1992, American Review of Respiratory Disease, V145, pA184	10	34	34	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 23	1994	343	8904					1009	1011		10.1016/S0140-6736(94)90128-7	http://dx.doi.org/10.1016/S0140-6736(94)90128-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NG682	7909050				2022-12-24	WOS:A1994NG68200011
J	ZHUO, M; HU, YH; SCHULTZ, C; KANDEL, ER; HAWKINS, RD				ZHUO, M; HU, YH; SCHULTZ, C; KANDEL, ER; HAWKINS, RD			ROLE OF GUANYLYL CYCLASE AND CGMP-DEPENDENT PROTEIN-KINASE IN LONG-TERM POTENTIATION	NATURE			English	Article							CYCLIC-GMP FORMATION; NITRIC-OXIDE; CORTICAL-NEURONS; INVOLVEMENT; CEREBELLUM; DEPRESSION; RELEASE	SEVERAL lines of evidence suggest that cyclic GMP might be involved in long-term potentiation (LTP) in the hippocampus1-6. Arachidonic acid, nitric oxide and carbon monoxide, three molecules that have been proposed to act as retrograde messengers in LTP7-9, all activate soluble guanylyl cyclase1,10,11. We report here that an inhibitor of guanylyl cyclase blocks the induction of LTP in the CA1 region of hippocampal slices. Conversely, cGMP analogues produce long-lasting enhancement of the excitatory postsynaptic potential if they are applied at the same time as weak tetanic stimulation of the presynaptic fibres. The enhancement is spatially restricted, is not blocked by valeric acid (APV), nifedipine, or picrotoxin, and partially occludes LTP. This synaptic enhancement may be mediated by the cGMP-dependent protein kinase (PKG). Inhibitors of PKG block the induction of LTP, and activators of PKG produce activity-dependent long-lasting enhancement. These results suggest that guanylyl cyclase and PKG contribute to LTP, possibly as activity-dependent presynaptic effectors of retrograde messengers.	NEW YORK STATE PSYCHIAT INST & HOSP,NEW YORK,NY 10032; HOWARD HUGHES MED INST,NEW YORK,NY 10032; UNIV CALIF SAN DIEGO,DEPT PHARMACOL,LA JOLLA,CA 92093	New York State Psychiatry Institute; Howard Hughes Medical Institute; University of California System; University of California San Diego	ZHUO, M (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,CTR NEUROBIOL & BEHAV,NEW YORK,NY 10032, USA.		Zhuo, Min/A-2072-2008	Zhuo, Min/0000-0001-9062-3241; Schultz, Carsten/0000-0002-5824-2171				Arancio O., 1993, Society for Neuroscience Abstracts, V19, P241; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BRONS JF, 1980, J NEUROPHYSIOL, V44, P605, DOI 10.1152/jn.1980.44.3.605; CHETKOVICH DM, 1993, NEUROREPORT, V4, P919, DOI 10.1097/00001756-199307000-00020; DEVENTE J, 1992, ACTA HISTOCHEM, V92, P13, DOI 10.1016/S0065-1281(11)80138-8; EAST SJ, 1991, NEUROSCI LETT, V123, P17, DOI 10.1016/0304-3940(91)90147-L; FLEISCH JH, 1984, J PHARMACOL EXP THER, V229, P681; FREY U, 1993, SCIENCE, V260, P1661, DOI 10.1126/science.8389057; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; GEIGER J, 1992, P NATL ACAD SCI USA, V89, P1031, DOI 10.1073/pnas.89.3.1031; HALEY JE, 1992, NEURON, V8, P211, DOI 10.1016/0896-6273(92)90288-O; HAWKINS RD, IN PRESS J NEUROBIOL; ITO M, 1989, ANNU REV NEUROSCI, V12, P85, DOI 10.1146/annurev.ne.12.030189.000505; Ito M, 1990, Neuroreport, V1, P129; SCHLICHTER DJ, 1978, NATURE, V273, P61, DOI 10.1038/273061a0; SCHULTZ C, 1993, J BIOL CHEM, V268, P6316; SCHULZ S, 1991, TRENDS PHARMACOL SCI, V12, P116, DOI 10.1016/0165-6147(91)90519-X; SHIBUKI K, 1991, NATURE, V349, P326, DOI 10.1038/349326a0; SNIDER RM, 1984, P NATL ACAD SCI-BIOL, V81, P3905, DOI 10.1073/pnas.81.12.3905; SQUIRE LR, 1991, SCIENCE, V253, P1380, DOI 10.1126/science.1896849; STEVENS CF, 1993, NATURE, V364, P147, DOI 10.1038/364147a0; TSOU K, 1993, P NATL ACAD SCI USA, V90, P3462, DOI 10.1073/pnas.90.8.3462; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; WHITE RE, 1993, NATURE, V361, P263, DOI 10.1038/361263a0; WIGSTROM H, 1986, ACTA PHYSIOL SCAND, V126, P317, DOI 10.1111/j.1748-1716.1986.tb07822.x; WOODY CD, 1978, BRAIN RES, V158, P373, DOI 10.1016/0006-8993(78)90682-0; ZHUO M, 1993, SCIENCE, V260, P1946, DOI 10.1126/science.8100368; ZHUO M, IN PRESS NEURO REPOR	28	331	347	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 14	1994	368	6472					635	639		10.1038/368635a0	http://dx.doi.org/10.1038/368635a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NF392	7908417				2022-12-24	WOS:A1994NF39200061
J	MAHAN, MJ				MAHAN, MJ			REVEALING BACTERIAL-INFECTION STRATEGIES	LANCET			English	Editorial Material							INTEGRATION HOST FACTOR; SALMONELLA-TYPHIMURIUM; VIRULENCE; AVIRULENT; STRAINS				MAHAN, MJ (corresponding author), UNIV CALIF SANTA BARBARA,SANTA BARBARA,CA 93106, USA.							CAMILLI A, IN PRESS P NATL ACAD; DORMAN CJ, 1987, J BACTERIOL, V169, P3840, DOI 10.1128/jb.169.8.3840-3843.1987; FIELDS PI, 1986, P NATL ACAD SCI USA, V83, P5189, DOI 10.1073/pnas.83.14.5189; FRIEDMAN DI, 1988, CELL, V55, P545, DOI 10.1016/0092-8674(88)90213-9; LEUNK RD, 1982, INFECT IMMUN, V36, P1168, DOI 10.1128/IAI.36.3.1168-1174.1982; LOCKMAN HA, 1992, INFECT IMMUN, V60, P491, DOI 10.1128/IAI.60.2.491-496.1992; MAHAN MJ, 1993, SCIENCE, V259, P666; MAHAN MJ, 1994, INFECTIOUS AGENTS DI, V2, P263; Makela P. H., 1984, HDB ENDOTOXIN, P59; MCFARLAND WC, 1987, MICROB PATHOGENESIS, V3, P129, DOI 10.1016/0882-4010(87)90071-4; MEKALANOS JJ, 1992, J BACTERIOL, V174, P1; MILLER JF, 1989, SCIENCE, V243, P916, DOI 10.1126/science.2537530; Neuhard J, 1987, ESCHERICHIA COLI SAL, P445; NNALUE NA, 1990, INFECT IMMUN, V58, P2493, DOI 10.1128/IAI.58.8.2493-2501.1990; PLUM G, 1994, INFECT IMMUN, V62, P476, DOI 10.1128/IAI.62.2.476-483.1994	15	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 9	1994	343	8902					869	870		10.1016/S0140-6736(94)90005-1	http://dx.doi.org/10.1016/S0140-6736(94)90005-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF213	7908355				2022-12-24	WOS:A1994NF21300005
J	HOPPLER, S; BIENZ, M				HOPPLER, S; BIENZ, M			SPECIFICATION OF A SINGLE-CELL TYPE BY A DROSOPHILA HOMEOTIC GENE	CELL			English	Article							HOMEOBOX-CONTAINING GENES; ECTOPIC EXPRESSION; VISCERAL MESODERM; C-ELEGANS; DEVELOPMENTAL ANALYSIS; ANTENNAPEDIA-COMPLEX; SPATIAL EXPRESSION; BITHORAX COMPLEX; AUTO-REGULATION; NERVOUS-SYSTEM	Homeotic genes function in blocks of cells along the body axis to specify diverse developmental pathways. Among the Drosophila homeotic genes, only one is known to be expressed in the endoderm. We show here that expression of this gene, labial (lab), coincides with copper cells, highly specialized cells of the larval midgut. lab is strictly required for copper cell formation, a requirement that starts in the embryo and extends through larval stages. This implies a function of lab not only in the determination and differentiation of copper cells, but also in the maintenance of their differentiated state. Ectopic expression of lab during embryogenesis reprograms other midgut cells within and outside the lab domain to become copper cell-like. Thus, lab functions in the larval midgut to specify a single cell type.			HOPPLER, S (corresponding author), MRC, MOLEC BIOL LAB, HILLS RD, CAMBRIDGE CB2 2QH, CAMBS, ENGLAND.			Hoppler, Stefan/0000-0003-0730-4798				AKAM M, 1987, DEVELOPMENT, V101, P1; AKAM M, 1989, CELL, V57, P347, DOI 10.1016/0092-8674(89)90909-4; BIENZ M, 1988, NATURE, V333, P576, DOI 10.1038/333576a0; BIENZ M, 1988, CELL, V53, P567, DOI 10.1016/0092-8674(88)90573-9; BLOCHLINGER K, 1991, GENE DEV, V5, P1124, DOI 10.1101/gad.5.7.1124; BURGLIN TR, 1991, NATURE, V351, P703, DOI 10.1038/351703a0; CABRERA CV, 1987, CELL, V50, P659, DOI 10.1016/0092-8674(87)90039-0; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; CHISHOLM A, 1991, DEVELOPMENT, V111, P921; CHOUINARD S, 1991, DEVELOPMENT, V113, P1267; CLARK SG, 1993, CELL, V74, P43, DOI 10.1016/0092-8674(93)90293-Y; DIEDERICH RJ, 1991, DEVELOPMENT, V113, P273; DIEDERICH RJ, 1989, GENE DEV, V3, P399, DOI 10.1101/gad.3.3.399; DUBOULE D, 1989, EMBO J, V8, P1497, DOI 10.1002/j.1460-2075.1989.tb03534.x; FILSHIE BK, 1971, TISSUE CELL, V3, P77, DOI 10.1016/S0040-8166(71)80033-2; Garcia-Bellido A, 1975, Ciba Found Symp, V0, P161; GIBSON G, 1988, DEVELOPMENT, V102, P657; GONZALEZREYES A, 1990, NATURE, V344, P78, DOI 10.1038/344078a0; HARTENSTEIN V, 1985, Wilhelm Roux's Archives of Developmental Biology, V194, P213, DOI 10.1007/BF00848248; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; HEITZLER P, 1991, CELL, V64, P1083, DOI 10.1016/0092-8674(91)90263-X; HEUER JG, 1992, DEVELOPMENT, V115, P35; HOOPER JE, 1986, EMBO J, V5, P2321, DOI 10.1002/j.1460-2075.1986.tb04500.x; IMMERGLUCK K, 1990, CELL, V62, P261, DOI 10.1016/0092-8674(90)90364-K; KAUFMAN TC, 1980, GENETICS, V94, P115; KENYON C, 1986, CELL, V46, P477, DOI 10.1016/0092-8674(86)90668-9; KUZIORA MA, 1988, CELL, V55, P477, DOI 10.1016/0092-8674(88)90034-7; Lawrence Peter A, 1993, MAKING FLY GENETICS, V6; LEMOUELLIC H, 1992, CELL, V69, P251, DOI 10.1016/0092-8674(92)90406-3; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; LEWIS EB, 1963, AM ZOOL, V3, P33; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; MANN RS, 1990, CELL, V60, P597, DOI 10.1016/0092-8674(90)90663-Y; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MERRILL VKL, 1989, DEV BIOL, V135, P376, DOI 10.1016/0012-1606(89)90187-5; MLODZIK M, 1988, EMBO J, V7, P2569, DOI 10.1002/j.1460-2075.1988.tb03106.x; MORATA G, 1976, ROUX ARCH DEV BIOL, V179, P125, DOI 10.1007/BF00848298; MULLER J, 1992, EMBO J, V11, P3653, DOI 10.1002/j.1460-2075.1992.tb05450.x; MURPHY P, 1991, DEVELOPMENT, V111, P61; MURTHA MT, 1991, P NATL ACAD SCI USA, V88, P10711, DOI 10.1073/pnas.88.23.10711; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; PANGANIBAN GEF, 1990, DEVELOPMENT, V110, P1041; PENVY L, 1991, NATURE, V349, P257; Poulsen D. F., 1952, Experimental Cell Research New York Supplement, VNo. 2, P161; Poulson D. F., 1950, BIOL DROSOPHILA, P168; POULSON DF, 1950, GENETICS, V35, P684; POULSON DF, 1960, AUST J BIOL SCI, V13, P540; QIAN S, 1991, EMBO J, V10, P1415, DOI 10.1002/j.1460-2075.1991.tb07662.x; REUTER R, 1990, DEVELOPMENT, V109, P289; REUTER R, 1990, DEVELOPMENT, V110, P1031; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; SANCHEZHERRERO E, 1985, NATURE, V313, P108, DOI 10.1038/313108a0; SCHALLER D, 1990, NUCLEIC ACIDS RES, V18, P2033, DOI 10.1093/nar/18.8.2033; SCHNEUWLY S, 1987, NATURE, V325, P816, DOI 10.1038/325816a0; SCHUMMER M, 1992, EMBO J, V11, P1815, DOI 10.1002/j.1460-2075.1992.tb05233.x; SEYDOUX G, 1989, CELL, V57, P1237, DOI 10.1016/0092-8674(89)90060-3; SKAER H, 1993, IN PRESS DEV DROSOPH; STRUHL G, 1982, P NATL ACAD SCI-BIOL, V79, P7380, DOI 10.1073/pnas.79.23.7380; SUNDIN OH, 1990, DEVELOPMENT, V108, P47; TEUGELS E, 1985, NATURE, V314, P558, DOI 10.1038/314558a0; TREMML G, 1992, DEVELOPMENT, V116, P447; TREMML G, 1989, EMBO J, V8, P2677, DOI 10.1002/j.1460-2075.1989.tb08408.x; TREMML G, 1991, THESIS U ZURICH ZURI; WAKIMOTO BT, 1981, DEV BIOL, V81, P51, DOI 10.1016/0012-1606(81)90347-X; WANG BB, 1993, CELL, V74, P29, DOI 10.1016/0092-8674(93)90292-X; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; WEINZIERL R, 1987, GENE DEV, V1, P386, DOI 10.1101/gad.1.4.386; WHITE RAH, 1984, CELL, V39, P163, DOI 10.1016/0092-8674(84)90202-2	71	89	93	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 25	1994	76	4					689	702		10.1016/0092-8674(94)90508-8	http://dx.doi.org/10.1016/0092-8674(94)90508-8			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MZ285	7907275				2022-12-24	WOS:A1994MZ28500011
J	WILSON, MM; CHELALA, C				WILSON, MM; CHELALA, C			CHOLERA IS WALKING SOUTH	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									MINIST HLTH & SOCIAL ACT,NATL COMMISS AGAINST CHOLERA,BUENOS AIRES,DF,ARGENTINA									TAUXE R, 1994, VIBRIO CHOLERAE CHOL; TAUXE RV, 1992, JAMA-J AM MED ASSOC, V267, P1388, DOI 10.1001/jama.267.10.1388; 1993, CHOLERA SITUATION AM; 1993, MMWR-MORBID MORTAL W, V42, P89; 1994, INFORME          JUN; 1994, EPIDEMIOL B, V15, P13	6	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 19	1994	272	15					1226	1227		10.1001/jama.272.15.1226	http://dx.doi.org/10.1001/jama.272.15.1226			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL212	7933354				2022-12-24	WOS:A1994PL21200040
J	DONALDSON, LJ; RANKIN, J; PROCTOR, S				DONALDSON, LJ; RANKIN, J; PROCTOR, S			IS IT POSSIBLE TO CATCH LEUKEMIA FROM A CAT	LANCET			English	Editorial Material							VIRUS; INFECTION				DONALDSON, LJ (corresponding author), UNIV NEWCASTLE UPON TYNE, NEWCASTLE UPON TYNE NE1 7RU, TYNE & WEAR, ENGLAND.							BROSS IDJ, 1972, AM J PUBLIC HEALTH N, V62, P1520, DOI 10.2105/AJPH.62.11.1520; BROSS IDJ, 1970, J MED, V1, P180; HOSIE MJ, 1989, VET REC, V125, P293, DOI 10.1136/vr.125.11.293; JARRETT O, 1991, J AM VET MED ASSOC, V199, P1279; JARRETT O, 1994, SYMP SOC GEN MICROBI, V51, P235; MORGAN RA, 1993, VIROLOGY, V193, P439, DOI 10.1006/viro.1993.1141; PEDERSEN NC, 1987, SCIENCE, V235, P790, DOI 10.1126/science.3643650; PILET C, 1989, B ACAD NAT MED PARIS, V173, P617; SORDILLO PP, 1982, JNCI-J NATL CANCER I, V69, P333; VIOLA MV, 1968, JAMA-J AM MED ASSOC, V205, P95; YAMAMOTO JK, 1989, J AM VET MED ASSOC, V194, P213	11	4	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	OCT 8	1994	344	8928					971	972		10.1016/S0140-6736(94)91636-5	http://dx.doi.org/10.1016/S0140-6736(94)91636-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PK978	7934425				2022-12-24	WOS:A1994PK97800004
J	HENG, MK; HENG, MCY				HENG, MK; HENG, MCY			HEAT-SHOCK PROTEIN-65 AND ACTIVATED GAMMA/DELTA T-CELLS IN INJURED ARTERIES	LANCET			English	Note							ATHEROSCLEROTIC LESIONS; HUMANS	Because immune mechanisms are implicated in atherogenesis, we investigated the T-lymphocyte subset and factors related to its activation after acute arterial ligation (22 ligated and 13 non-ligated specimens). Ligated arteries produced heat-shock protein 65 (hsp65) acid were infiltrated with activated T cells (mostly dendritic, CD3+, CD4-, CD8-, and gamma/delta T-cell-receptor bearing). The protein was found with dendritic T cells, with immunogold-labelled hsp65 beside the dendritic processes. Thus, the immune reaction after acute arterial injury may be associated with binding and recognition of in-situ hsp65 by dendritic gamma/delta T-cells.			HENG, MK (corresponding author), UNIV CALIF LOS ANGELES,SEPULVEDA VA MED CTR,DEPT MED,DIV CARDIOL,SEPULVEDA,CA 91343, USA.							BERBERIAN PA, 1990, AM J PATHOL, V136, P71; BERGSTRESSER PR, 1993, J INVEST DERMATOL, V100, pS80, DOI 10.1111/1523-1747.ep12356076; HAREGEWOIN A, 1989, NATURE, V340, P309, DOI 10.1038/340309a0; KLEINDIENST R, 1993, AM J PATHOL, V142, P1927; OBRIEN RL, 1989, CELL, V57, P668; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; STEMME S, 1992, ARTERIOSCLER THROMB, V12, P206, DOI 10.1161/01.ATV.12.2.206; VANDERWAL AC, 1989, LAB INVEST, V61, P166; XU QB, 1993, LANCET, V341, P255, DOI 10.1016/0140-6736(93)92613-X; XU QB, 1992, ARTERIOSCLER THROMB, V12, P789, DOI 10.1161/01.ATV.12.7.789	10	13	14	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 1	1994	344	8927					921	923		10.1016/S0140-6736(94)92271-3	http://dx.doi.org/10.1016/S0140-6736(94)92271-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PJ287	7934348				2022-12-24	WOS:A1994PJ28700012
J	MANCINI, GBJ				MANCINI, GBJ			MORE BAD-NEWS FOR COUCH POTATOES AND SMOKERS WHO ATONE THROUGH EXERCISE	LANCET			English	Editorial Material							PHYSICAL-ACTIVITY		VANCOUVER HOSP & HLTH SCI CTR,VANCOUVER,BC,CANADA	University of British Columbia	MANCINI, GBJ (corresponding author), UNIV BRITISH COLUMBIA,DEPT MED,VANCOUVER,BC,CANADA.							ABBOTT RD, 1994, AM J EPIDEMIOL, V139, P881, DOI 10.1093/oxfordjournals.aje.a117094; BERLIN JA, 1990, AM J EPIDEMIOL, V132, P612, DOI 10.1093/oxfordjournals.aje.a115704; BLAIR SN, 1992, ANNU REV PUBL HEALTH, V13, P99, DOI 10.1146/annurev.pu.13.050192.000531; Fletcher G F, 1993, Heart Dis Stroke, V2, P183; OCONNOR GT, 1989, CIRCULATION, V80, P234, DOI 10.1161/01.CIR.80.2.234; RODRIGUEZ BL, 1994, CIRCULATION, V89, P2540, DOI 10.1161/01.CIR.89.6.2540	6	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 3	1994	344	8923					629	630		10.1016/S0140-6736(94)92078-8	http://dx.doi.org/10.1016/S0140-6736(94)92078-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PE386	7915343				2022-12-24	WOS:A1994PE38600003
J	MULCAHY, HE; DUFFY, MJ; GIBBONS, D; MCCARTHY, P; PARFREY, NA; ODONOGHUE, DP; SHEAHAN, K				MULCAHY, HE; DUFFY, MJ; GIBBONS, D; MCCARTHY, P; PARFREY, NA; ODONOGHUE, DP; SHEAHAN, K			UROKINASE-TYPE PLASMINOGEN-ACTIVATOR AND OUTCOME IN DUKES B-COLORECTAL-CANCER	LANCET			English	Note							BREAST-CANCER; STROMAL CELLS; ADENOCARCINOMAS; RECEPTOR; COLON	Urokinase-type plasminogen activator (u-PA) is a serine protease involved in cancer metastasis. Using immunohistochemical methods, we examined the relation between u-PA and long-term survival in 70 patients with Dukes' B colorectal cancer. 8-year survival was 81% in patients whose tumours demonstrated low-grade epithelial u-PA staining and 43% in those with high-grade staining (log-rank test, p=0.01). Survival was unrelated to stromal u-PA staining. These results suggest that u-PA may be useful in the identification of patients with non-metastatic colorectal cancer at risk of tumour recurrence.	ST VINCENTS HOSP,DEPT PATHOL,DUBLIN 4,IRELAND; NATL UNIV IRELAND UNIV COLL DUBLIN,DUBLIN 4,IRELAND; ST VINCENTS HOSP,DEPT NUCL MED,DUBLIN 4,IRELAND; ST VINCENTS HOSP,GASTROENTEROL & LIVER UNIT,DUBLIN 4,IRELAND	University College Dublin; University College Dublin; University College Dublin; University College Dublin				mulcahy, hugh/0000-0002-7087-6177				DUFFY MJ, 1990, CANCER RES, V50, P6827; DUFFY MJ, 1992, CLIN EXP METASTAS, V10, P144; GELISTER JSK, 1986, BRIT MED J, V293, P728, DOI 10.1136/bmj.293.6549.728; GRONDAHLHANSEN J, 1991, AM J PATHOL, V138, P111; JANICKE F, 1990, FIBRINOLYSIS, V4, P69, DOI 10.1016/0268-9499(90)90001-Z; KOBAYASHI H, 1991, J BIOL CHEM, V266, P5147; MURNANE MJ, 1991, CANCER RES, V51, P1137; PYKE C, 1991, AM J PATHOL, V138, P1059; SIER CFM, 1991, HISTOPATHOLOGY, V19, P231, DOI 10.1111/j.1365-2559.1991.tb00027.x; TRYGGVASON K, 1987, BIOCHIM BIOPHYS ACTA, V907, P191, DOI 10.1016/0304-419X(87)90006-0	10	125	128	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 27	1994	344	8922					583	584		10.1016/S0140-6736(94)91968-2	http://dx.doi.org/10.1016/S0140-6736(94)91968-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD424	7914963				2022-12-24	WOS:A1994PD42400012
J	GARCIAFERNANDEZ, J; HOLLAND, PWH				GARCIAFERNANDEZ, J; HOLLAND, PWH			ARCHETYPAL ORGANIZATION OF THE AMPHIOXUS HOX GENE-CLUSTER	NATURE			English	Article							HOMEOBOX-CONTAINING GENES; CAENORHABDITIS-ELEGANS; VERTEBRATE EVOLUTION; EXPRESSION; METAZOAN; FAMILY; MOUSE	ORGANIZATION into gene clusters is an essential and diagnostic feature of Hox genes(1). Insect and nematode genomes possess single Hox gene clusters (split in Dvosophila); in mammals, there are 38 Hox genes in four clusters on different chromosomes(2,3). A collinear relationship between chromosomal position, activation time and anterior expression limit of vertebrate Hox genes suggests that clustering may be important for precise spatiotemporal gene regulation and hence embryonic patterning(2,4). Hox genes have a wide phylogenetic distribution within the metazoa, and are implicated in the control of regionalization along the anteroposterior body axis(2,5). It has been suggested that changes in Hox gene number and genomic organization played a role in metazoan body-plan evolution(6-8), but identifying significant changes is difficult because Hox gene organization is known from only very few and widely divergent taxa (principally insects, nematodes and vertebrates)(3). Here we analyse the complexity and organization of Hox genes in a cephalochordate, amphioxus, the taxon thought to be the sister group of the vertebrates(9). We find that the amphioxus genome has only one Hox gene cluster. It has similar genomic organization to the four mammalian Hox clusters, and contains homologues of at least the first ten paralogous groups of vertebrate Hox genes in a collinear array. Remarkably, this organization is compatible with that inferred for a direct ancestor of the vertebrates; we conclude; that amphioxus is a living representative of a critical intermediate stage in Hox cluster evolution.	UNIV OXFORD,DEPT ZOOL,OXFORD OX1 3PS,ENGLAND	University of Oxford			Garcia-Fernandez, Jordi/B-3839-2013	Garcia-Fernandez, Jordi/0000-0001-5677-5970; Holland, Peter/0000-0003-1533-9376				ACAMPORA D, 1989, NUCLEIC ACIDS RES, V17, P10385, DOI 10.1093/nar/17.24.10385; AKAM M, 1988, DEVELOPMENT, V104, P123; BELLEVILLE S, 1992, GENE, V114, P179, DOI 10.1016/0378-1119(92)90572-7; Burglin Thomas R., 1994, P25; BURGLIN TR, 1989, NATURE, V341, P239, DOI 10.1038/341239a0; BURGLIN TR, 1993, CURR OPIN GENET DEV, V3, P615, DOI 10.1016/0959-437X(93)90097-9; DEKKER EJ, 1992, MECH DEVELOP, V40, P3; HOLLAND P, 1992, BIOESSAYS, V14, P267, DOI 10.1002/bies.950140412; HOLLAND PWH, 1994, J MAR BIOL ASSOC UK, V74, P49, DOI 10.1017/S0025315400035657; HOLLAND PWH, 1992, DEVELOPMENT, V116, P653; HOLLAND PWH, 1993, ESSENTIAL DEV BIOL P, P243; IZPISUABELMONTE JC, 1991, EMBO J, V10, P2279, DOI 10.1002/j.1460-2075.1991.tb07764.x; IZPISUABELMONTE JC, 1991, NATURE, V350, P585, DOI 10.1038/350585a0; KAPPEN C, 1989, P NATL ACAD SCI USA, V86, P5459, DOI 10.1073/pnas.86.14.5459; KAPPEN C, 1993, GENOMICS, V18, P54, DOI 10.1006/geno.1993.1426; KAPPEN C, 1993, CURR OPIN GENET DEV, V3, P931, DOI 10.1016/0959-437X(93)90016-I; LUNDIN LG, 1993, GENOMICS, V16, P1, DOI 10.1006/geno.1993.1133; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MOLVEN A, 1993, BIOCHIM BIOPHYS ACTA, V1173, P102, DOI 10.1016/0167-4781(93)90253-A; PENDLETON JW, 1993, P NATL ACAD SCI USA, V90, P6300, DOI 10.1073/pnas.90.13.6300; RUBOCK MJ, 1990, P NATL ACAD SCI USA, V87, P4751, DOI 10.1073/pnas.87.12.4751; SANSOM IJ, 1992, SCIENCE, V256, P1308, DOI 10.1126/science.1598573; SCHUBERT FR, 1993, P NATL ACAD SCI USA, V90, P143, DOI 10.1073/pnas.90.1.143; SCHUGHART K, 1988, P NATL ACAD SCI USA, V85, P5582, DOI 10.1073/pnas.85.15.5582; SCOTT MP, 1992, CELL, V71, P551, DOI 10.1016/0092-8674(92)90588-4; SLACK JMW, 1993, NATURE, V361, P490, DOI 10.1038/361490a0; TABIN CJ, 1992, DEVELOPMENT, V116, P289; WEBSTER PJ, 1992, MECH DEVELOP, V38, P25, DOI 10.1016/0925-4773(92)90035-I; Willey A., 1894, AMPHIOXUS ANCESTRY V	29	471	483	4	43	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 18	1994	370	6490					563	566		10.1038/370563a0	http://dx.doi.org/10.1038/370563a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PC537	7914353				2022-12-24	WOS:A1994PC53700057
J	BRAUN, MM; CAPORASO, NE; PAGE, WF; HOOVER, RN				BRAUN, MM; CAPORASO, NE; PAGE, WF; HOOVER, RN			GENETIC COMPONENT OF LUNG-CANCER - COHORT STUDY OF TWINS	LANCET			English	Article							RISK; SUSCEPTIBILITY; ASSOCIATION; STATISTICS; MUTATIONS; MORTALITY; REGISTRY; SMOKING; LOCUS	Epidemiological and molecular epidemiological findings suggest that inherited predisposition may be a component of lung cancer risk and an important modulator of the carcinogenic effects of cigarette smoke. We have carried out a genetic analysis of lung cancer mortality on the National Academy of Sciences/National Research Council Twin Registry. The registry is composed of 15 924 male twin pairs who were born in the USA between 1917 and 1927 and who served in the armed forces during World War II. As evidence for a genetic effect on lung cancer, we required concordance for lung cancer death to be greater among monozygotic than among dizygotic twin pairs. No genetic effect on lung cancer mortality was observed. The ratio of observed to expected concordance among monozygotic twins did not exceed that among dizygotic twins (overall rate ratio 0.75 [95% CI 0.35-1.6]), even though monozygotic twin pairs are more likely to be concordant for smoking than dizygotic twin pairs in this population. A cohort analysis (accounting for age, sex, race, and smoking intensity) of lung cancer mortality found no lung cancer deaths during 300 person-years of follow-up (observed to expected ratio 0 [0-4.09]) among 47 monozygotic twin smokers whose smoking twins had died of lung cancer, even though smoking histories were very similar within twin pairs. In our study, there is little if any effect of inherited predisposition on development of lung cancer. Genetic factors are not likely to be strongly predictive of lung cancer risk in most male smokers older than 50, the age group in which the vast majority of cases occur.	NATL ACAD SCI, INST MED, MED FOLLOW UP AGCY, WASHINGTON, DC 20418 USA	National Academies of Sciences, Engineering & Medicine	BRAUN, MM (corresponding author), NCI, EPIDEMIOL & BIOSTAT PROGRAM, EPN 443, 6130 EXECUT BLVD, ROCKVILLE, MD 20852 USA.							[Anonymous], 1986, IARC MONOGRAPHS EVAL, V38; BORING CC, 1993, CA-CANCER J CLIN, V43, P7, DOI 10.3322/canjclin.43.1.7; BOYLE CA, 1990, AM J EPIDEMIOL, V131, P160, DOI 10.1093/oxfordjournals.aje.a115470; CAPORASO N, 1989, CANCER RES, V49, P3675; CARMELLI D, 1992, NEW ENGL J MED, V327, P829, DOI 10.1056/NEJM199209173271201; CARMELLI D, 1990, ACTA GENET MED GEMEL, V39, P91, DOI 10.1017/S0001566000005602; CEDERLOEF R, 1961, ACTA GENET STAT MED, V11, P338; DORN HF, 1959, PUBLIC HEALTH REP, V74, P581, DOI 10.2307/4590516; HALPERN MT, 1993, JNCI-J NATL CANCER I, V85, P457, DOI 10.1093/jnci/85.6.457; HARRIS CC, 1980, ANN INTERN MED, V92, P809, DOI 10.7326/0003-4819-92-6-809; HRUBEC Z, 1982, AM J HUM GENET, V34, P658; HRUBEC Z, 1977, TWIN RES, P153; JABLON S, 1967, AM J HUM GENET, V19, P133; KAHN HAROLD A., 1966, NAT CANCER INST MONOGR, V19, P1; KENDLER KS, 1983, AM J PSYCHIAT, V140, P1551; KRONTIRIS TG, 1993, NEW ENGL J MED, V329, P517, DOI 10.1056/NEJM199308193290801; MATTSON ME, 1987, AM J PUBLIC HEALTH, V77, P425, DOI 10.2105/AJPH.77.4.425; NAKACHI K, 1993, CANCER RES, V53, P2994; NICHOLS RC, 1966, ACTA GENET STAT MED, V16, P265; OOI WL, 1986, J NATL CANCER I, V76, P217; PERCY C, 1981, AM J PUBLIC HEALTH, V71, P242, DOI 10.2105/AJPH.71.3.242; PETO R, 1984, LUNG CANCER CAUSES P, P1; RIES LAG, 1991, NCI NIH912789 PUB; SAMET JM, 1986, AM REV RESPIR DIS, V134, P466; SELLERS TA, 1990, J NATL CANCER I, V82, P1272, DOI 10.1093/jnci/82.15.1272; SHAW GL, 1991, J CLIN EPIDEMIOL, V44, P429, DOI 10.1016/0895-4356(91)90082-K; SHIELDS PG, 1991, JAMA-J AM MED ASSOC, V266, P681, DOI 10.1001/jama.266.5.681; SUGIMURA H, 1990, CANCER RES, V50, P1857; TOKUHATA GEORGE K., 1963, JOUR NATL CANCER INST, V30, P289; VAHAKANGAS KH, 1992, LANCET, V339, P576, DOI 10.1016/0140-6736(92)90866-2	30	53	54	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 13	1994	344	8920					440	443		10.1016/S0140-6736(94)91770-1	http://dx.doi.org/10.1016/S0140-6736(94)91770-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB761	7914565				2022-12-24	WOS:A1994PB76100010
J	SCHUPF, N; KAPELL, D; LEE, JH; OTTMAN, R; MAYEUX, R				SCHUPF, N; KAPELL, D; LEE, JH; OTTMAN, R; MAYEUX, R			INCREASED RISK OF ALZHEIMERS-DISEASE IN MOTHERS OF ADULTS WITH DOWNS-SYNDROME	LANCET			English	Article							DEMENTIA; ASSOCIATION; AGE	Most adults with Down's syndrome (DS) develop neuropathology characteristic of Alzheimer's disease (AD) by the age of 40. Most of the non-dysjunction events in DS are of maternal origin. We postulated therefore that a shared genetic susceptibility to DS and AD would be associated with an increased frequency of AD among mothers, but not fathers, of individuals with DS. We further hypothesised that the shared susceptibility could involve an accelerated ageing process, leading to the birth of a child with DS to a relatively young mother and to an increased risk of dementia in the mother and her relatives. Families of 96 adults with DS and of 80 adults with other forms of mental retardation were ascertained through the New York State Developmental Disabilities services network. A semi-structured interview was used to obtain information on the presence or absence of non-stroke-related dementia and other disorders in parents. There was an increase in risk of dementia among mothers of DS probands compared with control mothers (risk ratio 2.6 [95% Cl 0.9-7.3]). The risk of dementia among mothers who were 35 or younger when their DS children were born was 5 times that of control mothers (4.9 [1.6-15.4]). There was no increase in risk of dementia among mothers who were older ( > 35 years) at the proband's birth (0.8 [0.2-3.4]). There was no difference in risk of dementia between fathers of DS cases and fathers of controls (1.2 [0.4-3.9]) and no discernible influence of age on this risk. Familial aggregation of dementia among mothers of adults with DS supports the hypothesis of a shared genetic susceptibility to DS and AD.	COLUMBIA UNIV, FAC MED, GERTRUDE H SERGIEVSKY CTR, NEW YORK, NY USA; COLUMBIA UNIV, SCH PUBL HLTH, DIV EPIDEMIOL, NEW YORK, NY USA; NEW YORK STATE PSYCHIAT INST & HOSP, EPIDEMIOL BRAIN DISORDERS RES DEPT, NEW YORK, NY USA; COLUMBIA UNIV, DEPT NEUROL, NEW YORK, NY USA; COLUMBIA UNIV, DEPT PSYCHIAT, NEW YORK, NY USA; COLUMBIA UNIV, DEPT PHYS & SURG, NEW YORK, NY USA	Columbia University; Columbia University; New York State Psychiatry Institute; Columbia University; Columbia University; Columbia University	SCHUPF, N (corresponding author), NEW YORK STATE INST BASIC RES DEV DISABIL, EPIDEMIOL LAB, 1050 FOREST HILL RD, STATEN ISL, NY 10314 USA.		Ottman, Ruth/O-2371-2013; Lee, Joseph H/D-2441-2012	Ottman, Ruth/0000-0001-7074-242X; Lee, Joseph H/0000-0002-2000-4821	NIA NIH HHS [AG10963, AG09400, AG08702] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R35AG010963, R01AG009400, P50AG008702] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AMADUCCI LA, 1986, NEUROLOGY, V36, P922, DOI 10.1212/WNL.36.7.922; BERR C, 1989, AM J MED GENET, V33, P545, DOI 10.1002/ajmg.1320330427; BROE GA, 1990, NEUROLOGY, V40, P1698, DOI 10.1212/WNL.40.11.1698; CHANDRA V, 1987, NEUROLOGY, V37, P1295, DOI 10.1212/WNL.37.8.1295; CUCKLE HS, 1987, BRIT J OBSTET GYNAEC, V94, P387, DOI 10.1111/j.1471-0528.1987.tb03115.x; FITCH N, 1988, ANN NEUROL, V23, P14, DOI 10.1002/ana.410230104; HASSOLD T, 1993, CURR OPIN GENET DEV, V3, P398, DOI 10.1016/0959-437X(93)90111-2; HASSOLD T, 1984, ANN HUM GENET, V48, P129, DOI 10.1111/j.1469-1809.1984.tb01008.x; HESTON LL, 1981, ARCH GEN PSYCHIAT, V38, P1085; HEYMAN A, 1984, ANN NEUROL, V15, P335, DOI 10.1002/ana.410150406; HOOK EB, 1982, DOWN SYNDROME ADV BI, P11; HUFF FJ, 1988, NEUROLOGY, V38, P786, DOI 10.1212/WNL.38.5.786; KLINE J, 1989, MONOGRAPHS EPIDEMIOL, V14, P102; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; LI G, 1989, ACTA PSYCHIAT SCAND, V79, P557, DOI 10.1111/j.1600-0447.1989.tb10303.x; LI G, 1992, NEUROLOGY, V42, P1481, DOI 10.1212/WNL.42.8.1481; Malamud N., 1972, NEUROPATHOLOGY ORGAN, P63; MARTIN RL, 1988, ARCH GEN PSYCHIAT, V45, P894; MENDEZ MF, 1992, NEUROLOGY, V42, P770, DOI 10.1212/WNL.42.4.770; STOLL C, 1990, AM J MED GENET, P79; SUSSER E, 1989, AM J EPIDEMIOL, V129, P23, DOI 10.1093/oxfordjournals.aje.a115119; THOMPSON JS, 1986, GENET MED, P119; VANDUIJN CM, 1991, INT J EPIDEMIOL, V20, pS13, DOI 10.1093/ije/20.Supplement_2.S13; WHALLEY LJ, 1982, BRIT J PSYCHIAT, V140, P249, DOI 10.1192/bjp.140.3.249; WISNIEWSKI KE, 1985, NEUROLOGY, V35, P957, DOI 10.1212/WNL.35.7.957; YATHAM LN, 1988, ACTA PSYCHIAT SCAND, V77, P38, DOI 10.1111/j.1600-0447.1988.tb05074.x	26	80	83	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 6	1994	344	8919					353	356		10.1016/S0140-6736(94)91398-6	http://dx.doi.org/10.1016/S0140-6736(94)91398-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PA303	7914304	hybrid			2022-12-24	WOS:A1994PA30300007
J	PIPPARD, MJ				PIPPARD, MJ			MEGALOBLASTIC-ANEMIA - GEOGRAPHY AND DIAGNOSIS	LANCET			English	Editorial Material							COBALAMIN DEFICIENCY; ANEMIA				PIPPARD, MJ (corresponding author), UNIV DUNDEE,NINEWELLS HOSP & MED SCH,DEPT HAEMATOL,DUNDEE DD1 9SY,SCOTLAND.							ALLEN RH, 1990, AM J HEMATOL, V34, P90, DOI 10.1002/ajh.2830340204; CARMEL R, 1978, NEW ENGL J MED, V298, P647, DOI 10.1056/NEJM197803232981203; CHANARIN I, 1985, LANCET, V2, P1168; Chanarin I, 1990, MEGALOBLASTIC ANAEMI; METZ J, 1968, BRIT J HAEMATOL, V14, P575, DOI 10.1111/j.1365-2141.1968.tb00364.x; SAVAGE D, 1994, BRIT J HAEMATOL, V86, P844, DOI 10.1111/j.1365-2141.1994.tb04840.x; STABLER SP, 1990, BLOOD, V76, P871	7	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 2	1994	344	8914					6	7		10.1016/S0140-6736(94)91043-X	http://dx.doi.org/10.1016/S0140-6736(94)91043-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU917	7912325				2022-12-24	WOS:A1994NU91700006
J	NEWELL, ML; DUNN, DT; PECKHAM, CS; ADES, AE; PARDI, G; SEMPRINI, AE; GIAQUINTO, C; TRUSCIA, D; DEROSSI, A; CHIECOBIANCHI, L; ZACHELLO, F; GROSCHWORNER, I; LANGHOF, M; MOK, J; JOHNSTONE, F; TERES, FO; BATES, I; GARCIARODRIQUEZ, MC; CANOSA, C; ASENSI, F; OTERO, MC; TAMARIT, AP; SCHERPBIER, H; MULDER, G; BOER, K; BOHLIN, AB; LINDGREN, S; FORSGREN, M; EHRNST, A; ANZEN, B; DEMARIA, A; FERRAZIN, A; GOTTA, C; LEVY, J; HOTTARD, A; PONCIN, M; SPRECHER, S; LEJEUNE, B; MUR, A; YAZBECK, H; LLORENZ, J; RAVIZZA, M; VUCETICH, A; ZUCOTTI, V; GUERRA, B; BIANCHI, S; DALLACASA, P; PRATI, E; TARANTINI, M; SCARAVELLI, G; STEGAGNO, M; QUINTI, I; DESANTIS, M; NOIA, G; MUGGIASCA, ML; MARCHISIO, P; IASCI, A; SPINILLO, A; MACCABRUNI, A; BIRAGHI, P; BUCCERI, A; GROSSI, E; FERRARIS, G; PLEBANI, A				NEWELL, ML; DUNN, DT; PECKHAM, CS; ADES, AE; PARDI, G; SEMPRINI, AE; GIAQUINTO, C; TRUSCIA, D; DEROSSI, A; CHIECOBIANCHI, L; ZACHELLO, F; GROSCHWORNER, I; LANGHOF, M; MOK, J; JOHNSTONE, F; TERES, FO; BATES, I; GARCIARODRIQUEZ, MC; CANOSA, C; ASENSI, F; OTERO, MC; TAMARIT, AP; SCHERPBIER, H; MULDER, G; BOER, K; BOHLIN, AB; LINDGREN, S; FORSGREN, M; EHRNST, A; ANZEN, B; DEMARIA, A; FERRAZIN, A; GOTTA, C; LEVY, J; HOTTARD, A; PONCIN, M; SPRECHER, S; LEJEUNE, B; MUR, A; YAZBECK, H; LLORENZ, J; RAVIZZA, M; VUCETICH, A; ZUCOTTI, V; GUERRA, B; BIANCHI, S; DALLACASA, P; PRATI, E; TARANTINI, M; SCARAVELLI, G; STEGAGNO, M; QUINTI, I; DESANTIS, M; NOIA, G; MUGGIASCA, ML; MARCHISIO, P; IASCI, A; SPINILLO, A; MACCABRUNI, A; BIRAGHI, P; BUCCERI, A; GROSSI, E; FERRARIS, G; PLEBANI, A			CESAREAN-SECTION AND RISK OF VERTICAL TRANSMISSION OF HIV-1 INFECTION	LANCET			English	Article							CESAREAN-SECTION; WOMEN; SECRETIONS	Indirect evidence suggests that a significant proportion of vertical transmission of HIV infection occurs late in pregnancy or during delivery. Caesarean section, therefore, may protect the fetus from infection. We looked at 1254 HIV-infected mothers and their children and the effects of different modes of delivery on transmission risk. We also included a detailed assessment of confounding factors associated with transmission risk. Women who had caesarean sections were more advanced in their disease progression which may cause the protective effect of caesarean section to be underestimated. When this and other potential confounding factors were taken into account, caesarean section was estimated to halve the rate of transmission. This finding is important in the design of studies to evaluate treatments aimed at reducing mother-to-child transmission.	UNIV PADUA,PADUA,ITALY; FREE UNIV BERLIN,KLINIKUM RUDOLF VIRCHOW,W-1000 BERLIN,GERMANY; CITY HOSP EDINBURGH,EDINBURGH,SCOTLAND; CTR REPROD BIOL,EDINBURGH,SCOTLAND; HOSP LA PAZ,MADRID,SPAIN; HOSP LA FE,E-46009 VALENCIA,SPAIN; ACAD MED CENTRUM,AMSTERDAM,NETHERLANDS; KAROLINSKA INST,HUDDINGE HOSP,S-10401 STOCKHOLM,SWEDEN; DANDERYD HOSP,STOCKHOLM,SWEDEN; CENT MICROBIOL LAB,STOCKHOLM,SWEDEN; IST GIANNINA GASLINI,I-16148 GENOA,ITALY; HOP ST PIERRE & ERASME,BRUSSELS,BELGIUM; HOSP DEL MAR,BARCELONA,SPAIN; OSPED SAN PAOLO,MILAN,ITALY; POLICLIN S ORSOLA,BOLOGNA,ITALY; UNIV BRESCIA,BRESCIA,ITALY; UNIV ROMA LA SAPIENZA,ROME,ITALY; UNIV CATTOLICA SACRO CUORE,ROME,ITALY; OSPED L SACCO,MILAN,ITALY; POLICLIN SAN MATTEO,I-27100 PAVIA,ITALY; CLIN MANGIAGALLI,MILAN,ITALY; CLIN DE MARCHI,MILAN,ITALY	University of Padua; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Hospital Universitario La Paz; Hospital Universitari i Politecnic La Fe; University of Amsterdam; Academic Medical Center Amsterdam; Karolinska Institutet; Danderyds Hospital; University of Genoa; IRCCS Istituto Giannina Gaslini; Universite Libre de Bruxelles; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; San Paolo-Polo Universitaria Hospital; IRCCS Azienda Ospedaliero-Universitaria di Bologna; University of Brescia; Sapienza University Rome; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; University of Milan; Luigi Sacco Hospital; IRCCS Fondazione San Matteo	NEWELL, ML (corresponding author), INST CHILD HLTH,DEPT EPIDEMIOL & BIOSTAT,30 GUILFORD ST,LONDON WC1N 1EH,ENGLAND.		Spinillo, Arsenio/AAB-9315-2022; Plebani, Alessandro/C-8593-2011; Newell, Marie-Louise/AAE-8222-2019; Giaquinto, Carlo/AAB-5016-2020; Grossi, Enzo/AAF-7765-2020; De Rossi, A./L-3128-2015; De Rossi, Anita/Q-4845-2019	Spinillo, Arsenio/0000-0002-7755-1084; Newell, Marie-Louise/0000-0002-1074-7699; De Rossi, A./0000-0001-6435-7509; De Rossi, Anita/0000-0001-6435-7509; Dunn, David/0000-0003-1836-4446; Alimenti, Ariane/0000-0003-4999-8230; GIAQUINTO, CARLO/0000-0001-9365-0413				[Anonymous], MMWR; BRYSON YJ, 1992, NEW ENGL J MED, V327, P1246, DOI 10.1056/NEJM199210223271718; Chiodo F, 1986, Lancet, V1, P739; CHOO V, 1994, LANCET, V343, P533, DOI 10.1016/S0140-6736(94)91477-X; CLEMETSON DBA, 1993, JAMA-J AM MED ASSOC, V269, P2860, DOI 10.1001/jama.269.22.2860; DANFORTH DN, 1985, JAMA-J AM MED ASSOC, V253, P811, DOI 10.1001/jama.253.6.811; DEMUYLDER X, 1993, HEALTH POLICY PLANN, V8, P101, DOI 10.1093/heapol/8.2.101; FUITH LC, 1992, LANCET, V339, P1603, DOI 10.1016/0140-6736(92)91863-4; GOEDERT JJ, 1991, LANCET, V338, P1471, DOI 10.1016/0140-6736(91)92297-F; HENIN Y, 1993, J ACQ IMMUN DEF SYND, V6, P72; KEIRSE MJN, 1989, EFFECTIVE CARE PREGN, V2, P1270; PECKHAM C, 1993, MEASURES DECREASE RI, P1; RUBIN DB, 1991, STATS MED, V110, P585; SACHS BP, 1983, JAMA-J AM MED ASSOC, V250, P2157, DOI 10.1001/jama.250.16.2157; SLADE MS, 1975, SURGERY, V78, P363; SMITH JR, 1991, BRIT J OBSTET GYNAEC, V98, P124, DOI 10.1111/j.1471-0528.1991.tb13356.x; TOVO PA, 1993, LANCET, V342, P630, DOI 10.1016/0140-6736(93)91753-9; VILLARI P, 1993, ONLINE J CURR CLIN T; 1991, LANCET, V337, P253; 1992, LANCET, V339, P1007; 1987, MMWR-MORBID MORTAL W, V36, P225	21	135	139	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 11	1994	343	8911					1464	1467						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NQ415	7911178				2022-12-24	WOS:A1994NQ41500009
J	JAAKKOLA, M; SILLANAUKEE, P; LOF, K; KOIVULA, T; NORDBACK, I				JAAKKOLA, M; SILLANAUKEE, P; LOF, K; KOIVULA, T; NORDBACK, I			BLOOD-TESTS FOR DETECTION OF ALCOHOLIC CAUSE OF ACUTE-PANCREATITIS	LANCET			English	Note							LIPASE AMYLASE RATIO; DRINKING; MARKER; SERUM; MEN	We investigated the ability of various blood markers to detect an alcoholic cause of acute pancreatitis. Serum carbohydrate-deficient transferrin (CDT) was significantly correlated with reported 2 month and 7 day ethanol consumptions and was significantly higher in 42 patients with alcoholic acute pancreatitis and in 24 patients with possibly alcoholic acute pancreatitis than in 20 patients with non-alcoholic disease. At a cutoff over 17 U/L, the specificity of CDT was 100% and the sensitivity was 75% to detect an alcoholic cause of acute pancreatitis. The lipase/amylase ratio index, erythrocyte mean corpuscular volume, and gamma glutamyl transferase could not distinguish alcoholic from non-alcoholic acute pancreatitis.	TAMPERE UNIV HOSP, DEPT SURG, SF-33250 TAMPERE, FINLAND; UNIV TAMPERE, DEPT CLIN MED, SF-33101 TAMPERE, FINLAND; TAMPERE UNIV HOSP, DEPT CLIN CHEM, TAMPERE, FINLAND; ALKO LTD, BIOMED RES CTR, TAMPERE, FINLAND	Tampere University; Tampere University Hospital; Tampere University; Tampere University; Tampere University Hospital								CHICK J, 1981, LANCET, V1, P1249; GUMASTE VV, 1991, GASTROENTEROLOGY, V101, P1361, DOI 10.1016/0016-5085(91)90089-4; MOORE RD, 1989, JAMA-J AM MED ASSOC, V261, P403, DOI 10.1001/jama.261.3.403; NORONHA M, 1981, AM J GASTROENTEROL, V76, P114; PEZZILLI R, 1993, DIGEST DIS SCI, V38, P1265, DOI 10.1007/BF01296077; SILLANAUKEE P, 1993, ALCOHOL CLIN EXP RES, V17, P230, DOI 10.1111/j.1530-0277.1993.tb00754.x; Sillanaukee P, 1992, SUOM LAAKARILEHTI, V31, P2919; STIBLER H, 1991, CLIN CHEM, V37, P2029; STIBLER H, 1991, ALCOHOL ALCOHOLISM, P451; Stibler H, 1980, Subst Alcohol Actions Misuse, V1, P247	10	42	43	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 28	1994	343	8909					1328	1329		10.1016/S0140-6736(94)92470-8	http://dx.doi.org/10.1016/S0140-6736(94)92470-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NN217	7910327				2022-12-24	WOS:A1994NN21700013
J	LUNDGREN, JD; PEDERSEN, C; CLUMECK, N; GATELL, JM; JOHNSON, AM; LEDERGERBER, B; VELLA, S; PHILLIPS, A; NIELSEN, JO; DEWIT, S; SOMMEREIJNS, B; NIELSEN, T; JENSEN, G; SKINHOJ, P; BENTSEN, K; GERSTOFT, J; MELBYE, M; RANKI, A; VALLE, SL; KATLAMA, C; BERLUREAU, P; DIETRICH, M; SCHWANDER, S; GOEBEL, FD; KOSMIDIS, J; STERGIOU, G; GOUZIA, T; PAPADOPOULOS, A; BANHEGYI, D; MULCAHY, F; YUST, I; BENISHAI, Z; BENTWICH, Z; SACKS, T; MAAYAN, S; CHIESI, A; ANCARANI, F; SCALISE, G; BERTAGGIA, A; FRANCAVILLA, E; CALONGHI, G; CARGNEL, A; ARLOTTI, M; CIAMMARUGHI, R; COLOMBA, A; DELALLA, F; FASSIO, P; FERLINI, A; FIACCADORI, F; PASETTI, G; GIANNELLI, F; GRILLONE, W; LAZZARIN, A; MONFORTE, AD; MIGNANI, E; NUNNARI, A; ORTONA, L; PANICHI, G; PAULUZZI, S; PIERSANTELLI, N; RANIERI, S; RICCIARDIELLO, P; ROSCIOLI, B; SORANZO, M; HEMMER, R; DANNER, S; ANTUNES, F; PROENCA, R; GONZALEZLAHOZ, J; MARTINEZBLANCO, L; CLOTET, B; BUIRA, E; MIRO, J; PEHRSON, P; LUTHY, R; OLSSON, C; GLAUSER, M; HIRSCHEL, B; HAWKES, S; BARTON, S; MORCINEK, J; PINCHING, A; COLEMAN, D				LUNDGREN, JD; PEDERSEN, C; CLUMECK, N; GATELL, JM; JOHNSON, AM; LEDERGERBER, B; VELLA, S; PHILLIPS, A; NIELSEN, JO; DEWIT, S; SOMMEREIJNS, B; NIELSEN, T; JENSEN, G; SKINHOJ, P; BENTSEN, K; GERSTOFT, J; MELBYE, M; RANKI, A; VALLE, SL; KATLAMA, C; BERLUREAU, P; DIETRICH, M; SCHWANDER, S; GOEBEL, FD; KOSMIDIS, J; STERGIOU, G; GOUZIA, T; PAPADOPOULOS, A; BANHEGYI, D; MULCAHY, F; YUST, I; BENISHAI, Z; BENTWICH, Z; SACKS, T; MAAYAN, S; CHIESI, A; ANCARANI, F; SCALISE, G; BERTAGGIA, A; FRANCAVILLA, E; CALONGHI, G; CARGNEL, A; ARLOTTI, M; CIAMMARUGHI, R; COLOMBA, A; DELALLA, F; FASSIO, P; FERLINI, A; FIACCADORI, F; PASETTI, G; GIANNELLI, F; GRILLONE, W; LAZZARIN, A; MONFORTE, AD; MIGNANI, E; NUNNARI, A; ORTONA, L; PANICHI, G; PAULUZZI, S; PIERSANTELLI, N; RANIERI, S; RICCIARDIELLO, P; ROSCIOLI, B; SORANZO, M; HEMMER, R; DANNER, S; ANTUNES, F; PROENCA, R; GONZALEZLAHOZ, J; MARTINEZBLANCO, L; CLOTET, B; BUIRA, E; MIRO, J; PEHRSON, P; LUTHY, R; OLSSON, C; GLAUSER, M; HIRSCHEL, B; HAWKES, S; BARTON, S; MORCINEK, J; PINCHING, A; COLEMAN, D			SURVIVAL DIFFERENCES IN EUROPEAN PATIENTS WITH AIDS, 1979-89	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; PNEUMOCYSTIS-CARINII PNEUMONIA; PLACEBO-CONTROLLED TRIAL; VIRUS INFECTION; TERM SURVIVAL; DOUBLE-BLIND; ZIDOVUDINE; EFFICACY; TRENDS; AZT	Objectives-To examine the pattern of survival and factors associated with the outcome of disease in patients with AIDS. Design-Inception cohort. Data collected retrospectively from patients' charts. Setting-52 clinical centres in 17 European countries. Subjects-6578 adults diagnosed with AIDS from 1 January 1979 to 31 December 1989. Main outcome measures-Survival after the time of diagnosis. Results-The median survival after diagnosis was 17 months, with an estimated survival at three years of 16% (95% confidence interval 15% to 17%). Patients diagnosed in southern Europe had a shorter survival, particularly immediately after the time of diagnosis, compared with patients diagnosed in central and northern Europe (survival at one year (95% confidence interval) 54% (52% to 56%) 66% (64% to 68%), 65% (63% to 66%), respectively. The three year survival, however, was similar for all regions. The regional differences in survival were less pronounced for patients diagnosed in 1989 compared with earlier years. Improved survival in recent years was observed for patients with a variety of manifestations used to define AIDS but was significant only for patients diagnosed with Pneumocystis carinii pneumonia. The three S ear survival, however, remains unchanged over time. Conclusions-Survival of AIDS patients seems to vary within Europe, being shorter in southern than central and northern Europe. The magnitude of these differences, however, has declined gradually over time. Short term survival has improved in recent years, but the long term prognosis has remained equally poor, reflecting the fact that the underlying infection with HIV and many of the complicating diseases remains essentially uncontrolled.	UNIV COPENHAGEN, HVIDOVRE HOSP, DK-2650 HVIDOVRE, DENMARK; FREE UNIV BRUSSELS, HOP ST PIERRE, BRUSSELS, BELGIUM; UCL, UNIV COLL & MIDDLESEX SCH MED, LONDON, ENGLAND; SWISS HIV COHORT STUDY, ZURICH, SWITZERLAND; IST SUPER SANITA, VIROL LAB, I-00161 ROME, ITALY; FREDERIKSBERG UNIV HOSP, COPENHAGEN, DENMARK; RIGSHOSP, DK-2100 COPENHAGEN, DENMARK; UNIV HELSINKI, CENT HOSP, HELSINKI, FINLAND; HOP LA PITIE SALPETRIERE, PARIS, FRANCE; BERNHARD NOCHT INST TROP MED, HAMBURG, GERMANY; MED POLIKLIN, MUNICH, GERMANY; LAIKO ATHENS GEN HOSP, ATHENS, GREECE; IKA HOSP 1, ATHENS, GREECE; POSTGRAD MED UNIV, H-1389 BUDAPEST, HUNGARY; ST JAMES HOSP, DUBLIN 8, IRELAND; ICHILOV HOSP, IL-64239 TEL AVIV, ISRAEL; RAMBAM MED CTR, HAIFA, ISRAEL; KAPLAN HOSP, IL-76100 REHOVOT, ISRAEL; HADASSAH UNIV HOSP, IL-91120 JERUSALEM, ISRAEL; UNIV ANCONA, ANCONA, ITALY; OSPED CIVILE, PADUA, ITALY; ARCISPEDALE SANTA MARIA NUOVA, REGIO EMILIA, ITALY; OSPED L SACCO, MILAN, ITALY; OSPED INFERMI RIMINI, RIMINI, ITALY; OSPED CASA DEL SOLE, PALERMO, ITALY; OSPED CIVILE, VICENZA, ITALY; OO RR BERGAMI, BERGAMO, ITALY; OSPED INFERMI FAENZA, FAENZA, ITALY; OSPED RIUNITI PARMA, PARMA, ITALY; OSPED NIGUARDA CA GRANDA, MILAN, ITALY; OSPED AMEDEO SAVOIA, TURIN, ITALY; OSPED L SACCO, MILAN, ITALY; OSPED SANTA ANDREA, LA SPEZIA, ITALY; UNIV CATANIA, CATANIA, ITALY; UNIV CATTOLICA SACRO CUORE, ROME, ITALY; UNIV SASSARI, I-07100 SASSARI, ITALY; POLICLIN MONTELUCE, PERUGIA, ITALY; OSPED GALLIERA, GENOA, ITALY; OSPED SANTA MARIA CROCI, RAVENNA, ITALY; OSPED MAGGIORE NOVARA, NOVARA, ITALY; OSPED SANTA MARIA MADDALENA, TRIESTE, ITALY; CTR HOSP, LUXEMBOURG, LUXEMBOURG; UNIV AMSTERDAM, ACAD ZIEKENHUIS, AMSTERDAM, NETHERLANDS; HOSP SANTA MARIA, LISBON, PORTUGAL; HOSP CURRY CABRAL, LISBON, PORTUGAL; INST SALUD CARLOS 3, MADRID, SPAIN; HOSP CLIN BARCELONA, BARCELONA, SPAIN; HOSP GERMANS TRIAS & PUJOL, BARCELONA, SPAIN; KAROLINSKA INST, STOCKHOLM, SWEDEN; CHU VAUDOIS, CH-1011 LAUSANNE, SWITZERLAND; UNIV GENEVA, HOP CANTONAL, CH-1211 GENEVA, SWITZERLAND; CHELSEA & WESTMINSTER HOSP, ST STEPHENS CLIN, LONDON, ENGLAND; ST MARYS HOSP, LONDON, ENGLAND	University of Copenhagen; Universite Libre de Bruxelles; Vrije Universiteit Brussel; University of London; University College London; Istituto Superiore di Sanita (ISS); Rigshospitalet; University of Copenhagen; University of Helsinki; Helsinki University Central Hospital; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Bernhard Nocht Institut fur Tropenmedizin; Laiko General Hospital; Trinity College Dublin; Tel Aviv University; Rambam Health Care Campus; Technion Israel Institute of Technology; Hebrew University of Jerusalem; Kaplan Medical Center; Hebrew University of Jerusalem; Marche Polytechnic University; IRCCS Arcispedale S. Maria Nuova; University of Milan; Luigi Sacco Hospital; Hospital of Rimini; IRCCS Ca Granda Ospedale Maggiore Policlinico; Ospedale Niguarda Ca' Granda; University of Milan; Luigi Sacco Hospital; University of Catania; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; University of Sassari; Ente Ospedaliero Ospedali Galliera; Luxembourg Hospital Center; University of Amsterdam; Universidade de Lisboa; Hospital Santa Maria; Instituto de Salud Carlos III; University of Barcelona; Hospital Clinic de Barcelona; Hospital Germans Trias i Pujol; Karolinska Institutet; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Geneva; Imperial College London; Imperial College London			VELLA, STEFANO/ABI-3368-2020; Lundgren, Jens/AAE-6876-2019; Stergiou, George/J-3083-2019; Phillips, Andrew N/B-4427-2008; Hawkes, Sarah/AAK-7375-2020; Ledergerber, Bruno/B-5656-2009; Vella, Stefano/GZM-0519-2022; VELLA, STEFANO/D-4912-2015	Stergiou, George/0000-0002-6132-0038; Phillips, Andrew N/0000-0003-2384-4807; Ledergerber, Bruno/0000-0002-6881-4401; Lundgren, Jens/0000-0001-8901-7850; VELLA, STEFANO/0000-0003-2347-5984; Johnson, Anne/0000-0003-1330-7100				ABOULKER JP, 1993, LANCET, V341, P889, DOI 10.1016/0140-6736(93)93096-J; BRENNER M, 1987, AM REV RESPIR DIS, V136, P1199, DOI 10.1164/ajrccm/136.5.1199; BUIRA E, 1992, J ACQ IMMUN DEF SYND, V5, P737; FISCHL MA, 1990, ANN INTERN MED, V112, P727, DOI 10.7326/0003-4819-112-10-727; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; FRIEDLAND GH, 1991, J ACQ IMMUN DEF SYND, V4, P144; HAMILTON JD, 1992, NEW ENGL J MED, V326, P437, DOI 10.1056/NEJM199202133260703; HARRIS J E, 1990, Journal of the American Medical Association, V263, P397, DOI 10.1001/jama.263.3.397; LEMP GF, 1992, J INFECT DIS, V166, P74, DOI 10.1093/infdis/166.1.74; LEMP GF, 1990, JAMA-J AM MED ASSOC, V263, P402, DOI 10.1001/jama.263.3.402; MOORE RD, 1991, NEW ENGL J MED, V324, P1412, DOI 10.1056/NEJM199105163242006; PEDERSEN C, 1990, AIDS, V4, P1111, DOI 10.1097/00002030-199011000-00009; PETERS BS, 1991, BRIT MED J, V302, P203, DOI 10.1136/bmj.302.6770.203; ROTHENBERG R, 1987, NEW ENGL J MED, V317, P1297, DOI 10.1056/NEJM198711193172101; VELLA S, 1992, JAMA-J AM MED ASSOC, V267, P1232, DOI 10.1001/jama.267.9.1232; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; 1989, MMWR S5, V38, P1; 1987, MMWR S, V36, P3; 1990, NEW ENGL J MED, V323, P1500	19	94	95	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 23	1994	308	6936					1068	1073		10.1136/bmj.308.6936.1068	http://dx.doi.org/10.1136/bmj.308.6936.1068			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NH489	7909698	Green Published			2022-12-24	WOS:A1994NH48900021
J	WEISSMANN, C				WEISSMANN, C			THE PRION CONNECTION - NOW IN YEAST	SCIENCE			English	Editorial Material							SCRAPIE; GENE; PROTEIN				WEISSMANN, C (corresponding author), UNIV ZURICH, INST MOLEC BIOL 1, CH-8093 ZURICH, SWITZERLAND.							AIGLE M, 1975, MOL GEN GENET, V136, P327, DOI 10.1007/BF00341717; ALPER T, 1967, NATURE, V214, P764, DOI 10.1038/214764a0; BASLER K, 1986, CELL, V46, P417, DOI 10.1016/0092-8674(86)90662-8; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; COSCHIGANO PW, 1991, MOL CELL BIOL, V11, P822, DOI 10.1128/MCB.11.2.822; GRIFFITH JS, 1967, NATURE, V215, P1043, DOI 10.1038/2151043a0; KELLINGS K, 1992, J GEN VIROL, V73, P1025, DOI 10.1099/0022-1317-73-4-1025; LACROUTE F, 1971, J BACTERIOL, V106, P519, DOI 10.1128/JB.106.2.519-522.1971; MCKINLEY MP, 1991, J VIROL, V65, P1340, DOI 10.1128/JVI.65.3.1340-1351.1991; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; PRUSINER SB, 1989, ANNU REV MICROBIOL, V43, P345, DOI 10.1146/annurev.mi.43.100189.002021; PRUSINER SB, 1993, PHILOS T R SOC B, V339, P239, DOI 10.1098/rstb.1993.0022; RAEBER AJ, 1992, J VIROL, V66, P6155, DOI 10.1128/JVI.66.10.6155-6163.1992	14	16	16	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 22	1994	264	5158					528	530		10.1126/science.7909168	http://dx.doi.org/10.1126/science.7909168			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NH010	7909168				2022-12-24	WOS:A1994NH01000024
J	ZAHN, R; SPITZFADEN, C; OTTIGER, M; WUTHRICH, K; PLUCKTHUN, A				ZAHN, R; SPITZFADEN, C; OTTIGER, M; WUTHRICH, K; PLUCKTHUN, A			DESTABILIZATION OF THE COMPLETE PROTEIN SECONDARY STRUCTURE ON BINDING TO THE CHAPERONE GROEL	NATURE			English	Article							MOLECULAR CHAPERONE; BETA-LACTAMASE; CYCLOPHILIN; RECONSTITUTION; COOPERATIVITY; AGGREGATION; POLYPEPTIDE; INVITRO; ATP; NMR	PROTEIN folding in vivo is mediated by helper proteins, the molecular chaperones(1-3), of which Hsp60 and its Escherichia coli variant GroEL are some of the best characterized. GroEL is an oligomeric protein with 14 subunits each of M(r) 60K(4-6), which possesses weak, co-operative ATPase activity(7-9) and high plasticity(10). GroEL seems to interact with non-native proteins, binding one or two molecules per 14-mer(11-19) in a 'central cavity'(20), but little is known about the conformational state of the bound polypeptides. Here we use nuclear magnetic resonance techniques to show that the interaction of the small protein cyclophilin(21,22) with GroEL is reversible by temperature changes, and all amide protons in GroEL-bound cyclophilin are exchanged with the solvent, although this exchange does not occur in free cyclophilin. The complete secondary structure of cyclophilin must be disrupted when bound to GroEL.	MAX PLANCK INST BIOCHEM,PROT ENGN GRP,D-82152 MARTINSRIED,GERMANY; ETH HONGGERBERG,INST MOLEK BIOL & BIOPHYS,CH-8093 ZURICH,SWITZERLAND	Max Planck Society; Swiss Federal Institutes of Technology Domain; ETH Zurich			Plückthun, Andreas/C-2746-2009	Plückthun, Andreas/0000-0003-4191-5306				BADCOE IG, 1991, BIOCHEMISTRY-US, V30, P9195, DOI 10.1021/bi00102a010; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P6796; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CHYAN CL, 1993, BIOCHEMISTRY-US, V32, P5681, DOI 10.1021/bi00072a025; ELLIS RJ, 1991, A REV BIOCH, V60, P621; FISCHER G, 1984, BIOMED BIOCHIM ACTA, V43, P1101; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HOHN T, 1979, J MOL BIOL, V129, P359, DOI 10.1016/0022-2836(79)90501-1; HOLLNEUGEBAUER B, 1991, BIOCHEMISTRY-US, V30, P11609; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; JAENICKE R, 1993, CURR OPIN STRUC BIOL, V3, P104, DOI 10.1016/0959-440X(93)90209-4; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAMINET AA, 1990, EMBO J, V9, P2315, DOI 10.1002/j.1460-2075.1990.tb07403.x; LANDRY SJ, 1991, BIOCHEMISTRY-US, V30, P7359, DOI 10.1021/bi00244a001; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; PACE CN, 1990, TRENDS BIOTECHNOL, V8, P93, DOI 10.1016/0167-7799(90)90146-O; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SPITZFADEN C, 1992, 15 INT C MAGN RES BI, P192; VIITANEN PV, 1991, BIOCHEMISTRY-US, V30, P9716, DOI 10.1021/bi00104a021; WEBER C, 1991, BIOCHEMISTRY-US, V30, P6563, DOI 10.1021/bi00240a029; WUTHRICH K, 1991, FEBS LETT, V285, P237, DOI 10.1016/0014-5793(91)80808-G; Wuthrich K., 1986, NMR PROTEINS NUCL AC; ZAHN R, 1993, J MOL BIOL, V229, P579, DOI 10.1006/jmbi.1993.1062; ZAHN R, 1992, BIOCHEMISTRY-US, V31, P3249, DOI 10.1021/bi00127a029	32	146	148	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 17	1994	368	6468					261	265		10.1038/368261a0	http://dx.doi.org/10.1038/368261a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NA870	7908413				2022-12-24	WOS:A1994NA87000061
J	BAUGHMAN, AL; WILLIAMS, WW; ATKINSON, WL; COOK, LG; COLLINS, M				BAUGHMAN, AL; WILLIAMS, WW; ATKINSON, WL; COOK, LG; COLLINS, M			THE IMPACT OF COLLEGE PREMATRICULATION IMMUNIZATION REQUIREMENTS ON RISK FOR MEASLES OUTBREAKS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES; ADULTS	Objective.-To assess whether prematriculation immunization requirements (PIRs) affect the number of measles cases on college campuses. Design.-We surveyed a stratified random sample of 880 colleges and universities to determine their immunization policies and practices and occurrence of measles outbreaks from 1988 through 1991. We merged national measles surveillance data with survey data by county to determine the risk for measles introduction on college campuses. We used logistic regression methods to estimate the effect of PIRs and assess risk factors for college measles outbreaks. Setting.-A total of 3205 US colleges and universities listed in standard guides. Results.-Of selected schools, 91 (11%) of the 796 responding schools reported one or more measles cases occurring from 1988 through 1991. Schools with a state-mandated PIR were significantly less likely to report measles outbreaks of two or more cases than other institutions (adjusted relative risk [RR]=0.30; 95% confidence interval [CI], 0.11 to 0.84). None of the 14 schools that reported outbreaks of 10 or more cases was subject to state regulation or had a PIR specifying two doses of measles vaccine in place. Of schools with introduction of measles, residential colleges were more likely to report extensive spread of measles (five or more cases) than nonresidential colleges (RR=35.8; 95% CI, 2.08 to 617.0). Of public schools, 4-year programs had a higher risk of a large outbreak (five or more cases) than 2-year programs. Conclusions.-These results strongly support current recommendations for requiring proof of vaccination of college students to decrease the risk for measles outbreaks on college campuses. State regulations mandating PIRs ensure the best protection against widespread measles transmission.	UNIV PENN,STUDENT HLTH SERV,PHILADELPHIA,PA 19104; AMER COLL HLTH ASSOC,BALTIMORE,MD	University of Pennsylvania	BAUGHMAN, AL (corresponding author), CTR DIS CONTROL & PREVENT,NATL IMMUNIZATION PROGRAM,1600 CLIFTON RD NE,MAILSTOP E-52,ATLANTA,GA 30333, USA.							ABBOTT RD, 1985, AM J EPIDEMIOL, V121, P465, DOI 10.1093/oxfordjournals.aje.a114019; ALLEN LJ, 1993, STAT MED, V12, P229, DOI 10.1002/sim.4780120307; BIRKHEAD GS, 1991, PUBLIC HEALTH REP, V106, P338; COLLINS M, 1987, Journal of American College Health, V35, P247; Cook L G, 1993, J Am Coll Health, V42, P91; DAVIS RM, 1987, AM J EPIDEMIOL, V126, P438, DOI 10.1093/oxfordjournals.aje.a114675; DAVIS SF, 1993, AM J PUBLIC HEALTH, V83, P1011, DOI 10.2105/AJPH.83.7.1011; DILTS SW, 1990, PETERSONS GUIDE 2 YE; Fleiss JL, 1981, STAT METHODS RATES P; GUSTAFSON TL, 1987, NEW ENGL J MED, V316, P771, DOI 10.1056/NEJM198703263161303; HERSH BS, 1991, AM J PUBLIC HEALTH, V81, P360, DOI 10.2105/AJPH.81.3.360; HERSH BS, 1992, JAMA-J AM MED ASSOC, V267, P1936, DOI 10.1001/jama.267.14.1936; Hosmer DW, 1989, APPL LOGISTIC REGRES, P238; NARAIN JP, 1985, AM J PUBLIC HEALTH, V75, P397, DOI 10.2105/AJPH.75.4.397; NKOWANE BM, 1987, AM J PUBLIC HLHT, V77, P424; ROBBINS KB, 1981, AM J PUBLIC HEALTH, V71, P270, DOI 10.2105/AJPH.71.3.270; SHAH BV, 1991, CROSSTAB PROCEDURE S; STRUEWING JP, 1993, AM J PUBLIC HEALTH, V83, P1717, DOI 10.2105/AJPH.83.12.1717; Williams W W, 1989, J Am Coll Health, V37, P197; WILLIAMS W W, 1987, Journal of American College Health, V35, P252; WILLIAMS WW, 1988, ANN INTERN MED, V108, P616, DOI 10.7326/0003-4819-108-4-616; 1983, J AM COLL HLTH, V32, P7; 1987, MMWR-MORBID MORTAL W, V36, P209; 1992, MODEL LEGISLATION AC; 1989, ACTION, V28, P5; 1979, MMWR MORBID MORTAL S, V27, P41; 1989, MMWR-MORBID MORTAL W, V38, P11; 1989, LOGISTIC PROCEDURE S, P1071; 1978, MMWR MORBID MORTAL S, V26, P23	29	42	42	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 12	1994	272	14					1127	1132		10.1001/jama.272.14.1127	http://dx.doi.org/10.1001/jama.272.14.1127			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PK124	7933326				2022-12-24	WOS:A1994PK12400033
J	COCKERELL, OC; JOHNSON, AL; SANDER, JWAS; HART, YM; GOODRIDGE, DMG; SHORVON, SD				COCKERELL, OC; JOHNSON, AL; SANDER, JWAS; HART, YM; GOODRIDGE, DMG; SHORVON, SD			MORTALITY FROM EPILEPSY - RESULTS FROM A PROSPECTIVE POPULATION-BASED STUDY	LANCET			English	Article							NATIONAL GENERAL-PRACTICE; ISCHEMIC HEART-DISEASE; COHORT; DRUGS	Patients with epilepsy may be subject to an increased risk of premature death from the underlying cause, or from the epilepsy intself. The extent and nature of this risk has been insufficiently investigated. Standard mortality ratios (SMRs) of patients with newly diagnosed epilepsy were determined in a prospective national population-based study. 1091 patients with newly diagnosed pr suspected epilepsy were ascertained who were attending one of 275 UK general practices from 1984-1987. 1091 patients were classified after 6 months as definite epilepsy (564), possible epilepsy (228), febrile seizures (220), or riot epilepsy (79). Over a median follow up of 6.9 years the SMR for patients with definite or possible epilepsy was 2.5 (95% Cl 2.1-2.9), and 3.0 (2.5-3.7) for definite epilepsy. The SMR was highest during the first year after diagnosis 5.1 (3.8-6.5), declined to 2.5 (1.5-3.9) at 3 years, and 1.3 (0.7-2.0) at 5 years. The commonest causes of death were pneumonia (SMR 7.2), cancer (3.5), and stroke (3.7). The SMR for patients with idiopathic epilepsy was 1.6 (1.0-2.4), remote symptomatic epilepsy 4.3 (3.3-5.5), and acute symptomatic epilepsy 2.9 (1.7-4.5). Mortality in patients with newly-diagnosed epilepsy was high, mainly due to the underlying cause. The SMR for idiopathic epilepsy was also raised, suggesting that epilepsy per se may carry a small risk of death.	INST NEUROL, LONDON, ENGLAND; CHALFONT CTR EPILEPSY, CHALFONT ST PETER SL9 0RJ, BUCKS, ENGLAND; INST PUBL HLTH, MRC, BIOSTAT UNIT, CAMBRIDGE, ENGLAND	University of London; University College London; MRC Biostatistics Unit; University of Cambridge	COCKERELL, OC (corresponding author), UCL NATL HOSP NEUROL & NEUROSURG, EPILEPSY RES GRP, LONDON, ENGLAND.		Sander, Josemir W/C-1576-2008; Shorvon, Simon D/A-2019-2009	Sander, Josemir W/0000-0001-6041-9661; Shorvon, Simon/0000-0003-0313-2001				ANNEGERS JF, 1984, EPILEPSIA, V25, P699, DOI 10.1111/j.1528-1157.1984.tb03480.x; ANNEGERS JF, 1976, EPILEPSIA, V17, P11, DOI 10.1111/j.1528-1157.1976.tb03376.x; BARRACLOUGH BM, 1987, ACTA PSYCHIAT SCAND, V76, P339, DOI 10.1111/j.1600-0447.1987.tb05616.x; BRADFORDHILL A, 1984, SHORT TXB MED STATIS, P259; COLEMAN MP, 1989, PERSON YEARS PYRS FU; Gowers WR., 1885, EPILEPSY OTHER CHRON; HART YM, 1989, NEUROEPIDEMIOLOGY, V8, P221; HART YM, 1990, LANCET, V336, P1271, DOI 10.1016/0140-6736(90)92960-P; HAUSER WA, 1980, EPILEPSIA, V21, P399, DOI 10.1111/j.1528-1157.1980.tb04088.x; JANCAR J, 1980, LANCET, V1, P484; JICK SS, 1992, PHARMACOEPIDEM DR S, V1, P59, DOI DOI 10.1002/PDS.2630010203; KLENERMAN P, 1993, J NEUROL NEUROSUR PS, V56, P149, DOI 10.1136/jnnp.56.2.149; Livingston Samuel, 1963, LIVING EPILEPTIC SEI; MASSEY E W, 1985, Neuroepidemiology, V4, P65; MOORE MT, 1959, JAMA-J AM MED ASSOC, V171, P1328, DOI 10.1001/jama.1959.03010280052013; Munson JF., 2010, MED REC, V77, P58; MUURONEN A, 1985, BRIT MED J, V291, P1481, DOI 10.1136/bmj.291.6507.1481; Rodin E, 1968, PROGNOSIS PATIENTS E, P156; SCHWADE ED, 1954, JAMA-J AM MED ASSOC, V156, P1526; WHITE SJ, 1979, LANCET, V2, P458; ZIELINSKI JJ, 1974, EPILEPSIA, V15, P191, DOI 10.1111/j.1528-1157.1974.tb04941.x	21	322	329	0	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	OCT 1	1994	344	8927					918	921		10.1016/S0140-6736(94)92270-5	http://dx.doi.org/10.1016/S0140-6736(94)92270-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PJ287	7934347				2022-12-24	WOS:A1994PJ28700011
J	DAVIS, MB; BATEMAN, D; QUINN, NP; MARSDEN, CD; HARDING, AE				DAVIS, MB; BATEMAN, D; QUINN, NP; MARSDEN, CD; HARDING, AE			MUTATION ANALYSIS IN PATIENTS WITH POSSIBLE BUT APPARENTLY SPORADIC HUNTINGTONS-DISEASE	LANCET			English	Article							TRINUCLEOTIDE REPEAT; MOLECULAR ANALYSIS; ONSET; LENGTH; AGE; INSTABILITY; EXPANSION; SIZE	Until the advent of mutation analysis it was impossible to make a certain diagnosis of Huntington's disease (HD) in the absence of a positive family history, and sporadic cases of possible HD presented a substantial diagnostic dilemma. We have looked for the characteristic expanded trinucleotide (CAG) repeat sequence in the HD gene in 44 patients with probable or possible HD who did not have similarly affected relatives. We used two methods, the traditional widely used method, which estimates both the CAG repeat and the flanking CCG repeat and gives the CAG length by subtraction, and the more precise CAG method, which estimates the repeat length directly. With the CAG method, the HD mutation was detected in 25 (89%) of 28 patients with the typical clinical features of HD and 5 (31%) of 16 in whom the diagnosis was more doubtful. The CAG-CCG method gave results in the borderline abnormal range of repeats for 13 of the 33 patients eventually shown to have an unequivocal repeat expansion by the CAG method. Most of these patients had late onset of symptoms. There was evidence of expansion of an intermediate-length paternal allele in 1 patient and of non-paternity in another. The identification of the mutation causing HD means that it is now possible to confirm or exclude the diagnosis with confidence, even in the absence of a family history, by analysis of DNA from a blood sample. The precise method of measuring the CAG repeat, which is technically more difficult than the traditional method, may be needed to clarify results in a substantial proportion of such patients.	UNIV LONDON,INST NEUROL,DEPT CLIN NEUROL,LONDON WC1N 3BG,ENGLAND	University of London; University College London								ANDREW SE, 1994, HUM MOL GENET, V3, P65, DOI 10.1093/hmg/3.1.65; ANDREW SE, 1993, NAT GENET, V4, P398, DOI 10.1038/ng0893-398; BARRON LH, 1993, J MED GENET, V30, P1003, DOI 10.1136/jmg.30.12.1003; BATEMAN D, 1992, ANN NEUROL, V31, P293, DOI 10.1002/ana.410310311; CRAUFURD D, 1993, J MED GENET, V30, P1008, DOI 10.1136/jmg.30.12.1008; DEROOIJ KE, 1993, J MED GENET, V30, P996, DOI 10.1136/jmg.30.12.996; DUYAO M, 1993, NAT GENET, V4, P387, DOI 10.1038/ng0893-387; GIBB WRG, 1989, NEUROLOGY, V39, P999, DOI 10.1212/WNL.39.7.999; GOLDBERG YP, 1993, HUM MOL GENET, V2, P635, DOI 10.1093/hmg/2.6.635; GOLDBERG YP, 1993, NAT GENET, V5, P174, DOI 10.1038/ng1093-174; KREMER B, 1993, J MED GENET, V30, P991, DOI 10.1136/jmg.30.12.991; MACMILLAN JC, 1993, LANCET, V342, P954, DOI 10.1016/0140-6736(93)92002-B; MYERS RH, 1993, NAT GENET, V5, P168, DOI 10.1038/ng1093-168; QUARRELL OWJ, 1986, CLIN GENET, V30, P433; RUBINSZTEIN DC, 1993, HUM MOL GENET, V2, P1713, DOI 10.1093/hmg/2.10.1713; SIMPSON SA, 1993, J MED GENET, V30, P1036, DOI 10.1136/jmg.30.12.1036; SNELL RG, 1993, NAT GENET, V4, P393, DOI 10.1038/ng0893-393; STINE OC, 1993, HUM MOL GENET, V2, P1547, DOI 10.1093/hmg/2.10.1547; WARNER JP, 1993, MOL CELL PROBE, V7, P235, DOI 10.1006/mcpr.1993.1034; 1993, CELL, V72, P971	20	45	47	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 10	1994	344	8924					714	717		10.1016/S0140-6736(94)92208-X	http://dx.doi.org/10.1016/S0140-6736(94)92208-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PF187	7915776				2022-12-24	WOS:A1994PF18700010
J	JAMES, I				JAMES, I			WHEN THE MUSIC HAS TO STOP	LANCET			English	Editorial Material							MEDICAL PROBLEMS				JAMES, I (corresponding author), UNIV LONDON ROYAL FREE HOSP,DEPT MED,LONDON NW3 2QG,ENGLAND.							FISHBEIN M, 1988, MED PROBL PERFORM AR, V3, P1; Fry H. J. H., 1986, MED PROBL PERFORM AR, V1, P1; JAMES IM, 1992, BRIT J RHEUMATOL, V31, P795; LAMBERT CM, 1992, BRIT J RHEUMATOL, V31, P265; LOCKWOOD AH, 1989, NEW ENGL J MED, V320, P221, DOI 10.1056/NEJM198901263200405; MOULTON B, 1992, BEHAV RES THER, V30, P375, DOI 10.1016/0005-7967(92)90049-M; PALIN SL, 1994, OCCUP MED-OXFORD, V44, P130, DOI 10.1093/occmed/44.3.130; SPEAKS C, 1970, JOM-J OCCUP MED, V12, P216, DOI 10.1097/00043764-197006000-00004	8	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 3	1994	344	8923					631	632		10.1016/S0140-6736(94)92080-X	http://dx.doi.org/10.1016/S0140-6736(94)92080-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PE386	7915345				2022-12-24	WOS:A1994PE38600005
J	CHARITE, J; DEGRAAFF, W; SHEN, SB; DESCHAMPS, J				CHARITE, J; DEGRAAFF, W; SHEN, SB; DESCHAMPS, J			ECTOPIC EXPRESSION OF HOXB-8 CAUSES DUPLICATION OF THE ZPA IN THE FORELIMB AND HOMEOTIC TRANSFORMATION OF AXIAL STRUCTURES	CELL			English	Article							HOX-2.4 HOMEOBOX GENE; CHICK WING BUD; LIMB-BUD; TARGETED DISRUPTION; TRANSGENIC MICE; RETINOIC ACID; DEVELOPMENTAL DEFECTS; ANTEROPOSTERIOR AXIS; POLARIZING ACTIVITY; MYELOID-LEUKEMIA	Transgenic embryos were generated carrying a Hoxb-8 transgene under control of the mouse RAR beta 2 promoter, which extends the normal expression domain to more anterior regions of the embryo. These embryos showed mirror-image duplications in the forelimb, analogous to the duplications observed in chick in response to transplantation of a ZPA to the anterior margin of the limb bud. Examination of Sonic hedgehog, Fgf-4, and Hoxd-11 gene expression confirmed that a second ZPA had been generated at the anterior side of the limb bud. Besides other alterations, posterior homeotic transformations of axial structures were observed, involving the first spinal (Froriep's) ganglion and several cervical vertebrae.			CHARITE, J (corresponding author), NETHERLANDS INST DEV BIOL,HUBRECHT LAB,UPPSALALAAN 8,3584 CT UTRECHT,NETHERLANDS.		Shen, Sanbing/E-3750-2015	Shen, Sanbing/0000-0002-8217-9811				ABERDAM D, 1991, MOL CELL BIOL, V11, P554, DOI 10.1128/MCB.11.1.554; BALLING R, 1989, CELL, V58, P337, DOI 10.1016/0092-8674(89)90848-9; BONNEROT C, 1987, P NATL ACAD SCI USA, V84, P6795, DOI 10.1073/pnas.84.19.6795; CHEVALLIER A, 1977, J EMBRYOL EXP MORPH, V42, P275; CHISAKA O, 1992, NATURE, V355, P516, DOI 10.1038/355516a0; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; CONDIE BG, 1993, DEVELOPMENT, V119, P579; COPP AJ, 1990, PROG NEUROBIOL, V35, P363, DOI 10.1016/0301-0082(90)90037-H; DESCHAMPS J, 1993, DEV BIOL, V156, P473, DOI 10.1006/dbio.1993.1093; DESCHAMPS J, 1992, Critical Reviews in Oncogenesis, V3, P117; DOLLE P, 1993, CELL, V75, P431, DOI 10.1016/0092-8674(93)90378-4; Hamburger V, 1938, J EXP ZOOL, V77, P379, DOI 10.1002/jez.1400770304; Harrison RG, 1918, J EXP ZOOL, V25, P413, DOI 10.1002/jez.1400250204; HINCHCLIFFE JR, 1983, DEV EVOLUTION; HONIG LS, 1985, J EMBRYOL EXP MORPH, V87, P163; HORNBRUCH A, 1991, DEVELOPMENT, V111, P725; HUNT P, 1991, NATURE, V353, P861, DOI 10.1038/353861a0; IZPISUABELMONTE JC, 1991, EMBO J, V10, P2279, DOI 10.1002/j.1460-2075.1991.tb07764.x; IZPISUABELMONTE JC, 1991, NATURE, V350, P585, DOI 10.1038/350585a0; JEANNOTTE L, 1993, GENE DEV, V7, P2085, DOI 10.1101/gad.7.11.2085; JEGALIAN BG, 1992, CELL, V71, P901, DOI 10.1016/0092-8674(92)90387-R; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; KIMMEL CA, 1981, STAIN TECHNOL, V56, P271, DOI 10.3109/10520298109067325; KONGSUWAN K, 1989, NUCLEIC ACIDS RES, V17, P1881, DOI 10.1093/nar/17.5.1881; KRESS C, 1990, DEVELOPMENT, V109, P775; LEMOUELLIC H, 1992, CELL, V69, P251, DOI 10.1016/0092-8674(92)90406-3; LIM TM, 1987, DEVELOPMENT, V100, P525; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; LUFKIN T, 1992, NATURE, V359, P835, DOI 10.1038/359835a0; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MORGAN BA, 1992, NATURE, V358, P236, DOI 10.1038/358236a0; NISWANDER L, 1993, CELL, V75, P579, DOI 10.1016/0092-8674(93)90391-3; NISWANDER L, 1992, DEVELOPMENT, V114, P755; OLIVER G, 1990, EMBO J, V9, P3093, DOI 10.1002/j.1460-2075.1990.tb07506.x; PERKINS A, 1990, P NATL ACAD SCI USA, V87, P8398, DOI 10.1073/pnas.87.21.8398; PERKINS AC, 1993, EMBO J, V12, P3835, DOI 10.1002/j.1460-2075.1993.tb06062.x; POLLOCK RA, 1992, CELL, V71, P911, DOI 10.1016/0092-8674(92)90388-S; RAMIREZSOLIS R, 1993, CELL, V73, P279, DOI 10.1016/0092-8674(93)90229-J; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; RUGH R, 1990, MOUSE ITS REPRODUCTI; Saunders J. W., 1968, EPITHELIAL MESENCHYM, P78; SAUNDERS JW, 1948, J EXP ZOOL, V108, P363, DOI 10.1002/jez.1401080304; SAUNDERS JW, 1977, VERTEBRATE LIMB SOMI, P1; SCHUGHART K, 1989, P NATL ACAD SCI USA, V86, P7067, DOI 10.1073/pnas.86.18.7067; Shen S, 1991, DNA Seq, V2, P111, DOI 10.3109/10425179109039679; SMITH JC, 1981, J EMBRYOL EXP MORPH, V63, P127; SMITH JC, 1980, J EMBRYOL EXP MORPH, V60, P321; SUMMERBELL D, 1981, J EMBRYOL EXP MORPH, V63, P161; TICKLE C, 1981, NATURE, V289, P295, DOI 10.1038/289295a0; TICKLE C, 1975, NATURE, V254, P199, DOI 10.1038/254199a0; VOGEL A, 1993, DEVELOPMENT, V119, P199; VOGELS R, 1993, DEVELOPMENT, V118, P71; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; ZELENT A, 1991, EMBO J, V10, P71, DOI 10.1002/j.1460-2075.1991.tb07922.x; ZWILLING E, 1956, J EXP ZOOL, V132, P157, DOI 10.1002/jez.1401320110	55	219	226	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 26	1994	78	4					589	601		10.1016/0092-8674(94)90524-X	http://dx.doi.org/10.1016/0092-8674(94)90524-X			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PD693	7915198				2022-12-24	WOS:A1994PD69300008
J	FONTES, P; RAO, AS; DEMETRIS, AJ; ZEEVI, A; TRUCCO, M; CARROLL, P; RYBKA, W; RUDERT, WA; RICORDI, C; DODSON, F; SHAPIRO, R; TZAKIS, A; TODO, S; ABUELMAGD, K; JORDAN, M; FUNG, JJ; STARZL, TE				FONTES, P; RAO, AS; DEMETRIS, AJ; ZEEVI, A; TRUCCO, M; CARROLL, P; RYBKA, W; RUDERT, WA; RICORDI, C; DODSON, F; SHAPIRO, R; TZAKIS, A; TODO, S; ABUELMAGD, K; JORDAN, M; FUNG, JJ; STARZL, TE			BONE-MARROW AUGMENTATION OF DONOR-CELL CHIMERISM IN KIDNEY, LIVER, HEART, AND PANCREAS ISLET TRANSPLANTATION	LANCET			English	Article							TOTAL LYMPHOID IRRADIATION; ORGAN-TRANSPLANTATION; GRAFT ACCEPTANCE; RENAL-ALLOGRAFT; RECIPIENTS; MIGRATION	We have previously postulated that donor cell chimerism in organ transplantation is needed to attain a tolerant state. Here we show that donor cell chimerism can be augmented in organ recipients if they are infused perioperatively with 3 x 10(8) per kg of unmodified donor bone marrow cells and are kept on a conventional immunosuppressive regimen of tacrolimus (FK506) and prednisolone. 36 patients took part, of whom the first 18 patients have good transplanted kidney (n=10), liver (n=7), and heart (n=7) function when followed up between 4 and 16 months. All patients are well. We found persistent multilineage leucocyte chimerism in blood of 17 recipients by flow cytometry and PCR techniques to detect donor alleles or Y chromosomes in female recipients of male organs. The use of the 5-antigen HLA matched same sex donor precluded detection of chimerism in one patient.	UNIV PITTSBURGH, MED CTR, PITTSBURGH TRANSPLANT INST, DEPT SURG, PITTSBURGH, PA 15213 USA; UNIV PITTSBURGH, DEPT PATHOL, PITTSBURGH, PA 15260 USA; UNIV PITTSBURGH, DEPT PAEDIAT, PITTSBURGH, PA 15260 USA; UNIV PITTSBURGH, DEPT MED, PITTSBURGH, PA 15260 USA; DIABET RES INST, MIAMI, FL USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh			RICORDI, CAMILLO/AAA-4740-2019; FUNG, John Julian/A-2679-2012; Rao, Abdul Sohail/E-1453-2011	FUNG, John Julian/0000-0002-3038-0441; Ricordi, Camillo/0000-0001-8092-7153	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK029961, R37DK029961] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK029961-19, DK 29961] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARBER WH, 1991, TRANSPLANTATION, V51, P70, DOI 10.1097/00007890-199101000-00011; BILLINGHAM RE, 1953, NATURE, V172, P603, DOI 10.1038/172603a0; KAHN DR, 1984, ANN THORAC SURG, V38, P169, DOI 10.1016/S0003-4975(10)62227-8; KOCOVA M, 1993, LANCET, V342, P140, DOI 10.1016/0140-6736(93)91345-M; MONACO AP, 1976, SURGERY, V79, P384; MYBURGH JA, 1989, TRANSPLANT P, V21, P826; NAJARIAN JS, 1982, ANN SURG, V196, P442, DOI 10.1097/00000658-198210000-00007; RICORDI C, 1988, DIABETES, V37, P413, DOI 10.2337/diabetes.37.4.413; ROLLES K, 1994, LANCET, V343, P263, DOI 10.1016/S0140-6736(94)91113-4; SALVATIERRA O, 1985, TRANSPLANTATION, V40, P654, DOI 10.1097/00007890-198512000-00016; STARZL TE, 1989, LANCET, V2, P1000; STARZL TE, 1963, SURG GYNECOL OBSTET, V117, P385; STARZL TE, 1993, HEPATOLOGY, V17, P1127; STARZL TE, 1993, TRANSPLANTATION, V55, P1272, DOI 10.1097/00007890-199306000-00012; STARZL TE, 1992, LANCET, V339, P1579, DOI 10.1016/0140-6736(92)91840-5; STARZL TE, 1993, IMMUNOL TODAY, V14, P326, DOI 10.1016/0167-5699(93)90054-O; STARZL TE, 1992, LANCET, V340, P876, DOI 10.1016/0140-6736(92)93286-V; STARZL TE, 1991, TRANSPLANT P, V23, P914; STARZL TE, IN PRESS TRANSPLANT	19	282	285	0	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 16	1994	344	8916					151	155		10.1016/S0140-6736(94)92756-1	http://dx.doi.org/10.1016/S0140-6736(94)92756-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW810	7912764	Green Accepted			2022-12-24	WOS:A1994NW81000008
J	KOIZUMI, A; AOKI, T; TSUKADA, M; NARUSE, M; SAITOH, N				KOIZUMI, A; AOKI, T; TSUKADA, M; NARUSE, M; SAITOH, N			MERCURY, NOT SULFUR-DIOXIDE, POISONING AS CAUSE OF SMELTER DISEASE IN INDUSTRIAL-PLANTS PRODUCING SULFURIC-ACID	LANCET			English	Article								Several episodes of ''smelter disease'', previously assumed to be caused by sulphur dioxide (SO2) poisoning, have been reported in workers replacing pipes in sulphuric acid manufacturing plants. One such incident, affecting 20 men, was recorded in Akita, Japan, in July, 1993, but the protection these workers used suggested that some cause other than SO2 needed to be looked for. 10 workers were affected despite wearing respirators with SO2 cartridges, the symptoms including dyspnoea, diarrhoea, colicky pain, muscle pain and eczema with erythema. Subsequently 10 other workers using face masks with supplied air were affected, though without respiratory symptoms. Sludge in the piping contained mercuric sulphate, and mercury fumes resulted when pipes were cut with gas burners. Blood and urine measurements confirmed heavy exposure to the metal, and simulation experiments in rats showed that skin absorption was likely too. The masks with supplied air ought to have excluded both SO2 and mercury fumes. The only way to avoid smelter disease reliably is to wear an encapsulated suit that prevents inhalation and skin absorption of industrial toxins.	SAKATA CITY HOSP,DEPT DERMATOL,MORIOKA,IWATE,JAPAN; IWATE PREFECTURAL LAB ENVIRONM SCI,MORIOKA,IWATE,JAPAN		KOIZUMI, A (corresponding author), AKITA UNIV,SCH MED,DEPT HYG,AKITA 010,JAPAN.							ELBERGER SY, 1993, HDB MED TOXICOLOGY, P285; HARA I, 1975, OSAKA FU KOEIKENKENK, V13, P31; SEATON A, 1978, BRIT J IND MED, V35, P258; WINDHOLZ M, 1983, MERCK INDEX, P841	4	10	10	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 4	1994	343	8910					1411	1412		10.1016/S0140-6736(94)92530-5	http://dx.doi.org/10.1016/S0140-6736(94)92530-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NP955	7910889				2022-12-24	WOS:A1994NP95500016
J	SACK, DA; HOQUE, ATMS; HUQ, A; ETHERIDGE, M				SACK, DA; HOQUE, ATMS; HUQ, A; ETHERIDGE, M			IS PROTECTION AGAINST SHIGELLOSIS INDUCED BY NATURAL INFECTION WITH PLESIOMONAS-SHIGELLOIDES	LANCET			English	Article							PEACE-CORPS VOLUNTEERS; DIARRHEAL DISEASE; ESCHERICHIA-COLI; UNITED-STATES; IMMUNIZATION; TEMPERATURE; ANTIBODIES; TRAVELERS; AEROMONAS; CHILDREN	Shigellosis due to Shigella sonnei is rare among people growing up and living in developing countries; however, infections due to S sonnei becomes more common than those due to S flexneri as societies develop economically. The relation between risk of S sonnei infection and economic development may be explained by the exposure of developing-country populations to Plesiomonas shigelloides. P shigelloides is often found in surface water, and one serotype (serotype 17) possesses a cell-wall lipopolysaccharide identical to that of S sonnei. Thus, exposure to P shigelloides by drinking contaminated water may immunise populations to S sonnei. As economic development occurs, water quality improves and populations become susceptible to S sonnei. Although drinking pure water has many advantages, immunisation against S sonnei may be one benefit of traditional water sources.	JOHNS HOPKINS UNIV,DEPT COMPARAT MED,BALTIMORE,MD 21205; UNIV MARYLAND,DEPT MICROBIOL,COLL PK,MD 20742	Johns Hopkins University; University System of Maryland; University of Maryland College Park	SACK, DA (corresponding author), JOHNS HOPKINS UNIV,DEPT INT HLTH,615 N WOLFE ST,BALTIMORE,MD 21205, USA.				NCRR NIH HHS [RR00130] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P40RR000130] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AHMED F, 1992, PEDIATRICS, V90, P406; AHMED ZU, 1990, VACCINE, V8, P153, DOI 10.1016/0264-410X(90)90139-D; AKMAN M, 1965, TURKISH J PEDIATR, V7, P155; ALDOVA E, 1987, ZBL BAKT-INT J MED M, V265, P253; ALDOVA E, 1987, J HYG EPIDEMIOL IMMU, V31, P76; ARAI T, 1980, J HYG-CAMBRIDGE, V84, P203, DOI 10.1017/S002217240002670X; BRENDEN RA, 1988, REV INFECT DIS, V10, P303; CHOWDHURY K A, 1988, Journal of Diarrhoeal Diseases Research, V6, P221; CLEMENS JD, 1988, J INFECT DIS, V158, P372, DOI 10.1093/infdis/158.2.372; COHEN D, 1991, INT J EPIDEMIOL, V20, P546, DOI 10.1093/ije/20.2.546; Ekwall E, 1988, SERODIAGN IMMUNOTHER, V2, P47; FERGUSON WW, 1947, J BACTERIOL, V54, P179, DOI 10.1128/JB.54.2.179-181.1947; FERRECCIO C, 1991, AM J EPIDEMIOL, V134, P614, DOI 10.1093/oxfordjournals.aje.a116134; GAINES S, 1968, MIL MED, V133, P114, DOI 10.1093/milmed/133.2.114; GOMES TAT, 1991, J INFECT DIS, V164, P331, DOI 10.1093/infdis/164.2.331; GORDON JE, 1964, B WORLD HEALTH ORGAN, V31, P1; HERRINGTON DA, 1990, VACCINE, V8, P353, DOI 10.1016/0264-410X(90)90094-3; HERRINGTON DA, 1987, INFECT IMMUN, V55, P979, DOI 10.1128/IAI.55.4.979-985.1987; HOLMBERG SD, 1986, ANN INTERN MED, V105, P690, DOI [10.7326/0003-4819-105-5-690, 10.7326/0003-4819-105-5-683]; HOLMBERG SD, 1984, REV INFECT DIS, V6, P633; HOUNG HSH, 1992, J BACTERIOL, V174, P5910, DOI 10.1128/jb.174.18.5910-5915.1992; HUQ A, 1991, CAN J MICROBIOL, V37, P800, DOI 10.1139/m91-138; JOSEPH S W, 1988, Journal of Diarrhoeal Diseases Research, V6, P80; KAGALWALLA AF, 1992, PEDIATR INFECT DIS J, V11, P215, DOI 10.1097/00006454-199203000-00009; KAIN KC, 1989, J CLIN MICROBIOL, V27, P998, DOI 10.1128/JCM.27.5.998-1001.1989; KHAN MU, 1985, INT J EPIDEMIOL, V14, P607, DOI 10.1093/ije/14.4.607; KHARDORI N, 1988, ANNU REV MICROBIOL, V42, P395, DOI 10.1146/annurev.mi.42.100188.002143; KWAGA JKP, 1988, MICROBIOLOGICA, V11, P165; LEE LA, 1991, J INFECT DIS, V164, P894, DOI 10.1093/infdis/164.5.894; LOPEZBREA M, 1983, T ROY SOC TROP MED H, V77, P140, DOI 10.1016/0035-9203(83)90047-0; Matsushita S, 1991, Kansenshogaku Zasshi, V65, P857; RUTALA WA, 1982, LANCET, V1, P739; SACK D A, 1988, Journal of Diarrhoeal Diseases Research, V6, P107; SACK DA, 1977, JOHNS HOPKINS MED J, V141, P63; SACK DA, 1978, NEW ENGL J MED, V298, P758, DOI 10.1056/NEJM197804062981402; SAYEED S, 1989, Bangladesh Journal of Microbiology, V6, P7; SAYEED S, 1992, J MED MICROBIOL, V37, P382, DOI 10.1099/00222615-37-6-382; TSUKAMOTO T, 1978, J HYG-CAMBRIDGE, V80, P275, DOI 10.1017/S0022172400053638; VANDEVERG LL, 1992, J INFECT DIS, V166, P158, DOI 10.1093/infdis/166.1.158	39	24	24	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 4	1994	343	8910					1413	1415		10.1016/S0140-6736(94)92531-3	http://dx.doi.org/10.1016/S0140-6736(94)92531-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NP955	7910890	hybrid			2022-12-24	WOS:A1994NP95500017
J	LILLEYMAN, JS; LENNARD, L				LILLEYMAN, JS; LENNARD, L			MERCAPTOPURINE METABOLISM AND RISK OF RELAPSE IN CHILDHOOD LYMPHOBLASTIC-LEUKEMIA	LANCET			English	Article							ACUTE LYMPHOCYTIC-LEUKEMIA; MAINTENANCE CHEMOTHERAPY; 6-MERCAPTOPURINE; CHILDREN	Many months' treatment with daily oral mercaptopurine is an important part of therapy for nearly all children with lymphoblastic leukaemia (ALL). Even when prescribed the same dose based on body surface area, patients have widely different intracellular concentrations of drug metabolites. Whether this variation matters in terms of disease control is not yet clear. To find out, we followed up a large group of children with ALL in whom mercaptopurine-derived thioguanine nucleotides in the red cells were measured during treatment with an identical dose of mercaptopurine early in first remission. 172 unselected children (100 boys, 72 girls) were recruited between 1980 and 1992. At median follow-up of 5 years from diagnosis 42 (24%) had relapsed; 30 had erythrocyte thioguanine nucleotide concentrations below the group median (284 pmol per 8 x 10(8) erythrocytes) and 12 had values above the median. The actuarial relapse-free survival at 5 years was 63% in the below-median group and 84% in the above-median group (difference 21% [95% Cl 3-39%], p = 0.0018). Multivariate analysis showed that erythrocyte thioguanine nucleotide concentration was independent of other prognostic variables including age, leukaemia immunophenotype, white-blood-cell count at diagnosis, trial protocol, and sex. Whatever the cause, in childhood ALL variable formation of intracellular mercaptopurine metabolites seems to be clinically important. Therapeutic schedules that include long-term daily oral mercaptopurine might be more effective if such metabolites are monitored.	UNIV SHEFFIELD,CHILDRENS HOSP,DEPT PAEDIAT,PAEDIAT HAEMATOL SECT,SHEFFIELD,S YORKSHIRE,ENGLAND; UNIV SHEFFIELD,ROYAL HALLAMSHIRE HOSP,DEPT MED & PHARMACOL,PHARMACOL & THERAPEUT SECT,SHEFFIELD,S YORKSHIRE,ENGLAND	Sheffield Children's NHS Foundation Trust; Sheffield Children's Hospital; University of Sheffield; University of Sheffield			Lennard, Lynne/E-1131-2011					ADAMSON PC, 1990, NEW ENGL J MED, V323, P1565; BOSTROM B, 1993, AM J PEDIAT HEMATOL, V15, P80; BURCHENAL JH, 1953, BLOOD, V8, P965, DOI 10.1182/blood.V8.11.965.965; CHESSELLS JM, 1992, LEUKEMIA, V6, P157; DAVIES HA, 1993, BRIT MED J, V306, P1239, DOI 10.1136/bmj.306.6887.1239; EDEN OB, 1991, BRIT J HAEMATOL, V78, P187, DOI 10.1111/j.1365-2141.1991.tb04415.x; GALE RP, 1991, LANCET, V338, P1315, DOI 10.1016/0140-6736(91)92604-Z; GUERCIOLINI R, 1991, CLIN PHARMACOL THER, V50, P663, DOI 10.1038/clpt.1991.205; HALE JP, 1991, ARCH DIS CHILD, V66, P462, DOI 10.1136/adc.66.4.462; HAYDER S, 1989, THER DRUG MONIT, V11, P617, DOI 10.1097/00007691-198911000-00001; KOREN G, 1990, NEW ENGL J MED, V323, P17, DOI 10.1056/NEJM199007053230104; LENNARD L, 1992, J CHROMATOGR-BIOMED, V583, P83, DOI 10.1016/0378-4347(92)80347-S; LENNARD L, 1990, LANCET, V336, P225, DOI 10.1016/0140-6736(90)91745-V; LENNARD L, 1993, BRIT J CLIN PHARMACO, V36, P277, DOI 10.1111/j.1365-2125.1993.tb00365.x; LENNARD L, 1987, LANCET, V2, P785; LENNARD L, 1989, J CLIN ONCOL, V7, P1816, DOI 10.1200/JCO.1989.7.12.1816; LILLEYMAN JS, 1984, BRIT J CANCER, V49, P703, DOI 10.1038/bjc.1984.111; PINKEL D, 1993, J CLIN ONCOL, V11, P1826, DOI 10.1200/JCO.1993.11.9.1826; WEINSHILBOUM RM, 1980, AM J HUM GENET, V32, P651; ZIMM S, 1983, NEW ENGL J MED, V308, P1005, DOI 10.1056/NEJM198304283081705; [No title captured]	21	190	195	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 14	1994	343	8907					1188	1190		10.1016/S0140-6736(94)92400-7	http://dx.doi.org/10.1016/S0140-6736(94)92400-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NL175	7909868				2022-12-24	WOS:A1994NL17500009
J	MARKUS, HS; DROSTE, DW; BROWN, MM				MARKUS, HS; DROSTE, DW; BROWN, MM			DETECTION OF ASYMPTOMATIC CEREBRAL EMBOLIC SIGNALS WITH DOPPLER ULTRASOUND	LANCET			English	Note								Can asymptomatic cerebral emboli be detected? With transcranial doppler ultrasonography of the middle cerebral artery, short-duration high-intensity asymptomatic embolic signals were detected in 6 of 25 patients with carotid stenosis and in 9 of 24 with prosthetic cardiac valves, but not in 20 normal controls. In carotid stenosis the signals were usually unilateral and ipsilateral to the stenosis. Embolic signals were significantly more common in patients with mechanical valves than with pig xenografts (8/13 vs 1/11). With mechanical valves embolic signals were usually bilateral. Detection of asymptomatic emboli may allow identification of and preventive treatment in at-risk patients.			MARKUS, HS (corresponding author), UNIV LONDON ST GEORGES HOSP,SCH MED,DIV CLIN NEUROSCI,CRANMER TERRACE,LONDON SW17 0RE,ENGLAND.			Brown, Martin M/0000-0002-3273-1356				AUSTEN WG, 1965, J SURG RES, V5, P283; Bland M., 1987, INTRO MED STAT, P276; HALL RJC, 1989, DISEASES CARDIAC VAL; MARKUS H, 1993, STROKE, V24, P1667, DOI 10.1161/01.STR.24.11.1667; MARKUS H, 1994, J NEUROL SCI, V122, P117, DOI 10.1016/0022-510X(94)90061-2; RUSSELL D, 1991, STROKE, V22, P253, DOI 10.1161/01.STR.22.2.253; RUSSELL D, 1992, RECENT ADV NEUROSONO, P57; RUSSELL RW, 1963, LANCET, V2, P1354; SIEBLER M, 1992, STROKE, V23, P1652, DOI 10.1161/01.STR.23.11.1652; SPENCER MP, 1990, STROKE, V21, P415, DOI 10.1161/01.STR.21.3.415; TEGLER CH, 1991, J NEUROIMAGING, V1, P61	11	63	64	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 23	1994	343	8904					1011	1012		10.1016/S0140-6736(94)90129-5	http://dx.doi.org/10.1016/S0140-6736(94)90129-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NG682	7909051				2022-12-24	WOS:A1994NG68200012
J	RODRIGUEZ, LAG; JICK, H				RODRIGUEZ, LAG; JICK, H			RISK OF UPPER GASTROINTESTINAL-BLEEDING AND PERFORATION ASSOCIATED WITH INDIVIDUAL NONSTEROIDAL ANTIINFLAMMATORY DRUGS	LANCET			English	Article							DISEASE	Exposure to non-steroidal anti-inflammatory drugs (NSAIDs) is known to increase substantially the risk of upper gastrointestinal bleeding and perforation (UGIB). We have carried out a population-based retrospective case-control study to assess the variation in risk associated with various individual NSAIDs, with adjustment for features of use and other independent risk factors. The study sample comprised 1457 cases of UGIB and 10 000 control subjects identified from general practitioners' computerised records in the UK. The adjusted estimate of relative risk of UGIB associated with current NSAID use was 4.7 (95% CI 3.8-5.7). Previous UGIB was the single most important predictor of UGIB (relative risk 13.5 [10.3-17.7]). For all NSAIDs together, the risk was greater for high doses than for tow doses (7.0 [5.2-9.6] vs 2.6 [1.8-3.8]). The estimates of risk associated with the individual NSAIDs varied widely. Users of azapropazone (23.4 [6.9-79.5]) and piroxicam (18.0 [8.2-39.6]) had the highest risk of UGIB among the NSAIDs studied. All the other NSAIDs with sufficient data for individual analysis (ibuprofen, naproxen, diclofenac, ketoprofen, and indomethacin) had relative risks similar to that for overall NSAID use. NSAIDS should be used cautiously in patients who have other risk factors for UGIB; these include advanced age, smoking, history of peptic ulcer, and use of oral corticosteroids or anticoagulants.			RODRIGUEZ, LAG (corresponding author), BOSTON UNIV,BOSTON COLLABORAT DRUG SURVELLANCE PROGRAM,11 MUZZEY ST,LEXINGTON,MA 02173, USA.		rodriguez, luis a garcia/B-1980-2010	Jick, Hershel/0000-0003-4270-5992				BOLLINI P, 1992, ARCH INTERN MED, V152, P1289, DOI 10.1001/archinte.152.6.1289; GRIFFIN MR, 1991, ANN INTERN MED, V114, P257, DOI 10.7326/0003-4819-114-4-257; HAWKEY CJ, 1990, BMJ-BRIT MED J, V300, P278, DOI 10.1136/bmj.300.6720.278; HOSMER DW, 1992, EPIDEMIOLOGY, V3, P452, DOI 10.1097/00001648-199209000-00012; JICK H, 1991, BRIT MED J, V302, P766, DOI 10.1136/bmj.302.6779.766; Jick H., 1992, PHARMACOEPIDEM DR S, V1, P347, DOI DOI 10.1002/PDS.2630010607; Perry J, 1978, OXMIS PROBLEM CODES	7	818	841	0	16	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 26	1994	343	8900					769	772		10.1016/S0140-6736(94)91843-0	http://dx.doi.org/10.1016/S0140-6736(94)91843-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NC351	7907735				2022-12-24	WOS:A1994NC35100015
J	BANNER, AS				BANNER, AS			THEOPHYLLINE - SHOULD WE DISCARD AN OLD FRIEND	LANCET			English	Editorial Material							AMINOPHYLLINE				BANNER, AS (corresponding author), HARVARD UNIV,SCH MED,CAMBRIDGE,MA 02138, USA.							[Anonymous], 1990, BMJ, V301, P797; HUANG D, 1993, ANN INTERN MED, V119, P1155, DOI 10.7326/0003-4819-119-12-199312150-00001; LITTENBERG B, 1988, JAMA-J AM MED ASSOC, V259, P1678, DOI 10.1001/jama.259.11.1678; MILGROM H, 1993, AM REV RESPIR DIS, V147, pS33, DOI 10.1164/ajrccm/147.6_Pt_2.S33; NEWHOUSE MT, 1990, CHEST, V98, P1, DOI 10.1378/chest.98.1.1; SHANNON M, 1993, ANN INTERN MED, V119, P1161, DOI 10.7326/0003-4819-119-12-199312150-00002; WRENN K, 1991, ANN INTERN MED, V115, P241, DOI 10.7326/0003-4819-115-4-241; 1991, 913042 US DEP HLTH H	8	11	11	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 12	1994	343	8898					618	618		10.1016/S0140-6736(94)92632-8	http://dx.doi.org/10.1016/S0140-6736(94)92632-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NA093	7906808				2022-12-24	WOS:A1994NA09300005
J	JACK, T; FOX, GL; MEYEROWITZ, EM				JACK, T; FOX, GL; MEYEROWITZ, EM			ARABIDOPSIS HOMEOTIC GENE APETALA3 ECTOPIC EXPRESSION - TRANSCRIPTIONAL AND POSTTRANSCRIPTIONAL REGULATION DETERMINE FLORAL ORGAN IDENTITY	CELL			English	Article							FLOWER DEVELOPMENT; PLANT TRANSFORMATION; MADS-BOX; THALIANA; DEFICIENS; LEAFY; INTERACTS; PRODUCT	APETALA3 (AP3) specifies the development of petals and stamens in the Arabidopsis flower. We constructed a transgenic line, 35S-AP3, that ectopically expresses AP3 under the control of a constitutive promoter. The resulting flowers exhibit a replacement of carpels by stamens and resemble flowers homozygous for the previously described Arabidopsis mutation superman. Although AP3 RNA is detected at high levels throughout the flower and stem in 35S-AP3, AP3 protein is detected at high levels only in the second, third, and fourth floral whorls, demonstrating that AP3 is posttranscriptionally regulated. Ectopic expression of AP3 causes a second floral homeotic gene, PISTILLATA (PI), to function in the fourth whorl of 35S-AP3 flowers. AP3 and PI also activate an AP3 promoter-reporter gene fusion, demonstrating that AP3 positively autoregulates.	CALTECH, DIV BIOL 15629, PASADENA, CA 91125 USA	California Institute of Technology			Meyerowitz, Elliot M/A-7118-2009		NIGMS NIH HHS [GM13667-5] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENFEY PN, 1990, SCIENCE, V250, P959, DOI 10.1126/science.250.4983.959; BOWMAN JL, 1991, DEVELOPMENT, V112, P1; BOWMAN JL, 1992, DEVELOPMENT, V114, P599; BOWMAN JL, 1991, PLANT CELL, V3, P749, DOI 10.1105/tpc.3.8.749; BOWMAN JL, 1993, DEVELOPMENT, V119, P721; BOWMAN JL, 1989, PLANT CELL, V1, P37, DOI 10.1105/tpc.1.1.37; CHAUDHURY AM, 1989, PLANT CELL REP, V8, P368, DOI 10.1007/BF00716676; COEN ES, 1991, NATURE, V353, P31, DOI 10.1038/353031a0; COX KH, 1988, PLANT MOL BIOL PRACT, P1; DREWS GN, 1991, CELL, V65, P991, DOI 10.1016/0092-8674(91)90551-9; FRALEY RT, 1985, BIO-TECHNOL, V3, P629, DOI 10.1038/nbt0785-629; HARLOW E, 1988, ANTIBODIES LABORATOR; HILL JP, 1989, CAN J BOT, V67, P2922, DOI 10.1139/b89-375; HUALA E, 1992, PLANT CELL, V4, P901, DOI 10.1105/tpc.4.8.901; IRISH VF, 1990, PLANT CELL, V2, P741, DOI 10.1105/tpc.2.8.741; JACK T, 1992, CELL, V68, P683, DOI 10.1016/0092-8674(92)90144-2; JACK T, 1988, GENE DEV, V2, P635, DOI 10.1101/gad.2.6.635; JEFFERSON RA, 1987, EMBO J, V6, P3901; KUNST L, 1989, PLANT CELL, V1, P1195, DOI 10.1105/tpc.1.12.1195; MANDEL MA, 1992, NATURE, V360, P273, DOI 10.1038/360273a0; MANDEL MA, 1992, CELL, V71, P133, DOI 10.1016/0092-8674(92)90272-E; MARTON L, 1991, PLANT CELL REP, V10, P235, DOI 10.1007/BF00232565; MCBRIDE KE, 1990, PLANT MOL BIOL, V14, P269, DOI 10.1007/BF00018567; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MEYEROWITZ EM, 1991, DEVELOPMENT, P157; MIZUKAMI Y, 1992, CELL, V71, P119, DOI 10.1016/0092-8674(92)90271-D; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; PASSMORE S, 1988, J MOL BIOL, V204, P593, DOI 10.1016/0022-2836(88)90358-0; SCHULTZ EA, 1991, PLANT CELL, V3, P1221, DOI 10.1105/tpc.3.11.1221; SCHULTZ EA, 1991, PLANT CELL, V3, P771, DOI 10.1105/tpc.3.8.771; SCHWARZSOMMER Z, 1992, EMBO J, V11, P251, DOI 10.1002/j.1460-2075.1992.tb05048.x; SMYTH DR, 1990, PLANT CELL, V2, P755, DOI 10.1105/tpc.2.8.755; SOMMER H, 1990, EMBO J, V9, P605, DOI 10.1002/j.1460-2075.1990.tb08152.x; Stomp A., 1992, GUS protocols: using the GUS gene as a reporter of gene expression., P103; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TROBNER W, 1992, EMBO J, V11, P4693, DOI 10.1002/j.1460-2075.1992.tb05574.x; VALVEKENS D, 1988, P NATL ACAD SCI USA, V85, P5536, DOI 10.1073/pnas.85.15.5536; WEIGEL D, 1993, SCIENCE, V261, P1723, DOI 10.1126/science.261.5129.1723; WEIGEL D, 1992, CELL, V69, P843, DOI 10.1016/0092-8674(92)90295-N; YANOFSKY MF, 1990, NATURE, V346, P35, DOI 10.1038/346035a0	40	314	328	6	40	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 25	1994	76	4					703	716		10.1016/0092-8674(94)90509-6	http://dx.doi.org/10.1016/0092-8674(94)90509-6			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MZ285	7907276				2022-12-24	WOS:A1994MZ28500012
J	JOHNSON, A				JOHNSON, A			VOICE RESTORATION AFTER LARYNGECTOMY	LANCET			English	Editorial Material											JOHNSON, A (corresponding author), QUEEN ELIZABETH HOSP,DEPT OTOLARYNGOL,BIRMINGHAM,W MIDLANDS,ENGLAND.							DUGUAY MJ, 1989, J VOICE, V3, P265; GRASL MC, 1993, LARYNGOSCOPE, V103, P96; PARKER AJ, 1992, J LARYNGOL OTOL, V106, P154, DOI 10.1017/S0022215100118936; SCOTT PMJ, 1993, J LARYNGOL OTOL, V107, P430, DOI 10.1017/S0022215100123345; SINGER MI, 1980, ANN OTO RHINOL LARYN, V89, P529, DOI 10.1177/000348948008900608; SINGER MI, 1986, OTOLARYNGOLOGY HEAD, P2073; STGUILY JL, 1992, ARCH OTOLARYNGOL, V118, P252	7	8	8	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 19	1994	343	8895					431	432		10.1016/S0140-6736(94)92685-9	http://dx.doi.org/10.1016/S0140-6736(94)92685-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW690	7905949				2022-12-24	WOS:A1994MW69000003
J	KESSLER, DA; ROSE, JL; TEMPLE, RJ; SCHAPIRO, R; GRIFFIN, JP				KESSLER, DA; ROSE, JL; TEMPLE, RJ; SCHAPIRO, R; GRIFFIN, JP			THERAPEUTIC-CLASS WARS - DRUG PROMOTION IN A COMPETITIVE MARKETPLACE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									US FDA,DIV DRUG MKT ADVERTISING & COMMUN,ROCKVILLE,MD 20857	US Food & Drug Administration (FDA)								ANDERS G, 1994, WALL STREET J   0628, pB1; CHREN MM, 1990, JAMA-J AM MED ASSOC, V263, P2178, DOI 10.1001/jama.1990.03440160039021; GOLDFINGER SE, 1987, NEW ENGL J MED, V316, P1408, DOI 10.1056/NEJM198705283162211; KASSIRER JP, 1994, NEW ENGL J MED, V331, P669, DOI 10.1056/NEJM199409083311009; KESSLER DA, 1991, NEW ENGL J MED, V325, P201, DOI 10.1056/NEJM199107183250310; Kolata Gina, 1994, N Y Times Web, pA12; TANOUYE E, 1994, WALL ST J       0531, pA1; WAUD DR, 1992, NEW ENGL J MED, V327, P351, DOI 10.1056/NEJM199207303270511; WILKES MS, 1992, ANN INTERN MED, V116, P912, DOI 10.7326/0003-4819-116-11-912; WOOSLEY RL, 1994, ISSUES SCI TECHNOL, V10, P59; 1993, US ETHICAL PHARM PLY; 1993, EARNING FAILING GRAD; 1993, STATISTICAL REPORT; 1994, MED ADVERTISING NEWS, P10	14	106	107	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 17	1994	331	20					1350	1353		10.1056/NEJM199411173312007	http://dx.doi.org/10.1056/NEJM199411173312007			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PR216	7935706	Bronze			2022-12-24	WOS:A1994PR21600007
J	BOHMANN, D; ELLIS, MC; STASZEWSKI, LM; MLODZIK, M				BOHMANN, D; ELLIS, MC; STASZEWSKI, LM; MLODZIK, M			DROSOPHILA JUN MEDIATES RAS-DEPENDENT PHOTORECEPTOR DETERMINATION	CELL			English	Article							RECEPTOR TYROSINE KINASE; GUANINE-NUCLEOTIDE EXCHANGE; TRANSCRIPTION FACTOR AP-1; C-JUN; SEVENLESS PROTEIN; CELL FATE; SIGNAL-TRANSDUCTION; FUNCTIONS DOWNSTREAM; ECTOPIC EXPRESSION; NEGATIVE REGULATOR	The expression of the D. melanogaster transcription factor Jun in the eye imaginal disc correlates temporally and spatially with the determination of neuronal photoreceptor fate. Expression of dominant negative forms of Jun in photoreceptor precursor cells results in dose-dependent loss of photoreceptors in the adult fly. Conversely, localized overexpression of Jun in the eye imaginal disc can induce the differentiation of additional photoreceptor cells. Furthermore, the transformation of nonneuronal cone cells into R7 neurons elicited by constitutively active forms of sevenless, Ras1, Raf, and MAP kinase is relieved in the presence of Jun mutants. These results demonstrate a requirement of Jun downstream of the sevenless/ras signaling pathway for neuronal development in the Drosophila eye.			BOHMANN, D (corresponding author), EUROPEAN MOLEC BIOL LAB, D-69012 HEIDELBERG, GERMANY.							ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BASLER K, 1990, GENE DEV, V4, P728, DOI 10.1101/gad.4.5.728; BASLER K, 1988, CELL, V54, P299; BASLER K, 1989, DEVELOPMENT, V107, P723; BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOHMANN D, 1988, COLD SPRING HARB SYM, V53, P695, DOI 10.1101/SQB.1988.053.01.079; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BROWN PH, 1993, ONCOGENE, V8, P877; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; CARTHEW RW, 1990, CELL, V63, P561, DOI 10.1016/0092-8674(90)90452-K; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; CURRAN T, 1987, ONCOGENE, V2, P79; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DICKSON B, 1992, GENE DEV, V6, P2327, DOI 10.1101/gad.6.12a.2327; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; DOYLE HJ, 1993, GENE DEV, V7, P633, DOI 10.1101/gad.7.4.633; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; FISCHERVIZE JA, 1992, DEVELOPMENT, V115, P89; FISCHERVIZE JA, 1992, DEVELOPMENT, V116, P985; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; FRIEDMAN AD, 1988, NATURE, V335, P452, DOI 10.1038/335452a0; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GRANGERSCHNARR M, 1992, P NATL ACAD SCI USA, V89, P4236, DOI 10.1073/pnas.89.10.4236; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; HAFEN E, 1987, SCIENCE, V236, P55, DOI 10.1126/science.2882603; HAFEN E, 1993, PHILOS T R SOC B, V340, P273, DOI 10.1098/rstb.1993.0068; HARLOW E, 1988, ANTIBODIES LABORATOR; HART AC, 1990, GENE DEV, V4, P1835, DOI 10.1101/gad.4.11.1835; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HIROMI Y, 1993, DEVELOPMENT, V118, P1123; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KIMMEL BE, 1990, GENE DEV, V4, P712, DOI 10.1101/gad.4.5.712; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; LU XY, 1993, GENE DEV, V7, P621, DOI 10.1101/gad.7.4.621; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; MULLINS MC, 1989, GENE DEV, V3, P729, DOI 10.1101/gad.3.5.729; MULLINS MC, 1991, P NATL ACAD SCI USA, V88, P9387, DOI 10.1073/pnas.88.21.9387; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PERKINS KK, 1990, GENE DEV, V4, P822, DOI 10.1101/gad.4.5.822; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; READY DF, 1989, TRENDS NEUROSCI, V12, P102, DOI 10.1016/0166-2236(89)90166-5; READY DF, 1976, DEV BIOL, V53, P217, DOI 10.1016/0012-1606(76)90225-6; ROGGE RD, 1991, CELL, V64, P39, DOI 10.1016/0092-8674(91)90207-F; RUBIN GM, 1991, TRENDS GENET, V7, P372, DOI 10.1016/0168-9525(91)90258-R; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TOMLINSON A, 1988, DEVELOPMENT, V104, P183; TOMLINSON A, 1988, CELL, V55, P771, DOI 10.1016/0092-8674(88)90133-X; TOMLINSON A, 1987, DEV BIOL, V120, P366, DOI 10.1016/0012-1606(87)90239-9; TOMLINSON A, 1987, CELL, V51, P143, DOI 10.1016/0092-8674(87)90019-5; TOMLINSON A, 1985, J EMBRYOL EXP MORPH, V89, P313; VANVACTOR DL, 1991, CELL, V67, P1145, DOI 10.1016/0092-8674(91)90291-6; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; ZHANG K, 1990, P NATL ACAD SCI USA, V87, P6281, DOI 10.1073/pnas.87.16.6281	73	84	84	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 23	1994	78	6					973	986		10.1016/0092-8674(94)90273-9	http://dx.doi.org/10.1016/0092-8674(94)90273-9			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PJ294	7923366				2022-12-24	WOS:A1994PJ29400009
J	KOIZUMI, A				KOIZUMI, A			FIGHTING MYTHS	LANCET			English	Editorial Material											KOIZUMI, A (corresponding author), AKITA UNIV,SCH MED,DEPT HYG,AKITA 010,JAPAN.							BALLANTYNE B, 1987, CLIN EXPT TOXICOLOGY, P473; KOIZUMI A, 1994, LANCET, V343, P1411, DOI 10.1016/S0140-6736(94)92530-5; NICHOLSON PJ, 1994, OCCUP MED-OXFORD, V44, P125, DOI 10.1093/occmed/44.3.125	3	0	0	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 27	1994	344	8922					559	560		10.1016/S0140-6736(94)91959-3	http://dx.doi.org/10.1016/S0140-6736(94)91959-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD424	7914954				2022-12-24	WOS:A1994PD42400003
J	SINGER, PA				SINGER, PA			DISEASE-SPECIFIC ADVANCE DIRECTIVES	LANCET			English	Editorial Material											SINGER, PA (corresponding author), UNIV TORONTO,CTR BIOETH,88 COLL ST,TORONTO M5G 1L4,ON,CANADA.								0	40	43	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 27	1994	344	8922					594	596		10.1016/S0140-6736(94)91971-2	http://dx.doi.org/10.1016/S0140-6736(94)91971-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD424	7914966				2022-12-24	WOS:A1994PD42400015
J	BUSTURIA, A; LAWRENCE, PA				BUSTURIA, A; LAWRENCE, PA			REGULATION OF CELL NUMBER IN DROSOPHILA	NATURE			English	Article							IMAGINAL WING DISK; PATTERN-FORMATION; FUSHI-TARAZU; FATE MAP; MELANOGASTER; EMBRYO; LARVAL; LOCALIZATION; PARASEGMENTS; REGENERATION	DURING animal development, different parts grow independently (such as the left and right hands) but they stop growing when they reach the correct size. In most insects, growth of the epidermis is so controlled that, at each moult, there is a precise and proportionate increase in cell number(1). The mechanisms responsible for this size regulation are not known(2), but rigid programming of the number of cell divisions is not a requirement as even sister cells in an epithelial sheet divide variably(3-5). In the abdomen of dipterans, such as Drosophila, the opportunity for regulation is limited, because mitoses occur only in the embryo and during metamorphosis and not during larval growth. Here we used embryos with a reduced number of cells in the abdominal primordia to determine,whether they can regulate towards the normal during subsequent growth. In contrast to expectations(6-8), we find no evidence for regulation of cell number.			BUSTURIA, A (corresponding author), MRC, MOLEC BIOL LAB, HILLS RD, CAMBRIDGE CB2 2QH, ENGLAND.			Lawrence, Peter/0000-0002-9554-8268				BECKER HJ, 1957, Z INDUKT ABSTAMM VER, V88, P333, DOI 10.1007/BF00309128; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; BRYANT PJ, 1975, J EXP ZOOL, V193, P49, DOI 10.1002/jez.1401930106; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; DRIEVER W, 1994, DEV DROSOPHILA MELAN, V1; GARCIABELLIDO A, 1971, DEV BIOL, V26, P264, DOI 10.1016/0012-1606(71)90126-6; HARTENSTEIN V, 1992, ROUX ARCH DEV BIOL, V194, P308; HAYNIE JL, 1977, ROUX ARCH DEV BIOL, V183, P85, DOI 10.1007/BF00848779; Lawrence P., 1973, DEVELOPMENTAL SYSTEM, P157; LAWRENCE PA, 1987, NATURE, V328, P440, DOI 10.1038/328440a0; LAWRENCE PA, 1989, DEVELOPMENT, V105, P761; Lawrence Peter A, 1993, MAKING FLY GENETICS, V6; LEHMANN R, 1986, CELL, V47, P141, DOI 10.1016/0092-8674(86)90375-2; LOHSSCHARDIN M, 1979, DEV BIOL, V73, P239, DOI 10.1016/0012-1606(79)90065-4; MADHAVAN MM, 1980, J EMBRYOL EXP MORPH, V60, P1; MADHAVAN MM, 1984, J EMBRYOL EXP MORPH, V82, P1; MEISE M, 1993, DEVELOPMENT, V118, P1107; MORATA G, 1975, DEV BIOL, V42, P211, DOI 10.1016/0012-1606(75)90330-9; NUSSLEINVOLHARD C, 1989, CIBA F SYMP, V144, P37; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; ORTEGA JAC, 1985, EMBRYONIC DEV DROSOP; ROSELAND CR, 1979, ROUX ARCH DEV BIOL, V186, P235, DOI 10.1007/BF00848591; SAMPEDRO J, 1993, DEVELOPMENT, V117, P677; SANTAMARIA P, 1972, J EMBRYOL EXP MORPH, V28, P397; SCHWEIZER P, 1972, BIOPHYSIK, V8, P158, DOI 10.1007/BF01188566; SIMPSON P, 1981, DEV BIOL, V85, P299, DOI 10.1016/0012-1606(81)90261-X; VINCENT JP, 1992, CELL, V68, P923, DOI 10.1016/0092-8674(92)90035-B; WIGGLESWORTH VB, 1965, PRINCIPLES INSECT PH, P61; WRIGHT DA, 1981, DEV BIOL, V85, P317, DOI 10.1016/0012-1606(81)90263-3; YASUDA GK, 1991, GENE DEV, V5, P1800, DOI 10.1101/gad.5.10.1800	30	24	24	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 18	1994	370	6490					561	563		10.1038/370561a0	http://dx.doi.org/10.1038/370561a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PC537	7914352				2022-12-24	WOS:A1994PC53700056
J	BRITTON, J; PAVORD, I; RICHARDS, K; WISNIEWSKI, A; KNOX, A; LEWIS, S; TATTERSFIELD, A; WEISS, S				BRITTON, J; PAVORD, I; RICHARDS, K; WISNIEWSKI, A; KNOX, A; LEWIS, S; TATTERSFIELD, A; WEISS, S			DIETARY MAGNESIUM, LUNG-FUNCTION, WHEEZING, AND AIRWAY HYPERREACTIVITY IN A RANDOM ADULT-POPULATION SAMPLE	LANCET			English	Article							BRONCHIAL RESPONSIVENESS; SMOOTH-MUSCLE; EXCRETION; SODIUM; QUESTIONNAIRE; HISTAMINE; POTASSIUM; SYMPTOMS; CALCIUM; SULFATE	Magnesium is involved in a wide range of biological activities, including some that may protect against the development of asthma and chronic airflow obstruction. We tested the hypothesis that high dietary magnesium intake is associated with better lung function, and a reduced risk of airway hyper-reactivity and wheezing in a random sample of adults. In 2633 adults aged 18-70 sampled from the electoral register of an administrative area of Nottingham, UK, we measured dietary magnesium intake by semiquantitative food-frequency questionnaire, lung function as the 1-sec forced expiratory volume (FEV(1)), and atopy as the mean shin-prick test response to three common environmental allergens. We measured airway reactivity to methacholine in 2415 individuals, defining hyper-reactivity as a 20% fall in FEV(1) after a cumulative dose of 12.25 mu mol or less. Mean (SD) daily intake of magnesium was 380 (114) mg/day. After adjusting for age, sex, and height, and for the effects of atopy and smoking, a 100 mg/day higher magnesium intake Was associated with a 27.7 (95% Cl, 11.9-43.5) mL higher FEV(1), and a reduction in the relative odds of hyper-reactivity by a ratio of 0.82 (0.72-0.93). The same incremental difference in magnesium intake was also associated with a reduction in the odds of self-reported wheeze within the past 12 months, adjusted for age, sex, smoking, atopy, and kilojoule intake, by a ratio of 0.85 (0.76-0.95). Dietary magnesium intake is independently related to lung function and the occurrence of airway hyper-reactivity and self-reported wheezing in the general population. Low magnesium intake may therefore be involved in the aetiology of asthma and chronic obstructive airways disease.	BRIGHAM & WOMENS HOSP,DEPT MED,CHANNING LAB,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital	BRITTON, J (corresponding author), UNIV NOTTINGHAM,CITY HOSP,DIV RESP MED,NOTTINGHAM NG5 1PB,ENGLAND.		Britton, John R/G-9705-2011	Knox, Alan/0000-0002-5906-4143; Pavord, Ian/0000-0002-4288-5973				BOIS P, 1963, BRIT J EXP PATHOL, V44, P151; BRITTON J, 1994, EUR RESPIR J, V7, P881; BRITTON J, 1993, AM REV RESPIR DIS, V147, P377; BRITTON J, 1993, AM REV RESPIR DIS, V147, P369; BURNEY PGJ, 1986, BRIT MED J, V292, P1483, DOI 10.1136/bmj.292.6534.1483; BURNEY PGJ, 1989, THORAX, V44, P36, DOI 10.1136/thx.44.1.36; BURNEY PGJ, 1989, EUR RESPIR J, V2, P940; DANGELO EKG, 1992, J CLIN INVEST, V89, P1988, DOI 10.1172/JCI115807; DELCASTILLO J, 1954, J PHYSIOL-LONDON, V124, P370, DOI 10.1113/jphysiol.1954.sp005114; DUNNETT J, 1978, J MOL CELL CARDIOL, V10, P487, DOI 10.1016/0022-2828(78)90369-3; DURLACH J, 1975, REV FR ALLERGOL, V15, P133, DOI 10.1016/S0335-7457(75)80025-6; DYCKNER T, 1984, DRUGS, V28, P161, DOI 10.2165/00003495-198400281-00016; Gregory F., 1990, DIETARY NUTR SURVEY; HAURY VG, 1938, J PHARMACOL EXP THER, V64, P4; KEMP PA, 1994, BRIT J PHARMACOL, V111, P325, DOI 10.1111/j.1476-5381.1994.tb14063.x; LEVINE BS, 1984, NEW ENGL J MED, V310, P1253, DOI 10.1056/NEJM198405103101910; LEWIS J, 1988, BRIT J NUTR, V60, P413, DOI 10.1079/BJN19880113; NADLER JL, 1987, HYPERTENSION, V9, P379, DOI 10.1161/01.HYP.9.4.379; NOPPEN M, 1990, CHEST, V97, P373, DOI 10.1378/chest.97.2.373; Paul A.A., 1988, MCCANCE WIDDOWSONS C; PISTELLI R, 1993, EUR RESPIR J, V6, P517; SCHROEDER HA, 1969, J CHRON DIS, V21, P815, DOI 10.1016/0021-9681(69)90027-7; SKOBELOFF EM, 1989, JAMA-J AM MED ASSOC, V262, P1210; SPARROW D, 1991, AM REV RESPIR DIS, V144, P722, DOI 10.1164/ajrccm/144.3_Pt_1.722; SPIVEY WH, 1990, ANN EMERG MED, V19, P1107, DOI 10.1016/S0196-0644(05)81513-6; WACKER WEC, 1958, NEW ENGL J MED, V259, P475, DOI 10.1056/NEJM195809042591005; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760; YARNELL JWG, 1983, HUM NUTR-APPL NUTR, V37, P103; 1991, SMOKING EPIDEMIC COU, V3; 1991, DIETARY REFERENCE VA, P146	30	199	205	1	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 6	1994	344	8919					357	362		10.1016/S0140-6736(94)91399-4	http://dx.doi.org/10.1016/S0140-6736(94)91399-4			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PA303	7914305				2022-12-24	WOS:A1994PA30300008
J	SAILER, A; BUELER, H; FISCHER, M; AGUZZI, A; WEISSMANN, C				SAILER, A; BUELER, H; FISCHER, M; AGUZZI, A; WEISSMANN, C			NO PROPAGATION OF PRIONS IN MICE DEVOID OF PRP	CELL			English	Note							SCRAPIE		UNIV ZURICH,INST NEUROPATHOL,CH-8091 ZURICH,SWITZERLAND	University of Zurich	SAILER, A (corresponding author), UNIV ZURICH,INST MOLEK BIOL 1,CH-8093 ZURICH,SWITZERLAND.		Büeler, Hansruedi/J-6965-2017; Aguzzi, Adriano/A-3351-2008; Sailer, Andreas/M-9913-2016	Büeler, Hansruedi/0000-0002-4892-7177; Aguzzi, Adriano/0000-0002-0344-6708; Sailer, Andreas/0000-0002-9015-7946				BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; CHESEBRO B, 1993, CURR BIOL, V3, P696, DOI 10.1016/0960-9822(93)90072-V; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; PRUSINER SB, 1993, P NATL ACAD SCI USA, V90, P10608, DOI 10.1073/pnas.90.22.10608	4	235	241	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 1	1994	77	7					967	968		10.1016/0092-8674(94)90436-7	http://dx.doi.org/10.1016/0092-8674(94)90436-7			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NV425	7912659				2022-12-24	WOS:A1994NV42500005
J	WAGA, S; HANNON, GJ; BEACH, D; STILLMAN, B				WAGA, S; HANNON, GJ; BEACH, D; STILLMAN, B			THE P21 INHIBITOR OF CYCLIN-DEPENDENT KINASES CONTROLS DNA-REPLICATION BY INTERACTION WITH PCNA	NATURE			English	Article							CELL NUCLEAR ANTIGEN; POLYMERASE-DELTA; STRAND SYNTHESIS; PROTEIN; INVITRO; P53; INITIATION; SUBUNIT; REPAIR; ORIGIN	THE p53 tumour-suppressor protein controls the expression of a gene encoding the p21 cyclin-dependent protein kinase (CDK) regulator(1-6). Levels of p21 protein are increased in senescent cells and p21 overexpression blocks the growth of tumour cells(1,3,7). In normal human cells, but not in many tumour cells, p21 exists in a guaternary complex with a cyclin, a CDK, and the proliferating-cell nuclear antigen (PCNA)(5,8). p21 controls CDK activity, thereby affecting cell-cycle control(2-4,6), whereas PCNA functions in both DNA replication(9-12) and repair(13). Here we use simian virus 40 DNA replication in vitro to show that p21 directly inhibits PCNA-dependent DNA replication in the absence of a cyclin/CDK. Furthermore, p21 blocks the ability of PCNA to activate DNA polymerase delta, the principal replicative DNA polymerase. This regulation results from a direct interaction between p21 and PCNA. Thus, during p53-mediated suppression of cell proliferation, p21 and PCNA mag be important for coordinating cell-cycle progression, DNA replication and repair of damaged DNA.	HOWARD HUGHES MED INST, COLD SPRING HARBOR, NY 11724 USA	Howard Hughes Medical Institute	WAGA, S (corresponding author), COLD SPRING HARBOR LAB, POB 100, BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA.		Hannon, Gregory/AAB-3568-2019	Waga, Shou/0000-0003-4986-8735; Stillman, Bruce/0000-0002-9453-4091				BAUER GA, 1988, P NATL ACAD SCI USA, V85, P7506, DOI 10.1073/pnas.85.20.7506; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARPER JW, 1993, CELL, V75, P805; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KONG XP, 1992, J CELL, V69, P425; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MELENDY T, 1992, NUCLEIC ACIDS MOL BI, V6, P129; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PRELICH G, 1987, NATURE, V326, P471, DOI 10.1038/326471a0; PRELICH G, 1988, CELL, V53, P117, DOI 10.1016/0092-8674(88)90493-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; STILLMAN BW, 1985, MOL CELL BIOL, V5, P2051, DOI 10.1128/MCB.5.8.2051; TAN CK, 1986, J BIOL CHEM, V261, P2310; TSURIMOTO T, 1990, NATURE, V346, P534, DOI 10.1038/346534a0; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1961; WAGA S, 1994, J BIOL CHEM, V269, P10923; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; WASEEM NH, 1992, EMBO J, V11, P5111, DOI 10.1002/j.1460-2075.1992.tb05618.x; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	29	1634	1691	34	345	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 16	1994	369	6481					574	578		10.1038/369574a0	http://dx.doi.org/10.1038/369574a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NR294	7911228				2022-12-24	WOS:A1994NR29400054
J	PAPANEK, PJ				PAPANEK, PJ			HOW CLEAN SHOULD THE OCEAN BE FOR SWIMMERS	LANCET			English	Editorial Material							WATER-QUALITY				PAPANEK, PJ (corresponding author), LOS ANGELES CTY DEPT HLTH SERV,LOS ANGELES,CA, USA.							CABELLI VJ, 1982, AM J EPIDEMIOL, V115, P606, DOI 10.1093/oxfordjournals.aje.a113342; CABELLI VJ, 1983, EPA800180031 HLTH EF; CHEUNG WHS, 1990, EPIDEMIOL INFECT, V105, P139, DOI 10.1017/S0950268800047737; CORBETT SJ, 1993, AM J PUBLIC HEALTH, V83, P1701, DOI 10.2105/AJPH.83.12.1701; FLEISHER JM, 1993, INT J EPIDEMIOL, V22, P698, DOI 10.1093/ije/22.4.698; FLEISHER JM, 1991, RES J WATER POLLUT C, V63, P259; GOLD M, 1990, ASSESSMENT INPUTS FE; HAILE RW, 1992, STUDY DESIGN INVESTI; KEBABJIAN R, 1994, J ENVIRON HEALTH, V56, P15; 1990, OCEAN HLTH STUDY STU	10	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 21	1994	343	8908					1238	1239		10.1016/S0140-6736(94)92144-X	http://dx.doi.org/10.1016/S0140-6736(94)92144-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NM144	7910268				2022-12-24	WOS:A1994NM14400002
J	PERTL, B; YAU, SC; SHERLOCK, J; DAVIES, AF; MATHEW, CG; ADINOLFI, M				PERTL, B; YAU, SC; SHERLOCK, J; DAVIES, AF; MATHEW, CG; ADINOLFI, M			RAPID MOLECULAR METHOD FOR PRENATAL DETECTION OF DOWNS-SYNDROME	LANCET			English	Note							PCR	We have evaluated a rapid method that allows prenatal detection of Down's syndrome in less than 24 hours. DNA from uncultured amniotic fluid, fetal blood, and tissue samples was amplified with the small tandem repeat (STR) marker D21S11. Quantitative analysis of fluorescent STR products with evaluation of their sizes provided clear evidence for trisomy 21. Whilst most normal samples showed two amplification peaks of equal size, Down's syndrome samples were characterised by either th ree STR peaks or two peaks with a ratio of 2:1. Co-amplification with a non-polymorphic sequence allowed analysis of Samples that were homozygous for the 21-derived STRs.	UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,DIV MED & MOLEC GENET,LONDON SE1 9RT,ENGLAND; GRAZ UNIV,DEPT OBSTET & GYNECOL,GRAZ,AUSTRIA	University of London; King's College London; University of Graz			Mathew, Christopher G/G-3434-2015	Mathew, Christopher G/0000-0003-4178-1838; Sherlock, Jon/0000-0001-5475-2361				Ferre F, 1992, PCR Methods Appl, V2, P1; GIBSON RA, 1993, HUM MOL GENET, V2, P35, DOI 10.1093/hmg/2.1.35; LUBIN MB, 1991, MOL CELL PROBE, V5, P307, DOI 10.1016/0890-8508(91)90054-N; MANSFIELD ES, 1993, HUM MOL GENET, V2, P43, DOI 10.1093/hmg/2.1.43; PETERSEN MB, 1991, AM J HUM GENET, V48, P65; SHARMA V, 1992, HUM MOL GENET, V1, P67, DOI 10.1093/hmg/1.1.67-a	6	115	152	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 14	1994	343	8907					1197	1198		10.1016/S0140-6736(94)92404-X	http://dx.doi.org/10.1016/S0140-6736(94)92404-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NL175	7909872				2022-12-24	WOS:A1994NL17500013
J	JELLINEK, EH				JELLINEK, EH			TRAUMA AND MULTIPLE-SCLEROSIS	LANCET			English	Editorial Material																		BAMFORD C, 1978, CAN J NEUROL SCI, V5, P41, DOI 10.1017/S0317167100024732; BAMFORD CR, 1981, NEUROLOGY, V31, P1229, DOI 10.1212/WNL.31.10.1229; EBERS GC, 1994, LANCET, V343, P275, DOI 10.1016/S0140-6736(94)91119-3; ENGELL T, 1989, ACTA NEUROL SCAND, V79, P428, DOI 10.1111/j.1600-0404.1989.tb03811.x; GEORGI W, 1961, SCHWEIZ MED WSCHR, V91, P605; GILBERT JJ, 1983, ARCH NEUROL-CHICAGO, V40, P533, DOI 10.1001/archneur.1983.04050080033003; JW D., 1916, EDINBURGH MED J, V17, P229, DOI [10.1007/978-3-319-02735-7, DOI 10.1007/978-3-319-02735-7]; KELLY R, 1985, HDB CLIN NEUROLOGY, P49; KELLY RE, 1961, BRIT MED J, V2, P421, DOI 10.1136/bmj.2.5249.421; MATTHEWS WB, 1991, MCALPINES MULTIPLE S, P112; MILLER DH, 1993, BRAIN, V116, P1077, DOI 10.1093/brain/116.5.1077; POSER CM, 1993, J NEUROL SCI S, V115, P3; SIBLEY W, 1993, NEUROLOGY, V41, P1871; SIBLEY WA, 1985, LANCET, V1, P1313; SIBLEY WA, 1991, J NEUROL NEUROSUR PS, V54, P584, DOI 10.1136/jnnp.54.7.584; SIVA A, 1993, NEUROLOGY, V43, P1878, DOI 10.1212/WNL.43.10.1878; VOST A, 1964, J PATHOL BACTERIOL, V88, P463, DOI 10.1002/path.1700880209	17	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 30	1994	343	8905					1053	1054		10.1016/S0140-6736(94)90178-3	http://dx.doi.org/10.1016/S0140-6736(94)90178-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NJ694	7909097				2022-12-24	WOS:A1994NJ69400006
J	RIDKER, PM; HENNEKENS, CH; STAMPFER, MJ; MANSON, JE; VAUGHAN, DE				RIDKER, PM; HENNEKENS, CH; STAMPFER, MJ; MANSON, JE; VAUGHAN, DE			PROSPECTIVE-STUDY OF ENDOGENOUS-TISSUE PLASMINOGEN-ACTIVATOR AND RISK OF STROKE	LANCET			English	Article							MYOCARDIAL-INFARCTION; RAPID INHIBITOR; DISEASE; PLASMA; FIBRINOGEN	Few haematological or lipid risk factors have been identified for stroke, by contrast with coronary heart disease. To find out whether a marker of endogenous fibrinolytic function might be associated with stroke risk, we measured tissue plasminogen activator (tPA) antigen concentrations in baseline plasma samples from 88 healthy participants in the Physicians' Health Study who subsequently had first-ever strokes (71 thromboembolic, 12 haemorrhagic, 5 indeterminate) and from 471 participants who remained free of cardiovascular disease during 5 years of follow-up (controls). Mean baseline tPA concentrations were significantly higher among men who later had strokes than in the controls (11.14 [SE 0.80] vs 9.59 [0.27] ng/mL, p = 0.03). The difference was largely due to an excess of abnormally high values among stroke cases. The age-adjusted relative risk for stroke among men with baseline tPA concentrations above the 95th percentile of the control distribution was 3 51 (95% CI 1.72-7.17, p=0.0006) for total stroke and 3.89 (1.83-8.26, p-0.0004) for thromboembolic stroke.These findings did not change substantially in analyses that also controlled for stroke risk factors (high blood pressure, body-mass index, smoking, presence of diabetes, and parental history of myocardial infarction) or the plasma lipid profile. This prospective study shows that high concentrations of tPA antigen among apparently healthy men are independently associated with high risks of future stroke, especially thromboembolic stroke. This finding is consistent with the hypothesis that activation of the endogenous fibrinolytic system occurs years in advance of arterial vascular occlusion.	BRIGHAM & WOMENS HOSP,DEPT MED,DIV CARDIOL,BOSTON,MA 02215; BRIGHAM & WOMENS HOSP,DEPT MED,CTR RES THROBOLYSIS,BOSTON,MA 02215; BRIGHAM & WOMENS HOSP,DEPT MED,CHANNING LAB,BOSTON,MA; HARVARD UNIV,SCH MED,DEPT AMBULATORY & PREVENT MED,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	RIDKER, PM (corresponding author), BRIGHAMS & WOMENS HOSP,DEPT MED,DIV PREVENT MED,900 COMMONWEALTH AVE E,BOSTON,MA 02215, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034595] Funding Source: NIH RePORTER; NCI NIH HHS [CA-34944] Funding Source: Medline; NHLBI NIH HHS [HL-34595, HL-26490] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDREOTTI F, 1988, AM J CARDIOL, V62, P635, DOI 10.1016/0002-9149(88)90669-8; ANGLETON P, 1989, CIRCULATION, V79, P101, DOI 10.1161/01.CIR.79.1.101; [Anonymous], 1989, NEW ENGL J MED, V321, P129; ATKINS D, 1993, ANN INTERN MED, V119, P136, DOI 10.7326/0003-4819-119-2-199307150-00008; DYKEN ML, 1984, STROKE, V15, P1105; ELIASSON M, 1993, FIBRINOLYSIS, V7, P316, DOI 10.1016/0268-9499(93)90147-N; FEINBERG WM, 1989, STROKE, V20, P592, DOI 10.1161/01.STR.20.5.592; HAMSTEN A, 1987, LANCET, V2, P3; HAMSTEN A, 1985, NEW ENGL J MED, V313, P1557, DOI 10.1056/NEJM198512193132501; HART RG, 1990, STROKE, V21, P1111, DOI 10.1161/01.STR.21.8.1111; KANNEL WB, 1987, JAMA-J AM MED ASSOC, V258, P1183, DOI 10.1001/jama.258.9.1183; LUCURE CL, 1991, CORONARY ARTERY DIS, V2, P157; MARMOT MG, 1992, LANCET, V339, P344, DOI 10.1016/0140-6736(92)91659-V; MARTINEZ HR, 1993, STROKE, V24, P19, DOI 10.1161/01.STR.24.1.19; MEADE TW, 1993, LANCET, V342, P1076, DOI 10.1016/0140-6736(93)92062-X; MEADE TW, 1986, LANCET, V2, P533, DOI 10.1016/S0140-6736(86)90111-X; RANBY M, 1986, CLIN CHEM, V32, P2160; RIDKER PM, 1993, LANCET, V341, P1165, DOI 10.1016/0140-6736(93)90998-V; RIDKER PM, 1992, CURR OPIN LIPIDOL, V3, P285; SALOMAA VV, 1993, CIRCULATION, V87, P22; SHINTANI S, 1993, STROKE, V24, P965, DOI 10.1161/01.STR.24.7.965; SMOKOVITIS A, 1908, HAEMOSTASIS, V18, P146; UNDERWOOD MJ, 1993, CARDIOVASC RES, V27, P882, DOI 10.1093/cvr/27.5.882; WILHELMSEN L, 1984, NEW ENGL J MED, V311, P501, DOI 10.1056/NEJM198408233110804; ZENKER G, 1986, STROKE, V17, P942, DOI 10.1161/01.STR.17.5.942; 1993, EUR HEART J, V14, P8	26	281	286	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 16	1994	343	8903					940	943		10.1016/S0140-6736(94)90064-7	http://dx.doi.org/10.1016/S0140-6736(94)90064-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF700	7909008				2022-12-24	WOS:A1994NF70000008
J	FALLON, JF; LOPEZ, A; ROS, MA; SAVAGE, MP; OLWIN, BB; SIMANDL, BK				FALLON, JF; LOPEZ, A; ROS, MA; SAVAGE, MP; OLWIN, BB; SIMANDL, BK			FGF-2 - APICAL ECTODERMAL RIDGE GROWTH SIGNAL FOR CHICK LIMB DEVELOPMENT	SCIENCE			English	Article							SKELETAL-MUSCLE; FACTOR RECEPTOR; BUD; EXPRESSION	The apical ectodermal ridge permits growth and elongation of amniote limb buds; removal causes rapid changes in mesodermal gene expression, patterned cell death, and truncation of the limb. Ectopic fibroblast growth factor (FGF)-2 supplied to the chick apical bud mesoderm after ridge removal will sustain normal gene expression and cell viability, and allow relatively normal limb development. A bioassay for FGFs demonstrated that FGF-2 was the only detectable FGF in chick limb bud extracts. By distribution and bioactivity, FGF-2 is the prime candidate for the chick limb bud apical ridge growth signal.	UNIV WISCONSIN,NEUROSCI TRAINING PROGRAM,MADISON,WI 53706; UNIV CANTABRIA,DEPT ANAT & BIOL CELULAR,E-39011 SANTANDER,SPAIN; PURDUE UNIV,DEPT BIOCHEM,W LAFAYETTE,IN 47907	University of Wisconsin System; University of Wisconsin Madison; Universidad de Cantabria; Purdue University System; Purdue University; Purdue University West Lafayette Campus	FALLON, JF (corresponding author), UNIV WISCONSIN,DEPT ANAT,1300 UNIV AVE,MADISON,WI 53706, USA.		Olwin, Bradley B/A-1333-2014; Ros, Maria A./K-8160-2014	Ros, Maria A./0000-0002-1224-7671	NICHD NIH HHS [HD20743] Funding Source: Medline; NIGMS NIH HHS [5T32GM07507] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD020743] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007507] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON R, 1993, DEVELOPMENT, V117, P1423; AONO H, 1988, DEV BIOL, V128, P136, DOI 10.1016/0012-1606(88)90275-8; BOWEN J, 1989, ANAT EMBRYOL, V179, P269, DOI 10.1007/BF00326592; CAIRNS JM, 1975, J EMBRYOL EXP MORPH, V34, P155; FALLON JF, 1993, LIMB DEV REGENERAT B; FALLON JF, 1993, LIMB DEV REGENERAT A; FLOTTRAHMEL B, 1992, NEUROREPORT, V3, P1077, DOI 10.1097/00001756-199212000-00011; FOX JC, 1993, IN VITRO CELL DEV-AN, V29A, P228; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HAYEK A, 1987, BIOCHEM BIOPH RES CO, V147, P876, DOI 10.1016/0006-291X(87)91011-4; IZPISUABELMONTE JC, 1992, EMBO J, V11, P1451, DOI 10.1002/j.1460-2075.1992.tb05189.x; KARDAMI E, 1985, P NATL ACAD SCI USA, V82, P8044, DOI 10.1073/pnas.82.23.8044; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; NISWANDER L, 1993, CELL, V75, P579, DOI 10.1016/0092-8674(93)90391-3; NISWANDER L, 1993, NATURE, V361, P68, DOI 10.1038/361068a0; OLWIN BB, 1986, BIOCHEMISTRY-US, V25, P3487, DOI 10.1021/bi00360a001; OLWIN BB, 1990, J CELL BIOL, V110, P503, DOI 10.1083/jcb.110.2.503; RILEY BB, 1993, DEVELOPMENT, V118, P95; ROS MA, 1992, DEVELOPMENT, V116, P811; ROWE DA, 1982, DEV BIOL, V93, P83, DOI 10.1016/0012-1606(82)90241-X; SAUNDERS JW, 1948, J EXP ZOOL, V108, P363, DOI 10.1002/jez.1401080304; SAVAGE MP, 1993, DEV DYNAM, V198, P159, DOI 10.1002/aja.1001980302; SEED J, 1988, DEV BIOL, V128, P40, DOI 10.1016/0012-1606(88)90264-3; SEED J, 1988, DEV BIOL, V128, P50, DOI 10.1016/0012-1606(88)90265-5; SLACK JMW, 1993, MECH DEVELOP, V41, P91, DOI 10.1016/0925-4773(93)90040-5; SUMMERBELL D, 1973, NATURE, V244, P492, DOI 10.1038/244492a0; TODT WL, 1984, J EMBRYOL EXP MORPH, V80, P21; WATANABE A, 1993, DEV BIOL, V159, P223, DOI 10.1006/dbio.1993.1235; ZWILLING E, 1956, J EXP ZOOL, V132, P219, DOI 10.1002/jez.1401320203; ZWILLING E, 1955, J EXP ZOOL, V128, P423, DOI 10.1002/jez.1401280304	30	416	425	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 1	1994	264	5155					104	107		10.1126/science.7908145	http://dx.doi.org/10.1126/science.7908145			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ND536	7908145				2022-12-24	WOS:A1994ND53600041
J	MASTROGIACOMO, A; PARSONS, SM; ZAMPIGHI, GA; JENDEN, DJ; UMBACH, JA; GUNDERSEN, CB				MASTROGIACOMO, A; PARSONS, SM; ZAMPIGHI, GA; JENDEN, DJ; UMBACH, JA; GUNDERSEN, CB			CYSTEINE STRING PROTEINS - A POTENTIAL LINK BETWEEN SYNAPTIC VESICLES AND PRESYNAPTIC CA2+ CHANNELS	SCIENCE			English	Article							CALCIUM CHANNELS; BETA-SUBUNIT; RELEASE; CELLS	Presynaptic calcium channels are key regulators of neurotransmitter release. Oocyte expression studies suggest that cysteine string proteins are essential subunits or modulators of these channels. Subcellular fractionation revealed that cysteine string proteins copurify with synaptic vesicles. An average vesicle had eight protein monomers with both the amino and carboxyl termini detected on the cytoplasmic face. Thus, docked synaptic vesicles may regulate presynaptic calcium channels and neurotransmitter release.	UNIV CALIF LOS ANGELES, SCH MED, DEPT MOLEC & MED PHARMACOL, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT ANAT & CELL BIOL, LOS ANGELES, CA 90024 USA; UNIV CALIF SANTA BARBARA, DEPT CHEM, SANTA BARBARA, CA 93106 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Santa Barbara				Parsons, Stanley/0000-0001-7097-8221				ANDERSON DC, 1986, J NEUROCHEM, V46, P1207, DOI 10.1111/j.1471-4159.1986.tb00639.x; AUGUSTINE GJ, 1987, ANNU REV NEUROSCI, V10, P633, DOI 10.1146/annurev.ne.10.030187.003221; BEAN BP, 1989, ANNU REV PHYSIOL, V51, P367, DOI 10.1146/annurev.physiol.51.1.367; BERTOLINO M, 1992, ANNU REV PHARMACOL, V32, P399, DOI 10.1146/annurev.pa.32.040192.002151; BUCKLEY K, 1985, J CELL BIOL, V100, P1284, DOI 10.1083/jcb.100.4.1284; CAPLAN AJ, 1993, MOL BIOL CELL, V4, P555, DOI 10.1091/mbc.4.6.555; GUNDERSEN CB, 1992, NEURON, V9, P527, DOI 10.1016/0896-6273(92)90190-O; GUNDERSEN CB, 1993, NEUR ABST, V19, P1329; HARLOW E, 1989, ANTIBODIES LABORATOR, P498; HILLE B, 1992, NEURON, V9, P187, DOI 10.1016/0896-6273(92)90158-A; JENDEN DJ, 1973, ANAL BIOCHEM, V55, P483; Katz B., 1969, RELEASE NEURAL TRANS; LACERDA AE, 1991, NATURE, V352, P527, DOI 10.1038/352527a0; MASTROGIACOMO A, IN PRESS J NEUROCHEM; MCCLESKEY EW, 1986, J EXP BIOL, V124, P177; MILLER RJ, 1990, FASEB J, V4, P3291, DOI 10.1096/fasebj.4.15.1979294; MILLER RJ, 1987, SCIENCE, V235, P46, DOI 10.1126/science.2432656; OCONNOR VM, 1993, FEBS LETT, V326, P255, DOI 10.1016/0014-5793(93)81802-7; SINGER D, 1991, SCIENCE, V253, P1553, DOI 10.1126/science.1716787; Snutch T P, 1992, Curr Opin Neurobiol, V2, P247, DOI 10.1016/0959-4388(92)90111-W; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; STANLEY EF, 1993, NEURON, V11, P1007, DOI 10.1016/0896-6273(93)90214-C; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; TRIMBLE WS, 1991, ANNU REV NEUROSCI, V14, P93, DOI 10.1146/annurev.ne.14.030191.000521; VARADI G, 1991, NATURE, V352, P159, DOI 10.1038/352159a0; YAMAGATA SK, 1989, J NEUROCHEM, V53, P1354, DOI 10.1111/j.1471-4159.1989.tb08525.x; ZAMPIGHI GA, 1989, J CELL BIOL, V108, P2255, DOI 10.1083/jcb.108.6.2255; ZINSMAIER KE, 1990, J NEUROGENET, V7, P15, DOI 10.3109/01677069009084150	28	161	162	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 18	1994	263	5149					981	982		10.1126/science.7906056	http://dx.doi.org/10.1126/science.7906056			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MX165	7906056				2022-12-24	WOS:A1994MX16500040
J	CAPOVILLA, M; BRANDT, M; BOTAS, J				CAPOVILLA, M; BRANDT, M; BOTAS, J			DIRECT REGULATION OF DECAPENTAPLEGIC BY ULTRABITHORAX AND ITS ROLE IN DROSOPHILA MIDGUT MORPHOGENESIS	CELL			English	Article							HOMEODOMAIN RECOGNITION HELIX; DNA-SEQUENCE RECOGNITION; HOMEOTIC GENE-EXPRESSION; VISCERAL MESODERM; BITHORAX COMPLEX; HOMEOBOX GENE; ANTENNAPEDIA HOMEODOMAIN; ECTOPIC EXPRESSION; PATTERN-FORMATION; GERM LAYERS	Drosophila homeotic genes encode transcription factors thought to control segmental identity by regulating expression of largely unknown target genes. The formation of the second midgut constriction requires the Ultrabithorax (Ubx) and abdominal-A (abd-A) homeotic genes and decapentaplegic (dpp), a gene encoding a member of the TGF beta family of proteins. We identified a 674 bp enhancer of dpp controlling its expression in the second constriction domain of the visceral mesoderm (parasegment 7). Normal enhancer function requires positive regulation by Ubx and negative regulation by abd-A. This enhancer contains UBX- and ABD-A-binding sites defined in vitro. By generating complementary alterations of the binding sites and the binding specificity of UBX, we show that Ubx directly regulates dpp expression. These regulatory interactions are relevant to normal development, because a transgene made with this enhancer driving a dpp transcription unit rescues the second midgut constriction and larval lethality phenotypes of dpp(s) mutations.	BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030	Baylor College of Medicine	CAPOVILLA, M (corresponding author), BAYLOR COLL MED,DEPT MOLEC & HUMAN GENET,HOUSTON,TX 77030, USA.		Capovilla, Maria/O-8483-2016	Capovilla, Maria/0000-0002-1308-7964				AFFOLTER M, 1990, P NATL ACAD SCI USA, V87, P4093, DOI 10.1073/pnas.87.11.4093; AKAM M, 1989, CELL, V57, P347, DOI 10.1016/0092-8674(89)90909-4; ANDREW DJ, 1992, NEW BIOL, V4, P5; APPEL B, 1993, EMBO J, V12, P1099, DOI 10.1002/j.1460-2075.1993.tb05751.x; AZPIAZU N, 1993, GENE DEV, V7, P1325, DOI 10.1101/gad.7.7b.1325; BEACHY PA, 1988, CELL, V55, P1069, DOI 10.1016/0092-8674(88)90251-6; BENDER W, 1983, SCIENCE, V221, P23, DOI 10.1126/science.221.4605.23; BIENZ M, 1988, NATURE, V333, P576, DOI 10.1038/333576a0; Botas J, 1993, CURR OPIN CELL BIOL, V5, P1015, DOI 10.1016/0955-0674(93)90086-6; DAVIDSON EH, 1991, DEVELOPMENT, V113, P1; DESSAIN S, 1992, EMBO J, V11, P991, DOI 10.1002/j.1460-2075.1992.tb05138.x; DOLLE P, 1989, NATURE, V342, P767, DOI 10.1038/342767a0; DRIEVER W, 1989, NATURE, V340, P363, DOI 10.1038/340363a0; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; DUBOULE D, 1989, EMBO J, V8, P1497, DOI 10.1002/j.1460-2075.1989.tb03534.x; Duboule D, 1991, CURR OPIN GENET DEV, V1, P211, DOI 10.1016/S0959-437X(05)80072-3; EKKER SC, 1991, EMBO J, V10, P1179, DOI 10.1002/j.1460-2075.1991.tb08058.x; EKKER SC, 1992, EMBO J, V11, P4059, DOI 10.1002/j.1460-2075.1992.tb05499.x; ERSELIUS JR, 1990, DEVELOPMENT, V110, P629; FROHMAN MA, 1990, DEVELOPMENT, V110, P589; GARCIABELLIDO A, 1977, AM ZOOL, V17, P613; GIBSON G, 1988, DEVELOPMENT, V102, P657; GONZALEZREYES A, 1990, CELL, V61, P515, DOI 10.1016/0092-8674(90)90533-K; GRAHAM A, 1989, CELL, V57, P367, DOI 10.1016/0092-8674(89)90912-4; HANES SD, 1991, SCIENCE, V251, P426, DOI 10.1126/science.1671176; HANES SD, 1989, CELL, V57, P1275, DOI 10.1016/0092-8674(89)90063-9; HAYASHI S, 1990, CELL, V63, P883, DOI 10.1016/0092-8674(90)90492-W; HOFFMANN FM, 1987, GENE DEV, V1, P615, DOI 10.1101/gad.1.6.615; HURSH DA, 1993, DEVELOPMENT, V117, P1211; IMMERGLUCK K, 1990, CELL, V62, P261, DOI 10.1016/0092-8674(90)90364-K; JONES B, 1993, GENE DEV, V7, P229, DOI 10.1101/gad.7.2.229; Kaufman T C, 1990, Adv Genet, V27, P309; KESSEL M, 1990, CELL, V61, P301, DOI 10.1016/0092-8674(90)90810-2; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; LAUGHON A, 1984, NATURE, V310, P25, DOI 10.1038/310025a0; LEMOUELLIC H, 1992, CELL, V69, P251, DOI 10.1016/0092-8674(92)90406-3; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; LOPEZ AJ, 1991, P NATL ACAD SCI USA, V88, P9924, DOI 10.1073/pnas.88.22.9924; LUFKIN T, 1992, NATURE, V359, P835, DOI 10.1038/359835a0; MALLCKI J, 1990, CELL, V63, P961; MCGINNIS N, 1990, CELL, V63, P969, DOI 10.1016/0092-8674(90)90500-E; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MCGINNIS W, 1984, NATURE, V308, P428, DOI 10.1038/308428a0; MORATA G, 1993, CURR OPIN GENET DEV, V3, P606, DOI 10.1016/0959-437X(93)90096-8; OHARA E, 1993, DEVELOPMENT, V117, P847; OLIVER G, 1988, EMBO J, V7, P3199, DOI 10.1002/j.1460-2075.1988.tb03187.x; OTTING G, 1988, EMBO J, V7, P4305, DOI 10.1002/j.1460-2075.1988.tb03329.x; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; PADGETT RW, 1993, P NATL ACAD SCI USA, V90, P2905, DOI 10.1073/pnas.90.7.2905; PANGANIBAN GEF, 1990, DEVELOPMENT, V110, P1041; PERCIVALSMITH A, 1990, EMBO J, V9, P3967, DOI 10.1002/j.1460-2075.1990.tb07617.x; PERCIVALSMITH A, 1990, EMBO J, V11, P382; RAMIREZSOLIS R, 1993, CELL, V73, P279, DOI 10.1016/0092-8674(93)90229-J; RAUSKOLB C, 1993, CELL, V74, P1101, DOI 10.1016/0092-8674(93)90731-5; REUTER R, 1990, DEVELOPMENT, V109, P289; REUTER R, 1990, DEVELOPMENT, V110, P1031; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SANCHEZHERRERO E, 1985, NATURE, V313, P108, DOI 10.1038/313108a0; SCHLER AF, 1992, NATURE, V356, P804; SCHMID P, 1991, DEVELOPMENT, V111, P117; SCOTT MP, 1984, P NATL ACAD SCI-BIOL, V81, P4115, DOI 10.1073/pnas.81.13.4115; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SLACK JMW, 1993, NATURE, V361, P490, DOI 10.1038/361490a0; SMITH DL, 1992, CELL, V68, P133, DOI 10.1016/0092-8674(92)90212-U; STJOHNSTON RD, 1987, EMBO J, V6, P2785, DOI 10.1002/j.1460-2075.1987.tb02574.x; STJOHNSTON RD, 1990, GENE DEV, V4, P1114, DOI 10.1101/gad.4.7.1114; TREISMAN J, 1989, CELL, V59, P553; TREMML G, 1989, EMBO J, V8, P2677, DOI 10.1002/j.1460-2075.1989.tb08408.x; VACHON G, 1992, CELL, V71, P437, DOI 10.1016/0092-8674(92)90513-C; ZHAO JJ, 1993, GENE DEV, V7, P343, DOI 10.1101/gad.7.3.343	71	167	168	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 11	1994	76	3					461	475		10.1016/0092-8674(94)90111-2	http://dx.doi.org/10.1016/0092-8674(94)90111-2			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MX207	7906203				2022-12-24	WOS:A1994MX20700008
J	POLLAK, MR; BROWN, EM; CHOU, YHW; HEBERT, SC; MARX, SJ; STEINMANN, B; LEVI, T; SEIDMAN, CE; SEIDMAN, JG				POLLAK, MR; BROWN, EM; CHOU, YHW; HEBERT, SC; MARX, SJ; STEINMANN, B; LEVI, T; SEIDMAN, CE; SEIDMAN, JG			MUTATIONS IN THE HUMAN CA2+-SENSING RECEPTOR GENE CAUSE FAMILIAL HYPOCALCIURIC HYPERCALCEMIA AND NEONATAL SEVERE HYPERPARATHYROIDISM	CELL			English	Article							KINDREDS	We demonstrate that mutations in the human Ca2+-sensing receptor gene cause familial hypocalciuric hypercalcemia (FHH) and neonatal severe hyperparathyroidism (NSHPT), two inherited conditions characterized by altered calcium homeostasis. The Ca2+-sensing receptor belongs to the superfamily of seven membrane-spanning G protein-coupled receptors. Three nonconservative missense mutations are reported: two occur in the extracellular N-terminal domain of the receptor; the third occurs in the final intracellular loop. One mutated receptor identified in FHH individuals was expressed in X. laevis oocytes. The expressed wild-type receptor elicted large inward currents in response to perfused polyvalent cations; a markedly attenuated response was observed with the mutated protein. We conclude that the mammalian Ca2+-sensing receptor ''sets'' the extracellular Ca2+ level and is defective in individuals with FHH and NSHPT.	BRIGHAM & WOMENS HOSP,DEPT MED,DIV ENDOCRINE HYPERTENS,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT MED,DIV CARDIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115; HARVARD UNIV,SCH MED,HOWARD HUGHES MED INST,BOSTON,MA 02115; NIDDKD,METAB DIS BRANCH,BETHESDA,MD 20892; UNIV ZURICH,DEPT PEDIAT,CH-8032 ZURICH,SWITZERLAND	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Zurich	POLLAK, MR (corresponding author), BRIGHAM & WOMENS HOSP,DEPT MED,DIV RENAL,BOSTON,MA 02115, USA.		Lima, Thaísa/AAG-6483-2021		NIDDK NIH HHS [DK46422, DK44588, DK02138] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K11DK002138, R01DK044588, R01DK046422] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ATTIE MF, 1983, J CLIN INVEST, V72, P667, DOI 10.1172/JCI111016; Ausubel F, 1989, MOL REPROD DEV, V1, P146; BELL GI, 1986, NUCLEIC ACIDS RES, V14, P8427, DOI 10.1093/nar/14.21.8427; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; BROWN EM, 1991, PHYSIOL REV, V71, P371, DOI 10.1152/physrev.1991.71.2.371; CHOU YHW, 1992, NAT GENET, V1, P295, DOI 10.1038/ng0792-295; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GAMBA G, 1993, P NATL ACAD SCI USA, V90, P2749, DOI 10.1073/pnas.90.7.2749; HOLCOMBE R F, 1987, Genomics, V1, P287, DOI 10.1016/0888-7543(87)90058-9; KHOSLA S, 1993, J CLIN ENDOCR METAB, V76, P715, DOI 10.1210/jc.76.3.715; KUNKEL MT, 1993, EMBO J, V12, P3809, DOI 10.1002/j.1460-2075.1993.tb06059.x; LAW WM, 1985, ANN INTERN MED, V102, P511, DOI 10.7326/0003-4819-102-4-511; MAGGIO R, 1993, P NATL ACAD SCI USA, V90, P3103, DOI 10.1073/pnas.90.7.3103; MARX SJ, 1977, AM J MED, V62, P698, DOI 10.1016/0002-9343(77)90873-7; MARX SJ, 1982, NEW ENGL J MED, V306, P257, DOI 10.1056/NEJM198202043060502; MARX SJ, 1981, MEDICINE, V60, P397, DOI 10.1097/00005792-198111000-00002; MARX SJ, 1986, J CLIN ENDOCR METAB, V62, P445, DOI 10.1210/jcem-62-2-445; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; OTT J, 1983, ANAL HUMAN GENETIC L; POLLAK MR, 1994, IN PRESS J CLIN INVE; ROSENZWEIG A, 1991, NEW ENGL J MED, V325, P1753, DOI 10.1056/NEJM199112193252501; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STEINMANN B, 1984, HELV PAEDIATR ACTA, V39, P171	24	807	829	1	29	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 31	1993	75	7					1297	1303		10.1016/0092-8674(93)90617-Y	http://dx.doi.org/10.1016/0092-8674(93)90617-Y			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MP869	7916660				2022-12-24	WOS:A1993MP86900009
J	REID, MM				REID, MM			SPLENECTOMY, SEPSIS, IMMUNIZATION, AND GUIDELINES	LANCET			English	Editorial Material							MANAGEMENT; CHILDHOOD				REID, MM (corresponding author), ROYAL VICTORIA INFIRM,DEPT HAEMATOL,NEWCASTLE TYNE NE1 4LP,TYNE & WEAR,ENGLAND.							EDEN OB, 1992, ARCH DIS CHILD, V67, P1056, DOI 10.1136/adc.67.8.1056; ERAKLIS AJ, 1972, J PEDIATR SURG, V7, P382, DOI 10.1016/0022-3468(72)90006-1; GRAHAM RCA, 1994, BRIT MED J, V308, P133, DOI 10.1136/bmj.308.6921.133b; MCMULLIN M, 1993, BRIT MED J, V307, P1372, DOI 10.1136/bmj.307.6916.1372; SHAPIRO ED, 1991, NEW ENGL J MED, V325, P1453, DOI 10.1056/NEJM199111213252101; WALKER W, 1976, BRIT J SURG, V63, P36, DOI 10.1002/bjs.1800630109; 1990, DRUG THER B, V28, P31; 1989, MMWR-MORBID MORTAL W, V38, P64; 1994, CMOS UPDATE, V1, P3; 1992, GUIDELINES ETHICAL C; 1992, IMMUNISATION INFECTI	11	22	22	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 8	1994	344	8928					970	971						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PK978	7934424				2022-12-24	WOS:A1994PK97800003
J	CHEN, JL; ATTARDI, LD; VERRIJZER, CP; YOKOMORI, K; TJIAN, R				CHEN, JL; ATTARDI, LD; VERRIJZER, CP; YOKOMORI, K; TJIAN, R			ASSEMBLY OF RECOMBINANT TFIID REVEALS DIFFERENTIAL COACTIVATOR REQUIREMENTS FOR DISTINCT TRANSCRIPTIONAL ACTIVATORS	CELL			English	Article							TATA-BINDING PROTEIN; RNA POLYMERASE-II; GENE-TRANSCRIPTION; MOLECULAR-CLONING; DNA-BINDING; SUBUNIT; COMPLEX; EXPRESSION; TBP; INTERACTS	We previously reported that transcriptional regulators can bind selected TAF subunits of the TFIID complex. However, the specificity and function of individual TAFs in mediating transcriptional activation remained unknown. Here we report the in vitro assembly and transcriptional properties of TBP-TAF complexes reconstituted from the nine recombinant subunits of Drosophila TFIID. A minimal complex containing TBP and TAF(II)250 directs basal but not activator-responsive transcription. By contrast, reconstituted hole TFIID supports activation by an assortment of activators. The activator NTF-1, which binds TAF(II)150, stimulates transcription with a complex containing only TBP, TAF(II)250, and TAF(II)150, whereas Sp1 binds and additionally requires TAF(II)110 for activation. Interestingly, TAF(II)150 enhances Spl activation even though this subunit does not bind directly to Sp1. These results establish that specific subcomplexes of TFIID can mediate activation by different classes of activators and suggest that TAFs perform multiple functions during activation.			CHEN, JL (corresponding author), UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720, USA.							ATTARDI LD, 1993, GENE DEV, V7, P1341, DOI 10.1101/gad.7.7b.1341; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; CHIANG CM, 1993, EMBO J, V12, P2749, DOI 10.1002/j.1460-2075.1993.tb05936.x; CHOY B, 1993, NATURE, V366, P531, DOI 10.1038/366531a0; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; DYNLACHT BD, 1993, NATURE, V363, P176, DOI 10.1038/363176a0; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; FERRERI K, 1994, P NATL ACAD SCI USA, V91, P1210, DOI 10.1073/pnas.91.4.1210; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; Gill G, 1992, CURR OPIN GENET DEV, V2, P236, DOI 10.1016/S0959-437X(05)80279-5; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; GOODRICH JA, 1994, CURR OPIN CELL BIOL, V6, P403; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HISATAKE K, 1993, NATURE, V362, P179, DOI 10.1038/362179a0; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; KAUFMANN J, 1994, GENE DEV, V8, P821, DOI 10.1101/gad.8.7.821; KLUG A, 1993, NATURE, V365, P486, DOI 10.1038/365486a0; KOKUBO T, 1993, GENE DEV, V7, P1033, DOI 10.1101/gad.7.6.1033; KOKUBO T, 1994, NATURE, V367, P484, DOI 10.1038/367484a0; KOKUBO T, 1993, P NATL ACAD SCI USA, V90, P5896, DOI 10.1073/pnas.90.13.5896; KOKUBO T, 1993, MOL CELL BIOL, V13, P7859, DOI 10.1128/MCB.13.12.7859; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RUPPERT S, 1993, NATURE, V362, P175, DOI 10.1038/362175a0; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; TIJAN R, 1994, CELL, V77, P5; VERRIJZER CP, 1994, SCIENCE, V264, P933, DOI 10.1126/science.8178153; WAMPLER SL, 1990, J BIOL CHEM, V265, P21223; WANG EH, 1994, SCIENCE, V263, P811, DOI 10.1126/science.8303298; WEINZIERL ROJ, 1993, EMBO J, V12, P5303, DOI 10.1002/j.1460-2075.1993.tb06226.x; WEINZIERL ROJ, 1993, NATURE, V362, P511, DOI 10.1038/362511a0; YOKOMORI K, 1993, GENE DEV, V7, P2235, DOI 10.1101/gad.7.11.2235; YOKOMORI K, 1993, GENE DEV, V7, P2587, DOI 10.1101/gad.7.12b.2587; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964	37	350	354	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 7	1994	79	1					93	105		10.1016/0092-8674(94)90403-0	http://dx.doi.org/10.1016/0092-8674(94)90403-0			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PK585	7923382				2022-12-24	WOS:A1994PK58500011
J	SCHIPPER, H; DICK, JAM				SCHIPPER, H; DICK, JAM			DOES CONSENSUS HELP IN BREAST-CANCER	LANCET			English	Editorial Material									MANITOBA BREAST CANC COUNCIL,WINNIPEG,MB,CANADA		SCHIPPER, H (corresponding author), UNIV MANITOBA,WINNIPEG,MB,CANADA.							CARTER CL, 1989, CANCER-AM CANCER SOC, V63, P181, DOI 10.1002/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO;2-H; Early Breast Cancer Trialists' Collaborative Group, 1992, LANCET, V339, P1; FERRARO S, 1993, NY TIMES MAGAZI 0815; GALEA MH, 1992, BREAST CANCER RES TR, V22, P207, DOI 10.1007/BF01840834; ROSEN PP, 1991, J CLIN ONCOL, V9, P1650, DOI 10.1200/JCO.1991.9.9.1650; 1991, JAMA-J AM MED ASSOC, V265, P391; 1993, BREAST CANCER B NCI; 1992, LANCET, V339, P71; 1994, 1ST AUSTR NAT BREAST	9	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 24	1994	344	8926					836	836		10.1016/S0140-6736(94)92823-1	http://dx.doi.org/10.1016/S0140-6736(94)92823-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PH253	7916397				2022-12-24	WOS:A1994PH25300007
J	VANDIJK, MA; MURRE, C				VANDIJK, MA; MURRE, C			EXTRADENTICLE RAISES THE DNA-BINDING SPECIFICITY OF HOMEOTIC SELECTOR GENE-PRODUCTS	CELL			English	Article							HUMAN PROTOONCOGENE PBX1; DROSOPHILA EMBRYOS; PRE-B; ULTRABITHORAX HOMEODOMAIN; DEVELOPMENTAL DEFECTS; TRANSLOCATION PROTEIN; TARGETED DISRUPTION; SEGMENTAL IDENTITY; CRYSTAL-STRUCTURE; HOMEOBOX GENES	Recently, a Drosophila gene has been identified, extradenticle, whose product modulates the morphological consequences of homeotic selector genes. We shaw here that extradenticle protein raises the DNA binding specificity of Ultrabithorax and abdominal-A but not that of Abdominal-B. We further show that extradenticle modulates the DNA binding activity of engrailed to a different target site. While a region N-terminal of the extradenticle homeodomain is required far Ultrabithorax and abdominal-A cooperativity, engrailed requires a domain C-terminal of the extradenticle homeobox. These studies show directly how the DNA binding specificity of selector gene products can be raised by extradenticle and provides a mechanism, cooperative DMA binding, that allows selector gene products to achieve some of their biological specificity.	UNIV CALIF SAN DIEGO,DEPT BIOL 0116,LA JOLLA,CA 92093	University of California System; University of California San Diego					NCI NIH HHS [CA54198-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA054198, R01CA054198] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEACHY PA, 1993, MOL CELL BIOL, V13, P6941, DOI 10.1128/MCB.13.11.6941; CELNIKER SE, 1989, GENE DEV, V3, P1424, DOI 10.1101/gad.3.9.1424; CHAN SK, 1993, GENE DEV, V7, P796, DOI 10.1101/gad.7.5.796; CHISAKA O, 1992, NATURE, V355, P516, DOI 10.1038/355516a0; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; DESPLAN C, 1988, CELL, V54, P1081, DOI 10.1016/0092-8674(88)90123-7; EKKER SC, 1991, EMBO J, V10, P1179, DOI 10.1002/j.1460-2075.1991.tb08058.x; FLEGEL WA, 1993, MECH DEVELOP, V41, P155, DOI 10.1016/0925-4773(93)90045-Y; HEEMSKERK J, 1991, NATURE, V352, P404, DOI 10.1038/352404a0; HOEY T, 1988, NATURE, V332, P858, DOI 10.1038/332858a0; JOHNSON A, 1992, TRANSCRIPTIONAL REGU, V2, P975; KAMPS MP, 1993, MOL CELL BIOL, V13, P351, DOI 10.1128/MCB.13.1.351; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KUZIORA MA, 1989, CELL, V59, P563, DOI 10.1016/0092-8674(89)90039-1; LAUGHON A, 1984, NATURE, V310, P25, DOI 10.1038/310025a0; LIN L, 1992, GENE DEV, V6, P1071, DOI 10.1101/gad.6.6.1071; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; MAK A, 1993, GENE DEV, V7, P1862, DOI 10.1101/gad.7.10.1862; MALICKI J, 1990, CELL, V63, P961, DOI 10.1016/0092-8674(90)90499-5; MANN RS, 1990, CELL, V60, P597, DOI 10.1016/0092-8674(90)90663-Y; MCGINNIS N, 1990, CELL, V63, P969, DOI 10.1016/0092-8674(90)90500-E; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MCGINNIS W, 1984, NATURE, V308, P428, DOI 10.1038/308428a0; MONICA K, 1991, MOL CELL BIOL, V11, P6149, DOI 10.1128/MCB.11.12.6149; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; PEIFER M, 1990, GENE DEV, V4, P1209, DOI 10.1101/gad.4.7.1209; QIAN YQ, 1989, CELL, V59, P573, DOI 10.1016/0092-8674(89)90040-8; RAMIREZSOLIS R, 1993, CELL, V73, P279, DOI 10.1016/0092-8674(93)90229-J; RAUSKOLB C, 1993, CELL, V74, P1101, DOI 10.1016/0092-8674(93)90731-5; SCOTT MP, 1984, P NATL ACAD SCI-BIOL, V81, P4115, DOI 10.1073/pnas.81.13.4115; VANDIJK MA, 1993, P NATL ACAD SCI USA, V90, P6061, DOI 10.1073/pnas.90.13.6061; VERSHON AK, 1993, CELL, V72, P105, DOI 10.1016/0092-8674(93)90054-T; WIESCHAUS E, 1986, ROUX ARCH DEV BIOL, V195, P63, DOI 10.1007/BF00444042; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5	36	237	238	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 26	1994	78	4					617	624		10.1016/0092-8674(94)90526-6	http://dx.doi.org/10.1016/0092-8674(94)90526-6			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PD693	7915200				2022-12-24	WOS:A1994PD69300010
J	WILLIAMS, B				WILLIAMS, B			INSULIN-RESISTANCE - THE SHAPE OF THINGS TO COME	LANCET			English	Article							CARDIOVASCULAR RISK-FACTORS; BLOOD-PRESSURE; BODY-FAT; HYPERTENSION; HYPERINSULINEMIA; DISEASE; OBESITY; LEVEL				WILLIAMS, B (corresponding author), LEICESTER ROYAL INFIRM,DEPT MED & THERAPEUT,CLIN SCI BLDG,POB 65,LEICESTER LE2 7LX,ENGLAND.			Williams, Bryan/0000-0002-8094-1841				BLACK HR, 1990, J CARDIOVASC PHARM, V15, pS26; CARRETTA R, 1989, J HYPERTENS, V7, pS196, DOI 10.1097/00004872-198900076-00094; COOPER ME, 1992, 9TH P INT C END; DEFRONZO RA, 1991, DIABETES CARE, V14, P173, DOI 10.2337/diacare.14.3.173; DONAHUE RP, 1990, AM J EPIDEMIOL, V132, P827, DOI 10.1093/oxfordjournals.aje.a115725; FAGARD RH, 1993, J HYPERTENS, V11, pS47; FERRANNINI E, 1987, NEW ENGL J MED, V317, P350, DOI 10.1056/NEJM198708063170605; GOLAY A, 1988, DIABETES METAB REV, V4, P727, DOI 10.1002/dmr.5610040803; HAFFNER SM, 1988, METABOLISM, V37, P338, DOI 10.1016/0026-0495(88)90133-3; HALL JE, 1991, FASEB J, V5, pA737; HARTMANN J, 1989, LIFE SCI, V45, P267, DOI 10.1016/0024-3205(89)90260-9; Himsworth HP, 1936, LANCET, V1, P127; HUANG HJS, 1992, HYPERTENSION S1, V19, P101; KANAI H, 1990, HYPERTENSION, V16, P484, DOI 10.1161/01.HYP.16.5.484; KISSEBAH AH, 1989, DIABETES METAB REV, V5, P83, DOI 10.1002/dmr.5610050202; LANDIN K, 1991, J INTERN MED, V229, P181, DOI 10.1111/j.1365-2796.1991.tb00328.x; LESLIE RDG, 1987, DIABETES ANN, V3, P39; LILLIOJA S, 1987, J CLIN INVEST, V80, P415, DOI 10.1172/JCI113088; MCKEIGUE PM, 1991, LANCET, V337, P382, DOI 10.1016/0140-6736(91)91164-P; NAGI DK, 1990, DIABETOLOGIA, V33, P532, DOI 10.1007/BF00404140; REAVEN GM, 1987, LANCET, V2, P435; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; SAAD MF, 1991, NEW ENGL J MED, V324, P733, DOI 10.1056/NEJM199103143241105; SAWICKIPT, 1992, DIABETOLOGIA, V35, P649; STRIDSBERG M, 1993, DIABETOLOGIA, V36, P843, DOI 10.1007/BF00400360; VAGUE P, 1986, METABOLISM, V35, P250, DOI 10.1016/0026-0495(86)90209-X; WEINSIER RL, 1985, HYPERTENSION, V7, P578, DOI 10.1161/01.HYP.7.4.578; WELBORN TA, 1966, LANCET, V1, P1336; Zavaroni I, 1989, NEW ENGL J MED, V320, P502	29	89	92	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 20	1994	344	8921					521	524		10.1016/S0140-6736(94)91904-6	http://dx.doi.org/10.1016/S0140-6736(94)91904-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PC535	7914619				2022-12-24	WOS:A1994PC53500015
J	MOREAU, T; THORPE, J; MILLER, D; MOSELEY, I; HALE, G; WALDMANN, H; CLAYTON, D; WING, M; SCOLDING, N; COMPSTON, A				MOREAU, T; THORPE, J; MILLER, D; MOSELEY, I; HALE, G; WALDMANN, H; CLAYTON, D; WING, M; SCOLDING, N; COMPSTON, A			PRELIMINARY EVIDENCE FROM MAGNETIC-RESONANCE-IMAGING FOR REDUCTION IN DISEASE-ACTIVITY AFTER LYMPHOCYTE DEPLETION IN MULTIPLE-SCLEROSIS	LANCET			English	Article							MONOCLONAL-ANTIBODY THERAPY; LESION DEVELOPMENT; GUIDELINES; TRIAL	The central nervous system lesions of multiple sclerosis (MS) can be detected by magnetic resonance imaging (MRI) and the initial perivascular inflammatory component is distinguished by the presence of gadolinium enhancement. To assess the effect of systemic lymphocyte depletion on disease activity, seven patients with MS received a 10-day intravenous course of the humanised monoclonal antibody CAMPATH-1H (anti-CDw52). With some variations in the protocol, enhanced cerebral MR images were obtained monthly for 3-4 months before and at least 6 months after treatment. 28 enhancing areas were detected on the first series of 7 scans; 51 additional active lesions were identified on 18 scans before treatment; 15 were detected on 20 scans done over the next 3 months, but only 2 active lesions were seen on 23 scans during follow-up beyond 3 months. The difference in lesion incidence rate before and after treatment varied and the rate ratio was significantly reduced in only three patients. Collectively, in a ''meta-analysis'', the rate ratios were 0.58 (95% Cl 0.09-0.24) for all seven patients and 0.24 (0.14-0.42; p < 0.001) with exclusion of the patient whose scanning schedule differed. The effect of CAMPATH-1H on disease activity provides direct, but preliminary, evidence that disease activity in MS depends on the availability of circulating lymphocytes and can be prevented by lymphocyte depletion. It is too early to say anything about the clinical results of treatment with this agent.	UNIV CAMBRIDGE,ADDENBROOKES HOSP,NEUROL UNIT,CAMBRIDGE CB2 2QQ,ENGLAND; INST NEUROL,NMR RES UNIT,LONDON WC1,ENGLAND; NATL HOSP,LONDON WC1,ENGLAND; UNIV CAMBRIDGE,DEPT PATHOL,DIV IMMUNOL,CAMBRIDGE CB2 1QP,ENGLAND; INST PUBL HLTH,MRC,BIOSTAT UNIT,CAMBRIDGE,CAMBS,ENGLAND; ADDENBROOKES HOSP,CTR MRC,MOLEC IMMUNOPATHOL UNIT,CAMBRIDGE,ENGLAND; MRC,CAMBRIDGE CTR BRAIN REPAIR,CAMBRIDGE,ENGLAND	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; University of Cambridge; MRC Biostatistics Unit; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Cambridge			waldmann, herman/W-8051-2019	Hale, Geoff/0000-0001-9473-423X; Waldmann, Herman/0000-0001-7519-6720				CLAYTON D, 1993, STAT MODELS EPIDEMIO, P110; EBERS GC, 1994, LANCET, V343, P275, DOI 10.1016/S0140-6736(94)91119-3; FFRENCHCONSTANT C, 1994, LANCET, V343, P271, DOI 10.1016/S0140-6736(94)91118-5; FILIIPPI M, IN PRESS NEUROLOGY; FILIPPI M, 1994, NEUROLOGY, V44, pA339; HAFLER DA, 1988, J IMMUNOL, V141, P131; HALE G, 1990, TISSUE ANTIGENS, V35, P1; ISAACS JD, 1992, LANCET, V340, P748, DOI 10.1016/0140-6736(92)92294-P; KATZ D, 1993, ANN NEUROL, V34, P661, DOI 10.1002/ana.410340507; KERMODE AG, 1990, BRAIN, V113, P1477, DOI 10.1093/brain/113.5.1477; LINDSEY JW, 1994, NEUROLOGY, V44, P413, DOI 10.1212/WNL.44.3_Part_1.413; LOCKWOOD CM, 1993, LANCET, V341, P1620, DOI 10.1016/0140-6736(93)90759-A; MILLER DH, 1991, J NEUROL NEUROSUR PS, V54, P683, DOI 10.1136/jnnp.54.8.683; NAUTA JJP, 1994, J NEUROL SCI, V122, P6, DOI 10.1016/0022-510X(94)90045-0; PATY DW, 1993, NEUROLOGY, V43, P662, DOI 10.1212/WNL.43.4.662; POSER CM, 1983, ANN NEUROL, V13, P227, DOI 10.1002/ana.410130302; RAINE CS, 1991, NEUROPATH APPL NEURO, V17, P265, DOI 10.1111/j.1365-2990.1991.tb00724.x; RIECHMANN L, 1988, NATURE, V332, P323, DOI 10.1038/332323a0; The IFNB Multiple Sclerosis Study Group, 1993, NEUROLOGY, V43, P655; WEINSHENKER BG, 1991, NEUROLOGY, V41, P1047, DOI 10.1212/WNL.41.7.1047; YOUL BD, 1991, BRAIN, V114, P2437, DOI 10.1093/brain/114.6.2437	21	161	168	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 30	1994	344	8918					298	301		10.1016/S0140-6736(94)91339-0	http://dx.doi.org/10.1016/S0140-6736(94)91339-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NZ233	7914262				2022-12-24	WOS:A1994NZ23300008
J	SCHMIDT, M; RUTKAT, K; RACHEL, R; PFEIFER, G; JAENICKE, R; VIITANEN, P; LORIMER, G; BUCHNER, J				SCHMIDT, M; RUTKAT, K; RACHEL, R; PFEIFER, G; JAENICKE, R; VIITANEN, P; LORIMER, G; BUCHNER, J			SYMMETRICAL COMPLEXES OF GROE CHAPERONINS AS PART OF THE FUNCTIONAL CYCLE	SCIENCE			English	Article							ESCHERICHIA-COLI; ELECTRON-MICROSCOPY; ATP HYDROLYSIS; CENTRAL CAVITY; PROTEIN; COOPERATIVITY; PURIFICATION; INTERACTS; SURFACE	The particular structural arrangement of chaperonins probably contributes to their ability to assist in the folding of proteins. The interaction of the oligomeric bacterial chaperonin GroEL and its cochaperonin, GroES, in the presence of adenosine diphosphate (ADP) forms an asymmetric complex. However, in the presence of adenosine triphosphate (ATP) or its nonhydrolyzable analogs, symmetric complexes were found by electron microscopy and image analysis. The existence of symmetric chaperonin complexes is not predicted by current models of the functional cycle for GroE-mediated protein folding. Because complete folding of a nonnative substrate protein in the presence of GroEL and GroES only occurs in the presence of ATP, but not with ADP, the symmetric chaperonin complexes formed during the GroE cycle are proposed to be functionally significant.	UNIV REGENSBURG,INST BIOPHYS & PHYS BIOCHEM,D-93040 REGENSBURG,GERMANY; UNIV REGENSBURG,INST MIKROBIOL,D-93040 REGENSBURG,GERMANY; MAX PLANCK INST BIOCHEM,D-82153 MARTINSRIED,GERMANY; DUPONT CO INC,DEPT CENT RES & DEV,DIV MOLEC BIOL,EXPTL STN,WILMINGTON,DE 19880	University of Regensburg; University of Regensburg; Max Planck Society; DuPont			Buchner, Johannes/A-2651-2010	Buchner, Johannes/0000-0003-1282-7737				AZEM A, 1994, SCIENCE, V265, P653, DOI 10.1126/science.7913553; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P6796; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P25672; BRAIG K, 1993, P NATL ACAD SCI USA, V90, P3978, DOI 10.1073/pnas.90.9.3978; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; FAYET O, 1986, MOL GEN GENET, V202, P435, DOI 10.1007/BF00333274; FRANK J, 1981, SCIENCE, V214, P1353, DOI 10.1126/science.7313694; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; HEGERL R, 1982, ULTRAMICROSCOPY, V9, P109, DOI 10.1016/0304-3991(82)90233-9; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; ISHII N, 1992, FEBS LETT, V299, P169, DOI 10.1016/0014-5793(92)80240-H; ISHII N, 1994, J MOL BIOL, V236, P691, DOI 10.1006/jmbi.1994.1181; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; JAENICKE R, 1993, CURR OPIN STRUC BIOL, V3, P104, DOI 10.1016/0959-440X(93)90209-4; LANDRY SJ, 1993, NATURE, V364, P255, DOI 10.1038/364255a0; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; SAIBIL HR, 1993, CURR BIOL, V3, P265, DOI 10.1016/0960-9822(93)90176-O; SAXTON WO, 1979, ULTRAMICROSCOPY, V9, P109; SCHMIDT M, 1994, J BIOL CHEM, V269, P10304; Schmidt M. K., UNPUB; SVENSSON LA, 1994, J MOL BIOL, V235, P47; TAGOUCHI H, 1991, J BIOL CHEM, V266, P22411; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; TODD MJ, 1993, BIOCHEMISTRY-US, V32, P8560, DOI 10.1021/bi00084a024; VANHEEL M, 1981, ULTRAMICROSCOPY, V6, P187, DOI 10.1016/S0304-3991(81)80197-0; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; VIITANEN PV, 1992, PROTEIN SCI, V1, P363; ZEILSTRARYALLS J, 1991, ANNU REV MICROBIOL, V45, P301, DOI 10.1146/annurev.mi.45.100191.001505; ZWICKL P, 1990, J STRUCT BIOL, V103, P197, DOI 10.1016/1047-8477(90)90037-D	33	186	187	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 29	1994	265	5172					656	659		10.1126/science.7913554	http://dx.doi.org/10.1126/science.7913554			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NZ538	7913554				2022-12-24	WOS:A1994NZ53800032
J	LOHMANN, T; LESLIE, RDG; HAWA, M; GEYSEN, M; RODDA, S; LONDEI, M				LOHMANN, T; LESLIE, RDG; HAWA, M; GEYSEN, M; RODDA, S; LONDEI, M			IMMUNODOMINANT EPITOPES OF GLUTAMIC-ACID DECARBOXYLASE-65 AND DECARBOXYLASE-67 IN INSULIN-DEPENDENT DIABETES-MELLITUS	LANCET			English	Note							GAD	To find the dominant epitopes of a major autoantigen in insulin-dependent diabetes mellitus (IDDM), glutamic acid decarboxylase (GAD), we studied the reactivity of peripheral blood T lymphocytes with peptides covering both major isoforms. A significant response to GAD 65 or GAD 67 peptides was detected in 13 of 15 IDDM patients and in 9 of 10 normal controls. Controls most frequently recognised the central region of GAD 65 (residues 161-243). IDDM patients preferentially recognised residues 473-555 (p < 0.03). T-cell responses to GAD 67 peptides were similar in IDDM patients and controls. T lymphocytes from IDDM patients recognise a distinct dominant epitope of GAD, which may be an important target for the disease process.	UNIV LONDON ST BARTHOLOMEWS HOSP & MED COLL,DEPT DIABET & METAB,LONDON EC1A 7BE,ENGLAND; KENNEDY INST,LONDON W6,ENGLAND; CHIRON MIMOTOPES,CLAYTON,VIC,AUSTRALIA	University of London; Queen Mary University London			Leslie, Richard/AAF-6977-2020; Rodda, Simone/S-9766-2018	Leslie, Richard/0000-0002-1786-1531; Rodda, Simone/0000-0002-7973-1003				ATKINSON MA, 1992, LANCET, V339, P458, DOI 10.1016/0140-6736(92)91061-C; BAEKKESKOV S, 1990, NATURE, V347, P151, DOI 10.1038/347151a0; BU DF, 1992, P NATL ACAD SCI USA, V89, P2115, DOI 10.1073/pnas.89.6.2115; CHRISTIE MR, 1992, DIABETES, V41, P782, DOI 10.2337/diabetes.41.7.782; HARRISON LC, 1993, LANCET, V341, P1365, DOI 10.1016/0140-6736(93)90940-I; KAUFMAN DL, 1993, NATURE, V366, P69, DOI 10.1038/366069a0; REECE JC, 1993, J IMMUNOL, V151, P6175; TISCH R, 1993, NATURE, V366, P72, DOI 10.1038/366072a0; Zhang J, 1992, Int Rev Immunol, V9, P183, DOI 10.3109/08830189209061790	9	100	102	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 25	1994	343	8913					1607	1608		10.1016/S0140-6736(94)93061-9	http://dx.doi.org/10.1016/S0140-6736(94)93061-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU354	7911924				2022-12-24	WOS:A1994NU35400014
J	HENGARTNER, MO; HORVITZ, HR				HENGARTNER, MO; HORVITZ, HR			ACTIVATION OF C-ELEGANS CELL-DEATH PROTEIN CED-9 BY AN AMINO-ACID SUBSTITUTION IN A DOMAIN CONSERVED IN BCL-2	NATURE			English	Article							CAENORHABDITIS-ELEGANS; SEQUENCE SIMILARITY; FOLLICULAR LYMPHOMA; GENE; TRANSLOCATION; EXPRESSION; NEMATODE; CLONING	THE Caenorhabditis elegans gene ced-9 and the human protooncogene bcl-2 both of which protect cells from programmed cell death, are members of the same gene family(1-11). ced-9 and bcl-2 were discovered because of the effects of dominant gain-of-function mutations(12-14). Such bcl-2 mutations, which are commonly found in follicular lymphoma, are translocations that result in overexpression of a normal Bcl-2 protein in B cells(1,13-16) Here we report that, by contrast, the ced-9(n1950) gain-of-function mutation affects the open reading frame of ced-9 and results in a glycine-to-glutamate substitution in a region highly conserved among all ced-9/bcl-2 family members. We conclude that this glycine has an important function in ced-9 regulation, and we suggest that alteration of this glycine in other members of the ced-9/bcl-2 family might lead to oncogenic activation. We also present genetic evidence suggesting that the CED-9 protein might exist in two distinct forms that have opposite effects on cell death.	MIT,HOWARD HUGHES MED INST,DEPT BIOL,CAMBRIDGE,MA 02139	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)			Hengartner, Michael O/A-7058-2008; Hengartner, Michael O/E-6235-2011	Hengartner, Michael/0000-0002-7584-596X				ALBRECHT JC, 1992, J VIROL, V66, P5047, DOI 10.1128/JVI.66.8.5047-5058.1992; AVERY L, 1987, CELL, V51, P1071, DOI 10.1016/0092-8674(87)90593-9; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CAZALSHATEM DL, 1992, BIOCHIM BIOPHYS ACTA, V1132, P109, DOI 10.1016/0167-4781(92)90064-7; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; EGUCHI Y, 1992, NUCLEIC ACIDS RES, V20, P4187, DOI 10.1093/nar/20.16.4187; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; FILES JG, 1983, J MOL BIOL, V164, P355, DOI 10.1016/0022-2836(83)90056-6; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; HENGARTNER MO, IN PRESS CURR OPIN G; KORSMEYER SJ, 1993, SEMIN CANCER BIOL, V4, P327; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; LIN EY, 1993, J IMMUNOL, V151, P1979; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; NEGRINI M, 1987, CELL, V49, P455, DOI 10.1016/0092-8674(87)90448-X; NEILAN JG, 1993, J VIROL, V67, P4391, DOI 10.1128/JVI.67.7.4391-4394.1993; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PEARSON GR, 1987, VIROLOGY, V160, P151, DOI 10.1016/0042-6822(87)90055-9; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; YUAN JY, 1992, DEVELOPMENT, V116, P309; YUNIS JJ, 1982, NEW ENGL J MED, V307, P1231, DOI 10.1056/NEJM198211113072002	28	153	158	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 26	1994	369	6478					318	320		10.1038/369318a0	http://dx.doi.org/10.1038/369318a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NN109	7910376				2022-12-24	WOS:A1994NN10900049
J	COHEN, FE; PAN, KM; HUANG, Z; BALDWIN, M; FLETTERICK, RJ; PRUSINER, SB				COHEN, FE; PAN, KM; HUANG, Z; BALDWIN, M; FLETTERICK, RJ; PRUSINER, SB			STRUCTURAL CLUES TO PRION REPLICATION	SCIENCE			English	Editorial Material							CREUTZFELDT-JAKOB DISEASE; TRANSGENIC MICE; PRP ISOFORMS; PROTEIN GENE; SCRAPIE; HAMSTERS; LINKAGE; CELLS		UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT NEUROL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco								ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; BASLER K, 1986, CELL, V46, P417, DOI 10.1016/0092-8674(86)90662-8; BESSEN RA, 1992, J GEN VIROL, V73, P329, DOI 10.1099/0022-1317-73-2-329; BORCHELT DR, 1990, J CELL BIOL, V110, P743, DOI 10.1083/jcb.110.3.743; BROWN P, 1990, P NATL ACAD SCI USA, V87, P7240, DOI 10.1073/pnas.87.18.7240; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; CARLSON GA, 1989, P NATL ACAD SCI USA, V86, P7475, DOI 10.1073/pnas.86.19.7475; CARLSON GA, IN PRESS P NATL ACAD; CAUGHEY B, 1989, J VIROL, V63, P175, DOI 10.1128/JVI.63.1.175-181.1989; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; DEARMOND SJ, 1993, P NATL ACAD SCI USA, V90, P6449, DOI 10.1073/pnas.90.14.6449; DICKINSON AG, 1968, J COMP PATHOL, V78, P293, DOI 10.1016/0021-9975(68)90005-4; DLOUHY SR, 1992, NAT GENET, V1, P64, DOI 10.1038/ng0492-64; GABIZON R, 1993, AM J HUM GENET, V33, P828; GASSET M, 1993, P NATL ACAD SCI USA, V90, P1, DOI 10.1073/pnas.90.1.1; GASSET M, 1992, P NATL ACAD SCI USA, V89, P10940, DOI 10.1073/pnas.89.22.10940; GOLDFARB LG, 1992, SCIENCE, V258, P806, DOI 10.1126/science.1439789; HECKER R, 1992, GENE DEV, V6, P1213, DOI 10.1101/gad.6.7.1213; HSIAO K, 1989, NATURE, V338, P342, DOI 10.1038/338342a0; HSIAO KK, 1990, SCIENCE, V250, P1587, DOI 10.1126/science.1980379; HUANG Z, IN PRESS P NATL ACAD; LIFSON S, 1980, PROTEIN FOLDING, P289; MCKINLEY MP, 1991, J VIROL, V65, P1440; MONARI L, 1994, P NATL ACAD SCI USA, V91, P2839, DOI 10.1073/pnas.91.7.2839; PALMER MS, 1991, NATURE, V352, P340, DOI 10.1038/352340a0; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; PETERSEN RB, 1992, NEUROLOGY, V42, P1859, DOI 10.1212/WNL.42.10.1859; POULTER M, 1992, BRAIN, V115, P675, DOI 10.1093/brain/115.3.675; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; PRUSINER SB, 1993, P NATL ACAD SCI USA, V90, P10608, DOI 10.1073/pnas.90.22.10608; PRUSINER SB, 1983, CELL, V35, P349, DOI 10.1016/0092-8674(83)90168-X; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; PRUSINER SB, 1993, P NATL ACAD SCI USA, V90, P2793, DOI 10.1073/pnas.90.7.2793; ROGERS M, 1993, P NATL ACAD SCI USA, V90, P3182, DOI 10.1073/pnas.90.8.3182; SAFAR J, 1993, PROTEIN SCI, V2, P2206, DOI 10.1002/pro.5560021220; SCOTT M, 1993, CELL, V73, P979, DOI 10.1016/0092-8674(93)90275-U; STAHL N, 1993, BIOCHEMISTRY-US, V32, P1991, DOI 10.1021/bi00059a016; STAHL N, 1987, CELL, V51, P229, DOI 10.1016/0092-8674(87)90150-4; TARABOULOS A, 1992, EMBO J, V11, P863; WESTAWAY D, 1987, CELL, V51, P651, DOI 10.1016/0092-8674(87)90134-6; WESTAWAY D, 1994, CELL, V76, P117, DOI 10.1016/0092-8674(94)90177-5; WESTAWAY D, IN PRESS P NATL ACAD	42	430	451	1	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 22	1994	264	5158					530	531		10.1126/science.7909169	http://dx.doi.org/10.1126/science.7909169			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NH010	7909169				2022-12-24	WOS:A1994NH01000025
J	BESSLER, M; MASON, P; HILLMEN, P; LUZZATTO, L				BESSLER, M; MASON, P; HILLMEN, P; LUZZATTO, L			SOMATIC MUTATIONS AND CELLULAR-SELECTION IN PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA	LANCET			English	Note							RED-CELLS; HEMOGLOBINURIA	Patients with paroxysmal nocturnal haemoglobinuria (PNH) have in their blood two red-cell populations, one normal and one deficient in proteins anchored to the membrane through a glycan phosphatidylinositol (GPI) structure. The PNH abnormality is due to a somatic mutation in the PIG-A gene, whose product is required for an early step in GPI anchor biosynthesis. We show that in two patients, two PNH clones with different mutations co-exist, and must therefore have arisen independently. This finding supports the concept that PNH develops under the pressures of a positive selection mechanism whereby GPI-anchor-deficient haemopoietic cells have a survival advantage.	HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,MRC,LRF LEUKAEMIA UNIT,LONDON,ENGLAND	Imperial College London	BESSLER, M (corresponding author), HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT HAEMATOL,DU CANE RD,LONDON W12 ONN,ENGLAND.		Mason, Philip J/B-1087-2008		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARMSTRONG C, 1992, J BIOL CHEM, V267, P25347; BESSLER M, 1994, EMBO J, V13, P110, DOI 10.1002/j.1460-2075.1994.tb06240.x; DACIE JV, 1972, SER HAEMATOL, V3, P3; HILLMEN P, 1993, BLOOD, V81, P193; MIYATA T, 1994, NEW ENGL J MED, V330, P249, DOI 10.1056/NEJM199401273300404; MIYATA T, 1993, SCIENCE, V259, P1318, DOI 10.1126/science.7680492; ONI SB, 1970, BLOOD-J HEMATOL, V36, P145, DOI 10.1182/blood.V36.2.145.145; ROSSE WF, 1973, BRIT J HAEMATOL, V24, P327, DOI 10.1111/j.1365-2141.1973.tb01657.x; Rotoli B, 1989, Baillieres Clin Haematol, V2, P113, DOI 10.1016/S0950-3536(89)80010-1; TAKEDA J, 1993, CELL, V73, P703, DOI 10.1016/0092-8674(93)90250-T	10	146	148	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 16	1994	343	8903					951	953		10.1016/S0140-6736(94)90068-X	http://dx.doi.org/10.1016/S0140-6736(94)90068-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF700	7909012				2022-12-24	WOS:A1994NF70000012
J	RAVINE, D; GIBSON, RN; WALKER, RG; SHEFFIELD, LJ; KINCAIDSMITH, P; DANKS, DM				RAVINE, D; GIBSON, RN; WALKER, RG; SHEFFIELD, LJ; KINCAIDSMITH, P; DANKS, DM			EVALUATION OF ULTRASONOGRAPHIC DIAGNOSTIC-CRITERIA FOR AUTOSOMAL-DOMINANT POLYCYSTIC KIDNEY DISEASE-1	LANCET			English	Article							CHROMOSOME-16; LOCUS; PKD1; MARKERS; GENE	Although ultrasound is commonly used for screening subjects at risk of polycystic kidney disease 1 (PKD1), there has been no evaluation of ultrasonographic diagnostic criteria. We used DNA linkage among subjects from 128 sibships within 18 PKD1 families as the basis for an assessment of ultrasound sensitivity. Positive and negative predictive values were calculated to allow assessment of different diagnostic cut-off points in previously undiagnosed cases. Currently used criteria (bilateral cysts with at least two in one kidney) provided good sensitivity (88.5% at age 15-29 years and 100% at 30 years and above) but performance could be improved by less stringent criteria in subjects aged 15-29 years and more stringent criteria in older family members, in whom simple renal cysts are frequent. The presence of at least two renal cysts (unilateral or bilateral) in individuals at risk and younger than 30 years may be regarded as sufficient to establish a diagnosis; among those aged 30-59 years, the presence of at least two cysts in each kidney may be required, and among those aged 60 years and above, at least four cysts in each kidney should be required.	ROYAL CHILDRENS HOSP,MURDOCH INST,PARKVILLE,VIC 3052,AUSTRALIA; ROYAL MELBOURNE HOSP,DEPT RADIOL,PARKVILLE,VIC 3050,AUSTRALIA; ROYAL MELBOURNE HOSP,DEPT NEPHROL,PARKVILLE,VIC 3050,AUSTRALIA	Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; Royal Melbourne Hospital; Royal Melbourne Hospital			Ravine, David/A-6797-2008					BEAR JC, 1984, AM J MED GENET, V18, P45, DOI 10.1002/ajmg.1320180108; BEAR JC, 1992, AM J MED GENET, V43, P548, DOI 10.1002/ajmg.1320430309; BENNETT WM, 1990, SEMIN NEPHROL, V10, P552; BREUNING MH, 1990, NUCLEIC ACIDS RES, V18, P3106, DOI 10.1093/nar/18.10.3106-a; BREUNING MH, 1987, LANCET, V2, P1359; COTO E, 1992, J MED GENET, V29, P243, DOI 10.1136/jmg.29.4.243; DISNEY APS, 1990, ANZDATA13TH QUEEN EL, P22; FICK GM, 1993, J AM SOC NEPHROL, V3, P1863; GERMINO GG, 1990, AM J HUM GENET, V46, P925; HOGEWIND BL, 1980, CLIN GENET, V18, P168; HYLAND VJ, 1990, HUM GENET, V84, P286; JARMAN AP, 1986, EMBO J, V5, P1857, DOI 10.1002/j.1460-2075.1986.tb04437.x; KIMBERLING WJ, 1993, GENOMICS, V18, P467, DOI 10.1016/S0888-7543(11)80001-7; KIMBERLING WJ, 1988, NEW ENGL J MED, V319, P913, DOI 10.1056/NEJM198810063191405; LATHROP GM, 1984, AM J HUM GENET, V36, P460; LATHROP GM, 1988, AM J HUM GENET, V42, P498; MCHUGH K, 1991, RADIOLOGY, V178, P383, DOI 10.1148/radiology.178.2.1987597; MILUTINOVIC J, 1980, LANCET, V1, P1203; MILUTINOVIC J, 1989, AM J KIDNEY DIS, V13, P340, DOI 10.1016/S0272-6386(89)80043-5; PARFREY PS, 1990, NEW ENGL J MED, V323, P1085, DOI 10.1056/NEJM199010183231601; PETERS DJM, 1993, NAT GENET, V5, P359, DOI 10.1038/ng1293-359; PETERS DJM, 1992, CONTRIB NEPHROL, V97, P128; RAVINE D, 1993, AM J KIDNEY DIS, V22, P803, DOI 10.1016/S0272-6386(12)70338-4; RAVINE D, 1992, LANCET, V340, P1300; REEDERS ST, 1985, NATURE, V317, P542, DOI 10.1038/317542a0; ROMEO G, 1988, LANCET, V2, P8; SACKETT DL, 1991, CLIN EPIDEMIOLOGY BA, P88; SNIJDEWINT FGM, 1990, NUCLEIC ACIDS RES, V18, P3108, DOI 10.1093/nar/18.10.3108-a; THOMPSON AD, 1992, GENOMICS, V13, P402, DOI 10.1016/0888-7543(92)90260-Y; Tufveson G, 1989, NEPHROL DIAL TRAN S4, V4, P5	30	442	465	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 2	1994	343	8901					824	827		10.1016/S0140-6736(94)92026-5	http://dx.doi.org/10.1016/S0140-6736(94)92026-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ND792	7908078				2022-12-24	WOS:A1994ND79200009
J	ARINAMI, T; ITOKAWA, M; ENGUCHI, H; TAGAYA, H; YANO, S; SHIMIZU, H; HAMAGUCHI, H; TORU, M				ARINAMI, T; ITOKAWA, M; ENGUCHI, H; TAGAYA, H; YANO, S; SHIMIZU, H; HAMAGUCHI, H; TORU, M			ASSOCIATION OF DOPAMINE D2 RECEPTOR MOLECULAR VARIANT WITH SCHIZOPHRENIA	LANCET			English	Note							GENE	We have examined a variant of the dopamine D2 receptor gene (Ser311-->Cys) in 156 Japanese schizophrenic patients and 300 controls. The allele frequency of Cys311 was significantly higher in the whole patient group (0.054), among patients with onset before age 25 (0.090), and among those with a family history (0.135) than in the controls (0.018). 3 patients were homozygous for Cys311. The patients with Cys311 showed significantly less severe thought disorder and negative symptoms of schizophrenia than those without Cys311. The Cys311 variant of the D2 receptor may be a genetic risk factor for some types of schizophrenia.	TOKYO MED & DENT UNIV,DEPT NEUROPSYCHIAT,TOKYO,TOKYO,JAPAN; HOKUSHIN GEN HOSP,DEPT PSYCHIAT,NAKANO,NAGANO,JAPAN	Tokyo Medical & Dental University (TMDU)	ARINAMI, T (corresponding author), UNIV TSUKUBA,INST BASIC MED SCI,DEPT MED GENET,TSUKUBA,IBARAKI 305,JAPAN.			Itokawa, Masanari/0000-0003-4433-8030				CATALANO M, 1992, NEUROPSYCHOBIOLOGY, V26, P1, DOI 10.1159/000118888; CROW TJ, 1980, BRIT MED J, V280, P66, DOI 10.1136/bmj.280.6207.66; DALTOSO R, 1989, EMBO J, V8, P4025, DOI 10.1002/j.1460-2075.1989.tb08585.x; GRANDY DK, 1989, P NATL ACAD SCI USA, V86, P9762, DOI 10.1073/pnas.86.24.9762; ITOKAWA M, 1993, BIOCHEM BIOPH RES CO, V196, P1369, DOI 10.1006/bbrc.1993.2404; KRAWIECKA M, 1977, ACTA PSYCHIAT SCAND, V55, P299, DOI 10.1111/j.1600-0447.1977.tb00174.x; SARKAR G, 1991, GENOMICS, V11, P8, DOI 10.1016/0888-7543(91)90096-W; SEEMAN P, 1993, NEUROPSYCHOPHARMACOL, V8, P137, DOI 10.1038/npp.1993.15; SEEMAN P, 1992, NEUROPSYCHOPHARMACOL, V7, P261; SU Y, 1993, ARCH GEN PSYCHIAT, V50, P205	10	168	173	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 19	1994	343	8899					703	704		10.1016/S0140-6736(94)91581-4	http://dx.doi.org/10.1016/S0140-6736(94)91581-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NB809	7907680				2022-12-24	WOS:A1994NB80900010
J	BARNETT, DB				BARNETT, DB			BETA-BLOCKERS IN HEART-FAILURE - A THERAPEUTIC PARADOX	LANCET			English	Editorial Material							IDIOPATHIC DILATED CARDIOMYOPATHY; CONGESTIVE CARDIOMYOPATHY; CARDIAC-FUNCTION; DOUBLE-BLIND; BLOCKADE; BUCINDOLOL; METOPROLOL				BARNETT, DB (corresponding author), UNIV LEICESTER, DEPT MED & THERAPEUT, LEICESTER, LEICS, ENGLAND.							COHN JN, 1984, NEW ENGL J MED, V31, P28; CURRIE PJ, 1984, J AM COLL CARDIOL, V3, P203, DOI 10.1016/S0735-1097(84)80449-0; ENGELMEIER RS, 1985, CIRCULATION, V72, P536, DOI 10.1161/01.CIR.72.3.536; FRANCIS GS, 1990, CIRCULATION, V82, P1724, DOI 10.1161/01.CIR.82.5.1724; GILBERT EM, 1990, AM J MED, V88, P223, DOI 10.1016/0002-9343(90)90146-5; IKRAM H, 1981, LANCET, V2, P490; LEVINE TB, 1982, AM J CARDIOL, V49, P1659, DOI 10.1016/0002-9149(82)90243-0; NEMANICH JW, 1990, AM J CARDIOL, V66, P843, DOI 10.1016/0002-9149(90)90362-5; POLLOCK SG, 1990, AM J CARDIOL, V66, P603, DOI 10.1016/0002-9149(90)90488-M; SWEDBERG K, 1980, BRIT HEART J, V44, P134; SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429; WAAGSTEIN F, 1975, BRIT HEART J, V37, P1022; WAAGSTEIN F, 1993, LANCET, V342, P1441, DOI 10.1016/0140-6736(93)92930-R; WOODLEY SL, 1991, CIRCULATION, V84, P2426, DOI 10.1161/01.CIR.84.6.2426	14	4	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 5	1994	343	8897					557	558		10.1016/S0140-6736(94)91518-0	http://dx.doi.org/10.1016/S0140-6736(94)91518-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY843	7906326				2022-12-24	WOS:A1994MY84300006
J	BUTLER, C				BUTLER, C			OVERPOPULATION, OVERCONSUMPTION, AND ECONOMICS	LANCET			English	Editorial Material							HEALTH						Butler, Colin D./H-2267-2019	Butler, Colin D./0000-0002-2942-5294				[Anonymous], 1973, SMALL IS BEAUTIFUL; BARBIER E, 1986, LIVING EC NEW EC MAK, P7; BUTLER CD, 1991, MED J AUSTRALIA, V155, P351, DOI 10.5694/j.1326-5377.1991.tb142316.x; Dalai Lama XIV, 1990, D LAMA POLICY KINDNE; EHRLICH PR, 1991, HEALING PLANET, P42; FELLOWS L, 1992, LANCET, V340, P1330; GORE A, 1992, EARTH BALANCE; HAINES A, 1993, LANCET, V342, P1464, DOI 10.1016/0140-6736(93)92937-O; Henderson H., 1981, POLITICS SOLAR AGE; KELLY J, 1993, LANCET, V342, P808; KING M, 1990, LANCET, V336, P664, DOI 10.1016/0140-6736(90)92156-C; KING M, 1993, LANCET, V341, P669, DOI 10.1016/0140-6736(93)90431-F; LAST JM, 1993, LANCET, V342, P508, DOI 10.1016/0140-6736(93)91641-X; LEAF A, 1989, NEW ENGL J MED, V321, P1577, DOI 10.1056/NEJM198912073212305; LOVELOCK J, 1988, AGES GAIA, P181; OMRAN AR, 1993, LANCET, V342, P808, DOI 10.1016/0140-6736(93)91574-6; ONEILL P, 1993, BRIT MED J, V307, P1162; PEETERS MA, 1993, LANCET, V342, P808; REDDY AKN, 1990, SCI AM, V263, P64; TROUNSON A, 1994, LANCET, V343, P59, DOI 10.1016/S0140-6736(94)90916-4; TYLLESKAR T, 1992, LANCET, V339, P208, DOI 10.1016/0140-6736(92)90006-O; VERKUYL DAA, 1993, LANCET, V342, P473, DOI 10.1016/0140-6736(93)91597-F; 1993, 1993 WORLD BANK WORL; 1993, LANCET, V342, P1125; 1993, LANCET, V342, P447	25	11	11	1	19	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 5	1994	343	8897					582	584		10.1016/S0140-6736(94)91526-1	http://dx.doi.org/10.1016/S0140-6736(94)91526-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MY843	7906334				2022-12-24	WOS:A1994MY84300014
J	DONALDSON, YK; BELL, JE; IRONSIDE, JW; BRETTLE, RP; ROBERTSON, JR; BUSUTTIL, A; SIMMONDS, P				DONALDSON, YK; BELL, JE; IRONSIDE, JW; BRETTLE, RP; ROBERTSON, JR; BUSUTTIL, A; SIMMONDS, P			REDISTRIBUTION OF HIV OUTSIDE THE LYMPHOID SYSTEM WITH ONSET OF AIDS	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; DEFICIENCY SYNDROME AIDS; INFECTED INDIVIDUALS; CELLS; BRAIN; MACROPHAGES; DISEASE; RNA; DNA	The basis for many of the symptoms and pathological changes found in patients with the acquired immunodeficiency syndrome (AIDS) remains poorly understood. We have used a quantitative polymerase chain reaction technique to investigate the extent to which direct infection with human immunodeficiency virus (HIV) produces the disease manifestations of AIDS. In five patients who died with AIDS-defining illnesses (Centers for Disease Control and Prevention class IV), we found variable, but in many cases extensive, infection by HIV at various sites, including brain, lung, colon, and liver. By contrast, in three HIV-positive subjects who died without HIV-related disease (CDC class II), we found no evidence of significant infection of any non-lymphoid organ. In both groups of patients there were high levels of infection in cells of the spleen, lymph nodes, and peripheral blood. Pathological examination of tissues from the AIDS patients revealed many abnormalities, of which some, such as giant-cell encephalitis in the brain, were specifically associated with the presence of high levels of HIV infection. These findings suggest that spread of HIV outside cells of the immune system is a late event in HIV infection and is extremely sensitive to the degree of immunosuppression in the patient.	UNIV EDINBURGH,SCH MED,DEPT MED MICROBIOL,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND; UNIV EDINBURGH,DEPT PATHOL,EDINBURGH,MIDLOTHIAN,SCOTLAND; WESTERN GEN HOSP,DEPT PATHOL,EDINBURGH,MIDLOTHIAN,SCOTLAND; CITY HOSP EDINBURGH,REG INFECT DIS UNIT,EDINBURGH,MIDLOTHIAN,SCOTLAND; MULRHOUSE GEN PRACTICE,EDINBURGH,MIDLOTHIAN,SCOTLAND	University of Edinburgh; University of Edinburgh; University of Edinburgh				Ironside, James/0000-0001-5869-2108; Simmonds, Peter/0000-0002-7964-4700				BELL JE, 1993, J INFECT DIS, V168, P819; Budka H, 1991, BRAIN PATHOL, V1, P143, DOI 10.1111/j.1750-3639.1991.tb00653.x; CAOY, 1992, AIDS, V6, P65; CLARKE JR, 1990, AIDS, V4, P1133, DOI 10.1097/00002030-199011000-00012; DAVIS LE, 1992, NEUROLOGY, V42, P1736, DOI 10.1212/WNL.42.9.1736; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; FOX CH, 1989, J INFECT DIS, V159, P467, DOI 10.1093/infdis/159.3.467; FOX CH, 1991, J INFECT DIS, V164, P1051, DOI 10.1093/infdis/164.6.1051; GRAY F, 1988, BRAIN, V111, P245, DOI 10.1093/brain/111.2.245; HO DD, 1986, J CLIN INVEST, V77, P1712, DOI 10.1172/JCI112491; HO DD, 1987, NEW ENGL J MED, V317, P278; HOUSSET C, 1990, HUM PATHOL, V21, P404, DOI 10.1016/0046-8177(90)90202-G; LEVY JA, 1985, VIROLOGY, V147, P441, DOI 10.1016/0042-6822(85)90146-1; MACATONIA SE, 1990, IMMUNOLOGY, V71, P38; MOYER MP, 1990, AIDS RES HUM RETROV, V6, P1409, DOI 10.1089/aid.1990.6.1409; PANG S, 1990, NATURE, V343, P85, DOI 10.1038/343085a0; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; SCHNEIDERMAN DJ, 1987, HEPATOLOGY, V7, P925, DOI 10.1002/hep.1840070522; SCHNITTMAN SM, 1989, SCIENCE, V245, P305, DOI 10.1126/science.2665081; SIMMONDS P, 1990, J VIROL, V64, P864, DOI 10.1128/JVI.64.2.864-872.1990; SINCLAIR E, 1992, J NEUROL, V239, P469, DOI 10.1007/BF00856814; WATKINS BA, 1990, SCIENCE, V249, P549, DOI 10.1126/science.2200125; WILLEY CA, 1986, P NATL ACAD SCI USA, V83, P7089	23	90	91	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 12	1994	343	8894					382	385		10.1016/S0140-6736(94)91222-X	http://dx.doi.org/10.1016/S0140-6736(94)91222-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW283	7905551				2022-12-24	WOS:A1994MW28300008
J	GRIFFITH, MJ; GARRATT, CJ; MOUNSEY, P; CAMM, AJ				GRIFFITH, MJ; GARRATT, CJ; MOUNSEY, P; CAMM, AJ			VENTRICULAR-TACHYCARDIA AS DEFAULT DIAGNOSIS IN BROAD COMPLEX TACHYCARDIA	LANCET			English	Article							DIFFERENTIAL-DIAGNOSIS; ELECTROCARDIOGRAPHIC CRITERIA; MIS-DIAGNOSIS	In the differential diagnosis of broad complex tachycardia, the most important decision is whether or not the tachycardia is ventricular, since this type carries the worst prognosis. However, the rules for a diagnosis of ventricular tachycardia are so complex that they are not satisfied in many cases, and the default diagnosis, supraventricular tachycardia, is erroneously accepted. We sought to reverse this strategy; unless simple rules for a positive diagnosis of supraventricular tachycardia were satisfied, ventricular tachycardia was diagnosed by default. The criterion for a diagnosis of supraventricular tachycardia was electrocardiographic (ECG) findings typical of bundle branch block (left = rS or QS wave in leads V1 and V2, delay to S wave nadir < 70 ms, and R wave and no Q wave in lead V6; right = rSR' wave in lead V1 and an RS wave in lead V6, with R wave height greater than S wave depth). Twelve-lead ECGs were done for 102 consecutive patients with broad-complex tachycardia (QRS width > 110 ms). Two observers, who were unaware of definitive diagnoses validated by electrophysiology, by our diagnostic rules made correct diagnosis of ventricular tachycardia in 63 and 62 of 69 patients, respectively, and correct diagnoses of supraventricular tachycardia in 28 and 22 of 33 patients (sensitivity for ventricular tachycardia 90% and 91%, specificity 67% and 85%). One observer then sought independent P waves in cases diagnosed as supraventricular tachycardia; sensitivity for the diagnosis of ventricular tachycardia rose to 96%, with a specificity of 64%. These criteria, which require only knowledge of typical bundle branch block patterns, were highly sensitive for the important diagnosis of ventricular tachycardia.	FREEMAN RD HOSP,NEWCASTLE TYNE,TYNE & WEAR,ENGLAND; ST GEORGE HOSP,LONDON,ENGLAND; GROBY RD HOSP,LEICESTER,W YORKSHIRE,ENGLAND	Newcastle Freeman Hospital; St Georges University London	GRIFFITH, MJ (corresponding author), QUEEN ELIZABETH HOSP,DEPT CARDIAC,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND.							BRUGADA P, 1991, CIRCULATION, V83, P1649, DOI 10.1161/01.CIR.83.5.1649; DANCY M, 1985, LANCET, V2, P320; DANCY M, 1985, BRIT MED J, V291, P1036, DOI 10.1136/bmj.291.6501.1036; GRIFFITH MJ, 1992, EUR HEART J, V13, P478, DOI 10.1093/oxfordjournals.eurheartj.a060200; GRIFFITH MJ, 1991, BRIT HEART J, V66, P166; GRIFFITH MJ, 1988, LANCET, V1, P672; KINDWALL KE, 1988, AM J CARDIOL, V61, P1279, DOI 10.1016/0002-9149(88)91169-1; Marriott H. J. L., 1966, PROG CARDIOVASC DIS, V9, P18; MARRIOTT HJ, 1970, GERIATRICS, V25, P91; STEWART RB, 1986, ANN INTERN MED, V104, P766, DOI 10.7326/0003-4819-104-6-766; TCHOU P, 1988, AM J MED, V84, P53, DOI 10.1016/0002-9343(88)90008-3; Wellens H J, 1987, Cardiol Clin, V5, P511	12	72	78	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 12	1994	343	8894					386	388		10.1016/S0140-6736(94)91223-8	http://dx.doi.org/10.1016/S0140-6736(94)91223-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW283	7905552				2022-12-24	WOS:A1994MW28300009
J	BRAIG, HR; GUZMAN, H; TESH, RB; ONEILL, SL				BRAIG, HR; GUZMAN, H; TESH, RB; ONEILL, SL			REPLACEMENT OF THE NATURAL WOLBACHIA SYMBIONT OF DROSOPHILA-SIMULANS WITH A MOSQUITO COUNTERPART	NATURE			English	Article							CYTOPLASMIC INCOMPATIBILITY; REPRODUCTIVE ISOLATION; POPULATIONS	INHERITED rickettsial symbionts of the genus Wolbachia occur commonly in arthropods and have been implicated in the expression of parthenogenesis1,2, feminization2,3 and cytoplasmic incompatibility phenomena in their respective hosts4-7. Here we use purified Wolbachia from the Asian tiger mosquito, Aedes albopictus, to replace the natural infection of Drosophila simulans by means of embryonic microinjection techniques. The transferred Wolbachia infection behaves like a natural Drosophila infection with regard to its inheritance, cytoskeleton interactions and ability to induce incompatibility when crossed with uninfected flies. The trans-infected flies are bidirectionally incompatible with all other naturally infected strains of Drosophila simulans, however, and as such represent a unique crossing type. The successful transfer of this symbiont between distantly related hosts suggests that it may be possible to introduce this agent experimentally into arthropod species of medical and agricultural importance in order to manipulate natural populations genetically.			BRAIG, HR (corresponding author), YALE UNIV,SCH MED,DEPT EPIDEMIOL & PUBL HLTH,POB 3333,NEW HAVEN,CT 06510, USA.		O'Neill, Scott/R-9560-2019; Braig, Henk/I-5477-2013; O'Neill, Scott L/B-3568-2009	O'Neill, Scott/0000-0002-4131-3615; Braig, Henk/0000-0001-9592-1141; O'Neill, Scott L/0000-0002-4131-3615				BEARD CB, 1993, PARASITOL TODAY, V9, P179, DOI 10.1016/0169-4758(93)90142-3; BOYLE L, 1993, SCIENCE, V260, P1796, DOI 10.1126/science.8511587; Breeuwer J.A.J., 1992, Insect Molecular Biology, V1, P25, DOI 10.1111/j.1365-2583.1993.tb00074.x; BREEUWER JAJ, 1990, NATURE, V346, P558, DOI 10.1038/346558a0; BREEUWER JAJ, 1993, GENETICS, V135, P565; CURTIS CF, 1992, NATURE, V357, P450, DOI 10.1038/357450b0; HOFFMANN AA, 1986, EVOLUTION, V40, P692, DOI 10.1111/j.1558-5646.1986.tb00531.x; HOLTON TA, 1991, NUCLEIC ACIDS RES, V19, P1156, DOI 10.1093/nar/19.5.1156; HSIAO C, 1985, J INVERTEBR PATHOL, V45, P244, DOI 10.1016/0022-2011(85)90016-3; JOST E, 1970, THEOR APPL GENET, V40, P251, DOI 10.1007/BF00282034; LAVEN H, 1959, COLD SPRING HARB SYM, V24, P166, DOI 10.1101/SQB.1959.024.01.017; MONTCHAMPMOREAU C, 1991, GENETICS, V129, P399; NIGRO L, 1991, HEREDITY, V66, P41, DOI 10.1038/hdy.1991.5; ONEILL SL, 1992, P NATL ACAD SCI USA, V89, P2699, DOI 10.1073/pnas.89.7.2699; ONEILL SL, 1990, NATURE, V348, P178, DOI 10.1038/348178a0; RIGAUD T, 1993, GENETICS, V133, P247; ROUSSET F, 1992, P ROY SOC B-BIOL SCI, V250, P91, DOI 10.1098/rspb.1992.0135; ROUSSET F, 1992, P ROY SOC B-BIOL SCI, V247, P163, DOI 10.1098/rspb.1992.0023; RYAN SL, 1968, MOL GEN GENET, V103, P29, DOI 10.1007/BF00271154; Simon C., 1991, MOL TECHNIQUES TAXON, P329; SOUTHAMER R, 1993, NATURE, V361, P66; TURELLI M, 1991, NATURE, V353, P440, DOI 10.1038/353440a0; WADE MJ, 1985, SCIENCE, V227, P527, DOI 10.1126/science.3966160; YEN JH, 1971, NATURE, V232, P657, DOI 10.1038/232657a0	24	127	143	2	24	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 3	1994	367	6462					453	455		10.1038/367453a0	http://dx.doi.org/10.1038/367453a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MU679	7906391				2022-12-24	WOS:A1994MU67900052
J	POLANECZKY, M; SLAP, G; FORKE, C; RAPPAPORT, A; SONDHEIMER, S				POLANECZKY, M; SLAP, G; FORKE, C; RAPPAPORT, A; SONDHEIMER, S			THE USE OF LEVONORGESTREL IMPLANTS (NORPLANT) FOR CONTRACEPTION IN ADOLESCENT MOTHERS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							UNITED-STATES; PREGNANCY; RISK	Background. Although levonorgestrel implants (Norplant) would appear to be a good contraceptive option for adolescent mothers, there is little information about the use of Norplant in this population. Methods. We studied 100 postpartum adolescents who chose a contraceptive method at an urban teaching hospital between September 1991 and July 1992. Structured interviews were conducted and medical records were reviewed soon after delivery and at a mean (+/-SD) of 15.5+/-2.9 months post partum. Results. Forty-eight of the adolescent mothers chose Norplant, 50 chose oral contraceptives, and 2 (not further studied) chose barrier methods of contraception. The factors significantly associated with the choice of Norplant were older age (16.7 years among those who chose Norplant, vs. 16.2 years among those who chose oral contraceptives), multiparity (24 subjects vs. 6 subjects), and previous use of oral contraceptives (34 subjects vs. 21 subjects). During follow-up, there were no differences between the Norplant group and the oral-contraceptive group in the frequency of clinic visits (an average of 2.3 visits per subject in each group), failure to return after the postpartum visit (9 subjects vs. 11 subjects), or the incidence of sexually transmitted diseases (42 percent vs. 36 percent). At follow-up, 95 percent of the subjects in the Norplant group and 33 percent of those in the oral-contraceptive group were still using the method they had chosen (P<0.001). During the first postpartum year 1 subject in the Norplant group and 19 in the oral-contraceptive group became pregnant (P<0.001). Norplant users did not differ from all other adolescents studied with regard to sexual activity or condom use. Conclusions. The selection of Norplant by adolescent mothers as a method of contraception is associated with higher rates of continued use and lower rates of new pregnancy than the selection of oral contraceptives and does not affect the use of health care services, sexual activity, condom use, or the rate of sexually transmitted diseases.	UNIV PENN,SCH MED,DEPT MED,DIV GEN INTERNAL MED,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT OBSTET & GYNECOL,PHILADELPHIA,PA 19104; QUEENS UNIV,KINGSTON,ON,CANADA	University of Pennsylvania; University of Pennsylvania; Queens University - Canada	POLANECZKY, M (corresponding author), NEW YORK HOSP,CORNELL MED CTR,DEPT OBSTET & GYNECOL,DIV WOMENS HLTH,BOX 392,525 E 68TH ST,NEW YORK,NY 10021, USA.							BALASSONE ML, 1989, J ADOLESCENT HEALTH, V10, P527, DOI 10.1016/0197-0070(89)90016-8; COOPERSMITH S, 1986, ANTECEDENTS SELF EST; DEWITT K, 1992, NY TIMES        1215, pA7; EMANS SJ, 1987, JAMA-J AM MED ASSOC, V257, P3377, DOI 10.1001/jama.257.24.3377; FORD K, 1983, FAM PLANN PERSPECT, V15, P268, DOI 10.2307/2135292; FREEMAN EW, 1982, AM J PUBLIC HEALTH, V72, P815, DOI 10.2105/AJPH.72.8.815; FREEMAN EW, 1993, EARLY CHILDBEARING P, P172; FURSTENBERG FF, 1972, FAM PLANN PERSPECT, V4, P54, DOI 10.2307/2133939; FURSTENBERG FF, 1987, FAM PLANN PERSPECT, V19, P142, DOI 10.2307/2135159; HARLAP S, 1991, PREVENTING PREGNANCY, P31; HENSHAW SK, 1993, FAM PLANN PERSPECT, V25, P122, DOI 10.2307/2136160; HOFFERTH SL, 1987, FAM PLANN PERSPECT, V19, P46, DOI 10.2307/2135048; IPSEN J, 1970, BANCROFTS INTRO BIOS, P153; JONES EF, 1989, FAM PLANN PERSPECT, V21, P103, DOI 10.2307/2135659; JONES EF, 1985, FAM PLANN PERSPECT, V17, P53, DOI 10.2307/2135261; JONES EF, 1992, FAM PLANN PERSPECT, V24, P19; KANTROWITZ B, 1993, NEWSWEEK        1224, P37; LEE E T, 1972, Computer Programs in Biomedicine, V2, P315, DOI 10.1016/0010-468X(72)90019-0; MOTT FL, 1986, FAM PLANN PERSPECT, V18, P5, DOI 10.2307/2135193; Rosenberg M., 1965, MEASUREMENT SELF EST, DOI [10.1515/9781400876136, DOI 10.1515/9781400876136]; SHOUPE D, 1991, OBSTET GYNECOL, V77, P256, DOI 10.1097/00006250-199102000-00018; SHOUPE D, 1989, AM J OBSTET GYNECOL, V160, P1268; SIVIN I, 1988, STUD FAMILY PLANN, V19, P81, DOI 10.2307/1966493; SLAP GB, 1991, J ADOLESCENT HEALTH, V12, P434, DOI 10.1016/1054-139X(91)90020-X; SOKAL RR, 1987, INTRO BIOSTATISTICS, P112; WOODS ER, 1992, AM J OBSTET GYNECOL, V166, P901, DOI 10.1016/0002-9378(92)91359-I; Zar J. H, 1984, BIOSTAT ANAL, P176; Zar JH, 1984, BIOSTAT ANAL, P150; ZELNIK M, 1980, FAM PLANN PERSPECT, V12, P69, DOI 10.2307/2134748	29	128	128	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 3	1994	331	18					1201	1206		10.1056/NEJM199411033311806	http://dx.doi.org/10.1056/NEJM199411033311806			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PN806	7935659				2022-12-24	WOS:A1994PN80600006
J	JOHNSON, A				JOHNSON, A			LARYNGEAL-CANCER - VARIATIONS IN TREATMENT	LANCET			English	Editorial Material							RADIATION-THERAPY; GLOTTIC CANCER; CARCINOMA; TOBACCO; ALCOHOL; RISK; HEAD				JOHNSON, A (corresponding author), QUEEN ELIZABETH HOSP,DEPT OTOLARYNGOL,BIRMINGHAM,W MIDLANDS,ENGLAND.							[Anonymous], 1991, NEW ENGL J MED, V324, P1685; ECKEL HE, 1992, ANN OTO RHINOL LARYN, V101, P113, DOI 10.1177/000348949210100202; KIM RY, 1992, RADIOLOGY, V182, P273, DOI 10.1148/radiology.182.1.1727295; MAIER H, 1992, CLIN INVESTIGATOR, V70, P320; MCDONALD S, 1989, INT J RADIAT ONCOL, V17, P457, DOI 10.1016/0360-3016(89)90095-3; MUSCAT JE, 1992, CANCER, V69, P2244, DOI 10.1002/1097-0142(19920501)69:9&lt;2244::AID-CNCR2820690906&gt;3.0.CO;2-O; OSULLIVAN B, 1994, RADIOTHER ONCOL, V31, P23, DOI 10.1016/0167-8140(94)90410-3; OTT S, 1992, LARYNGO RHINO OTOL, V71, P236, DOI 10.1055/s-2007-997287; ROBIN PE, 1987, S BROWNS OTOLARYNGOL, V5, P194; ROBSON NLK, 1990, J LARYNGOL OTOL, V104, P699, DOI 10.1017/S0022215100113660; SMALL W, 1992, RADIOLOGY, V183, P789, DOI 10.1148/radiology.183.3.1584935; TERHAARD CHJ, 1992, CLIN OTOLARYNGOL, V17, P393, DOI 10.1111/j.1365-2273.1992.tb01681.x	12	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 29	1994	344	8931					1173	1174		10.1016/S0140-6736(94)90503-7	http://dx.doi.org/10.1016/S0140-6736(94)90503-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN803	7934535				2022-12-24	WOS:A1994PN80300004
J	ALPERS, DH				ALPERS, DH			ZINC AND DEFICIENCIES OF TASTE AND SMELL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							DOUBLE-BLIND; DYSFUNCTION				ALPERS, DH (corresponding author), WASHINGTON UNIV,SCH MED,ST LOUIS,MO, USA.							BALES CW, 1986, AM J CLIN NUTR, V44, P664, DOI 10.1093/ajcn/44.5.664; HENKIN RI, 1976, AM J MED SCI, V272, P285, DOI 10.1097/00000441-197611000-00006; HENKIN RI, 1975, ARCH NEUROL-CHICAGO, V32, P745, DOI 10.1001/archneur.1975.00490530067006; MAHAJAN SK, 1980, AM J CLIN NUTR, V33, P1517, DOI 10.1093/ajcn/33.7.1517; WEIFFENBACH JM, 1982, J GERONTOL, V37, P372, DOI 10.1093/geronj/37.3.372; WOLMAN SL, 1979, GASTROENTEROLOGY, V76, P458	6	14	14	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 26	1994	272	16					1233	1234						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN068	7933356				2022-12-24	WOS:A1994PN06800003
J	HOGG, RS; STRATHDEE, SA; CRAIB, KJP; OSHAUGHNESSY, MV; MONTANER, JSG; SCHECHTER, MT				HOGG, RS; STRATHDEE, SA; CRAIB, KJP; OSHAUGHNESSY, MV; MONTANER, JSG; SCHECHTER, MT			LOWER SOCIOECONOMIC-STATUS AND SHORTER SURVIVAL FOLLOWING HIV-INFECTION	LANCET			English	Article							ACQUIRED IMMUNODEFICIENCY SYNDROME; HOMOSEXUAL MEN; MORTALITY; AIDS; PROGRESSION; HEALTH	We studied the association between socioeconomic status and survival in a prospective study of 364 HIV-infected homosexual men who were recruited during 1982-84. The participants were divided by annual income; those earning above Canadian $10 000 (high-income; n=274) and those below $10 000 (low-income; n=90) at recruitment. The latter threshold closely approximated to the poverty level for this population. Low income men were significantly younger than high income men but the groups were similar with respect to baseline CD4 counts, subsequent use of anti-retrovirals and prophylaxis against Pneumocystis carinii pneumonia (PCP), and number of visits attended during follow-up. Subjects were followed for a median of 9.5 years (range 1.8-13.1). By Dec 31, 1993, there were 135 deaths yielding a cumulative mortality rate of mean 45% (SD 4.0) at 11.5 years. Men aged 30 or more at infection had poorer survival than those under 30 (mortality risk ratio 1.56; 95% CI 1.09-2.24; p=0.015), and longer survival was significantly associated with a higher CD4 count at the earliest seropositive visit. The age-adjusted mortality risk ratio for low income men compared with high income men was significantly increased at 1.63 (95% CI 1.11-2.40; p=0.013). The significant risk of death for low income men persisted despite adjustment for age at infection, CD4 count, use of zidovudine, dideoxyinosine, and dideoxycytidine, use of PCP prophylaxis, and year of infection. We cannot attribute our findings to income loss as a result of more rapid HIV progression because the same effect was present in people who provided income data before seroconversion. Similarly, our findings are not due to differential access to care because the study was done within the context of a universal health care system, and the two income groups received treatments equally. This finding is consistent with the association socioeconomic status with increased mortality observed within large populations and in other diseases.	UNIV BRITISH COLUMBIA,BRITISH COLUMBIA CTR EXCELLENCE IN HIV AIDS,VANCOUVER V6Z 1Y6,BC,CANADA; UNIV BRITISH COLUMBIA,DEPT HLTH CARE & EPIDEMIOL,VANCOUVER V6Z 1Y6,BC,CANADA; UNIV BRITISH COLUMBIA,DEPT MED,VANCOUVER V6Z 1Y6,BC,CANADA; ST PAULS HOSP,VANCOUVER V6Z 1Y6,BC,CANADA	University of British Columbia; University of British Columbia; University of British Columbia; St. Paul's Hospital; University of Saskatchewan			Strathdee, Steffanie A/B-9042-2009; Montaner, Julio/K-7621-2012; Hogg, Robert S/B-2783-2012	Hogg, Robert S/0000-0003-3463-5488; Schechter, Martin/0000-0001-6063-2155				BLAXTER M, 1983, SOC SCI MED, V17, P1139, DOI 10.1016/0277-9536(83)90006-0; CALDWELL JC, 1986, POPUL DEV REV, V12, P171, DOI 10.2307/1973108; CAPITANIO JP, 1991, AIDS, V5, P1103, DOI 10.1097/00002030-199109000-00007; CELLA DF, 1991, J CLIN ONCOL, V9, P1500, DOI 10.1200/JCO.1991.9.8.1500; COOMBS RW, 1989, NEW ENGL J MED, V321, P1626, DOI 10.1056/NEJM198912143212402; HOGG RS, 1994, CAN MED ASSOC J, V150, P711; HOUSE JS, 1988, SCIENCE, V241, P540, DOI 10.1037/0003-066X.59.8.676; HUANG CM, 1988, CLIN CHEM, V34, P1957; KASS NE, 1994, J ACQ IMMUN DEF SYND, V7, P86; KESSLER RC, 1988, SOC SCI MED, V27, P569, DOI 10.1016/0277-9536(88)90004-4; KOOT M, 1993, ANN INTERN MED, V321, P1626; MARNEROS A, 1990, ACTA PSYCHIAT SCAND, V82, P352, DOI 10.1111/j.1600-0447.1990.tb01400.x; MOSESON M, 1989, J ACQ IMMUN DEF SYND, V2, P235; MOSS AR, 1988, BRIT MED J, V297, P1067, DOI 10.1136/bmj.297.6656.1067; PAPPAS G, 1993, NEW ENGL J MED, V329, P103, DOI 10.1056/NEJM199307083290207; ROTHENBERG R, 1987, NEW ENGL J MED, V317, P1297, DOI 10.1056/NEJM198711193172101; SAAH AJ, 1994, J ACQ IMMUN DEF SYND, V7, P287; SCHECHTER MT, 1989, AIDS, V3, P347, DOI 10.1097/00002030-198906000-00002; SCHECHTER MT, 1994, J CLIN EPIDEMIOL, V47, P59, DOI 10.1016/0895-4356(94)90034-5; SCHECHTER MT, 1986, CAN MED ASSOC J, V118, P681; STEIN MD, 1991, J GEN INTERN MED, V6, P35, DOI 10.1007/BF02599388; SYME SL, 1976, AM J EPIDEMIOL, V104, P1; TANG AM, 1993, AM J EPIDEMIOL, V138, P937, DOI 10.1093/oxfordjournals.aje.a116814; VEUGELERS PJ, IN PRESS AM J EPIDEM; Wilkins R, 1989, Health Rep, V1, P137; WILKINSON RG, 1992, BRIT MED J, V304, P165, DOI 10.1136/bmj.304.6820.165; WISE PH, 1985, NEW ENGL J MED, V313, P360, DOI 10.1056/NEJM198508083130605; 1982, INCOME DISTRIBUTIONS; 1987, MMWR-MORBID MORTAL W, V36, P24; 1993, JAMA-J AM MED ASSOC, V270, P305	30	89	91	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 22	1994	344	8930					1120	1124		10.1016/S0140-6736(94)90631-9	http://dx.doi.org/10.1016/S0140-6736(94)90631-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PN066	7934494				2022-12-24	WOS:A1994PN06600010
J	KOENIG, W; SUND, M; LOWE, GDO; LEE, AJ; RESCH, KL; TUNSTALLPEDOE, H; KEIL, U; ERNST, E				KOENIG, W; SUND, M; LOWE, GDO; LEE, AJ; RESCH, KL; TUNSTALLPEDOE, H; KEIL, U; ERNST, E			GEOGRAPHICAL VARIATIONS IN PLASMA VISCOSITY AND RELATION TO CORONARY EVENT RATES	LANCET			English	Article							CARDIOVASCULAR RISK FACTOR; BLOOD-VISCOSITY; MONICA PROJECT; FIBRINOGEN; POPULATION; RHEOLOGY; DISEASE	Plasma viscosity is reported to be predictive of coronary heart disease (CHD) and stroke. To find out whether regional differences in CHD event rates correlate with differences in plasma viscosity, we compared plasma viscosity in a high-risk area for CHD (Glasgow Multinational Monitoring of Trends and Determinants in Cardiovascular Disease [MONICA] and Scottish Heart Health Study population surveys, 1985/86; n=1166) and in a lower-risk area (MONICA Augsburg survey, 1984/85; n=3258) in men and women aged 25-64 years. Mean plasma viscosity (37 degrees C) was 1.261 (SD 0.067) mPa s in Augsburg and 1.327 (0.093) mPa s in the west of Scotland for men, and 1.248 (0.066) mPa s and 1.318 (0.087) mPa s, respectively, for women. The unadjusted difference of the means between the west of Scotland and Augsburg was 0.066 (95% Cl from weighted regression 0.058-0.073) mPa s for men and 0.070 (0.062-0.078) mPa s for women. Adjustment for age, smoking behaviour, total and high-density-lipoprotein cholesterol, systolic and diastolic blood pressure, and body-mass index had no effect on these differences. Age-standardised coronary event rates in 1985-87 were at least two times higher among men, and four times higher among women, in MONICA Glasgow than in MONICA Augsburg. This large geographical difference in plasma viscosity might partly explain the differences in CHD event rates between these populations. Further studies are needed on the determinants of plasma viscosity, and on its potential roles in atherosclerosis, thrombosis, and ischaemia.	GESELL STRAHLEN & UMWELTFORSCH MBH,ENVIRONM RES CTR,W-8042 NEUHERBERG,GERMANY; HLTH MEDIS INST,NEUHERBERG,GERMANY; UNIV GLASGOW,ROYAL INFIRM,DEPT MED,GLASGOW G31 2ER,SCOTLAND; UNIV DUNDEE,NINEWELLS HOSP & MED SCH,CARDIOVASC EPIDEMIOL UNIT,DUNDEE DD1 9SY,SCOTLAND; UNIV VIENNA,DEPT PHYS MED & REHABIL,VIENNA,AUSTRIA; UNIV MUNSTER,INST EPIDEMIOL & SOCIAL MED,W-4400 MUNSTER,GERMANY; UNIV EXETER,POSTGRAD MED SCH,EXETER,ENGLAND	Royal Infirmary of Edinburgh; University of Glasgow; University of Dundee; University of Vienna; University of Munster; University of Exeter	KOENIG, W (corresponding author), UNIV ULM,MED CTR,DEPT INTERNAL MED 2,ROBERT KOCH STR 8,D-89081 ULM,GERMANY.							[Anonymous], 1982, CLIN LAB HAEMATOL, V4, P83; [Anonymous], 1990, WHO MONICA PROJECT M; BOETHIG S, 1989, INT J EPIDEMIOL S1, V18, P29; BRAY GA, 1978, INT J OBESITY, V2, P99; CHAMBLESS L, 1987, GSF3186 GES STRAHL U; DESIMONE G, 1990, CIRCULATION, V81, P107, DOI 10.1161/01.CIR.81.1.107; ERNST E, 1993, ANN INTERN MED, V118, P956, DOI 10.7326/0003-4819-118-12-199306150-00008; ERNST E, 1988, ARTERIOSCLEROSIS, V8, P385, DOI 10.1161/01.ATV.8.4.385; HARKNESS J, 1963, LANCET, V2, P280; KEIL U, 1988, ACTA MED SCAND S, V728, P119; KEIL U, 1985, GSF2085 GES STRAHL U; KOENIG W, 1992, CIRCULATION, V86, P1045, DOI 10.1161/01.CIR.86.3.1045; KOENIG W, 1992, CIRCULATION, V85, P2197, DOI 10.1161/01.CIR.85.6.2197; LOWE GDO, 1988, CLIN HEMORHEOL, V8, P517; LOWE GDO, 1993, CIRCULATION, V87, P1915, DOI 10.1161/01.CIR.87.6.1915; RESCH KL, 1992, ANN INTERN MED, V117, P371, DOI 10.7326/0003-4819-117-5-371; SMITH W C S, 1987, Health Bulletin (Edinburgh), V45, P211; SMITH WCS, 1989, SCOT MED J, V34, P550, DOI 10.1177/003693308903400603; SMITH WCS, 1992, J HYPERTENS, V10, P467, DOI 10.1097/00004872-199205000-00010; TUNSTALLPEDOE H, 1994, CIRCULATION, V90, P583, DOI 10.1161/01.CIR.90.1.583; YARNELL JWG, 1991, CIRCULATION, V83, P836, DOI 10.1161/01.CIR.83.3.836; 1984, J CLIN PATHOL, V37, P1147; 1988, J CLIN EPIDEMIOL, V34, P105	23	53	53	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 10	1994	344	8924					711	714		10.1016/S0140-6736(94)92207-1	http://dx.doi.org/10.1016/S0140-6736(94)92207-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PF187	7915775				2022-12-24	WOS:A1994PF18700009
J	KAPLAN, NM				KAPLAN, NM			ETHNIC ASPECTS OF HYPERTENSION	LANCET			English	Article							BLOOD-PRESSURE; UNITED-STATES; BLACK; RISK; MORTALITY; DISEASE; IMPACT; WHITES; AGENTS; RACE				KAPLAN, NM (corresponding author), UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,5323 HARRY HINES BLVD,DALLAS,TX 75235, USA.							BARLEY J, 1991, J HYPERTENS, V9, P993, DOI 10.1097/00004872-199111000-00003; BIANCHI S, 1994, AM J HYPERTENS, V7, P23, DOI 10.1093/ajh/7.1.23; CAMPESE VM, 1991, HYPERTENSION, V18, P805, DOI 10.1161/01.HYP.18.6.805; CHATURVEDI N, 1993, HYPERTENSION, V22, P90, DOI 10.1161/01.HYP.22.1.90; COOPER RS, 1992, CIRCULATION, V85, P12; CORNONIHUNTLEY J, 1989, ARCH INTERN MED, V149, P780, DOI 10.1001/archinte.149.4.780; CRUICKSHANK JK, 1985, J HYPERTENS, V3, P365, DOI 10.1097/00004872-198508000-00009; DYSART JN, 1994, AM J HYPERTENS, V7, P15, DOI 10.1093/ajh/7.1.15; FALKNER B, 1990, HYPERTENSION, V15, P681, DOI 10.1161/01.HYP.15.6.681; FISHER NDL, 1994, HYPERTENSION, V23, P179, DOI 10.1161/01.HYP.23.2.179; GRETLER DD, 1994, AM J HYPERTENS, V7, P7, DOI 10.1093/ajh/7.1.7; JAMERSON KA, 1993, CLIN EXP HYPERTENS, V15, P979, DOI 10.3109/10641969309037086; KAPLAN NM, 1994, HYPERTENSION POPULAT, P1; KOREN MJ, 1993, AM J HYPERTENS, V6, P815, DOI 10.1093/ajh/6.10.815; LOPES AAS, 1993, J AM SOC NEPHROL, V3, P1961; MANTUNGA AK, 1993, HYPERTENSION, V22, P84; MATERSON BJ, 1993, NEW ENGL J MED, V328, P914, DOI 10.1056/NEJM199304013281303; OOI WL, 1989, HYPERTENSION, V14, P227, DOI 10.1161/01.HYP.14.3.227; OTTEN MW, 1990, JAMA-J AM MED ASSOC, V263, P845, DOI 10.1001/jama.263.6.845; POULTER NR, 1990, BMJ-BRIT MED J, V300, P967, DOI 10.1136/bmj.300.6730.967; ROWLAND M, 1982, NCHS ADV DATA, V84; SEEDAT YK, 1989, J HYPERTENS, V7, P515, DOI 10.1097/00004872-198907000-00001; SORLIE P, 1992, LANCET, V340, P346, DOI 10.1016/0140-6736(92)91413-3; VERDECCHIA P, 1993, CIRCULATION, V88, P986, DOI 10.1161/01.CIR.88.3.986; WALKER WG, 1992, JAMA-J AM MED ASSOC, V268, P3085, DOI 10.1001/jama.268.21.3085; 1993, ARCH INTERN MED, V153, P154	26	71	71	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 13	1994	344	8920					450	452		10.1016/S0140-6736(94)91774-4	http://dx.doi.org/10.1016/S0140-6736(94)91774-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB761	7914569				2022-12-24	WOS:A1994PB76100014
J	HABIB, F; DUTKA, D; CROSSMAN, D; OAKLEY, CM; CLELAND, JGF				HABIB, F; DUTKA, D; CROSSMAN, D; OAKLEY, CM; CLELAND, JGF			ENHANCED BASAL NITRIC-OXIDE PRODUCTION IN HEART-FAILURE - ANOTHER FAILED COUNTER-REGULATORY VASODILATOR MECHANISM	LANCET			English	Note							SYNTHASE	Endothelial dysfunction in heart failure could impair nitric oxide production and lead to increased vascular resistance. If endogenous production of nitric oxide is reduced, N-G-monomethyl-L-arginine (L-NMMA), an inhibitor of such production, should have a diminished vasoconstrictor effect. We administered L-NMMA to 12 patients being investigated for heart failure. L-NMMA increased median pulmonary and systemic vascular resistances by 61 (range - 3 to 240) and 430 (63 to 1609)dynes s cm(-5), respectively (p<0.03 and p<0.005). Arterial pressures also increased. Median cardiac output fell by 0.6 (0 to -2.3) L per min (p<0.005). These data suggest that vascular nitric oxide may be another example of a failed counter-regulatory vasodilator system in heart failure.	HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT MED CARDIOL,LONDON W12,ENGLAND	Imperial College London			Cleland, John G./AAZ-4185-2020	Cleland, John G./0000-0002-1471-7016; Crossman, David/0000-0003-4762-8623				CABANES L, 1992, NEW ENGL J MED, V326, P1661, DOI 10.1056/NEJM199206183262503; CLELAND JGF, 1991, BRIT HEART J, V66, P264; COHN JN, 1990, AM J CARDIOL, V66, P1507, DOI 10.1016/0002-9149(90)90544-B; DEBELDER AJ, 1993, LANCET, V341, P84, DOI 10.1016/0140-6736(93)92559-C; DREXLER H, 1992, AM J CARDIOL, V69, P1596, DOI 10.1016/0002-9149(92)90710-G; LOH E, 1993, CIRCULATION, V88, P25; NUNOKAWA Y, 1993, BIOCHEM BIOPH RES CO, V191, P89, DOI 10.1006/bbrc.1993.1188; ONTKEAN M, 1991, CIRC RES, V69, P1088, DOI 10.1161/01.RES.69.4.1088; PACKER M, 1992, LANCET, V340, P88, DOI 10.1016/0140-6736(92)90405-R; WAAGSTEIN F, 1993, LANCET, V342, P1441, DOI 10.1016/0140-6736(93)92930-R; WIESHAMMER S, 1993, BRIT HEART J, V70, P17	11	132	136	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 6	1994	344	8919					371	373		10.1016/S0140-6736(94)91402-8	http://dx.doi.org/10.1016/S0140-6736(94)91402-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PA303	7914308				2022-12-24	WOS:A1994PA30300011
J	GOH, HS; CHAN, CS; KHINE, K; SMITH, DR				GOH, HS; CHAN, CS; KHINE, K; SMITH, DR			P53 AND BEHAVIOR OF COLORECTAL-CANCER	LANCET			English	Note							TUMOR SUPPRESSOR GENE; CARCINOMAS	The tumour suppressor gene p53 is altered in most colorectal tumours. We found that lymphatic dissemination was driven by the presence of mutated p53 whether or not the cell contained wild-type p53. In a total sample of 187 specimens, point mutation of the p53 gene occurred in 70% and 43% of cases with and without lymph-node involvement, respectively. By contrast, haematogenous dissemination was apparently the result of absent functional wild-type p53 (whether or not the cell contained mutated p53). These results are of potential importance in the prediction of the clinical behaviour of a tumour.			GOH, HS (corresponding author), SINGAPORE GEN HOSP,DEPT COLORECTAL SURG,OUTRAM RD,SINGAPORE 0316,SINGAPORE.		Smith, Duncan R/C-6891-2011	Smith, Duncan R/0000-0002-6592-9852				BARLOGIE B, 1983, CANCER RES, V43, P3982; CHANG FJ, 1993, AM J GASTROENTEROL, V88, P174; FEARON ER, 1992, FASEB J, V6, P2783, DOI 10.1096/fasebj.6.10.1321771; HINDS PW, 1994, CURR OPIN GENET DEV, V4, P135, DOI 10.1016/0959-437X(94)90102-3; KHINE K, 1994, CANCER, V73, P28, DOI 10.1002/1097-0142(19940101)73:1<28::AID-CNCR2820730107>3.0.CO;2-3; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; MELING GI, 1993, BRIT J CANCER, V67, P93, DOI 10.1038/bjc.1993.15; SAKAI E, 1992, ONCOGENE, V7, P927; TURNBULL RB, 1967, ANN SURG, V166, P420	9	72	73	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 23	1994	344	8917					233	234		10.1016/S0140-6736(94)93000-7	http://dx.doi.org/10.1016/S0140-6736(94)93000-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY060	7913159				2022-12-24	WOS:A1994NY06000012
J	GORDON, RD				GORDON, RD			MINERALOCORTICOID HYPERTENSION	LANCET			English	Article							GLUCOCORTICOID-REMEDIABLE ALDOSTERONISM; HYPERALDOSTERONISM; ADENOMA; VARIETY				GORDON, RD (corresponding author), GREENSLOPES HOSP,HYPERTENS UNIT,BRISBANE,QLD 4120,AUSTRALIA.		Gordon, Richard D/K-2555-2012					BOTEROVELEZ M, 1994, NEW ENGL J MED, V330, P178, DOI 10.1056/NEJM199401203300305; Gordon R D, 1987, J Hypertens Suppl, V5, pS103; GORDON RD, 1991, CLIN EXP PHARMACOL P, V18, P283, DOI 10.1111/j.1440-1681.1991.tb01446.x; GORDON RD, 1992, LANCET, V340, P159, DOI 10.1016/0140-6736(92)93225-C; GORDON RD, 1993, J HYPERTENS, V11, pS310; Gordon RD., 1994, TXB HYPERTENSION, P865; HIRAMATSU K, 1981, ARCH INTERN MED, V141, P1589, DOI 10.1001/archinte.141.12.1589; IRONY I, 1987, J CLIN ENDOCR METAB, V65, P836, DOI 10.1210/jcem-65-5-836; LIFTON RP, 1992, NATURE, V355, P262, DOI 10.1038/355262a0; LONDON N, 1992, POSTGRAD MED J, V68, P976, DOI 10.1136/pgmj.68.806.976; RICH GM, 1992, ANN INTERN MED, V116, P813, DOI 10.7326/0003-4819-116-10-813; SOMA R, 1989, J ENDOCRINOL INVEST, V12, P183, DOI 10.1007/BF03349956; STEWART PM, 1988, J CLIN INVEST, V82, P340, DOI 10.1172/JCI113592; STOWASSER M, 1992, CLIN EXP PHARMACOL P, V19, P319, DOI 10.1111/j.1440-1681.1992.tb00462.x; STOWASSER M, 1993, J CLIN ENDOCR METAB, V77, P800, DOI 10.1210/jc.77.3.800	15	102	106	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 23	1994	344	8917					240	243		10.1016/S0140-6736(94)93003-1	http://dx.doi.org/10.1016/S0140-6736(94)93003-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY060	7913162				2022-12-24	WOS:A1994NY06000015
J	KWOK, RPS; LUNDBLAD, JR; CHRIVIA, JC; RICHARDS, JP; BACHINGER, HP; BRENNAN, RG; ROBERTS, SGE; GREEN, MR; GOODMAN, RH				KWOK, RPS; LUNDBLAD, JR; CHRIVIA, JC; RICHARDS, JP; BACHINGER, HP; BRENNAN, RG; ROBERTS, SGE; GREEN, MR; GOODMAN, RH			NUCLEAR-PROTEIN CBP IS A COACTIVATOR FOR THE TRANSCRIPTION FACTOR CREB	NATURE			English	Article							CYCLIC-AMP; SOMATOSTATIN GENE; ESCHERICHIA-COLI; FACTOR-TFIIB; ACTIVATION; ELEMENT; BINDING; DNA; PHOSPHORYLATION; IDENTIFICATION	THE transcription factor CREB binds to a DNA element known as the cAMP-regulated enhancer (CRE)(1-5). CREB is activated through phosphorylation by protein kinase A (PKA)(6), but precisely how phosphorylation stimulates CREB function is unknown. One model is that phosphorylation may allow the recruitment of coactivators which then interact with basal transcription factors. We have previously identified a nuclear protein of M(r) 265K, CBP, that binds specifically to the PKA-phosphorylated form of CREB(7). We have used fluorescence anisotropy measurements to define the equilibrium binding parameters of the phosphoCREB:CBP interaction and report here that CBP can activate transcription through a region in its carboxy terminus. The activation,domain of CBP interacts with the basal transcription factor TFIIB through a domain that is conserved in the yeast coactivator ADA-1 (ref. 8). Consistent with its role as a coactivator, CBP augments the activity of phosphorylated CREB to activate transcription of cAM-responsive genes.	OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT BIOCHEM,PORTLAND,OR 97201; ST LOUIS UNIV,DEPT PHARMACOL & PHYSIOL SCI,ST LOUIS,MO 63014; SHRINERS HOSP CRIPPLED CHILDRENS,PORTLAND,OR 97201; UNIV MASSACHUSETTS,MED CTR,PROGRAM MOLEC MED,WORCESTER,MA 01605	Oregon Health & Science University; Oregon Health & Science University; Saint Louis University; University of Massachusetts System; University of Massachusetts Worcester			Roberts, Stefan GE/R-5537-2016	Roberts, Stefan GE/0000-0002-7535-6365; Brennan, Richard/0000-0001-7647-485X				BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; DWARKI VJ, 1990, EMBO J, V9, P225, DOI 10.1002/j.1460-2075.1990.tb08099.x; FERRERI K, 1994, P NATL ACAD SCI USA, V91, P1210, DOI 10.1073/pnas.91.4.1210; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HEYDUK T, 1993, NATURE, V364, P548, DOI 10.1038/364548a0; HEYDUK T, 1990, P NATL ACAD SCI USA, V87, P1744, DOI 10.1073/pnas.87.5.1744; HOEFFLER JP, 1988, SCIENCE, V242, P1428; LETILLY V, 1993, BIOCHEMISTRY-US, V32, P7753, DOI 10.1021/bi00081a021; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LORIAUX MM, 1993, P NATL ACAD SCI USA, V90, P9046, DOI 10.1073/pnas.90.19.9046; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; ROBERTS SGE, 1993, NATURE, V363, P741, DOI 10.1038/363741a0; SHORT JM, 1986, J BIOL CHEM, V261, P9721; WILLIAMS JS, 1993, DNA CELL BIOL, V12, P183, DOI 10.1089/dna.1993.12.183	19	1282	1311	1	58	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 21	1994	370	6486					223	226		10.1038/370223a0	http://dx.doi.org/10.1038/370223a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NX971	7913207				2022-12-24	WOS:A1994NX97100055
J	HARRAP, SB				HARRAP, SB			HYPERTENSION - GENES VERSUS ENVIRONMENT	LANCET			English	Article							BLOOD-PRESSURE; MIGRATION; MARKERS; DISEASE; RISK				HARRAP, SB (corresponding author), ALFRED HOSP,MONASH MED SCH,DEPT SOCIAL & PREVENT MED,COMMERCIAL RD,PRAHRAN,VIC 3181,AUSTRALIA.			Harrap, Stephen/0000-0003-2907-6714				BEAGLEHOLE R, 1990, EPIDEMIOL REV, V12, P1; BENNETT CL, 1993, BIOCHEM BIOPH RES CO, V197, P833, DOI 10.1006/bbrc.1993.2554; DEUTSCHER S, 1966, CIRCULATION, V33, P911, DOI 10.1161/01.CIR.33.6.911; ELFORD J, 1990, BRIT MED J, V300, P291, DOI 10.1136/bmj.300.6720.291; GENNSER G, 1988, BMJ-BRIT MED J, V296, P1498, DOI 10.1136/bmj.296.6635.1498; HOWE JR, 1992, SURGERY, V112, P219; HUNT SC, 1989, AM J EPIDEMIOL, V129, P625, DOI 10.1093/oxfordjournals.aje.a115175; JEUNEMAITRE X, 1992, CELL, V71, P169, DOI 10.1016/0092-8674(92)90275-H; LIFTON RP, 1992, NATURE, V355, P262, DOI 10.1038/355262a0; LONGINI IM, 1984, AM J EPIDEMIOL, V120, P131, DOI 10.1093/oxfordjournals.aje.a113862; MOLL PP, 1979, GENETIC ANAL COMMON, P307; MONGEAU JG, 1989, SEMIN NEPHROL, V9, P208; MONGEAU JG, 1986, CLIN EXP HYPERTENS A, V8, P653, DOI 10.3109/10641968609046581; MURPHY EA, 1964, J CHRON DIS, V17, P301, DOI 10.1016/0021-9681(64)90073-6; PICKERING GW, 1959, LANCET, V2, P1027; PLATT R, 1947, Q J MED, V16, P111; REEDERS ST, 1986, BRIT MED J, V292, P851, DOI 10.1136/bmj.292.6524.851; Rose G, 1987, Ciba Found Symp, V130, P247; SALMOND CE, 1989, AM J EPIDEMIOL, V130, P37, DOI 10.1093/oxfordjournals.aje.a115321; SUZUKI DT, 1989, INTRO GENETIC ANAL, P641; WARD R, 1990, HYPERTENSION PATHOPH, P81; WATT GCM, 1992, J HYPERTENS, V10, P474	22	78	82	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 16	1994	344	8916					169	171		10.1016/S0140-6736(94)92762-6	http://dx.doi.org/10.1016/S0140-6736(94)92762-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW810	7912770				2022-12-24	WOS:A1994NW81000014
J	CIANFARANI, S; VACCARO, F; BOSCHERINI, B				CIANFARANI, S; VACCARO, F; BOSCHERINI, B			WHAT IS THE RATIONALE FOR GROWTH-HORMONE THERAPY IN TURNERS-SYNDROME	LANCET			English	Editorial Material							OXANDROLONE; SECRETION; OBESITY; GH				CIANFARANI, S (corresponding author), UNIV ROMA TOR VERGATA, DEPT PAEDIAT, VIA O RAIMONDO, I-00173 ROME, ITALY.		Geremia, Caterina/AAA-9380-2020; cianfarani, stefano/K-2079-2016	cianfarani, stefano/0000-0002-2580-8781				CAPRIO S, 1992, J PEDIATR-US, V120, P238, DOI 10.1016/S0022-3476(05)80434-2; CIANFARANI S, 1994, HORM RES, V41, P27, DOI 10.1159/000183873; KOPELMAN PG, 1988, CLIN ENDOCRINOL, V28, P675; LANES R, 1990, J CLIN ENDOCR METAB, V71, P770, DOI 10.1210/jcem-71-3-770; LU PW, 1991, ARCH DIS CHILD, V66, P1184, DOI 10.1136/adc.66.10.1184; PASQUINO AM, 1992, HORM RES, V38, P120, DOI 10.1159/000182526; RANKE MB, 1993, ACTA PAEDIATR, V82, P82, DOI 10.1111/j.1651-2227.1993.tb12936.x; RANKE MB, 1987, ACTA ENDOCRINOL-COP, V116, P305, DOI 10.1530/acta.0.1160305; RAPPAPORT R, 1989, ACTA PAEDIATR SCAND, P82; ROSENFELD RG, 1992, J PEDIATR-US, V121, P49, DOI 10.1016/S0022-3476(05)82540-5; ROSS JL, 1985, J PEDIATR-US, V106, P202, DOI 10.1016/S0022-3476(85)80287-0; VANVLIET G, 1986, HUMAN GROWTH HORMONE, P115; WALKER JM, 1990, LANCET, V336, P1331, DOI 10.1016/0140-6736(90)92891-K; WEISE M, 1993, HORM RES, V39, P25, DOI 10.1159/000182763; WILSON DM, 1988, J PEDIATR-US, V112, P210, DOI 10.1016/S0022-3476(88)80057-X; ZADIK Z, 1992, J CLIN ENDOCR METAB, V75, P412, DOI 10.1210/jc.75.2.412	16	15	15	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 9	1994	344	8915					114	115		10.1016/S0140-6736(94)91288-2	http://dx.doi.org/10.1016/S0140-6736(94)91288-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NV732	7912351				2022-12-24	WOS:A1994NV73200016
J	PARPURA, V; BASARSKY, TA; LIU, F; JEFTINIJA, K; JEFTINIJA, S; HAYDON, PG				PARPURA, V; BASARSKY, TA; LIU, F; JEFTINIJA, K; JEFTINIJA, S; HAYDON, PG			GLUTAMATE-MEDIATED ASTROCYTE NEURON SIGNALING	NATURE			English	Article							CALCIUM WAVES; HIPPOCAMPAL-NEURONS; SYNAPTIC CURRENTS; ASPARTATE; RESPONSES; RECEPTORS; CULTURES	NEUROTRANSMITTER released from neurons is known to signal to neighbouring neurons and glia(1-3). Here we demonstrate an additional signalling pathway in which glutamate is released from astrocytes and causes an NMDA (N-methyl-D-aspartate) receptor-mediated increase in neuronal calcium. Internal calcium was elevated and glutamate release stimulated by application of the neuroligand bradykinin to cultured astrocytes. Elevation of astrocyte internal calcium was also sufficient to induce glutamate release. To determine whether this released glutamate signals to neurons, we studied astrocyte-neuron co-cultures. Bradykinin significantly increased calcium levels in neurons co-cultured with astrocytes, but not in solitary neurons. The glutamate receptor antagonists D-2-amino-5-phosphonopentanoic acid and D-glutamylglycine prevented bradykinin-induced neuronal calcium elevation. When single astrocytes were directly stimulated to increase internal calcium and release glutamate, calcium levels of adjacent neurons were increased; this increase could be blocked by D-glutamyl-glycine. Thus, astrocytes regulate neuronal calcium levels through the calcium-dependent release of glutamate. -	IOWA STATE UNIV SCI & TECHNOL, DEPT ZOOL & GENET, AMES, IA 50011 USA; IOWA STATE UNIV SCI & TECHNOL, DEPT VET ANAT, AMES, IA 50011 USA; IOWA STATE UNIV SCI & TECHNOL, NEUROSCI PROGRAM, AMES, IA 50011 USA	Iowa State University; Iowa State University; Iowa State University			Parpura, Vladimir/A-1242-2010	Parpura, Vladimir/0000-0002-4643-2197				BALCAR VJ, 1972, J NEUROCHEM, V19, P2657, DOI 10.1111/j.1471-4159.1972.tb01325.x; BASARSKY TA, IN PRESS J NEUROSCI; CHARLES AC, 1991, NEURON, V6, P983, DOI 10.1016/0896-6273(91)90238-U; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CORNELLBELL AH, 1990, SCIENCE, V247, P470, DOI 10.1126/science.1967852; CORNELLBELL AH, 1991, CELL CALCIUM, V12, P185, DOI 10.1016/0143-4160(91)90020-F; DANI JW, 1992, NEURON, V8, P429, DOI 10.1016/0896-6273(92)90271-E; GLAUM SR, 1990, P NATL ACAD SCI USA, V87, P3454, DOI 10.1073/pnas.87.9.3454; GUTHRIE PB, 1991, NATURE, V354, P76, DOI 10.1038/354076a0; HUETTNER JE, 1986, J NEUROSCI, V6, P3044; INAGAKI N, 1991, NEUROSCI LETT, V128, P257, DOI 10.1016/0304-3940(91)90274-W; ISAACSON JS, 1993, J NEUROPHYSIOL, V70, P2187, DOI 10.1152/jn.1993.70.5.2187; JENSEN AM, 1991, J NEUROSCI, V11, P1674; JONES AW, 1984, NEUROSCIENCE, V13, P573, DOI 10.1016/0306-4522(84)90250-1; KAO JPY, 1989, J BIOL CHEM, V264, P8179; KIMELBERG HK, 1990, J NEUROSCI, V10, P1583; LEVISON SW, 1991, CULTURING NERVE CELL, P309; MA J, 1988, SCIENCE, V242, P99, DOI 10.1126/science.2459777; MALGAROLI A, 1992, NATURE, V357, P134, DOI 10.1038/357134a0; MCCARTHY KD, 1991, NEUROSCIENCE, V41, P325, DOI 10.1016/0306-4522(91)90330-Q; MCLARNON JG, 1991, CAN J PHYSIOL PHARM, V69, P1422, DOI 10.1139/y91-213; MENNERICK S, 1994, NATURE, V368, P59, DOI 10.1038/368059a0; MURPHY TH, 1993, J NEUROSCI, V13, P2672, DOI 10.1523/JNEUROSCI.13-06-02672.1993; NEDERGAARD M, 1994, SCIENCE, V263, P1768, DOI 10.1126/science.8134839; PARPURA V, 1993, J CELL SCI, V104, P427; REISER G, 1989, J CELL SCI, V93, P545; SCHEFFE H, 1953, BIOMETRIKA, V40, P87, DOI 10.1093/biomet/40.1-2.87; Sokal R. R., 1981, BIOMETRY PRINCIPLES, P400; TRIGGLE DJ, 1991, ANN NY ACAD SCI, V635, P123, DOI 10.1111/j.1749-6632.1991.tb36487.x	29	1336	1368	3	84	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUN 30	1994	369	6483					744	747		10.1038/369744a0	http://dx.doi.org/10.1038/369744a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NU581	7911978				2022-12-24	WOS:A1994NU58100060
J	VOORBERG, J; ROELSE, J; KOOPMAN, R; BULLER, H; BERENDS, F; TENCATE, JW; MERTENS, K; VANMOURIK, JA				VOORBERG, J; ROELSE, J; KOOPMAN, R; BULLER, H; BERENDS, F; TENCATE, JW; MERTENS, K; VANMOURIK, JA			ASSOCIATION OF IDIOPATHIC VENOUS THROMBOEMBOLISM WITH SINGLE POINT-MUTATION AT ARG(506) OF FACTOR-V	LANCET			English	Note							ACTIVATED PROTEIN-C; POOR ANTICOAGULANT RESPONSE; THROMBOPHILIA; THROMBOSIS	Abnormal coagulation factor V may underlie the thrombotic events associated with resistance to activated protein C (APC). We analysed 27 consecutive patients with documented idiopathic (recurrent) thromboembolism for the occurrence of point mutations within the APC sensitive regions of blood coagulation factor V. In 10 patients we observed a single basepair mutation resulting in a substitution of Arg(506) to Gln. This mutation was significantly linked to in-vitro resistance to APC in these subjects. This mutation at Arg(506) of factor V may form the molecular basis for the thrombotic events associated with APC resistance.	UNIV AMSTERDAM,ACAD MED CTR,CTR HEMOSTASIS THROMBOSIS ATHEROSCLEROSIS & INFLA,1105 AZ AMSTERDAM,NETHERLANDS	University of Amsterdam; Academic Medical Center Amsterdam	VOORBERG, J (corresponding author), NETHERLANDS RED CROSS,BLOOD TRANSFUS SERV,CENT LAB,DEPT BLOOD COAGULAT,PLESMANLAAN 125,1066 CX AMSTERDAM,NETHERLANDS.			Voorberg, Jan/0000-0003-4585-2621				BAUER KA, 1994, NEW ENGL J MED, V330, P566, DOI 10.1056/NEJM199402243300810; CUYPERS HTM, 1992, J CLIN MICROBIOL, V30, P3220, DOI 10.1128/JCM.30.12.3220-3224.1992; DAHLBACK B, 1993, P NATL ACAD SCI USA, V90, P1004, DOI 10.1073/pnas.90.3.1004; DAHLBACK B, 1994, P NATL ACAD SCI USA, V91, P1396, DOI 10.1073/pnas.91.4.1396; GRIFFIN JH, 1993, BLOOD, V82, P1989; HEYBOER H, 1990, NEW ENGL J MED, V323, P1512; KALAFATIS M, 1993, J BIOL CHEM, V268, P27246; KOSTER T, 1993, LANCET, V342, P1503, DOI 10.1016/S0140-6736(05)80081-9; MILETICH JP, 1993, CELL, V72, P477, DOI 10.1016/0092-8674(93)90063-V; SVENSSON PJ, 1994, NEW ENGL J MED, V330, P517, DOI 10.1056/NEJM199402243300801	10	445	458	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 18	1994	343	8912					1535	1536		10.1016/S0140-6736(94)92939-4	http://dx.doi.org/10.1016/S0140-6736(94)92939-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NR329	7911872				2022-12-24	WOS:A1994NR32900009
J	BOLSHAKOV, VY; SIEGELBAUM, SA				BOLSHAKOV, VY; SIEGELBAUM, SA			POSTSYNAPTIC INDUCTION AND PRESYNAPTIC EXPRESSION OF HIPPOCAMPAL LONG-TERM DEPRESSION	SCIENCE			English	Article							RAT VISUAL-CORTEX; CALCIUM CHANNELS; AREA CA1; NITRIC-OXIDE; POTENTIATION; ENHANCEMENT; INVOLVEMENT; RECEPTORS; BLOCKADE; SLICES	Long-term depression (LTD) is an activity-dependent decrease in synaptic efficacy that together with its counterpart, long-term potentiation, is thought to be an important cellular mechanism for learning and memory in the mammalian brain. The induction of LTD in hippocampal CA1 pyramidal neurons in neonatal rats is shown to depend on postsynaptic calcium ion entry through L-type voltage-gated calcium channels paired with the activation of metabotropic glutamate receptors. Although induced postsynaptically, LTD is due to a long-term decrease in transmitter release from presynaptic terminals. This suggests that LTD is likely to require the production of a retrograde messenger.			BOLSHAKOV, VY (corresponding author), COLUMBIA UNIV,HOWARD HUGHES MED INST,CTR NEUROBIOL & BEHAV,DEPT PHARMACOL,NEW YORK,NY 10032, USA.							ABRAHAM WC, 1991, BRAIN RES, V546, P336, DOI 10.1016/0006-8993(91)91498-P; ARONIADOU VA, 1991, BRAIN RES, V562, P136, DOI 10.1016/0006-8993(91)91197-9; ARTOLA A, 1990, NATURE, V347, P69, DOI 10.1038/347069a0; BASHIR ZI, 1993, EUR J PHARMACOL, V239, P265, DOI 10.1016/0014-2999(93)91009-C; BASHIR ZI, 1993, NATURE, V363, P347, DOI 10.1038/363347a0; BASKYS A, 1991, J PHYSIOL-LONDON, V444, P687, DOI 10.1113/jphysiol.1991.sp018901; BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOHME GA, 1991, EUR J PHARMACOL, V199, P379, DOI 10.1016/0014-2999(91)90505-K; BOLSHAKOV VY, UNPUB; CHRISTIE BR, 1992, SYNAPSE, V10, P1, DOI 10.1002/syn.890100102; DANIEL H, 1992, EXP BRAIN RES, V90, P327; Davies C. H., 1993, Society for Neuroscience Abstracts, V19, P276; DUDEK SM, 1992, P NATL ACAD SCI USA, V89, P4363, DOI 10.1073/pnas.89.10.4363; DUDEK SM, 1993, J NEUROSCI, V13, P2910; EATON SA, 1993, EUR J PHARM-MOLEC PH, V244, P195, DOI 10.1016/0922-4106(93)90028-8; EDWARDS F, 1991, NATURE, V350, P271, DOI 10.1038/350271a0; ELLIOT LS, 1993, NATURE, V361, P634; Foster T C, 1991, Hippocampus, V1, P79, DOI 10.1002/hipo.450010108; ITO M, 1989, ANNU REV NEUROSCI, V12, P85, DOI 10.1146/annurev.ne.12.030189.000505; IZUMI Y, 1993, NEUROREPORT, V4, P1131; KATO N, 1993, P NATL ACAD SCI USA, V90, P3650, DOI 10.1073/pnas.90.8.3650; Kimura F, 1990, Neuroreport, V1, P65, DOI 10.1097/00001756-199009000-00018; KORN H, 1991, TRENDS NEUROSCI, V14, P439, DOI 10.1016/0166-2236(91)90042-S; KULLMANN DM, 1992, NATURE, V357, P240, DOI 10.1038/357240a0; LARKMAN A, 1992, NATURE, V360, P70, DOI 10.1038/360070a0; MALENKA RC, 1993, P NATL ACAD SCI USA, V90, P3121, DOI 10.1073/pnas.90.8.3121; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MANABE T, 1992, NATURE, V355, P50, DOI 10.1038/355050a0; MANABE T, 1993, J NEUROPHYSIOL, V70, P1451, DOI 10.1152/jn.1993.70.4.1451; MORAD M, 1988, SCIENCE, V241, P842, DOI 10.1126/science.2457253; MULKEY RM, 1992, NEURON, V9, P967, DOI 10.1016/0896-6273(92)90248-C; SAKURAI M, 1990, P NATL ACAD SCI USA, V87, P3383, DOI 10.1073/pnas.87.9.3383; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; STANTON PK, 1989, NATURE, V339, P215, DOI 10.1038/339215a0; STANTON PK, 1991, NEUROSCI LETT, V127, P61, DOI 10.1016/0304-3940(91)90895-Z; STEVENS CF, 1993, NATURE, V364, P147, DOI 10.1038/364147a0; WICKENS JR, 1991, NEUROSCI LETT, V130, P128, DOI 10.1016/0304-3940(91)90244-N; WILLIAMS JH, 1989, NATURE, V341, P739, DOI 10.1038/341739a0; ZHUO M, 1993, SCIENCE, V260, P1946, DOI 10.1126/science.8100368	40	414	424	1	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 20	1994	264	5162					1148	1152		10.1126/science.7909958	http://dx.doi.org/10.1126/science.7909958			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NM146	7909958				2022-12-24	WOS:A1994NM14600033
J	DONDERO, TJ; CURRAN, JW				DONDERO, TJ; CURRAN, JW			EXCESS DEATHS IN AFRICA FROM HIV - CONFIRMED AND QUANTIFIED	LANCET			English	Editorial Material							IVORY-COAST; ABIDJAN		CTR DIS CONTROL & PREVENT,OFF DIRECTOR,ATLANTA,GA	Centers for Disease Control & Prevention - USA	DONDERO, TJ (corresponding author), CTR DIS CONTROL & PREVENT,CTR INFECT DIS,DIV HIV AIDS,ATLANTA,GA 30341, USA.							DECOCK KM, 1991, AIDS, V5, P393, DOI 10.1097/00002030-199104000-00006; DECOCK KM, 1989, LANCET, V2, P408; RICHARDS SB, IN PRESS TUBERCULE L	3	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 23	1994	343	8904					989	990		10.1016/S0140-6736(94)90120-1	http://dx.doi.org/10.1016/S0140-6736(94)90120-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NG682	7909087				2022-12-24	WOS:A1994NG68200003
J	GOODALE, MA				GOODALE, MA			PERCEIVING THE WORLD AND GRASPING IT - IS THERE A DIFFERENCE	LANCET			English	Editorial Material							OPTIC ATAXIA; PERCEPTION; OBJECTS		UNIV WESTERN ONTARIO,GRAD PROGRAM NEUROSCI,LONDON N6A 3K7,ONTARIO,CANADA	Western University (University of Western Ontario)	GOODALE, MA (corresponding author), UNIV WESTERN ONTARIO,DEPT PSYCHOL,LONDON N6A 3K7,ONTARIO,CANADA.		Goodale, Melvyn A/M-5907-2013	Goodale, Melvyn A/0000-0001-6748-0561				BRIDGEMAN B, 1981, PERCEPT PSYCHOPHYS, V34, P149; BRIDGEMAN B, IN PRESS BEHAV BRAIN; Goodale M. A, 1988, COMPUTATIONAL PROCES, P262; GOODALE MA, 1992, TRENDS NEUROSCI, V15, P20, DOI 10.1016/0166-2236(92)90344-8; GOODALE MA, 1991, NATURE, V349, P154, DOI 10.1038/349154a0; JAKOBSON LS, 1991, NEUROPSYCHOLOGIA, V29, P803, DOI 10.1016/0028-3932(91)90073-H; MILNER AD, 1991, BRAIN, V114, P405, DOI 10.1093/brain/114.1.405; PERENIN MT, 1988, BRAIN, V111, P643, DOI 10.1093/brain/111.3.643; Ungerleider LG., 1982, ANAL VISUAL BEHAV, P549	9	2	2	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 16	1994	343	8903					930	931		10.1016/S0140-6736(94)90061-2	http://dx.doi.org/10.1016/S0140-6736(94)90061-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NF700	7909006				2022-12-24	WOS:A1994NF70000005
J	TAYLOR, CJ				TAYLOR, CJ			COLONIC STRICTURES IN CYSTIC-FIBROSIS	LANCET			English	Editorial Material											TAYLOR, CJ (corresponding author), UNIV SHEFFIELD,DEPT PAEDIAT,SHEFFIELD,ENGLAND.							BAXTER PS, 1988, ARCH DIS CHILD, V63, P1496, DOI 10.1136/adc.63.12.1496; HEIJERMAN HG, 1991, ANN INTERN MED, V114, P200, DOI 10.7326/0003-4819-114-3-200; SMYTH RL, 1994, LANCET, V343, P85, DOI 10.1016/S0140-6736(94)90817-6; 1994, LANCET, V343, P109; 1994, LANCET, V343, P599	5	32	32	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 12	1994	343	8898					615	616		10.1016/S0140-6736(94)92629-8	http://dx.doi.org/10.1016/S0140-6736(94)92629-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NA093	7906805				2022-12-24	WOS:A1994NA09300002
J	ROBERTS, WM; RIVERA, GK; RAIMONDI, SC; SANTANA, VM; SANDLUND, JT; CRIST, WM; PUI, CH				ROBERTS, WM; RIVERA, GK; RAIMONDI, SC; SANTANA, VM; SANDLUND, JT; CRIST, WM; PUI, CH			INTENSIVE CHEMOTHERAPY FOR PHILADELPHIA-CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC-LEUKEMIA	LANCET			English	Note							LEUKEMIA	Childhood acute lymphoblastic leukaemia with the classic Philadelphia chromosome translocation is fatal in patients treated with chemotherapy alone. We report probable cures in three adolescents and one child who received extensively reinforced, early chemotherapy followed by rotational treatment with pairs of non-cross-resistant drugs. The median duration of leukaemia-free survival in this subgroup is 6.5 years (range 6-8 years). The two patients with long-term bone marrow surveillance for residual disease showed no evidence of the Philadelphia chromosome at 31 and 53 months post-remission. Such intensive chemotherapy is a reasonable option for patients who are not able to undergo bone marrow transplantation.	ST JUDE CHILDRENS RES HOSP, DEPT PATHOL & LAB MED, MEMPHIS, TN 38101 USA; UNIV TENNESSEE, CTR HLTH SCI, COLL MED, DEPT PEDIAT, MEMPHIS, TN 38163 USA; UNIV TENNESSEE, CTR HLTH SCI, COLL MED, DEPT PATHOL, MEMPHIS, TN 38163 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center	ROBERTS, WM (corresponding author), ST JUDE CHILDRENS RES HOSP, DEPT HEMATOL ONCOL, 332 N LAUDERDALE, POB 318, MEMPHIS, TN 38101 USA.		Raimondi, Susana C/N-8166-2018; Pui, Ching-Hon/N-8076-2018	Pui, Ching-Hon/0000-0003-0303-5658	NATIONAL CANCER INSTITUTE [P01CA020180, P30CA021765] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA20180, P30 CA 21765] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARRETT AJ, 1992, BLOOD, V79, P3067; CRIST W, 1990, BLOOD, V76, P489; DOW LW, 1989, BLOOD, V73, P1291; FLETCHER JA, 1992, LEUKEMIA LYMPHOMA, V8, P75, DOI 10.3109/10428199209049820; MIYAMURA K, 1993, BLOOD, V81, P1089; PRIEST JR, 1980, BLOOD, V56, P15; PUI CH, 1991, NEW ENGL J MED, V325, P1682, DOI 10.1056/NEJM199112123252402; RIBEIRO RC, 1993, HEMATOL PATHOL, V7, P121; RIBEIRO RC, 1987, BLOOD, V70, P948; RIVERA GK, 1991, LANCET, V337, P61, DOI 10.1016/0140-6736(91)90733-6; SURYANARAYAN K, 1991, BLOOD, V77, P324	11	48	48	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	FEB 5	1994	343	8893					331	332		10.1016/S0140-6736(94)91166-5	http://dx.doi.org/10.1016/S0140-6736(94)91166-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MU985	7905148				2022-12-24	WOS:A1994MU98500012
J	LI, XL; NOLL, M				LI, XL; NOLL, M			EVOLUTION OF DISTINCT DEVELOPMENTAL FUNCTIONS OF 3 DROSOPHILA GENES BY ACQUISITION OF DIFFERENT CIS-REGULATORY REGIONS	NATURE			English	Article							SEGMENT POLARITY GENES; EVEN-SKIPPED PROTEIN; INT-1 PROTOONCOGENE; SPATIAL EXPRESSION; PAIRED GENE; POX-NEURO; EMBRYOS; PATTERN; DNA; EMBRYOGENESIS	IT is generally accepted that the specific function of a gene depends on its coding sequence. The three paired-box and homeobox genes paired (prd), gooseberry (gsb) and gooseberry neuro (gsbn) have distinct developmental functions in Drosophila embryogenesis1-5. During the syncytial blastoderm stage, the pair-rule gene prd4,6 activates segment-polarity genes, such as gsb7, wingless (wg), and engrailed (en), in segmentally repeated stripes8. After germ-band extension, gsb maintains the expression of wg, which in turn specifies the denticle pattern by repressing a default state of ubiquitous denticle formation in the ventral epidermis9. In addition, gsb activates gsbn5, which is expressed mainly in the central nervous system2,3, suggesting that gsbn is involved in neural development. Here we show that, despite the functional difference and the considerably diverged coding sequence of these genes, their proteins have conserved the same function. The finding that the essential difference between genes may reside in their cis-regulatory regions exemplifies an important evolutionary mechanism of how function diversifies after gene duplication.			LI, XL (corresponding author), UNIV ZURICH,INST MOLEC BIOL 2,WINTERTHURERSTR 190,CH-8057 ZURICH,SWITZERLAND.							BAUMGARTNER S, 1987, GENE DEV, V1, P1247, DOI 10.1101/gad.1.10.1247; BEJSOVEC A, 1991, DEVELOPMENT, V113, P471; BOPP D, 1986, CELL, V47, P1033, DOI 10.1016/0092-8674(86)90818-4; BOPP D, 1989, EMBO J, V8, P3447, DOI 10.1002/j.1460-2075.1989.tb08509.x; COTE S, 1987, EMBO J, V6, P2793, DOI 10.1002/j.1460-2075.1987.tb02575.x; DAMBLYCHAUDIERE C, 1992, CELL, V69, P159, DOI 10.1016/0092-8674(92)90127-X; DINARDO S, 1987, GENE DEV, V1, P1212, DOI 10.1101/gad.1.10.1212; DOE CQ, 1988, NATURE, V333, P376, DOI 10.1038/333376a0; FRASCH M, 1987, EMBO J, V6, P749, DOI 10.1002/j.1460-2075.1987.tb04817.x; FRIGERIO G, 1986, CELL, V47, P735, DOI 10.1016/0092-8674(86)90516-7; GUTJAHR T, 1993, DEVELOPMENT, V117, P609; GUTJAHR T, 1993, DEVELOPMENT, V118, P21; HIDALGO A, 1991, MECH DEVELOP, V35, P77, DOI 10.1016/0925-4773(91)90059-F; HOEY T, 1988, NATURE, V332, P858, DOI 10.1038/332858a0; INGHAM PW, 1992, CELL, V68, P221, DOI 10.1016/0092-8674(92)90467-Q; ISHHOROWICZ D, 1987, CELL, V51, P405, DOI 10.1016/0092-8674(87)90636-2; JACOB F, 1977, SCIENCE, V196, P1161, DOI 10.1126/science.860134; JOYNER AL, 1991, SCIENCE, V251, P1239, DOI 10.1126/science.1672471; KILCHHERR F, 1986, NATURE, V321, P493, DOI 10.1038/321493a0; KLEMENZ R, 1987, NUCLEIC ACIDS RES, V15, P3947, DOI 10.1093/nar/15.10.3947; LI XL, 1993, EMBO J, V12, P4499, DOI 10.1002/j.1460-2075.1993.tb06139.x; LI XL, 1993, EMBO J, V12, P1427, DOI 10.1002/j.1460-2075.1993.tb05786.x; LOHNES D, 1993, CELL, V73, P643, DOI 10.1016/0092-8674(93)90246-M; MANOUKIAN AS, 1993, DEVELOPMENT, V118, P785; MANOUKIAN AS, 1992, GENE DEV, V6, P1740, DOI 10.1101/gad.6.9.1740; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MORRISSEY D, 1991, GENE DEV, V5, P1684, DOI 10.1101/gad.5.9.1684; NOLL M, 1993, CURR OPIN GENET DEV, V3, P595, DOI 10.1016/0959-437X(93)90095-7; PATEL NH, 1989, GENE DEV, V3, P890, DOI 10.1101/gad.3.6.890; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; STANOJEVIC D, 1989, NATURE, V341, P331, DOI 10.1038/341331a0; STRUHL G, 1985, NATURE, V318, P677, DOI 10.1038/318677a0; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; Wieschaus E., 1986, P199	36	123	129	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 6	1994	367	6458					83	87		10.1038/367083a0	http://dx.doi.org/10.1038/367083a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MP865	7906390				2022-12-24	WOS:A1994MP86500065
J	NIKOSKELAINEN, EK; SAVONTAUS, ML; HUOPONEN, K; ANTILA, K; HARTIALA, J				NIKOSKELAINEN, EK; SAVONTAUS, ML; HUOPONEN, K; ANTILA, K; HARTIALA, J			PREEXCITATION SYNDROME IN LEBERS HEREDITARY OPTIC NEUROPATHY	LANCET			English	Note							ELECTROCARDIOGRAPHIC ABNORMALITIES; NEURORETINOPATHY; ATROPHY	Pre-excitation syndrome is common in families with Leber's hereditary optic neuropathy (LHON). 24 Finnish families with LHON were screened for the 11778 and the 3460 mitochondrial DNA mutations. 5 of 30 individuals with LHON and the 11778 mutation had the Wolff-Parhinson-White pre-excitation syndrome. None of 10 with the 3460 mutation or of 11 with ''other'' mutations had this syndrome. Overall, 5 of 51 LHON patients and 9 of 112 symptom-free maternal relatives had Wolff-Parhinson-White syndrome (9%). In paternal relatives, the frequency was 1.6%. Mitochondrial DNA causal for LHON may contribute to pre-excitation syndrome.	UNIV TURKU,DEPT MED GENET,SF-20520 TURKU,FINLAND; UNIV TURKU,DEPT CLIN PHYSIOL,SF-20520 TURKU,FINLAND	University of Turku; University of Turku	NIKOSKELAINEN, EK (corresponding author), UNIV TURKU,DEPT OPHTHALMOL,SF-20520 TURKU,FINLAND.				NEI NIH HHS [I-RO EY 409040-01] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BIGGER JT, 1980, HEART DIS TXB CARDIO, V1, P682; BOWER SPC, 1992, LANCET, V339, P1427, DOI 10.1016/0140-6736(92)91257-9; FEDERICO A, 1987, J INHERIT METAB DIS, V10, P256, DOI 10.1007/BF01811419; HIRANO M, 1992, NEUROMUSCULAR DISORD, V2, P125, DOI 10.1016/0960-8966(92)90045-8; HUOPONEN K, 1993, HUM GENET, V92, P379, DOI 10.1007/BF01247339; NIKOSKELAINEN E, 1985, LANCET, V1, P696; NIKOSKELAINEN EK, 1987, ARCH OPHTHALMOL-CHIC, V105, P665, DOI 10.1001/archopht.1987.01060050083043; ORTIZ RG, 1992, AM J OPHTHALMOL, V113, P561, DOI 10.1016/S0002-9394(14)74730-0; ROSE FC, 1970, BRIT J OPHTHALMOL, V54, P388, DOI 10.1136/bjo.54.6.388; VIDAILLET HJ, 1987, NEW ENGL J MED, V317, P65, DOI 10.1056/NEJM198707093170201	10	60	62	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 24	1994	344	8926					857	858		10.1016/S0140-6736(94)92830-4	http://dx.doi.org/10.1016/S0140-6736(94)92830-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PH253	7916404				2022-12-24	WOS:A1994PH25300014
J	PORTER, A				PORTER, A			GODS FOOLS	LANCET			English	Editorial Material														Porter, Alan MW/0000-0001-5622-7288				BENDA J, 1928, TRAHISON CLERCS; CHESNAIS JC, 1994, NEW SCI, V143, P32; Festinger L., 1957, THEORY COGNITIVE DIS, V2; KING M, 1993, LANCET, V341, P669, DOI 10.1016/0140-6736(93)90431-F; PORTER AMW, 1993, J HUM EVOL, V25, P417, DOI 10.1006/jhev.1993.1059; RUSSELL C, 1979, J MED ETHICS, V5, P108, DOI 10.1136/jme.5.3.108; WHEELER PE, 1993, J HUM EVOL, V24, P13, DOI 10.1006/jhev.1993.1003	7	0	0	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 24	1994	344	8926					835	836		10.1016/S0140-6736(94)92822-3	http://dx.doi.org/10.1016/S0140-6736(94)92822-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PH253	7916396				2022-12-24	WOS:A1994PH25300006
J	LINN, FHH; WIJDICKS, EFM; VANDERGRAAF, Y; WEERDESTEYNVANVLIET, FAC; BARTELDS, AIM; VANGIJN, J				LINN, FHH; WIJDICKS, EFM; VANDERGRAAF, Y; WEERDESTEYNVANVLIET, FAC; BARTELDS, AIM; VANGIJN, J			PROSPECTIVE-STUDY OF SENTINEL HEADACHE IN ANEURYSMAL SUBARACHNOID HEMORRHAGE	LANCET			English	Article							INTRACRANIAL ANEURYSM; STROKE INCIDENCE; CASE FATALITY; WARNING LEAK; FOLLOW-UP; HEMORRHAGE; RUPTURE; POPULATION; EPIDEMIOLOGY; MANAGEMENT	Retrospective surveys of patients with subarachnoid haemorrhage suggest that minor episodes with sudden headache (warning leaks) may precede rupture of an aneurysm, and that early recognition and surgery might lead to improved outcome. We studied 148 patients with sudden and severe headache (possible sentinel headache) seen by 252 general practitioners in a 5-year period in the Netherlands. Subarachnoid haemorrhage was the cause in 37 patients (25%) (proven aneurysm in 21, negative angiogram in 6, no angiogram done in 6, sudden headache followed by death in 4). 103 patients had headache as the only symptom, 12 of whom proved to have subarachnoid haemorrhage (6 with a ruptured aneurysm). Previous bouts of sudden headache had occurred in only 2. Other serious neurological conditions were diagnosed in 18. In the remaining 93, no underlying cause of headache was found; follow-up over 1 year showed no subsequent subarachnoid haemorrhage or sudden death. In this cohort, acute, severe headache in general practice indicated a serious neurological disorder in 37% (95% CI 29-45%), and subarachnoid haemorrhage in 25% (18-32%). 12% (5-18%) of those with headache as the only symptom. The notion of warning leaks as a less serious variant of subarachnoid haemorrhage is not supported by this study. Early recognition of subarachnoid haemorrhage is important but will probably have only limited impact on the outcome in the general population.	UNIV UTRECHT,DEPT EPIDEMIOL,UTRECHT,NETHERLANDS; NETHERLANDS INST PRIMARY HLTH CARE,UTRECHT,NETHERLANDS	Utrecht University	LINN, FHH (corresponding author), UNIV UTRECHT,DEPT NEUROL,HEIDELBERGLAAN 100,3584 CX UTRECHT,NETHERLANDS.		van Gijn, Jan/A-9444-2008					BALL MJ, 1975, CAN MED ASSOC J, V112, P78; BAMFORD J, 1990, J NEUROL NEUROSUR PS, V53, P16, DOI 10.1136/jnnp.53.1.16; BONITA R, 1985, STROKE, V16, P591, DOI 10.1161/01.STR.16.4.591; BROUWERS PJAM, 1993, STROKE, V24, P809, DOI 10.1161/01.STR.24.6.809; COLLETTE HJA, 1982, ENV EPIDEMIOLOGY, P149; DUFFY GP, 1983, MED J AUSTRALIA, V1, P514, DOI 10.5694/j.1326-5377.1983.tb136193.x; GIROUD M, 1991, INT J EPIDEMIOL, V20, P892, DOI 10.1093/ije/20.4.892; HAUERBERG J, 1991, ACTA NEUROL SCAND, V83, P61; HERMAN B, 1982, STROKE, V13, P629, DOI 10.1161/01.STR.13.5.629; HIJDRA A, 1990, STROKE, V21, P1156, DOI 10.1161/01.STR.21.8.1156; HIJDRA A, 1987, STROKE, V18, P1061, DOI 10.1161/01.STR.18.6.1061; INGALL TJ, 1989, STROKE, V20, P718, DOI 10.1161/01.STR.20.6.718; JENNETT B, 1975, LANCET, V1, P480; JUVELA S, 1992, NEUROSURGERY, V30, P7, DOI 10.1227/00006123-199201000-00002; KASSELL NF, 1990, J NEUROSURG, V73, P18, DOI 10.3171/jns.1990.73.1.0018; KISSEL JT, 1983, ANN NEUROL, V13, P149, DOI 10.1002/ana.410130207; LEBLANC R, 1985, CAN MED ASSOC J, V131, P1235; MARKUS HS, 1991, J NEUROL NEUROSUR PS, V54, P1117, DOI 10.1136/jnnp.54.12.1117; OKAWARA SH, 1973, J NEUROSURG, V38, P575, DOI 10.3171/jns.1973.38.5.0575; Pakarinen S, 1967, ACTA NEUROL SCAN S29, V43, P1; RAJA IA, 1972, J NEUROSURG, V36, P548, DOI 10.3171/jns.1972.36.5.0548; RASMUSSEN BK, 1992, NEUROLOGY, V42, P1225, DOI 10.1212/WNL.42.6.1225; RICCI S, 1991, J NEUROL NEUROSUR PS, V54, P695, DOI 10.1136/jnnp.54.8.695; RINKEL GJE, 1991, AM J NEURORADIOL, V12, P829; TEASDALE G, 1974, LANCET, V2, P81; VERMEULEN M, 1990, J NEUROL NEUROSUR PS, V53, P365, DOI 10.1136/jnnp.53.5.365; VERWEIJ RD, 1988, ARCH NEUROL-CHICAGO, V45, P1019, DOI 10.1001/archneur.1988.00520330109018; WIJDICKS EFM, 1988, LANCET, V2, P68; 1989, CBS ANN PUBLICATI A1	29	172	174	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 27	1994	344	8922					590	593		10.1016/S0140-6736(94)91970-4	http://dx.doi.org/10.1016/S0140-6736(94)91970-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD424	7914965	Green Submitted			2022-12-24	WOS:A1994PD42400014
J	MANI, SK; ALLEN, JMC; CLARK, JH; BLAUSTEIN, JD; OMALLEY, BW				MANI, SK; ALLEN, JMC; CLARK, JH; BLAUSTEIN, JD; OMALLEY, BW			CONVERGENT PATHWAYS FOR STEROID HORMONE-INDUCED AND NEUROTRANSMITTER-INDUCED RAT SEXUAL-BEHAVIOR	SCIENCE			English	Article							MESSENGER RIBONUCLEIC-ACID; LIGAND-INDEPENDENT ACTIVATION; CENTRAL NERVOUS-SYSTEM; FEMALE GUINEA-PIGS; GROWTH FACTOR-I; PROGESTIN RECEPTORS; ESTROGEN-RECEPTOR; LORDOSIS BEHAVIOR; CONCENTRATING CELLS; OVARIECTOMIZED RATS	Estrogen and progesterone modulate gene expression in rodents by activation of intracellular receptors in the hypothalamus, which regulate neuronal networks that control female sexual behavior. However, the neurotransmitter dopamine has been shown to activate certain steroid receptors in a ligand-independent manner. A dopamine receptor stimulant and a D-1 receptor agonist, but not a D-2 receptor agonist, mimicked the effects of progesterone in facilitating sexual behavior in female rats. The facilitatory effect of the neurotransmitter was blocked by progesterone receptor antagonists, a D-1 receptor antagonist, or antisense oligonucleotides to the progesterone receptor. The results suggest that in rodents neurotransmitters may regulate in vivo gene expression and behavior by means of cross-talk with steroid receptors in the brain.	BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; UNIV MASSACHUSETTS,DEPT PSYCHOL,AMHERST,MA 01003; UNIV MASSACHUSETTS,NEUROSCI BEHAV PROGRAM,AMHERST,MA 01003	Baylor College of Medicine; University of Massachusetts System; University of Massachusetts Amherst; University of Massachusetts System; University of Massachusetts Amherst					NIMH NIH HHS [MH-00885] Funding Source: Medline; NINDS NIH HHS [NS 19327] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [K02MH000885] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019327] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AHLENIUS S, 1993, NEUROSCI BIOBEHAV R, V17, P43, DOI 10.1016/S0149-7634(05)80229-5; ALLAN GF, 1992, J BIOL CHEM, V267, P19513; ANTUNESR.J, 1970, P SOC EXP BIOL MED, V133, P1464; ARONICA SM, 1993, MOL ENDOCRINOL, V7, P743, DOI 10.1210/me.7.6.743; Blaustein J. D., 1989, Advances in Comparative and Environmental Physiology, V3, P31; BLAUSTEIN JD, 1987, BRAIN RES, V436, P253, DOI 10.1016/0006-8993(87)91669-6; BLAUSTEIN JD, 1982, BRAIN RES, V243, P287, DOI 10.1016/0006-8993(82)90252-9; BLAUSTEIN JD, 1980, ENDOCRINOLOGY, V106, P1061, DOI 10.1210/endo-106-4-1061; BLAUSTEIN JD, 1989, J NEUROENDOCRINOL, V1, P333, DOI 10.1111/j.1365-2826.1989.tb00125.x; BLAUSTEIN JD, 1986, NEUROENDOCRINOLOGY, V43, P143, DOI 10.1159/000124521; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN T J, 1990, Molecular and Cellular Neuroscience, V1, P58, DOI 10.1016/1044-7431(90)90042-3; BROWN TJ, 1986, BRAIN RES, V373, P103, DOI 10.1016/0006-8993(86)90320-3; BROWN TJ, 1987, ENDOCRINOLOGY, V121, P298, DOI 10.1210/endo-121-1-298; BROWN TJ, 1984, BRAIN RES, V301, P343, DOI 10.1016/0006-8993(84)91103-X; DIAUGUSTINE RP, 1988, ENDOCRINOLOGY, V122, P2355, DOI 10.1210/endo-122-6-2355; DLUZEN DE, 1989, BRAIN RES, V494, P122, DOI 10.1016/0006-8993(89)90150-9; EVERITT BJ, 1974, EUR J PHARMACOL, V29, P187, DOI 10.1016/0014-2999(74)90190-3; FEDER HH, 1977, ANN NY ACAD SCI, V286, P331, DOI 10.1111/j.1749-6632.1977.tb29428.x; FOREMAN MM, 1979, PHYSIOL BEHAV, V22, P283, DOI 10.1016/0031-9384(79)90088-X; FOREMAN MM, 1987, PSYCHOPHARMACOLOGY, V91, P96, DOI 10.1007/BF00690934; FUXE K, 1976, SUBCELLULAR MECHANIS, P193; HAMBURGERBAR R, 1975, EUR J PHARMACOL, V32, P357, DOI 10.1016/0014-2999(75)90304-0; IGNARTROWBRIDGE DM, 1992, P NATL ACAD SCI USA, V89, P4658, DOI 10.1073/pnas.89.10.4658; KATZENELLENBOGEN BS, 1990, ENDOCRINOLOGY, V126, P891, DOI 10.1210/endo-126-2-891; MACLUSKY NJ, 1980, ENDOCRINOLOGY, V106, P192, DOI 10.1210/endo-106-1-192; MANI S, UNPUB; MCEWEN BS, 1982, RECENT PROG HORM RES, V38, P41; MCEWEN BS, 1988, J STEROID BIOCHEM, V30, P179, DOI 10.1016/0022-4731(88)90091-X; MORISSETTE M, 1993, J NEUROCHEM, V60, P1876, DOI 10.1111/j.1471-4159.1993.tb13415.x; MORRELL JI, 1978, AM ZOOL, V18, P447; MORRIN LP, 1977, PHYSIOL BEHAV, V18, P701; NELSON KG, 1992, ENDOCRINOLOGY, V131, P1657, DOI 10.1210/en.131.4.1657; NOCK B, 1981, BRAIN RES, V20, P371; OGAWA S, 1994, J NEUROSCI, V14, P1766, DOI 10.1523/JNEUROSCI.14-03-01766.1994; PARSONS B, 1980, ENDOCRINOLOGY, V107, P774, DOI 10.1210/endo-107-3-774; PFAFF D, 1973, J COMP NEUROL, V151, P121, DOI 10.1002/cne.901510204; PFAFF DW, 1983, SCIENCE, V219, P808, DOI 10.1126/science.6297008; PFAFF DW, 1988, PHYSL REPRODUCTION, V1, P1487; POLLIO G, 1993, MOL BRAIN RES, V19, P135, DOI 10.1016/0169-328X(93)90158-L; POWER RF, 1991, SCIENCE, V252, P1546, DOI 10.1126/science.2047861; POWER RF, 1991, SCIENCE, V254, P1636, DOI 10.1126/science.1749936; POWERS JB, 1976, PHYSIOL BEHAV, V117, P493; ROMANO GJ, 1988, MOL ENDOCRINOL, V2, P1320, DOI 10.1210/mend-2-12-1320; ROMANO GJ, 1989, MOL ENDOCRINOL, V3, P1295, DOI 10.1210/mend-3-8-1295; SMITH CL, 1993, P NATL ACAD SCI USA, V90, P6120, DOI 10.1073/pnas.90.13.6120; STANCEL GM, 1990, PROG CLIN BIOL RES, V322, P213; THORTON JE, 1986, BRAIN RES, V377, P1155; TITUS RD, 1983, J MED CHEM, V26, P1112, DOI 10.1021/jm00362a005; VATHY IU, 1989, HORM BEHAV, V23, P43, DOI 10.1016/0018-506X(89)90073-1; WILCOX JN, 1985, ENDOCRINOLOGY, V117, P2392, DOI 10.1210/endo-117-6-2392	51	287	288	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 26	1994	265	5176					1246	1249		10.1126/science.7915049	http://dx.doi.org/10.1126/science.7915049			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PD422	7915049				2022-12-24	WOS:A1994PD42200042
J	PRESTON, NW				PRESTON, NW			PERTUSSIS VACCINATION - NEITHER PANIC NOR COMPLACENCY	LANCET			English	Editorial Material											PRESTON, NW (corresponding author), UNIV MANCHESTER,SCH MED,DEPT MED MICROBIOL,PERTUSSIS REFERENCE LAB,MANCHESTER,ENGLAND.							BARAFF LJ, 1984, PEDIATRICS, V73, P37; BOOY R, 1992, LANCET, V339, P507, DOI 10.1016/0140-6736(92)90336-2; CHRISTIE CDC, 1994, NEW ENGL J MED, V331, P16, DOI 10.1056/NEJM199407073310104; KHATTAK MN, 1993, J INFECTION, V27, P119, DOI 10.1016/0163-4453(93)94566-T; KNOWLES K, 1993, 33RD INT C ANT AG CH; MARCHANT CD, 1994, J INFECT DIS, V169, P1297, DOI 10.1093/infdis/169.6.1297; Miller E, 1992, Commun Dis Rep CDR Rev, V2, pR152; Preston N. W., 1994, Tropical Diseases Bulletin, V91, pR151; Preston N W, 1992, Commun Dis Rep CDR Rev, V2, pR155; Preston N W, 1970, Lab Pract, V19, P482; PRESTON NW, 1988, PATHOGENESIS IMMUNIT, P1; STOTT NCH, 1981, BRIT MED J, V282, P1871, DOI 10.1136/bmj.282.6279.1871-a; WARDLAW AC, 1992, VACCINE, V10, P643, DOI 10.1016/0264-410X(92)90083-V	13	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 20	1994	344	8921					491	492		10.1016/S0140-6736(94)91894-5	http://dx.doi.org/10.1016/S0140-6736(94)91894-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PC535	7914610				2022-12-24	WOS:A1994PC53500005
J	OXMAN, TE				OXMAN, TE			DELAYED RECALL - DEMENTED, DEPRESSED, OR TREATED	LANCET			English	Editorial Material							ALZHEIMERS		DARTMOUTH COLL,SCH MED,DEPT COMMUNITY & FAMILY MED,HANOVER,NH 03755	Dartmouth College	OXMAN, TE (corresponding author), DARTMOUTH COLL,SCH MED,DEPT PSYCHIAT,HANOVER,NH 03755, USA.							ALBERT MS, 1991, COMPREHENSIVE REV GE, P223; EMERY VO, 1992, AM J PSYCHIAT, V149, P305; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; HINDMARCH I, 1992, PSYCHOPHARMACOLOGY S, V105, pS49; LACHNER G, 1994, J NERV MENT DIS, V181, P34; MASSMAN PJ, 1992, J CLIN EXP NEUROPSYC, V14, P687, DOI 10.1080/01688639208402856; NIEDEREHE G, 1994, DEMENTIA PRESENTATIO, P19; OXMAN AD, 1993, JAMA-J AM MED ASSOC, V270, P2093; RABINS PV, 1984, BRIT J PSYCHIAT, V144, P488, DOI 10.1192/bjp.144.5.488; REIFLER BV, 1989, AM J PSYCHIAT, V146, P45; TERI L, 1991, GERONTOLOGIST, V31, P413, DOI 10.1093/geront/31.3.413	11	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 23	1994	344	8917					213	214		10.1016/S0140-6736(94)92994-7	http://dx.doi.org/10.1016/S0140-6736(94)92994-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NY060	7913154				2022-12-24	WOS:A1994NY06000006
J	CLERICI, M; BEVILACQUA, M; VAGO, T; VILLA, ML; SHEARER, GM; NORBIATO, G				CLERICI, M; BEVILACQUA, M; VAGO, T; VILLA, ML; SHEARER, GM; NORBIATO, G			AN IMMUNOENDOCRINOLOGICAL HYPOTHESIS OF HIV-INFECTION	LANCET			English	Note							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; HUMAN MEDULLARY THYMOCYTES; GLUCOCORTICOID RECEPTOR; T-CELLS; IMMUNE-RESPONSES; IMMUNOGLOBULIN-E; GENE-EXPRESSION; INTERLEUKIN-2; DEHYDROEPIANDROSTERONE; SYSTEM		OSPED L SACCO,SERV ENDOCRINOL,MILAN,ITALY; NCI,EXPTL IMMUNOL BRANCH,BETHESDA,MD 20892	University of Milan; Luigi Sacco Hospital; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	CLERICI, M (corresponding author), UNIV MILAN,CATTEDRA IMMUNOL,VIA VENEZIA 1,I-20133 MILAN,ITALY.			Clerici, Mario/0000-0001-5920-6191				BROWNE ES, 1993, J STEROID BIOCHEM, V45, P517, DOI 10.1016/0960-0760(93)90168-V; CHEHIMI J, 1994, J EXP MED, V179, P1361, DOI 10.1084/jem.179.4.1361; CHRISTEFF N, 1992, J ACQ IMMUN DEF SYND, V5, P841; CLERICI M, 1993, SCIENCE, V262, P1721, DOI 10.1126/science.7903123; CLERICI M, 1994, J CLIN INVEST, V93, P768, DOI 10.1172/JCI117031; CLERICI M, 1993, IMMUNOL TODAY, V14, P107, DOI 10.1016/0167-5699(93)90208-3; CLERICI M, IN PRESS P NATL ACAD; DAYNES RA, 1989, EUR J IMMUNOL, V19, P2319, DOI 10.1002/eji.1830191221; FIORENTINO DF, 1989, J EXP MED, V170, P2081, DOI 10.1084/jem.170.6.2081; GRINSPOON SK, 1992, NEW ENGL J MED, V327, P1360, DOI 10.1056/NEJM199211053271906; GROUX H, 1993, EUR J IMMUNOL, V23, P1623, DOI 10.1002/eji.1830230734; HELMBERG A, 1990, J IMMUNOL, V145, P4332; HERRSCHER RF, 1992, J CLIN INVEST, V90, P596, DOI 10.1172/JCI115898; KAM JC, 1993, J IMMUNOL, V151, P3460; MANETTI R, 1993, J EXP MED, V177, P1199, DOI 10.1084/jem.177.4.1199; MEEYARD L, 1993, INNUMOL TODAY, V14, P161; MULDER JW, 1992, J INFECT DIS, V165, P413, DOI 10.1093/infdis/165.3.413; NIETO MA, 1990, J IMMUNOL, V145, P1364; NORBIATO G, 1992, J CLIN ENDOCR METAB, V74, P608, DOI 10.1210/jc.74.3.608; POLI G, 1993, CLIN RES, V41, pA211; RISDON G, 1990, AM J PATHOL, V136, P759; SALKOWSKI CA, 1992, J IMMUNOL, V148, P2770; SEDER RA, 1992, J EXP MED, V176, P1091, DOI 10.1084/jem.176.4.1091; TANG WW, 1993, AM J MED, V94, P169, DOI 10.1016/0002-9343(93)90179-S; VACCA A, 1992, J EXP MED, V175, P637, DOI 10.1084/jem.175.3.637; WRIGHT DN, 1990, J ALLERGY CLIN IMMUN, V85, P445, DOI 10.1016/0091-6749(90)90154-V; WU CY, 1991, J CLIN INVEST, V87, P870, DOI 10.1172/JCI115092	27	55	56	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 18	1994	343	8912					1552	1553		10.1016/S0140-6736(94)92944-0	http://dx.doi.org/10.1016/S0140-6736(94)92944-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NR329	7911876				2022-12-24	WOS:A1994NR32900014
J	SCHLITT, HJ; HUNDRIESER, J; HISANAGA, M; UTHOFF, K; KARCK, M; WAHLERS, T; WONIGEIT, K; PICHLMAYR, R				SCHLITT, HJ; HUNDRIESER, J; HISANAGA, M; UTHOFF, K; KARCK, M; WAHLERS, T; WONIGEIT, K; PICHLMAYR, R			PATTERNS OF DONOR-TYPE MICROCHIMERISM AFTER HEART-TRANSPLANTATION	LANCET			English	Note							ALLOGRAFTS; CHIMERISM; LIVER	Allogeneic microchimerism of donor-type has been demonstrated in stable patients in the long-term after organ transplantation. We have analysed microchimerism in shin and blood of 47 heart-transplanted patients after transplantation with polymerase-chain-reaction amplification specific for donor HLA-DRB1. Microchimerism was detectable in 50% of the patients in the first 6 months, in 100% between 6 months and 2 years, and in 58% in the third postoperative year or later. The state of chimerism was not related to acute or chronic rejections. Patterns of microchimerism after heart transplantation may be dynamic, but any association with clinical and immunological variables remains to be elucidated.	HANNOVER MED SCH,THORAX HERZ & GEFASSCHIRURG KLIN,D-30623 HANNOVER,GERMANY	Hannover Medical School	SCHLITT, HJ (corresponding author), HANNOVER MED SCH,ABDOMINAL & TRANSPLANTAT CHIRURG KLIN,D-30623 HANNOVER,GERMANY.		Schlitt, Hans J./ABG-4368-2020					BEIN G, 1992, TISSUE ANTIGENS, V39, P68, DOI 10.1111/j.1399-0039.1992.tb01909.x; CICCONE E, 1992, J EXP MED, V175, P709, DOI 10.1084/jem.175.3.709; DEMETRIS AJ, 1993, TRANSPL P, V25, P3337; LARSEN CP, 1990, ANN SURG, V212, P308, DOI 10.1097/00000658-199009000-00009; QIAN S, IN PRESS HEPATOLOGY; SCHLITT HJ, 1994, NEW ENGL J MED, V330, P646, DOI 10.1056/NEJM199403033300919; SCHLITT HJ, 1993, TRANSPLANTATION, V56, P951, DOI 10.1097/00007890-199310000-00033; SCHLITT HJ, 1992, TRANSPLANTATION, V56, P1001; STARZL TE, 1993, TRANSPLANTATION, V55, P1272, DOI 10.1097/00007890-199306000-00012; STARZL TE, 1992, LANCET, V340, P876, DOI 10.1016/0140-6736(92)93286-V	10	130	132	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 11	1994	343	8911					1469	1471		10.1016/S0140-6736(94)92584-4	http://dx.doi.org/10.1016/S0140-6736(94)92584-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NQ415	7911180				2022-12-24	WOS:A1994NQ41500011
J	BOOTH, IW				BOOTH, IW			COSTING MALNUTRITION - ADD OR MULTIPLY	LANCET			English	Editorial Material							CHILDREN; RISK				BOOTH, IW (corresponding author), UNIV BIRMINGHAM,INST CHILD HLTH,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND.							BRIEND A, 1987, LANCET, V2, P725; CHEN LC, 1980, AM J CLIN NUTR, V33, P1836, DOI 10.1093/ajcn/33.8.1836; FAWZI WW, 1993, JAMA-J AM MED ASSOC, V269, P898, DOI 10.1001/jama.269.7.898; PELLETIER DL, 1993, AM J PUBLIC HEALTH, V83, P1130, DOI 10.2105/AJPH.83.8.1130; VANDENBROECK J, 1993, LANCET, V341, P1491, DOI 10.1016/0140-6736(93)90632-Q; Waterlow JC, 1992, PROTEIN ENERGY MALNU	6	1	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 5	1994	343	8897					554	555		10.1016/S0140-6736(94)91514-8	http://dx.doi.org/10.1016/S0140-6736(94)91514-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY843	7906322				2022-12-24	WOS:A1994MY84300002
J	VONGERSDORFF, H; MATTHEWS, G				VONGERSDORFF, H; MATTHEWS, G			DYNAMICS OF SYNAPTIC VESICLE FUSION AND MEMBRANE RETRIEVAL IN SYNAPTIC TERMINALS	NATURE			English	Article							TRANSMITTER RELEASE; NERVE-TERMINALS; CALCIUM INFLUX; BIPOLAR CELLS; CAPACITANCE MEASUREMENTS; INTRACELLULAR CALCIUM; GOLDFISH RETINA; AMINO-ACIDS; EXOCYTOSIS; CURRENTS	COMMUNICATION among neurons occurs at specialized synaptic junctions, where neurotransmitter is released via calcium-dependent exocytosis from the synaptic terminal of the presynaptic cell onto the postsynaptic target neuron. Here we exploit the unique properties of giant synaptic terminals1-4 of bipolar neurons from goldfish retina to establish the kinetics and calcium-dependence of exocytosis, and the characteristics of membrane retrieval following secretion in presynaptic terminals. Simultaneous patch-clamp, calcium-indicator dye and time-resolved capacitance measurements reveal that activation of calcium current drives secretion at a rapid rate of about 10,000 vesicles per s and the, calcium level necessary to drive secretion is locally greater than 50 muM. Two components of membrane retrieval were observed following secretory stimulation. After strong stimulation, capacitance returned to rest with a time constant of about 30 s, but after weaker stimuli recovery was much faster, with a time constant of about 2 s. Secretion in a vertebrate central nervous system neuron was thus found to differ substantially from that in other secretory cells in its rapid rate of vesicle fusion, requirement for high levels of intracellular calcium, and the high speed and completeness of membrane retrieval. These distinctive features reflect the specialization of neuronal synaptic terminals for rapid and focally directed release of neurotransmitter.			VONGERSDORFF, H (corresponding author), SUNY STONY BROOK,DEPT NEUROBIOL & BEHAV,STONY BROOK,NY 11794, USA.							ADLER EM, 1991, J NEUROSCI, V11, P1496; AUGUSTINE GJ, 1992, J PHYSIOL-LONDON, V450, P247, DOI 10.1113/jphysiol.1992.sp019126; BETZ WJ, 1992, J NEUROSCI, V12, P363, DOI 10.1523/jneurosci.12-02-00363.1992; DELCASTILLO J, 1954, J PHYSIOL-LONDON, V124, P553, DOI 10.1113/jphysiol.1954.sp005128; FERNANDEZ JM, 1984, NATURE, V312, P453, DOI 10.1038/312453a0; HEIDELBERGER R, 1992, J PHYSIOL-LONDON, V447, P235, DOI 10.1113/jphysiol.1992.sp019000; HEUSER JE, 1981, J CELL BIOL, V88, P564, DOI 10.1083/jcb.88.3.564; ISHIDA AT, 1980, J COMP NEUROL, V191, P315, DOI 10.1002/cne.901910302; JAFFE LA, 1978, DEV BIOL, V67, P243, DOI 10.1016/0012-1606(78)90314-7; KANDEL ER, 1991, PRINCIPLES NEURAL SC, P200; KANEKO A, 1985, J PHYSIOL-LONDON, V358, P131, DOI 10.1113/jphysiol.1985.sp015544; KELLY RB, 1993, NEURON S, V10, P43; LIM NF, 1990, NATURE, V344, P449, DOI 10.1038/344449a0; LINDAU M, 1992, BIOPHYS J, V61, P19, DOI 10.1016/S0006-3495(92)81812-X; LINDAU M, 1988, PFLUG ARCH EUR J PHY, V411, P137, DOI 10.1007/BF00582306; MARC RE, 1989, NATO ASI SERIES H, V31, P53; MAYCOX PR, 1992, J CELL BIOL, V118, P1379, DOI 10.1083/jcb.118.6.1379; NEHER E, 1993, NEURON, V10, P21, DOI 10.1016/0896-6273(93)90238-M; NEHER E, 1982, P NATL ACAD SCI-BIOL, V79, P6712, DOI 10.1073/pnas.79.21.6712; RAJU B, 1989, AM J PHYSIOL, V256, pC540, DOI 10.1152/ajpcell.1989.256.3.C540; RYAN TA, 1993, NEURON, V11, P7132; SHERRY DM, 1993, J COMP NEUROL, V329, P188, DOI 10.1002/cne.903290204; SIMON SM, 1985, BIOPHYS J, V48, P485, DOI 10.1016/S0006-3495(85)83804-2; STERN MD, 1992, CELL CALCIUM, V13, P183, DOI 10.1016/0143-4160(92)90046-U; TACHIBANA M, 1991, J NEUROSCI, V11, P2199; TACHIBANA M, 1993, J NEUROSCI, V13, P2898; THOMAS P, 1993, EMBO J, V12, P303, DOI 10.1002/j.1460-2075.1993.tb05657.x; THOMAS P, 1990, NEURON, V5, P723, DOI 10.1016/0896-6273(90)90226-6; VERHAGE M, 1991, NEURON, V6, P517, DOI 10.1016/0896-6273(91)90054-4; ZUCKER RS, 1986, P NATL ACAD SCI USA, V83, P3032, DOI 10.1073/pnas.83.9.3032	30	383	389	0	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 24	1994	367	6465					735	739		10.1038/367735a0	http://dx.doi.org/10.1038/367735a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MX631	7906397				2022-12-24	WOS:A1994MX63100058
J	TOFT, AD				TOFT, AD			IF I SHOULD LIVE TO BE 100	LANCET			English	Editorial Material											TOFT, AD (corresponding author), ROYAL INFIRM, EDINBURGH, SCOTLAND.							CUTLER RG, 1991, ANN NY ACAD SCI, V621, P1; MARRIOTTI S, 1993, J CLIN ENDOCR METAB, V77, P1130; MARTIN GR, 1993, ANNU REV MED, V44, P419, DOI 10.1146/annurev.me.44.020193.002223	3	2	2	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	FEB 19	1994	343	8895					434	434		10.1016/S0140-6736(94)92688-3	http://dx.doi.org/10.1016/S0140-6736(94)92688-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW690	7905952				2022-12-24	WOS:A1994MW69000006
J	BOURTCHULADZE, R; FRENGUELLI, B; BLENDY, J; CIOFFI, D; SCHUTZ, G; SILVA, AJ				BOURTCHULADZE, R; FRENGUELLI, B; BLENDY, J; CIOFFI, D; SCHUTZ, G; SILVA, AJ			DEFICIENT LONG-TERM-MEMORY IN MICE WITH A TARGETED MUTATION OF THE CAMP-RESPONSIVE ELEMENT-BINDING PROTEIN	CELL			English	Article							APLYSIA SENSORY NEURONS; HIPPOCAMPAL; POTENTIATION; RAT; FACILITATION; SHOCK; FEAR; LTP; MECHANISMS; NALOXONE	The cAMP-responsive element-binding protein (CREB) has been implicated in the activation of protein synthesis required for long-term facilitation, a cellular model of memory in Aplysia. Our studies with fear conditioning and with the water maze show that mice with a targeted disruption of the alpha and delta isoforms of CREB are profoundly deficient in long-term memory. In contrast, short-term memory, lasting between 30 and 60 min, is normal. Consistent with models claiming a role for long-term potentiation (LTP) in memory, LTP in hippocampal slices from CREB mutants decayed to baseline 90 min after tetanic stimulation. However, paired-pulse facilitation and posttetanic potentiation are normal. These results implicate CREB-dependent transcription in mammalian long-term memory.	UNIV HEIDELBERG, GERMAN CANC RES CTR, D-69120 HEIDELBERG, GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg	BOURTCHULADZE, R (corresponding author), COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA.		Frenguelli, Bruno/C-5007-2015; Silva, Alcino/ABD-7684-2021	Frenguelli, Bruno/0000-0001-7214-3172; Silva, Alcino/0000-0002-1587-4558; Silva, Alcino/0000-0001-5525-0494				ALBERINI CM, 1994, CELL, V76, P1099, DOI 10.1016/0092-8674(94)90386-7; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BRANDEIS R, 1989, INT J NEUROSCI, V48, P29, DOI 10.3109/00207458909002151; DASH PK, 1990, NATURE, V345, P718, DOI 10.1038/345718a0; DAVIS HP, 1984, PSYCHOL BULL, V96, P518, DOI 10.1037/0033-2909.96.3.518; DICKINSON A, 1978, ANNU REV PSYCHOL, V29, P587, DOI 10.1146/annurev.ps.29.020178.003103; EICHENBAUM H, 1993, TRENDS NEUROSCI, V16, P163, DOI 10.1016/0166-2236(93)90140-H; EICHENBAUM H, 1992, BEHAV NEURAL BIOL, V57, P2, DOI 10.1016/0163-1047(92)90724-I; FANSELOW MS, 1979, B PSYCHONOMIC SOC, V14, P88; FANSELOW MS, 1986, LEARN MOTIV, V17, P16, DOI 10.1016/0023-9690(86)90018-4; FANSELOW MS, 1979, J COMP PHYSIOL PSYCH, V93, P736, DOI 10.1037/h0077609; FLOOD JF, 1975, PHYSIOL BEHAV, V15, P97, DOI 10.1016/0031-9384(75)90285-1; FREY U, 1988, BRAIN RES, V452, P57, DOI 10.1016/0006-8993(88)90008-X; FREY U, 1993, SCIENCE, V260, P1661, DOI 10.1126/science.8389057; HESS G, 1987, NEUROSCI LETT, V77, P187, DOI 10.1016/0304-3940(87)90584-2; Huang Y Y, 1994, Learn Mem, V1, P74; HUMMLER E, 1994, P NATL ACAD SCI USA, V91, P5647, DOI 10.1073/pnas.91.12.5647; KAANG BK, 1993, NEURON, V10, P427, DOI 10.1016/0896-6273(93)90331-K; KIM JJ, 1992, BEHAV NEUROSCI, V106, P591, DOI 10.1037/0735-7044.106.4.591; KIM JJ, 1993, BEHAV NEUROSCI, V107, P1093, DOI 10.1037/0735-7044.107.6.1093; KIM JJ, 1992, SCIENCE, V256, P675, DOI 10.1126/science.1585183; LEE KAW, 1993, BIOCHIM BIOPHYS ACTA, V1174, P221, DOI 10.1016/0167-4781(93)90191-F; MATTHIES H, 1989, PROG NEUROBIOL, V32, P277, DOI 10.1016/0301-0082(89)90024-5; MCNAUGHTON BL, 1982, J PHYSIOL-LONDON, V324, P249, DOI 10.1113/jphysiol.1982.sp014110; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MORRIS RGM, 1981, LEARN MOTIV, V12, P239, DOI 10.1016/0023-9690(81)90020-5; MULLER D, 1989, BRAIN RES, V479, P290, DOI 10.1016/0006-8993(89)91631-4; PHILLIPS RG, 1992, BEHAV NEUROSCI, V106, P274, DOI 10.1037/0735-7044.106.2.274; REYMANN KG, 1993, FUNCT NEUROL S, V5, P7; RUDY JW, 1994, BEHAV NEUROSCI, V108, P227, DOI 10.1037/0735-7044.108.2.227; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; STANTON PK, 1984, J NEUROSCI, V4, P3080; SUTHERLAND RJ, 1982, NEUROSCI LETT, V31, P271, DOI 10.1016/0304-3940(82)90032-5; TULLY T, 1991, NEUROBIOLOGY LEARNIN, P30; YIN JCP, 1994, CELL, V79, P49, DOI 10.1016/0092-8674(94)90399-9; ZALUTSKY RA, 1990, SCIENCE, V248, P1619, DOI 10.1126/science.2114039; [No title captured]	38	1496	1543	3	82	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 7	1994	79	1					59	68		10.1016/0092-8674(94)90400-6	http://dx.doi.org/10.1016/0092-8674(94)90400-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PK585	7923378				2022-12-24	WOS:A1994PK58500008
J	WEISSKOPF, MG; CASTILLO, PE; ZALUTSKY, RA; NICOLL, RA				WEISSKOPF, MG; CASTILLO, PE; ZALUTSKY, RA; NICOLL, RA			MEDIATION OF HIPPOCAMPAL MOSSY FIBER LONG-TERM POTENTIATION BY CYCLIC-AMP	SCIENCE			English	Article							DEPENDENT PROTEIN-KINASE; CRAYFISH NEUROMUSCULAR-JUNCTION; ADENYLATE-CYCLASE; SYNAPTIC PLASTICITY; GLUTAMATE RECEPTORS; TRANSMITTER RELEASE; SYMPATHETIC-GANGLIA; SYNAPSES; NEURONS; FACILITATION	Repetitive activation of hippocampal messy fibers evokes a long-term potentiation (LTP) of synaptic responses in pyramidal cells in the CA3 region that is independent of N-methyl-D-aspartate receptor activation. Previous results suggest that the site for both the induction and expression of this form of LTP is presynaptic. Experimental elevation of cyclic adenosine 3',5'-monophosphate(cAMP) both mimics and interferes with tetanus-induced mossy fiber LTP, and blockers of the cAMP cascade block messy fiber LTP. It is proposed that calcium entry into the presynaptic terminal may activate Ca2+-calmodulin-sensitive adenylyl cyclase I which, through protein kinase A, causes a persistent enhancement of evoked glutamate release.	UNIV CALIF SAN FRANCISCO,DEPT PHARMACOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,GRAD PROGRAM NEUROSCI,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco				Castillo, Pablo/0000-0002-9834-1801				BAXTER DA, 1985, P NATL ACAD SCI USA, V82, P5978, DOI 10.1073/pnas.82.17.5978; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BRIDGES AJ, 1988, J MED CHEM, V31, P1282, DOI 10.1021/jm00402a004; BRIGGS CA, 1985, J PHYSIOL-LONDON, V359, P503, DOI 10.1113/jphysiol.1985.sp015599; BRIGGS CA, 1988, J PHYSIOL-LONDON, V404, P129, DOI 10.1113/jphysiol.1988.sp017282; BYRNE JH, 1993, ADV SEC MESS PHOSPH, V27, P47; CABELL L, 1993, INT J DEV NEUROSCI, V11, P357, DOI 10.1016/0736-5748(93)90007-Z; CALI JJ, 1994, J BIOL CHEM, V269, P12190; CASTILLO PE, 1994, NEURON, V12, P261, DOI 10.1016/0896-6273(94)90269-0; CHAVEZNORIEGA LE, 1994, J NEUROSCI, V14, P310; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; DIXON D, 1989, J NEUROSCI, V9, P4246; DOSTMANN WRG, 1990, J BIOL CHEM, V265, P10484; DUDAI Y, 1988, ANNU REV NEUROSCI, V11, P537, DOI 10.1146/annurev.ne.11.030188.002541; EGEBJERG J, 1991, NATURE, V351, P745, DOI 10.1038/351745a0; FREY U, 1993, SCIENCE, V260, P1661, DOI 10.1126/science.8389057; GLATT CE, 1993, NATURE, V361, P536, DOI 10.1038/361536a0; HAAS HL, 1987, NEUROSCI LETT, V78, P171, DOI 10.1016/0304-3940(87)90628-8; HARRIS EW, 1986, NEUROSCI LETT, V70, P132, DOI 10.1016/0304-3940(86)90451-9; HASHIMOTO H, 1993, NEURON, V11, P333, DOI 10.1016/0896-6273(93)90188-W; HAWKINS RD, 1993, ANNU REV NEUROSCI, V16, P625, DOI 10.1146/annurev.ne.16.030193.003205; HOPKINS WF, 1988, J NEUROPHYSIOL, V59, P667, DOI 10.1152/jn.1988.59.2.667; HOSHI T, 1988, SCIENCE, V240, P1652, DOI 10.1126/science.2454506; Huang Y Y, 1994, Learn Mem, V1, P74; ITO I, 1991, NEUROREPORT, V2, P333, DOI 10.1097/00001756-199106000-00008; JAFFE D, 1990, J NEUROPHYSIOL, V64, P948, DOI 10.1152/jn.1990.64.3.948; KASE H, 1987, BIOCHEM BIOPH RES CO, V142, P436, DOI 10.1016/0006-291X(87)90293-2; KATSUKI H, 1991, NEUROSCI RES, V12, P393, DOI 10.1016/0168-0102(91)90070-F; KATZ B, 1968, J PHYSIOL-LONDON, V195, P481, DOI 10.1113/jphysiol.1968.sp008469; KUBA K, 1986, J PHYSIOL-LONDON, V374, P515, DOI 10.1113/jphysiol.1986.sp016095; Langdon Ronald B., 1993, Society for Neuroscience Abstracts, V19, P433; LAURENZA A, 1989, TRENDS PHARMACOL SCI, V10, P442, DOI 10.1016/S0165-6147(89)80008-2; MADISON DV, 1986, J PHYSIOL-LONDON, V372, P245, DOI 10.1113/jphysiol.1986.sp016007; MALENKA RC, 1993, TRENDS NEUROSCI, V16, P521, DOI 10.1016/0166-2236(93)90197-T; MALLART A, 1968, J PHYSIOL-LONDON, V196, P593, DOI 10.1113/jphysiol.1968.sp008525; MANABE T, 1993, J NEUROPHYSIOL, V70, P1451, DOI 10.1152/jn.1993.70.4.1451; MATTHIES H, 1993, NEUROREPORT, V4, P712, DOI 10.1097/00001756-199306000-00028; MINOTA S, 1991, J PHYSIOL-LONDON, V435, P421, DOI 10.1113/jphysiol.1991.sp018517; NICOLL RA, 1981, J NEUROSCI METH, V4, P153, DOI 10.1016/0165-0270(81)90049-2; PARSONS ME, 1977, AGENTS ACTIONS, V7, P31, DOI 10.1007/BF01964878; RAYMOND LA, 1993, NATURE, V361, P637, DOI 10.1038/361637a0; REGEHR WG, 1991, NEURON, V7, P451, DOI 10.1016/0896-6273(91)90297-D; REGEHR WG, 1994, J NEUROSCI, V14, P523; SARVEY J M, 1988, P329; SCHACHER S, 1988, SCIENCE, V240, P1667, DOI 10.1126/science.2454509; SCHOLZ KP, 1988, SCIENCE, V240, P1664, DOI 10.1126/science.2837826; SEAMON KB, 1986, ADV CYCLIC NUCL PROT, V20, P1; STAUBLI U, 1990, SYNAPSE, V5, P333, DOI 10.1002/syn.890050410; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; VANHAASTERT PJM, 1984, J BIOL CHEM, V259, P20; WANG LY, 1993, SCIENCE, V259, P1173, DOI 10.1126/science.8382377; WEISSKOPF MG, 1993, NATURE, V362, P423, DOI 10.1038/362423a0; WEISSKOPF MG, 1993, SOC NEUR ABSTR, V19, P1708; WIEPRECHT M, 1994, BIOCHEM J, V297, P241, DOI 10.1042/bj2970241; WILLIAMS S, 1989, NEURON, V3, P583, DOI 10.1016/0896-6273(89)90268-7; WOJTOWICZ JM, 1988, J NEUROSCI, V8, P4667; WORLEY PF, 1986, P NATL ACAD SCI USA, V83, P4053, DOI 10.1073/pnas.83.11.4053; WU ZL, 1993, J BIOL CHEM, V268, P23766; XIA ZG, 1991, NEURON, V6, P431, DOI 10.1016/0896-6273(91)90251-T; ZALUTSKY RA, 1990, SCIENCE, V248, P1619, DOI 10.1126/science.2114039; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.neuro.12.1.13	61	458	466	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 23	1994	265	5180					1878	1882		10.1126/science.7916482	http://dx.doi.org/10.1126/science.7916482			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PH258	7916482				2022-12-24	WOS:A1994PH25800037
J	PHILLIPS, AN; SABIN, CA; ELFORD, J; BOFILL, M; JANOSSY, G; LEE, CA				PHILLIPS, AN; SABIN, CA; ELFORD, J; BOFILL, M; JANOSSY, G; LEE, CA			USE OF CD4 LYMPHOCYTE COUNT TO PREDICT LONG-TERM SURVIVAL FREE OF AIDS AFTER HIV-INFECTION	BRITISH MEDICAL JOURNAL			English	Article							IMMUNODEFICIENCY VIRUS-INFECTION; HEMOPHILIC COHORT; NATURAL-HISTORY; HOMOSEXUAL MEN; PROGRESSION; MARKERS; DISEASE; SEROCONVERTERS; INCUBATION; FOLLOW	Objective-To estimate the probability remaining free of AIDS for up to 25 years after infection with HIV by extrapolation of changes in CD4 lymphocyte count. Design-Cohort study of subjects followed from time of HIV seroconversion until 1 January 1993. Creation of model by using extrapolated linear regression slopes of CD4 count to predict development of AIDS after 1993. Setting-Regional haemophilia centre in teaching hospital. Subjects-111 men with haemophilia infected with HIV during 1979-85. Median length of follow up 10.1 years, median number of CD4 counts 17. The model was not fitted for three men because only one CD4 measurement was available. Main outcome measures-Development of AIDS. Interventions-From 1989 prophylaxis against candida and Pneumocystis carinii pneumonia and antiretroviral drugs when CD4 count fell below 200 x 10(6)/1. Results-44 men developed AIDS up to 1 January 1993. When AIDS was defined as a CD4 count of 50 x 10(6)/1 the model predicted that 25% (95% confidence interval 16% to 34%) would survive for 20 years after seroconversion and 18% (11% to 25%) for 25 years. Changing the CD4 count at which AIDS was assumed to occur did not alter the results. Younger patients had a higher chance of 20 year survival than older patients (32% (12% to 52%) for those aged < 15, 26% (14% to 38%) for those aged 15-29, and 15% (0% to 31%) for those aged greater than or equal to 30). Conclusions-These results suggest that even with currently available treatment up to a quarter of patients with HIV infection will survive for 20 years after seroconversion without developing AIDS.	ROYAL FREE HOSP,SCH MED,DEPT CLIN IMMUNOL,LONDON NW3 2PF,ENGLAND; ROYAL FREE HOSP,SCH MED,CTR HAEMOPHILIA,LONDON NW3 2PF,ENGLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	PHILLIPS, AN (corresponding author), UNIV LONDON,ROYAL FREE HOSP,SCH MED,DEPT PUBL HLTH,LONDON NW3 2PF,ENGLAND.		Phillips, Andrew N/B-4427-2008; Sabin, Caroline/C-2464-2008	Phillips, Andrew N/0000-0003-2384-4807; Sabin, Caroline/0000-0001-5173-2760				ALCABES P, 1993, EPIDEMIOL REV, V15, P303, DOI 10.1093/oxfordjournals.epirev.a036122; [Anonymous], MMWR; BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; BIGGAR RJ, 1990, AIDS, V4, P1059, DOI 10.1097/00002030-199011000-00002; BOFILL M, 1992, CLIN EXP IMMUNOL, V88, P243, DOI 10.1111/j.1365-2249.1992.tb03068.x; Cox D. R., 1984, ANAL SURVIVAL DATA; CROWE SM, 1991, J ACQ IMMUN DEF SYND, V4, P770; DARBY SC, 1989, BRIT MED J, V298, P1064, DOI 10.1136/bmj.298.6680.1064; DEGRUTTOLA V, 1991, J AM STAT ASSOC, V86, P569, DOI 10.2307/2290384; EYSTER ME, 1987, ANN INTERN MED, V107, P1, DOI 10.7326/0003-4819-107-1-1; FAHEY JL, 1990, NEW ENGL J MED, V322, P166, DOI 10.1056/NEJM199001183220305; GALAI N, 1993, STAT MED, V12, P2133, DOI 10.1002/sim.4780122207; GOEDERT JJ, 1989, NEW ENGL J MED, V321, P1141, DOI 10.1056/NEJM198910263211701; HENDRIKS JCM, 1993, AIDS, V7, P231, DOI 10.1097/00002030-199302000-00012; HUGHES MD, 1994, J INFECT DIS, V169, P28, DOI 10.1093/infdis/169.1.28; KRAMER A, 1992, AM J EPIDEMIOL, V136, P71; LANE HC, 1985, AM J MED, V78, P417, DOI 10.1016/0002-9343(85)90332-8; LANG W, 1989, J ACQ IMMUN DEF SYND, V2, P63; LEE CA, 1989, BRIT J HAEMATOL, V73, P228, DOI 10.1111/j.1365-2141.1989.tb00257.x; LENDERKING WR, 1994, NEW ENGL J MED, V330, P738, DOI 10.1056/NEJM199403173301102; LUNDGREN JD, 1994, JAMA-J AM MED ASSOC, V271, P1088, DOI 10.1001/jama.271.14.1088; LUNDGREN JD, 1994, BMJ-BRIT MED J, V308, P1068, DOI 10.1136/bmj.308.6936.1068; MASUR H, 1989, ANN INTERN MED, V111, P223, DOI 10.7326/0003-4819-111-3-223; MOSS AR, 1988, BRIT MED J, V296, P745, DOI 10.1136/bmj.296.6624.745; PHILLIPS A, 1989, AIDS, V3, P737, DOI 10.1097/00002030-198911000-00008; PHILLIPS AN, 1991, LANCET, V337, P389; RUTHERFORD GW, 1990, BRIT MED J, V301, P1183, DOI 10.1136/bmj.301.6762.1183; SABIN C, 1993, BRIT J HAEMATOL, V83, P330, DOI 10.1111/j.1365-2141.1993.tb08290.x; SABIN C, IN PRESS THROMBOSIS; SCHECHTER MT, 1989, AIDS, V3, P347, DOI 10.1097/00002030-198906000-00002; SCHWARTLANDER B, 1992, AIDS, V6, P413, DOI 10.1097/00002030-199204000-00009; SEREMETIS SV, 1993, LANCET, V342, P700, DOI 10.1016/0140-6736(93)91706-R; STEIN DS, 1992, J INFECT DIS, V165, P352, DOI 10.1093/infdis/165.2.352; VANLEEUWEN R, 1992, IMMUNODEFICIENCY HIV, P32; 1993, COMMUNICABLE DISE S1, V3, pS1; 1993, STAT MED, V12, P2061; 1992, AIDS, V6, P421; 1994, LANCET, V343, P871; 1987, MMWR S1S, V36, pS3; 1992, MMWR-MORBID MORTAL W, V41, P1	40	61	61	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 30	1994	309	6950					309	313		10.1136/bmj.309.6950.309	http://dx.doi.org/10.1136/bmj.309.6950.309			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PA373	7916226	Green Published			2022-12-24	WOS:A1994PA37300019
J	CONDIE, BG; CAPECCHI, MR				CONDIE, BG; CAPECCHI, MR			MICE WITH TARGETED DISRUPTIONS IN THE PARALOGOUS GENES HOXA-3 AND HORD-3 REVEAL SYNERGISTIC INTERACTIONS	NATURE			English	Article							HOMEOBOX GENE; HOMEOTIC TRANSFORMATIONS; DEVELOPMENTAL DEFECTS; MUTANT MICE; MOUSE; HOX-1.6; HINDBRAIN; EXPRESSION; VERTEBRAE; REGION	THE Hox genes encode transcription factors which mediate the formation of the mammalian body plan along the anteroposterior and appendicular axes(1-15). Paralogous Hox genes within the separate linkage groups are closely related with respect to DNA sequence and expression(16,17), suggesting that they could have at least partially redundant functions. We showed previously that mice homozygous for independent targeted disruptions in the paralogous genes hoxa-3 and hoxd-3 had no defects in common(1,8). But our current analysis of double mutants has revealed strong, dosage-dependent interactions between these genes. We report here that in hoxd-3(-) homozygotes the first cervical vertebra, the atlas, is homeotically transformed to the adjacent anterior structure. Unexpectedly, in double mutants, rather than observing a more extensive homeotic transformation, the entire atlas is deleted. These observations are interpreted in terms of a model in which these Hox genes differentially regulate the proliferation rates of the appropriate sets of precursor cells.	UNIV UTAH, SCH MED, HOWARD HUGHES MED INST, DEPT HUMAN GENET, SALT LAKE CITY, UT 84112 USA	Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah								ABERDAM D, 1991, MOL CELL BIOL, V11, P554, DOI 10.1128/MCB.11.1.554; CARPENTER EM, 1993, DEVELOPMENT, V118, P1063; CHISAKA O, 1992, NATURE, V355, P516, DOI 10.1038/355516a0; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; CONDIE BG, 1993, DEVELOPMENT, V119, P579; DAVIS AP, IN PRESS DEVELOPMENT; DOLLE P, 1993, CELL, V75, P431, DOI 10.1016/0092-8674(93)90378-4; DOLLE P, 1993, P NATL ACAD SCI USA, V90, P7666, DOI 10.1073/pnas.90.16.7666; GENDRONMAGUIRE M, 1993, CELL, V75, P1317, DOI 10.1016/0092-8674(93)90619-2; HUNT P, 1991, NATURE, V353, P861, DOI 10.1038/353861a0; JEANNOTTE L, 1993, GENE DEV, V7, P2085, DOI 10.1101/gad.7.11.2085; JEGALIAN BG, 1992, CELL, V71, P901, DOI 10.1016/0092-8674(92)90387-R; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; KOSTIC D, IN PRESS MECH DEV; LEMOUELLIC H, 1992, CELL, V69, P251, DOI 10.1016/0092-8674(92)90406-3; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; MANSOUR SL, 1993, DEVELOPMENT, V117, P13; MARK M, 1993, DEVELOPMENT, V119, P319; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; RAMIREZSOLIS R, 1993, CELL, V73, P279, DOI 10.1016/0092-8674(93)90229-J; RIJLI FM, 1993, CELL, V75, P1333, DOI 10.1016/0092-8674(93)90620-6; SMALL KM, 1993, GENE DEV, V7, P2318, DOI 10.1101/gad.7.12a.2318	22	223	224	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 28	1994	370	6487					304	307		10.1038/370304a0	http://dx.doi.org/10.1038/370304a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NZ229	7913519				2022-12-24	WOS:A1994NZ22900067
J	PICKERING, TG				PICKERING, TG			BLOOD-PRESSURE MEASUREMENT AND DETECTION OF HYPERTENSION	LANCET			English	Article							WHITE COAT HYPERTENSION; PROGNOSTIC VALUE; HEART; POPULATION				PICKERING, TG (corresponding author), NEW YORK HOSP,CORNELL MED CTR,CTR HYPERTENS,525 E 68TH ST,NEW YORK,NY 10021, USA.							DUNNE FP, 1991, J AMBUL MONIT, V4, P275; FRATTOLA A, 1993, J HYPERTENS, V11, P1133, DOI 10.1097/00004872-199310000-00019; FREESTONE S, 1982, AM J MED, V73, P348, DOI 10.1016/0002-9343(82)90725-2; FRIEDMANN E, 1982, PSYCHOSOM MED, V44, P545, DOI 10.1097/00006842-198212000-00006; GOSSE P, 1993, HYPERTENSION, V22, P766, DOI 10.1161/01.HYP.22.5.766; HARSHFIELD GA, 1990, BLOOD PRESSURE MEASU, P241; HOEGHOLM A, 1993, AM J HYPERTENS, V6, P282, DOI 10.1093/ajh/6.4.282; IMAI Y, 1993, HYPERTENSION, V22, P900, DOI 10.1161/01.HYP.22.6.900; KENNEY MJ, 1993, HYPERTENSION, V22, P653, DOI 10.1161/01.HYP.22.5.653; LACOURCIERE Y, 1990, AM J CARDIOL, V65, P467, DOI 10.1016/0002-9149(90)90812-F; LIPSITZ LA, 1983, NEW ENGL J MED, V309, P81, DOI 10.1056/NEJM198307143090205; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MANCIA G, 1983, CIRC RES, V53, P96, DOI 10.1161/01.RES.53.1.96; MANN SJ, 1991, JAMA-J AM MED ASSOC, V265, P2226, DOI 10.1001/jama.265.17.2226; MCKAY DW, 1990, J HUM HYPERTENS, V4, P639; MENARD J, 1988, HYPERTENSION, V11, P153, DOI 10.1161/01.HYP.11.2.153; MILLARCRAIG MW, 1978, LANCET, V1, P795; PEARCE KA, 1992, ARCH INTERN MED, V152, P750, DOI 10.1001/archinte.152.4.750; PERLOFF D, 1989, J HYPERTENS, V7, pS3; PERLOFF D, 1983, JAMA-J AM MED ASSOC, V249, P2792, DOI 10.1001/jama.249.20.2792; PICKERING G, 1968, HIGH BLOOD PRESSURE; PICKERING TG, 1988, JAMA-J AM MED ASSOC, V259, P225, DOI 10.1001/jama.259.2.225; PICKERING TG, 1992, J HYPERTENS, V10, P401, DOI 10.1097/00004872-199205000-00001; PICKERING TG, 1989, J HYPERTENS, V7, pS65; Pickering TG., 1991, AMBULATORY MONITORIN; SEVER P, 1993, BMJ-BRIT MED J, V306, P983, DOI 10.1136/bmj.306.6883.983; STAESSEN J, 1992, AM J HYPERTENS, V5, P386, DOI 10.1093/ajh/5.6.386; VANMONTFRANS GA, 1987, BRIT MED J, V295, P354, DOI 10.1136/bmj.295.6594.354; VEERMAN DP, 1993, J HYPERTENS, V11, P287, DOI 10.1097/00004872-199303000-00009; VERDECCHIA P, 1993, CIRCULATION, V88, P986, DOI 10.1161/01.CIR.88.3.986; VERDECCHIA P, 1990, CIRCULATION, V81, P528, DOI 10.1161/01.CIR.81.2.528; WHITE WB, 1990, AM J CARDIOL, V65, P60, DOI 10.1016/0002-9149(90)90026-W; YELDERMAN M, 1979, ANESTHESIOLOGY, V50, P253, DOI 10.1097/00000542-197903000-00022; 1993, NIH931088 PUBL; 1993, ANN INTERN MED, V118, P889	35	114	116	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 2	1994	344	8914					31	35						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU917	7912303				2022-12-24	WOS:A1994NU91700016
J	ZOLLER, B; DAHLBACK, B				ZOLLER, B; DAHLBACK, B			LINKAGE BETWEEN INHERITED RESISTANCE TO ACTIVATED PROTEIN-C AND FACTOR-V GENE MUTATION IN VENOUS THROMBOSIS	LANCET			English	Note							POOR ANTICOAGULANT RESPONSE; THROMBOPHILIA; COFACTOR	Resistance to activated protein C (APC) is a major cause of familial thrombophilia, and can be corrected by an anticoagulant activity expressed by purified factor V. We investigated linkage between APC resistance and the factor V gene in a large kindred with familial thrombophilia. Restriction fragment length polymorphisms in exon 13 of the factor V gene were informative in 14 family members. The 100% linkage between factor V gene polymorphism and APC resistance strongly suggested a factor V gene mutation as a cause of APC resistance. A point mutation changing Arg(506) in the APC cleavage site to a Gin was found in APC resistant individuals. These results suggest factor V gene mutation to be the most common genetic cause of thrombophilia.	LUND UNIV,MALMO GEN HOSP,DEPT CLIN CHEM,S-21401 MALMO,SWEDEN	Lund University			Zöller, Bengt/H-8856-2012; Zöller, Bengt/M-3217-2019	Zöller, Bengt/0000-0002-8250-5613; Zöller, Bengt/0000-0002-8250-5613; Dahlback, Bjorn/0000-0003-1546-0328				DAHLBACK B, 1993, P NATL ACAD SCI USA, V90, P1004, DOI 10.1073/pnas.90.3.1004; DAHLBACK B, 1994, P NATL ACAD SCI USA, V91, P1396, DOI 10.1073/pnas.91.4.1396; DAHLBACK B, 1994, MOL BASIS BLOOD DISE, P599; EWART AK, 1993, P NATL ACAD SCI USA, V90, P3226, DOI 10.1073/pnas.90.8.3226; FAIONI EM, 1993, THROMB HAEMOSTASIS, V70, P1067; GRIFFIN JH, 1993, BLOOD, V82, P1989; KOSTER T, 1993, LANCET, V342, P1503, DOI 10.1016/S0140-6736(05)80081-9; SHEN NLL, 1993, J IMMUNOL, V150, P2992; SVENSSON PJ, 1994, NEW ENGL J MED, V330, P517, DOI 10.1056/NEJM199402243300801; WANG H, 1988, GENOMICS, V2, P234	10	411	420	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 18	1994	343	8912					1536	1538		10.1016/S0140-6736(94)92940-8	http://dx.doi.org/10.1016/S0140-6736(94)92940-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NR329	7911873				2022-12-24	WOS:A1994NR32900010
J	DRUCKER, E; ALCABES, P; BOSWORTH, W; SCKELL, B				DRUCKER, E; ALCABES, P; BOSWORTH, W; SCKELL, B			CHILDHOOD TUBERCULOSIS IN THE BRONX, NEW-YORK	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; INTRAVENOUS DRUG-USERS; INFECTION; RATES; RISK; AIDS	The resurgence of tuberculosis (TB) in New York City in the period 1978-92 has been closely linked to the AIDS epidemic but the increase of active TB in areas of urban poverty also implies increased community exposure. We have examined the ecological relation between community rates of AIDS and residential crowding and cases of active TB in Bronx children under age 5. Residential crowding was defined as the percent of households with more than 1 person per room. All childhood TB cases reported between 1986 and 1992 for the Bronx (n = 75) were included. Cumulative AIDS mortality rates for adult females through 1990 represented community HIV burden. All data were coded by the 64 health areas of the borough. We examined trends in these data and used Poisson regression to model the effect of HIV burden and residential crowding on TB risk. For the Bronx as a whole the two variables of TB and residential crowding showed a clear temporal correspondence for the period 1970-90. Residential crowding was associated with poverty and greater dependence on public assistance, large household size, Hispanic ethnicity, and a higher proportion of young children. The overall TB case rate increased with the proportion of crowded households, with a rise from 1.47 to over 8 cases per 10 000 children as the proportion of crowded households increased. At both the lowest and highest levels of AIDS mortality in these areas, the childhood TB risk increased as crowding increased. Children living in areas of the Bronx in which over 12 percent of homes are severely overcrowded were 5.6-fold more likely to develop active TB, even after holding constant the presumed HIV burden in each local community. While HIV infection, the newest risk factor for TB, appears to play a critical role in the resurgent epidemic, our findings show that the earliest known TB risk factors, poverty and household crowding, are still potent forces.	YALE UNIV,SCH MED,AIDS PROGRAM,NEW HAVEN,CT; CUNY HERBERT H LEHMAN COLL,DEPT POLIT SCI,BRONX,NY 10468; CUNY HERBERT H LEHMAN COLL,BRONX DATA CTR,BRONX,NY 10468	Yale University; City University of New York (CUNY) System; Lehman College (CUNY); City University of New York (CUNY) System; Lehman College (CUNY)	DRUCKER, E (corresponding author), MONTEFIORE MED CTR,ALBERT EINSTEIN COLL MED,DEPT EPIDEMIOL & SOCIAL MED,BRONX,NY 10467, USA.							BARNES PF, 1991, NEW ENGL J MED, V324, P1644, DOI 10.1056/NEJM199106063242307; BATES B, 1992, BARGAINING LIFE; BELLIN E, 1993, JAMA-J AM MED ASSOC, V259, P2228; BRESLOW NE, 1980, STATISTICAL METHODS; BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745, DOI 10.1164/ajrccm/144.4.745; CHAPMAN JS, 1984, AM REV RESPIR DIS, V90, P48; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; DIPERRI G, 1989, LANCET, V2, P1502; DRUCKER E, 1989, AM J EPIDEMIOL, V130, P133, DOI 10.1093/oxfordjournals.aje.a115304; DRUCKER E, 1987, FRANKLIN AVE SHELTER; DRUCKER E, 1993, NY TIMES        0820, pA28; Dubos Rene, 1987, WHITE PLAGUE TUBERCU; DUGGER C, 1992, NY TIMES        0216, P1; DUGGER CW, 1993, NY TIMES        1116, pA1; DUGGER CW, 1993, NY TIMES        1116, pB4; NOVICK LF, 1991, AM J PUBLIC HEALTH, V81, P15, DOI 10.2105/AJPH.81.Suppl.15; SCHOENBAUM EE, 1989, NEW ENGL J MED, V321, P874, DOI 10.1056/NEJM198909283211306; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SNIDER DE, 1992, NEW ENGL J MED, V326, P703, DOI 10.1056/NEJM199203053261011; STLOUIS ME, 1990, NEW ENGL J MED, V323, P213, DOI 10.1056/NEJM199007263230401; SUNDERAM G, 1986, JAMA-J AM MED ASSOC, V256, P362, DOI 10.1001/jama.256.3.362; WALLACE R, 1988, ENVIRON RES, V47, P1, DOI 10.1016/S0013-9351(88)80018-5; 1986, MMWR-MORBID MORTAL W, V28, P587; 1986, MMWR-MORBID MORTAL W, V35, P74; 1992, INFORMATION SUMMARY	25	86	90	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 11	1994	343	8911					1482	1485		10.1016/S0140-6736(94)92588-7	http://dx.doi.org/10.1016/S0140-6736(94)92588-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NQ415	7911184				2022-12-24	WOS:A1994NQ41500015
J	LEES, C; CAMPBELL, S; JAUNIAUX, E; BROWN, R; RAMSAY, B; GIBB, D; MONCADA, S; MARTIN, JF				LEES, C; CAMPBELL, S; JAUNIAUX, E; BROWN, R; RAMSAY, B; GIBB, D; MONCADA, S; MARTIN, JF			ARREST OF PRETERM LABOR AND PROLONGATION OF GESTATION WITH GLYCERYL TRINITRATE, A NITRIC-OXIDE DONOR	LANCET			English	Note							INDOMETHACIN	13 women admitted consecutively in preterm labour were recruited to an observational study of the effect of glyceryl trinitrate (GTN) patches on uterine contractions and prolongation of pregnancy. All twenty episodes of preterm labour (at 23-33 weeks' gestation) responded. 1 patient delivered because of cervical incompetence despite cessation of uterine contractions. The mean prolongation of pregnancy was 34 days. 8 babies have been born so far, and are progressing well. GTN patches appear to be a safe, well-tolerated, and non-invasive method of suppressing uterine contractions in preterm labour.	UNIV LONDON KINGS COLL HOSP,SCH MED & DENT,DEPT OBSTET & GYNAECOL,LONDON SE5 8RX,ENGLAND; UNIV LONDON KINGS COLL HOSP,SCH MED & DENT,DEPT MED,LONDON SE5 8RX,ENGLAND; WELLCOME RES LABS,BECKENHAM BR3 3BS,KENT,ENGLAND	King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; GlaxoSmithKline; Wellcome Research Laboratories			Brown, Richard/I-3851-2019	Brown, Richard/0000-0002-5476-2698				BIVINS HA, 1993, AM J OBSTET GYNECOL, V169, P1065, DOI 10.1016/0002-9378(93)90055-N; BOOTSTAYLOR B, 1994, AM J OBSTET GYNECO S, V179, P281; GREENSPOON JS, 1991, LANCET, V338, P124, DOI 10.1016/0140-6736(91)90122-6; Hankins G.D.V., 1991, CRITICAL CARE OBSTET, P231; IZUMI H, 1993, AM J OBSTET GYNECOL, V169, P1327, DOI 10.1016/0002-9378(93)90301-X; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; NORTON ME, 1993, NEW ENGL J MED, V329, P1602, DOI 10.1056/NEJM199311253292202; RAMSAY B, 1994, EUR J CLIN INVEST, V24, P76, DOI 10.1111/j.1365-2362.1994.tb02064.x; SLADEK SM, 1993, AM J OBSTET GYNECOL, V169, P1285, DOI 10.1016/0002-9378(93)90295-T; 1992, NEW ENGL J MED, V327, P308	10	176	183	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 28	1994	343	8909					1325	1326		10.1016/S0140-6736(94)92468-6	http://dx.doi.org/10.1016/S0140-6736(94)92468-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NN217	7910325				2022-12-24	WOS:A1994NN21700011
J	MOULTON, C; PENNYCOOK, AG				MOULTON, C; PENNYCOOK, AG			RELATION BETWEEN GLASGOW COMA SCORE AND COUGH REFLEX	LANCET			English	Note								How unconscious does a patient need to be, to be intubated without drugs? In 76 comatose patients (Glasgow coma score [GCS] less than or equal to 8) who were treated consecutively in an emergency department, the integrity of the cough reflex was not related to GCS. All comatose patients must be treated as if their airway is compromised but even at the lowest coma scores, there are many patients whose airway reflexes are sufficiently intact to make procedures such as endotracheal intubation difficult and dangerous without drugs. The state of the airway should be assessed independently of conscious level.	MANCHESTER ROYAL INFIRM, DEPT ACCID & EMERGENCY MED, MANCHESTER M13 9WL, LANCS, ENGLAND; SOUTHAMPTON GEN HOSP, SOUTHAMPTON, HANTS, ENGLAND	University of Manchester; University of Southampton								[Anonymous], 1976, BMJ-BRIT MED J, V2, P1187; ATKINSON RS, 1987, SYNOPSIS ANAESTHESIA, P165; BRADLEY RD, 1987, OXFORD TXB MED, V2; KULIG K, 1982, LANCET, V1, P565; MOULTON C, 1991, BRIT MED J, V303, P1240, DOI 10.1136/bmj.303.6812.1240; MURPHY PJ, 1993, BRIT J ANAESTH, V70, P131, DOI 10.1093/bja/70.2.131; PONTOPPIDAN H, 1960, JAMA-J AM MED ASSOC, V174, P2209, DOI 10.1001/jama.1960.03030180029007; SEKIZAWA K, 1990, LANCET, V335, P1228, DOI 10.1016/0140-6736(90)92758-A; YATES DW, 1985, LECTURE NOTES ACCIDE, P8; 1989, ADV TRAUMA LIFE SUPP, P31	10	63	65	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 21	1994	343	8908					1261	1262		10.1016/S0140-6736(94)92155-5	http://dx.doi.org/10.1016/S0140-6736(94)92155-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NM144	7910279				2022-12-24	WOS:A1994NM14400013
J	BLASZYK, H; VAUGHN, CB; HARTMANN, A; MCGOVERN, RM; SCHROEDER, JJ; CUNNINGHAM, J; SCHAID, D; SOMMER, SS; KOVACH, JS				BLASZYK, H; VAUGHN, CB; HARTMANN, A; MCGOVERN, RM; SCHROEDER, JJ; CUNNINGHAM, J; SCHAID, D; SOMMER, SS; KOVACH, JS			NOVEL PATTERN OF P53 GENE-MUTATIONS IN AN AMERICAN BLACK COHORT WITH HIGH MORTALITY FROM BREAST-CANCER	LANCET			English	Note								The pattern of acquired mutations in the p53 gene can be used to study differences in factors contributing to carcinogenesis. We investigated mutations in exons 5-9 and adjacent intronic regions in 47 breast cancers of black women from Michigan, a population with the highest breast-cancer mortality in the US. The 16 mutations detected differed from those of other populations. In particular, the black women had an excess of A:T-->G:C transitions compared with rural white US midwest women. While the causes of the different pattern of acquired mutation remain to be determined, this molecular epidemiological approach detects the consequences of mutagenic processes in specific populations. Mutation patterns will constrain hypotheses to mechanisms consistent with the observed biochemical alterations.	MAYO CLIN & MAYO FDN,DEPT ONCOL,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT BIOCHEM & MOLEC BIOL,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT HLTH SCI RES,ROCHESTER,MN 55905; SOUTHFIELD ONCOL INST,SOUTHFIELD,MI	Mayo Clinic; Mayo Clinic; Mayo Clinic					NATIONAL CANCER INSTITUTE [R01CA056881] Funding Source: NIH RePORTER; NCI NIH HHS [NCI 5 R01 CA56881-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BIGGS PJ, 1993, MUTAGENESIS, V8, P275, DOI 10.1093/mutage/8.4.275; COLES C, 1992, CANCER RES, V52, P5291; GOSTOUT B, 1993, HUM MOL GENET, V2, P293, DOI 10.1093/hmg/2.3.293; HABUCHI T, 1993, CANCER RES, V53, P3795; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; JONES PA, 1991, CANCER RES, V51, P3617; RIES LAG, 1991, DHEW NIH912789 PUBL; SOMMER SS, 1990, NATURE, V346, P22, DOI 10.1038/346022b0; SOMMER SS, 1992, J NATL CANCER I, V84, P246, DOI 10.1093/jnci/84.4.246; WINK DA, 1991, SCIENCE, V254, P1001, DOI 10.1126/science.1948068	10	64	65	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 14	1994	343	8907					1195	1197		10.1016/S0140-6736(94)92403-1	http://dx.doi.org/10.1016/S0140-6736(94)92403-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NL175	7909871				2022-12-24	WOS:A1994NL17500012
J	SUTHERLAND, LR; VERHOEF, M; WALLACE, JL; VANROSENDAAL, G; CRUTCHER, R; MEDDINGS, JB				SUTHERLAND, LR; VERHOEF, M; WALLACE, JL; VANROSENDAAL, G; CRUTCHER, R; MEDDINGS, JB			A SIMPLE, NONINVASIVE MARKER OF GASTRIC DAMAGE - SUCROSE PERMEABILITY	LANCET			English	Article							CROHNS-DISEASE; INTESTINAL PERMEABILITY; MISOPROSTOL; SUGARS	Disaccharides do not cross intact gastrointestinal mucosa to any appreciable extent unless there is damage to the epithelium. Furthermore, since sucrose is rapidly broken down in the small intestine, the absorption of intact sucrose implies damage to proximal epithelium. We have reported that measurement of sucrose permeability detects gastric damage in animals. Whilst such a non-specific test could not replace endoscopy, it might represent a clinically useful technique to identify patients who would benefit from endoscopy. 189 patients underwent endoscopy and assessment of sucrose permeability to evaluate the effectiveness of increased sucrose permeability in the prediction of endoscopic findings. The endoscopist was blinded to results of the sucrose assay. Gastric damage, particularly ulcers and severe gastritis, was successfully detected with this technique. Increased sucrose permeability, however, did not reliably detect mild gastritis, oesophagitis, or duodenal disease. The sensitivity of the test for gastric ulceration was 84% and specificity in predicting an abnormal endoscopy was 96%. Measurement of sucrose permeability is a simple way of screening for gastric damage. It has a sensitivity similar to that for upper gastrointestinal radiology and provides a new way to effectively screen large populations at risk of gastric damage.	UNIV CALGARY, GASTROINTESTINAL RES GRP, CALGARY T2N 4N1, AB, CANADA	University of Calgary								DAWSON DJ, 1988, CLIN SCI, V74, P427, DOI 10.1042/cs0740427; GRAHAM DY, 1988, LANCET, V2, P1277; HERLINGER H, 1977, CLIN RADIOL, V28, P307, DOI 10.1016/S0009-9260(77)80187-6; LAUFER I, 1976, GASTROENTEROLOGY, V71, P874; MEDDINGS JB, 1993, GASTROENTEROLOGY, V104, P1619, DOI 10.1016/0016-5085(93)90637-R; MURPHY MS, 1989, ARCH DIS CHILD, V64, P321, DOI 10.1136/adc.64.3.321; ROTH S, 1989, ARCH INTERN MED, V149, P775, DOI 10.1001/archinte.149.4.775; UKABAM SO, 1983, DIGESTION, V27, P70, DOI 10.1159/000198932; VANELBURG RM, 1992, SCAND J GASTROENTERO, V27, P19, DOI 10.3109/00365529209096021	9	120	122	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 23	1994	343	8904					998	1000		10.1016/S0140-6736(94)90125-2	http://dx.doi.org/10.1016/S0140-6736(94)90125-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NG682	7909091				2022-12-24	WOS:A1994NG68200008
J	ROBINSON, IA; MCKEE, G; NICHOLSON, A; DARCY, J; JACKSON, PA; COOK, MG; KISSIN, MW				ROBINSON, IA; MCKEE, G; NICHOLSON, A; DARCY, J; JACKSON, PA; COOK, MG; KISSIN, MW			PROGNOSTIC VALUE OF CYTOLOGICAL GRADING OF FINE-NEEDLE ASPIRATES FROM BREAST CARCINOMAS	LANCET			English	Article							TERM FOLLOW-UP; CANCER; INDEX	Because neoadjuvant therapy, including preoperative chemotherapy and tamoxifen, is becoming increasingly common for early breast cancer, it is desirable to grade tumours before surgery so that the most appropriate medical regimen can be selected. We have used a cytological grading system for ductal carcinoma of type not otherwise specified (NOS). Wet-fixed Papanicolaou-stained breast aspirates are examined for the extent of cell dissociation, cell size and uniformity, and the appearance of nucleoli, the nuclear margin, and chromatin. 377 invasive breast carcinomas were removed after preoperative diagnostic fine-needle aspiration. cytology (FNAC) during the 25 months of the study. 286 tumours were ductal carcinomas NOS on histology. We established three cytological grades and found that cytological grade corresponded well with the established histological grades (Elston's modified Bloom and Richardson method). All cytological features included in the score were equally important on regression analysis. This study shows that grading of breast cancer on FNAC is feasible and reproducible. Cytological grade may substitute for histological grade, so a combination of FNAC and mammography can provide information on tumour type, grade, and size before surgery. We recommend this grading system to centres that use FNAC for the diagnosis of breast cancers.	ROYAL SURREY CTY HOSP, DEPT CYTOPATHOL, EGERTON RD, GUILDFORD GU2 5XX, SURREY, ENGLAND; ROYAL SURREY CTY HOSP, DEPT SURG, GUILDFORD GU2 5XX, SURREY, ENGLAND; ROYAL SURREY CTY HOSP, DEPT HISTOPATHOL, GUILDFORD GU2 5XX, SURREY, ENGLAND	Royal Surrey County Hospital; Royal Surrey County Hospital; Royal Surrey County Hospital								BLACK MM, 1955, SURG GYNECOL OBSTET, V100, P543; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; BLOOM HJG, 1957, BRIT J CANCER, V11, P359, DOI 10.1038/bjc.1957.43; CIATTO S, 1993, DIAGN CYTOPATHOL, V9, P160, DOI 10.1002/dc.2840090210; DOUSSAL V, 1989, CANCER, V64, P1914; Early Breast Cancer Trialists' Collaborative Group, 1992, LANCET, V339, P1; Eichner W J, 1970, Nebr State Med J, V55, P405; ELLIS IO, 1992, HISTOPATHOLOGY, V20, P479; ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x; ELSTON CW, 1987, DIAGNOSTIC HISTOPATH, P300; FISHER E, 1984, SURG CLIN N AM, V64, P361; Fisher E R, 1980, Pathol Annu, V15, P239; HAYBITTLE JL, 1982, BRIT J CANCER, V45, P361, DOI 10.1038/bjc.1982.62; Hunt C M, 1990, Cytopathology, V1, P287, DOI 10.1111/j.1365-2303.1990.tb00362.x; MORGAN D, 1993, BREAST, V2, P206; MOSSLER JA, 1982, ACTA CYTOL, V26, P417; MOURIQUAND J, 1986, J CLIN PATHOL, V39, P489, DOI 10.1136/jcp.39.5.489; NIH, 1991, ONCOLOGY, V5, P120; Page DL, 1987, DIAGNOSTIC HISTOPATH; POWLES T, 1993, BREAST, V2, P187; SCHULTE E, 1987, DIAGN CYTOPATHOL, V3, P256, DOI 10.1002/dc.2840030316; SMITH IE, 1993, EUR J CANCER, V29A, P1796, DOI 10.1016/0959-8049(93)90133-Z; SNEIGE N, 1989, DIAGN CYTOPATHOL, V5, P371, DOI 10.1002/dc.2840050406; THOMAS JS, 1989, J CLIN PATHOL, V42, P28, DOI 10.1136/jcp.42.1.28; TODD JH, 1987, BRIT J CANCER, V56, P489, DOI 10.1038/bjc.1987.230; ZAJDELA A, 1984, ACTA CYTOL, V23, P75; ZAJICEK J, 1974, ASPIRATION BIOPSY CY, P166; ZURRIDA S, 1993, BREAST, V2, P187	28	137	140	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	APR 16	1994	343	8903					947	949		10.1016/S0140-6736(94)90066-3	http://dx.doi.org/10.1016/S0140-6736(94)90066-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF700	7909010				2022-12-24	WOS:A1994NF70000010
J	ROBERTS, M; WILLISON, H; VINCENT, A; NEWSOMDAVIS, J				ROBERTS, M; WILLISON, H; VINCENT, A; NEWSOMDAVIS, J			SERUM FACTOR IN MILLER-FISHER VARIANT OF GUILLAIN-BARRE-SYNDROME AND NEUROTRANSMITTER RELEASE	LANCET			English	Note								Serum IgG autoantibodies to GQ1b ganglioside are associated with the acute phase of the Miller-Fisher syndrome (MFS). We investigated the effects of three anti-GQ1b-positive MFS sera in the mouse phrenic-nerve/diaphragm preparation. Miniature endplate potential frequencies increased eight-fold within 25 min, declined rapidly, and ceased altogether after 3 h, when nerve stimulation no longer evoked a response. One MFS convalescent serum (anti-GQ1b negative) and sera from healthy controls and from patients with other neurological diseases were without effect. Thus muscle weakness in MFS may be caused by a serum factor, likely to be GQ1b antibody, that leads to failure of acetylcholine release from motor nerve terminals.	UNIV OXFORD,JOHN RADCLIFFE HOSP,INST MOLEC MED,DEPT CLIN NEUROL,NEUROSCI GRP,OXFORD OX3 9DU,ENGLAND; UNIV GLASGOW,SO GEN HOSP,INST NEUROL SCI,DEPT NEUROL,GLASGOW G51 4TF,SCOTLAND	University of Oxford; University of Glasgow			willison, hugh/HCI-7819-2022					CHIBA A, 1992, ANN NEUROL, V31, P677, DOI 10.1002/ana.410310619; FISHER M, 1956, NEW ENGL J MED, V255, P57, DOI 10.1056/NEJM195607122550201; LANG B, 1981, LANCET, V2, P224; MONTECUCCO C, 1988, BIOCHEM J, V251, P379, DOI 10.1042/bj2510379; WILLISON HJ, 1993, J NEUROIMMUNOL, V46, P105, DOI 10.1016/0165-5728(93)90239-U; WILLISON HJ, 1993, J NEUROL NEUROSUR PS, V56, P204, DOI 10.1136/jnnp.56.2.204; WILLISON HJ, IN PRESS J NEUROIMMU; YUKI N, 1993, NEUROLOGY, V43, P414, DOI 10.1212/WNL.43.2.414	8	151	153	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 19	1994	343	8895					454	455		10.1016/S0140-6736(94)92694-8	http://dx.doi.org/10.1016/S0140-6736(94)92694-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW690	7905957				2022-12-24	WOS:A1994MW69000012
J	KELLY, TJ; MARTIN, GS; FORSBURG, SL; STEPHEN, RJ; RUSSO, A; NURSE, P				KELLY, TJ; MARTIN, GS; FORSBURG, SL; STEPHEN, RJ; RUSSO, A; NURSE, P			THE FISSION YEAST CDC18+ GENE-PRODUCT COUPLES S-PHASE TO START AND MITOSIS	CELL			English	Article							CELL-DIVISION CYCLE; DNA-SYNTHESIS GENES; SCHIZOSACCHAROMYCES-POMBE ENCODES; CEREVISIAE CDC6 GENE; SACCHAROMYCES-CEREVISIAE; BUDDING YEAST; DEPENDENT TRANSCRIPTION; REPLICATION GENES; NUCLEAR DIVISION; HO GENE	Commitment to the cell cycle in fission yeast requires the function of the cdc10+ transcriptional activator at START. The product of the cdc18+ gene is a major downstream target of cdc10+ and transcription of cdc18+ is activated by cdc10+ during passage through START. The cdc18+ function is required for entry into S phase. In addition, the product of the cdc18+ gene is part of the checkpoint control that prevents mitosis from occurring until S phase is completed. Thus, cdc18+ plays a key role in coupling S phase to START and mitosis.	JOHNS HOPKINS UNIV, SCH MED, DEPT MOLEC BIOL & GENET, BALTIMORE, MD 21205 USA; UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, DIV BIOCHEM & MOLEC BIOL, BERKELEY, CA 94720 USA	Johns Hopkins University; University of California System; University of California Berkeley	KELLY, TJ (corresponding author), UNIV OXFORD, DEPT BIOCHEM, IMPERIAL CANC RES FUND, CELL CYCLE GRP, OXFORD OX1 3QU, ENGLAND.			Forsburg, Susan L/0000-0002-4895-8598	NCI NIH HHS [CA17542, CA16519] Funding Source: Medline; NIGMS NIH HHS [GM44173] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA016519, R01CA017542, R37CA017542] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044173] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALKHODAIRY F, 1992, EMBO J, V11, P1343, DOI 10.1002/j.1460-2075.1992.tb05179.x; ANDREWS BJ, 1989, CELL, V57, P21, DOI 10.1016/0092-8674(89)90168-2; ANDREWS BJ, 1989, NATURE, V342, P830, DOI 10.1038/342830a0; AVES SJ, 1985, EMBO J, V4, P457, DOI 10.1002/j.1460-2075.1985.tb03651.x; BARBET N, 1992, GENE, V114, P59, DOI 10.1016/0378-1119(92)90707-V; BASI G, 1993, GENE, V123, P131, DOI 10.1016/0378-1119(93)90552-E; BECKER DM, 1991, METHOD ENZYMOL, V194, P182; BREEDEN L, 1987, NATURE, V329, P651, DOI 10.1038/329651a0; BROEK D, 1991, NATURE, V349, P388, DOI 10.1038/349388a0; BUENO A, 1992, EMBO J, V11, P2167, DOI 10.1002/j.1460-2075.1992.tb05276.x; CALIGIURI M, 1993, CELL, V72, P607, DOI 10.1016/0092-8674(93)90079-6; CULOTTI J, 1971, EXP CELL RES, V67, P389, DOI 10.1016/0014-4827(71)90424-1; DIRICK L, 1992, NATURE, V357, P508, DOI 10.1038/357508a0; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; ENOCH T, 1991, COLD SPRING HARB SYM, V56, P409; ENOCH T, 1992, GENE DEV, V6, P2035, DOI 10.1101/gad.6.11.2035; FERNANDEZSARABIA MJ, 1992, GENE DEV, V6, P2417, DOI 10.1101/gad.6.12a.2417; FORSBURG SL, 1991, ANNU REV CELL BIOL, V7, P227, DOI 10.1146/annurev.cb.07.110191.001303; GORDON CB, 1986, EMBO J, V5, P2981, DOI 10.1002/j.1460-2075.1986.tb04595.x; GORDON CB, 1991, P NATL ACAD SCI USA, V88, P6058, DOI 10.1073/pnas.88.14.6058; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARTWELL LH, 1976, J MOL BIOL, V104, P803, DOI 10.1016/0022-2836(76)90183-2; HENNESSY KM, 1991, GENE DEV, V5, P958, DOI 10.1101/gad.5.6.958; HOGAN E, 1992, P NATL ACAD SCI USA, V89, P3098, DOI 10.1073/pnas.89.7.3098; JOHNSTON LH, 1992, NUCLEIC ACIDS RES, V20, P2403, DOI 10.1093/nar/20.10.2403; LISZIEWICZ J, 1988, NUCLEIC ACIDS RES, V16, P11507, DOI 10.1093/nar/16.24.11507; LOWNDES NF, 1992, NATURE, V357, P505, DOI 10.1038/357505a0; LOWNDES NF, 1992, NATURE, V355, P449, DOI 10.1038/355449a0; LOWNDES NF, 1991, NATURE, V350, P247, DOI 10.1038/350247a0; MARKS J, 1992, J CELL SCI, V101, P517; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MCINTOSH EM, 1991, MOL CELL BIOL, V11, P329, DOI 10.1128/MCB.11.1.329; MERRILL GF, 1992, BIOESSAYS, V14, P823, DOI 10.1002/bies.950141206; MORENO S, 1991, METHOD ENZYMOL, V194, P795; NASMYTH K, 1981, MOL GEN GENET, V182, P119, DOI 10.1007/BF00422777; NASMYTH K, 1991, CELL, V66, P995, DOI 10.1016/0092-8674(91)90444-4; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; NURSE P, 1976, MOL GEN GENET, V146, P167, DOI 10.1007/BF00268085; OGAS J, 1991, CELL, V66, P1015, DOI 10.1016/0092-8674(91)90445-5; PALMER RE, 1990, GENETICS, V125, P763; PRIMIG M, 1992, NATURE, V358, P593, DOI 10.1038/358593a0; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; ROWLEY R, 1992, EMBO J, V11, P1335, DOI 10.1002/j.1460-2075.1992.tb05178.x; SAZER S, 1990, J CELL SCI, V97, P509; SIMANIS V, 1989, J CELL SCI, V92, P51; TABA MRM, 1991, GENE DEV, V5, P2000, DOI 10.1101/gad.5.11.2000; TANAKA K, 1992, EMBO J, V11, P4923, DOI 10.1002/j.1460-2075.1992.tb05599.x; UZAWA S, 1990, CELL, V62, P913, DOI 10.1016/0092-8674(90)90266-H; VERMA R, 1991, P NATL ACAD SCI USA, V88, P7155, DOI 10.1073/pnas.88.16.7155; WASEEM NH, 1992, EMBO J, V11, P5111, DOI 10.1002/j.1460-2075.1992.tb05618.x; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WHITE JHM, 1986, EMBO J, V5, P1705, DOI 10.1002/j.1460-2075.1986.tb04414.x; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H; ZHOU C, 1989, J BIOL CHEM, V264, P9022	56	416	420	0	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 30	1993	74	2					371	382		10.1016/0092-8674(93)90427-R	http://dx.doi.org/10.1016/0092-8674(93)90427-R			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LP726	7916658				2022-12-24	WOS:A1993LP72600017
J	FELTON, CV; CROOK, D; DAVIES, MJ; OLIVER, MF				FELTON, CV; CROOK, D; DAVIES, MJ; OLIVER, MF			DIETARY POLYUNSATURATED FATTY-ACIDS AND COMPOSITION OF HUMAN AORTIC PLAQUES	LANCET			English	Note							CORONARY HEART-DISEASE	How long-term dietary intake of essential fatty acids affects the fatty-acid content of aortic plaques is not clear. We compared the fatty-acid composition of aortic plaques with that of post-mortem serum and adipose tissue, in which essential fatty-acid content reflects dietary intake. Positive associations were found between serum and plaque omega 6 (r=0.75) and omega 3 (r=0.93) polyunsaturated fatty acids, and monounsaturates (r=0.70), and also between adipose tissue and plaque omega 6 polyunsaturated fatty acids (r=0.89). No associations were found with saturated fatty acids. These findings imply a direct influence of dietary polyunsaturated fatty acids on aortic plaque formation and suggest that current trends favouring increased intake of polyunsaturated fatty acids should be reconsidered.	ST GEORGE HOSP,SCH MED,BRITISH HEART FDN,CARDIOVASC PATHOL UNIT,LONDON,ENGLAND; NATL HEART & LUNG INST,LONDON,ENGLAND	St Georges University London; University of London; University College London; UCL Medical School; Imperial College London	FELTON, CV (corresponding author), WYNN INST METAB RES,21 WELLINGTON RD,LONDON NW8 9SQ,ENGLAND.		Davies, Michael/GWV-2527-2022	Crook, David/0000-0002-9587-3730				ELVEVOLL EO, 1990, ATHEROSCLEROSIS, V81, P71, DOI 10.1016/0021-9150(90)90060-V; Felton CV, 1993, J VASC MED BIOL, V4, P228; HEFFERNAN AGA, 1963, CLIN SCI, V25, P423; HEGSTED DM, 1993, AM J CLIN NUTR, V57, P875, DOI 10.1093/ajcn/57.6.875; KROMHOUT D, 1985, NEW ENGL J MED, V312, P1205, DOI 10.1056/NEJM198505093121901; RAPP JH, 1991, ARTERIOSCLER THROMB, V11, P903, DOI 10.1161/01.ATV.11.4.903; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; ULBRICHT TLV, 1991, LANCET, V338, P985, DOI 10.1016/0140-6736(91)91846-M; WOOD DA, 1992, CORONARY HEART DISEA, P179	9	29	34	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 29	1994	344	8931					1195	1196		10.1016/S0140-6736(94)90511-8	http://dx.doi.org/10.1016/S0140-6736(94)90511-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN803	7934543				2022-12-24	WOS:A1994PN80300012
J	JOHNSON, AG				JOHNSON, AG			SURGERY AS A PLACEBO	LANCET			English	Article							TRIAL				JOHNSON, AG (corresponding author), UNIV SHEFFIELD,ROYAL HALLAMSHIRE HOSP,SURG UNIT,SHEFFIELD S10 2JF,S YORKSHIRE,ENGLAND.							ADAMS R, 1958, NEW ENGL J MED, V258, P113, DOI 10.1056/NEJM195801162580302; AITCHISON M, 1989, BRIT J UROL, V64, P478, DOI 10.1111/j.1464-410X.1989.tb05280.x; Balint M., 1957, DOCTOR; BARKER AT, 1984, LANCET, V1, P994; BARKER AT, 1985, PHYSIOTHERAPY, V12, P500; BEECHER HK, 1961, JAMA-J AM MED ASSOC, V176, P1102, DOI 10.1001/jama.1961.63040260007008; COBB LA, 1959, NEW ENGL J MED, V260, P1115, DOI 10.1056/NEJM195905282602204; GOLIGHER JC, 1979, ANN SURG, V189, P18, DOI 10.1097/00000658-197901000-00004; GOTZSCHE PC, 1994, LANCET, V344, P925; MAJEED AW, 1994, APR ASS SURG GB IR A; MCMAHON AJ, 1994, LANCET, V343, P135, DOI 10.1016/S0140-6736(94)90932-6; NICHOLL JP, 1992, LANCET, V340, P801, DOI 10.1016/0140-6736(92)92682-6; TATE JJT, 1993, LANCET, V342, P633, DOI 10.1016/0140-6736(93)91757-D; WOLF S, 1959, PHARMACOL REV, V11, P689	14	120	121	1	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 22	1994	344	8930					1140	1142		10.1016/S0140-6736(94)90637-8	http://dx.doi.org/10.1016/S0140-6736(94)90637-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN066	7934500				2022-12-24	WOS:A1994PN06600016
J	COPE, H; DAVID, A; PELOSI, A; MANN, A				COPE, H; DAVID, A; PELOSI, A; MANN, A			PREDICTORS OF CHRONIC POSTVIRAL FATIGUE	LANCET			English	Article							GENERAL-PRACTICE; MUSCLE	We set out to determine the relation between a general practitioner (GP) diagnosis of viral illness and development of chronic fatigue 6 months later. 618 subjects who attended GPs clinics in London, south, and southwest England and who received a diagnosis of viral illness were followed prospectively and fatigue was assessed by questionnaire after 6 months. At presentation, GPs recorded fatigue in 62.6% of subjects, usually since the onset of symptoms. 502 (81.2%) subjects completed the 6-month questionnaire, of whom 88 (17.5%) met criteria for chronic fatigue and 65 (12.9%) had no reported fatigue before the viral illness. Compared with a similar group of non-postviral GP attenders, the risk ratio for chronic fatigue in the present cohort was 1.45 (95% CI 1.14-2.04). Infective symptoms did not predict fatigue 6 months later. Psychiatric morbidity, belief in vulnerability to viruses, and attributional style at initial presentation were all associated with self-designated postviral fatigue. Logistic regression showed that somatic attributional style, less definite diagnosis by the GP, and sick certification were the only significant predictors of chronic fatigue after viral infection when other factors were controlled for. Chronic severe fatigue 6 months after GP-diagnosed viral illness is related to symptom-attributional style and doctor behaviour, rather than to features of the viral illness. Some subjects with apparent postviral fatigue had complained of tiredness before their presentation with a viral illness.	INST PSYCHIAT,DEPT PSYCHOL MED,LONDON SE5 8AF,ENGLAND; INST PSYCHIAT,EPIDEMIOL & GEN PRACTICE SECT,LONDON SE5 8AF,ENGLAND; HALRMYRES HOSP,GLASGOW,LANARK,SCOTLAND	University of London; King's College London; University of London; King's College London			David, Anthony S/C-1315-2011; David, Anthony/O-1750-2019	David, Anthony S/0000-0003-0967-774X; David, Anthony/0000-0003-0967-774X; Pelosi, Anthony/0000-0002-5501-2661				BARTLETT FC, 1932, REMEMBERING, P20; BRUCEJONES WDA, 1994, PSYCHOL MED, V24, P651, DOI 10.1017/S003329170002780X; COHEN S, 1993, J PERS SOC PSYCHOL, V64, P131, DOI 10.1037/0022-3514.64.1.131; COPE H, 1994, J PSYCHOSOM RES, V38, P89, DOI 10.1016/0022-3999(94)90082-5; DAVID A, 1990, BMJ-BRIT MED J, V301, P1199, DOI 10.1136/bmj.301.6762.1199; DAVID AS, 1988, BRIT MED J, V296, P696, DOI 10.1136/bmj.296.6623.696; DAVID AS, 1991, BRIT J HOSP MED, V45, P158; DAVID AS, 1991, BRIT MED BULL, V47, P966, DOI 10.1093/oxfordjournals.bmb.a072524; Goldthorpe J. H., 1974, SOCIAL GRADING OCCUP; GOW JW, 1991, BRIT MED J, V302, P692, DOI 10.1136/bmj.302.6778.692; GOW JW, 1992, J CLIN PATHOL, V45, P1058, DOI 10.1136/jcp.45.12.1058; GOW JW, 1994, IN PRESS CLIN INFECT; HANSEN V, 1989, BRIT MED J, V299, P85, DOI 10.1136/bmj.299.6691.85; IMBODEN J, 1961, ARCH INTERN MED, V108, P115; KATON WJ, 1991, J GENERAL INT MED, V6, P227; KLEINMANN A, 1993, CIBA F S, V173; MCDONALD E, 1993, PSYCHOL MED, V23, P987, DOI 10.1017/S0033291700026453; MILLER NA, 1991, BMJ-BRIT MED J, V302, P140, DOI 10.1136/bmj.302.6769.140; PAWLIKOWSKA T, 1994, BRIT MED J, V308, P763, DOI 10.1136/bmj.308.6931.763; Ramsay M, 1986, POSTVIRAL FATIGUE SY; RIDSDALE L, 1993, BMJ-BRIT MED J, V307, P103, DOI 10.1136/bmj.307.6896.103; ROBBINS JM, 1991, PSYCHOL MED, V21, P1029, DOI 10.1017/S0033291700030026; RUTHERFORD OM, 1991, J NEUROL NEUROSUR PS, V54, P961, DOI 10.1136/jnnp.54.11.961; SCHLUEDERBERG A, 1992, ANN INTERN MED, V117, P325, DOI 10.7326/0003-4819-117-4-325; SHARPE MC, 1991, J ROY SOC MED, V84, P118, DOI 10.1177/014107689108400224; WESSELY S, 1990, PSYCHOL MED, V20, P35, DOI 10.1017/S0033291700013210; WESSELY S, 1989, J NEUROL NEUROSUR PS, V52, P940, DOI 10.1136/jnnp.52.8.940; WOOD GC, 1991, PSYCHOL MED, V21, P619, DOI 10.1017/S003329170002225X	28	102	104	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 24	1994	344	8926					864	868		10.1016/S0140-6736(94)92833-9	http://dx.doi.org/10.1016/S0140-6736(94)92833-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PH253	7916407				2022-12-24	WOS:A1994PH25300017
J	MORIN, PA; MOORE, JJ; CHAKRABORTY, R; JIN, L; GOODALL, J; WOODRUFF, DS				MORIN, PA; MOORE, JJ; CHAKRABORTY, R; JIN, L; GOODALL, J; WOODRUFF, DS			KIN SELECTION, SOCIAL-STRUCTURE, GENE FLOW, AND THE EVOLUTION OF CHIMPANZEES	SCIENCE			English	Article							HUMAN MITOCHONDRIAL-DNA; DINUCLEOTIDE REPEAT POLYMORPHISMS; CYTOCHROME-B SEQUENCE; D-LOOP REGION; PHYLOGENETIC-RELATIONSHIPS; NATURAL-POPULATIONS; COMMON ANCESTOR; LOCI; AMPLIFICATION; NUMBER	Hypotheses about chimpanzee social behavior, phylogeography, and evolution were evaluated by noninvasive genotyping of free-ranging individuals from 20 African sites. Degrees of relatedness among individuals in one community were inferred from allele-sharing at eight nuclear simple sequence repeat (SSR) loci. Males are related on the order of half-siblings, and homozygosity is significantly increased at several SSR loci compared to Hardy-Weinberg expectations. These data support the kin-selection hypothesis for the evolution of cooperation among males. Sequence variation patterns at two mitochondrial loci indicate historically high long-distance gene flow and clarify the relationships among three allopatric subspecies. The unexpectedly large genetic distance between the western subspecies, Pan troglodytes verus, and the other two subspecies suggests a divergence time of about 1.58 million years. This result, if confirmed at nuclear loci and supported by eco-behavioral data, implies that P. t. verus should be elevated to full species rank.	UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, CTR MOLEC GENET, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT ANTHROPOL, LA JOLLA, CA 92093 USA; UNIV TEXAS, GRAD SCH BIOMED SCI, CTR DEMOG & POPULAT GENET, HOUSTON, TX 77225 USA; JANE GOODALL INST USA, RIDGEFIELD, CT 06877 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of Texas System			Morin, Phillip A/E-9515-2010; Jin, Li/C-1468-2009; Klein, Richard G/B-5910-2009; Jin, Li/M-5063-2019	Jin, Li/0000-0002-4546-2415; Morin, Phillip/0000-0002-3279-1519	NHGRI NIH HHS [1T32 HG00005-02] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [T32HG000005] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; BROWN AHD, 1980, GENETICS, V96, P523; BROWN WM, 1982, J MOL EVOL, V18, P225, DOI 10.1007/BF01734101; CHAKRABORTY R, 1994, HUM HERED, V44, P1, DOI 10.1159/000154181; CHAKRABORTY R, 1984, GENETICS, V108, P719; COPPENS Y, 1994, SCI AM, V270, P88, DOI 10.1038/scientificamerican0594-88; DEKA R, 1991, GENOMICS, V11, P83, DOI 10.1016/0888-7543(91)90104-M; DIRIENZO A, 1991, P NATL ACAD SCI USA, V88, P1597, DOI 10.1073/pnas.88.5.1597; EDWARDS A, 1992, GENOMICS, V12, P241, DOI 10.1016/0888-7543(92)90371-X; EDWARDS A, 1991, AM J HUM GENET, V49, P746; EPPLEN JT, 1991, EXPER SUPPL, V58, P50; FERRIS SD, 1981, P NATL ACAD SCI-BIOL, V78, P6319, DOI 10.1073/pnas.78.10.6319; FORAN DR, 1988, NUCLEIC ACIDS RES, V16, P5841, DOI 10.1093/nar/16.13.5841; Garza JC, 1992, MOL PHYLOGENET EVOL, V1, P202, DOI 10.1016/1055-7903(92)90016-A; GEFFEN E, 1992, J ZOOL, V228, P27, DOI 10.1111/j.1469-7998.1992.tb04430.x; GOODALL J, 1990, UNDERSTANDING CHIMPA, P360; Goodall J, 1986, CHIMPANZEES GOMBE, DOI DOI 10.1002/AJPA.1330730313; Groves C., 1989, THEORY HUMAN PRIMATE; GROVES CP, 1992, J HUM EVOL, V22, P327, DOI 10.1016/0047-2484(92)90063-F; GUO SW, 1992, BIOMETRICS, V48, P361, DOI 10.2307/2532296; Hamilton A.C., 1988, P13; HASEGAWA M, 1990, J MOL EVOL, V31, P113, DOI 10.1007/BF02109480; HIGUCHI R, 1984, NATURE, V312, P282, DOI 10.1038/312282a0; Hill W. C. O., 1969, P22; HOELZEL AR, 1991, MOL BIOL EVOL, V8, P475; HORAI S, 1992, J MOL EVOL, V35, P32, DOI 10.1007/BF00160258; KIMURA M, 1980, J MOL EVOL, V16, P111, DOI 10.1007/BF01731581; KOCHER TD, 1989, P NATL ACAD SCI USA, V86, P6196, DOI 10.1073/pnas.86.16.6196; KOCHER TD, 1991, EVOLUTION OF LIFE, P391; KUMAR S, 1994, COMPUT APPL BIOSCI, V10, P189; LI CC, 1976, 1ST COURSE POPULATIO; LITT M, 1989, AM J HUM GENET, V44, P397; LYNCH M, 1990, EVOLUTION, V44, P1725, DOI 10.1111/j.1558-5646.1990.tb05244.x; LYNCH M, 1992, P INT CO CONSERVATIO, P258; MERCURE A, 1993, EVOLUTION, V47, P1313, DOI 10.1111/j.1558-5646.1993.tb02157.x; MOON MA, 1993, NIH RES RESOURCES RE, V17, P7; MORIN PA, 1992, PATERNITY IN PRIMATES : GENETIC TESTS AND THEORIES, P63; MORIN PA, 1993, PRIMATES, V34, P347, DOI 10.1007/BF02382630; MORIN PA, 1992, P ROY SOC B-BIOL SCI, V249, P293, DOI 10.1098/rspb.1992.0117; MORIN PA, 1993, YEARB PHYS ANTHROPOL, V36, P179; MORIN PA, 1992, THESIS U CALIFORNIA; MORIN PA, IN PRESS MOL ECOL; MORIN PA, 1979, GREAT APES, P73; MORTON NE, 1992, P NATL ACAD SCI USA, V89, P2556, DOI 10.1073/pnas.89.7.2556; NEI M, 1992, MOL BIOL EVOL, V9, P1176; NEI M, 1978, GENETICS, V89, P583; NEI M, 1987, MOL EVOLUTIONARY GEN, P276; Nishida T., 1979, GREAT APES, P73; Nishida T., 1990, CHIMPANZEES MAHALE M; NORMARK BB, 1991, MOL BIOL EVOL, V8, P819; NOWAK RM, 1991, WALKERS MAMMALS WORL, V1; PESOLE G, 1992, MOL BIOL EVOL, V9, P587; Pusey A, 1979, GREAT APES, P465; PUSEY AE, 1980, ANIM BEHAV, V28, P543, DOI 10.1016/S0003-3472(80)80063-7; RIER KB, 1992, FACES FOREST; ROGERS J, 1993, J HUM EVOL, V25, P201, DOI 10.1006/jhev.1993.1044; RUANO G, 1992, MOL BIOL EVOL, V9, P575; RUVOLO M, 1993, MOL BIOL EVOL, V10, P1115; RUVOLO M, 1994, AM J PHYS ANTHROPOL, V94, P89, DOI 10.1002/ajpa.1330940108; RUVOLO M, 1993, SCIENCE, V260, P892; RUVOLO M, COMMUNICATION; RYDER OA, 1986, TRENDS ECOL EVOL, V1, P9, DOI 10.1016/0169-5347(86)90059-5; SAITOU N, 1991, AM J PHYS ANTHROPOL, V84, P75, DOI 10.1002/ajpa.1330840107; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SARICH VM, 1967, SCIENCE, V158, P1200, DOI 10.1126/science.158.3805.1200; SEAL US, 1986, PRIMATES ROAD SELF S, P47; Shea Brian T., 1993, P265; SHEA BT, 1988, J HUM EVOL, V17, P671, DOI 10.1016/0047-2484(88)90024-3; SMITH MF, 1991, MOL BIOL EVOL, V8, P85; Sokal Robert R., 1969, BIOMETRY; Spiess EB, 1989, GENES POPULATIONS; Stanley S. M., 1979, MACROEVOLUTION; STAUB KC, 1990, AM MALACOL BULL, V7, P93; STONEKING M, 1991, AM J HUM GENET, V48, P370; STRIER KB, 1993, J ZOO WILDLIFE MED, V24, P229; SWOFFORD DL, 1991, PAUP PHYLOGENETIC AN; TAMURA K, 1993, MOL BIOL EVOL, V10, P512, DOI 10.1093/oxfordjournals.molbev.a040023; VANDENBUSSCHE RA, 1993, MOL BIOL EVOL, V10, P944; VANDENBUSSCHE RA, 1993, J MAMMAL, V74, P793, DOI 10.2307/1382304; VIGILANT L, 1991, SCIENCE, V253, P1503, DOI 10.1126/science.1840702; Vineberg EO, 1991, LAST APE PYGMY CHIMP; WAKELEY J, 1994, MOL BIOL EVOL, V11, P436; WEBER JL, 1990, NUCLEIC ACIDS RES, V18, P6465, DOI 10.1093/nar/18.21.6465-a; WEBER JL, 1990, NUCLEIC ACIDS RES, V18, P4034, DOI 10.1093/nar/18.13.4034; WEBER JL, 1989, AM J HUM GENET, V44, P388; WEBER JL, 1990, NUCLEIC ACIDS RES, V18, P4038, DOI 10.1093/nar/18.13.4038; WILLS C, IN PRESS EVOLUTION; WILSON AC, 1987, TRENDS GENET, V3, P241, DOI 10.1016/0168-9525(87)90257-5; WILSON AC, 1985, BIOL J LINN SOC, V26, P375, DOI 10.1111/j.1095-8312.1985.tb02048.x; Wilson DE, 1993, MAMMAL SPECIES WORLD; Woodford M. H., 1994, P178; WOODRUFF DS, 1993, PRIMATES, V34, P333, DOI 10.1007/BF02382629; WOODRUFF DS, 1990, J SCI SOC THAILAND, V16, P117; WOODRUFF DS, 1990, PRESERVATION VALUATI, P119; WRANGHAM RW, 1979, CURRENT PROBLEMS SOC, P481; WU CI, 1991, GENETICS, V127, P429; ZIHLMAN AL, 1978, NATURE, V275, P744, DOI 10.1038/275744a0; 1991, GLOBAL CAPTIVE ACTIO	98	424	441	1	121	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 26	1994	265	5176					1193	1201		10.1126/science.7915048	http://dx.doi.org/10.1126/science.7915048			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PD422	7915048				2022-12-24	WOS:A1994PD42200025
J	WEISSMAN, JS; KASHI, Y; FENTON, WA; HORWICH, AL				WEISSMAN, JS; KASHI, Y; FENTON, WA; HORWICH, AL			GROEL-MEDIATED PROTEIN-FOLDING PROCEEDS BY MULTIPLE ROUNDS OF BINDING AND RELEASE OF NONNATIVE FORMS	CELL			English	Article							HEAT-SHOCK PROTEINS; MOLECULAR CHAPERONE; ORNITHINE TRANSCARBAMYLASE; ESCHERICHIA-COLI; CENTRAL CAVITY; RHODANESE; INTERMEDIATE; HYDROLYSIS; TRANSLOCATION; PRECURSOR	The chaperonin GroEL is a ribosome-sized double-ring structure that assists in folding a diverse set of polypeptides. We have examined the fate of a polypeptide during a chaperonin-mediated folding reaction. Strikingly, we find that, upon addition of ATP and the cochaperonin GroES, polypeptide is released rapidly from GroEL in a predominantly nonnative conformation that can be trapped by mutant forms of GroEL that are capable of binding but not releasing substrate. Released polypeptide undergoes kinetic partitioning: a fraction completes folding while the remainder is rebound rapidly by other GroEL molecules. Folding appears to occur in an all-or-none manner, as proteolysis and tryptophan fluorescence indicate that after rebinding, polypeptide has the same structure as in the original complex. These observations suggest that GroEL functions by carrying out multiple rounds of binding aggregation-prone or kinetically trapped intermediates, maintaining them in an unfolded state, and releasing them to attempt to fold in solution.	YALE UNIV, SCH MED, BOYER CTR MOLEC MED, DEPT GENET, NEW HAVEN, CT 06510 USA	Yale University	WEISSMAN, JS (corresponding author), YALE UNIV, SCH MED, BOYER CTR MOLEC MED, HOWARD HUGHES MED INST, NEW HAVEN, CT 06510 USA.		Kashi, Yechezkel/D-5433-2013					ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; AZEM A, 1994, SCIENCE, V265, P653, DOI 10.1126/science.7913553; BRAIG K, 1993, P NATL ACAD SCI USA, V90, P3978, DOI 10.1073/pnas.90.9.3978; BRIGGS MS, 1992, P NATL ACAD SCI USA, V89, P2017, DOI 10.1073/pnas.89.6.2017; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CHAN HS, 1993, J CHEM PHYS, V99, P2116, DOI 10.1063/1.465277; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; CHENG MY, 1990, NATURE, V348, P455, DOI 10.1038/348455a0; DOERING D, 1992, THESIS MIT CAMBRIDGE; ELLIS J, 1987, NATURE, V328, P378, DOI 10.1038/328378a0; FAYET O, 1989, J BACTERIOL, V171, P1379, DOI 10.1128/JB.171.3.1379-1385.1989; GAO Y, 1994, J CELL BIOL, V125, P989, DOI 10.1083/jcb.125.5.989; GAO YJ, 1992, CELL, V69, P1043, DOI 10.1016/0092-8674(92)90622-J; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HOOGENRAAD NJ, 1980, ANAL BIOCHEM, V101, P97, DOI 10.1016/0003-2697(80)90045-7; HORWICH AL, 1993, PHILOS T R SOC B, V339, P313, DOI 10.1098/rstb.1993.0030; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; ISHII N, 1992, FEBS LETT, V299, P169, DOI 10.1016/0014-5793(92)80240-H; ISHII N, 1994, J MOL BIOL, V236, P691, DOI 10.1006/jmbi.1994.1181; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; KALOUSEK F, 1978, J BIOL CHEM, V253, P3939; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KIEFHABER T, 1992, PROTEINS, V12, P171, DOI 10.1002/prot.340120210; LAMINET AA, 1990, EMBO J, V9, P2315, DOI 10.1002/j.1460-2075.1990.tb07403.x; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LISSIN NM, 1990, NATURE, V348, P339, DOI 10.1038/348339a0; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; MENDOZA JA, 1992, J BIOL CHEM, V267, P24648; MENDOZA JA, 1991, J BIOL CHEM, V266, P16973; MILLER DM, 1991, J BIOL CHEM, V266, P4686; NELSON RJ, 1992, CELL, V71, P97, DOI 10.1016/0092-8674(92)90269-I; RADFORD SE, 1992, NATURE, V358, P302, DOI 10.1038/358302a0; SAIBIL HR, 1993, CURR BIOL, V3, P265, DOI 10.1016/0960-9822(93)90176-O; SCHMIDT M, 1994, J BIOL CHEM, V269, P10304; SCHMIDT M, 1994, SCIENCE, V265, P656, DOI 10.1126/science.7913554; SOSNICK TR, 1994, NAT STRUCT BIOL, V1, P149, DOI 10.1038/nsb0394-149; TANDON S, 1989, J BIOL CHEM, V264, P9859; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; TODD MJ, 1993, BIOCHEMISTRY-US, V32, P8560, DOI 10.1021/bi00084a024; UDGAONKAR JB, 1990, P NATL ACAD SCI USA, V87, P8197, DOI 10.1073/pnas.87.21.8197; VLITANEN PV, 1991, BIOCHEMISTRY-US, V30, P9716; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; WANG Z, 1992, PROTEIN SCI, V1, P522; WEISSMAN JS, 1992, CELL, V71, P841, DOI 10.1016/0092-8674(92)90559-U; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783; YAFFE MB, 1992, NATURE, V358, P245, DOI 10.1038/358245a0; ZAHN R, 1994, NATURE, V368, P261, DOI 10.1038/368261a0; ZHENG XX, 1993, J BIOL CHEM, V268, P7489	52	341	346	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 26	1994	78	4					693	702		10.1016/0092-8674(94)90533-9	http://dx.doi.org/10.1016/0092-8674(94)90533-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PD693	7915201				2022-12-24	WOS:A1994PD69300017
J	GRINES, CL; WEAVER, WD				GRINES, CL; WEAVER, WD			TREATING MYOCARDIAL-INFARCTION - AND IMPORTANCE OF EARLY REPERFUSION	LANCET			English	Editorial Material							THROMBOLYSIS; ANGIOPLASTY		UNIV WASHINGTON, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle	GRINES, CL (corresponding author), WILLIAM BEAUMONT HOSP, DEPT MED, DIV CARDIOL, ROYAL OAK, MI 48072 USA.							BADIMON L, 1991, TRENDS CARDIOVAS MED, V1, P261, DOI 10.1016/1050-1738(91)90032-A; BECKER RC, 1991, CARDIOLOGY, V79, P49, DOI 10.1159/000174860; Cannon Christopher P., 1993, Journal of the American College of Cardiology, V21, p136A; DEBONO DP, 1992, BRIT HEART J, V67, P122; GATENBY R, 1992, BMJ-BRIT MED J, V305, P548; GRINES CL, 1993, NEW ENGL J MED, V328, P673, DOI 10.1056/NEJM199303113281001; HERLITZ J, 1992, EUR HEART J, V13, P171, DOI 10.1093/oxfordjournals.eurheartj.a060142; KLEIMAN NS, 1992, CIRCULATION, V86, P260; LIDON RM, 1994, CIRCULATION, V89, P1567, DOI 10.1161/01.CIR.89.4.1567; ROSS AM, 1993, NEW ENGL J MED, V329, P1615; ROUX S, 1992, J AM COLL CARDIOL, V19, P671, DOI 10.1016/S0735-1097(10)80290-6; TCHENG JE, 1993, CIRCULATION, V88, P1; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; TOPOL EJ, 1994, CIRCULATION, V89, P1557, DOI 10.1161/01.CIR.89.4.1557; TOPOL EJ, 1994, LANCET, V343, P881, DOI 10.1016/S0140-6736(94)90007-8; ZIJLSTRA F, 1993, NEW ENGL J MED, V328, P680, DOI 10.1056/NEJM199303113281002; 1993, EUR HEART J        S, V14, P48	17	7	7	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 20	1994	344	8921					490	491		10.1016/S0140-6736(94)91893-7	http://dx.doi.org/10.1016/S0140-6736(94)91893-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PC535	7914609				2022-12-24	WOS:A1994PC53500004
J	YUEN, KY; WONG, SSY; TSANG, DNCT; CHAU, PY				YUEN, KY; WONG, SSY; TSANG, DNCT; CHAU, PY			SERODIAGNOSIS OF PENICILLIUM-MARNEFFEI INFECTION	LANCET			English	Note							HUMAN-IMMUNODEFICIENCY-VIRUS	Diagnosis of Penicillium marneffei infection is often made late. We evaluated an indirect immunofluorescent antibody test for P marneffei in serum from 103 patients with persistent fever and from 78 normal subjects. Germinating conidia (initial tissue-invasion phase) and yeast-hyphae (tissue multiplication phase) forms were used as antigen. All 8 documented P marneffei cases (8%) had an IgG titre of 160 or more; the other 95 patients and all the healthy controls had an IgG titre of 40 or below. Blood culture was positive in only 1 case with HIV infection. Biopsy and culture of tissues were necessary for confirmation in the other 7 cases. The test could provide rapid presumptive diagnosis and supplement conventional culture.	QUEEN ELIZABETH HOSP,KOWLOON,HONG KONG		YUEN, KY (corresponding author), UNIV HONG KONG,QUEEN MARY HOSP,DEPT MICROBIOL,UNIV PATHOL BLDG,POKFULAM RD,HONG KONG,HONG KONG.		Yuen, Kwok Yung/C-4465-2009; Wong, Samson/C-4446-2009	Yuen, Kwok-yung/0000-0002-2083-1552				DISALVO AF, 1973, AM J CLIN PATHOL, V60, P259; HILMARSDOTTIR I, 1993, J ACQ IMMUN DEF SYND, V6, P466; QUINDOS G, 1990, EUR J CLIN MICROBIOL, V9, P178, DOI 10.1007/BF01963834; SALTINI C, 1993, J INFECT DIS, V168, P1409, DOI 10.1093/infdis/168.6.1409; SEKHON AS, 1982, MYCOPATHOLOGIA, V77, P51, DOI 10.1007/BF00588658; SO SY, 1985, AM REV RESPIR DIS, V131, P662, DOI 10.1164/arrd.1985.131.4.662; SUPPARATPINYO K, 1992, CLIN INFECT DIS, V14, P871, DOI 10.1093/clinids/14.4.871; TSANG DNC, 1991, REV INFECT DIS, V13, P766; VIVIANI MA, 1993, EUR J EPIDEMIOL, V9, P79, DOI 10.1007/BF00463094; YUEN KY, 1992, J INFECTION, V25, P29, DOI 10.1016/0163-4453(92)93441-R	10	76	79	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 13	1994	344	8920					444	445		10.1016/S0140-6736(94)91771-X	http://dx.doi.org/10.1016/S0140-6736(94)91771-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB761	7914566				2022-12-24	WOS:A1994PB76100011
J	CRANSTON, I; LOMAS, J; MARAN, A; MACDONALD, I; AMIEL, SA				CRANSTON, I; LOMAS, J; MARAN, A; MACDONALD, I; AMIEL, SA			RESTORATION OF HYPOGLYCEMIA AWARENESS IN PATIENTS WITH LONG-DURATION INSULIN-DEPENDENT DIABETES	LANCET			English	Article							NOCTURNAL HYPOGLYCEMIA; UNAWARENESS; COUNTERREGULATION; RESPONSES; SYMPTOMS; HUMANS; IDDM; NEUROENDOCRINE; REVERSIBILITY; PREVALENCE	Hypoglycaemia without warning is a dangerous complication of insulin-dependent diabetes mellitus and it limits the use of intensified insulin therapy to reduce chronic diabetic complications. To investigate the possibility of restoring awareness; symptomatic, cognitive, and hormonal responses to controlled hypoglycaemia were studied in insulin-dependent diabetic patients with long disease duration (6 with good glycaemic control and 6 with poor control) before and after hypoglycaemia avoidance. At the start of the study, all had loss of hypoglycaemia awareness. Responses to the initial challenge were small (pooled area under curve [AUC] adrenaline 5.75 [SE 0.07] nmol/L per 260 min, pooled AUC symptom score 80 [1.3]) and only started when plasma glucose was significantly lower than the 2.8 (0.1) mmol/L at which cognitive function deteriorated. After 4.1 (1.1) months' scrupulous hypoglycaemia avoidance, hormone and symptom responses to the challenge were increased (AUC adrenaline 15.9 [0.1] nmol/L per 260 min, p = 0.01; AUC symptom score 275 [7], p < 0.001), starting at plasma glucose concentrations significantly higher than that causing cognitive dysfunction. Glycosylated haemoglobin did not deteriorate significantly. We conclude that the normal hierarchy of subjective awareness before cognitive dysfunction during hypoglycaemia can be restored by avoiding hypoglycaemia. This is independent of disease duration or initial metabolic control.	CATTEDRA MALATTIE RICAMBIO, PADUA, ITALY; UNIV NOTTINGHAM, QUEENS MED CTR, DEPT PHYSIOL & PHARMACOL, NOTTINGHAM NG7 2RD, ENGLAND	University of Nottingham	CRANSTON, I (corresponding author), GUYS HOSP, METAB MED UNIT, LONDON SE1 9RT, ENGLAND.		Greiver, Michelle/N-8764-2015	Greiver, Michelle/0000-0001-8957-0285; Macdonald, Ian/0000-0002-7540-9850				AMIEL SA, 1991, DIABETES CARE, V14, P109, DOI 10.2337/diacare.14.2.109; AMIEL SA, 1987, DIABETES, V36, P518, DOI 10.2337/diabetes.36.4.518; BIGGERS DW, 1989, DIABETES, V38, P7, DOI 10.2337/diabetes.38.1.7; CASPARIE AF, 1985, DIABETES CARE, V8, P141, DOI 10.2337/diacare.8.2.141; CLARKE WL, 1991, DIABETES, V40, P680, DOI 10.2337/diabetes.40.6.680; COX D, 1993, DIABETES, V42, pA126; DCCT Res Grp, 1991, AM J MED, V90, P450, DOI 10.1016/0002-9343(91)80085-Z; FANELLI CG, 1993, DIABETES, V42, P1683, DOI 10.2337/diabetes.42.11.1683; GALE EAM, 1979, LANCET, V1, P1049; HELLER SR, 1991, DIABETES, V40, P223, DOI 10.2337/diabetes.40.2.223; HEPBURN DA, 1991, DIABETES CARE, V14, P949, DOI 10.2337/diacare.14.11.949; HEPBURN DA, 1990, DIABETIC MED, V7, P711, DOI 10.1111/j.1464-5491.1990.tb01475.x; LAGER I, 1986, DIABETIC MED, V3, P322, DOI 10.1111/j.1464-5491.1986.tb00772.x; LIU D, 1992, DIABETOLOGIA, V35, P287, DOI 10.1007/BF00400932; MACDONALD IA, 1985, J NEUROSCI METH, V13, P239, DOI 10.1016/0165-0270(85)90072-X; MARAN A, 1992, DIABETIC MED, V9, P765, DOI 10.1111/j.1464-5491.1992.tb01889.x; MARAN A, 1993, DIABETES, V42, pA17; MARAN A, 1994, DIABETIC MED, V11, P114; MAZLAN M, 1989, THESIS U LONDON LOND; MCCALL AL, 1986, AM J PHYSIOL, V251, pE442, DOI 10.1152/ajpendo.1986.251.4.E442; MITRAKOU A, 1993, NEW ENGL J MED, V329, P834, DOI 10.1056/NEJM199309163291203; MORGAN CR, 1963, DIABETES, V12, P115, DOI 10.2337/diab.12.2.115; NAGY RJ, 1992, DIABETES, V41, P69; RYDER RJ, 1980, BRIT MED J, V301, P783; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SJOBOM NC, 1989, DIABETOLOGIA, V32, P818; TCHOBROUTSKY G, 1981, DIABETOLOGIA, V21, P335; VENEMAN T, 1993, DIABETES, V42, P1233, DOI 10.2337/diabetes.42.9.1233; WIDOM B, 1990, DIABETOLOGIA, V33, P84; WISE JK, 1973, NEW ENGL J MED, V288, P487, DOI 10.1056/NEJM197303082881003	30	315	314	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 30	1994	344	8918					283	287		10.1016/S0140-6736(94)91336-6	http://dx.doi.org/10.1016/S0140-6736(94)91336-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NZ233	7914259				2022-12-24	WOS:A1994NZ23300005
J	HANENBERG, RS; ROJANAPITHAYAKORN, W; KUNASOL, P; SOKAL, DC				HANENBERG, RS; ROJANAPITHAYAKORN, W; KUNASOL, P; SOKAL, DC			IMPACT OF THAILAND HIV-CONTROL PROGRAM AS INDICATED BY THE DECLINE OF SEXUALLY-TRANSMITTED DISEASES	LANCET			English	Article								The Thai government began an HIV-control programme in 1989. The programme had the following parts: the government bought and distributed sufficient condoms to protect much of the commercial sex in the country; sanctions were brought against commercial sex establishments where condoms were not used consistently; and a media campaign bluntly advised men to use condoms with prostitutes. Between 1989 and 1993 the use of condoms in commercial sex in Thailand increased from 14 to 94%, according to surveys of prostitutes, and the number of cases of the five major sexually transmitted diseases declined by 79% in men. We estimate that sex acts with prostitutes where there was a risk of HIV transmission declined from about 2.6% in June, 1989, to about 1.6% in June, 1993. If condom use in commercial sex stays high, future cohorts of young men and women may experience lower HIV incidence rates than those of the recent past. However, although condom use is high, there are many more infected prostitutes than before and many infected men who will pass HIV to their wives.	FAMILY HLTH INT,RES TRIANGLE PK,NC 27709; MINIST PUBL HLTH,DEPT COMMUNICABLE DIS CONTROL,BANGKOK,THAILAND	Ministry of Public Health - Thailand								ROJANAPITHAYAKO.W, 1991, 100 PERCENT CONDOM P; ROJANAPITHAYAKO.W, 1993, 100 PERCENT CONDOM U; Ungchusak K., 1990, Thai AIDS Journal, V2, P45; Ungchusak K., 1989, Thai AIDS Journal, V1, P57; 1991, STATUS TRENDS AIDS E	5	347	348	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 23	1994	344	8917					243	245		10.1016/S0140-6736(94)93004-X	http://dx.doi.org/10.1016/S0140-6736(94)93004-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY060	7913163				2022-12-24	WOS:A1994NY06000016
J	OSMOND, D; CHARLEBOIS, E; LANG, W; SHIBOSKI, S; MOSS, A				OSMOND, D; CHARLEBOIS, E; LANG, W; SHIBOSKI, S; MOSS, A			CHANGES IN AIDS SURVIVAL-TIME IN 2 SAN-FRANCISCO COHORTS OF HOMOSEXUAL MEN, 1983 TO 1993	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PNEUMOCYSTIS-CARINII PNEUMONIA; CONTROLLED TRIAL; TRIMETHOPRIM SULFAMETHOXAZOLE; AEROSOLIZED PENTAMIDINE; INCUBATION PERIOD; HIV-INFECTION; ZIDOVUDINE; RISK; PROPHYLAXIS	Background.-During the first decade since the recognition of the acquired immunodeficiency syndrome (AIDS), new therapies have been introduced and the frequency of clinical manifestations has changed. The impact of these changes on AIDS survival, however, has not been well characterized. Design.-A prospective cohort study of the outcomes of human immunodeficiency virus (HIV) infection. Setting.-Homosexual and bisexual men residing in San Francisco, Calif, recruited in 1983 and 1984 for two prospective studies and followed up for more than 9 years with clinical examinations. Participants.-A total of 761 HIV-positive homosexual and bisexual men. MaIn Outcome Measures.-Survival time from a CD4 lymphocyte count at 0.20 x 10(9)/L (200/muL) and from a clinical AIDS diagnosis to death. Results.-Median survival time from a CD4 lymphocyte count at 0.20 x 10(9)/L increased from 28.4 months in the October 1983 to November 1986 period to 40.1 months in the November 1986 to November 1988 period and is estimated at 38.1 months in the November 1988 to February 1993 period. Patients diagnosed with Pneumocystis carinii pneumonia (PCP) accounted for most of this increase with a gain in median survival time of 9.7 months (P=.0009), compared with a nonsignificant decline in the survival time of those patients without a PCP diagnosis. Multivariate analysis showed that rate of CD4 lymphocyte loss (P<.001) and receipt of both PCP prophylaxis and antiretroviral therapy (P=.04) were significantly associated with longer survival time, whereas antiretroviral therapy alone was not (P=.81). Time to death from a clinical AIDS diagnosis was 14.7 months in the 1983 to 1986 period, 19.1 months in the 1986 to 1988 period, and an estimated 15.7 months in the 1988 to 1993 period. Conclusions.-Survival time from a CD4 lymphocyte count at 0.20 x 10(9)/L has improved significantly by about 1 year, yet survival time using the 1987 AIDS case definition has shown small improvement. The largest increase in survival time from a CD4 lymphocyte count at 0.20 x 10(9)/L was in patients diagnosed with PCP, suggesting that PCP prophylaxis and treatment were more important factors in longer survival time than antiretroviral therapy.	CALIF PACIFIC MED CTR,SAN FRANCISCO,CA	California Pacific Medical Center	OSMOND, D (corresponding author), UNIV CALIF SAN FRANCISCO,SAN FRANCISCO GEN HOSP,DEPT EPIDEMIOL & BIOSTAT,DIV EPIDEMIOL & MED,SAN FRANCISCO,CA 94110, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI082515] Funding Source: NIH RePORTER; NIAID NIH HHS [NIAID N01-AI-82515] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABOULKER JP, 1993, LANCET, V341, P889, DOI 10.1016/0140-6736(93)93096-J; [Anonymous], 1992, MMWR MORB MORTAL WKL, V41, P1; BACCHETTI P, 1989, NATURE, V338, P251, DOI 10.1038/338251a0; BACCHETTI P, 1988, J INFECT DIS, V157, P104; CHAISSON RE, 1992, ARCH INTERN MED, V152, P2009, DOI 10.1001/archinte.152.10.2009; CREAGHKIRK T, 1988, JAMA-J AM MED ASSOC, V260, P3009, DOI 10.1001/jama.260.20.3009; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; FISCHL MA, 1990, NEW ENGL J MED, V323, P1090; HAMILTON JD, 1992, NEW ENGL J MED, V326, P437, DOI 10.1056/NEJM199202133260703; HARDY WD, 1992, NEW ENGL J MED, V327, P1842, DOI 10.1056/NEJM199212243272604; LANG W, 1989, LANCET, V1, P1397; LANG W, 1987, JAMA-J AM MED ASSOC, V257, P326, DOI 10.1001/jama.257.3.326; LANGE N, 1992, J AM STAT ASSOC, V87, P615, DOI 10.2307/2290194; LEMP GF, 1990, JAMA-J AM MED ASSOC, V263, P402, DOI 10.1001/jama.263.3.402; LUI KJ, 1988, SCIENCE, V240, P1333, DOI 10.1126/science.3163848; LUNDGREN JD, 1993, 9TH INT C AIDS BERL; Miller R. G., 1981, SURVIVAL ANAL; MOORE RD, 1991, NEW ENGL J MED, V324, P1412, DOI 10.1056/NEJM199105163242006; MOSS AR, 1988, BRIT MED J, V296, P745, DOI 10.1136/bmj.296.6624.745; MOSS AR, 1987, AM J EPIDEMIOL, V125, P1035, DOI 10.1093/oxfordjournals.aje.a114619; PHILLIPS AN, 1992, JAMA-J AM MED ASSOC, V268, P2662, DOI 10.1001/jama.268.19.2662; SCHNEIDER MME, 1992, NEW ENGL J MED, V327, P1836, DOI 10.1056/NEJM199212243272603; SEAGE GR, 1990, AM J PUBLIC HEALTH, V80, P835, DOI 10.2105/AJPH.80.7.835; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; WINKELSTEIN W, 1987, JAMA-J AM MED ASSOC, V257, P321, DOI 10.1001/jama.257.3.321; 1987, SAS STAT GUIDE PERSO; 1987, MMWR MORB MORTAL WKL, V34, P373; IN PRESS HIV AIDS SU	28	98	98	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 13	1994	271	14					1083	1087		10.1001/jama.271.14.1083	http://dx.doi.org/10.1001/jama.271.14.1083			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NE228	7908703				2022-12-24	WOS:A1994NE22800029
J	VANDERMAST, BJ; HORNSTRA, N; RUIGROK, MB; CLAAS, FHJ; VANROOD, JJ; LAGAAIJ, EL				VANDERMAST, BJ; HORNSTRA, N; RUIGROK, MB; CLAAS, FHJ; VANROOD, JJ; LAGAAIJ, EL			TRANSFUSION-ASSOCIATED GRAFT-VERSUS-HOST DISEASE IN IMMUNOCOMPETENT PATIENTS - A SELF-PROTECTIVE MECHANISM	LANCET			English	Article							NONIMMUNOCOMPROMISED HOSTS; BLOOD-TRANSFUSIONS; T-CELLS; RESISTANCE; TRANSPLANTATION; HEART; RATS	Transfusion-associated graft-versus-host disease (TA-GVHD) is a rare but hazardous complication caused by transfusion of leucocyte-containing blood. It is not clear why some patients are at risk for TA-GVHD, but others are not. We studied TA-GVHD in immunocompetent individuals by looking at donor-anti-host reactivity after transfusion of leucocyte-containing blood. We tested reactivity in 62 donor-recipient combinations in vitro before and at different times after blood transfusion with mixed lymphocyte culture. One patient was studied in more detail. Reactivity of blood donors against hosts gradually decreased after blood transfusion. This decrease significantly correlated with time (p<0.001). Studies in a single patient showed that absence of donor-host reactivity was due to host T cells that inhibited the response. These data indicate that an active mechanism exists in immunocompetent individuals which inhibits the graft-versus-host reaction of the donor against the host. This mechanism might be exploited in organ transplantation by pre-transplant blood transfer.	UNIV HOSP LEIDEN,DEPT IMMUNOHAEMATOL & BLOOD BANK,2333 AA LEIDEN,NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC)								ANDERSEN CB, 1992, HUM PATHOL, V23, P831, DOI 10.1016/0046-8177(92)90355-7; AVOY DR, 1990, TRANSFUSION, V30, P849, DOI 10.1046/j.1537-2995.1990.30991048795.x; BELGRAU DL, 1978, J EXP MED, V148, P103; BURDICK JF, 1988, NEW ENGL J MED, V318, P689, DOI 10.1056/NEJM198803173181107; DEGAST GC, 1991, BONE MARROW TRANSPL, V7, P293; DESFORGES JF, 1990, NEW ENGL J MED, V323, P315; GOULMY E, 1983, HLA TYPING METHODOLO, V2, P105; GREENBAUM BH, 1991, J CLIN ONCOL, V9, P1889, DOI 10.1200/JCO.1991.9.10.1889; KIMURA H, 1984, J EXP MED, V160, P652, DOI 10.1084/jem.160.3.652; KIMURA H, 1984, NATURE, V308, P463, DOI 10.1038/308463a0; KOSMATOPOULOS K, 1987, J IMMUNOL, V138, P1038; KOSMATOPOULOS K, 1988, TRANSPLANTATION, V46, P570, DOI 10.1097/00007890-198810000-00021; KOSMATOPOULOS K, 1987, TRANSPLANTATION, V44, P267, DOI 10.1097/00007890-198708000-00018; LAGAAIJ EL, 1989, NEW ENGL J MED, V321, P701, DOI 10.1056/NEJM198909143211101; LEHMANN PV, 1991, J EXP MED, V173, P333, DOI 10.1084/jem.173.2.333; MARCUS JN, 1989, NEW ENGL J MED, V322, P1004; OHTO H, 1992, TRANSFUSION, V32, P691, DOI 10.1046/j.1537-2995.1992.32792391051.x; OPELZ G, 1973, TRANSPLANT P, V5, P253; PIRENNE J, 1991, TRANSPLANTATION, V51, P51, DOI 10.1097/00007890-199101000-00007; SAKAKIBARA T, 1986, LANCET, V2, P1099; SAZAMA K, 1990, TRANSFUSION, V30, P583, DOI 10.1046/j.1537-2995.1990.30790385515.x; SHIVDASANI RA, 1993, NEW ENGL J MED, V328, P766, DOI 10.1056/NEJM199303183281105; SPITZER TR, 1990, CANCER-AM CANCER SOC, V66, P2346, DOI 10.1002/1097-0142(19901201)66:11<2346::AID-CNCR2820661116>3.0.CO;2-T; SUZUKI K, 1992, TRANSFUSION, V32, P358, DOI 10.1046/j.1537-2995.1992.32492263452.x; VOGELSANG GB, 1990, TRANSFUSION, V30, P101, DOI 10.1046/j.1537-2995.1990.30290162892.x; WILSON DB, 1989, IMMUNOL REV, V107, P159, DOI 10.1111/j.1600-065X.1989.tb00008.x; 1989, LANCET, V2, P529	27	32	32	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 26	1994	343	8900					753	757		10.1016/S0140-6736(94)91836-8	http://dx.doi.org/10.1016/S0140-6736(94)91836-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NC351	7907730				2022-12-24	WOS:A1994NC35100008
J	FARRANT, M; FELDMEYER, D; TAKAHASHI, T; CULLCANDY, SG				FARRANT, M; FELDMEYER, D; TAKAHASHI, T; CULLCANDY, SG			NMDA-RECEPTOR CHANNEL DIVERSITY IN THE DEVELOPING CEREBELLUM	NATURE			English	Article							METHYL-D-ASPARTATE; NEURONS; RAT; GLUTAMATE; ACTIVATION; CURRENTS; ADULT; CELLS; DISTINCTION; RESPONSES	IN the cerebellum, NMDA (N-methyl-D-aspartate) receptors play an important role in neuronal differentiation(1,2) and excitatory synaptic transmission(3-5). During early cerebellar development, marked changes occur in the distribution of messenger RNAs encoding various NMDA-receptor subunits(6). To determine whether these changes result in the appearance of functionally distinct NMDA receptors(7-9), we have recorded single-channel currents in rat cerebellar granule cells during the period of their migration from the external germinal layer to the inner granular layer(10). Here we show that before synapse formation(10,11), pre-migratory and migrating granule cells express NMDA receptors possessing single-channel properties similar to those previously described for many central neurons(12,16). In contrast, mature post-migratory cells also express an atypical form of NMDA receptor that has a lower single-channel conductance and distinct kinetic behaviour. The properties of these 'low-conductance' channels correspond to those described(17) for recombinant NMDA receptors formed by coexpression of NR1 and NR2C subunits(8,9). The NR2C subunit appears postnatally and is found predominantly in the adult cerebellum(6-8). Our data demonstrate developmental changes in NMDA-receptor properties at the single-channel level, and suggest that is the cerebellum the expression of a specific subunit protein results in a distinct form of native receptor.	UNIV TOKYO, FAC MED,INST BRAIN RES,DEPT NEUROPHYSIOL,BUNKYO KU, TOKYO 113, JAPAN	University of Tokyo	FARRANT, M (corresponding author), UCL, DEPT PHARMACOL, GOWER ST, LONDON WC1E 6BT, ENGLAND.		Feldmeyer, Dirk/H-5940-2013; Takahashi, Tomoyuki/G-5951-2015	Feldmeyer, Dirk/0000-0002-1716-8972; Takahashi, Tomoyuki/0000-0002-8771-7666; Farrant, Mark/0000-0002-9918-0376; Cull-Candy, Stuart G/0000-0002-0831-8326	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALTMAN J, 1972, J COMP NEUROL, V145, P465, DOI 10.1002/cne.901450403; BLANTON MG, 1992, J NEUROPHYSIOL, V67, P1185, DOI 10.1152/jn.1992.67.5.1185; CARMIGNOTO G, 1992, SCIENCE, V258, P1007, DOI 10.1126/science.1279803; Colquhoun D, 1983, SINGLE CHANNEL RECOR, P191; CULLCANDY SG, 1987, NATURE, V325, P525, DOI 10.1038/325525a0; DANGELO E, 1993, NEUROSCIENCE, V53, P121, DOI 10.1016/0306-4522(93)90290-V; EDWARDS FA, 1989, PFLUG ARCH EUR J PHY, V414, P600, DOI 10.1007/BF00580998; GARTHWAITE G, 1987, DEV BRAIN RES, V36, P288, DOI 10.1016/0165-3806(87)90034-4; GARTHWAITE J, 1989, NEUROSCIENCE, V29, P401, DOI 10.1016/0306-4522(89)90067-5; GIBB AJ, 1992, J PHYSIOL-LONDON, V456, P143, DOI 10.1113/jphysiol.1992.sp019331; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HAMORI J, 1983, J COMP NEUROL, V220, P365, DOI 10.1002/cne.902200402; HESTRIN S, 1992, NATURE, V357, P686, DOI 10.1038/357686a0; HOWE JR, 1991, J PHYSIOL-LONDON, V432, P143, DOI 10.1113/jphysiol.1991.sp018381; ISHII T, 1993, J BIOL CHEM, V268, P2836; JAHR CE, 1987, NATURE, V325, P522, DOI 10.1038/325522a0; JOHNSON JW, 1987, NATURE, V325, P529, DOI 10.1038/325529a0; KOMURO H, 1993, SCIENCE, V260, P95, DOI 10.1126/science.8096653; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MISHINA M, 1986, NATURE, V321, P406, DOI 10.1038/321406a0; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; RABACCHI S, 1992, SCIENCE, V256, P1823, DOI 10.1126/science.1352066; ROSSI DJ, 1993, NEUROPHARMACOLOGY, V32, P1239, DOI 10.1016/0028-3908(93)90018-X; SAH P, 1989, SCIENCE, V246, P815, DOI 10.1126/science.2573153; SIGWORTH FJ, 1987, BIOPHYS J, V52, P1047, DOI 10.1016/S0006-3495(87)83298-8; SILVER RA, 1992, NATURE, V355, P163, DOI 10.1038/355163a0; STERN P, 1992, P ROY SOC B-BIOL SCI, V250, P271, DOI 10.1098/rspb.1992.0159; TAKAHASHI T, 1992, NEURON, V9, P1155, DOI 10.1016/0896-6273(92)90073-M; WATANABE M, 1992, NEUROREPORT, V3, P1138, DOI 10.1097/00001756-199212000-00027	31	265	267	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 24	1994	368	6469					335	339		10.1038/368335a0	http://dx.doi.org/10.1038/368335a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NB985	7907398				2022-12-24	WOS:A1994NB98500046
J	BERKLEY, S				BERKLEY, S			DIAGNOSTIC-TESTS FOR SEXUALLY-TRANSMITTED DISEASES - A CHALLENGE	LANCET			English	Editorial Material											BERKLEY, S (corresponding author), ROCKEFELLER FDN,DIV HLTH SCI,NEW YORK,NY 10036, USA.								0	7	7	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 19	1994	343	8899					685	686		10.1016/S0140-6736(94)91575-X	http://dx.doi.org/10.1016/S0140-6736(94)91575-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NB809	7907675				2022-12-24	WOS:A1994NB80900004
J	MORTIMER, PP				MORTIMER, PP			A LURKING ENDEMIC	LANCET			English	Editorial Material											MORTIMER, PP (corresponding author), CENT PUBL HLTH LAB,HEPATITIS & RETROVIRUS LAB,DIV VIRUS REFERENCE,LONDON,ENGLAND.							CHANT K, 1993, LANCET, V342, P1548, DOI 10.1016/S0140-6736(05)80112-6; CIESIELSKI C, 1992, ANN INTERN MED, V116, P798, DOI 10.7326/0003-4819-116-10-798; Flaum A., 1926, ACTA MED SCAND, V16, P544; HERSH S, 1993, AIDS, V7, P1617; Laird S. M., 1947, GLASGOW MED JOUR, V28, P199; MCNEE J, 1952, BMJ-BRIT MED J, V1, P1367, DOI 10.1136/bmj.1.4773.1367; PATRASCU IV, 1993, AIDS RES HUM RETROV, V9, P99, DOI 10.1089/aid.1993.9.99; POKROVSKY VV, 1989, 5 INT C AIDS MONTR; Salaman MH, 1944, LANCET, V2, P7; Sheehan HL, 1944, LANCET, V2, P8; VICKERS J, 1994, CDR REV, V4, P1; 1922, REPORTS SALVARSAN CO, V2; 1993, MMWR, V24, P969; 1943, LANCET, V1, P83	14	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 12	1994	343	8894					368	370		10.1016/S0140-6736(94)91216-5	http://dx.doi.org/10.1016/S0140-6736(94)91216-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW283	7905545				2022-12-24	WOS:A1994MW28300002
J	HOFSTRA, RMW; LANDSVATER, RM; CECCHERINI, I; STULP, RP; STELWAGEN, T; LUO, Y; PASINI, B; HOPPENER, JWM; VANAMSTEL, HKP; ROMEO, G; LIPS, CJM; BUYS, CHCM				HOFSTRA, RMW; LANDSVATER, RM; CECCHERINI, I; STULP, RP; STELWAGEN, T; LUO, Y; PASINI, B; HOPPENER, JWM; VANAMSTEL, HKP; ROMEO, G; LIPS, CJM; BUYS, CHCM			A MUTATION IN THE RET PROTOONCOGENE ASSOCIATED WITH MULTIPLE ENDOCRINE NEOPLASIA TYPE-2B AND SPORADIC MEDULLARY-THYROID CARCINOMA	NATURE			English	Article							CHROMOSOME-10; LINKAGE; DOMAINS; KINASE	MULTIPLE endocrine neoplasia type 2 (MEN 2) comprises three clinically distinct, dominantly inherited cancer syndromes. MEN 2A patients develop medullary thyroid carcinoma (MTC) and phaeochromocytoma. MEN 2B patients show in addition ganglioneuromas of the gastrointestinal tract and skeletal abnormalities. In familial MTC, only the thyroid is affected. Germ-line mutations of the RET proto-oncogene have recently been reported in association with MEN 2A and familial MTC1,2. All mutations occurred within codons specifying cysteine residues in the transition point between the RET protein extracellular and transmembrane domains. We now show that MEN 2B is also associated with mutation of the RET proto-oncogene. A mutation in codon 664, causing the substitution of a threonine for a methionine in the tyrosine kinase domain of the protein, was found in all nine unrelated MEN 2B patients studied. The same mutation was found in six out of 18 sporadic tumours.	UNIV GRONINGEN,DEPT MED GENET,ANT DEUSINGLAAN 4,9713 AW GRONINGEN,NETHERLANDS; UNIV UTRECHT HOSP,CTR CLIN GENET,DEPT INTERNAL MED & PATHOL,3584 CX UTRECHT,NETHERLANDS; INST G GASLINI,GENET MOLEC LAB,I-16148 GENOA,ITALY	University of Groningen; Utrecht University; Utrecht University Medical Center; University of Genoa; IRCCS Istituto Giannina Gaslini			Pasini, Barbara/AHI-2004-2022; Ceccherini, Isabella/P-8195-2014	Pasini, Barbara/0000-0002-4373-1212; Ceccherini, Isabella/0000-0001-8732-1955; Hofstra, Robert/0000-0001-7498-3829				CECCHERINI I, 1993, BIOCHEM BIOPH RES CO, V196, P1288, DOI 10.1006/bbrc.1993.2392; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; JACKSON CE, 1979, AM J HUM GENET, V101, P704; LANDSVATER RM, 1989, GENOMICS, V4, P246, DOI 10.1016/0888-7543(89)90327-3; MATHEW CGP, 1987, NATURE, V328, P527, DOI 10.1038/328527a0; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; NELKIN BD, 1989, CANCER RES, V49, P4114; NORUM RA, 1990, GENOMICS, V8, P313, DOI 10.1016/0888-7543(90)90287-5; ORITA M, 1989, GENOMICS, V5, P873; SCHNEIDER R, 1992, TRENDS BIOCHEM SCI, V17, P468, DOI 10.1016/0968-0004(92)90490-Z; SCHUCHARDT A, 1992, COLD SPRING HARBOR M; SIMPSON NE, 1987, NATURE, V328, P528, DOI 10.1038/328528a0; TAKAHASHI M, 1988, ONCOGENE, V3, P571	14	955	980	1	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 27	1994	367	6461					375	376		10.1038/367375a0	http://dx.doi.org/10.1038/367375a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MT540	7906866				2022-12-24	WOS:A1994MT54000069
J	SYM, M; ENGEBRECHT, J; ROEDER, GS				SYM, M; ENGEBRECHT, J; ROEDER, GS			ZIP1 IS A SYNAPTONEMAL COMPLEX PROTEIN REQUIRED FOR MEIOTIC CHROMOSOME SYNAPSIS	CELL			English	Article							DNA TOPOISOMERASE-II; AMINO-ACID-SEQUENCE; GLUTATHIONE-S-TRANSFERASE; DOUBLE-STRAND BREAKS; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; GENE CONVERSION; YEAST CHROMOSOMES; MYOSIN ROD; MEIOSIS	ZIP1 is a novel meiosis-specific gene required for chromosome synapsis and cell cycle progression in S. cerevisiae. zip1 strains undergo homologous chromosome pairing, but are defective in synaptonemal complex (SC) formation. The zip1 mutation confers a uniform arrest in meiosis prior to the first division. zip1 strains display nearly wild-type levels of commitment to melotic recombination; however, mature reciprocal recombinants are not formed until cells are released from meiotic arrest by return to growth medium. DNA sequence analysis of ZIP1 reveals structural homology to a number of proteins containing coiled coils. Immunofluorescence experiments using anti-ZIP1 antibodies demonstrate that the ZIP1 protein localizes to synapsed meiotic chromosomes but not to unsynapsed axial elements. Taken together, these data suggest that ZIP1 is a component of the central region of the SC. We propose a model in which ZIP1 acts as a molecular zipper to bring homologous chromosomes in close apposition.			SYM, M (corresponding author), YALE UNIV, DEPT BIOL, NEW HAVEN, CT 06511 USA.		Engebrecht, JoAnne/K-3355-2019	Engebrecht, JoAnne/0000-0002-2733-7506	NIGMS NIH HHS [2 T32 GM07223-18, GM28904] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007223, R01GM028904] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANI E, 1989, GENETICS, V122, P47; ALANI E, 1990, CELL, V61, P419, DOI 10.1016/0092-8674(90)90524-I; Ausubel FA, 1990, CURRENT PROTOCOLS MO; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; BOLIVAR F, 1977, GENE, V2, P95, DOI 10.1016/0378-1119(77)90000-2; BORTS RH, 1986, GENETICS, V113, P551; BUCKINGHAM LE, 1990, P NATL ACAD SCI USA, V87, P9406, DOI 10.1073/pnas.87.23.9406; BYERS B, 1975, P NATL ACAD SCI USA, V72, P5056, DOI 10.1073/pnas.72.12.5056; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; Carpenter ATC, 1988, GENETIC RECOMBINATIO, P529, DOI [10.1038/ng1287, DOI 10.1038/NG1287]; CHU G, 1986, SCIENCE, V234, P1582, DOI 10.1126/science.3538420; COHEN C, 1986, TRENDS BIOCHEM SCI, V11, P245, DOI 10.1016/0968-0004(86)90186-6; DAVIDOW LS, 1984, GENETICS, V106, P165; DRESSER ME, 1988, J CELL BIOL, V106, P567, DOI 10.1083/jcb.106.3.567; EGEL R, 1978, HEREDITY, V41, P233, DOI 10.1038/hdy.1978.92; ELLEDGE SJ, 1988, GENE, V70, P303, DOI 10.1016/0378-1119(88)90202-8; ENGEBRECHT J, 1990, MOL CELL BIOL, V10, P2379, DOI 10.1128/MCB.10.5.2379; ENGEBRECHT JA, 1989, GENETICS, V121, P237; Fraser R.D.B., 1973, CONFORMATION FIBROUS; Game J., 1983, YEAST GENETICS FUNDA, P109; GIROUX CN, 1988, GENETIC RECOMBINATIO, P465; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HESLOPHARRISON JS, 1985, J CELL SCI, V75, P85; HEYTING C, 1987, EUR J CELL BIOL, V43, P148; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HOLLINGSWORTH NM, 1989, GENETICS, V121, P445; HOLLINGSWORTH NM, 1990, CELL, V61, P73, DOI 10.1016/0092-8674(90)90216-2; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; HOLM C, 1989, MOL CELL BIOL, V9, P159, DOI 10.1128/MCB.9.1.159; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JONES GH, 1984, CONTROLLING EVENTS M, P293; KLECKNER N, 1991, COLD SH Q B, V56, P729; LICHTEN M, 1990, P NATL ACAD SCI USA, V87, P7653, DOI 10.1073/pnas.87.19.7653; LUCHE RM, 1990, MOL CELL BIOL, V10, P3884, DOI 10.1128/MCB.10.8.3884; MAGUIRE MP, 1972, GENETICS, V70, P353; MAGUIRE MP, 1978, EXP CELL RES, V112, P297, DOI 10.1016/0014-4827(78)90213-6; MCLACHLAN AD, 1983, J MOL BIOL, V164, P605, DOI 10.1016/0022-2836(83)90053-0; MCLACHLAN AD, 1982, NATURE, V299, P226, DOI 10.1038/299226a0; MENEES TM, 1992, MOL CELL BIOL, V12, P1340, DOI 10.1128/MCB.12.3.1340; MENEES TM, 1989, GENETICS, V123, P675; MOENS PB, 1985, CHROMOSOMA, V91, P113, DOI 10.1007/BF00294054; MOENS PB, 1987, J CELL BIOL, V105, P93, DOI 10.1083/jcb.105.1.93; PADMORE R, 1991, CELL, V66, P1239, DOI 10.1016/0092-8674(91)90046-2; PARRY DAD, 1977, J MOL BIOL, V113, P449, DOI 10.1016/0022-2836(77)90153-X; PETES TD, 1991, MOL BIOL YEAST SACCH, P406; RASMUSSEN SW, 1986, CARLSBERG RES COMMUN, V51, P401, DOI 10.1007/BF02907315; ROCKMILL B, 1988, P NATL ACAD SCI USA, V85, P6057, DOI 10.1073/pnas.85.16.6057; ROCKMILL B, 1990, GENETICS, V126, P563; ROCKMILL B, 1991, GENE DEV, V5, P2392, DOI 10.1101/gad.5.12b.2392; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; SAEZ L, 1986, NUCLEIC ACIDS RES, V14, P2951, DOI 10.1093/nar/14.7.2951; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEIFERT HS, 1986, P NATL ACAD SCI USA, V83, P735, DOI 10.1073/pnas.83.3.735; Sherman F., 1986, METHODS YEAST GENETI; SHUSTER EO, 1989, GENETICS, V123, P29; SMITH A, 1992, EXP CELL RES, V198, P291, DOI 10.1016/0014-4827(92)90382-I; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SNYDER M, 1989, J CELL BIOL, V108, P1419, DOI 10.1083/jcb.108.4.1419; SOLARI AJ, 1973, J CELL BIOL, V56, P145, DOI 10.1083/jcb.56.1.145; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STONE D, 1978, J BIOL CHEM, V253, P1137; SUN H, 1989, NATURE, V338, P87, DOI 10.1038/338087a0; THOMPSON EA, 1989, MOL GEN GENET, V218, P293, DOI 10.1007/BF00331281; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; UEMURA T, 1986, EMBO J, V5, P1003, DOI 10.1002/j.1460-2075.1986.tb04315.x; VOELKELMEIMAN K, 1990, GENETICS, V124, P561; VONWETTSTEIN D, 1984, ANNU REV GENET, V18, P331, DOI 10.1146/annurev.ge.18.120184.001555; WEBER L, 1992, GENETICS, V131, P55; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; ZICKLER D, 1992, GENETICS, V132, P135	71	495	502	3	17	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 12	1993	72	3					365	378		10.1016/0092-8674(93)90114-6	http://dx.doi.org/10.1016/0092-8674(93)90114-6			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KM162	7916652				2022-12-24	WOS:A1993KM16200007
J	TERADA, K; KATAMINE, S; EGUCHI, K; MORIUCHI, R; KITA, M; SHIMADA, H; YAMASHITA, I; IWATA, K; TSUJI, Y; NAGATAKI, S; MIYAMOTO, T				TERADA, K; KATAMINE, S; EGUCHI, K; MORIUCHI, R; KITA, M; SHIMADA, H; YAMASHITA, I; IWATA, K; TSUJI, Y; NAGATAKI, S; MIYAMOTO, T			PREVALENCE OF SERUM AND SALIVARY ANTIBODIES TO HTLV-1 IN SJOGRENS-SYNDROME	LANCET			English	Article							T-CELL LEUKEMIA; VIRUS TYPE-I; CLINICAL ENTITY; TRANSMISSION; MYELOPATHY; PROLIFERATION; IMPROVEMENT; ANTIGEN; PROTEIN; GENE	There is accumulating evidence that human T-lymphotropic virus-1 (HTLV-1) infection contributes to the development of various inflammatory disorders. To elucidate the relation between the infection and Sjogren's syndrome, seroepidemiological and virological studies were conducted on patients with this syndrome in Nagasaki Prefecture, Japan, an area heavily endemic for HTLV-1. The HTLV-1 seroprevalence rate among the patients with Sjogren's syndrome (17/74, 23%) was significantly higher than that among blood donors (916/27 284, 3%), whereas the difference between patients with systemic lupus erythematosus and blood donors was insignificant. Moreover, among Sjogren's syndrome patients the seroprevalence was high irrespective of age, unlike that among blood donors, which rose with age. Titres of serum antibodies in the HTLV-1 seropositive patients with Sjojgren's syndrome were similar to those among patients with HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) and significantly higher than those among healthy carriers. IgM class antibodies were commonly detected in the serum of patients with Sjogren's syndrome. However, unlike that in HAM/TSP patients, the viral load in peripheral-blood mononuclear cells was not necessarily high in the seropositive Sjogren syndrome group. Salivary IgA antibodies to HTLV-1 were common among seropositive patients with Sjojgren's syndrome (5/7), which might be due to increased viral activity in the salivary glands. These antibodies were barely detectable in HAM/TSP patients (prevalence 1/10) or in healthy carriers (0/11). The findings strongly suggest that HTLV-1 is involved in the pathogenesis of the disease in a subset of patients with Sjogren's syndrome in endemic areas.	NAGASAKI UNIV,SCH MED,DEPT BACTERIOL,NAGASAKI 852,JAPAN; NAGASAKI UNIV,SCH MED,DEPT INTERNAL MED 1,NAGASAKI 852,JAPAN; NAGASAKI UNIV,SCH MED,DEPT PREVENT MED & HLTH PROMOT,NAGASAKI 852,JAPAN; NAGASAKI UNIV,SCH MED,DEPT PAEDIAT,NAGASAKI 852,JAPAN	Nagasaki University; Nagasaki University; Nagasaki University; Nagasaki University				nagataki, shigenobu/0000-0002-9974-3554				BIEBERICH CJ, 1993, VIROLOGY, V196, P309, DOI 10.1006/viro.1993.1481; EGUCHI K, 1992, ANN RHEUM DIS, V51, P769, DOI 10.1136/ard.51.6.769; FUJINO R, 1991, JPN J CANCER RES, V82, P367, DOI 10.1111/j.1349-7006.1991.tb01856.x; FURUKAWA Y, 1992, BLOOD, V80, P1012; GESSAIN A, 1985, LANCET, V2, P407; GREEN JE, 1989, NATURE, V341, P72, DOI 10.1038/341072a0; HINO S, 1985, JPN J CANCER RES, V76, P474; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; KATAMINE S, 1994, LANCET, V343, P1326, DOI 10.1016/S0140-6736(94)92469-4; KAWASE K, 1992, JPN J CANCER RES, V83, P968, DOI 10.1111/j.1349-7006.1992.tb02009.x; KUGA T, 1988, JPN J CANCER RES, V79, P1168, DOI 10.1111/j.1349-7006.1988.tb01541.x; MARIETTE X, 1993, ARTHRITIS RHEUM-US, V36, P1423, DOI 10.1002/art.1780361015; MESTECKY J, 1987, ADV IMMUNOL, V40, P153, DOI 10.1016/S0065-2776(08)60240-0; MIYAKOSHI H, 1992, J CLIN MICROBIOL, V30, P2555, DOI 10.1128/JCM.30.10.2555-2559.1992; MOCHIZUKI M, 1992, JPN J CANCER RES, V83, P236, DOI 10.1111/j.1349-7006.1992.tb00092.x; MOUTSOPOULOS HM, 1994, HARRISONS PRINCIPLES, P1662; NISHIOKA K, 1989, LANCET, V1, P441; OSAME M, 1986, LANCET, V1, P1031; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; RICHARDSON JH, 1990, J VIROL, V64, P5682, DOI 10.1128/JVI.64.11.5682-5687.1990; SAKAI M, 1993, J CLIN INVEST, V92, P1957, DOI 10.1172/JCI116789; SEIKI M, 1983, P NATL ACAD SCI-BIOL, V80, P3618, DOI 10.1073/pnas.80.12.3618; TAJIMA K, 1982, GANN, V73, P893; TALAL N, 1987, SJOGRENS SYNDROME CL; VERNANT JC, 1988, LANCET, V1, P177; YASUKAWA K, 1987, EMBO J, V6, P2939, DOI 10.1002/j.1460-2075.1987.tb02598.x; YOSHIDA M, 1989, ANN NEUROL, V26, P331, DOI 10.1002/ana.410260304; 1990, WKLY EPIDEMIOL REC, V65, P281	28	185	189	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 22	1994	344	8930					1116	1119		10.1016/S0140-6736(94)90630-0	http://dx.doi.org/10.1016/S0140-6736(94)90630-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN066	7934493				2022-12-24	WOS:A1994PN06600009
J	HUANG, YY; LI, XC; KANDEL, ER				HUANG, YY; LI, XC; KANDEL, ER			CAMP CONTRIBUTES TO MESSY FIBER LTP BY INITIATING BOTH A COVALENTLY MEDIATED EARLY PHASE AND MACROMOLECULAR SYNTHESIS-DEPENDENT LATE-PHASE	CELL			English	Article							LONG-TERM POTENTIATION; APLYSIA SENSORY NEURONS; PROTEIN-KINASE; BEHAVIORAL SENSITIZATION; TRANSMITTER RELEASE; WITHDRAWAL REFLEX; GILL-WITHDRAWAL; MUTANT MICE; MEMORY; FACILITATION	Memory storage has a short-term phase that depends on preexisting proteins and a long-term phase that requires new protein and RNA synthesis. Hippocampal long-term potentiation (LTP) is thought to contribute to memory storage. Consistent with this idea, a cellular representation of these phases has been demonstrated in NMDA receptor-dependent LTP. By contrast, little is known a bout the NMDA receptor-independent LTP of the messy fiber pathway. We find that messy fiber LTP also has phases. Only late phase is blocked by protein and RNA synthesis inhibitors, but both phases are blocked by inhibitors of cAMP-dependent protein kinase, and both are stimulated by forskolin and Sp-cAMPS. During early phase, paired-pulse facilitation is occluded. This occlusion decays with the onset of late phase, consistent with its using a different mechanism. Thus, although Schaffer collateral and mossy fiber pathways use very different mechanisms for early phase, both use a cAMP-mediated mechanism far late phase.			HUANG, YY (corresponding author), COLUMBIA UNIV,COLL PHYS & SURG,CTR NEUROBIOL & BEHAV,HOWARD HUGHES MED INST,NEW YORK,NY 10032, USA.				NIGMS NIH HHS [GM32099] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM032099] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERINI CM, 1994, CELL, V76, P1099, DOI 10.1016/0092-8674(94)90386-7; ALKON DL, 1988, SCIENCE, V239, P998, DOI 10.1126/science.2830669; Amaral D G, 1993, Curr Opin Neurobiol, V3, P225, DOI 10.1016/0959-4388(93)90214-J; ANDERSEN P, 1971, EXP BRAIN RES, V13, P222; BACSKAI BJ, 1993, SCIENCE, V260, P222, DOI 10.1126/science.7682336; BAILEY CH, 1993, ANNU REV PHYSIOL, V55, P397, DOI 10.1146/annurev.ph.55.030193.002145; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BYRNE JH, 1993, ADV SEC MESS PHOSPH, V27, P47; BYRNE JH, 1987, PHYSIOL REV, V67, P329, DOI 10.1152/physrev.1987.67.2.329; CAREW TJ, 1986, ANNU REV NEUROSCI, V9, P435, DOI 10.1146/annurev.ne.09.030186.002251; CASTELLUCCI V, 1976, SCIENCE, V194, P1176, DOI 10.1126/science.11560; CASTELLUCCI VF, 1989, J NEUROBIOL, V20, P1, DOI 10.1002/neu.480200102; CROW T, 1990, P NATL ACAD SCI USA, V87, P4490, DOI 10.1073/pnas.87.12.4490; DALE N, 1987, J NEUROSCI, V7, P2232; DASH PK, 1990, NATURE, V345, P718, DOI 10.1038/345718a0; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; DAVIS HP, 1984, PSYCHOL BULL, V96, P518, DOI 10.1037/0033-2909.96.3.518; DRAIN P, 1991, NEURON, V6, P71, DOI 10.1016/0896-6273(91)90123-H; FREY U, 1993, SCIENCE, V260, P1661, DOI 10.1126/science.8389057; FROST WN, 1985, P NATL ACAD SCI USA, V82, P8266, DOI 10.1073/pnas.82.23.8266; GHIRARDI M, 1992, NEURON, V9, P479, DOI 10.1016/0896-6273(92)90185-G; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GLANZMAN DL, 1990, SCIENCE, V249, P799, DOI 10.1126/science.2389145; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; Hawkins RD, 1987, HDB PHYSL 1, VV, P25; Huang Y Y, 1994, Learn Mem, V1, P74; ITO I, 1991, NEUROSCI LETT, V121, P119, DOI 10.1016/0304-3940(91)90663-E; JOHNSTON D, 1992, ANNU REV PHYSIOL, V54, P489; KAANG BK, 1993, NEURON, V10, P427, DOI 10.1016/0896-6273(93)90331-K; LATHORN TH, 1984, BRAIN RES, V290, P174; LYNCH G, 1983, NATURE, V305, P719, DOI 10.1038/305719a0; MALENKA RC, 1989, NATURE, V340, P554, DOI 10.1038/340554a0; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MATTHIES H, 1993, NEUROREPORT, V4, P712, DOI 10.1097/00001756-199306000-00028; MILNER B, 1985, WE KNOW; MONTAROLO PG, 1986, SCIENCE, V234, P1249, DOI 10.1126/science.3775383; MORRIS RGM, 1990, EUR J NEUROSCI, V2, P1016, DOI 10.1111/j.1460-9568.1990.tb00014.x; NAZIF FA, 1991, BRAIN RES, V539, P324, DOI 10.1016/0006-8993(91)91638-H; NGUYEN PV, 1994, SCIENCE, V265, P1104, DOI 10.1126/science.8066450; NICOLL RA, 1988, NEURON, V1, P97, DOI 10.1016/0896-6273(88)90193-6; OTANI S, 1992, NEUROSCIENCE, V47, P265, DOI 10.1016/0306-4522(92)90242-T; POLSTER MR, 1991, J COGNITIVE NEUROSCI, V3, P95, DOI 10.1162/jocn.1991.3.2.95; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SMELLIE FW, 1979, LIFE SCI, V24, P2475, DOI 10.1016/0024-3205(79)90458-2; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; TULLY T, 1994, CELL, V7, P35; YIN JC, 1994, CELL, V7, P49; ZALUTSKY RA, 1990, SCIENCE, V248, P1619, DOI 10.1126/science.2114039; ZOLAMORGAN S, 1986, J NEUROSCI, V6, P2950; ZUCKER RS, 1973, J PHYSIOL-LONDON, V229, P787, DOI 10.1113/jphysiol.1973.sp010167	52	432	438	1	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 7	1994	79	1					69	79		10.1016/0092-8674(94)90401-4	http://dx.doi.org/10.1016/0092-8674(94)90401-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PK585	7923379				2022-12-24	WOS:A1994PK58500009
J	FENWICK, JC; CAMERON, M; NAIMAN, SC; HALEY, LP; RONCO, JJ; WIGGS, BR; TWEEDDALE, MG				FENWICK, JC; CAMERON, M; NAIMAN, SC; HALEY, LP; RONCO, JJ; WIGGS, BR; TWEEDDALE, MG			BLOOD-TRANSFUSION AS A CAUSE OF LEUKOCYTOSIS IN CRITICALLY ILL PATIENTS	LANCET			English	Note								The diagnosis of infection in the intensive care unit is confounded by the presence of non-infectious causes of leucocytosis. Unless such causes are recognised, time and effort will be spent on unnecessary investigations and treatments. In a prospective study we have shown that the transfusion of blood frequently (45/50 patients) causes an acute leucocytosis in such patients. This effect was not seen in 8 patients who received plasma. Blood transfusion should be added to the list of non-infectious causes of leucocytosis in the critically ill.	UNIV BRITISH COLUMBIA,VANCOUVER GEN HOSP,DIV HEMATOPATHOL,VANCOUVER V5Z 1M9,BC,CANADA; UNIV BRITISH COLUMBIA,ST PAULS HOSP,VANCOUVER,BC,CANADA	University of British Columbia; St. Paul's Hospital; University of British Columbia; University of Saskatchewan	FENWICK, JC (corresponding author), UNIV BRITISH COLUMBIA,VANCOUVER GEN HOSP,INTENS CARE UNIT,PROGRAM CRIT CARE MED,ROOM 2438,VANCOUVER V5Z 1M9,BC,CANADA.							Crowder M.J., 1990, ANAL REPEATED MEASUR; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LEE RG, 1993, WINTROBES CLIN HEMAT; MAYNE E E, 1970, Acta Haematologica (Basel), V44, P155; MUIR AL, 1984, J APPL PHYSIOL, V57, P711, DOI 10.1152/jappl.1984.57.3.711; 1992, CHEST, V101, P1644	6	26	28	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 24	1994	344	8926					855	856		10.1016/S0140-6736(94)92828-2	http://dx.doi.org/10.1016/S0140-6736(94)92828-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PH253	7916402				2022-12-24	WOS:A1994PH25300012
J	MCCLURE, N; HEALY, DL; ROGERS, PAW; SULLIVAN, J; BEATON, L; HANING, RV; CONNOLLY, DT; ROBERTSON, DM				MCCLURE, N; HEALY, DL; ROGERS, PAW; SULLIVAN, J; BEATON, L; HANING, RV; CONNOLLY, DT; ROBERTSON, DM			VASCULAR ENDOTHELIAL GROWTH-FACTOR AS CAPILLARY-PERMEABILITY AGENT IN OVARIAN HYPERSTIMULATION SYNDROME	LANCET			English	Note								We investigated the role of vascular endothelial growth factor (VEGF) in ovarian hyperstimulation syndrome (OHSS). Two similar peaks of permeability activity were seen in OHSS ascites and liver ascites spiked with recombinant human VEGF (rhVEGF); no activity was seen in control liver ascites. Incubation with rhVEGF antiserum decreased activity in the two OHSS peaks by 79% and 65% and the two spiked liver peaks by 49% and 50%. Control serum produced 24% and 27%, and 17% and 0% reductions, respectively, This is evidence that the major capillary permeability agent in OHSS ascites fluid is VEGF.	MONASH UNIV,DEPT OBSTET & GYNAECOL,CLAYTON,VIC 3168,AUSTRALIA; MONASH MED CTR,PRINCE HENRYS INST MED RES,CLAYTON,VIC 3168,AUSTRALIA; BROWN UNIV,WOMEN & INFANTS HOSP,DEPT OBSTET & GYNECOL,PROVIDENCE,RI; MONSANTO CO,HLTH SCI,ST LOUIS,MO	Monash University; Monash University; Prince Henry's Institute of Medical Research; Brown University; Women & Infants Hospital Rhode Island; Monsanto			Rogers, Peter AW/C-2651-2008	Rogers, Peter AW/0000-0002-7399-8997				Basset DL, 1943, AM J ANAT, V73, P251, DOI 10.1002/aja.1000730206; CAVENDER JL, 1988, BIOL REPROD, V39, P989, DOI 10.1095/biolreprod39.4.989; FERRARA N, 1991, J CELL BIOCHEM, V47, P211, DOI 10.1002/jcb.240470305; MCCLURE N, 1992, HUM REPROD, V7, P758, DOI 10.1093/oxfordjournals.humrep.a137733; MCCLURE N, IN PRESS J PHARM TOX; PHILLIPS HS, 1990, ENDOCRINOLOGY, V127, P965, DOI 10.1210/endo-127-2-965; RAVINDRANATH N, 1992, ENDOCRINOLOGY, V131, P254, DOI 10.1210/en.131.1.254; 1991, LANCET, V338, P1111	8	304	317	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 23	1994	344	8917					235	236		10.1016/S0140-6736(94)93001-5	http://dx.doi.org/10.1016/S0140-6736(94)93001-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY060	7913160				2022-12-24	WOS:A1994NY06000013
J	LALLEMANT, M; BAILLOU, A; LALLEMANTLECOEUR, S; NZINGOULA, S; MAMPAKA, M; MPELE, P; BARIN, F; ESSEX, M				LALLEMANT, M; BAILLOU, A; LALLEMANTLECOEUR, S; NZINGOULA, S; MAMPAKA, M; MPELE, P; BARIN, F; ESSEX, M			MATERNAL ANTIBODY-RESPONSE AT DELIVERY AND PERINATAL TRANSMISSION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 IN AFRICAN WOMEN	LANCET			English	Article							TO-INFANT TRANSMISSION; VERTICAL TRANSMISSION; HIV-1; GP120; INFECTION; MOTHER; SEQUENCE; DOMAIN; PHENOTYPE; CHILDREN	Prospective cohort studies indicate that 13-45% of human immunodeficiency virus type 1 (HIV-1)-infected pregnant women transmit the virus to their infants. Although factors that influence perinatal transmission are not well understood, drug and immunotherapy trials to interrupt transmission are underway. The identification of women most at risk is essential for prevention, counselling, and medical intervention. We assessed 70 HIV-1-infected pregnant women enrolled in a prospective study of perinatal transmission in Brazzaville, Congo. The relations between maternal health status, antibody levels to selected HIV-1 structural antigens at delivery, and infant outcome were explored. Independent of clinical stage, higher maternal antibody titres to peptides corresponding to the V3 region of gp120 and the immunodominant domain of gp41 were correlated with a higher risk of perinatal transmission. In a logistic regression model, the predicted risk of transmission for symptom-free women whose antibody titres to V3 and gp41 were lowest was 0.02, whereas it was 0.88 for symptomatic women whose antibody titres to V3 and TMSP18 were highest. These associations may give new insight into the mechanisms of perinatal transmission and they may also provide a powerful means of identifying women who would most benefit from intervention trials to halt perinatal transmission.	BRETONNEAU HOSP, VIROL LAB, TOURS, FRANCE; MINIST HLTH, NATL PROGRAM AIDS, Brazzaville, REP CONGO; MINIST HLTH, DEPT MOTHER & CHILD HLTH, Brazzaville, REP CONGO	CHU Tours	LALLEMANT, M (corresponding author), HARVARD UNIV, SCH PUBL HLTH, DEPT CANC BIOL, FRENCH RES INST DEV COOPERAT, 665 HUNTINGTON AVE, BOSTON, MA 02115 USA.							ARENDRUP M, 1992, J ACQ IMMUN DEF SYND, V5, P303; BAILLOU A, 1991, J CLIN MICROBIOL, V29, P1387, DOI 10.1128/JCM.29.7.1387-1391.1991; BLANCHE S, 1989, NEW ENGL J MED, V320, P1643, DOI 10.1056/NEJM198906223202502; BORKOWSKY W, 1992, PEDIATRICS, V90, P133; CHIN J, 1990, LANCET, V336, P221, DOI 10.1016/0140-6736(90)91743-T; DABIS F, 1993, AIDS, V7, P1139, DOI 10.1097/00002030-199308000-00027; DEVASH Y, 1990, P NATL ACAD SCI USA, V87, P3445, DOI 10.1073/pnas.87.9.3445; EHRNST A, 1991, LANCET, V338, P203, DOI 10.1016/0140-6736(91)90347-R; FOUCHIER RAM, 1992, J VIROL, V66, P3183, DOI 10.1128/JVI.66.5.3183-3187.1992; GOEDERT JJ, 1989, LANCET, V2, P1351; HALSEY NA, 1992, J ACQ IMMUN DEF SYND, V5, P153; HIRA SK, 1989, BRIT MED J, V299, P1250, DOI 10.1136/bmj.299.6710.1250; LALLEMANT M, 1989, AIDS, V3, P643, DOI 10.1097/00002030-198910000-00004; LAROSA GJ, 1990, SCIENCE, V249, P932, DOI 10.1126/science.2392685; LINDGREN S, 1991, AIDS, V5, P1111, DOI 10.1097/00002030-199109000-00009; NEWELL ML, 1992, LANCET, V339, P1007; NOWAK MA, 1991, SCIENCE, V254, P963, DOI 10.1126/science.1683006; PAREKH BS, 1991, AIDS, V5, P1179, DOI 10.1097/00002030-199110000-00004; ROBERTSON CA, 1992, J INFECT DIS, V166, P704, DOI 10.1093/infdis/166.4.704; ROBINSON WE, 1990, P NATL ACAD SCI USA, V87, P3185, DOI 10.1073/pnas.87.8.3185; ROSSI P, 1989, P NATL ACAD SCI USA, V86, P8055, DOI 10.1073/pnas.86.20.8055; RYDER RW, 1989, NEW ENGL J MED, V320, P1637, DOI 10.1056/NEJM198906223202501; SCHUITEMAKER H, 1992, J VIROL, V66, P1354, DOI 10.1128/JVI.66.3.1354-1360.1992; TERSMETTE M, 1989, J VIROL, V63, P2118, DOI 10.1128/JVI.63.5.2118-2125.1989; UKWU HN, 1992, OBSTET GYNECOL, V80, P458; VANDEPERRE P, 1991, NEW ENGL J MED, V325, P593, DOI 10.1056/NEJM199108293250901; WOLFS TFW, 1990, P NATL ACAD SCI USA, V87, P9938, DOI 10.1073/pnas.87.24.9938; WOLINSKY SM, 1992, SCIENCE, V255, P1134, DOI 10.1126/science.1546316; 1986, WKLY EPIDEMIOL REC, V61, P69; 1992, J ACQUIR IMM DEFIC S, V5, P1019	30	42	42	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 23	1994	343	8904					1001	1005		10.1016/S0140-6736(94)90126-0	http://dx.doi.org/10.1016/S0140-6736(94)90126-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NG682	7909048				2022-12-24	WOS:A1994NG68200009
J	CASPARI, R; FRIEDL, W; MANDL, M; MOSLEIN, G; KADMON, M; KNAPP, M; JACOBASCH, KH; ECKER, KW; KREISSLERHAAG, D; TIMMERMANS, G; PROPPING, P				CASPARI, R; FRIEDL, W; MANDL, M; MOSLEIN, G; KADMON, M; KNAPP, M; JACOBASCH, KH; ECKER, KW; KREISSLERHAAG, D; TIMMERMANS, G; PROPPING, P			FAMILIAL ADENOMATOUS POLYPOSIS - MUTATION AT CODON-1309 AND EARLY-ONSET OF COLON-CANCER	LANCET			English	Article							GERM-LINE MUTATIONS; APC GENE; CHROMOSOME-5Q21; IDENTIFICATION; FAP	The clinical course of familial adenomatous polyposis (FAP) varies considerably between patients. Prediction of the severity of the disease is important in the interest of effective cancer prevention. We examined whether age at diagnosis of FAP due to gastrointestinal symptoms and age at death due to colorectal cancer are related to the site of mutation in the responsible gene. 225 families with FAP were screened for mutations. The deletion of 5 base pairs at codon 1309 within exon 15 (known to be the most common mutation) was identified in 20 families; other mutations within exons 7-15 were found in 49 families. In patients with the 5 base-pair deletion at codon 1309, gastrointestinal symptoms and death from colorectal cancer occurred about 10 years earlier than in patients with other mutations. The 1309 mutation leads to development of colonic polyps at a younger age, thus giving rise to an earlier malignant tranformation. This relationship should be taken into account in strategies for preventing cancer in patients with FAP.	UNIV BONN,INST HUMAN GENET,D-53111 BONN,GERMANY; UNIV DUSSELDORF,SURG CLIN,DUSSELDORF,GERMANY; UNIV HEIDELBERG,SURG CLIN,HEIDELBERG,GERMANY; UNIV BONN,INST MED STAT,BONN,GERMANY; UNIV CLIN RUDOLF VIRCHOW,BERLIN,GERMANY; UNIV HOMBURG SAAR,SURG CLIN,HOMBURG,GERMANY	University of Bonn; Heinrich Heine University Dusseldorf; Ruprecht Karls University Heidelberg; University of Bonn			Ecker, Karl-Wilhelm/ABF-6313-2020	Ecker, Karl-Wilhelm/0000-0002-9672-2504				CASPARI R, 1993, Z GASTROENTEROL, V31, P646; COTTRELL S, 1992, LANCET, V340, P626, DOI 10.1016/0140-6736(92)92169-G; FODDE R, 1992, GENOMICS, V13, P1162, DOI 10.1016/0888-7543(92)90032-N; FRIEDL W, 1993, HUM MOL GENET, V2, P1481, DOI 10.1093/hmg/2.9.1481; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; GRODEN J, 1993, AM J HUM GENET, V52, P262; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KIRK RE, 1968, EXPT DESIGN PROCEDUR, P299; MANDL M, 1994, HUM MOL GENET, V3, P181, DOI 10.1093/hmg/3.1.181; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MIYOSHI Y, 1992, P NATL ACAD SCI USA, V89, P4452, DOI 10.1073/pnas.89.10.4452; NAGASE H, 1993, HUM MUTAT, V2, P425, DOI 10.1002/humu.1380020602; Nagase Hiroki, 1992, Human Mutation, V1, P467, DOI 10.1002/humu.1380010603; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; OLSCHWANG S, 1993, AM J HUM GENET, V52, P273; OLSCHWANG S, 1993, CELL, V75, P959, DOI 10.1016/0092-8674(93)90539-3; PAUL P, 1993, HUM MOL GENET, V2, P925, DOI 10.1093/hmg/2.7.925; PRESCIUTTINI S, 1993, ANN HUM GENET, V57, P105, DOI 10.1111/j.1469-1809.1993.tb00892.x; REED TE, 1955, AM J HUM GENET, V7, P236; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; SMITH KJ, 1993, P NATL ACAD SCI USA, V90, P2846, DOI 10.1073/pnas.90.7.2846; SPIRIO L, 1993, CELL, V75, P951, DOI 10.1016/0092-8674(93)90538-2; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; UTSONOMIYA J, 1980, CANCER, V45, P198; VARESCO L, 1993, AM J HUM GENET, V52, P280; VEALE AMO, 1965, EUGEN LAB, V40, P1	26	191	196	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 12	1994	343	8898					629	632		10.1016/S0140-6736(94)92634-4	http://dx.doi.org/10.1016/S0140-6736(94)92634-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NA093	7906810				2022-12-24	WOS:A1994NA09300007
J	CORMAN, ML				CORMAN, ML			UNDERSTANDING SURVEILLANCE COLONOSCOPY	LANCET			English	Editorial Material							ULCERATIVE-COLITIS; DYSPLASIA; CANCER; PROGRAM				CORMAN, ML (corresponding author), SANSUM MED CLIN,SANTA BARBARA,CA 93105, USA.							BERNSTEIN CN, 1994, LANCET, V343, P71; CHOI PM, 1993, GASTROENTEROLOGY, V105, P418, DOI 10.1016/0016-5085(93)90715-O; COLLINS RH, 1987, NEW ENGL J MED, V316, P1654, DOI 10.1056/NEJM198706253162609; KIRSNER JB, 1982, NEW ENGL J MED, V306, P775, DOI 10.1056/NEJM198204013061304; LASHNER BA, 1992, AM J GASTROENTEROL, V87, P168; LEIDENIUS M, 1991, GUT, V32, P1521, DOI 10.1136/gut.32.12.1521; LENNARDJONES JE, 1986, GUT, V27, P1403, DOI 10.1136/gut.27.12.1403; LORBERG R, 1990, GASTROENTEROLOGY, V99, P1021; MORSON BC, 1967, GUT, V8, P423, DOI 10.1136/gut.8.5.423; NUGENT FW, 1991, GASTROENTEROLOGY, V100, P1241, DOI 10.1016/0016-5085(91)70010-U; NUGENT FW, 1979, GASTROENTEROLOGY, V76, P1; NUGENT FW, 1984, GASTROENTEROLOGY, V86, P1197; RUBIO CA, 1984, DIS COLON RECTUM, V27, P283, DOI 10.1007/BF02555626	13	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 5	1994	343	8897					556	557		10.1016/S0140-6736(94)91517-2	http://dx.doi.org/10.1016/S0140-6736(94)91517-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY843	7906325				2022-12-24	WOS:A1994MY84300005
J	CHESTER, KA; BEGENT, RHJ; ROBSON, L; KEEP, P; PEDLEY, RB; BODEN, JA; BOXER, G; GREEN, A; WINTER, G; COCHET, O; HAWKINS, RE				CHESTER, KA; BEGENT, RHJ; ROBSON, L; KEEP, P; PEDLEY, RB; BODEN, JA; BOXER, G; GREEN, A; WINTER, G; COCHET, O; HAWKINS, RE			PHAGE LIBRARIES FOR GENERATION OF CLINICALLY USEFUL ANTIBODIES	LANCET			English	Note							MONOCLONAL-ANTIBODIES; AFFINITY	Insertion of antibody genes into filamentous bacteriophage makes it possible to generate and screen libraries of 10(7) or more antibodies. Each phage expresses an antibody on its surface and contains the corresponding antibody gene. Genes that encode antibodies with desired characteristics are readily selected and their antibodies expressed as soluble proteins in Escherichia coli. We used this system to produce an antibody to carcinoembryonic antigen with higher affinity and better tumour specificity than antibodies currently in use.	ROYAL FREE HOSP,SCH MED,LONDON NW3 2PF,ENGLAND; CTR PROT ENGN,CAMBRIDGE,CAMBS,ENGLAND; ADDENBROOKES HOSP,CTR PROT ENGN,CAMBRIDGE,CAMBS,ENGLAND; ADDENBROOKES HOSP,DEPT CLIN ONCOL,CAMBRIDGE,CAMBS,ENGLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge			Chester, Kerry/AAE-2856-2020					BEGENT RHJ, 1990, SCI CANCER TREATMENT, V2, P161; CLACKSON T, 1991, NATURE, V352, P624, DOI 10.1038/352624a0; HAWKINS RE, 1992, J MOL BIOL, V226, P889, DOI 10.1016/0022-2836(92)90639-2; HAWKINS RE, 1992, BRIT MED J, V305, P1348, DOI 10.1136/bmj.305.6865.1348; MCCAFFERTY J, 1990, NATURE, V348, P552, DOI 10.1038/348552a0; NAP M, 1992, CANCER RES, V52, P2329	6	164	175	0	13	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 19	1994	343	8895					455	456		10.1016/S0140-6736(94)92695-6	http://dx.doi.org/10.1016/S0140-6736(94)92695-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW690	7905958				2022-12-24	WOS:A1994MW69000013
J	WETTER, LA; HAMADEH, RM; GRIFFISS, JM; OESTERLE, A; AAGAARD, B; WAY, LW				WETTER, LA; HAMADEH, RM; GRIFFISS, JM; OESTERLE, A; AAGAARD, B; WAY, LW			DIFFERENCES IN OUTER-MEMBRANE CHARACTERISTICS BETWEEN GALLSTONE-ASSOCIATED BACTERIA AND NORMAL BACTERIAL-FLORA	LANCET			English	Article							ESCHERICHIA-COLI; POLYACRYLAMIDE GELS; HEMOLYSIN PRODUCTION; ANTI-GAL; STONES; HEMAGGLUTINATION; ERYTHROCYTES; RECOGNITION; MANNOSE; BILE	Previous studies with scanning electron microscopy (SEM) have suggested that pigment gallstones contain bacteria. We set out to culture these bacteria and to study their membrane characteristics. We studied gallstones from 54 patients (36 men, 18 women; mean age 55.4 years) admitted consecutively to two hospitals for cholecystectomy. SEM detected bacteria in all of 14 brown pigment stones, 2 of 14 black pigment stones, and in the pigmented centres of 9 of 19 mixed cholesterol stones; no bacteria were detected in 14 pure cholesterol stones or within the cholesterol portions of mixed stones. We were able to culture bacteria from all gallstones with bacteria seen on SEM and for which sufficient material was available (n=16). 20 bacterial species were recovered from these stones. Gallstones containing bacteria were associated with clinical sepsis and cholangitis. All bacteria obtained from gallstones agglutinated human O P1 erythrocytes, which reflects the presence of P1-specific fimbriae. 5 strains were positive for Forssman-antigen-specific fimbriae. None showed evidence of mannose-specific fimbriae. All of the organisms bound anti-Gal, a ubiquitous naturally occurring IgG specific for a-galactosyl residues. The presence of P1 fimbriae and alpha-galactosyl residues and the absence of mannose-specific fimbriae distinguish these organisms from gut flora. We postulate that possession of these unusual properties may enhance the ability of bacteria to colonise the biliary tree and initiate pigment gallstone formation.	UNIV CALIF SAN FRANCISCO,DEPT SURG,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT LAB MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CTR IMMUNOCHEM,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NIAID NIH HHS [AI 21171] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021171] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKIYOSHI T, 1990, DIGEST DIS SCI, V35, P27, DOI 10.1007/BF01537218; BERNHOFT RA, 1984, AM J SURG, V148, P77, DOI 10.1016/0002-9610(84)90292-7; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CETTA F, 1991, ANN SURG, V213, P315, DOI 10.1097/00000658-199104000-00006; CETTA FM, 1986, HEPATOLOGY, V6, P482, DOI 10.1002/hep.1840060327; DONOVAN JM, 1991, GASTROENTEROL CLIN N, V20, P47; DUGUID JP, 1980, BACTERIAL ADHERENC B, V6, P185; EVANS DJ, 1979, INFECT IMMUN, V23, P336, DOI 10.1128/IAI.23.2.336-346.1979; GALILI U, 1984, J EXP MED, V160, P1519, DOI 10.1084/jem.160.5.1519; GALILI U, 1985, J EXP MED, V162, P573, DOI 10.1084/jem.162.2.573; GREEN CP, 1981, INFECT IMMUN, V31, P309, DOI 10.1128/IAI.31.1.309-315.1981; HAMADEH R, 1991, CLIN RES, V39, pA439; HAMADEH RM, 1990, J CLIN MICROBIOL, V28, P20, DOI 10.1128/JCM.28.1.20-26.1990; HAMADEH RM, 1992, J CLIN INVEST, V89, P1223, DOI 10.1172/JCI115706; HITCHCOCK PJ, 1983, J BACTERIOL, V154, P269, DOI 10.1128/JB.154.1.269-277.1983; KALLENIUS G, 1980, FEMS MICROBIOL LETT, V7, P297, DOI 10.1111/j.1574-6941.1980.tb01608.x; KIM JJ, 1989, INFECT IMMUN, V57, P602, DOI 10.1128/IAI.57.2.602-608.1989; KORHONEN TK, 1985, INFECT IMMUN, V48, P486, DOI 10.1128/IAI.48.2.486-491.1985; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAKI T, 1966, ANN SURG, V164, P90, DOI 10.1097/00000658-196607000-00010; OHANLEY P, 1985, NEW ENGL J MED, V313, P414, DOI 10.1056/NEJM198508153130704; OKADA Y, 1988, J IMMUNOL METHODS, V112, P243, DOI 10.1016/0022-1759(88)90364-X; OLD DC, 1972, J GEN MICROBIOL, V71, P149, DOI 10.1099/00221287-71-1-149; SKAR V, 1988, SCAND J GASTROENTERO, V23, P83, DOI 10.3109/00365528809093853; SMITH AL, 1989, ARCH SURG-CHICAGO, V124, P629; STEWART L, 1987, ANN SURG, V206, P242, DOI 10.1097/00000658-198709000-00002; SUNG JY, 1992, DIGEST DIS SCI, V37, P689, DOI 10.1007/BF01296423; TSAI CM, 1982, ANAL BIOCHEM, V119, P115, DOI 10.1016/0003-2697(82)90673-X; VAISANEN V, 1981, LANCET, V2, P1366	29	35	37	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 19	1994	343	8895					444	448		10.1016/S0140-6736(94)92691-3	http://dx.doi.org/10.1016/S0140-6736(94)92691-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW690	7905954				2022-12-24	WOS:A1994MW69000009
J	NIGHTINGALE, SL				NIGHTINGALE, SL			NEW DEVICE APPROVED FOR USE BY PARAPLEGICS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 15	1994	271	23					1818	1818						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NP959	7910857				2022-12-24	WOS:A1994NP95900006
J	NIGHTINGALE, SL				NIGHTINGALE, SL			PACLITAXEL APPROVED FOR TREATMENT OF CERTAIN BREAST-CANCER PATIENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 15	1994	271	23					1818	1818						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NP959	7910857				2022-12-24	WOS:A1994NP95900005
